|
Ramsay Health Care Limited is a private healthcare provider operating hospitals and health care services in Australia, the United Kingdom, and Europe. The company offers a range of services including primary care and specialist clinics, diagnostics and imaging centres, mental health hospitals and residential settings, psychology outpatient services, and virtual or telehealth services. Founded in 1964 by Paul Ramsay, the company listed on the Australian Stock Exchange in 1997. Key subsidiaries and joint ventures include Ramsay Santé in France and Ramsay Sime Darby Health Care in Asia, the latter of which was sold. Ramsay Santé acquired Générale de Santé and Capio AB, while Ramsay acquired Elysium Healthcare in the UK and GHP Specialty Care in Sweden. The company serves millions of patients annually across its global network. Summarised from the company's own disclosures, fiscal year ended Jun 2026 |
Industry Health Care Equipment & Services | Homepage ramsayhealth.com |
| Sector Healthcare | IR page ramsayhealth.com/en/investors | |
|
Tags
private hospitals, mental health, diagnostics, imaging, primary care, specialist clinics, telehealth, residential care, psychology services, Ramsay Santé, Ramsay Sime Darby Health Care, Générale de Santé, Capio AB, Elysium Healthcare, GHP Specialty Care
|
Press page — |
Metrics
| Valuation | |
|---|---|
| Market cap | A$ 12.929B |
| Market cap (USD) | $ 8.883B |
| P/E | 32.29 |
| PEG | 12.71 |
| P/BV | 1.86 |
| P/S | 0.70 |
| P/OCF | 9.04 |
| P/FCF | — |
| Dividend yield | — |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | 5.7% |
| ROI | 3.0% |
| ROIC | 3.0% |
| Profit margin | 1.7% |
| Growth | |
|---|---|
| Revenue growing | Yes |
| Profits growing | Yes |
| Revenue up 3y | Yes |
| Revenue up 5y | Yes |
| Earnings growth 3y (net profit CAGR) | 2.5% |
| Quality | |
|---|---|
| Profitable | Yes |
| Margin expanding | Yes |
| Buying back stock | — |
| Diluting (TTM) | No |
| Debt/Equity | 94.6% |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 0 |
| Quality score | 62.5% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
| Figure | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2014 | FY 2013 | FY 2012 | FY 2011 | FY 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 18.578B | 17.792B | 16.66B | 14.964B | 13.312B | 12.864B | 12.16B | 11.553B | 9.181B | 4.909B | 4.175B | 3.956B | 3.72B | 3.399B |
| Net profit | 321.4M | 46.3M | 263.3M | 298.1M | 274M | 449M | 284M | 545.5M | 388.348M | 303.759M | 266.404M | 244.105M | 198.375M | 148.282M |
Podcast Mentions
Announcements lodged with ASX, newest first, routine forms (director and substantial-holding notices, daily buy-back and quotation notices) included. The link opens the announcement on ASX. Press releases from the company's own website, newest first.
230 239 267 294 303
312 316
Organisation chart and organisation Main shareholders Related‑party transactions Additional information on the share capital
ADDITIONAL INFORMATION
RISK FACTORS AND RISK MANAGEMENT Risk factors Risk management Coverage of risks
Administrative, management, supervisory and Executive Management bodies Functioning of the administrative and management bodies Remuneration and benefits of corporate officers
7.6 7.7
Person responsible for the Universal Registration Document Statutory Auditors Research and development – brands, trademarks and licences Material contracts Information incorporated by reference and documents accessible to the public Abbreviations Reference tables
329
330 347 364
381 382 386 393 398
417 418 418 419 420 421 422 423
UNIVERSAL REGISTRATION DOCUMENT 2026
INCLUDING THE ANNUAL FINANCIAL REPORT
Ramsay Santé is the European leader in the global care offer. The Group currently has 44,000 employees and works with nearly 10,000 independent practitioners. Present in five countries, France, Sweden, Norway, Denmark and Italy, the Group treats more than 13 million patients per year in its 491 facilities.
This Universal Registration Document was filed on 19 October 2026 with the French Financial Markets Authority (AMF - Autorité des Marchés Financiers) as the competent authority under Regulation (EU) 2017/1129, without prior approval in accordance with Article 9 of said regulation. The Universal Registration Document may be used for the purposes of a public offering of financial securities or the admission of financial securities to trading on a regulated market if it is supplemented by a security note and, where applicable, a summary and any amendments made to the Universal Registration Document. The resulting package is approved by the AMF in accordance with Regulation (EU) 2017/1129. Copies of the Universal Registration Document are available free of charge from Ramsay Générale de Santé SA, Immeuble REIWA, 67 rue Arago, 93400 Saint‑Ouen‑sur‑Seine, France, as well as on the websites of Ramsay Santé (http://www.ramsaysante.fr) and the AMF (http://www.amf‑france.org). This Universal Registration Document is a reproduction of the official version of the Universal Registration Document, including the 2026 annual financial report, which was prepared in the European Single Electronic Format (ESEF) and is available on our website www.ramsaysante.fr
Ramsay Santé / Universal Registration Document 2026
1
MESSAGE FROM THE CHAIR OF BOARD OF DIRECTORS AND THE CEO
PASCAL ROCHÉ CEO Ramsay Santé
A new chapter for Ramsay Santé Following a pivotal year for Ramsay Santé, marked by the completion of Yes We Care 2025, the announcement of a potentially new shareholder structure and the start of a new strategic cycle, Natalie Davis, Chair of the Board of Directors of Ramsay Santé and Group CEO of Ramsay Health Care, and Pascal Roché, Chief Executive Officer of Ramsay Santé, come together to reflect on the Group’s success and achievements at the end of a strategic cycle and the priorities for the next chapter. After five years of transformation under the “Yes We Care 2025” roadmap, how would you describe Ramsay Santé today?
activities and strengthened its position across Europe, while maintaining high standards of care in an increasingly demanding healthcare environment.
Natalie Davis (ND): Over the past five years, Ramsay Santé has successfully grown into a leading integrated European healthcare platform, operating across five countries, caring for 13 million patients each year through a network of 491 care facilities. The Group’s platform now covers a broad continuum of care, from prevention and primary care to mental health, rehabilitation and acute care.
Pascal Roché (PR): In France, our quality outcomes exceed national benchmarks, demonstrating the tangible impact of this transformation on patient care. Our record Group patient Net Promoter Score of 73% illustrates the trust placed in our teams and medical partners. This transformation has also strengthened our operating model. In FY2026, revenue grew by 3.3% to €5.4 billion and EBITDA by 2.6% to €638 million, driven by solid activity in France, strong fundamentals in the Nordic countries and continued operational discipline.
Guided by an ambitious roadmap, Yes We Care 2025, the Group has expanded access to care, broadened its
2
Ramsay Santé / Universal Registration Document 2026
The successful refinancing of our senior debt in July 2026, extending maturities to 2033, has further strengthened our financial flexibility. Crédit Agricole Assurances’ reaffirmed commitment as a long-term shareholder provides further stability as the Group enters this next phase. We therefore enter this new phase with a clear roadmap and greater financial visibility. How will Connecting Care 2030 shape the next phase of Ramsay Santé’s development?
NATALIE DAVIS
PR: Connecting Care 2030 is about unlocking the full potential of that platform with a clear ambition: connecting more patients across a greater share of their care journey, expanding where we have structural untapped potential, developing new revenue streams, and leveraging digitisation and productivity to translate growth into stronger profitability.
2026 also marks a proposed evolution in Ramsay Santé’s shareholder structure. What does this mean for the Group?
At the heart of this strategy is medical excellence, which underpins everything we do: continuously improving patient outcomes and safety, sharing best practices across our European network, and scaling clinical innovation, research and training. This commitment makes us the partner of choice for patients, physicians and employees, and a trusted reference partner for governments and healthcare systems, reflecting our critical role in delivering accessible and high-quality care across our markets.
Chair, Ramsay Santé Group CEO, Ramsay Health Care
ND: Ramsay Health Care’s proposed demerger of its shareholding represents an important milestone for Ramsay Santé. Subject to the necessary approvals, the transaction is expected to broaden Ramsay Santé’s shareholder base, and will create even greater focus for Ramsay Santé to pursue its European focused strategy and transformation. Throughout this transition, the Board has remained focused on ensuring continuity and strong governance, while safeguarding the long-term interests of Ramsay Santé and its stakeholders. PR: The proposed change in shareholding does not alter our operational priorities: Ramsay Santé has long operated with its own strategic direction and financing framework.
Leveraging a unique model of cross-country innovation and knowledge sharing, “Connecting Care 2030” provides a clear path towards sustained organic growth, gradual margin improvement and continued deleveraging, supported by disciplined capital allocation, ultimately creating sustainable long-term value for all our stakeholders. We believe medical quality, responsible performance and long-term value creation are inseparable.
Natalie Davis et Pascal Roché Ramsay Santé / Universal Registration Document 2026
3
4
Ramsay Santé / Universal Registration Document 2026
1.1
ABOUT THE ISSUER
6
1.1.1 1.1.2 1.1.3
Administration information as of today Introducing Ramsay Santé group History: from a French company to a European leader
6 6 10
1.2
A CLOSER LOOK AT MAJOR COUNTRIES AND MARKETS
13
1.2.1 1.2.2 1.2.3
The healthcare market in France A closer look at the Nordics (Sweden, Norway and Denmark) A closer look at Italy
21 23
1.3
BUSINESS OVERVIEW
24
1.3.1 1.3.2 1.3.3 1.3.4
A unique position on the European market The Group’s strategy Medical excellence The Group’s activities in each country
24 27 31 32
1.4
EXCEPTIONAL EVENTS
37
13
1
GENERAL PRESENTATION OF THE GROUP
Ramsay Santé / Universal Registration Document 2026
5
1
GENERAL PRESENTATION OF THE GROUP About the issuer
1.1
About the issuer
1.1.1
Administration information as of today
Company name The Company's corporate name is "Ramsay Générale de Santé".
This name is a trademark registered with the INPI under the national number 15 4 209 389.
Trade and Companies Register, APE, LEI The Company is registered in the Paris Trade and Companies Register under number B 383 699 048.
The Company is listed on the Eurolist of Euronext Paris, ISIN code FR0000044471 (Euroclear France SA code 4447).
Its APE code (Code of the principal activity carried out) is 6430Z. It corresponds to the activity of investment funds and similar financial entities.
The Company’s unique identification number or LEI (Legal Entity Identification) is 969500I1EJGUAT223F44. This is the unique identification number for entities trading on the financial markets.
Date of incorporation and term The Company was incorporated on 29 November 1991 for a period of ninety‑nine years from the date of its registration, except in the event of early dissolution or extension as provided for by law or decided by the General Shareholders’ Meeting.
Registered office, legal form and applicable legislation The Company’s registered office is located at Immeuble REIWA, 67 rue Arago, 93400 Saint‑Ouen‑sur‑Seine, France. Ramsay Générale de Santé is a limited liability Company with a Board of Directors (société anonyme à Conseil d’administration). It is specified that the Company’s registered office was transferred to this address with effect from 19 October 2026 by decision of the Board of Directors. This transfer will be submitted to the Company’s General Meeting for ratification. The registered office was formerly located at 39, rue Mstislav Rostropovitch - 75017 Paris. The applicable law is French law.
Company contact details The Company’s offices are located at Immeuble REIWA, 67 rue Arago, 93400 Saint‑Ouen‑sur‑Seine, France with the postal address of all its central services at: 67 rue Arago - CS 90309 - Saint‑Ouen‑sur‑Seine Cedex, France. The switchboard telephone number is: ■ ■
from France: 01 87 86 20 93; from abroad: +33 1 87 86 20 93;
The Company’s website can be accessed at the following address: http://www.ramsaysante.fr, it being specified that the information on this website does not form part of this document.
1.1.2
Introducing Ramsay Santé group
The Company and all its subsidiaries together form the third‑largest private player in healthcare and related services in Europe. As of the date of this document, it operates through 491 healthcare facilities and employs almost 44,000 people, including over 28,000 in France, nearly 14,000 in Sweden,
960 in Norway, around 850 in Denmark, and 220 in Italy. Additionally, over 10,000 practitioners work in these facilities, including 7,700 in mainland France — the largest community of hospital‑based private practitioners in the country (1).
(1)
The headcount mentioned above differs from that presented in section 4.4.1 Human Capital of Ramsay Santé, as the headcount above includes employees with non‑guaranteed hours
6
Ramsay Santé / Universal Registration Document 2026
GENERAL PRESENTATION OF THE GROUP About the issuer
The maps below show the European geographical locations of the Ramsay Santé group as of the date of this document.
1
OUR FACILITIES IN FRANCE & ITALY
11 Lille
5 5 Douai
Arras / Bois-Bernard Le Havre 3
Compiègne
Pierrefonds
2 Soissons
Caen 3 Guipavas
54 19
Alençon Rennes 4
2 Changé
Naveil
4
Orléans
Royan
FRANCE
Gien Chaulgnes
Central
Poitiers La Rochelle
3 Dijon
Chalonsur-Saône 2
121 facilities
Commelle-Vernay La Roche Blanche
4
12 Lyon
Montélimar
ITALY
Pierrelatte
Fronton
6
Toulouse
Montpellier
Aubagne / La Penne-sur-H.
10 4
Marseille
2026, June
3 Annemasse Argonay Omegna
2 Bourg-de-Péage Valence
34 facilities
Dax
Oyonnax
3 Saint-Étienne
South
Bayonne / Biarritz
Louhans
Bourg-en-Bresse Arnas
Niort
Issoire
Capbreton
37 facilities
Île de France – except Paris –
Chambraylès-Tours
Nantes
North
Paris
Saint-Raphaël
Ollioules
100 km
Ramsay Santé / Universal Registration Document 2026
7
1
GENERAL PRESENTATION OF THE GROUP About the issuer
OUR FACILITIES
IN SWEDEN, DENMARK & NORWAY
Umeå Tromsø
4
SWEDEN
Mo i Rana
2 Trondheim Sundsvall
NORWAY
Bergen 3
Oslo Drammen
7
Moss Stavanger
Porsgrunn
Sandnes
Falun
Hamar
Gjøvik
Aurskog
Västra Götaland Northeast
12
Göteborg
Central Jutland
Southern Denmark
13
2026, June
Ramsay Santé operates across the entire healthcare chain: preventive care, primary medicine, Medicine‑Surgery‑Obstetrics (MSO), oncology, medical imaging, medical care and rehabilitation, home hospitalisation, mental health care and addiction treatment, geriatrics, tele‑monitoring and e‑health. The Group contributes to public service missions and regional healthcare provision in all its regions. In particular, it does this by deploying local medical centres in Sweden, France, Norway and Denmark, opening mental health day‑care centres, contributing
8
Ramsay Santé / Universal Registration Document 2026
Borås
Jönköping
Kungsbacka Växjö
5
Helsingborg / Skåne Northwest
DENMARK
3 Örebro
114
Stockholm
Hallsberg Timmersdala Motala Norrköping 2 Linköping 4 Skövde
Varberg 2 Falkenberg Halmstad
6 6
Västerås 2
Vålberg
22
Vallda North Jutland
Uppsala Enköping 2
Kristinehamn Sarpsborg Fjugesta
2 Fredrikstad
Gävle 3
Capital Region
9
5 Zealand
Ronneby
12
5 Skåne Northeast
/ 14 12 Ystad Skåne Southeast Malmö / Lund 100 km
to emergency services, and managing complex medical conditions. Ramsay Santé is present at the European level through brands such as Ramsay Santé, Capio and Volvat. The Group’s critical mass, combined with a blend of medical and business expertise, provides a fertile ground for the exchange of best practices. This enables the company to strengthen its position as a leader in high‑quality integrated care year after year.
GENERAL PRESENTATION OF THE GROUP About the issuer
The following overview shows the care activities in the five countries in which the Group operates:
1
MEDICINE SURGERY OBSTETRICS DIALYSIS
MCR
IMAGING
MENTAL HEALTH
OVERNIGHT STAYS DAYTIME
PRIMARY CARE
GERIATRICS
HOME CARE
TELEMEDICINE E-HEALTH
Ramsay Santé develops a care offer that combines high‑quality, safe care with organisational efficiency and a human touch, and provides comprehensive care with personalised support, taking into account all the patient’s needs and integrating them into a coordinated care pathway. The Group thus contributes to public health services and to the healthcare network in the regions where it operates.
Each year, the Group invests nearly EUR 200 million in innovation and digitalisation, purchasing and upgrading cutting‑edge equipment, and modernising and restructuring facilities. The Group is also innovating its organisational structure and operating methods to deliver more effective care for patients, through advances such as robot integration and the use of Artificial Intelligence.
The Group prioritises the quality and safety of care. As such, it is now a leading provider of modern medicine, particularly with regard to outpatient care and enhanced recovery from surgery. The Group has achieved this by investing in technologies that enable optimised, personalised care pathways for the benefit of patients.
During the 2026 financial year, the Group provided expertise to around 13 million patients, including almost 8 million outside of a hospital stay and over 850,000 via digital solutions. These represented more than 7% of total patient visits.
Ramsay Santé / Universal Registration Document 2026
9
1
GENERAL PRESENTATION OF THE GROUP About the issuer
1.1.3
History: from a French company to a European leader Ramsay Health Care and PREDICA (Crédit Agricole Assurances) acquired Groupe Proclif, laying the foundation for Ramsay Santé
1994
Establishment of Capio through the acquisition of Lundby Hospital in Gothenburg (Sweden)
Merger of Générale de Launch of the Santé with Ramsay strategic plan Santé, creating the new Ramsay Générale de Santé Group €4.0bn €3.7bn €3.4bn €2.2bn
Générale de Santé completed its IPO on Euronext Paris
Creation of Générale de Santé by Compagnie Générale des Eaux
1987
Acquisition of 12 Cosem centers in France, enhancing the primary care platform
1999
2001
2002
2010
2015
2018
2019
2020
Acquisition of Capio, creating a European Healthcare leader
Capio begins operating St. Göran hospital (Stockholm)
2021
Ramsay Santé becomes a Mission company
€4.3bn
€4.7bn
€5.0bn
Launch of the strategic plan
€5.2bn
€5.4bn Revenue evolution1
2022
2023
2024
2025
2026
Acquisition of GHP Speciality Care, expanding Nordic presence
Capio’ expansion into the French market through the acquisition of Clininvest
Source: Company information Notes: Revenue evolution after 2015 presented on the FY basis (YE Jun-30)
1.1.3.1
From its creation to 2018
A NEW CARE OFFER In 1987, whilst at the helm of the Compagnie Générale des Eaux, Guy Dejouany decided to take the Group he led into the health sector and to create Compagnie Générale de Santé. The plan was to provide a health offer to complement that of hospitals, particularly public hospitals, with a focus on rethinking quality of care. Driven by this initiative, the first clusters of clinics were quickly established, and the Group began to expand into the fields of medicine, surgery and obstetrics. Compagnie Générale de Santé expanded its care offer to cover all areas of health, notably psychiatry as well as medical and rehabilitation care; it also developed just as actively in the medico‑social sector and in services dedicated to the hospital sector, such as the upkeep of facilities and their specialist equipment, maintenance and catering. In the early 1990s, the Group increased its acquisitions of leading organisations in their respective fields or those offering complementary services to its existing facilities, in order to capitalise on synergies and expand its local network of care and services. However, the Group did not lose sight of organic growth. An active recruitment policy targeting recognised practitioners enabled it to round out its care offer. La Générale de Santé gradually became a fully‑fledged, structured Group organised around centres of excellence, and the leading player in private hospital care in France.
10
Ramsay Santé / Universal Registration Document 2026
From 1991 onwards, acquisitions also expanded internationally with the purchase of its first clinic in Italy. Also noteworthy was the acquisition of the British company BMI Healthcare, which became General Healthcare Group and was then the second‑largest operator of private clinics in the United Kingdom. This international expansion would take the Group as far as South America. IPO In 1997, Générale de Santé left Générale des Eaux when the latter sold the hospital group to Cinven, a British investment fund present in continental Europe. The British subsidiary General Healthcare group was then sold to BC Partners, while the Group prepared its listing on the Paris Stock Exchange. On 20 June 2001, this IPO was successfully completed: 51% of the share capital was placed with the public, with the Cinven fund retaining 39.5%. The new millennium was also characterised by efforts to promote the Générale de Santé brand and foster a sense of team spirit amongst employees and practitioners. This was accompanied by an ambitious investment programme. At the same time, a review was carried out into the changing landscape of health professions and, in this context, a model for grouping healthcare facilities was devised and then implemented: small local clinics were brought together within a large private hospital offering a wide range of care offers across its catchment area. It was in this way that the major, iconic institutions of the modern private hospital sector were successively established, such as the Hôpital Privé d’Antony and the Hôpital Privé Jean Mermoz in Lyon, and they continue to play a leading role in their respective healthcare regions to this day.
GENERAL PRESENTATION OF THE GROUP About the issuer
In June 2003, the Group experienced a significant milestone in its share capital history with the arrival of Doctor Antonino Ligresti, a doctor and investor. In partnership with the Italian bank Efibanca, he acquired the majority of shares held by Cinven. After disposing of medico‑social activities to refocus on the core healthcare business lines, Générale de Santé once again committed to a proactive policy of external growth. In 2005, the company acquired the Chiche group (four facilities in the Paris region) and subsequently the Fleming Labs group, which comprises diagnostic and medical analysis centres in Italy. The following year, the Hexagone group (comprising 10 hospitals and clinics, primarily in the Paris region) joined the Group, while its hospital services subsidiaries were sold to Elior. A new turning point came in March 2007 with the launch of a simplified takeover bid by Santé Développement Europe, which brought together the concert parties of Santé Holding (Doctor Ligresti), the Italian group De Agostini, and the Italian bank Mediobanca. Following this transaction, a long‑term major shareholder structure was established and began participating in the Group's governance. The Group continued its development strategy and refocused its care offer on medicine, surgery, obstetrics, medical care and rehabilitation. Ten years after its IPO and almost 25 years since its inception, the Group is consistently implementing a strategy tailored to changes in the sector and significant medical and societal challenges. This includes the formation of regional health divisions as part of a strategic plan.
1.1.3.2
A STRENGTHENED POSITION In 2013, the Company entered into an agreement with the Australian group Ramsay Health Care to sell its mental health activities and some of its medical care and rehabilitation facilities. This strengthened Ramsay Health Care's position in France, a few years after it took over eight clinics from the Procliff group with the support of the Crédit Agricole group. On 1 October 2014, Ramsay Health Care (UK) Limited and Prévoyance Dialogue du Crédit Agricole (Predica), shareholders of Ramsay Santé, acquired all shares in Générale de Santé held by Santé SA and Santé Développement Europe SAS. The shareholding of the Group’s new major shareholders represented 83.43% of the share capital. Ramsay Health Care (UK) Limited and Predica then initiated a simplified takeover bid for all of the Group’s shares. Following this, the two major shareholders increased their stake to 85.61% of Générale de Santé’s share capital. An important milestone was reached on 1 July 2015 with the implementation of the announced merger between Générale de Santé and Ramsay Santé. The entities and facilities that were previously grouped under the same parent holding company now carry out their activities within this unique entity, which is now called Ramsay Générale de Santé. The Group is constantly working to optimise its locations and is continuing an acquisition programme for its major divisions. This includes the Hôpital Privé Métropole in Lille, which was completed at the end of 2018 with the purchase of the Croisé Laroche facility, and the Hôpital Privé de l’Est Lyonnais, which was acquired in July 2017. Between 2017 and 2018, the Group also entered the medical transport sector by acquiring the Step group in Lyon in July 2017 and Lambulance in the North in July 2018. This was supplemented in the following months by the acquisition of smaller structures that meet geographical network needs.
Since 2018 and the integration of Capio
CAPIO: A SUCCESSFUL TAKEOVER BID On 13 July 2018, the Company announced a takeover bid for all of Capio AB's shares. Capio AB is one of the European leaders in the provision of health and care services, and is headquartered in Sweden, with additional locations in Germany, Denmark, France and Norway. On 8 November 2018, Ramsay Générale de Santé announced that it would hold 98.51% of Capio AB's share capital, enabling it to establish itself as a leading pan‑European provider of private hospitalisation and primary care. With a strong presence in six countries, including a significant presence in Scandinavia and France, the Group now boasts a variety of unique strengths and offers promising growth opportunities centred on European leadership and a commitment to delivering high‑quality health and care services. Thanks to its balanced portfolio of activities and geographical diversification, the Group operates in major markets with
significant growth drivers. It is recognised for its innovative treatment model, which is characterised by its expertise in care specialisation and the use of modern medicine for the benefit of patients and the community. The Group is also recognised for its expertise and in‑depth knowledge of the digitalisation of healthcare. A EUROPEAN GROUP Following the withdrawal procedure governed by Swedish law, Ramsay Générale de Santé now holds 100% of the share capital of Capio AB, which has been removed from the Stockholm Stock Exchange. The Group has consolidated its strong positions in France and Scandinavia, and is now a major European provider of care services thanks to its extensive network of 491 facilities, including hospitals, primary care centres, specialised facilities, and imaging centres.
Ramsay Santé / Universal Registration Document 2026
11
1
1
GENERAL PRESENTATION OF THE GROUP About the issuer
A COMMON BRAND In line with the Group’s strategy, the Group has communicated under its “Ramsay Santé” brand since the end of 2019. This shorter name facilitates identification among the general public and healthcare professionals. In Sweden, Norway and Denmark, however, the Group will continue to operate under the Capio and Volvat identities, while highlighting its affiliation with the Ramsay Santé brand through the tagline 'Part of Ramsay Santé'. A COHERENT REGIONAL DEVELOPMENT STRATEGY The Group's development strategy is based on strengthening its presence in regions where it can become a leader in the healthcare sector. It is now the market leader in private hospitalisation in its four main operating countries: France, Sweden, Norway and Denmark. Consequently, in 2020, the Group decided to sell its six facilities in Germany. In order to consolidate its position as a leader in the regions where it operates, the Group has made numerous acquisitions in recent years. Significant acquisitions include GHP Specialty Care AB, which operates 25 facilities in Sweden and Denmark, in 2022. This acquisition has considerably strengthened Ramsay Santé's presence in the Nordic countries, enabling it to seize growth opportunities in public contracts and private insurance care. In 2024, the Group took over 12 COSEM primary care centres in France, strengthening its position in this market segment. The Group is continuing to expand and develop by creating new structures in all its strategic areas. During the last financial year, eight new psychiatric day‑care centres opened across France, in Orléans, Montreuil, Niort, Laval, Compiègne, Soissons, Roost‑Warendin and Rennes. In France, the Group is committed to improving access to care for all, even in challenging circumstances. Only a third of patient cases incur additional fees. No excess fees are applied to public service missions, such as emergency care, oncology and dialysis, and our practitioners working in mental health and MCR activities do not charge additional fees. Furthermore, all of our activities in outpatient medical centres are carried out under agreed sector 1 tariffs. Additionally, 60% of our facilities are located in sparsely populated areas. Of the 149 MSO, MCR, and mental health facilities and primary care centres in France, 39 are located in priority intervention areas. TAKEOVER OF 12 COSEM PRIMARY CARE CENTRES IN FRANCE (2024) In June 2024, the Group took over the 12 existing COSEM primary care centres in Paris and other major French cities. These centres handle nearly one million patient consultations
12
Ramsay Santé / Universal Registration Document 2026
per year in general and specialised medicine, dental care, imaging, and biomedical analysis. Ramsay Santé is committed to ensuring the long‑term viability of these facilities across all specialities and has retained all caregivers, including over 1,100 professionals and 660 doctors. This acquisition has strengthened Ramsay Santé's primary care offer, aligning with its strategic objective of covering the entire patient journey, from prevention to functional care, while creating synergies with its hospitals. TESTING NEW BUSINESS MODELS In line with its strategy, Ramsay Santé is trialling new organisational and financing methods for the French healthcare system. These methods are inspired by the Scandinavian care centre model, which is based on a flat‑rate payment system. In this context, we have opened five medical centres since September 2021, located in Pierrelatte, Bourg‑de‑Péage, Oyonnax, Argenteuil and Ris‑Orangis. These initiatives were implemented under Article 51 of the French Social Security Financing law, which allows for exceptional trials. The Ramsay Santé medical centres aim to reduce economic barriers to accessing care for patients and promote a high‑quality care offer in areas lacking specific types of medical care. A final evaluation will be conducted following this trial scheme to make recommendations. Through this trial, Ramsay Santé hopes to improve geographical and economic access to non‑hospital care professionals in under‑resourced regions in the short term, and to further develop a new economic model. MISSION COMPANY In 2020, Ramsay Santé defined the pillars of its new strategy, Yes We Care 2025, and officially incorporated the Group's purpose into its bylaws on 11 December: 'Improving health by constant innovation'. This purpose demonstrates Ramsay Santé’s commitment to making a lasting and positive impact on the healthcare sector by providing innovative solutions. As an extension of this commitment, at the end of 2022, the Group chose to become a Mission company by including four social and environmental objectives in its legal bylaws: promote access to healthcare for all; develop medical innovation to provide the best possible care; systematise dialogue with our stakeholders; and protect the planet to improve health. These objectives now guide the Company's decision‑making processes. Through them, Ramsay Santé prioritises the public interest in its daily operations, positioning its development within a framework that strengthens its responsibility towards all stakeholders: patients, employees, practitioners, the planet, and society.
GENERAL PRESENTATION OF THE GROUP A closer look at major countries and markets
1.2
A closer look at major countries and markets ■
The health sector is undergoing major changes and is facing new technological and societal challenges
■
The healthcare sector is undergoing several changes that impact all its stakeholders, including patients and their companions, the medical community, social bodies, governments and market players, and these changes present many challenges: ■
■
■ ■
an ageing population: the proportion of older people is growing (around 21% of the Swedish population was aged 65 or over in 2025 (1), and 22.2% of the French population was aged 60 or over in early 2026 (2)). The health needs of this population are changing in terms of both nature (an increase in multiple pathologies) and quantity (an increase in the needs of a more fragile population); the prevalence of chronic diseases: the latter are increasing due to an ageing population, environmental factors and lifestyle choices. This leads to a greater need for constant care throughout people's lives; the increase in health inequalities socio‑economic and geographical factors;
linked
to
therapeutic innovation and progress require continuous monitoring and training of medical staff as well as increased financing, in order to provide patients with the best possible care. As a result: ■
the conditions of the medical care are changing due to the accelerating pace of therapeutic and technological innovation and the growing use of data,
■
the care pathways, which are increasingly provided outside hospitals, require a review of organisations and practices,
■
new players are also entering the market;
the medical and paramedical professions remain unattractive and healthcare players are facing difficulties in terms of recruitment; patients are increasingly adopting a consumerist attitude towards health. This requires adjustments to resources and approaches, particularly to meet the need for greater visibility and autonomy.
A constrained and demanding regulatory environment ■
■ ■
■
■
The practice of medicine is subject to systems covering certification, authorisation and oversight, aimed at guaranteeing the safety and quality of care for all; Medical expertise is essential in order to meet patients' needs and provide effective, minimally invasive responses; Medical practice requires a network of health and care professionals to meet a variety of needs in terms of location, pathology and treatment modality; Significant and recurring investments are required for care techniques and innovation in healthcare in order to maintain existing facilities, enable new types of care and contribute to clinical research; Public authorities are key stakeholders, and the health sector relies heavily on public policies for development and financing.
1.2.1
The healthcare market in France
1.2.1.1
Presentation of the French health and medico‑social system
Note: the figures contained in this section are provided for general information purposes from sources available at the date of this document. They are likely to vary from one year to another. The French health system lies at the heart of the country’s economic life. In 2024 (the latest year available as of the date of this document), France’s current international healthcare expenditure (dépense courante de santé au sens international – DCSi) amounted to EUR 333 billion, or 11.4% of its gross
(1)
1
domestic product (GDP). This figure had peaked at 12.3% in 2021. DCSi growth was among the lowest in the European Union in 2024, at +3.6%, compared to +3.4% in 2023. Nevertheless, this growth rate is faster than that observed before the health crisis (+1.9% on average per year between 2013 and 2019). This aggregate, which is used for international comparisons, places France in fourth place among OECD countries, behind the United States, Germany, and Austria.
World Bank Group
(2) Insee, Population by sex and age group, 2026 annual data
Ramsay Santé / Universal Registration Document 2026
13
1
GENERAL PRESENTATION OF THE GROUP A closer look at major countries and markets
Hospital care is the largest component of healthcare spending at a total amount of EUR 121 billion in 2024, up 7.1% compared to 2023 (and +5.8% on average per year between 2020 and 2022), of which EUR 93.7 billion for the public sector and EUR 27.1 billion for the private sector. Hospital care remains the leading growth factor in Medical Care and Goods Consumption in terms of value in 2024. In MSO, public hospital activity has returned to its 2019 level, while the private sector has experienced steadier growth, driven more by volumes than by prices. Health insurance ('Assurance Maladie') is the main source of financing for health expenses, covering 79.4% of expenditure in 2024. Supplementary bodies financed 12.8%, while households paid just 7.8%, one of the lowest rates in the OECD. The health crisis has had a lasting impact on the Company financial statements. After a historic deficit of EUR 39.7 billion in 2020, the 2025 financial year resulted in a deficit of EUR 21.6 billion for the general scheme and the Old‑Age Solidarity Fund. While forecasts for 2026 point to a reduced deficit of €19.4 billion, the outlook remains worrying given the trajectory of the 2026 Social Security Financing law and its fragile assumptions for 2026. Multi‑year projections indicate that the deficit will rise again in subsequent years, reaching EUR 23.7 billion in 2029. Therefore, controlling the development of healthcare spending without reducing the quality of care or exacerbating social inequalities is a major challenge. France remains one of the countries with the highest level of public expenditure relative to national wealth. The Covid crisis and inflation have reinforced this trend, contributing to an increase in public debt and raising questions about its long‑term sustainability. However, the ageing population and the rise in chronic diseases are set to continue, putting increasing pressure on healthcare spending.
(1)
14
Overview of healthcare facilities, 2026 Ed, DREES.
Ramsay Santé / Universal Registration Document 2026
Place of private facilities in the French hospital sector According to DREES data (1), the French hospital landscape at the end of 2024 consisted of 2,962 hospital facilities, including 1,330 public hospitals, 977 private for‑profit facilities (private facilities) and 655 private non‑profit facilities. Between 2013 and 2024, the hospital sector lost 159 entities (-5.1%), with the decline mainly affecting public hospitals. The number of private facilities decreased more moderately (-4.1%), as did the private non‑profit sector (-4.0%). Inpatient capacity followed a similar pattern: the number of inpatient beds stood at 367,100 at the end of 2024, which was 45,700 fewer than in 2013. Meanwhile, the number of outpatient places increased by 23,200 to reach 91,100. This reflects the 'outpatient shift': the steady reduction in inpatient beds has been accompanied by a significant rise in day hospitalisation. The private sector plays a decisive role in reorganising the offer: ■
■
private facilities (33% of the total) are particularly prevalent in the short- and medium‑stay markets, accounting for 39% and 44% of outpatient spaces respectively. This underlines their leading role in developing outpatient care, particularly surgery. the French hospital system is characterised by the principle of patients being free to choose between the Public and Private Hospital Sectors.
Changes in the capacity of the French hospital sector are closely regulated by the state, which determines population needs and organises the distribution of public and private medical facilities.
GENERAL PRESENTATION OF THE GROUP A closer look at major countries and markets
1.2.1.2
Regulatory and legislative environment in France
Hospital planning – The authorisation system Hospital law 31/12/1970
■ Creation of the health map: 1st planning tool, aimed at
regulating the hospital supply by setting indices of needs expressed in beds per inhabitant
Law of 31/07/1991
■ The region becomes the scope within which the health
system is organised
■ Creation of regional health organisation schemes
(SROS): 2nd planning tool, which distributes facilities geographically
Order of 24/02/1996
■ Regionalisation of the financing and activity of facilities ■ Creation of Regional Hospitalisation Agencies (ARH)
■ Creation of multi-year agreements on targets and
resources (CPOMs): concluded between the ARHs and the facilities setting the strategic orientations resulting from the objectives of the SROS
Order of 04/09/2003
■ Abolition of the health map
■ Creation of the Healthcare territories
■ Simplification of the authorisation system. The SROS
becomes the sole planning tool
“HPST” law of 21/07/2009
■ More comprehensive approach to hospital planning
taking into account all healthcare players
■ Creation of the ARS and extension of their intervention:
hospital, non-hospital care, medico-social
■ Implementation of the ARS strategy within the regional
health programme (RHP), including the regional health plan (SRS) (formerly SROS) extended to outpatient care
Law of 26/01/2016
■ Creation of regional hospital groups (GHTs): mandatory
cooperation between public facilities at regional level
■ Reaffirmation of the SPH ■ Redesign of the RHP
Order of 03/01/2018 and decree of 09/02/2018
■ Strengthening of the link between health authorisation
and quality
■ Simplification of administrative procedures
■ Extension of the term of authorisations to seven years ■ Reform of compliance visits
“OTSS” law of 24/07/2019 and order of 12 May 2021 ■ Strengthens quality of care requirements ■ Promotes
the development of alternatives to hospitalisation ■ Simplifies authorisation procedures ■ Extends the healthcare activity and EML authorisations in force until the issuance of new reformed authorisations
“Ratios Law” of 29 January 2025, which entered into force in 2027 ■ Institutes a minimum ratio of carers per bed or per
number of outpatient visits for each specialty and each type of care activity, taking into account the burden of associated care ■ These ratios must be established by decree after consultation with the HAS for a maximum period of five years
In France, health planning was initially national and intended to ensure the efficiency of the healthcare system and make care accessible to everyone by reducing inequalities and geographical disparities in health as much as possible. However, it has gradually been decentralised in a context of budgetary constraints. A comprehensive review of the healthcare system began in the 1970s. Taking into account the need to rationalise healthcare expenditure and limit competition between healthcare facilities, the aim was to make them more complementary and organised in order to respond fairly to the needs of the population. Regulation was therefore put in place for the provision of care. In practice, however, health planning was reduced to determining the number of beds and equipment within a health map drawn up at a national level according to the number of inhabitants. It was not until the 31 July 1991 law that the regional level became the reference point for healthcare. A new health planning instrument was set up: the Regional Health Organisation Scheme (SROS), which would later become the Regional Health Scheme (SRS). This scheme specifies how the health map should be organised based on the actual needs of the population, and defines the guidelines and organisation of the hospital offer. However, at this stage, the focus was more on the regionalisation of state action than on actual decentralisation. The order of 24 April 1996 then entrusted the Regional Hospitalisation Agencies (ARH) (Public Interest Group (GIP) comprising State and health insurance organisation representatives at a local level) with the mission previously granted to the prefect for planning regional hospital care policy. The regional health organisation scheme is approved by the ARH director for a period of five years, after consulting the regional health organisation committee, which brings together representatives of local authorities, medical and non‑medical professionals, and public and private healthcare facilities. The ARH regulates this offer by (i) issuing activity authorisations (ii) allocating heavy equipment, and lastly (iii) signing multi‑year agreements on targets and resources with healthcare facilities. This reform unified the regime applied to public and private non‑profit facilities and profit‑making private facilities. Previously, the former were subject to the state's budgetary supervision, while the latter depended on regional health insurance funds with which they had signed agreements. Notification of activity authorisation is equivalent to operating authorisation, provided that a declaration of commencement of activity is made and a compliance visit is carried out no later than six months after the start of the activity, with a positive result. Three generations of regional health organisation schemes (SROS) have succeeded each other, contributing to the regionalisation of the care offer: ■
SROS 1 (1991–1999) focused on establishing hospitals in areas with a population of 200,000;
Ramsay Santé / Universal Registration Document 2026
15
1
1
GENERAL PRESENTATION OF THE GROUP A closer look at major countries and markets
■
■
SROS 2 (1999–2004) sought to reconcile quality, proximity and costs by relying on a three‑tier regional organisation: region, living areas and health sectors; SROS 3 (2006–2011) saw the concept of health sectors replaced by health territories. Within the regions, these territories aimed to ensure a better match between the care offer and the needs of the local population through consultation between elected officials and users.
SROS 3, alongside other reforms such as activity payment rates, the 2007 Hospital Plan and the 2007 General Review of Public Policies, aimed to simplify hospital planning and develop preventive, curative and palliative care offers. It was also within the framework of SROS 3 that the health territories and quantified care targets were defined by the Regional Hospitalisation Agencies themselves, based on an analysis of the territory's needs. The SROS became the sole planning tool when the health map was abolished by the 'Hospital Plan 2007' order on 4 September 2003.
At the same time, the desire to guarantee a certain standard of care offer was developed through: ■ ■
■
an internal assessment by the facilities of their professional practices and their methods of organising care (see below); independent certification of the mandatory assessment of the level of quality and safety of care in healthcare facilities (both public and private), carried out every four years by health professionals (known as “expert‑visitors”) appointed first by the National Agency for Accreditation and Evaluation in Health (ANAES), and, from 2004, by the French National Authority for Health (HAS) (see below); the implementation of a Contract for Improving the Quality and Efficiency of Care (CAQES) under the 2016 French Social Security Financing law. This contract brings together the ARS, the local health insurance body and healthcare facilities, with the aim of improving practices, regulating the care offer and making health insurance spending more efficient.
No single method was used in the analysis of existing and future prospects or in selecting the objectives to prepare the SROS. Each region adopted its own approach, taking into account its geographical and demographic characteristics, the state of the care offer, and the human resources available to it. Above all, the approach taken depended on the way in which consultation between the stakeholders was conducted.
The legal regime for health authorisations has integrated this qualitative dimension. As a result:
Subsequently, the HPST law, passed on 21 July 2009, introduced widespread reform with four key objectives. (i) modernising healthcare facilities; (ii) improving access to quality care; (iii) focusing on prevention and public health, and treating patients as active participants in their own health; and (iv) simplifying and clarifying the regional organisation of the health system. This was achieved in particular through the establishment of ARS, which replaced several organisations (ARH, DRASS, DASS, URCAM, CRAM and GRSP). The powers of the ARS were extended beyond those of the ARH, particularly with regard to non‑hospital care, the medico‑social offer, the organisation of health monitoring (regional health observatories), and the response to health emergencies.
■
The objective was to ensure better coordination of healthcare facility actions to meet population needs, distribute care more evenly across the region and develop prevention and public health policies. The ARS therefore discontinued the SROS, which set the objectives of the care offer by care activities and equipment in each region according to the needs of the population and the imperatives related to the requirements of geographical efficiency and accessibility. Multi‑year agreements on targets and resources (CPOMs) were then drawn up between the ARS and each healthcare facility, setting out accessibility and activity volume objectives for each establishment. Activity constraints were subsequently removed by Decree No. 2012‑192 of 7 February 2012. The quantified objectives of the care offer were then expressed in terms of the number of healthcare activities.
16
Ramsay Santé / Universal Registration Document 2026
■
■
many of the implementation conditions or technical operating conditions (as set out in the Public Health Code and required to obtain authorisation for healthcare activities) refer directly to it, unless they are provisions of regional health projects themselves; since 1991, the renewal of authorisations has required the preparation of an assessment file for the activity in question, which takes into account the quality of care through patient assessment questionnaires; certain healthcare activities require the achievement of certain thresholds, set by ministerial decree; below these thresholds, the activity can no longer continue.
As the body responsible for health planning and for regulating care offers, the ARS plays a major role in hospital restructuring policy. This is particularly the case when cooperation or even mergers between healthcare facilities are necessary in order to adapt provision, preserve the quality of care, solve problems in recruiting doctors by sharing medical time, and optimise imaging equipment and technical platforms. To implement this policy, the ARS has many tools at its disposal, including incentives such as multi‑year agreements on targets and resources, and assistance with contractualisation, as well as coercive measures such as withdrawal of authorisations and imposition of mergers or cooperation. In recent years, the legal system for health authorisations has been reviewed to align with the public authorities' aim of reorganising the health system: ■
the 26 January 2016 law on modernising our health system resulted in Order No. 2018‑4 of 3 January 2018 and Decree No. 2018‑117 of 8 February 2018, both of which relate to simplifying and modernising the authorisation systems for healthcare activities and heavy equipment.
GENERAL PRESENTATION OF THE GROUP A closer look at major countries and markets
On the one hand, the link between health authorisation and quality of care is strengthened when (i) authorisation is granted based on the elements of certification reports issued by the HAS, and (ii) authorisation is refused if the project has quality or safety defects. Currently, health authorisations are only granted and maintained for specific activities if three conditions are met cumulatively: ■
■
■
the applicant's project must (i) meet the health needs of the population identified by the SRS; (ii) be compatible with the quantified objectives of the care offer set by this scheme; (iii) and satisfy the location and technical operating conditions; the authorisation is also linked to the fulfilment of commitments relating to: (i) expenses payable by health insurance or the volume of activity; and (ii) a positive assessment result verifying the compatibility of healthcare activity results or major equipment use with the SRS's objectives and the CPOM's commitments; finally, authorisation may be subject to: (i) special conditions imposed in the interest of public health; (ii) participation in one or more of the public service missions listed by law; (iii) a commitment to implementing cooperative measures to promote the shared use of resources and continuity of care.
On the other hand, the simplification of administrative procedures involved (i) the option to submit authorisation requests electronically, (ii) the requirement to send the initial renewal request relating to the applicant's identity to the ARS only if the applicant's situation changes, (iii) authorisations being extended by five to seven years, and (iv) the inspection visit by the ARS for care provision authorised by the supervisory authority becoming non‑mandatory. ■
The law of 24 July 2019 on the organisation and transformation of the healthcare system resulted in the publication of three Orders: Order No. 2021‑583 of 12 May 2021 amending the regime for authorisations relating to healthcare activity and major items of equipment; Order No. 2021‑584 of 12 May 2021 on regional professional healthcare communities and nursing homes; and Order No. 2021‑582 of 12 May 2021 on labelling, governance and the operation of local hospitals.
The objective is, in particular, to consider quality requirements and technical care conditions when authorising various activities. In light of the observation that the regulations relating to each activity varied greatly (with certain activities being poorly regulated in the absence of conditions for setting up and/or technical operating conditions, despite being high‑risk, such as surgery excluding cardiac and neurosurgery, and intervention activities), working groups were set up. These groups brought together representatives of national professional boards, federations, ARS, expert agencies, and the Ministry of Solidarity
and Health. The work of these groups has resulted in the publication of decrees reforming the conditions for setting up and technical operating conditions for various authorised activities. The objective is also to improve the organisation of the regional distribution of the care offer using a grading system and by developing alternatives to hospitalisation. In order to identify 'expert centres', three levels need to be redefined, with each facility focusing on the most relevant care for its level: (i) local care involving medicine, geriatrics, rehabilitation and unscheduled care; (ii) specialised care involving surgery, maternity and specialised medicine; and (iii) ultra‑specialised care involving state‑of‑the‑art technical platforms. The reform aimed to extend the scope of healthcare activities requiring authorisation. For instance, home hospitalisation, previously categorised as a type of hospitalisation, has been recognised as a distinct care activity since 1 June 2023, necessitating the submission of an authorisation request to the ARS. Similarly, nuclear medicine is now a healthcare activity in its own right, whereas previously it was a medical imaging activity requiring a heavy equipment authorisation. Lastly, the reform aimed to streamline the processes and criteria for granting authorisations for healthcare activities. For instance, renewing a health authorisation will no longer require the submission of a file; instead, it will take the form of a simple request, unless the ARS orders otherwise. In accordance with the provisions of Order No. 2021‑583 of 12 May 2021, the ARS had a period until 1 November 2023 to publish the new SRS. In this context, each ARS published a new SRS for its region during October 2023. Order No. 2021‑583 of 12 May 2021 extended all authorisations relating to healthcare activities and major items of equipment until a new decision was made based on the revised SRS. Applications for healthcare activities and EML (major items of equipment) must be submitted when the first application window opens. This reopens competition for the allocation of healthcare and EML activity authorisations. In accordance with law No. 2023‑1268 of 27 December 2023, also known as the 'Valletoux' law, which aims to 'improve access to care through the regional commitment of professionals', and its first implementing decree No. 2024‑268 of 25 March 2024, certain healthcare activities will be subject to a traditional renewal process consisting of filing a 'simplified' renewal application, despite having been reformed. The following healthcare activities are affected: ■ ■
■
medicine; rehabilitation medical care for the following: musculoskeletal disorders, nervous system disorders, cardiovascular disorders, respiratory disorders, burns disorders, disorders related to addictive behaviour; cardiac surgery;
Ramsay Santé / Universal Registration Document 2026
17
1
1
GENERAL PRESENTATION OF THE GROUP A closer look at major countries and markets
■ ■ ■ ■
neurosurgery; interventional activities neuroradiology;
by
endovascular
route
in
clinical and biological activities in medically assisted reproduction; cancer treatment for external radiotherapy and brachytherapy.
Since the beginning of 2024, the ARS have opened various deadlines for submitting authorisation requests, in accordance with their own schedules. This allows all healthcare facilities to submit their applications for authorisation, care activity and major items of equipment, in accordance with the terms resulting from the reform of healthcare activities. These initiatives have continued throughout 2024 and 2025, and are ongoing in 2026. Ultimately, they will lead to a review of the majority of activities carried out within healthcare facilities.
Quality and risk management approach, certification system Since the beginning of 1997, the primary objective of the ARS has been to ensure consistency and compliance with the assessment and certification policy for healthcare facilities. ASSESSMENT OF FACILITIES All healthcare facilities are required to develop a policy for evaluating their professional practices and their methods of organising care. The aim is to ensure health and safety, the quality of the patient care offer and the effective regulation of the latter. To carry out such an analysis, each facility must implement medical information systems that take into account pathologies and methods of patient admission. These systems must be implemented in accordance with medical confidentiality and patient rights, and must be capable of preparing a summary of medical data and processing it by computer. In addition, each facility must summarise and computerise the data contained in its patients' medical records. To this end, practitioners at the hospital must provide the doctor responsible for medical information with the necessary medical data for monitoring and analysing the facility's activity. The facility manager must send non‑identifiable statistics relating to the
18
Ramsay Santé / Universal Registration Document 2026
facility's activity and operating resources to the departments of the ministries of health, health insurance organisations and ARS, using appropriate coding of patient care. Transmitting this information contributes to the development and revision of regional health plans, as well as the assessment of care quality. It also serves as a tool for measuring each facility's activity. This analysis tool enables comparisons to be made between facilities and optimises the care offer. CERTIFICATION OF FACILITIES BY THE FRENCH NATIONAL AUTHORITY FOR HEALTH (“HAS”) All healthcare facilities, whether public or private, undergo an external assessment procedure known as certification. Conducted by the French National Authority for Health (HAS), this procedure provides an independent evaluation of the facility's quality using indicators, criteria, and guidelines related to procedures, best clinical practices, and the outcomes of its various services and activities. The assessment also takes into account the measures taken by the facility to ensure respect for the rights of patients and users, as well as the results of patient satisfaction and experience assessments. In March 2020, amid the Covid‑19 health crisis, the HAS suspended certification visits according to the V2014 standard. This was subsequently replaced by a new certification procedure for healthcare facilities focusing on quality of care, which was gradually rolled out beginning in April 2021 in accordance with successive versions of the framework (V2021 and subsequent updates). Version V2025 has been in force since September 2025. The results of the quality of care certification are based on four levels: High quality of care (certified with distinction), Quality of care confirmed (certified), Quality of care to be confirmed (certified under certain conditions), and Insufficient quality of care (not certified). As of 30 June 2026, 106 Ramsay Santé group facilities had applied for and received their results for the new quality of care certification. To date, 98% of our facilities are certified. 33% of our facilities have been awarded the highest level of certification, 'High Quality of Care', and 58% have been awarded 'Quality of Care Confirmed'.
GENERAL PRESENTATION OF THE GROUP A closer look at major countries and markets
CERTIFICATION RESULTS FOR RAMSAY SANTÉ FACILITIES (FIGURES AS OF 30 JUNE 2026)
Regulation of care expenditure and hospital pricing To regulate health expenditure, French Social Security Financing law sets an annual national health insurance expenditure target (ONDAM), which is intended to finance health expenditure covered by insurance. From 2006 to 2016, the ONDAM was divided into two hospital sub‑targets according to the type of expenditure of healthcare facilities: T2A expenditure and other healthcare facility expenditure. Since 2017, these two sub‑targets have been merged into a single sub‑target, 'ONDAM healthcare facilities', to improve clarity and monitoring of hospital expenditure. This new sub‑target comprises several budgets: ■
■
■
the ODMCO (national target for expenditure on medicine, surgery, obstetrics and odontology), which covers all health insurance expenses corresponding to the MSO tariff bracket. This includes home hospitalisation, annual flat‑rate payments, and expenditure on drugs and medical devices; allocations to finance general interest missions and internal contracting assistance (MIGAC), which are intended to finance activities that cannot be converted into individual healthcare services with an applicable price. Examples of such activities include research and teaching; the ODSSR (national target for functional care and rehabilitation expenditure), which covers all expenses of these facilities, particularly the annual funding allocation (DAF), the price‑per‑day and the modulated allocation by activity (dotation modulée à l’activité – “DMA”);
■
■
■
1
the ODAM (health insurance expenditure target), which aggregates the expenditure of MSOs and mental health facilities under the annual funding allocation, as well as that of long‑term care units (USLD); the OQN (national quantified target), which includes the expenditure of private mental health facilities financed on a price‑per‑day basis; the Fund for the Modernisation of Public and Private Healthcare Facilities (Fonds de modernisation des établissements de santé publics et privés – “FMESPP”), which in 2021 became the Modernisation Fund for Investment in Health (Fonds de modernisation pour l’investissement en santé – “FMIS”), which contributes to the financing of hospital investment.
Since the 2004 French Social Security Financing law, the financing methods for healthcare facilities have been determined by their legal status and the disciplines practised. For medicine‑surgery‑obstetrics (MSO) activities, the financing model primarily uses activity‑based payment rates (T2A). This was introduced in 2004 for public and private non‑profit facilities that were previously funded by a global endowment ('former CEO facilities'), and in 2005 for private facilities ('former OQN') that were previously remunerated on a price‑per‑day basis and technical flat rates. T2A remuneration covers the care activities carried out in these disciplines, regardless of the type of stay (inpatient beds, outpatient services or home hospitalisation) or the facility's status. Historically, medical care and rehabilitation (MCR) units, mental health units and long‑term care units (USLD) have been funded through an annual funding allocation (DAF) for public and private non‑profit facilities, or on a per‑day basis for private for‑profit facilities (or private non‑profit facilities that have opted for this method of funding).
Ramsay Santé / Universal Registration Document 2026
19
1
GENERAL PRESENTATION OF THE GROUP A closer look at major countries and markets
Financing methods for healthcare facilities have undergone several changes in recent years and continue to evolve, particularly as part of the Health System Transformation Strategy (Stratégie de transformation du système de santé – STSS), which was launched by the government in February 2018. In this context, a specific project was carried out on reforming the health system's financing. In 2020, these measures were reviewed and supplemented, particularly as part of the 'Ségur de la Santé' initiative in July 2020. The aim was to move towards the target of 50% of facilities' resources being established outside of activity payment rates. In 2022, the key elements of the pricing campaign also include a salary revaluation linked to the Ségur de la Santé, with an increase of 1.8% in resources, but only an increase of 0.01% in prices, as regards MSO (1). The financing method adaptations in the MSO sector are essentially aimed at reducing the proportion of funding allocated to facility activities and better meeting patient needs. Since 1 October 2019, a 'chronic pathologies' flat‑rate payment has also been introduced for the care offer provided by healthcare facilities (MSOs) to patients with chronic stage 4 and 5 kidney disease (CKD). The objective of this flat‑rate financing is to promote the establishment of multi‑professional patient monitoring teams by ensuring the financing of paramedical and socio‑educational staff, and to develop care throughout the year along a patient pathway. This will promote prevention and limit complications related to the condition. Since 1 January 2022, the new funding model for emergency structures and SMURs has been in force. This model includes three components: population allocation, a provision for the quality of the care offer and activity‑based funding. Furthermore, a change to the funding arrangements has been introduced into general law to include remote monitoring, which is likely to become more widespread across many care pathways, with a wide range of potential applications. Article 78 of the 2016 French Law on the Financing of Social Security (LFSS) introduced a new funding model for medical care and rehabilitation activities (MCR). The initial objective of this reform is to address the negative effects of the historical financing model for these activities, which differ according to the OQN and DAF sectors. This has historically resulted in significant disparities in the allocation of budgetary resources between regions and facilities. The target model, which applies to both the public and private sectors, is based on modulated activity‑based financing (DMA), which comprises a 'base' component and an 'activity' component, both of which are based on a description of MCR activity. Implementation of the new financing model began on 1 March 2017, with a transition period during which MCR facilities combined old and new financing methods. However, the target model proved difficult to implement and was likely to hinder organisational transformation and the development of
(1)
20
specialised care in response to population needs. As part of the LFSS for 2020, the funding model was overhauled. It now comprises mixed methods, including an activity‑based part valued on the basis of national prices, a quality component, and a flat‑rate part including a population‑based allocation. The aim is to support the transformation of the market for the provision of the MCR care offer, particularly to promote the development of outpatient care. The implementation of these funding arrangements was postponed to 1 July 2023. Reform of the funding of mental health activities is also underway. As with the MCR, the initial objective of this reform is to address the negative effects of historical funding methods for these activities. These methods differ depending on whether the activities fall under the OQN or DAF sectors, leading to significant inequalities in the allocation of mental health resources between sectors and regions. The overhaul of mental health funding introduced by Article 34 of the LFSS for 2020 therefore unifies the DAF and OQN sectors within a single funding model. The new funding model introduces a population‑based allocation, taking into account the population size, available medical resources, and regional deprivation. Alongside the population allocation, additional allocations will be introduced to account for hospital and non‑hospital activity and the specific missions of the facilities. This new funding model came into effect on 1 January 2022. All mental health facilities are mainly funded on the basis of an allocation calculated according to active files and population size. However, the weight of each compartment in the funding of facilities differs between sectors under DAF and OQN. The model is not yet fully stabilised and adjustments are expected. Lastly, the quality of financing has increased significantly in recent years and is set to increase further. To better reflect the quality of care provided by healthcare facilities, Article 51 of the LFSS for 2015 introduced a quality and safety dimension to T2A. In 2016, a financial incentive for quality improvement (incitation financière à l’amélioration de la qualité – IFAQ) was introduced. Initially implemented on an experimental basis in 2014, this approach was expanded in 2016 to encompass all facilities in the MSO sector, as well as home hospitalisation facilities (HAD). It was further extended in 2017 to include MCR facilities. This model positions the quality of the patient care offer as a criterion for allocating budgetary resources to healthcare facilities. The IFAQ system has recently expanded. While initially subject to a budget of EUR 50 million in 2018, this figure has gradually increased to EUR 200 million in 2019, EUR 400 million in 2020, and EUR 450 million in 2021, reaching EUR 700 million in 2022. The target is to exceed EUR 1 billion in the coming years. For the first time in 2022, mental health facilities are included in the scope of the IFAQ system. This major change in scale means that quality financing has become a pricing category in its own right for healthcare facilities, with a significant budget.
fhpmco.fr/5‑mn‑pour‑comprendre‑la‑camapgne‑tarifaire‑2022‑n°16‑juin‑2022
Ramsay Santé / Universal Registration Document 2026
GENERAL PRESENTATION OF THE GROUP A closer look at major countries and markets
1.2.2
A closer look at the Nordics (Sweden, Norway and Denmark)
1.2.2.1
A closer look at the Nordics
The healthcare system in the Nordic countries is dominated by the public sector. It is characterised by its “semi‑decentralised” nature and the empowerment of local players. In the Nordic countries, healthcare provision involves stakeholders at local, regional and national levels, reflecting a tiered system of care. Local operators play a significant role in the organisation, management and financing of the healthcare system through local taxation, which funds public and private health services contracted by the local authority. All healthcare providers must register their activities or obtain a licence from an authority to practise. In the wake of the economic recessions of the 1990s, governments had to balance their obligation to provide high‑quality care with policies aimed at improving efficiency and responsiveness. Reforms based on the concept of ‘new public management’ were implemented, reducing the number of regions and local authorities, alongside health prevention policies (in schools, in the workplace, through town and country planning policies, etc.).
1.2.2.2
In recent years, the central government has tightened its control over healthcare spending. This has resulted in a maximum annual contribution being introduced for policyholders, as well as a reduction in the number of beds and the length of stays. Additionally, due to ongoing challenges in accessing and improving the efficiency of care in public facilities, all the Nordic countries are privatising certain health services. The majority of practitioners in the Nordic countries are salaried employees. Even though they work on private contracts (often part‑time), as in Norway for example, they are contracted and paid by public health services, whether regional or local. In recent years, the Nordic countries have adopted mixed payment models (salary, capitation and fee‑for‑service) to introduce patient choice, encourage high‑quality care from doctors and reduce waiting lists.
The healthcare system in Sweden
PRESENTATION OF THE SWEDISH HEALTH AND MEDICO‑SOCIAL SYSTEM Sweden spent between 10.9% and 11.3% of GDP on healthcare expenses between 2020 and 20241, a level similar to the 2015 to 2019 period. In 2024 (1), this expenditure amounted to SEK 719 billion (2), of which 86% was financed by public expenditure and around 7% by private insurance. Health expenditure is therefore mainly financed by taxes. The Swedish healthcare system is relatively advanced in terms of so‑called modern medicine (acute care, share of outpatient care, measurement of the quality of care, use of digital). The main difficulties relate to productivity, accessibility and the coordination of the care pathway as a whole. The Ministry of Health and Social Affairs and the bodies attached to it (notably the National Board of Health and Social Welfare) strive to achieve the healthcare targets set by the Parliament by monitoring and evaluating the health services provided. They also issue the necessary approvals to healthcare professionals and keep registers of healthcare providers and health data. The regions and municipalities are responsible for ensuring that everyone in the country has access to quality care. The 21
(1)
1
regions are responsible for financing and organising care, while the 290 municipalities are responsible for supporting the elderly and people with disabilities at a local level. The freedom of the regions to organise health services may result in variations in the provision of such services, as well as in the costs patients bear (up to an annual ceiling), depending on where they live. Thus, access to primary care is primarily provided by local health centres, which are governed by the regions. These centres include general practitioners, nurses — who have extensive medical responsibilities and are often the first point of contact for patients within the healthcare system — and paramedical staff. Regional and university hospitals are responsible for providing specialised and highly specialised care, which requires state‑of‑the‑art technology. Once hospital care has ended, responsibility for patients is transferred back to the municipality for functional rehabilitation. Care plans in this context aim to facilitate the coordination of patient services, improve collaboration between municipalities and regions, and develop more integrated services, particularly for the elderly.
OECD economic studies.
(2) SCB Statistics Sweden.
Ramsay Santé / Universal Registration Document 2026
21
1
GENERAL PRESENTATION OF THE GROUP A closer look at major countries and markets
The majority of practitioners in Sweden are employed by local health centres and regional hospitals. Wages and employment conditions are negotiated by the local authority federations on behalf of employers, and by the associations that represent health professionals. THE ROLE OF PRIVATE OPERATORS IN SWEDEN While the role of private operators in Sweden has historically been minimal, due particularly to the regions' monopoly over care organisation within their territories, the market has gradually opened up. This was due to the 1990s' introduction of the option to outsource operations, and the 2000s' reform allowing free choice and provision of non‑hospital healthcare. Nevertheless, the public sector still dominates the market with a share of 86%. Due to ongoing accessibility issues (such as waiting lists for specialist appointments or surgery) and concerns about the quality of care in public facilities, the trend towards opening up the sector to private operators is likely to continue. In this context, the private insurance market, which remains limited, is growing rapidly.
1.2.2.3
Consequently, the private sector holds a larger share of the market, mainly catering to patients with private insurance and those paying out of pocket (covering the remaining amount). As well as operating in the private financing market, private providers can engage with the public sector through tenders, resulting in short‑term contracts of two to four years. THE HEALTHCARE SYSTEM IN NORWAY In 2024, health spending represented 9.7% of GDP in Norway. Historically, most hospitals in the Norwegian healthcare system were owned by the counties, who were responsible for their administration. In 2002, the state took over this responsibility through the Healthcare Companies Act, which was adopted as part of a large‑scale hospital reform. Currently, the state supervises four regional health authorities that are responsible for providing specialised care and own hospitals. Patients must first be referred to these services by a general practitioner or the emergency services. Meanwhile, municipalities are responsible for primary care
22
FINANCING ARRANGEMENTS In Sweden, prices are set or regulated by national or regional supervisory authorities. Therefore, the prices for all care provided by Capio are regulated by public authorities. Depending on the activity, one of three systems applies: a capitation system, a global allocation system or a call for tenders system.
The healthcare systems in Norway and Denmark
The Norwegian and Danish healthcare systems share many similarities with the Swedish system in terms of modern care, such as outpatient services, length of stay and publication of quality indicators at a national level. Both systems face challenges in aligning healthcare expenditure with national wealth generation, leading to accessibility issues and inefficient management of resources. Additionally, employers are increasingly offering health insurance to their employees.
(1)
Private healthcare operators, including Capio, are largely financed by public resources as part of a tendering process for hospitalisation services and primary care practice licences, which are awarded for periods of five to eight years. The Stockholm Region has therefore outsourced services at St Göran acute care hospital since 1999. Capio has operated the hospital since that date and obtained a renewal in October 2025, which took effect in January 2026 and will last for eight years. Other services outsourced to private providers cover a wide range of primary and secondary care.
% of total health expenses.
Ramsay Santé / Universal Registration Document 2026
and have freedom in organising health services in conjunction with other sectors that influence population health (notably housing, education and employment). In addition to defining the national health policy and preparing major reforms, the Ministry of Health and Healthcare Services (assisted by several technical bodies) controls regional decisions on healthcare services through financial incentives and its ability to intervene in many areas, such as the accreditation of healthcare providers and the certification of specialists, or the definition of quality and safety care standards and pathways. Overall, the private sector represents a 15% market share (1) in Norway. THE HEALTHCARE SYSTEM IN DENMARK In 2024, health spending represented 10% of Denmark’s GDP. In the Danish healthcare system, the regions are primarily responsible for providing specialised healthcare services and for owning and financing hospitals. The municipalities are responsible for (i) primary care (general practitioners are paid by the regions according to a scale negotiated by the Organisation of General Practitioners and the Danish regions), (ii) prevention, (iii) health promotion, (iv) rehabilitation outside hospitals, and (v) services for the elderly. To ensure coordination between administrative levels, binding partnerships have been established between municipalities and regions through health coordination committees.
GENERAL PRESENTATION OF THE GROUP A closer look at major countries and markets
The Ministries of Health and Finance play a significant role in organising and managing healthcare at regional and municipal levels, including issuing and withdrawing licences to practise, as well as supervising and partially funding municipalities and regions. Additionally, regional competencies are overseen by an independent professional commission to ensure that the
1.2.3
regions meet national priorities. An ongoing reform of the health system will grant municipalities greater powers, particularly with regard to primary healthcare. The reform will be fully in force by 2027. Overall, the private sector represents an 18% market share (1) in Denmark.
A closer look at Italy
The Italian healthcare system (Servizio Sanitario Nazionale – SSN), which was established by Law No. 833 of 1978, guarantees universal health coverage that is mainly financed by general taxation. The system is organised according to a decentralised model, whereby the state defines the fundamental principles, while the regions are responsible for organising and delivering health services. At the national level, the Ministry of Health collaborates with other institutional bodies to define the health system's strategic guidelines, identify the Essential Assistance Levels (LEA) that must be uniformly guaranteed throughout the country, and contribute to distributing the National Health Fund's resources among the regions and autonomous provinces.
Local Health Authorities (ASL) Local health authorities are the main operational level of the health system. They are responsible for providing prevention services, territorial assistance, and socio‑health integration services. Local health authorities may provide health services directly or be assisted by: ■ ■ ■ ■
public hospitals; hospitals; public IRCCS; accredited private establishments affiliated to the National Health Service.
The role of the Regions
The role of accredited private service providers
The Autonomous Regions and Provinces organise their respective regional health services in accordance with the fundamental principles established by the state and the Essential Assistance Levels.
A notable feature of the Italian healthcare system is the significant number of accredited private providers that contribute to the delivery of services included in the LEA. These operators are authorised and accredited by the Regions, and are remunerated by the Regional Health Service in accordance with the procedures established by current legislation.
They participate in the definition of the main national health policies and in resource planning within the framework of the Conference of States‑Regions.
In summary, three distinctive aspects of the Italian model should be highlighted: ■ ■ ■
(1)
the universality of the SSN; high level of regionalisation of health governance; structural integration between accredited public and private providers.
% of total health expenses.
Ramsay Santé / Universal Registration Document 2026
23
1
1
GENERAL PRESENTATION OF THE GROUP Business overview
1.3
Business overview
1.3.1
A unique position on the European market
The Company believes that its main competitive strengths are as follows:
A responsible leadership position A LEADING GROUP IN THE MARKETS IN WHICH IT OPERATES With global revenue of EUR 5.4 billion at the end of June 2026 and approximately 13 million patient visits during the 2026 financial year, Ramsay Santé has established itself as a
leader in its various markets. As France’s leading private healthcare and services group, it represents around 21% of the MSO (Medecine - Surgery - Obstetrics) market share for private hospitalisation in France and is a leading provider of cardiology services at the Jacques Cartier Centre of Excellence. The Group also holds a leading position in the private healthcare markets in the Nordic countries: it is number 1 in Sweden with nearly 10% of the population enrolled in its health centres, number 1 in Denmark and number 2 in Norway.
The diagram below shows the breakdown of the Group’s consolidated revenue for the financial year ended 30 June 2026 by business sub‑segment.
The Group is committed to setting itself apart by providing high‑quality, modern and safe care offers and treatment to patients. This is achieved by focusing on three key areas of value creation: ■
■
■
24
establishing itself as a European player to provide a solid and secure base and diversify the risks to which the Group is exposed; strengthened competitiveness by establishing a range of integrated treatment offers and services throughout the patient care pathway; creating an attractive professional environment for all doctors and employees (through contributions to medical research and career development, for example).
Ramsay Santé / Universal Registration Document 2026
A PLAYER IN THE REGIONAL HEALTHCARE OFFER For over thirty years, Ramsay Santé has cultivated a medico‑economic model that aligns fully with the care systems of the regions in which it operates. The company manages the latter's resource constraints and strives to welcome all patients, without exception, to its facilities, where it treats all pathologies, from the simplest to the most complex. In France, in particular, this commitment is demonstrated in a variety of ways: ■
12 per cent of patients are covered by means‑tested social care supplementary health insurance, rising to 23 per cent for mental health patients;
GENERAL PRESENTATION OF THE GROUP Business overview
■
Ramsay Santé is present in medically underserved regions. In total, 60% of our facilities are located in sparsely populated areas. Of the 149 MSO, MCR (medical care and rehabilitation) and mental health facilities, as well as primary care centres, in France, 39 are located in priority intervention areas. The Group is a major operator in the Seine‑Saint‑Denis department, with three MSO facilities (including three emergency departments and a major dialysis centre), two MCR facilities, and centres specialising in radiotherapy, nuclear medicine and imaging;
■
as part of the development of the local primary care business, Ramsay Santé has taken over 12 COSEM medical and dental centres since the opening of five centres in areas where access to healthcare is limited (Bourg‑de‑Péage, Pierrelatte, Ris‑Orangis, Argenteuil and Oyonnax). These centres care for more than 1 million patients in Paris, Évry, Caen, Orléans, Saint-Étienne and Marseille. This brings the total number of medical centres in France offering general and specialised medicine, dentistry, imaging and laboratory analyses to 25. Thirty‑three mental health day‑care centres have also opened in France.
barriers to entry and gives established players a competitive advantage. The increased dynamism of public hospitals, particularly through regional hospital groups, presents both challenges and opportunities for cooperation. In the Nordic countries, health sector regulation operates in two parts: referral of patients to health centres for non‑hospital medical treatment and awarding of contracts through regionally orchestrated tenders. The increase in healthcare needs and the challenges public structures face in providing access to care offer new opportunities for the private sector. In Sweden, for example, access to care is always through the primary care centre to which the patient is registered. The Group has the largest network of primary care centres in the country, with 10% of the population registered with one of its centres. RAMSAY SANTÉ: A MISSION COMPANY The Mission Committee appointed in 2023 met four times during the 2025‑2026 financial year: on 22 September 2025, 13 December 2025, 26 March 2026 and 17 June 2026. Over the period, the Company focused on aligning its mission objectives with those of the new 2030 strategy.
Through its local brands, such as Capio and Volvat, Ramsay Santé is trying to provide healthcare support throughout the Nordic countries.
The committee defined its mission framework around three key areas:
A SOLID COMPETITIVE POSITION
■
In France, the private hospital sector is highly regulated, particularly to provide a framework for hospital capacity in France, taking a dual approach to controlling costs and improving the quality of the care offer. This creates strong
■
■
accessibility of care and prevention; symmetry of patient/caregiver interactions; and sustainability through reducing the environmental footprint of the Group’s activities.
The audit report was published on the Company’s website.
4 SOCIAL AND ENVIRONMENTAL OBJECTIVES
Actively support clinical research
Support the professional
development of teams
Strengthen the innovation
strategy through living labs
3
Y
MPAN
SIO MIS N
ES
R VI EC 1 E N BJ O
O
4
MPAN
Y
O N TI M E VE NT
Y
MPAN
2
2
"Improving health by constant innovation"
C
C
O
Promote medical innovation to offer the best care
1G O OB VE JE
O
CE AN RN T IVE C
SSION MI
Welcome all patients and pathologies
Ensure quality of life at work
for all employees
Simplify the health pathway
L OBJECTIV
Y
MPAN
CIA
1
C
C
O
SSION MI
Promote access to healthcare for all
SO
SSION MI
Systematise the dialogue with our stakeholders
Build stakeholder confidence
Involve local authorities
and associations
Mission management
Protect the planet to improve health
Reduce our Impact on climate
change
Better waste management
and fight against waste
Involve our suppliers in
our environmental approach
Ramsay Santé / Universal Registration Document 2026
25
1
1
GENERAL PRESENTATION OF THE GROUP Business overview
A GROUP COMMITTED TO A CSR STRATEGY The Ramsay Santé group has been built around a commitment to continuous innovation, with the sole aim of improving the treatment and care offered to patients. These actions form part of a responsible corporate approach, taking into account all stakeholders who contribute to the Group's activities, including employees, practitioners, patients, the planet and society. In 2020, Ramsay Santé made Corporate Social Responsibility (CSR) a shared Group‑wide issue and began to coordinate initiatives that were previously launched at facility level. In 2022, by becoming a Mission company, the Group naturally integrated CSR into its core values. CSR is a tool for reducing the negative environmental, social, economic and ethical effects or risks inherent in our activities, and constitutes the operational implementation of a Mission‑driven company. Since adopting its purpose and status as a Mission company in 2022, Ramsay Santé has centred its development around its sustainability strategy. The four social and environmental objectives set out in its bylaws provide a framework for its actions, guiding all its initiatives (see 4.1.3.1.1). A double materiality analysis was carried out in 2024–25 as part of the implementation of the CSRD, identifying the Group's most material environmental, social and governance impacts, risks and opportunities, as well as the expectations of its main stakeholders. In 2026, Ramsay Santé used these results to develop its sustainability strategy, creating a sustainability compass common to all of its operating countries. While the four objectives of the Mission company remain unchanged, the commitments, objectives, targets and associated indicators have been revised to better address the material challenges identified and to strengthen the Group's level of ambition. This change aims to better integrate sustainability matters into the Company's strategy and management. The Impact & Sustainability Department was strengthened to accelerate the deployment of the Group’s sustainability compass, support facilities and business departments, and consolidate the management of non‑financial performance. This approach is based on governance involving all of the Group’s functions and a network of CSR officers within the facilities.
A truly integrated care offer, anchored in medical excellence Ramsay Santé welcomes all patients to its facilities, where all pathologies are treated, from the simplest to the most complex. The Group has a local and national presence, offering the most comprehensive range of healthcare services possible, including preventive and primary care, medical and rehabilitation care, mental health services, geriatrics, home care, and telemedicine. This diversity enables the Group to provide its patients with all the healthcare services they require, while also meeting national and regional healthcare objectives.
26
Ramsay Santé / Universal Registration Document 2026
Furthermore, the Group achieves excellent results in the quality indicators it manages. Its quality‑based approach ensures it remains at the highest level of market standards (see section 1.3.3 Medical Excellence). In France, the Group's facilities are mainly located in large urban areas with a growing population. The Group also operates in underserved areas, both urban and non‑urban. The purpose, “Improving health by constant innovation”, is embodied in the exchange of knowledge and best practices between its countries, which accelerates innovation and strengthens expertise. This is particularly evident through initiatives such as the Innovation Awards and Innovation Hubs.
A partner of choice for patients, doctors and employees and a reference and trusted partner for public authorities and healthcare systems Ramsay Santé's size, leading position in its various markets and regional network coverage make it a key player for patients, institutional bodies, doctors and employees. A KEY PLAYER FOR ITS PATIENTS The Group is recognised by patients for the high quality of its care pathways, as evidenced by its consistently high and rising Net Promoter Scores (NPS). For instance, it received an “excellent” score of 74 in France (compared to 70 in 2023) and 69 in Sweden (compared to 66 in 2023). The Company is committed to providing holistic care for its patients. Going beyond mere treatment, it offers care pathway coordination and personalised support services. In France, the development of divisional medical projects with practitioners supports this approach, creating a network of facilities in their catchment area. This makes it possible to establish care networks according to need. In this area, Ramsay Santé particularly relies on the experience developed with the oncology divisions. The Group’s strong presence in primary care in Sweden and its development of this activity in France, Denmark and Norway plays a major role in providing this comprehensive, coordinated care throughout patients' health journeys. A PLAYER RECOGNISED BY THE AUTHORITIES AND THE MARKETS The size of the Ramsay Santé group, the third‑largest healthcare player in Europe, and its position as a responsible leader make it a key player for authorities and markets. Furthermore, its status as a Mission company, commitment to medical excellence, and long‑standing presence in the healthcare market have established it as a trusted partner of institutional bodies and a leading partner in shaping the provision of care offers within health regions.
GENERAL PRESENTATION OF THE GROUP Business overview
As a member of various professional bodies, the Ramsay Santé group helps to meet the health needs of the regions in which it operates, while also promoting high‑quality, excellent care in those regions. The Ramsay Santé Foundation works in the field of health prevention, running programmes that currently benefit six million people. The Foundation also supports 190 start‑ups and organisations that aim to promote prevention. A BENCHMARK PARTNER IN MEDICINE The Group's ambition is to anticipate and meet new health needs by offering expanded, coordinated and sustainable care offers. This ambition is based on the partnerships that the Group has forged with practitioners in private practice (mainly in France) and with employees (in part in France and in northern European countries). The Group is committed to providing the medical community with the best possible human, technical and organisational environment. In France, private practice is the most developed and has proven its relevance by constantly adapting to medical progress, patient expectations, and the collective, solidarity‑based coverage of healthcare expenses. Medicalising the decision‑making processes is a genuine commitment that has strengthened links with the medical and scientific community, optimised and guided the processes by integrating them into an organisation that is more closely aligned to the regions and its stakeholders. This has informed the medical orientations for the divisions' medical projects, including major investment and purchase decisions. AN EMPLOYEE VALUE PROPOSITION TO RETAIN TALENT
All managers implement its European leadership model. This involves training 300 managers each year and making managerial development resources available. The Group also prioritises the well‑being, support and inclusion of its employees. All employees are covered by a health and safety system and initiatives on physical and mental well‑being are implemented across all countries. Flexible working arrangements, particularly for parents, support work‑life balance.
Digitalisation and use of artificial intelligence (AI) for the benefit of all its stakeholders The Ramsay Santé Group is a leader in the integration of digital and physical care, and in adopting innovations driven by artificial intelligence to improve access to care, clinical decision‑making, efficiency, and continuity of care. The Group invests in and forges partnerships with digital and AI healthcare companies for the benefit of: ■
■
■
The Ramsay Santé group strives to attract and retain the best talent for the benefit of patients, particularly by investing in their development. As the largest employer of nurses and the third‑largest employer of doctors in Sweden, Ramsay Santé is one of the largest employers in the healthcare sector. The Group is strongly committed to promoting inclusion and diversity. Around 6% of its French employees have disabilities.
■ ■
patients: the aim is to provide access to care at any time and in any place, offer personalised care pathways and enable patients to play an active role in managing their health. This will ensure continuity of care and improve quality. the medical community: the aim is to use digitalisation and artificial intelligence to reduce administrative tasks, make information more accessible, free up time for patient care and improve decision‑making and communication with patients; the Group’s managers: the aim is threefold: to enhance operational performance in the interests of patient care; to improve decision‑making by providing real‑time information and analysis; and to offer optimised care pathways; institutional bodies, by facilitating the sharing information in a transparent and efficient manner;
of
society, through the avenues of clinical research opened up by the regulated and secure use of data.
It promotes a culture of continuous learning to develop its employees and maintain their employability. In the 2026 financial year, it provided more than 420,000 hours of training in France, and more than 5,000 employees received artificial intelligence training, as did 200 young doctors.
1.3.2
The Group’s strategy
Ramsay Santé is a leading provider of private hospitalisation and primary care in Europe. By combining the medical excellence of the public sector with the flexibility of the private sector, and by admitting all patients regardless of their circumstances, Ramsay Santé has established itself as a
trusted partner. The Group is committed to making Ramsay Santé the obvious choice for care, providing support throughout the healthcare journey and at different stages of life.
Ramsay Santé / Universal Registration Document 2026
27
1
1
GENERAL PRESENTATION OF THE GROUP Business overview
Our “Connecting Care 2030” strategy emerged from a strategic review involving the Group’s 2,000 managers. It is a global strategy adapted to local challenges. Our ambition is to provide 'quality care, at every stage of the care pathway, for everyone', becoming the primary point of entry into the healthcare system for all, regardless of their needs, thanks to the quality of our care and our physical and digital services.
1.3.2.1
This ambitious strategy is based on five pillars of business development and seven core principles. Building on the results of the previous strategy, 'Yes We Care 2025', these aim to accelerate the success of the global Ramsay Santé platform.
The five pillars of the strategy One ambition: quality care, at everystep, for everyone Ensure active portfolio and contract management
Acc
eler
ate
Strengthen the integrated and accessible Healthcare offering
Ensure
Accelerate additional profitable growth through new revenue streams
en
ngth
nt Co AMPLIFYING THE DIGITAL TRANSFORMATION OF THE CARE PATHWAY The Ramsay Santé group intends to continue digitalising care pathways and to expand the use of data and artificial intelligence across its entire platform. This will improve the patient journey, care delivery and environmental impact of the business. This will
28
Ramsay Santé / Universal Registration Document 2026
e
The Ramsay Santé group already offers integrated care, covering the entire patient journey with multiple access points and a well‑established network of facilities, particularly in major urban areas. This structure gives the Group significant growth potential in its existing markets. It plans to enhance its care provision in areas where it already has recognised expertise, drawing on its MSO network and the development of primary care in Sweden, as well as continuing to roll out its imaging capabilities. The Group also intends to expand its efforts in the areas of prevention and patient follow‑up.
ac
STRENGTHENING AN INTEGRATED AND ACCESSIBLE CARE OFFER
br
Continue to focus on cost initiatives measures
Em
inu
e
Stre
Embrace the digital transformation of Healthcare delivery
involve integrating tools for telemedicine and remote monitoring, as well as primary care pathways incorporating artificial intelligence, and revenue cycle management tools. There will also be a wider deployment of digital tools and artificial intelligence to simplify administrative processes, support clinical decision‑making, and improve operational efficiency. The Group also plans to scale up the most promising innovations from its European network. ENSURING ACTIVE MANAGEMENT OF THE BUSINESS PORTFOLIO AND CONTRACTS The Ramsay Santé group intends to continue actively managing its portfolio and various contracts to optimise the deployment of its resources, focusing on activities with the best growth and profitability prospects. The ongoing rationalisation of the portfolio aims to improve margins by making better use of capacity, aligning activities more closely with changing patient demand and making the healthcare network more agile and efficient.
GENERAL PRESENTATION OF THE GROUP Business overview
CONTINUING COST OPTIMISATION INITIATIVES
- Employees
The Ramsay Santé group intends to continue rolling out targeted performance plans in France and the Nordic countries. The aim is to improve margins by reducing costs and making better use of existing capacity, for example by increasing operating theatre utilisation rates, improving the efficiency of medical teams, optimising procurement and administrative costs, planning the workforce more effectively and making work processes more efficient by taking advantage of the opportunities offered by digital technology.
The Group’s employees, including those in the medical community (whether employees or private practitioners), are at the heart of the Group’s commitment.
ACCELERATING THE DEVELOPMENT OF NEW, PROFITABLE GROWTH DRIVERS In addition to growing its existing activities, the Ramsay Santé group plans to develop additional revenue streams by leveraging the strengths of its care platform. The Group intends to grow its home and outpatient mental health services, as well as its private and occupational health insurance services in Sweden. This will create new sources of profitable growth around its core businesses.
1.3.2.2
Seven strategic fundamentals
In order to implement these new strategic pillars, Ramsay Santé has identified seven fundamental areas of transformation in line with its previous strategic plan. These fundamentals, on which Ramsay Santé is basing its transformation, require significant investment, which is possible given the size of the Group. Implementing these seven fundamentals will drive strategic business projects and develop critical know‑how at a Group level for the years to come.
- Medical excellence The Ramsay Santé group is a European medical community that ensures medical excellence. This is driven by networks for sharing the best medical practices, a medical ethics framework and the Choosing Wisely initiative. The Group manages its results through quality (CROM, PROM, PREM) and medical efficiency measures. The aim is to ensure that medical innovation remains at the heart of the Group’s thinking, thereby constantly improving the way it meets patients’ needs. This commitment to innovation is one of the most important foundations for Ramsay Santé, as the quality and safety of care are the Group’s top priorities. Consequently, the Group aims to continue developing high‑quality, data‑driven clinical approaches to deliver the best possible medical outcomes, thereby maintaining its position as a healthcare provider offering the highest standards of care. In addition to operating to the highest quality standards to secure authorisations and certifications in its markets, the Group is committed to providing an attractive, modern working environment for doctors and employees in order to ensure the long‑term availability of skilled personnel.
This is why Ramsay Santé continues to develop its employer brand and employee and medical value proposition, attracting the best talent to meet its needs while providing its teams with the support they need to cope with rapid changes in the market and in skills. This helps to maintain their employability. The Group also strives to strengthen its culture and sense of belonging on a daily basis to guarantee the success of its managerial model and the well‑being of its employees. 3) IT infrastructure Securing the use of digital tools is essential for the adoption of health technologies. Despite having country‑specific IT organisations, the Group's IT requirements align with the highest market standards. European communities dedicated to sharing expertise support the local implementation of best practices. By 2030, the Group intends to continue developing a robust, integrated information system to support the ambitious business initiatives of each pillar of the strategy. 4) Data and AI The Data and AI pillar aims to enable data‑driven decision‑making at strategic and operational levels by providing reliable, secure and accessible data, thereby realising the full potential of artificial intelligence. Ramsay Santé is a Europe‑wide organisation with expertise in data management, AI and digitalisation. The Group's Data and AI roadmap guides these efforts. The Ramsay Companion AI tool, which is a secure interface that enables the use of existing engines, was launched across Europe in 2026. To date, 5,000 members of staff have been trained to use it. Since 2020, Ramsay Santé has also organised the Innovation Awards to identify and select innovation projects within the organisation, ensuring the scaling up of the most promising innovations. 5) Sustainability The Ramsay Santé group has a Group CSR function and programme, as well as key CSR performance indicators, to ensure sustainable operations and performance across the Group. As a Mission company, the Group has commitments on a global scale. As part of the Connecting Care 2030 strategy, the sustainability priorities are to demonstrate the contribution of non‑financial performance to the Company's overall performance; to structure a climate roadmap; to promote sustainable care and position it as a competitive advantage; and to remain proactive in terms of the health and safety of the Group's employees.
Ramsay Santé / Universal Registration Document 2026
29
1
1
GENERAL PRESENTATION OF THE GROUP Business overview
- Brand and Reputation
SWEDEN
The ’Brand and reputation’ pillar aims to protect the Group’s reputation and raise its profile by implementing a robust and comprehensive strategy.
In Sweden, the Ramsay Santé group intends to continue 'actively' managing its contracts through its Capio brand. It will seek to outperform at St Göran, further reducing administrative complexity to improve patient care. This will position Capio as a leader in innovative, high‑quality care, as part of a strategy of continuous improvement and productivity gains.
The Group Communication Team manages the common Ramsay Santé brand platform, regularly measuring key performance indicators relating to brand awareness and reputation in the markets. 7) Customer focus In response to patients' increasingly consumer‑oriented behaviour, Ramsay Santé is leading a European network with the aim of strengthening the customer focus of its operations and the medical community. The network will also seek to develop business concepts and opportunities targeting new groups of patients and customers. In support of the Connecting Care 2030 strategy, this initiative will also seek to develop new business models in response to evolving patient requirements, with the ultimate goal of improving medical outcomes.
1.3.2.3
Breakdown by country
Although the Ramsay Santé group strategy is applicable to the entire group, it is also rolled out locally in order to address the specific challenges of each country. FRANCE In France, the Ramsay Santé group intends to continue actively managing its business portfolio by aligning its offerings with patient needs, accelerating the deployment of cross‑division activities, and continuing to develop Centres of Excellence within its facilities. It also aims to strengthen care pathway development within each division and expand its network of imaging, primary care and mental health day clinics. The Group is committed to digital transformation, which it is achieving through the optimisation of operational processes using standardised tools and AI, the deployment of its Ramsay Services digital platform, and the acceleration of R&D driven by its Health Data Warehouse. It also aims to become a pioneer of the virtual hospital. All aspects of the “Choosing Wisely” programme will be implemented. Ramsay Santé France is also continuing its cost‑control programme, through measures such as optimising its supplier portfolio in collaboration with doctors, adjusting its staff costs in line with activity levels, and improving bed occupancy rates. The Group also intends to implement profitable growth strategies, such as establishing an integrated care pathway incorporating virtual hospitals, developing home care services, and creating preventive healthcare offerings.
30
Ramsay Santé / Universal Registration Document 2026
To strengthen its integrated and accessible care offer, Sweden plans to increase its geographical presence to achieve sustainable growth, further develop integrated regional care and expand its network of primary care centres. It also aims to facilitate access to faster care pathways and to refer patients through internal referrals. Continued digital transformation should enable the development of new care pathway concepts and home hospitalisation, as well as the proposal of new care approaches through AI and data analysis, whilst involving patients in their care pathway. Sweden will roll out the Choosing Wisely concept in medical and administrative contexts, and will continue cost control initiatives. These include developing digital working environments to improve staff efficiency and optimise patient and staff scheduling, optimising purchasing and other productivity measures, such as reducing the average length of stay and expanding outpatient surgery. Sweden aims to develop new revenue streams, particularly in the private insurance segment, through economies of scale and a strengthened value proposition. It also intends to promote a new occupational health prevention offer and expand further into the private care segment through new services and concepts. NORWAY In Norway, the Group plans to further promote integrated care offers, in line with the Choosing Wisely programme. It also aims to strengthen proposals for care pathways, particularly for older people. Finally, the goal is to continue developing primary care centres based on innovative partnership systems with doctors. DENMARK In Denmark, the Group aims to continue developing personalised care pathways, in line with the Choosing Wisely programme, by building on partnerships. It wishes to meet the needs of all patients, regardless of whether they use the public, insurance or private system. Lastly, it wants to further improve the digital patient experience. ITALY In Italy, the Group aims to continue providing excellent care within the established contractual framework by implementing the Choosing Wisely programme, advancing the digitalisation of the patient journey, and developing new offers.
GENERAL PRESENTATION OF THE GROUP Business overview
1.3.3
Medical excellence
1.3.3.1
Medical excellence at the heart of the Ramsay Santé group’s business and organisation
Medical Orientation Committees meet at European and national levels to share the latest innovations in care, whether technical, technological or organisational. These committees bring together doctors, paramedics and facility managers. This exchange of best practices is also based on the implementation of rigorous quality standards, the coordination of clinical research, and the processing of medical data. These committees have also been established in French facilities, where they are known as Facility Medical Boards. The Group also closely monitors patients’ views on the quality of care provided through Net Promoter Scores (NPS). All of the Group’s countries have NPS ratings ranging from “very good” to “excellent”, which are well above the market performance standard. The NPS scores by country in 2025 were as follows: 74 in France, 69 in Sweden, 71 in Norway and 83 in Denmark. The Ramsay Santé group’s commitment to medical excellence is also evident in its clinical performance indicators, including a surgical mortality rate lower than the French average, less invasive care techniques compared to Swedish medical standards, lower recurrence rates than our peers for certain interventions and increased postoperative rehabilitation speed compared to the national average. The Group is also recognised as a leader in clinical research, which fuels excellence in patient care and attracts the best doctors: ■ ■ ■ ■
among the Group’s doctors, one in five physicians participates in research; 10,000 patients have participated in 770 clinical studies since 2022; nearly 1,200 scientific publications were validated by our peers, 40% of which were ranked among the best; the Group is the leading player in clinical research in France. It represents nearly half of all clinical research carried out by the private sector, positioning itself on an equal footing with university research centres;
1.3.3.2
■
1
in France, more than 50% of medical interns choose the Ramsay Santé group for their internship in the private sector (with more than 1,000 interns supported since 2017).
The Group also invests in medical innovation for the benefit of patients. For example: ■
■
around 30 robots have been installed in various specialities (digestive and thoracic surgery, orthopaedics, oncology, etc.) to limit post‑operative complications; online applications are used in Mental Health to closely monitor patients' progress, enabling them to avoid inpatient care in some cases.
Dedicated networks for specific pathologies (such as sports medicine, obesity, ophthalmology and anaesthesia) enable the sharing and implementation of European best practice, and establish the Group as a leading authority in certain medical fields. The Ramsay Santé group firmly believes that prevention is key to quality care. It therefore invests in various prevention actions, such as: ■
■
through the Ramsay Santé Foundation, the Prevent2Care programme incubates or has incubated more than 190 disease prevention start‑ups; through a fully digitalised national prevention programme in Sweden, Capio Lifestyle, which supports patients with chronic diseases.
The Ramsay Santé group is committed to taking full advantage of digitalisation and artificial intelligence to improve the quality of care. In Sweden, for example, mammography imaging is now assisted by AI, which increases the probability of cancer detection by 12% and reduces false positives by 13%. This allows radiologists to address the growing demand for their services without extending waiting times. In France, the development of a Health Data Warehouse enables the personalisation of patient pathways to be strengthened while reducing the administrative burden for caregivers, in compliance with applicable regulations.
Continuation of the quality policy
Ramsay Santé is committed to improving the quality of its services, and the Group invests significantly every year to modernise its facilities. The Group is committed to improving medical quality and patient satisfaction. All facilities follow a standardised quality process, measuring and reporting on certain Quality Performance Indicators (“QPI”), i.e. clinical outcomes measured by medical professionals (Clinician
Reported Outcome Measurements – “CROM”), Patient Reported Outcome Measurements (“PROM”) and Patient Reported Experience Measurements (“PREM”). The quality policy aims to standardise programmes and treatment processes according to a protocol based on clinical data and a defined process (Clinical and Process Input – “CPI”) to ensure high‑quality results in these three areas.
Ramsay Santé / Universal Registration Document 2026
31
1
GENERAL PRESENTATION OF THE GROUP Business overview
In France, the Group is rolling out an ambitious quality initiative, enrolling all its facilities in the certification process overseen by the French National Authority for Health (Haute Autorité de Santé – 'HAS'). This involves service certification or ISO 9001:2000 certification for high‑risk processes such as sterilisation. Ramsay Santé facilities are at the top of the French MSO market as a whole, outperforming other private players.
1.3.3.3
Constant promotion and retention of the medical community
Ramsay Santé establishes a genuine dialogue between facility managers and doctors within its facilities. At a national level, this dialogue takes place within the Medical Orientation Council and specialist clubs. It also takes place during Ramsay Santé Days, which are attended by the chairmen of the Facility Medical Boards, and within multiple working and focus groups. In each facility, the CME is involved in daily life and medical projects. The Group is constantly working to improve this dialogue, recognising the energy and motivation required of practitioners for the proper functioning of CMEs and the performance of cross‑functional missions.
In France, the Group is particularly committed to the principles of private practice medicine. It recognises the importance of the role of practitioners in the quality of the care offer, understands the challenges they face, and is committed to supporting them in the long term. At Group level, networks of specialties are managed to promote the exchange of best practices and medical results. National Medical Orientation Committees also meet regularly at the European level to ensure the international sharing of new and best care practices. Training is also a priority, with certain Group facilities receiving medical and surgical interns for their initial training and promoting continuing medical education for Group practitioners.
1.3.4
The Group’s activities in each country
1.3.4.1
Ramsay Santé in France
The map below shows the geographical locations of Ramsay Santé in France as of 30 June 2026 in greater detail. The facilities in France follow a regional healthcare approach and are organised into divisions, which may be constituted around a single facility or several facilities. Hospitals, clinics and centres are located in the main catchment areas of mainland France. The 17 divisions cover Paris and the Île‑de‑France,
32
In the Nordic countries (Sweden, Norway and Denmark), medical quality results and process measures are shared with regional governments and national quality registries. An annual quality report is published to highlight medical quality work, processes and key operational results.
Ramsay Santé / Universal Registration Document 2026
Hauts‑de‑France, Normandy, Nouvelle‑Aquitaine, BourgogneFranche‑Comté, Auvergne‑Rhône‑Alpes, Occitanie, and Provence‑Alpes‑Côte d’Azur, and provide care in the fields of medicine, surgery, obstetrics, medical care and rehabilitation, or mental health. Mental health facilities and primary care centres operate as separate business divisions.
GENERAL PRESENTATION OF THE GROUP Business overview
OUR FACILITIES IN FRANCE
Imagerie médicale CLIMAL (CSCO) (Marcq-en-Barœul - 59) Cl. du Sport et de Chirurgie Orthopédique (Marcq-en-Barœul - 59) Cl. Ambroise Paré (Lille - 59) HP Le Bois (Lille - 59) I. M. du Parc (Lille - 59)
Cl. de la Victoire (Tourcoing - 59)
HP de Villeneuve-d’Ascq (Villeneuve d’Ascq - 59)
Centre Médical Évry-Courcouronnes (Évry-Courcouronnes - 91)
IDF Sud-Est Cl. du Mousseau (Évry-Courcouronnes - 91)
Cl. de l’Escrebieux (Esquerchin - 59)
Cl. Lille Sud (Lesquin - 59) I. M. de Bois Bernard (Bois-Bernard - 62) HP Bois-Bernard (Bois-Bernard - 62)
Lille Metropole cluster
Centre Médipsy Douai (Roost-Warendin - 59)
Artois cluster HP Arras - Les Bonnettes (Arras - 62) TEP Jean Perrin (Arras - 62) TEP Henri Becquerel (Arras - 62)
HP de l’Estuaire (Le Havre - 76) I. M. Saint-Martin (Caen - 14)
Cl. du Petit Colmoulins (Harfleur - 76)
Normandy cluster
HP Saint-Martin (Caen - 14)
Cl. Eugénie (Pierrefonds - 60) Centre Médipsy Compiègne (Compiègne - 60)
Centre Médipsy Alençon (Alençon - 61)
th Nor tral Cen
M.A.S. du Vendômois (Naveil - 41)
Cl. Belle Allée (Chaingy - 45)
Cl. du Pont de Gien (Gien - 45)
Cl. Château du Tremblay (Chaulgnes - 58)
Cl. du Parc (Nantes - 44)
Central
Centre Médipsy Niort (Niort - 79)
Cl. de l’Atlantique (Puilboreau - 17)
Centre Alcoologique Alpha (Royan - 17)
Aquitaine cluster
South
Cl. Aguiléra (Biarritz - 64) Scanner Aguiléra (Biarritz - 64)
Cl. Jean le Bon (Dax - 40) Cl. Belharra (Bayonne - 64)
Centre de Cardiologie du Pays Basque (Bayonne - 64)
Cl. de la Recouvrance (Fronton - 31)
HP Dijon Bourgogne (Dijon - 21)
Burgundy cluster
Cl. Les Rosiers (Dijon - 21)
Polyclinique du Parc Drevon (Dijon - 21)
Cl. du Chalonnais (Châtenoy-le-Royal - 71)
Cl. de Beaupuy (Beaupuy - 31)
Toulouse cluster
Cl. La Croix du Sud (Quint-Fonsegrives - 31)
Cl. des Cèdres Centre Médical Toulouse (Cornebarrieu - 31) (Toulouse - 31)
HP des Peupliers CdR des Peupliers I. M. des Peupliers (Paris XIIIe)
Paris cluster Centre de santé des Peupliers (Paris XIIIe)
HP Sainte-Marie (Chalon-sur-Saône - 71) Cl. Le Gouz (Louhans - 71)
Centre Médical Bourg-de-Péage (Bourg-de-Péage - 26)
Cl. La Parisière (Bourg-de-Péage - 26)
HP Drôme Ardèche Cl. Kennedy (Montélimar - 26)
Cl. Rech (Montpellier - 34)
Polyclinique du Beaujolais (Arnas - 69)
Centre de Soins Ambulatoires en Psychiatrie – CSAP (Villeurbanne - 69) Cl. de la Sauvegarde Centre (Lyon IXe) Gérontopsychiatrique de l’Ouest Cl. Centre Médical Sans Souci Lyonnais – CGOL Mon Repos (Lyon IIIe) (L’Arbresle - 69) (Ecully - 69) Médipôle Hôpital privé
(Villeurbanne - 69) Cl. Iris (Marcyl’Etoile - 69) HP Jean Mermoz (Lyon VIIIe) I. M. Jean Mermoz (Lyon VIIIe)
Loire & Drome cluster Lyon cluster
Centre Médical Pierrelatte (Pierrelatte - 26)
Cl. Le Marquisat (Saint-Jean - 31)
Cl. Maussins-Nollet (Paris XIXe)
I. M. Bachaumont (Paris IIe) HP Geoffroy Centre Médipsy Saint-Hilaire Montreuil (Paris Ve) (Montreuil - 93) Cl. du Sport (Paris Ve)
North
Cl. de l’Union (Saint-Jean - 31) CERS Capbreton (Capbreton - 40)
Centre Médical Atlas (Paris XIXe)
Central
HP Pays de Savoie Centre Médical Oyonnax (Annemasse - 74) (Oyonnax - 01) Centre Médical Cl. Convert Annemasse (Bourg-en-Bresse - 01) (Annemasse - 74) Cl. des Monts du Forez Cl. d’Argonay CdR Haute-Savoie Nord (Commelle-Vernay - 42) (Argonay - 74) (Contamine-sur-Arve - 74) Centre Médical Bresse-Savoie cluster Saint-Étienne Cl. de l’Auzon (La Roche-Blanche - 63) (Saint-Étienne - 42) Centre Médipsy Issoire (Issoire - 63) Cl. Saint-Victor (Saint-Victor-sur-Loire - 42) HP de la Loire (Saint-Étienne - 42)
Ce ntra Sou l th
South al Centr
Centre Médical Poitiers (Poitiers - 86)
Cl. Marcel Sembat I. M. Marcel Sembat (BoulogneBillancourt - 92)
Centre Médical Orléans Centre (Orléans - 45) Centre Médical Orléans La Source (Orléans - 45)
Cl. Ronsard (Chambray-lès-Tours - 37)
Centre Médical Magenta (Paris Xe)
Centre Médical Miromesnil (Paris VIIIe) Cl. de la Muette (Paris XVIe) Centre Médical Saint-Michel (Paris Ve) Cl. Jouvenet I. M. Jouvenet (Paris XVIe) I. M. Blomet (Paris XVe)
North
Centre Médipsy Orléans (La ChapelleSaint-Mesmin - 45)
Centre Médipsy Laval (Changé - 53) Cl. NotreDame de Pritz (Changé - 53)
Cl. de la Roseraie (Soissons - 02) Centre Médipsy Soissons (Soissons - 02)
Cl. d’Yveline (Vieille-Eglise-en-Yvelines - 78)
Cl. de l’Espérance (Rennes - 35)
Centre Médipsy Rennes (Rennes - 35) Cl. du Moulin (Bruz - 35) Cl. Philaé (Pont-Péan - 35)
Centre Médical Auber (Paris IXe) Centre Médical Saint-Lazare (Paris VIIIe)
Cl. de l’Ange Gardien (Chamigny - 77)
Centre Médical Caen (Caen - 14)
Cl. du Landy (Saint-Ouen - 93)
Centre Médical Haussmann (Paris IXe)
HDJ de Douai (Douai - 59)
Cl. Saint-Amé I. M. Douai (Lambres-lez-Douai - 59) (Lambres-lez-Douai - 59)
Cl. Océane (Le Havre - 76)
Cl. Pen An Dalar (Guipavas - 29)
HP Claude Galien (Quincy-sous-Sénart - 91)
Centre Médical Ris-Orangis (Ris-Orangis- 91)
Cl. du Parc Monceau (Lille - 59)
HP La Louvière (Lille - 59)
Cl. Maison Fleurie (Faches-Thumesnil - 59)
1
HP de la Seine-St-Denis (Le Blanc-Mesnil - 93) Imagerie en coupe du Blanc Mesnil IDF Nord (Le Blanc-Mesnil - 93) Cl. des Platanes (Épinay-sur-Seine - 95) Cl. Claude Bernard (Ermont - 95) HP de l’Est Parisien Imagerie Nucléaire (Aulnay-sous-Bois - 93) Plaine de France Cl. du Bourget (Tremblay-en-France - 93) I. M. du Bourget Centre Médical Argenteuil (Le Bourget - 93) HP du Vert Galant (Argenteuil - 95) I. M. du Vert Galant Cl. du Plateau Scanner du Vert Galant Cl. du Bois d’Amour (Tremblay-en-France - 93) I.M. de Drancy (Bezons - 95) HP La Montagne Lambert (Drancy - 93) (Drancy - 93) I. M. de Lambert (La Garenne-Colombes - 92) I. M. Marne Chantereine CdR de Bobigny HP Marne Chantereine Cl. de La Défense (Bobigny
Centre Médical Rueil-Malmaison (Brou-sur-Chantereine - 77) (Nanterre - 92) Paris I.M. Watteau (Nogent-sur-M. - 94) (Rueil-Malmaison - 92) Cl. Les Martinets HP Marne-la-Vallée Cl. Montévrain HP Armand Brillard I. M. des Martinets HP Parly II – Le Chesnay (Bry-sur-M. - 94) (Montévrain - 77) (Nogent-sur-M. 94) (Rueil-Malmaison 92) (Le Chesnay-Rocquencourt - 78) I.M. Bry-sur-Marne (Bry-sur-M. - 94) HP Paul d’Egine (Champigny-sur-M. - 94) Cl. de Châtillon Cl. de Champigny (Châtillon - 92) I. M. de Champigny Cl. de Choisy IDF Est (Champigny-sur-M. - 94) HP de Versailles (Choisy-le-Roi - 94) (Versailles - 78) IDF HP de HP d’Antony l’Ouest Parisien Ouest Cl. L ’Amandier (Antony - 92) I. M. de Villeneuve-Saint-Georges (Trappes - 78) (Châtenay(Villeneuve-St-Georges - 94) HP Jacques Cartier Malabry - 92) I. M. Jacques Cartier Cl. de Villeneuve-Saint-Georges (Massy - 91) IDF Sud (Villeneuve-St-Georges - 94) Cl. de Domont (Domont - 95)
IDF Nord-Ouest
IMHOTEP (Lyon VIIIe) HP Est Lyonnais (Saint-Priest - 69) Cl. Iris (Saint-Priest - 69)
CERS Saint-Raphaël (Saint-Raphaël - 83)
Cl. Saint-Martin (Ollioules - 83)
Medicine – Surgery – Obstetric with or without subacute department (34 sites)
Cl. Saint-Barnabé (Marseille XIVe)
Cl. des Quatre Saisons Cl. des Trois Cyprès (Marseille XIe) (La Pennesur-Huveaune - 13) Centre Cl. Saint-Michel Médipsy (Aubagne - 13) Marseille (Marseille Xe) HDJ Le Prélude CdR Beauregard (Aubagne - 13) (Marseille XIIe) Centre Médical Marseille (Marseille VIe) Cl. Provence Cl. MonticelliBourbonne Vélodrome (Aubagne - 13) (Marseille VIIIe) I. M. Monticelli-Vélodrome (Marseille VIIIe)
Medicine – Surgery – Obstetric with emergency department (31 sites)
Marseille cluster
Subacute facilities (17 sites)
I. M. Clairval (Marseille IXe) CdR Clairval (Marseille IXe) HP Clairval (Marseille IXe)
Radiotherapy center (5 sites) Primary Care Center (24 sites) Mental Health clinic (49 sites) Medical imaging center (27 sites) Imaging center – Nuclear medicine (4 sites)
2026, June
The North / Central / South territorial division applies to MSO/rehab activities. Mental health facilities (identified by green triangles) have a different national distribution
Ramsay Santé / Universal Registration Document 2026
33
1
GENERAL PRESENTATION OF THE GROUP Business overview
A major player in healthcare in France The Ramsay Santé group operates throughout France, providing care to patients in the fields of Medicine‑Surgery‑Obstetrics, Rehabilitation, Imaging and Radiotherapy, Mental Health and Primary Care. It is the leading player in oncology, orthopaedics, ophthalmology and cardiac surgery, and the leading dialysis provider. It has nearly 900 operating theatres. It is the third‑largest provider of rehabilitation care, and one of the leaders in medical imaging and radiotherapy, with almost 140 imaging machines and around 12 radiotherapy units. It is also the second‑largest provider of private mental health care, handling almost 50,000 local consultations as part of a mental health care pathway this year. It also has the largest network of primary care centres in France, based on the number of consultations, with nearly 1.2 million consultations taking place there this year. 85,000 patients have chosen to register with a general practitioner at one of its primary care centres. Competition between players, including public hospitals, focuses on catchment areas made up of populations that are geographically close and behave similarly in terms of their use of healthcare structures. The Ramsay Santé group believes that it is in a solid competitive position in its main operating areas, as its size and reputation make it a go‑to partner for discussions with local authorities, such as Regional Health Agencies (Agences Régionales de Santé – “ARS”), a natural partner for external growth initiatives, with a proven track record of collaboration with complementary organisations. The private hospital sector has undergone an intense consolidation trend in recent years. Elsan is the main player outside Ramsay Santé in the fields of medicine, surgery and obstetrics. Clariane and Emeis are the main players in the functional care, rehabilitation and mental health sectors. Both are also national operators in the care of the elderly sector.
Promoting the coordination of stakeholders in the regions The Ramsay Santé model is also efficient because it takes a regional approach to healthcare needs and resources. The Group has been committed to these approaches for a long time: grouping of facilities, creation of reference centres, design and deployment of divisional medical projects, and fluidity of exchanges between non‑hospital medical professionals and hospitals. This makes the Group one of the players capable of managing a health organisation at the regional level. NETWORKED HEALTHCARE FACILITY MANAGEMENT, BASED ON DIVISIONS The creation of regional divisions, which bring together MSO and, in some cases, MCR facilities, as well as mental health activities and primary care centres, has made it possible to set up a networked approach to managing the care offer. This is the most effective structural response to the demands of a given region, ensuring a standard of clinical and care quality and strengthening synergies through increased and facilitated coordination. The divisions strengthen links with high‑level
34
Ramsay Santé / Universal Registration Document 2026
medical professionals by creating advanced medical consultation centres, providing both upstream acute care and downstream follow‑up care, thereby promoting comprehensive, coordinated patient pathways. COOPERATION WITH THE PUBLIC HOSPITAL SERVICE Active participation in the organisation of French hospital services is based on the ongoing collaboration of all healthcare professionals, as well as contributions to public hospital services, such as emergency care and training. In accordance with local opportunities and needs, Ramsay Santé participates in cooperative actions to optimise the care offer provided to users. To this end, the Group’s facilities have signed agreements with public hospitals, private healthcare facilities of collective interest (Etablissements de Santé Privé d’Intérêt Collectif – “ESPIC”) and private practice doctors. These agreements allow for the joint use of major equipment and care for specific pathologies, among other things. Public‑private partnerships have also led to the creation of joint structures bringing together hospitals and a clinic in the form of Healthcare Cooperation Groups (groupements de coopération sanitaire – “GCS”). These groupings, which are regulated by the French Public Health Code, can facilitate the development of a joint medical service between a public and a private hospital based on joint operation and cost‑sharing, thereby streamlining care within a given region. It is in this same spirit that the Group has played an active role in tackling the COVID‑19 health crisis, drawing on constant coordination between supervisory authorities (ARS), public hospital partners (including AP‑HP) and facilities that have mobilised and adapted their hospital capacities.
Relations with practitioners At the end of June 2026, the Group had more than 10,000 doctors practising professionally within its structures, including more than 7,000 in France. The majority of these doctors work on a private practice basis, although some may be employed in certain specialities, such as medical care and rehabilitation, or in primary care centres. For these French practitioners, the contractual link with a facility is established by signing a private practice agreement. This agreement is governed by the provisions summarised in the paragraph ’Legislative and regulatory framework in France’. Where there is no written contract, the contractual link is established by a de facto agreement, subject to professional usage (as defined by the Order of Doctors and case law). PRIVATE PRACTICE CONTRACT In accordance with Article 83 of the French Code of Ethics and in application of Articles L.4113‑9 to L.4113‑11 of the French Public Health Code, the usual practice of medicine within facilities is subject to a written contract. This contract defines the respective obligations of the parties involved, and specifies the resources made available to doctors by the facility. These resources include premises, medical equipment, and personnel. Doctors practise in accordance with their professional independence and the provisions of the French Code of Ethics.
GENERAL PRESENTATION OF THE GROUP Business overview
Given the private practice nature of their exercise, they are not subject to a relationship of subordination with the facility. The Group provides facilities in its network with practice agreements based on a standard model that it has drawn up. A new version of the contract was released at the beginning of 2025, in order to take into account, in particular, the necessary legislative and regulatory changes, as well as to strengthen the fundamental role of practitioners in the operation of healthcare facilities: participation in structuring initiatives in conjunction with supervisory bodies (ARS, HAS), compliance with commitments related to Ethics and Compliance, taking into account environmental imperatives in the development of innovation and best practices. The majority of facilities and their partner doctors have signed open‑ended contracts. Facilities benefit from a contract model that guarantees a certain degree of consistency in relations between facilities and practitioners. These standard agreements can be adapted according to the nature of the practitioner's work. In this respect, there is an agreement for individual practitioners, as well as an agreement for practices in companies (companies operating as private practices – “SEL”, or professional civil companies – “SCP”). These agreements generally end automatically when the practitioner reaches full retirement age, unless they are extended by written agreement between the parties each year. The practitioner must communicate these agreements to the Council of the Order of Doctors, which is responsible for verifying that the contractual provisions comply with the Medical Code of Ethics. MAIN RECIPROCAL OBLIGATIONS OF FACILITIES AND DOCTORS The Group’s facilities provide practitioners with operating theatres, hospitalisation facilities and other premises, as well as specific and sometimes high‑tech equipment. They provide permanent assistance from qualified personnel in accordance with regulatory standards, whether assigned to hospitalisation services or operating theatres. In return, practitioners undertake to practise their profession, in whole or in part, within the facility. They do so with the full professional independence that private practice implies, and are solely responsible for their actions. They have insurance cover for this at their own expense. REMUNERATION OF FACILITIES AND DOCTORS The practice contract between the practitioner and the facility is not a direct source of profit for the facilities. Pursuant to Article R.162‑33‑1 of the French Social Security Code, the facilities receive tariff payments for hospitalisation directly from health insurance organisations (so‑called “GHS”), determined by annual decrees of the Minister for Health, in proportion to the resources in terms of equipment and people mobilised to receive patients in the facilities. This is still known as “responsibility tariffs”.
The payments received by private facilities as remuneration for inpatient care services do not cover the remuneration of private practitioners who additionally invoice, in their name, the fees corresponding to the procedures they have performed on behalf of patients during their hospitalisation (Article R.162‑33‑2 of the French Social Security Code). Furthermore, the lump‑sum payments received by healthcare facilities do not cover staff remuneration, as practitioners pay them directly for their work. Pursuant to Articles R.161‑40 et seq. of the French Social Security Code, this invoicing is carried out on a single billing slip (form S3404) which summarises all the services provided by the facility as well as the fees invoiced by the doctors. This form is completed and sent by the administrative services of private healthcare facilities to social agencies. The agencies then send hospitalisation flat‑rate payments to the clinic’s account and practitioners’ fees either directly to the practitioners or to a “practitioner representative” account. Costs incurred by facilities to facilitate the practice of doctors, and which are not covered by said responsibility tariffs, are re‑invoiced to practitioners in the form of fees. The absence of re‑invoicing could be considered an abnormal act of management, or a benefit in kind prohibited by Articles L.1453‑3 and L.1453‑5 of the French Public Health Code. Regarding the amount of fees, the Court of Cassation regularly reiterates that it must be appropriate, in its nature and cost, to the service provided by the facility to the practitioner. It can be proportional to the actual cost incurred by the healthcare facility, or a flat rate, as a percentage or fixed amount. Lastly, even a high flat‑rate fee is lawful if it is in line with the services rendered.
An employer serving its talents The Ramsay Santé group is one of the main employers and recruiters in the private healthcare sector in France. It invests in the development of its employees: one in two employees participates in training annually and 420,000 hours of training were provided this year. The Group monitors employee satisfaction through its annual engagement survey: the 2026 score was 65%, rising year on year.
An integrated, modern, innovative and coherent care offer In line with its commitment to care and medical excellence, the Ramsay Santé group offers integrated pathways that take into account the latest innovations in care. The group is therefore committed to developing coordinated medical pathways in its hospitals, ensuring the availability of referring physicians in primary care centres to relieve congestion in emergency rooms. It also supports close collaboration between doctors and nursing staff through a pragmatic, collaborative and flexible approach, with the aim of offering the best possible care in an effective and efficient framework.
Ramsay Santé / Universal Registration Document 2026
35
1
1
GENERAL PRESENTATION OF THE GROUP Business overview
Digital technology and artificial intelligence are used at all stages of the patient pathway to facilitate admission, streamline invoicing and improve clinical approaches. This
1.3.4.2
meets the expectations and needs of patients and healthcare professionals, while freeing up time for quality care.
The Ramsay Santé group in Northern Europe payment method depending on the specialty. Specialised facilities providing primary care are eligible for bonuses based on targets:
Competitive positioning of the Group in Sweden With a geographical presence in 15 of Sweden's 21 regions and across the entire healthcare value chain, Capio is the country's leading private healthcare operator. Nearly 10% of the Swedish population is registered with one of Capio's 131 primary healthcare centres. Capio St Göran Hospital, with 370 beds and 2,300 employees, is the only Swedish hospital with an emergency department to be operated by a private player. It has a nationwide reputation and is recognised for the excellence of its care, achieving the highest quality rating from the Stockholm region each year. With 235 healthcare facilities, Capio is a de facto essential partner and reference for the supervisory authorities. The market has undergone a consolidation trend driven mainly by the Capio and Aleris groups (the latter of which was recently acquired). The market remains relatively fragmented, particularly in primary care, orthopaedics, and mental health. Capio enjoys a very strong reputation among its employees and patients.
Care services offered Capio is involved throughout the care chain in Sweden. Capio operates in the following sectors: ■
■ ■
36
in primary care, it treats nearly 962,000 patients in 13 regions across 131 facilities. The primary care activity is closely linked to the number of patients registered with these same centres. The main funding method is therefore based on a capitation approach, an amount is defined per patient registered, according to their profile and medical history. The amounts paid per patient registered with Capio centres are paid monthly by the local health authorities. A remainder to be paid, set by the authorities, is borne by the patients, and mainly consists of the price of drugs. Fee‑for‑service payments can be made in very specific and limited cases. In addition, subsidies may also be granted in the event of the achievement of objectives previously negotiated with the supervisory authorities; in orthopaedics, it covers the entire pathway from diagnosis to rehabilitation in six regions of Sweden; In specialised facilities in ophthalmology, mental health and outpatient care in ten regions. The 64 specialised Capio facilities in Sweden are primarily financed through a global allocation system. This system involves the supervisory authorities allocating a budget according to the medical services offered and the types of care provided, which is then paid monthly. Some regions also offer a fee‑for‑service
Ramsay Santé / Universal Registration Document 2026
■
■ ■
At the St Göran Hospital in Stockholm, considered the benchmark for healthcare in Sweden. The Capio hospitals and in particular the St Göran Hospital in Stockholm benefit from mixed financing, which consists mainly of fee‑for‑service payments but also set budgets paid on the basis of quality and environmental indicators. This Capio service is contractualised. In geriatric and mobility care, at home or in a centre, in two regions; In partnership with more than 15 care partners.
A benchmark employer Capio is one of the leading employers in Sweden and is ranked No. 1 by nurses and No. 3 by doctors in terms of attractiveness.
Digitalisation to improve quality of care Capio has developed a digital interface that can be used for different types of care, such as prevention, asynchronous or real‑time, face‑to‑face or online care. It can be used for follow‑up care, where data is managed over time, as well as for consultation care, where reports are generated using artificial intelligence and support is provided for imaging analysis. It can also be used for administrative management, such as registration, payment and patient satisfaction.
The Norwegian and Danish scopes In Norway, Volvat and Aleris dominate the market. Volvat focuses primarily on those activities financed by private funds, while Aleris focuses more on activities related to public financing. ■ ■
it operates on 25 sites and has around 400,000 patient visits per year; it operates in primary care, Medicine‑Surgery‑Obstetrics, rehabilitation care, mental health and telemedicine.
In Denmark, Ramsay Santé (Capio and WeCare) dominates the market along with Aleris (number 2): ■ ■
operating on 39 sites and five hospitals, and has more than 120,000 patients listed in its primary care centres; it covers the following areas of care: primary care centres, Medicine‑Surgery‑Obstetrics, rehabilitation, imaging, mental health and telemedicine.
GENERAL PRESENTATION OF THE GROUP Exceptional events
1.3.4.3
The Ramsay Santé group in Italy
The Company operates in Italy through a public‑private partnership. Ramsay Santé has managed the Omegna Public Hospital in Italy's Piedmont region since 2002. Following a refocusing of the facility's activities to specialise in orthopaedics and related disciplines such as functional rehabilitation, neurosurgery and plastic surgery, the Group has retained its outpatient surgery and in‑house medicine activities in order to meet local care
1.4
needs. In consultation with the local health authorities, the centre is managed by Coq SpA, a mixed public/private company in which the Italian public structure Asl Vco14 holds a 51% stake and Ramsay Santé holds a 49% stake. Ramsay Santé is responsible for organising care and for the administration and maintenance of the whole facility. The contract was established as a 30‑year management agreement and will expire in 2031.
Exceptional events
An exceptional event took place during the 2026 financial year: On 20 February, the Ramsay Santé group announced that its shareholder, Ramsay Health Care Limited (RHC), would carry out a distribution in kind of its 52.79% stake in Ramsay Générale de Santé to its own shareholders. Pascal Roché, the Chief Executive Officer, said that this project would mark a new phase for Ramsay Santé. He added that the Group's strength of resources and positions would enable it to approach this evolution with confidence while remaining fully committed to providing high‑quality, innovative, accessible care in close collaboration with healthcare professionals and regions. Ramsay Santé will analyse all the potential legal, financial and operational implications of this operation and ensure the stability of its capital structure is preserved amid the potential expansion of the free float. According to information provided by RHC, the Project could be implemented in the fourth quarter of 2026, subject to the required approvals. As part of this transaction, following the end of the 2026 financial year, Ramsay Générale de Santé has applied for admission as an exempt foreign entity on the ASX. The Company also plans to put in place arrangements enabling RHC shareholders to hold their stake in Ramsay Générale de Santé in the form of CHESS Depositary Interests (CDIs), which will be tradable on the ASX, subject to the necessary approvals. A CDI would confer economic exposure and voting rights equivalent to those attached to a Ramsay Générale de Santé ordinary share. Ramsay Générale de Santé shares would remain listed on Euronext Paris. For detailed information on significant events during the financial year, see chapter 2, section 2.3.2 Note 2 – Highlights of the financial year.
Ramsay Santé / Universal Registration Document 2026
37
1
38
Ramsay Santé / Universal Registration Document 2026
2.1
FINANCIAL INFORMATION
40
2.1.1
Group consolidated financial statements
40
2.2
REVIEW OF FINANCIAL POSITION AND RESULTS
43
2.2.1
Comments on the Group’s results and financial position Liquidity and capital resources
43 48
FINANCIAL INFORMATION CONCERNING THE ASSETS, FINANCIAL POSITION AND RESULTS OF THE ISSUER (AND STATUTORY AUDITORS’ REPORT)
50
2.2.2
2.3
2.3.1 2.3.2
Historical financial information Group consolidated financial statements for the financial year ended 30 June 2026 Company financial statements Age of financial information Dividend distribution policy Disputes Significant changes in the financial or commercial position
51 119 138 138 138
2.4
CASH AND CAPITAL
139
2.4.1 2.4.2 2.4.3
Financing Cash and capital Debt position at 30 June 2026
139 139 140
2.5
INFORMATION ON PROFIT TRENDS, FORECASTS AND ESTIMATES
141
2.5.1 2.5.2 2.5.3
Recent developments and outlook Group profit forecasts Group objectives
141 141 142
2.6
PROPERTY AND EQUIPMENT
143
2.6.1 2.6.2
Management of property assets General description of the real estate assets occupied by the healthcare facilities The Group’s main movable equipment assets Material investments made during the financial year ended 30 June 2026
143
2.3.3 2.3.4 2.3.5 2.3.6 2.3.7
2.6.3 2.6.4
50
138
144 145 146
2
ANNUAL FINANCIAL INFORMATION
Ramsay Santé / Universal Registration Document 2026
39
2
ANNUAL FINANCIAL INFORMATION Financial information
2.1
Financial information
2.1.1
Group consolidated financial statements
The tables below present the Group’s consolidated income statement, consolidated statement of other comprehensive income, consolidated statement of financial position, condensed consolidated statement of cash flows and net financial debt for the financial years ended 30 June 2025 and 30 June 2026.
GROUP CONSOLIDATED INCOME STATEMENT From 1 July 2025 to 30 June 2026
From 1 July 2024 to 30 June 2025
Change
REVENUE
5,381.1
5,207.9(1)
3.3%
Of which revenue on a like‑for‑like basis(2)
5,326.8
5,207.9(1)
2.3%
EBITDA
637.7
621.4
2.6%
Current operating profit
196.9
187.4
5.1%
Operating profit
186.3
173.2
7.6%
Net borrowing cost
(191.2)
(194.4)
1.6%
Other finance income and expenses
(2.1)
(12.2)
82.6%
Income tax
(19.5)
(1.6)
-1,118.8%
Net profit from discontinued operations
(6.8)
(3.1)
-119.4%
NET PROFIT OF THE CONSOLIDATED GROUP
(33.3)
(38.1)
12.6%
■
Net profit attributable to owners of the parent
(48.3)
(54.1)
10.7%
■
Non‑controlling interests
15.0
16.0
-6.3%
NET EARNINGS PER SHARE (in euros)
(0.44)
(0.49)
10.2%
DILUTED NET EARNINGS PER SHARE (in euros)
(0.44)
(0.49)
10.2%
(in millions of euros)
(1) Adjusted for a reclassification of EUR (34.1) million on revenue and EUR 34.1 million on purchases used, with no impact on EBITDA. (2) The revenue presented is restated in accordance with the specific rules presented in section 2.2.1 in order to calculate the change in revenue on a like‑for‑like basis.
CONSOLIDATED STATEMENT OF OTHER COMPREHENSIVE INCOME From 1 July 2025 to 30 June 2026
From 1 July 2024 to 30 June 2025
Change
(33.3)
(38.1)
12.6%
Exchange differences
1.1
9.5
-88.4%
Fair value of hedging instruments
14.1
(9.9)
242.4%
Comprehensive income that can be subsequently reclassified to profit or loss
15.2
(0.4)
3,900.0%
Actuarial gains and losses on obligations for retirement bonuses
6.3
4.9
28.6%
Other
2.3
0.5
360.0%
Comprehensive income that cannot be subsequently reclassified to profit or loss
8.6
5.4
59.3%
Other comprehensive income after tax
23.8
5.0
376.0%
COMPREHENSIVE INCOME
(9.5)
(33.1)
71.3%
(24.5)
(49.1)
50.1%
15.0
16.0
-6.3%
(in millions of euros)
NET PROFIT OF THE CONSOLIDATED GROUP
40
■
Comprehensive income attributable to owners of the parent
■
Non‑controlling interests
Ramsay Santé / Universal Registration Document 2026
ANNUAL FINANCIAL INFORMATION Financial information
GROUP CONSOLIDATED STATEMENT OF FINANCIAL POSITION ASSETS (in millions of euros)
Goodwill & Other intangible assets Property, plant and equipment
30 June 2026
30 June 2025
2,273.6
2,293.4
931.2
936.0
Right of use
1,904.4
2,028.2
Investments in equity‑accounted companies and non‑current financial assets
255.4
160.2
Deferred tax assets NON‑CURRENT ASSETS
127.6
114.7
5,492.2
5,532.5
Inventories
131.3
125.1
Trade receivables
470.9
527.5
Other current assets
269.2
260.7
Current tax assets
7.3
6.3
Current financial assets
8.9
17.5
Cash and cash equivalents
302.2
366.5
CURRENT ASSETS
1,189.8
1,303.6
Assets held for sale TOTAL ASSETS LIABILITIES (in millions of euros)
Share capital Share premium and consolidated reserves
--
2.9
6,682.1
6,839.0
30 June 2026
30 June 2025
82.7
82.7
1,086.3
1,116.6
Net profit attributable to owners of the parent
(48.3)
(54.1)
Equity attributable to owners of the parent
1,120.7
1,145.2
Non‑controlling interests
35.1
36.6
TOTAL EQUITY
1,155.8
1,181.8
Borrowings and financial debt
1,854.6
1,841.2
13.3
16.9
1,849.0
1,890.5
Provisions for retirement and other employee benefits
100.9
102.9
Non‑current provisions
137.9
139.4
Debt on commitments to purchase non‑controlling interests Non‑current lease liability (IFRS 16)
Other non‑current liabilities
6.3
16.2
Deferred tax liabilities
38.4
29.4
NON‑CURRENT LIABILITIES
4,000.4
4,036.5
Current provisions
26.6
33.6
Suppliers
427.7
432.3
Other current liabilities and current tax liabilities
734.5
816.5
Current financial debt
68.2
61.0
Debt on commitments to purchase non‑controlling interests Current lease liability (IFRS 16) CURRENT LIABILITIES Liabilities related to assets held for sale TOTAL LIABILITIES
9.5
5.2
259.4
268.7
1,525.9
1,617.4
--
3.3
6,682.1
6,839.0
Ramsay Santé / Universal Registration Document 2026
2
41
2
ANNUAL FINANCIAL INFORMATION Financial information
GROUP CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS From 1 July 2025 to 30 June 2026
From 1 July 2024 to 30 June 2025
EBITDA
637.7
621.4
Cash flow from operations before net borrowing cost and tax
593.6
578.0
NET CASH FLOW FROM OPERATING ACTIVITIES
524.7
693.7
NET CASH FLOW FROM INVESTING ACTIVITIES
(132.9)
(138.4)
NET CASH FLOW FROM FINANCING ACTIVITIES
(454.0)
(550.2)
CHANGE IN NET CASH POSITION
(62.2)
5.1
(2.1)
2.4
Opening cash balance
366.5
359.0
Closing cash balance
302.2
366.5
30 June 2026
30 June 2025
Non‑current financial liabilities
1,854.6
1,841.2
Non‑current lease liability
1,849.0
1,890.5
Current lease liability
259.4
268.7
Current financial liabilities
68.2
61.0
(Cash)
(302.2)
(366.5)
Other financial (assets) and liabilities
(144.1)
(47.4)
3,584.9
3,647.5
(in millions of euros)
Impact of changes in foreign exchange rates
NET FINANCIAL DEBT (in millions of euros)
Net financial debt
42
Ramsay Santé / Universal Registration Document 2026
ANNUAL FINANCIAL INFORMATION Review of financial position and results
2.2 Review of financial position and results 2.2.1
2
Comments on the Group’s results and financial position
The following comments and analysis on the Group’s financial position should be read in conjunction with this Universal Registration Document as a whole, and in particular with the Group’s consolidated financial statements for the financial years ended 30 June 2025 and 30 June 2026. The alternative performance indicators are as follows: Alternative performance indicators
Definition
Rationale for use
Organic growth
This is growth measured on a like‑for‑like basis.
Used to assess the attractiveness of the model and to measure the development of activity linked to the acquisition of new patients on a like‑for‑like basis and excluding the impact of exchange rate fluctuations.
External growth
This is growth that is not organic growth.
Measures the impact of acquisitions that have led to a change in the scope of the company.
Like‑for‑like basis
Used to compare financial statements from The restatement of incoming entities one financial year to another and to measure consists of: ■ for entries in the current year’s scope, the economic and financial performance of deducting the contribution of the the company without acquisition or disposal acquisition of the current year’s of activities. aggregates; ■ for entries in the scope of the previous year, deducting, in the current year, the contribution of the acquisition of the aggregates of the months prior to the month of acquisition. The restatement of outgoing entities consists of: ■ for exits in the current year, deducting, in the previous year, the contribution of the exiting entity from the aggregates from the month of exit; ■ for exits in the previous year, deducting the contribution of the exiting entity for the entire previous year.
Constant exchange rate
This is a development after translation of the current period’s foreign currency figure at the exchange rate of the comparative period.
Current operating profit
Measures the Group’s recurring profit Operating profit before other non‑current excluding items that do not reflect the income and expenses consisting of restructuring costs (charges and provisions); Group’s recurring operating performance. gains or losses on disposals, significant and unusual impairment of non‑current property, plant and equipment or intangible assets and other unusual operating income and expenses.
Ramsay Santé / Universal Registration Document 2026
43
2
ANNUAL FINANCIAL INFORMATION Review of financial position and results
Alternative performance indicators
Definition
Rationale for use
EBITDA
Current operating profit before depreciation and amortisation (charges and provisions in the income statement are grouped according to their nature).
Reflects the pure performance and profitability of the Group’s business activity, independent of its depreciation system, financing and non‑recurring events.
Net financial debt
Net financial debt consists of gross financial This credit or debit position of the Group visdebt less financial assets. à-vis third parties outside the operating cycle is used for several financial ratios, including Gross financial debt consists of: ■ borrowings from credit institutions, the calculation of the leverage ratio. including accrued interest; ■ lease debt falling within the scope of IFRS 16 Leases; ■ the fair value of hedging instruments recorded in the balance sheet, net of tax; ■ current financial debt relating to non‑Group financial current accounts; ■ bank overdrafts. Financial assets consist of: ■ the fair value of hedging instruments recorded in the balance sheet, net of tax; ■ current financial receivables relating to non‑Group financial current accounts; ■ cash and cash equivalents, including treasury shares held by the Group (considered as marketable securities); ■ financial assets directly related to loans taken out and recognised in gross financial debt.
Gross financial debt
Gross financial debt consists of: Measures the sum of the Group’s financing commitments. borrowings from credit institutions, including accrued interest; ■ lease debt falling within the scope of IFRS 16 Leases; ■ the fair value of hedging instruments recorded in the balance sheet, net of tax; ■ current financial debt relating to non‑Group financial current accounts; ■ bank overdrafts. ■
Net cash position
The net cash position consists of: cash and cash equivalents; ■ bank overdrafts. ■
44
Ramsay Santé / Universal Registration Document 2026
Used to identify financial resources that can be quickly mobilised by the Group.
ANNUAL FINANCIAL INFORMATION Review of financial position and results
2.2.1.1
Revenue and operating results
2.2.1.1.1 Revenue See notes 4.1.1 and 5.1. The Group’s consolidated revenue for the financial year ended 30 June 2026 amounted to EUR 5,381.1 million, compared with EUR 5,207.9 million for the financial year ended 30 June 2025. The following table shows the respective share of healthcare, related services and fees paid by practitioners and others in the revenue of Ramsay Santé over the past two financial years ended 30 June 2025 and 2026: Financial year ended Business activity
30 June 2026 (in millions of euros)
30 June 2025 (% of revenue) (in millions of euros)
(% of revenue)
4,972.9
92.4%
4,789.2(1)
92.0%
Related services
197.6
3.7%
193.2
3.7%
Fees paid by practitioners and others
210.6
3.9%
225.5
4.3%
100.0%
(1)
100.0%
Healthcare
TOTAL
5,381.1
5,207.9
(1) Adjusted for a reclassification of EUR (34.1) million on revenue and EUR 34.1 million on purchases used, with no impact on EBITDA.
The following table presents the Group’s reported consolidated revenue on a like‑for‑like basis for the financial years ended 30 June 2025 and 30 June 2026. (in millions of euros)
From 1 July 2025 to 30 June 2026
From 1 July 2024 to 30 June 2025
Change
Reported revenue
5,381.1
5,207.9(1)
+3.3%
5,326.8
(1)
+2.3%
Revenue on a like‑for‑like basis Changes in the scope of consolidation and exchange rates
5,207.9
54.3
(1) Adjusted for a reclassification of EUR (34.1) million on revenue and EUR 34.1 million on purchases used, with no impact on EBITDA.
On a like‑for‑like basis, the Group’s revenue increased by 2.3%.
2.2.1.1.2 Costs and Fees The table below shows the breakdown of the costs and fees incurred by the Group over the past two financial years, as well as their representative share (as a percentage) of the Group’s revenue: 30 June 2026 Financial year ended
(in millions of euros)
Employee benefits
(2,735.3)
30 June 2025 (% of revenue) (in millions of euros)
(% of revenue)
-50.8%
(2,655.9)
-51.0%
(1)
Purchases used
(1,150.7)
-21.4%
(1,124.0)
-21.6%
Other operating income and expenses
(631.6)
-11.7%
(570.7)
-11.0%
Taxes and duties
(142.5)
-2.6%
(148.5)
-2.9%
Rents
(83.3)
-1.5%
(87.4)
-1.7%
TOTAL
(4,743.4)
-88.1%
(4,586.5)
-88.1%
(1) Adjusted for a reclassification of EUR (34.1) million on revenue and EUR 34.1 million on purchases used, with no impact on EBITDA.
Ramsay Santé / Universal Registration Document 2026
45
2
2
ANNUAL FINANCIAL INFORMATION Review of financial position and results
The main operating costs include: ■
■
■ ■
employee benefits, which are primarily made up of wages and salaries, social security contributions and other employee benefits such as incentives and profit‑sharing. These costs depend predominantly on the number of employees and the level of salaries; purchases used, which include the costs of drugs, consumables and medical supplies, chemotherapy molecules, blood and prostheses as well as other external purchases; other operating income and expenses as described in section 5.2.2 of the notes to the financial statements; taxes and duties, which mainly include payroll taxes and other tax charges as well as the business property tax (cotisation foncière des entreprises – “CFE”). In accordance with the provisions of IAS 12 Income Taxes, the corporate value‑added
levy (cotisation sur la valeur ajoutée des entreprises – “CVAE”) recognised in France meets the definition of an income tax. The corresponding expense of EUR 6.5 million at 30 June 2026 is recognised under “Income tax”; ■
rents, which mainly include those paid under contracts with a low unit value or those entered into for a term of less than one year and all taxes related to lease contracts.
2.2.1.1.3 EBITDA and current operating profit The table below shows the breakdown of the Group’s gross operating profit (“EBITDA”) and current operating profit for the past two financial years. EBITDA corresponds to current operating profit before depreciation and amortisation. In accordance with IAS 1 Presentation of Financial Statements, charges and provisions in the income statement are grouped according to their nature.
30 June 2026 Financial year ended
(in millions of euros)
EBITDA
30 June 2025 (% of revenue) (in millions of euros)
(% of revenue)
637.7
11.9%
621.4
11.9%
Depreciation/amortisation
(440.8)
-8.2%
(434.0)
-8.3%
Current operating profit
196.9
3.7%
187.4
3.6%
EBITDA at 30 June 2026 was EUR 637.7 million, up 2.6% compared to EUR 621.4 million at 30 June 2025. The reported EBITDA/Revenue margin was 11.9% at 30 June 2026, stable compared to the financial year ended 30 June 2025.
Current operating profit amounted to EUR 196.9 million at 30 June 2026, representing 3.7% of revenue, compared to EUR 187.4 million at 30 June 2025, representing 3.6% of revenue. Depreciation and amortisation amounted to EUR (440.8) million at 30 June 2026, i.e. -8.2% of revenue. At 30 June 2025, depreciation and amortisation amounted to EUR (434.0) million with a depreciation/revenue ratio of -8.3%.
2.2.1.1.4 Net borrowing cost and other non‑current income and expenses The table below shows the breakdown of the Group’s net borrowing cost and other non‑current income and expenses for the past two financial years: 30 June 2026
30 June 2025
Financial year ended
(in millions of euros)
(% of revenue) (in millions of euros)
Net borrowing cost
(191.2)
-3.6%
(194.4)
(% of revenue)
-3.7%
Net interest
(109.6)
-2.0%
(114.3)
-2.2%
Interest related to IFRS 16 lease debt
(81.6)
-1.5%
(80.1)
-1.5%
Other non‑current income & expenses
(10.6)
-0.2%
(14.2)
-0.3%
(18.9)
-0.4%
(17.5)
-0.3%
8.3
0.2%
3.3
0.1%
Of which: ■
Non‑current costs
■
Profit from the management of property and financial assets
At 30 June 2026, the net borrowing cost was a net expense of EUR 191.2 million (including EUR 81.6 million in financial interest related to lease debt under IFRS 16 Leases), versus EUR 194.4 million at 30 June 2025.
46
Ramsay Santé / Universal Registration Document 2026
The interest rate (financial expenses in relation to the average gross financial debt) was approximately 5.01% at 30 June 2026, stable compared to 30 June 2025.
ANNUAL FINANCIAL INFORMATION Review of financial position and results
2.2.1.1.5 Operating results The following table shows Ramsay Santé’s net profit attributable to owners of the parent for the last two financial years: 30 June 2026 Financial year ended
(in millions of euros)
30 June 2025 (% of revenue) (in millions of euros)
2
Net profit attributable to owners of the parent
(48.3)
2.2.1.2
year. Historically, the Group has observed that patients generally do not undertake non‑emergency care during the holidays, in August and December. The Group’s revenue is therefore lower during these two months. Conversely, the volume of consumption of hospital services (and therefore the Group’s revenue and profit) is particularly high in September and January (re‑entry periods).
Factors influencing the results
The Group’s results are largely dependent on the following four factors: ■ ■ ■
■
changes in the volume of care provided; changes in the rates charged for the care provided (mainly rates set by public authorities); changes in the costs incurred by the Group in providing this care (in particular purchase inflation, salary trends, etc.); and changes in the cost of debt.
2.2.1.2.1 External and internal growth The Group makes strategic acquisitions and disposals in order to: ■
■
strengthen its presence in geographical areas where it has chosen to be a key player and expand its geographical footprint; increase its service offering so as to have a presence in all segments of the care offer.
See notes 2 and 3. In addition to its external growth, Ramsay Santé has continuously pursued its internal efforts to improve its operating margins. These efforts have focused on increasing the volume of care provided, in particular through capacity investments (aimed at implementing new administrative authorisations and/or changes in the facility’s capacity, whether in terms of accommodation, operating theatres or major equipment) and improving the utilisation rates of these operating theatres and major equipment. Ramsay Santé also relies on the quality and scope of its offer as well as the reputation of its medical teams and equipment to attract new patients and increase the volume of care provided.
2.2.1.2.2 Seasonality The Group’s revenue and profit are subject to a slight seasonality in the volume of treatments performed during the
-0.9%
(% of revenue)
(54.1)
-1.0%
2.2.1.2.3 Price indexation Ramsay Santé operates in a regulated environment.
2.2.1.2.4 Costs incurred by the Group Faced with regulatory constraints, the Group is determined to control its costs through ongoing optimisation efforts (non‑healthcare services).
2.2.1.2.5 A new phase in Ramsay Santé's shareholder structure and associated costs On February 20th, 2026, Ramsay Santé publicly noted the announcement by its shareholder, Ramsay Health Care Limited (RHC), of a proposed plan to distribute its 52.79% shareholding in Ramsay Santé to RHC’s own shareholders. The costs associated with this transaction, which will be borne by the Group, are estimated at approximately €19.3 million before tax (net of Ramsay Health Care Contribution), of which €5.7 million was recognised in the financial year ended 30 June 2026. These costs mainly consist of advisory fees (financial, legal and tax), as well as expenses related to the implementation of the transaction (including the listing of CDIs on the ASX and the rebranding process). These amounts are based on estimates and may be adjusted to reflect the actual costs incurred.
2.2.1.3
Accounting principles, methods and estimates
Please refer to note 1 to the financial statements.
Ramsay Santé / Universal Registration Document 2026
47
2
ANNUAL FINANCIAL INFORMATION Review of financial position and results
2.2.2
Liquidity and capital resources
2.2.2.1
Cash and cash equivalents
During the 2026 financial year, the Group mainly used its cash for: ■ ■ ■
■ ■
investments in property, plant and equipment and intangible assets (EUR 143.9 million at 30 June 2026); financial investments, i.e. the acquisition of entities (EUR 2.7 million at 30 June 2026); the payment of dividends to non‑controlling interests of consolidated companies (EUR 16.5 million at 30 June 2026); net interest (EUR 191.2 million at 30 June 2026); the repayment of financial debt and lease liabilities (EUR 336.0 million at 30 June 2026).
Its main sources of cash are: ■ ■
net cash flow from operating activities (EUR 524.7 million);
At 30 June 2026, the Group had a positive cash position of EUR 302.2 million, compared to EUR 366.5 million at 30 June 2025. At the same date, the change in the working capital requirement related to the business activity was EUR (44.0) million, compared to EUR 135.4 million at 30 June 2025. At 30 June 2026, the Group had invested EUR 192.5 million in capital expenditure related to fixed assets (industrial investments: acquisition of buildings and equipment), of which EUR 143.9 million disbursed and EUR 48.6 million of industrial investments financed by leasing. At 30 June 2026, financial investment amounted to EUR 2.7 million. The total amount (cash and leasing) of industrial and financial investments therefore stood at EUR 195.2 million at 30 June 2026.
disposals of subsidiaries (EUR 1.6 million).
The following table shows the breakdown of expenses by type of investment: 30 June 2026 Financial year ended
(% of revenue) (in millions of euros)
(% of revenue)
Maintenance/renewal investments
110.5
2.1%
115.8
2.2%
IT systems modernisation investments
23.0
0.4%
18.9
0.4%
Combinations/creations/reconversions
10.0
0.2%
9.4
0.1%
TOTAL INDUSTRIAL INVESTMENTS EXCLUDING CAPACITY
143.5
2.7%
144.1
2.7%
Capacity/innovation investments
49.0
0.9%
45.8
0.9%
TOTAL NET INDUSTRIAL INVESTMENTS
192.5
3.6%
189.9
3.6%
TOTAL FINANCIAL INVESTMENTS TOTAL INVESTMENTS
48
(in millions of euros)
30 June 2025
Ramsay Santé / Universal Registration Document 2026
2.7
5.1
195.2
195.0
ANNUAL FINANCIAL INFORMATION Review of financial position and results
2.2.2.2 Financing The tables below show the Group’s cash flows and net financial debt for the financial years ended 30 June 2025 and 30 June 2026: From 1 July 2025 to 30 June 2026
From 1 July 2024 to 30 June 2025
EBITDA
637.7
621.4
Change in working capital requirement
(44.0)
135.4
Net interest paid
(102.9)
(107.0)
Interest related to IFRS 16 lease debt
(81.6)
(80.1)
Income tax paid
(21.3)
(17.9)
Non‑current and other
(44.1)
(43.4)
Investment in property, plant and equipment and intangible assets
(143.9)
(142.8)
FREE CASH FLOW*
199.9
365.6
Disposals of property, plant and equipment and intangible assets
50.3
7.0
Net impact of discontinued operations
(7.0)
(2.2)
Loan issue costs
(1.0)
(14.2)
Acquisition of subsidiaries
(2.7)
(5.1)
Disposal of subsidiaries
(1.6)
1.3
Change in other financial assets
(32.5)
Dividends paid out or received
(15.6)
(12.8)
CASH FLOW (before financing operations)
189.8
339.6
(in millions of euros)
2
- Net cash flow from operating activities after interest paid and after investment in property, plant and equipment and intangible assets.
(in millions of euros)
30 June 2026
30 June 2025
NET DEBT AT OPENING
3,647.5
3,610.9
Cash flow (before financing operations)
(189.8)
(339.6)
Capitalised loan issue costs
7.3
(3.6)
Fair value of hedging instruments
(14.1)
15.3
Changes in scope of consolidation and other
(96.5)
(1.5)
IFRS 16 lease liabilities
230.5
366.0
NET DEBT AT CLOSING
3,584.9
3,647.5
An analysis of the Group’s net financial debt structure at 30 June 2025 and 30 June 2026 is presented in note 9.2 to the financial statements.
2.2.2.3 Company commitments Schedule of financial debt
Off‑balance sheet commitments
Please refer to note 9.5.2 to the financial statements.
Please refer to note 13.1 to the financial statements.
Ramsay Santé / Universal Registration Document 2026
49
2
ANNUAL FINANCIAL INFORMATION Financial information concerning the assets, financial position and results of the issuer (and Statutory Auditors’ report)
2.3 Financial information concerning the assets, financial position and results of the issuer (and Statutory Auditors’ report) 2.3.1
Historical financial information
The Universal Registration Document for the financial year ended 30 June 2025 is available on the Company’s website (http:// www.ramsaysante.eu) and the French Financial Markets Authority (AMF - Autorité des Marchés Financiers) website (http:// www.amf‑france.org/en).
50
Ramsay Santé / Universal Registration Document 2026
ANNUAL FINANCIAL INFORMATION Financial information concerning the assets, financial position and results of the issuer (and Statutory Auditors’ report)
2.3.2
Group consolidated financial statements for the financial year ended 30 June 2026
2.3.2.1
Consolidated statements of income, comprehensive income, financial position, changes in equity and cash flows for the financial year ended 30 June 2026
2
CONSOLIDATED STATEMENT OF INCOME (in millions of euros)
Note
From 1 July 2025 to 30 June 2026
From 1 July 2024 to 30 June 2025
REVENUE
4.1.1
5,381.1
5,207.9(1)
Employee benefits
5.2.1
(2,735.3)
(2,655.9)
(1,150.7)
(1,124.0)(1)
(631.6)
(570.7)
(142.5)
(148.5)
(83.3)
(87.4)
EBITDA
637.7
621.4
Depreciation and amortisation
(440.8)
(434.0)
Current operating profit
196.9
187.4
(10.6)
(14.2)
186.3
173.2
Purchases used Other operating income and expenses
5.2.2
Taxes and duties Rents
Other non‑current income & expenses
7.1.4
5.2.3
Operating profit Gross borrowing cost
9.1.1
(112.8)
(119.0)
Income from cash and cash equivalents
9.1.1
3.2
4.7
Financial interest related to IFRS 16 lease debt
7.1.3
(81.6)
(80.1)
Net borrowing cost
9.1.1
(191.2)
(194.4)
Other financial income
4.7
3.5
Other financial expenses
(6.8)
(15.7)
9.1.2
(2.1)
(12.2)
11
(19.5)
(1.6)
(6.8)
(3.1)
NET PROFIT OF THE CONSOLIDATED GROUP
(33.3)
(38.1)
■
Net profit attributable to owners of the parent
(48.3)
(54.1)
■
Non‑controlling interests
15.0
16.0
NET EARNINGS PER SHARE (in euros)
(0.44)
(0.49)
DILUTED NET EARNINGS PER SHARE (in euros)
(0.44)
(0.49)
Other finance income and expenses Income tax Net profit from discontinued operations
(1) Adjusted for a reclassification of EUR (34.1) million on revenue and EUR 34.1 million on purchases used, with no impact on EBITDA.
Ramsay Santé / Universal Registration Document 2026
51
2
ANNUAL FINANCIAL INFORMATION Financial information concerning the assets, financial position and results of the issuer (and Statutory Auditors’ report)
CONSOLIDATED STATEMENT OF OTHER COMPREHENSIVE INCOME From 1 July 2025 to 30 June 2026
From 1 July 2024 to 30 June 2025
(33.3)
(38.1)
Exchange differences
1.1
9.5
Fair value of hedging instruments
14.1
(9.9)
Comprehensive income that can be subsequently reclassified to profit or loss
15.2
(0.4)
6.3
4.9
Other
2.3
0.5
Comprehensive income that cannot be subsequently reclassified to profit or loss
8.6
5.4
Other comprehensive income after tax
23.8
5.0
COMPREHENSIVE INCOME
(9.5)
(33.1)
(24.5)
(49.1)
15.0
16.0
(in millions of euros)
Note
NET PROFIT OF THE CONSOLIDATED GROUP
Actuarial gains and losses on obligations for retirement bonuses
52
■
Comprehensive income attributable to owners of the parent
■
Non‑controlling interests
Ramsay Santé / Universal Registration Document 2026
10.3
ANNUAL FINANCIAL INFORMATION Financial information concerning the assets, financial position and results of the issuer (and Statutory Auditors’ report)
CONSOLIDATED STATEMENT OF FINANCIAL POSITION – ASSETS (in millions of euros)
Note
30 June 2026
30 June 2025
Goodwill
6.1
2,063.4
2,087.9
Other intangible assets
6.2
210.2
205.5
Property, plant and equipment
6.3
931.2
936.0
Right of use (IFRS 16)
7.1.1
1,904.4
2,028.2
Investments in equity‑accounted companies
16.1.2
0.2
0.2
Non‑current financial assets
9.4.1
255.2
160.0
Deferred tax assets
11.4
127.6
114.7
NON‑CURRENT ASSETS
5,492.2
5,532.5
Inventories
5.2.4
131.3
125.1
Trade receivables
5.2.4
470.9
527.5
Other current assets
5.2.4
269.2
260.7
Current tax assets
11.3
7.3
6.3
Current financial assets
9.2
8.9
17.5
Cash and cash equivalents
302.2
366.5
CURRENT ASSETS
1,189.8
1,303.6
ASSETS HELD FOR SALE
3.2
TOTAL ASSETS
--
2.9
6,682.1
6,839.0
2
CONSOLIDATED STATEMENT OF FINANCIAL POSITION – LIABILITIES AND EQUITY (in millions of euros)
Note
30 June 2026
30 June 2025
Capital
12.1
82.7
82.7
Share premium
611.2
611.2
Consolidated reserves
475.1
505.4
Net profit attributable to owners of the parent
CSOCI
(48.3)
(54.1)
Equity attributable to owners of the parent
E
1,120.7
1,145.2
Non‑controlling interests
E
35.1
36.6
TOTAL EQUITY Borrowings and financial debt
E
1,155.8
1,181.8
9.2
1,854.6
1,841.2
13.3
16.9
7.1.2
1,849.0
1,890.5
10.3.2
100.9
102.9
8.1
137.9
139.4
6.3
16.2
Debt on commitments to purchase non‑controlling interests Non‑current lease liability (IFRS 16) Provisions for retirement and other employee benefits Non‑current provisions Other non‑current liabilities Deferred tax liabilities
11.4
38.4
29.4
4,000.4
4,036.5
8.1
26.6
33.6
5.2.4
427.7
432.3
5.2.4.3
721.3
811.1
NON‑CURRENT LIABILITIES Current provisions Suppliers Other current liabilities Current tax liabilities
11.3
13.2
5.4
Current financial debt
9.2
68.2
61.0
9.5
5.3
7.1.2
259.4
268.7
1,525.9
1,617.4
--
3.3
6,682.1
6,839.0
Debt on commitments to purchase non‑controlling interests Current lease liability (IFRS 16) CURRENT LIABILITIES LIABILITIES RELATED TO ASSETS HELD FOR SALE TOTAL LIABILITIES
3.2
Ramsay Santé / Universal Registration Document 2026
53
2
ANNUAL FINANCIAL INFORMATION Financial information concerning the assets, financial position and results of the issuer (and Statutory Auditors’ report)
CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
(in millions of euros)
Note
Noncontrolling interests
Equity
Capital
Premium
Reserves
82.7
611.2
615.6
(61.3)
(53.9)
1,194.3
35.4
1,229.7
--
--
--
--
--
--
--
--
Treasury shares
--
--
--
--
--
--
--
--
Stock options and bonus shares
--
--
--
--
--
--
--
--
Result N‑1 to be allocated
--
--
(53.9)
--
53.9
--
--
--
--
--
--
--
--
--
(14.4)
(14.4)
Changes in scope of consolidation and other
--
--
--
--
--
--
(0.4)
(0.4)
Comprehensive income for the year
--
--
--
5.0
(54.1)
(49.1)
16.0
(33.1)
82.7
611.2
561.7
(56.3)
(54.1)
1,145.2
36.6
1,181.8
Profit recognised Net profit/ directly in (loss) Group equity share
Equity attributable to owners of the parent
Noncontrolling interests
Equity
At 30 June 2024 Capital increase (after deduction of issue costs net of tax)
Dividend distribution
SCF
SCF
At 30 June 2025
(in millions of euros)
Note
Capital
Premium
Reserves
82.7
611.2
561.7
(56.3)
(54.1)
1,145.2
36.6
1,181.8
--
--
--
--
--
--
--
--
Treasury shares
--
--
--
--
--
--
--
--
Stock options and bonus shares
--
--
--
--
--
--
--
--
Result N‑1 to be allocated
--
--
(54.1)
--
54.1
--
--
--
--
--
--
--
--
--
(16.5)
(16.5)
Changes in scope of consolidation and other
--
--
--
--
--
--
--
--
Comprehensive income for the year
--
--
--
23.8
(48.3)
(24.5)
15.0
(9.5)
82.7
611.2
507.6
(32.5)
(48.3)
1,120.7
35.1
1,155.8
At 30 June 2025 Capital increase (after deduction of issue costs net of tax)
Dividend distribution
SCF
SCF
At 30 June 2026
54
Equity Profit attributrecognised Net profit/ able to directly in (loss) Group owners of equity share the parent
Ramsay Santé / Universal Registration Document 2026
ANNUAL FINANCIAL INFORMATION Financial information concerning the assets, financial position and results of the issuer (and Statutory Auditors’ report)
CONSOLIDATED STATEMENT OF CASH FLOWS (in millions of euros)
Note
From 1 July 2025 to 30 June 2026
From 1 July 2024 to 30 June 2025
Net profit of the consolidated group
CSOCI
(33.3)
(38.1)
Depreciation and amortisation
CSOCI
440.8
434.0
Other non‑current income & expenses
CSOCI
10.6
14.2
Other finance income and expenses
CSOCI
2.1
12.2
Financial interest related to IFRS 16 lease debt
CSOCI
81.6
80.1
Net borrowing cost excluding financial interest related to lease debt
CSOCI
109.6
114.3
Income tax
CSOCI
19.5
1.6
6.8
3.1
CSOCI
637.7
621.4
Net profit from discontinued operations EBITDA Non‑cash items relating to recognition and reversal of provisions (transactions of a non‑cash nature) Other non‑current income and expenses paid
9.2
(8.2)
(4.2)
5.2.3
(17.4)
(16.5)
(18.5)
(22.7)
Change in other non‑current assets and liabilities Cash flow from operations before cost of net financial debt and tax Income tax paid Change in working capital requirement
593.6
578.0
11.3
(21.3)
(17.9)
5.2.4
(44.0)
135.4
Impact of discontinued operations on operating cash flows
(3.6)
(1.8)
NET CASH FLOW FROM OPERATING ACTIVITIES: (A)
524.7
693.7
Investment in property, plant and equipment and intangible assets
(143.9)
(142.8)
Disposals of property, plant and equipment and intangible assets
50.3
7.0
Acquisition of subsidiaries
(2.7)
(5.1)
Disposal of subsidiaries
(1.6)
1.3
Change in other financial assets Dividends received
9.1.2
Impact of discontinued operations on investment flows NET CASH FLOW FROM INVESTING ACTIVITIES: (B)
(32.5)
0.9
1.6
(3.4)
(0.4)
(132.9)
(138.4)
--
--
Capital increase and share premium: (a)
E
Capital increase of subsidiaries subscribed by third parties: (b)
E
--
--
Dividends paid to minority shareholders of consolidated companies: (c)
E
(16.5)
(14.4)
9.1.1
(104.5)
(108.5)
1.6
1.5
(81.6)
(80.1)
Interest paid: (d) Financial income received and other financial expenses paid: (e) Financial interest related to lease debt (IFRS 16): (f)
7.1.3
Loan issue costs: (g) Flow before debt: (h) = (A + B + a + b + c + d + e + f + g)
(1.0)
(14.2)
189.8
339.6
Increase in financial debt: (i)
9.2.1
76.3
63.1
Repayment of financial debt: ( j)
9.2.1
(45.4)
(148.2)
Decrease in lease debt (IFRS 16): (k)
9.2.1
(290.6)
(251.6)
7.7
2.2
NET CASH FLOWS FROM FINANCING OPERATIONS: (C) = a + b + c + d + e + f + g + i + j + k + l
(454.0)
(550.2)
CHANGE IN NET CASH POSITION: (A + B + C)
(62.2)
5.1
Impact of changes in foreign exchange rates
(2.1)
2.4
Impact of discontinued operations on financing flows: (l)
Opening cash balance
366.5
359.0
Closing cash balance
302.2
366.5
2
The “Note” column indicates the appropriate note numbers and / or “CSOCI”, “B”, “E”, “SCF”, with “CSOCI” = consolidated statement of comprehensive income, “B” = consolidated statement of financial position, “E” = consolidated statement of changes in equity and “SCF” = consolidated statement of cash flows.
Ramsay Santé / Universal Registration Document 2026
55
2
ANNUAL FINANCIAL INFORMATION Financial information concerning the assets, financial position and results of the issuer (and Statutory Auditors’ report)
SUMMARY CONSOLIDATED FINANCIAL STATEMENTS
NOTE 1 BASIS FOR PREPARATION OF THE CONSOLIDATED FINANCIAL STATEMENTS
57
NOTE 10 WORKFORCE, EMPLOYEE‑RELATED EXPENSES AND BENEFITS, REMUNERATION
1.1 1.2 1.3 1.4
57 57 58 58
10.1 10.2 10.3 10.4
Declaration of compliance Changes in accounting standards Translation of foreign currency items Use of estimates and judgements
NOTE 2 SIGNIFICANT EVENTS OF THE FINANCIAL YEAR
59
NOTE 3 SCOPE OF CONSOLIDATION
60
3.1 3.2
61
Main changes in the scope of consolidation Assets held for sale and discontinued operations
NOTE 4 SEGMENT INFORMATION
4.1
64
64
95
95 95 95 98
NOTE 11 INCOME TAX
98
11.1 11.2
99
11.3 11.4 11.5 11.6
Tax expense for the financial year Reconciliation between the theoretical and effective tax rates Current tax assets and liabilities Deferred tax assets and liabilities Unrecognised deferred taxes Taxes on income and expenses recognised directly in equity
99 100 100 100 101
NOTE 5 OPERATING DATA
66
NOTE 12 EQUITY AND EARNINGS PER SHARE
101
5.1 5.2
66 68
12.1 12.2
101
Revenue Operating profit
NOTE 6 INTANGIBLE ASSETS AND PROPERTY, PLANT AND EQUIPMENT
73
6.1 6.2 6.3 6.4
74 75 75 76
Goodwill Other intangible assets Property, plant and equipment Impairment testing
NOTE 7 LEASES
78
7.1
79
Leases
12.3 12.4 12.5
Share capital Income and expenses recognised directly in equity Dividends Non‑controlling interests Net earnings per share
102 102 102 102
NOTE 13 UNRECOGNISED ITEMS
103
13.1 13.2
103 103
Off‑balance sheet commitments Litigation and contingent liabilities
NOTE 14 STATUTORY AUDITORS’ FEES
104
NOTE 8 PROVISIONS
81
NOTE 15 POST‑CLOSING EVENTS
104
8.1 8.2
82 83
NOTE 16 OTHER INFORMATION
104
16.1
104
NOTE 9 FINANCING AND FINANCIAL INSTRUMENTS
84
9.1 9.2 9.3 9.4
84 85 89
NOTE 17 MAIN ENTITIES INCLUDED IN THE SCOPE OF CONSOLIDATION
9.5
56
Consolidated income statement and balance sheet by operating segment
63
Workforce Employee‑related expenses Pension and similar commitments Remuneration and similar benefits granted to members of the Board of Directors and to the Chief Executive
Provisions Mermoz litigation Financial profit (loss) Net financial debt Derivatives Financial assets and liabilities and fair value hierarchy Financial risk management
Ramsay Santé / Universal Registration Document 2026
89 93
Related‑party information
105
ANNUAL FINANCIAL INFORMATION Financial information concerning the assets, financial position and results of the issuer (and Statutory Auditors’ report)
Note 1
1.1
Basis for preparation of the consolidated financial statements
Declaration of compliance
Ramsay Générale de Santé is a limited liability company (société anonyme) under French law having its registered office at 67 rue Arago, 93400 Saint‑Ouen‑sur‑Seine, France. It is the parent company of a group that carries out all its activities in the Hospital Healthcare and Services segment. The Group’s main shareholders are Ramsay Health Care and Predica. The Ramsay Santé group prepares its consolidated financial statements in accordance with the International Financial Reporting Standards (IFRS) in force at 30 June 2026 as adopted by the European Union and available on the website:
They are presented in millions of euros. In some cases, rounding may result in an insignificant difference in the totals. The consolidated financial statements closed at 30 June 2026, including the notes to the financial statements, were prepared by Ramsay Santé’s Executive Management and reviewed on 5 October 2026 by the Audit Committee, then examined and approved by the Board of Directors on 6 October 2026.
https://finance.ec.europa.eu/index_en
1.2
Changes in accounting standards
1.2.1 New standards, amendments and interpretations in force within the European Union that are mandatory for financial years beginning on or after 1 July 2025 When preparing its consolidated financial statements for the financial year ended 30 June 2026, the Ramsay Santé group has applied the same accounting standards, interpretations and policies as those applied for its financial statements for the year ended 30 June 2025, as well as the new standards, amendments and interpretations adopted by the European Union and applicable as of 1 July 2025 as defined in the table below: Standard
Date of first application in the Group’s consolidated financial statements
Description
Amendments to IAS 21 The Effects of changes in foreign Effects of Changes in Foreign exchange rates: no Exchange Rates convertibility.
1 July 2025
Impacts
No material impact on the financial statements.
1.2.2 Texts adopted by the European Union Standard, amendments and interpretations
Description
Date of application
Amendments to IFRS 9 and IFRS 7
Classification and measurement of financial instruments.
1 January 2026
Amendments to IFRS 1, IFRS 7, IFRS 9, IFRS 10 Annual improvements - Volume 11. and IAS 7
1 January 2026
IFRS 18 Presentation and disclosure in financial statements
1 January 2027
Presentation and disclosure in financial statements.
For the Ramsay Santé group, the first mandatory application of IFRS 18 Presentation of Financial Statements and Disclosures will take place in respect of the first financial year commencing after 1 January 2027. The Group is continuing its analysis of the implications of this standard, in particular on the structure of the income statement, the subtotals presented, the principles of aggregation and disaggregation, and the information relating to the performance measures
defined by management. At this stage, the Group expects this standard to mainly have an impact on the presentation of the financial statements and the disclosures. Ramsay Santé does not anticipate any material impact on the consolidated financial statements due to the application of other texts. The Group has not opted for the early application of any texts.
Ramsay Santé / Universal Registration Document 2026
57
2
2
ANNUAL FINANCIAL INFORMATION Financial information concerning the assets, financial position and results of the issuer (and Statutory Auditors’ report)
1.3
Translation of foreign currency items
The Group presents its financial statements in euros.
1.3.1 Translation of financial statements denominated in foreign currencies The assets and liabilities of consolidated foreign subsidiaries whose functional currency is different from the Group’s reporting currency are translated at the exchange rates prevailing at closing. Their income statement items are translated using the average rate for the period. The resulting exchange differences are recorded under “exchange differences” in other comprehensive income. The exchange rates used to convert currencies into euros are as follows: At 30 June 2026
Closing price
Average price
SEK (Sweden)
11.0749
10.9149
DKK (Denmark)
7.4740
7.4686
NOK (Norway)
11.3037
11.4772
1.3.2 Translation of foreign currency transactions Transactions carried out by a company in a currency other than its functional currency are translated at the exchange rate prevailing on the date of the transaction. Intragroup financing made available to certain Group subsidiaries and for which repayment is neither planned nor probable is considered to be an integral part of net investments made abroad; the exchange differences generated at the time of their successive remeasurements at each balance sheet date are then recognised directly in other comprehensive income, in accordance with the provisions of IAS 21 Effects of Changes in Foreign Exchange Rates.
1.4
Use of estimates and judgements
The preparation of consolidated financial statements in accordance with international accounting standards requires that the Group’s management exercise judgement and make estimates based on certain assumptions that have an impact on the amount of assets and liabilities recognised at the balance sheet date and the amount of income and expenses for the year. Estimates are based on information available at the time of their preparation and may be revised if the circumstances on which they were based change or as new information becomes available. Actual results may differ from these estimates. Items requiring significant estimates or a significant degree of judgement by management when preparing the financial statements relate mainly to: ■
58
the valuation of goodwill, property, plant and equipment and intangible assets and the determination of Cash‑Generating Units (CGUs) in the context of impairment testing;
Ramsay Santé / Universal Registration Document 2026
■ ■ ■ ■ ■ ■
estimated lease terms and the valuation of right‑of‑use assets and lease liabilities; the measurement of discounts; the measurement of the fair value of identifiable assets acquired and liabilities in business combinations; the assessment of the future profit outlook for the recognition of deferred tax assets and their use; estimated pension commitments; the measurement of provisions.
ANNUAL FINANCIAL INFORMATION Financial information concerning the assets, financial position and results of the issuer (and Statutory Auditors’ report)
Note 2
Significant events of the financial year
Announcement of the proposed distribution by Ramsay Health Care to its shareholders of its stake in Ramsay Santé
Optimisation of the real estate asset portfolio: sales and lease‑back of four facilities in France in May 2026
On 20 February 2026, Ramsay Santé took note of the project announced by its shareholder, Ramsay Health Care Limited (RHC), to carry out a distribution in kind of its 52.79% stake in Ramsay Générale de Santé to its own shareholders. The project would be implemented through a 'scheme of arrangement' under Australian law, subject to the approval of the RHC Board of Directors and shareholders, as well as the necessary judicial and regulatory approvals. Ramsay Santé will analyse all the potential legal, financial and operational implications of this project and ensure the stability of its capital structure is preserved amid the potential expansion of the free float. According to information provided by RHC, the project could be implemented in the fourth quarter of 2026, subject to the necessary approvals being granted. In accordance with the applicable regulations, Ramsay Santé has conducted the necessary information and consultation procedures with its employee representative bodies.
The Group sold the real estate assets of four of its French facilities at the end of May 2026 to La Française REM for EUR 45 million (net of duties). It leases these assets under 12‑year leases. Ramsay Santé continues to operate these three mental health facilities and this MSO facility, which are firmly anchored in their respective territories. Additional work will be carried out to enhance the value of the real estate properties and adapt them to the requirements of the energy transition. This transaction generates additional liquidity through the sale of a limited part of the Group’s real estate portfolio so that it can finance its activity while maintaining operational control of these facilities over the long term. It also demonstrates the attractiveness of the Group’s assets and the robustness of the activities concerned. See note 5.2.3 in the appendix.
Group subsidiary Capio started the new St. Göran hospital management contract in January 2026
On 30 July 2025, Ramsay Santé acquired the Hôpital Privé Jean Mermoz building by exercising the EUR 30.7 million purchase option provided for in the expiring finance lease. At the same time, the Group took out a 12‑year mortgage loan for EUR 65 million, a transaction that follows on from the previous financing on this hospital asset.
On 5 January 2026, Group subsidiary Capio began the execution of the new contract for the management of the St. Göran hospital entrusted by the Stockholm region. Capio won the tender for this contract on 22 October 2024 for a minimum period of eight years, with an option for the Stockholm region to extend it for a maximum of four years. The transition went according to plan.
2
Hôpital Privé Jean Mermoz real estate transaction
Changes in scope In December 2025, Volvat, the Group’s Norwegian subsidiary, acquired an ophthalmology facility, thus strengthening its expertise and service offering. See note 3.1.1 in the appendix. In June 2026, Ramsay divested two separate, non‑strategic and non‑hospital activities: (i) the Baya Hotel in Cape Breton, France, sold to Parallel Hospitality, and (ii) the medical transport activities in the Lyon region, also in France, sold to Hunault group (specialist provider of medical transport services). The net proceeds from the disposal and the contribution to the income statement of these activities are not material for the Group. The medical transport activity had been classified as “Discontinued operations” in the Group’s financial statements since the financial year ended 30 June 2025.
Ramsay Santé / Universal Registration Document 2026
59
2
ANNUAL FINANCIAL INFORMATION Financial information concerning the assets, financial position and results of the issuer (and Statutory Auditors’ report)
Note 3
Scope of consolidation
Accounting principles Full consolidation of subsidiaries The full consolidation method is applied to consolidate the financial statements of entities in which Ramsay Santé exercises direct or indirect control. Control is assessed by the Group’s exposure to the entity’s returns and the potential to influence these returns due to the power exercised over the entity. New companies entering the scope of consolidation are consolidated from the date on which they are taken over by Ramsay Santé. All transactions between consolidated companies are eliminated, as are intragroup results. Equity method for associates and joint ventures Entities over which Ramsay Santé exercises significant influence or joint control are recognised using the equity method. Significant influence is presumed to exist when more than 20% of the voting rights are held. Joint control is a contractual sharing of power between two or more partners who act together to direct the relevant activities of an entity. Equity‑accounted investments are initially recognised at their acquisition cost and this carrying amount is increased or decreased by the Group’s share in the results of the entity held after the acquisition date. Business combinations Business combinations are accounted for using the acquisition method. The acquisition cost is the fair value, at the acquisition date, of the components of remuneration given to the seller in exchange for control of the acquired entity. Goodwill is recognised in the statement of financial position for the difference between: ■ ■
the counterparty transferred, plus the amount of any non‑controlling interests, and, where applicable, the fair value of any previously held equity interests; and the fair value of identifiable assets acquired and liabilities assumed at the date on which control was obtained.
For each takeover involving an equity stake of less than 100%, the portion of interests not acquired, corresponding to non‑controlling interests, is measured: ■ ■
either at its share in the identifiable net assets of the entity acquired, leading to the recognition of goodwill only in respect of the portion acquired (“partial goodwill” method); or at its fair value, resulting in the recognition of goodwill in respect of the non‑controlling interests (“full goodwill” method).
On the date of acquisition, the Group identifies and measures at fair value the assets acquired and liabilities assumed. It has a period of 12 months from the date of the takeover to finalise the accounting of the business combination. Any adjustments or earn‑outs are included in the price and measured at fair value from the acquisition date, regardless of their likelihood of occurrence. During the allocation period, subsequent adjustments are recognised as goodwill when they relate to facts and circumstances that existed at the acquisition date; otherwise and beyond that, they are recognised directly in income. When the takeover is carried out in stages, the Group’s previous stake is remeasured at fair value, on the date of takeover, through profit or loss. To determine goodwill, the acquisition price is increased by the fair value of the stake previously held. Costs directly attributable to the acquisition are recognised in “Non‑current income and expenses” over the period in which they are incurred.
60
Ramsay Santé / Universal Registration Document 2026
ANNUAL FINANCIAL INFORMATION Financial information concerning the assets, financial position and results of the issuer (and Statutory Auditors’ report)
Assets held for sale and discontinued operations Where the Group expects to recover the value of an asset, or group of assets, through a sale rather than use, the asset is presented separately on the line “Assets held for sale” in the statement of financial position. Liabilities relating to this asset, if any, are also presented on a separate line of the statement of financial position (“Liabilities related to assets held for sale”). An asset classified as such is measured at the lower of its net carrying amount and its fair value less estimated disposal costs.
2
A discontinued operation is a component that the Group has divested, or that is classified as held for sale, meeting at least one of the following criteria: ■ ■ ■
it represents a core and distinct line of business or geographical area for the Group; it is part of a single and coordinated plan for the disposal of a core and distinct line of business or geographical area; it is an activity acquired exclusively with a view to resale.
Income and the capital gains or losses from the sale of these activities are presented, net of tax, on a separate line of the income statement. The net cash flows attributable to these activities are presented separately in the statement of cash flows. Assets related to discontinued operations are presented in “Assets held for sale” in the statement of financial position and the associated liabilities are presented as “Liabilities related to assets held for sale” after elimination of intragroup positions.
A list of the main subsidiaries included in the scope of consolidation at 30 June 2026 can be found in note 17.
3.1
Main changes in the scope of consolidation
The number of entities consolidated in the scope of consolidation has changed as follows:
Change of method
Disposals/ Mergers/ Liquidations
30 June 2026
4
(10)
369
1
1
376
4
(10)
370
30 June 2025
Acquisitions/ Creations
Full consolidation
375
Equity method
Consolidation method
TOTAL
Ramsay Santé / Universal Registration Document 2026
61
2
ANNUAL FINANCIAL INFORMATION Financial information concerning the assets, financial position and results of the issuer (and Statutory Auditors’ report)
3.1.1 Acquisitions/Creations During the financial year, the Group acquired/created the following entities: ACQUISITIONS: ■ ■
Volvat Synkirurgi AS (purchased on 1 December 2025); PMP Eyecare AS (purchased on 1 December 2025).
The cumulative impact of acquisitions within the scope of the revised IFRS 3 Business combinations on the consolidated balance sheet is as follows: Balance sheet at 30 June 2026 (in millions of euros)
Carrying amount
Intangible assets
Property, plant and equipment
0.2
Non‑current financial assets
Deferred tax assets
Total non‑current assets
0.2
Receivables, inventories and other current assets
(0.3)
Other current non‑cash financial assets
0.2
Cash
0.1
Total current assets
Financial debt
2.0
Provisions and other non‑current liabilities
Deferred tax liabilities
Total non‑current liabilities
2.0
Current liabilities
0.3
Total current liabilities
0.3
Price
1.9
Goodwill
4.0
For acquisitions that were made less than a year ago at the date of the consolidated financial statements, the valuation work is still underway. As a result, the goodwill recognised for these entities remains provisional. Revenue and profit before tax from acquisitions during the financial year are as follows for a 12‑month period: (in millions of euros)
Contribution of acquisitions
Revenue
Profit before tax
12.7
1.7
In addition, the goodwill recognised at 30 June 2026 was modified by EUR 0.6 million following the valuation work completed for the entities acquired during the previous financial year. CREATIONS: ■ ■
62
GCS Centre d’Imagerie Nucléaire de la Plaine de France (created in October 2025); Imagerie médicale CLIMAL CSCO (created in November 2025).
Ramsay Santé / Universal Registration Document 2026
ANNUAL FINANCIAL INFORMATION Financial information concerning the assets, financial position and results of the issuer (and Statutory Auditors’ report)
3.1.2 Disposals/Mergers - Liquidations During the financial year, the Group carried out the following transactions: DISPOSALS:
LIQUIDATIONS:
■
■
■ ■
BAYA HOTEL & SPA (sold in June 2026); Rhône Assistance (sold on 5 June 2026); Ambulances Davin (sold on 5 June 2026).
MERGERS: ■ ■ ■
IRIDIS Nord (merger with Compagnie Générale de Santé on 4 July 2025);
■ ■ ■
2
Capio UK Ltd (liquidated on 5 February 2026); Ancienne Clinique Générale de Savoie (liquidated in March 2026); SCI les Allouettes (liquidated in May 2026); SCI La Rochelle (liquidated in May 2026).
Clinique du Parisis (merger with Capio Cliniques on 18 September 2025); Volvat Medisinske Senter Nord og Midt‑Norge AS (merger with Volvat Medisinske Senter AS on 1 October 2025).
3.2
Assets held for sale and discontinued operations
The net profit from discontinued operations(1) for the financial year is as follows: From 1 July 2025 to 30 June 2026
From 1 July 2024 to 30 June 2025
Revenue
4.5
5.6
EBITDA
(2.2)
(1.8)
Operating profit
(2.7)
(2.3)
Net profit attributable to owners of the parent
(6.8)
(3.1)
30 June 2026
30 June 2025
Non‑current assets
--
1.3
Current assets
--
1.6
Total assets
--
2.9
Non‑current liabilities
--
0.7
Current liabilities
--
2.6
Total liabilities
--
3.3
Income statement (in millions of euros)
(1) Corresponds to the medical transport business line.
The statement of financial position of discontinued operations is as follows: Statement of financial position (in millions of euros)
Ramsay Santé / Universal Registration Document 2026
63
2
ANNUAL FINANCIAL INFORMATION Financial information concerning the assets, financial position and results of the issuer (and Statutory Auditors’ report)
Note 4
Segment information
Accounting principles In accordance with IFRS 8 Operating segments, the segment information presented below is based on the Group’s internal reporting, which is used by the Executive Committee (defined as the main operational decision‑maker) to assess operational performance and implement the allocation of resources required for the segments’ development according to certain operating performance indicators (EBITDA, current operating profit) and operating cash flows (WCR, Capex).
At 30 June 2026, the Group’s business activity was divided into 13 operating segments: Nouvelle‑Aquitaine, Bourgogne‑Franche‑Comté, Brittany, Centre‑Val de Loire, Hauts‑de‑France, Normandy, Provence‑Alpes‑Côte d’Azur, Île‑de‑France, Auvergne‑Rhône Alpes, Occitanie, Italy, the Nordics and Head office.
4.1
Consolidated income statement and balance sheet by operating segment
4.1.1 Segment results CONSOLIDATED INCOME STATEMENT AT 30 JUNE 2026 AuvergneRhône- Hauts- deAlpes France
ProvenceNouvelle- Alpes- Côte Aquitaine d’Azur
(in millions of euros)
Île‑deFrance
Other regions(1)
Italy
Nordics
TOTAL
REVENUE
1,347.8
690.7
450.0
335.5
206.7
201.4
410.3
26.6
1,712.1
5,381.1
Operating expenses excluding depreciation and amortisation
(1,216.4)
(640.8)
(379.3)
(311.7)
(177.6)
(170.4)
(302.3)
(24.0)
(1,520.9)
(4,743.4)
EBITDA
131.4
49.9
70.7
23.8
29.1
31.0
108.0
2.6
191.2
637.7
Depreciation and amortisation
(119.1)
(50.4)
(44.7)
(21.5)
(14.7)
(21.5)
(45.2)
(0.9)
(122.8)
(440.8)
Current operating profit
12.3
(0.5)
26.0
2.3
14.4
9.5
62.8
1.7
68.4
196.9
Other non‑current income & expenses
0.4
12.5
(1.2)
(0.8)
13.5
5.8
(38.8)
(0.2)
(1.8)
(10.6)
Operating profit
12.7
12.0
24.8
1.5
27.9
15.3
24.0
1.5
66.6
186.3
Occitanie
(1) “Other regions” is made up of five segments (Bourgogne‑Franche‑Comté, Brittany, Centre‑Val de Loire, Normandy and Head office).
CONSOLIDATED INCOME STATEMENT AT 30 JUNE 2025
(in millions of euros)
Île‑deFrance
AuvergneRhône- Hauts- deAlpes France
Occitanie
ProvenceNouvelle- Alpes- Côte Aquitaine d’Azur
Other regions(1)
Italy
Nordics
TOTAL
1,327.4(2)
683.4
442.4
322.5
206.2
198.5
393.1
26.5
1,607.9
5,207.9(2)
Operating expenses excluding depreciation and amortisation (1,189.6)(2)
(629.6)
(369.5)
(304.8)
(174.7)
(160.4)
(288.0)
(23.5)
(1,446.4)
(4,586.5)(2)
REVENUE
EBITDA
137.8
53.8
72.9
17.7
31.5
38.1
105.1
3.0
161.5
621.4
Depreciation and amortisation
(117.7)
(51.1)
(44.5)
(21.9)
(14.9)
(21.7)
(46.8)
(1.0)
(114.4)
(434.0)
Current operating profit
20.1
2.7
28.4
(4.2)
16.6
16.4
58.3
2.0
47.1
187.4
Other non‑current income & expenses
(4.0)
(3.6)
9.3
(2.2)
0.4
0.0
(8.9)
(0.2)
(5.0)
(14.2)
Operating profit
16.1
(0.9)
37.7
(6.4)
17.0
16.4
49.4
1.8
42.1
173.2
(1) “Other regions” is made up of five segments (Bourgogne‑Franche‑Comté, Brittany, Centre‑Val de Loire, Normandy and Head office). (2) Adjusted for a reclassification of EUR (34.1) million on revenue and EUR 34.1 million on purchases used, with no impact on EBITDA.
64
Ramsay Santé / Universal Registration Document 2026
ANNUAL FINANCIAL INFORMATION Financial information concerning the assets, financial position and results of the issuer (and Statutory Auditors’ report)
4.1.2 Segment balance sheets CONSOLIDATED BALANCE SHEET AT 30 JUNE 2026 AuvergneRhône- Hauts- deAlpes France
ProvenceNouvelle- Alpes- Côte Aquitaine d’Azur
(in millions of euros)
Île‑deFrance
Non‑current sector assets(1)
1,502.2
530.3
376.9
280.0
208.8
191.8
104.0
72.6
41.9
25.8
Current sector assets(2)
Occitanie
Other regions(5)
Italy
Nordics
TOTAL
128.5
412.6
7.3
1,662.5
5,109.1
34.1
186.0
12.5
202.7
871.4
Non‑sector assets
2
701.6
TOTAL ASSETS
6,682.1 (3)
Non‑current sector liabilities (4)
Current sector liabilities
623.3
275.5
135.8
231.2
104.5
84.8
282.4
1.3
348.9
2,087.7
360.4
176.6
156.4
81.5
50.0
64.0
206.9
8.2
340.5
1,444.5
Non‑sector liabilities
3,149.9
TOTAL LIABILITIES
6,682.1
(1) Non‑current sector assets are the sum of goodwill, intangible assets, property, plant and equipment and rights of use. (2) Current sector assets are the sum of inventories, trade receivables and other current assets. (3) Non‑current sector liabilities are the sum of non‑current lease liabilities, provisions for retirement and other employee benefits and non‑current provisions. (4) Current sector liabilities are the sum of current provisions, trade payables, other current liabilities and current lease liabilities. (5) “Other regions” is made up of five segments (Bourgogne‑Franche‑Comté, Brittany, Centre‑Val de Loire, Normandy and Head office).
CONSOLIDATED BALANCE SHEET AT 30 JUNE 2025 Île‑deFrance
(in millions of euros)
Non‑current sector assets(1)
AuvergneRhône- Hauts- deAlpes France
Occitanie
ProvenceNouvelle- Alpes- Côte Aquitaine d’Azur
Other regions(5)
Italy
Nordics
TOTAL
1,555.4
523.0
395.2
281.6
203.9
130.3
430.7
6.7
1,730.7
5,257.5
209.0
118.2
68.8
47.1
30.7
34.8
194.6
11.9
198.4
913.4
Non‑sector assets
665.2
Assets held for sale
2.9
(2)
Current sector assets
TOTAL ASSETS
6,839.0
Non‑current sector liabilities(3)
642.4
285.2
151.3
232.9
92.6
74.1
299.2
1.1
358.8
2,137.6
Current sector liabilities(4)
402.1
213.2
164.0
100.2
53.6
59.6
187.4
8.0
354.0
1,542.0
Non‑sector liabilities
3,156.1
Liabilities related to assets held for sale
3.3
TOTAL LIABILITIES
6,839.0
(1) Non‑current sector assets are the sum of goodwill, intangible assets, property, plant and equipment and rights of use. (2) Current sector assets are the sum of inventories, trade receivables and other current assets. (3) Non‑current sector liabilities are the sum of non‑current lease liabilities, provisions for retirement and other employee benefits and non‑current provisions. (4) Current sector liabilities are the sum of current provisions, trade payables, other current liabilities and current lease liabilities. (5) “Other regions” is made up of five segments (Bourgogne‑Franche‑Comté, Brittany, Centre‑Val de Loire, Normandy and Head office).
Ramsay Santé / Universal Registration Document 2026
65
2
ANNUAL FINANCIAL INFORMATION Financial information concerning the assets, financial position and results of the issuer (and Statutory Auditors’ report)
Note 5 5.1
Operating data
Revenue
Accounting principles Revenue corresponds to the value of goods and services provided by the Group in the normal course of its business activity. Ramsay Santé’s revenue in France is mainly generated by the payments received from (1) the French Social Security system, on the basis of tariffs set each year by the public authorities, and (2) the regional health agencies (Agences régionales de santé - ARS), in respect of the care and services provided by the Group and, to a lesser extent, from patients or supplementary insurance companies to cover residual amounts, corresponding in particular to services related to the care provided, such as private room accommodation. The healthcare activities of healthcare facilities are mainly financed via T2A (activity payment rate) and, to a lesser extent, by flat‑rate payments. Revenue is recognised in the income statement when the service is rendered. For certain specialities (Emergency, Mental Health, MCR), the activity of healthcare facilities is now financed by a system of annual allocations. Emergency The Emergency Financing Reform (SU/SMUR) came into force on 1 January 2021 and is based on three financing vehicles: ■ ■ ■
a base allocation from the regional population allocation, the amount of which is allocated to each facility and recognised on a pro rata basis; an additional allocation based on criteria related to improving the quality and organisation of the care offer in the Emergency and SMUR departments; activity‑based revenues invoiced on the basis of flat‑rate payments that came into force on 1 January 2022.
At 30 June 2026, the amounts recognised as revenue in respect of the allocation for Emergency care and flat‑rate payments amounted to EUR 48.7 million and EUR 14.3 million, respectively. Mental Health The Mental Health funding reform came into force on 1 January 2022 and is based on the following: ■
psychiatric facilities receive a monthly transitional advance payment until the final notification of the amount of the allocation per compartment, mainly including the active file allocation and the population allocation.
The amount recognised as revenue in respect of the provisions relating to the Mental Health funding reform amounted to EUR 178.8 million at 30 June 2026. Medical Care and Rehabilitation (MCR) The Medical Care and Rehabilitation (MCR) funding reform came into force on 1 July 2023. The new model is a mixed funding model and is based on revenues directly linked to the business activity, as well as additional components: ■
■
an “activity” component, which corresponds to the funding per stay (intended to supplement the financing of the “flat‑rate” component to allow the facility to benefit from resources related to its real activity, in order to support business momentum); a “flat‑rate” component, for which the amount recognised in revenue was EUR 119.5 million at 30 June 2026. During the transition period up to and including 2027, the flat‑rate component is increased or decreased for each facility by an amount that takes into account the impact of the new model on the facilities (transition allowance: EUR 8.1 million recognised in revenue at 30 June 2026).
Facilities are also eligible for three additional components to fund certain specific activities or missions.
66
Ramsay Santé / Universal Registration Document 2026
ANNUAL FINANCIAL INFORMATION Financial information concerning the assets, financial position and results of the issuer (and Statutory Auditors’ report)
Nordics The services provided in Sweden are mainly financed by public expenditure, whether national, regional or local. Healthcare facilities in Sweden are remunerated on a fee‑for‑service basis or according to a global allocation system or a capitation approach.
2
Healthcare provided in Norway is mainly financed by the private sector: patients, business and insurance companies. In Denmark, medical care is mainly financed by the public authorities, with a residual part being paid by private insurance companies and patients. Italy The main funder is the Italian National Health Service, through contracts with regional health authorities. Private funders (e.g. direct payments or supplementary private insurance) account for a minor share of revenue. The consolidated revenue represents the cumulative amount of the services, detailed above, provided by the consolidated subsidiaries after elimination of intragroup transactions.
The Ramsay Santé group presents information relating to the five geographical areas (France, Italy, Sweden, Norway, Denmark) in which it operates. From 1 July 2025 to 30 June 2026
%
From 1 July 2024 to 30 June 2025
%
France
3,642.3
67.7%
3,573.5(1)
68.6%
Sweden
1,465.7
27.2%
1,364.1
26.2%
Norway
128.8
2.4%
126.1
2.4%
Denmark
117.6
2.2%
117.7
2.3%
Revenue (in millions of euros)
Italy
26.7
0.5%
26.5
0.5%
TOTAL
5,381.1
100%
5,207.9(1)
100%
(1) Adjusted for a reclassification of EUR (34.1) million on revenue and EUR 34.1 million on purchases used, with no impact on EBITDA.
Revenue, by geographical area, includes all activities for the financial year, including those sold during the financial year. At 30 June 2026, the income from care activities billed represented 92.4% of the Group’s revenue, while the proceeds from hotel services, paid for by complementary private insurance companies and patients, represented 3.7%
of the Group’s revenue. The balance of the Group’s revenue (3.9% at 30 June 2026) is mainly derived from the fees paid by practitioners for general, administrative and leasing services provided by the Group’s facilities, such as the billing of procedures and the collection of their fees from the Social Security system, insurance companies and patients.
Ramsay Santé / Universal Registration Document 2026
67
2
ANNUAL FINANCIAL INFORMATION Financial information concerning the assets, financial position and results of the issuer (and Statutory Auditors’ report)
5.2
Operating profit
5.2.1 Employee benefits (in millions of euros)
From 1 July 2025 to 30 June 2026
From 1 July 2024 to 30 June 2025
Wages and salaries
(1,887.9)
(1,834.4)
Social security contributions
(691.8)
(664.9)
(5.0)
(8.2)
Incentives
(5.1)
(4.9)
Profit‑sharing
(8.5)
(7.7)
Interim
(137.1)
(137.0)
Other
0.1
1.2
(2,735.3)
(2,655.9)
From 1 July 2025 to 30 June 2026
From 1 July 2024 to 30 June 2025
(751.2)
(718.3)
Retirement bonuses
TOTAL
CSOCI
5.2.2 Other operating income and expenses (in millions of euros)
Other operating expenses Other operating income TOTAL
At 30 June 2026, other operating expenses mainly comprised subcontracting costs, maintenance and servicing expenses, general services, fees and insurance. At 30 June 2026, other operating income mainly included current hospital subsidies, which were stable over time and represent EUR 77.7 million at 30 June 2026, compared with EUR 76.5 million at 30 June 2025.
CSOCI
119.6
147.6
(631.6)
(570.7)
As a reminder, during the previous financial year, EUR 19.9 million related to the financial support for the activity‑based guarantee was recognised in “Other operating income”. This subsidy was withdrawn in 2025.
5.2.3 Other non‑current income and expenses Accounting principles In order to facilitate understanding of the Group’s performance, items that are unusual and material at Group level, as well as those that by their nature do not contribute to the assessment of current operating performance, are recorded “Other non‑current income and expenses” in the income statement. “Other non‑current income and expenses” includes: ■ ■ ■ ■
68
restructuring costs (charges and provisions); capital gains or losses on the disposal of fixed assets and entities and other impacts related to changes in the scope of consolidation (costs and fees directly related to transactions, revaluation of previously held shareholdings); significant and unusual impairment of non‑current assets (in particular impairment losses recognised in the context of impairment testing); and other exceptional operating income and expenses.
Ramsay Santé / Universal Registration Document 2026
ANNUAL FINANCIAL INFORMATION Financial information concerning the assets, financial position and results of the issuer (and Statutory Auditors’ report)
From 1 July 2025 to 30 June 2026
From 1 July 2024 to 30 June 2025
Integration and restructuring expenses
(17.4)
(8.8)
Project fees
(6.3)
(1.3)
(in millions of euros)
Note
Other expenses / income
(4.8)
(7.4)
Total net non‑current costs
(18.9)
(17.5)
Revaluation of debt on commitments to purchase non‑controlling interests (Nordics scope) Disposal of medical transport (Meriaux)
1.0
3.3
(1.0)
Disposal of Baya hotel
2.2
Other changes in the scope of consolidation
0.4
2.4
Sale and lease back of 4 facilities in France
8.9
Disposals of fixed assets
1.4
2.6
Scrapping of fixed assets
(1.9)
Acquisition costs and fees
(0.6)
(0.4)
Impairment of assets (facilities)
(4.2)
(2.2)
Other
(0.8)
0.5
Total Profit from the management of property and financial assets
8.3
3.3
(10.6)
(14.2)
TOTAL
CSOCI
Impact statement of cash flows (other non‑current income & expenses paid)
SCF
(16.5)
Impact statement of cash flows (disposal of subsidiaries)
SCF
1.3
9.3 million and the elimination of the risk related to the accrual of paid leave during a work stoppage in France prior to the date of application of the law for EUR 4.7 million, as well as exceptional impairment costs and transaction fees;
Other non‑current income and expenses represented a net expense of EUR (10.6) million for the financial year ended 30 June 2026 (net expense of EUR (14.2) million in the previous financial year), and mainly comprised: ■ ■
■
■
costs directly related to the integration of acquisitions and development costs, in the amount of EUR (4.3) million; restructuring expenses of EUR (16.6) million related to the reorganisation of the Group, including in particular the projects to optimise maternity services; fees, including EUR (5.7) million directly related to the proposed distribution by Ramsay Health Care to its shareholders of its stake in Ramsay Santé (see note 2); other non‑current income and expenses, which mainly include reversals of provisions following the favourable outcome of a tax dispute (VAT) in Sweden for EUR
2
■ ■ ■
■
a revaluation at fair value of purchase commitments for EUR 1 million; a net capital gain of EUR 8.9 million related to the sale and lease‑back of four real estate assets in France (see note 2); capital gains on the disposal of fixed assets for EUR 1.4 million and a hotel operating company for EUR 2.2 million (see note 2); impairment of the carrying amount of the assets of a facility in France for EUR (4.2) million, reflecting the underperformance of this healthcare facility.
Ramsay Santé / Universal Registration Document 2026
69
2
ANNUAL FINANCIAL INFORMATION Financial information concerning the assets, financial position and results of the issuer (and Statutory Auditors’ report)
5.2.4 Working capital requirements related to operations 5.2.4.1
CHANGE IN WORKING CAPITAL REQUIREMENTS RELATED TO OPERATIONS Changes
(in millions of euros)
Note 30 June 2025
related to business activity
related to fixed asset receivables and payables
Other(1) 30 June 2026
Inventories – gross value
134.0
4.3
138.3
Impairment
(8.9)
1.9
(7.0)
Inventories
125.2
6.2
131.3
Trade receivables – gross values
607.7
(14.9)
(42.5)
550.4
Impairment
(80.2)
0.1
0.6
(79.4)
Trade receivables
527.5
(14.8)
(41.9)
470.9
Other current assets – gross values
280.4
(27.4)
(3.2)
40.0
289.8
Impairment
(19.7)
(0.3)
(0.6)
(20.6)
Other current assets
260.7
(27.7)
(3.2)
39.4
269.2
Total inventories, receivables and other current assets (I)
913.4
(36.3)
(3.2)
(2.5)
871.4
Trade payables
432.3
(2.7)
(1.9)
427.7
Other current liabilities and debt related to commitments to purchase non‑controlling interests Total trade and other payables (II)
812.1
(77.6)
0.3
(5.3)
729.5
1,244.4
(80.3)
0.3
(7.2)
1,157.2
(331.1)
44.0
(3.6)
4.7
(285.9)
WORKING CAPITAL REQUIREMENTS (I) – (II) Impact on the Statement of cash flows (II) – (I)
SCF
(1) The “Other” column mainly consists of changes in the scope of consolidation, currency effects and various reclassifications during the financial year, including the reclassification of discounts receivable from “Trade receivables” to “Other current assets” amounting to EUR 42.1 million.
Inventories consist mainly of pharmaceuticals and medical supplies. Inventories are valued using the weighted average unit cost method and impaired according to their degree of obsolescence or non‑use. The payment period for Trade receivables and Suppliers breaks down as follows: Payment deadline (in days)
30 June 2026
30 June 2025
Trade receivables
30.8
33.0(1)
Suppliers
65.1
63.4
(1) At 30 June 2025, net of cash advances from the government relating to the introduction of the new pricing structure.
70
Ramsay Santé / Universal Registration Document 2026
ANNUAL FINANCIAL INFORMATION Financial information concerning the assets, financial position and results of the issuer (and Statutory Auditors’ report)
5.2.4.2
TRADE RECEIVABLES AND OTHER CURRENT ASSETS AND CREDIT RISK MANAGEMENT
Accounting principles A trade receivable is recognised as soon as the entity has an unconditional right to receive payment. This unconditional right exists from the moment when only the passage of time makes the payment due.
2
Trade receivables mainly relate to patients, health insurance funds, mutuals and other private insurers, as well as fees receivable from health professionals. Upon initial recognition, trade receivables are recognised at their transaction price within the meaning of IFRS 15 “Income from contracts with customers”, which generally corresponds to their nominal value. Impairment of receivables is determined in accordance with the simplified model set out in IFRS 9 Financial instruments, based on expected credit losses over their lifetime. This is estimated at each reporting date for the whole portfolio of exposures, based on an average expected loss rate. This rate is calculated using historical loss rates, the counterparty’s risk profile, and the amount of estimated losses for exposures where a credit event has been identified. This rate may be adjusted if there are indications of a significant deterioration in credit risk Receivables transferred to banking institutions for financing purposes are only removed from the balance sheet if the monetisation contract is said to be deconsolidating, i.e. without recourse, and it transfers to the transferee full ownership and control and almost all risks and benefits related to the receivables.
TRADE RECEIVABLES AND OTHER CURRENT ASSETS
“Trade receivables” and “Other current assets” are broken down as follows: (in millions of euros)
30 June 2026
30 June 2025
Patient customers
68.4
63.1
Mandatory plan (health insurance funds and regions)
133.1
129.3
Supplementary plan (mutuals and private insurance)
56.1
64.6
Invoices to be issued to customers
219.9
267.8
Practitioner customers (fees)
46.9
55.2
Other
25.9
27.7
Impairment of trade receivables
(79.4)
(80.2)
TRADE RECEIVABLES
470.9
527.5
State - other taxes and duties
21.5
31.7
Trade payables - advances and deposits, debtors
15.6
14.3
Prepaid expenses
64.2
87.1
Miscellaneous debtors
95.4
96.6
Receivables on disposals of fixed assets
40.4
40.5
Discounts receivable
44.3
--
Other
8.4
10.1
Impairment of other current assets
(20.6)
(19.6)
OTHER CURRENT ASSETS
269.2
260.7
TOTAL
740.1
788.2
The Group’s revenue is dependent on the pricing set by the public authorities. At 30 June 2026, 86% of the Group’s revenue was generated with public authorities, stable compared with 30 June 2025. The breakdown by country is as follows: Financial year ended
France
Sweden
Norway
Denmark
Italy
Total
30 June 2026
87%
94%
5%
73%
92%
86%
30 June 2025
87%
94%
6%
74%
95%
86%
At 30 June 2026, the Group entered into an agreement for the disposal without recourse by way of discounting of T2A receivables for a total amount of EUR 80 million, identical to the amount at 30 June 2025. As this agreement is deconsolidating, these transferred receivables, usually recognised as trade receivables, no longer appear in the Group’s balance sheet at 30 June 2026.
Ramsay Santé / Universal Registration Document 2026
71
2
ANNUAL FINANCIAL INFORMATION Financial information concerning the assets, financial position and results of the issuer (and Statutory Auditors’ report)
Movements in provisions for impairment were as follows: 30 June 2025
Allocations
Reversals
Other movements
30 June 2026
Provisions for impairment of trade receivables
(80.2)
(65.1)
65.3
0.6
(79.4)
Provisions for impairment of other current assets
(19.6)
(2.0)
1.6
(0.6)
(20.6)
TOTAL
(99.8)
(67.1)
66.9
--
(100.0)
(in millions of euros)
CREDIT AND COUNTERPARTY RISK
The Group may have to deal with late payments on certain receivables or debtors who do not honour their debts when due. The Group’s exposure to credit risk is mainly influenced by the individual characteristics of its customers (payer profile). The Group has put in place a receivables monitoring policy that
enables it to constantly monitor its credit risk exposure by third party. The credit risk on overdue receivables that have not been impaired is controlled. The ageing of “trade receivables” breaks down as follows:
30 June 2026 (in millions of euros)
Not past due
0‑3 months
3‑6 months
6‑12 months
More than 1 year
Total
Patient customers
23.9
8.0
3.9
4.9
27.7
68.4
Mandatory plan (health insurance funds)
70.3
23.3
8.2
4.4
26.8
133.1
Supplementary plan (mutuals and private insurance)
17.3
11.9
3.7
5.2
17.8
56.1
219.9
--
--
--
--
219.9
Practitioner customers (fees)
6.6
13.4
4.7
3.9
18.3
46.9
Other
4.9
5.0
1.3
1.6
13.1
25.8
Impairment of trade receivables
(4.9)
(2.0)
(1.3)
(7.8)
(63.5)
(79.4)
338.2
59.7
20.6
12.2
40.2
470.9
Invoices to be issued to customers
TRADE RECEIVABLES
5.2.4.3
OTHER CURRENT LIABILITIES
Other current liabilities break down as follows: (in millions of euros)
30 June 2026
30 June 2025
Payables related to employee and social agencies
469.9
449.1
Advances and deposits received
96.3
185.2
Deferred income
45.0
48.7
Operating tax liabilities
41.5
43.7
Payables related to suppliers of fixed assets
11.4
14.1
Other miscellaneous accounts payable
57.2
70.3
TOTAL
721.3
811.1
The decrease in advances and deposits received during the financial year is mainly due to the receipt, during the previous financial year, of advances paid in April and May 2025 to offset delays in invoicing resulting from the late publication of T2A tariffs in France. These advances had not yet been repaid at 30 June 2025.
72
Ramsay Santé / Universal Registration Document 2026
ANNUAL FINANCIAL INFORMATION Financial information concerning the assets, financial position and results of the issuer (and Statutory Auditors’ report)
Note 6
Intangible assets and property, plant and equipment
Accounting principles
2
Goodwill
Goodwill represents the difference between the acquisition cost of the securities of a company newly included in the scope of consolidation and the Group’s share in the fair value, at the acquisition date, of the assets, liabilities and contingent liabilities relating to the acquired company. When an entity is first consolidated, the fair value of assets and liabilities at the acquisition date is determined within a maximum period of 12 months. Other intangible assets
Intangible assets, other than goodwill, consist primarily of the Capio and Volvat brands, as well as healthcare service contracts and patient lists in Sweden, and software. The brands were measured at fair value upon acquisition of the Capio group and are not amortised. Other intangible assets are amortised on a straight‑line basis over their useful lives. Fees paid for the use of software as a SaaS (Software as a Service) are recognised as expenses as the services are provided. To be recognised as a fixed asset, expenditure on SaaS contracts (configuration, customisation, etc.) must confer a right of control on the user, in addition to access to the software for a fixed contractual period. Property, plant and equipment
Property, plant and equipment are recorded at historical cost less accumulated depreciation and any accumulated impairment losses. When items of property, plant and equipment have different useful lives, they are recognised as separate items of property, plant and equipment. Property, plant and equipment, with the exception of land, which is not depreciated, is depreciated on a straight‑line basis over its estimated useful life from the date the asset is brought into service, using the component approach: ■ ■ ■ ■ ■ ■ ■ ■
Buildings: 20 to 40 years; Fixtures and fittings for buildings: 10 to 20 years; Industrial equipment and tools: 3 to 10 years; General installations, miscellaneous fittings: 5 to 15 years; Transport equipment: 4 to 5 years; Office equipment: 4 to 5 years; IT equipment: 3 to 5 years; Furniture: 5 to 10 years.
Investment subsidies
The Ramsay Santé group receives public investment subsidies. They are recognised as a deduction from the carrying amount of the assets they were used to finance and follow the same depreciation schedule.
Ramsay Santé / Universal Registration Document 2026
73
2
ANNUAL FINANCIAL INFORMATION Financial information concerning the assets, financial position and results of the issuer (and Statutory Auditors’ report)
6.1
Goodwill
(in millions of euros)
Note
30 June 2026
30 June 2025
B
2,162.3
2,156.7
3.1.1
4.0
3.9
(3.1)
2.5
5.9
(30.9)(1)
(1.1)
2,137.9
2,162.3
GROSS VALUE Balance at the beginning of the financial year New consolidation Deconsolidation Exchange differences Other movements Balance at the end of the financial year
B
(1) Other movements related to a reclassification of the “Goodwill” item to the “Non‑current financial assets” item following the entry into force of the new management contract for St. Göran hospital.
(in millions of euros)
Note
30 June 2026
30 June 2025
B
(74.5)
(75.6)
IMPAIRMENT Balance at the beginning of the financial year Impairment losses recognised during the financial year Deconsolidation
Other movements
1.1
Balance at the end of the financial year
B
(74.5)
(74.5)
At the beginning of the financial year
B
2,087.9
2,081.1
At the end of the financial year
B
2,063.4
2,087.9
Note
30 June 2026
30 June 2025
Nouvelle‑Aquitaine
103.5
103.5
Bourgogne‑Franche‑Comté
52.7
52.7
1.6
1.6
160.5
160.9
4.5
4.5
Île‑de‑France
544.0
543.8
Auvergne‑Rhône‑Alpes
150.5
150.5
Occitanie
67.1
67.1
Italy
0.3
0.3
978.7
1,003.1
2,063.4
2,087.9
NET CARRYING AMOUNT
Net goodwill allocated to groups of CGUs is as follows: (in millions of euros)
Brittany Centre‑Val de Loire Hauts‑de‑France Normandy Provence‑Alpes‑Côte d’Azur
Nordics TOTAL
74
Ramsay Santé / Universal Registration Document 2026
B
ANNUAL FINANCIAL INFORMATION Financial information concerning the assets, financial position and results of the issuer (and Statutory Auditors’ report)
6.2
Other intangible assets Gross
(in millions of euros)
Depreciation and amortisation Other move- 30 June 30 June ments(1) 2026 2025
Allocations and impairment
Sales / Reversals Transfers
NCA
Other move- 30 June 30 June 30 June ments(2) 2026 2025 2026
30 June 2025
Acq.
Sales / Transfers
Software
131.5
3.7
(3.3)
5.1
137.0
(122.3)
(6.8)
3.4
(1.8)
(127.5)
9.2
9.5
Service contracts
134.3
(0.7)
0.3
133.9
(88.6)
(4.6)
0.7
(0.2)
(92.7)
45.7
41.2
Note
Other intangible assets TOTAL
B
168.8
13.2
(1.3)
(2.4)
178.3
(18.2)
(1.7)
0.9
0.2
(18.8)
150.6
159.5
434.6
16.9
(5.3)
3.0
449.2
(229.1)
(13.1)
5.0
(1.8)
(239.0)
205.5
210.2
2
(1) Of which exchange difference. (2) Of which acquisition and exchange difference.
6.3
Property, plant and equipment Gross
(in millions of euros)
Note
Land
30 June 2025
Acq.(1)
Depreciation and amortisation
Other Sales / moveTransfers ments(2)
30 June 2026
Allocations 30 June and 2025 impairment(3)
Sales / Reversals Transfers
NCA Other movements(4)
30 June 30 June 30 June 2026 2025 2026
91.8
2.1
(5.6)
19.7
108.0
(1.8)
(0.1)
0.1
0.1
(1.7)
90.0
106.3
Buildings
1,317.4
23.9
(49.9)
58.6
1,350.0
(843.4)
(57.5)
35.9
1.2
(863.8)
474.0
486.2
Fixtures, fittings, technical facilities, equipment and tools
1,735.5
90.8
(85.2)
9.1
1,750.2
(1,418.9)
(113.2)
76.6
(2.0)
(1,457.5)
316.6
292.8
0.5
(3.7)
55.3
45.9
(0.3) (2,326.7)
936.0
931.2
Property, plant and equipment in progress TOTAL (1) (2) (3) (4)
B
56.4
38.0
(5.7)
(39.0)
49.6
(1.1)
(3.2)
0.1
3,201.2
154.7
(146.4)
48.3
3,257.8
(2,265.2)
(173.9)
112.7
Of which acquisition and increase. Of which exchange difference. Of which impairment test. Of which acquisition and exchange difference.
Ramsay Santé / Universal Registration Document 2026
75
2
ANNUAL FINANCIAL INFORMATION Financial information concerning the assets, financial position and results of the issuer (and Statutory Auditors’ report)
6.4
Impairment testing
Accounting principles Main methods used to carry out impairment testing
Impairment testing on intangible assets, property, plant and equipment and rights of use is carried out as soon as there is objective evidence of impairment and at least once a year, in the last quarter before the year‑end, based on net assets at 30 April, at the level of Cash‑Generating Units (CGUs). Goodwill impairment tests are performed by grouping together CGUs that carry out their activities in the same region. According to the definition in IAS 36.6 Impairment of Assets, a Cash‑Generating Unit (CGU) is defined as the smallest identifiable group of assets generating cash inflows that are largely independent of the cash inflows generated by other assets or groups of assets. Therefore, within the Ramsay Santé group, the CGUs are determined to be one or more healthcare facilities or sites particularly linked in their cash flows because they operate in a defined geographical area and offer similar or complementary specialities aimed at patients from the same area. In France, the grouping of CGUs at the regional level is justified by the missions of the ARS (Regional Health Agency) within these administrative areas: ■ ■ ■
implementation of a real regional health project; regulation of the health and medico‑social offer; control of the quality and efficiency of the regional health system.
As a result, there are important economic dependencies between our facilities and the ARS. All decisions regarding the organisation of care are taken at regional level and our scope operations are justified at this level and, in most cases, give rise to mergers and restructurings negotiated with the ARS. In the Nordic region, goodwill is monitored and tested within a grouping of CGUs that encompasses the countries in which the Group operates (Sweden, Denmark and Norway), in view of the synergies between them. For Italy, goodwill is tested at country level (one facility). The Group selected twelve groups of CGUs to test for goodwill: Nouvelle‑Aquitaine, Bourgogne‑Franche‑Comté, Brittany, Centre‑Val de Loire, Hauts‑de‑France, Normandy, Provence‑Alpes‑Côte d’Azur, Île‑de‑France, Auvergne‑Rhône‑Alpes, Occitanie, Italy, and Nordics. Determination of recoverable amount
The recoverable amount is the higher of the fair value less costs to sell and the value in use. The fair value less costs to sell is the amount that can be obtained from the sale of an asset or a CGU in an arm’s length transaction between knowledgeable and willing parties, minus exit costs. Value in use is the present value of the sum of future cash flows before tax and financial items from the ongoing use of an asset or CGU and the cash flows arising upon disposal of the asset. Future cash flows used for impairment testing are calculated on the basis of a 5‑year corporate plan. The terminal value takes into account a perpetual growth rate of 1.75% for France and 2.00% for the Nordics. The discount rate used corresponds to the weighted average cost of capital, calculated on a country‑by‑country basis as at 30 June 2026 using market data. It reflects market players’ current assessments of the time value of money and the risks specific to the asset or group of assets. It is 6.20% for France and Italy and 6.71% for the Nordics. The projections used for impairment tests are based on the EBITDA assumptions used by the Group in its corporate plan. Recognition of impairment
Impairment is recognised under “Other non‑current income and expenses” if the test reveals an impairment loss, i.e. if the net carrying amount of the CGU exceeds its recoverable amount. This impairment loss is allocated first to goodwill and then, where appropriate, to the other assets of the CGU in proportion to their net carrying amount. Any impairment of goodwill is irreversible. Impairment losses recorded on property, plant and equipment may be reversed at a later date, if the recoverable amount exceeds the net carrying amount, up to the limit of the impairment loss initially recognised. The reversal of the impairment loss is allocated pro rata to their net carrying amount. In addition, the reversal of the impairment loss must not result in the carrying amount of the asset being higher than its original value net of the depreciation that would have been applied in the absence of the impairment. The net carrying amount of a CGU includes the carrying amount of the assets directly attributed to the CGU, including rights of use, but does not include lease liabilities.
76
Ramsay Santé / Universal Registration Document 2026
ANNUAL FINANCIAL INFORMATION Financial information concerning the assets, financial position and results of the issuer (and Statutory Auditors’ report)
Results of impairment tests In accordance with the provisions of IAS 36 Impairment of Assets, the Group performed impairment testing on CGUs and groups of CGUs to which goodwill and fixed assets, including rights of use, are allocated. The following assumptions were used: 30 June 2026
2
30 June 2025
France and Italy
Nordics
France and Italy
Nordics
Discount rate before tax
6.20%
6.71%
6.04%
6.99%
Perpetual growth rate
1.75%
2.00%
1.75%
2.75%
The tests performed on the basis of the net assets at the end of April 2026 and at the level of groups of CGUs, did not give rise to any impairment of goodwill. At 30 June 2026, the impairment tests carried out at the level of the CGUs led the Group to recognise a non‑current expense with no cash impact in the total amount of EUR (4.3) million, mainly reflecting the underperformance of one facility in France. No significant change in the assets tested was observed between 30 April 2026 and 30 June 2026.
Sensitivity of the recoverable amount to assumptions The Group performed sensitivity analyses on the main parameters used in impairment testing (discount rate, perpetual growth rate) and a sensitivity analysis on the key financial and operating assumptions used in the impairment tests (-5% decrease in future cash flows). The main parameters identified in this last test stem from the analysis of the main risk factors: pricing/regulatory (level of financing of the sector, ability to maintain our authorisations/contracts),
level of expense inflation (in particular, mandatory annual negotiations for personnel costs, medical purchases, subcontracting), and ability to retain/attract doctors and healthcare professionals (impact on business volumes). At Group level, sensitivity analyses were performed by comparing each of the following scenarios to the baseline scenario: ■
■
■
■
a 0.5‑point increase in the discount rate, applied alone, would lead to a decrease of EUR 920.9 million in the recoverable amount; a 0.5‑point decrease in the perpetual growth rate, applied in isolation, would lead to a decrease of EUR 641.1 million in the recoverable amount; the simultaneous application of the two previous scenarios would result in a decrease of EUR 2,671.0 million in the recoverable amount; a 5% decrease in future cash flows would result in a decrease of EUR 890.9 million in the recoverable amount.
Sensitivity simulations do not lead to the recognition of additional impairment of goodwill.
Ramsay Santé / Universal Registration Document 2026
77
2
ANNUAL FINANCIAL INFORMATION Financial information concerning the assets, financial position and results of the issuer (and Statutory Auditors’ report)
Note 7
Leases
Accounting principles The assets leased by the Group are mainly premises for hospitals, facilities, healthcare centres and offices, as well as major items of medical equipment. The Group’s extensive geographical presence means that it has to deal with a wide variety of legal arrangements when drawing up contracts. Definition of a lease
A lease grants the right to use an underlying asset for a specified period of time in exchange for consideration. Leases are recognised in the Group’s balance sheet as follows: ■ ■
an asset representing the right to use the underlying asset during the term of the lease; a liability in respect of the obligation to pay rent.
Right of use
Right of use is initially measured at cost on the effective date of the contract, i.e. the date on which the underlying asset is made available to the Group. The right of use is amortised on a straight‑line basis over the term of the contract. It is tested for impairment in accordance with IAS 36 Impairment of Assets. Lease liabilities
The lease liability is initially measured at the present value of future payments due over the term of the contract. IFRS 16 Leases requires the discount rate for each lease to be determined by reference to the marginal borrowing rate of the contracting subsidiary. In practice, given the way the Group’s financing is organised, the rate used is calculated over the term of each lease (average term weighted by rental flows) using a risk‑free rate curve and a single spread per country, corresponding to a portfolio of contracts with reasonably similar characteristics. The lease liability is remeasured when rents are revised or when the Group changes its assessment of the likelihood that a renewal option will be exercised. In such cases, the carrying amount of the right of use is adjusted for an equivalent amount. Liabilities relating to leases, recognised in accordance with IFRS 16 Leases, are not taken into account for the calculation of covenants. Term of leases
The term of a lease is the non‑cancellable period, plus any periods covered by a renewal option where there is reasonable certainty that the option will be exercised. Where a lease includes renewal options, the Group takes into account all relevant factors (expected length of time the sites will be in operation, consistency with investments made, etc.) to define the period during which it is reasonably certain that the lease will continue. After the effective date of the lease, the Group may revise the term of a lease in the event of a significant event or change in circumstances that affects the reasonable certainty of the exercise (or non‑exercise) of a renewal option. The term used when the lease commitment is equal to 12 months, but renewable by tacit agreement, is consistent with the expected period of use of the assets invested in connection with this contract, in reality longer than one year. More specifically, for commercial leases (3‑6‑9), the Group generally recognises a period of nine years as enforceable at the start of the lease. However, if it is decided that the lease will be terminated at the end of a three‑year period, the lease liability is adjusted accordingly. Commercial leases (3‑6‑9) may provide for tacit extension or renewal. In this case, the term applied is that which is reasonably certain to be exercised by the Group. Short‑term contracts or contracts involving low‑value assets
The Group applies the exemption from balance sheet recognition for contracts: ■ ■
with a life of less than one year and no option for renewal; on assets with a low individual new value of less than EUR 5,000.
Rents associated with these contracts are recognised as an expense in the income statement on a straight‑line basis over their term.
78
Ramsay Santé / Universal Registration Document 2026
ANNUAL FINANCIAL INFORMATION Financial information concerning the assets, financial position and results of the issuer (and Statutory Auditors’ report)
7.1
Leases
At 30 June 2026, the rights of use and associated debt were mainly impacted by increases of EUR 230.5 million, of which: ■ ■
EUR 122.6 million related to lease revisions;
2
EUR 107.9 million related to new leases.
7.1.1 Rights of use Technical operating facilities
Fixtures and fittings - furniture
Total
(in millions of euros)
Land
Building Construction
At 30 June 2025
22.7
1,839.4
121.7
44.4
2,028.2
Business combinations
Increases
172.2
49.2
9.1
230.5
Decreases
(18.6)
(79.8)
(98.4)
Depreciation/amortisation
(215.5)
(41.8)
(14.1)
(271.4)
Exchange differences
2.9
0.1
3.0
Other
12.4
(0.1)
0.2
12.5
4.1
1,731.6
129.0
39.7
1,904.4
At 30 June 2026
7.1.2 Lease liabilities (in millions of euros)
Total
At 30 June 2025
2,159.2
Business combinations
Increases
230.5
Payments
(372.2)
Interest expense
81.6
Exchange differences
4.1
Other
5.2
At 30 June 2026
2,108.4
The maturities of the lease liability are as follows: (in millions of euros)
30 June 2026
30 June 2025
Less than one year
259.4
268.7
Between 1 and 5 years
868.3
784.7
Beyond 5 years
980.7
1,105.8
2,108.4
2,159.2
TOTAL
Ramsay Santé / Universal Registration Document 2026
79
2
ANNUAL FINANCIAL INFORMATION Financial information concerning the assets, financial position and results of the issuer (and Statutory Auditors’ report)
7.1.3 Amounts recognised in the income statement For the 2026 financial year, the restatement relating to the recognition of leases in accordance with IFRS 16 Leases had the following impact: ■ ■ ■
neutralisation of EUR 344.8 million in rents; recognition of EUR (271.4) million in amortisation and impairment of right‑of‑use assets; recognition of EUR (81.6) million in interest on lease liabilities. From 1 July 2025 to 30 June 2026
From 1 July 2024 to 30 June 2025
Waiver of rents
344.8
332.9
Recognition of depreciation and impairment losses on rights of use
(271.4)
(260.4)
Recognition of interest expense on lease liabilities
(81.6)
(80.1)
NET IMPACT OF THE APPLICATION OF IFRS 16
(8.2)
(7.6)
From 1 July 2025 to 30 June 2026
From 1 July 2024 to 30 June 2025
Property rentals (operating leases)
(47.3)
(47.7)
Equipment rentals (operating leases)
(36.0)
(39.7)
(83.3)
(87.4)
(in millions of euros)
From 1 July 2025 to 30 June 2026
From 1 July 2024 to 30 June 2025
VAT on contracts
(17.4)
(17.6)
Real estate and other taxes on contracts
(35.4)
(34.9)
Contracts of less than one year
(6.1)
(6.5)
Contracts with a low unit value
(24.4)
(28.4)
(83.3)
(87.4)
(in millions of euros)
7.1.4 Remaining rents and taxes (in millions of euros)
TOTAL
CSOCI
The balance of the amount remaining in rents at 30 June 2026 is broken down as follows:
TOTAL
80
Ramsay Santé / Universal Registration Document 2026
CSOCI
ANNUAL FINANCIAL INFORMATION Financial information concerning the assets, financial position and results of the issuer (and Statutory Auditors’ report)
Note 8
Provisions
Accounting principles
2
A provision is recognised when the Group has a current obligation to a third party as a result of past events, the settlement of which is expected to result in an outflow of resources representing economic benefits to the Group and the amount of which can be reliably estimated. Identified risks of all kinds are regularly monitored and provisions are assessed taking into account the most likely assumptions at the reporting date. Provisions for restructuring include the cost of business combination operations. A business combination is considered to be completed at the closing date, and its expected effects are reflected in the annual financial statements, if the following three criteria are met: ■ ■ ■
the Group’s Board of Directors has expressly authorised the business combination and agreed on a formalised restructuring plan; the main features of the plan have been announced; the administrative authorisation for the business combination has been obtained.
In the case of transactions meeting the criteria set out above, the main effects reflected in the financial statements, where they can be reasonably estimated, are as follows: ■ ■
provisioning for the costs of terminating doctors’ contracts; provisioning for costs related to employee benefit plans.
Some contracts whose terms are significantly out of line with the market are considered onerous contracts. An impairment of the right of use is recognised for the difference in rent excluding tax between the current onerous contract and the same contract at market conditions over the remaining term of the contract. Provisions are made for VAT and other taxes on contracts. The other provisions are intended to deal with specific identified risks and disputes related to operations.
Ramsay Santé / Universal Registration Document 2026
81
2
ANNUAL FINANCIAL INFORMATION Financial information concerning the assets, financial position and results of the issuer (and Statutory Auditors’ report)
8.1
Provisions
During the financial year, provisions for liabilities evolved as follows: (in millions of euros)
30 June 2025
Note
Allocations
Reversals with use
Reversals without use
Other movements
30 June 2026
PROVISIONS FOR RETIREMENT AND OTHER EMPLOYEE BENEFITS Provisions for retirement bonuses Total
10.3
102.9
10.2
(6.5)
(5.7)(1)
100.9
B
102.9
10.2
(6.5)
(5.7)
100.9
19.7
4.6
(1.7)
(4.3)
1.6
19.9
NON‑CURRENT PROVISIONS Provisions for litigation Provisions for restructuring
8.1.1
92.0
9.8
(2.9)
(4.1)
2.5
97.3
Other provisions for liabilities and charges
8.1.2
27.7
2.2
(2.0)
(7.2)
20.7
B
139.4
16.6
(6.6)
(8.4)
(3.1)
137.9
3.5
1.6
(0.8)
(0.4)
3.9
Total CURRENT PROVISIONS Provisions for litigation Provisions for taxes
8.1.2
10.0
0.2
(0.2)
(9.3)
0.1
0.8
Other provisions for liabilities and charges
8.1.2
20.1
5.9
(2.4)
(6.0)
4.3
21.9
B
33.6
7.7
(3.4)
(15.7)
4.4
26.6
CURRENT AND NON‑CURRENT PROVISIONS
173.0
24.3
(10.0)
(24.1)
1.3
164.5
TOTAL PROVISIONS
275.9
34.5
(16.5)
(24.1)
(4.4)
265.4
Total
(1) Exchange rate and actuarial impacts.
IMPACTS OF PROVISION FLOWS ON THE INCOME STATEMENT Net impact 30 June 2025
Allocations
Reversals with use
Reversals without use
Net impact 30 June 2026
(16.0)
7.7
2.5
(5.8)
4.1
(6.3)
5.7
3.6
3.0
Taxes & duties
(0.6)
EBITDA
3.5
(22.3)
13.4
6.1
(2.8)
Other non‑current income & expenses
4.8
(12.0)
2.9
8.7
(0.4)
Other finance income and expenses
(4.1)
Taxes
(0.2)
0.2
9.3
9.3
TOTAL
4.2
(34.5)
16.5
24.1
6.1
(in millions of euros)
Note
Employee benefits Other operating expenses
Impact Statement of Cash Flows
82
Ramsay Santé / Universal Registration Document 2026
SCF
(4.2)
(8.2)
ANNUAL FINANCIAL INFORMATION Financial information concerning the assets, financial position and results of the issuer (and Statutory Auditors’ report)
8.1.1 Provisions for restructuring At 30 June 2026, the balance of the restructuring provisions amounted to EUR 97.3 million. It mainly consists of the provision relating to the Mermoz dispute in the amount of EUR 77.4 million, a provision of EUR 1.9 million in connection with the announcement of the closure of Clinique Blomet’s activity, a provision of EUR 2.5 million relating to the transfer of the activity of the Saint‑Jean‑du‑Languedoc facility to the Croix du Sud facility and provisions totalling EUR 6.5 million for restructuring projects and the optimisation of maternity services.
8.1.2 Other provisions for liabilities and charges Under non‑current liabilities, the Group recognised provisions relating to onerous contracts in connection with the acquisition of the Capio group, with a balance of EUR 18.6 million at 30 June 2026.
8.2
Current liabilities also include provisions for onerous contracts (property leases) of EUR 2 million, provisions for bonuses (Long Term Incentives or LTIs) of EUR 9.1 million and other operating provisions mainly comprising patient disputes and a dispute related to a health inspection in Italy. A favourable outcome in a tax dispute (VAT) in Sweden has led to the unused reversal of EUR 9.3 million. ACCRUAL OF PAID LEAVE DURING A WORK STOPPAGE IN FRANCE In order to bring French law into line with European Union law, in three judgments delivered on 13 September 2023, the Court of Cassation called into question the rules applied until now in terms of paid leave and work stoppages. The French Labour Code was thus amended following the enactment of Law No. 2024‑376 of 23 April 2024. At 30 June 2026, the Group fully reversed the provision for liabilities and charges in the amount of EUR 4.7 million for years prior to the entry into force of the law following the expiry of the limitation period.
Mermoz litigation
The Tribunal de Grande Instance de Lyon rendered its judgment on 24 September 2019 in which the plaintiffs, namely Compagnie Générale de Santé, SCI de l’Europe, Hôpital Privé Jean Mermoz and Centre d’Imagerie Mermoz, all subsidiaries of the Group, were granted their principal claims and were compensated for a total amount, excluding interest, of EUR 66.5 million, plus interest for late payment of EUR 10.9 million. As part of this long‑awaited decision, the Group’s claims were recognised and the judgment was provisionally enforced under a condition that the plaintiffs implemented with their counsel. In the immediate aftermath of the judgment, several of the parties involved appealed the decision.
No additional amount had been collected during the financial year. At 30 June 2026, the Group has a receivable of EUR 47.4 million in assets corresponding to the compensation awarded by the judgment, which is yet to be received. In view of the ongoing appeals and the uncertainties regarding the final outcome of the proceedings, the Group is also maintaining a separate provision of EUR 77.4 million corresponding to its best estimate of the financial consequences of the appeal decision. The accounting effects of the decision on appeal will be recorded when the decision is available and its consequences can be reliably assessed.
This case was pleaded before the Court of Appeal in May 2026 and the ruling is expected in October 2026.
Ramsay Santé / Universal Registration Document 2026
83
2
2
ANNUAL FINANCIAL INFORMATION Financial information concerning the assets, financial position and results of the issuer (and Statutory Auditors’ report)
Note 9 9.1
Financing and financial instruments
Financial profit (loss)
Accounting principles Net borrowing cost includes interest expenses related to financial debt, income from interest rate hedges related to this financing, as well as interest income on loans and financial income from cash investments. Other finance income and expenses mainly include dividends received from non‑consolidated companies, interest income from assets used to hedge retirement benefit obligations, as well as interest expenses for the financial year on liabilities, the ineffective portion of hedging transactions and the costs associated with lines of credit.
9.1.1 Net borrowing cost (in millions of euros)
Note
From 1 July 2025 to 30 June 2026
From 1 July 2024 to 30 June 2025
Income from interest generated by cash and cash equivalents
3.2
4.7
Sub‑total income from cash and cash equivalents
3.2
4.7
Interest on bank borrowings and other financial debt
(95.8)
(115.3)
Profit (loss) on interest rate hedges
(8.7)
6.9
Amortisation of debt issuance costs
(1)
(8.3)
(10.6)
Sub‑total gross borrowing cost
(112.8)
(119.0)
(5.4)
(5.3)
Interest on equipment financed under operating leases
(76.2)
(74.8)
Sub‑total financial interest related to lease debt
(81.6)
(80.1)
(191.2)
(194.4)
Interest on property financed under finance leases
TOTAL NET BORROWING COST
CSOCI
(1) As part of the upcoming spin‑off, the Group revalued its financial liabilities. An analysis of the variation in contractual cash flows led to a revision of the effective interest rate. This revaluation led to the accelerated amortisation of the remaining issuance costs, for an amount of EUR 6.6 million, recognised in financial profit (loss).
The interest rate (ratio of financial expenses to average gross financial debt) was approximately 5.01% at 30 June 2026, stable compared to 30 June 2025.
9.1.2 Other finance income and expenses (in millions of euros)
Note
From 1 July 2025 to 30 June 2026
From 1 July 2024 to 30 June 2025
Dividends
SCF
0.9
1.6
1.9
1.7
Return on plan assets Other financial income
1.9
0.2
Sub‑total other financial income
4.7
3.5
Discounting costs
(3.9)
(4.0)
(7.2)(1)
Change in fair value of financial instruments and the reclassification of items in other comprehensive income to profit or loss Other financial expenses
(2.9)
(4.5)
Sub‑total other financial expenses
(6.8)
(15.7)
(2.1)
(12.2)
TOTAL OTHER FINANCE INCOME & EXPENSES
CSOCI
(1) This amount includes the change in fair value of ineffective financial instruments from 1 July 2024 to 30 June 2025, totalling EUR (5.2) million, as well as the reversal of the value of hedging instruments that have become ineffective and were historically included in equity, totalling EUR (2.0) million, in the income statement.
84
Ramsay Santé / Universal Registration Document 2026
ANNUAL FINANCIAL INFORMATION Financial information concerning the assets, financial position and results of the issuer (and Statutory Auditors’ report)
9.2
Net financial debt
Accounting principles Net financial debt consists of gross financial debt less certain financial assets.
2
Gross financial debt consists of: ■ ■ ■ ■ ■
borrowings from credit institutions, including accrued interest; lease debt falling under the scope of IFRS 16 Leases; the fair value of hedging instruments recorded in the balance sheet net of tax; current financial debt, in particular relating to financial current accounts with minority investors; bank overdrafts.
Financial assets consist of: ■ ■ ■ ■
the fair value of hedging instruments recorded in the balance sheet net of tax; current financial receivables, in particular relating to financial current accounts with minority investors; cash and cash equivalents, including treasury shares held by the Group considered to be marketable securities; financial assets directly related to loans taken out and recognised in gross financial debt.
Ramsay Santé / Universal Registration Document 2026
85
2
ANNUAL FINANCIAL INFORMATION Financial information concerning the assets, financial position and results of the issuer (and Statutory Auditors’ report)
Net financial debt breaks down as follows: 30 June 2025 (in millions of euros)
Note
Term loan B5 Revolving Credit Facility Capex debt Debt - credit agreement
30 June 2026
TOTAL
Non‑current
Current
TOTAL
1,465.5
1,450.0
15.5
1,465.5
15.0
15.0
15.0 1,480.5
1,480.5
1,465.0
15.5
Euro Private Placement bond issue
101.8
100.0
1.8
101.8
Security Trust
226.8
165.2
30.5
195.7
97.3
125.6
16.8
142.4
1,890.5
1,849.0
1,849.0 259.4
Other borrowings Non‑current lease liability Current lease liability
268.7
259.4
Debt issuance costs
(8.8)
(1.2)
(0.3)
(1.5)
4,056.8
3,703.6
323.7
4,027.3
Long‑term financial debt Financial current accounts liabilities GROSS FINANCIAL DEBT (I)
4.6
3.9
3.9
4,061.4
3,703.6
327.6
4,031.2
Fair value of hedging instruments
9.9
(5.1)
0.9
(4.2)
FINANCIAL INSTRUMENTS (II)
9.9
(5.1)
0.9
(4.2)(1)
(4.7)
(5.7)
(5.7)
Cash
Financial current accounts assets
(366.5)
(302.2)
(302.2)
Other financial assets
(52.3)
(131.0)
(3.2)
(134.2)
Ramsay Générale de Santé treasury shares (marketable securities)
(0.3)
FINANCIAL ASSETS (III)
(423.8)
(131.0)
(311.1)
(442.1)
NET FINANCIAL DEBT (I) + (II) + (III)
3,647.5
3,567.5
17.4
3,584.9
CLOSING BALANCE SHEET: Borrowings and financial debt (a)
1,841.2
1,854.6(2)
Non‑current lease liability (b)
1,890.5
1,849.0
Current financial debt (c)
61.0
68.2
Current lease liability (d)
268.7
259.4
4,061.4
4,031.2
GROSS FINANCIAL DEBTS A = (a) + (b) + (c) + (d) Other non‑current liabilities (e)
9.4
Other current liabilities (f)
4.1
1.2
Deferred taxes (g)
(3.5)
(0.3)
Other net non‑current liabilities (fair value of financial instruments) B = (e) + (f) + (g)
10.0
0.9
Other non‑current financial assets (fair value of financial instruments) (h)
(0.2)
(6.8)
Other current financial assets (fair value of financial instruments) (i)
0.1
1.7
FINANCIAL INSTRUMENTS(1) C = (B) + (h) + (i) + ( j)
9.9
(4.2)
Current financial assets (k)
(17.5)
(8.9)
Non‑current financial assets (l)
(39.5)
(131.0)
Cash (m)
(366.5)
(302.2)
Deferred taxes ( j)
Ramsay Générale de Santé treasury shares (marketable securities) (n) FINANCIAL ASSETS D = (k) + (l) + (m) + (n) NET FINANCIAL DEBT (A + C + D)
SCF
(0.3)
(423.8)
(442.1)
3,647.5
3,584.9
(1) Fair value of hedging instruments EUR (5.6) million plus tax of EUR 1.4 million. (2) Borrowings and financial debt of EUR 1,854.6 million = Gross financial debt (non‑current) of EUR 3,703.6 million - Non‑current lease liability of EUR 1,849.0 million.
86
Ramsay Santé / Universal Registration Document 2026
ANNUAL FINANCIAL INFORMATION Financial information concerning the assets, financial position and results of the issuer (and Statutory Auditors’ report)
9.2.1 Explanatory data on changes in net debt (in millions of euros)
Note
Term Loan B5
Debt position at 30 June 2025
New borrowings
Reimbursements
Change in net scope
Debt position at 30 June Other 2026
1,450.0
1,450.0
Accrued interest on debt
15.5
15.5
Revolving Credit Facility
15.0
15.0
1,480.5
1,480.5
Euro Private Placement bond issue
101.8
101.8
Security Trust
226.8
Capex debt Total Credit agreements
Other borrowings
(31.1)
195.7
97.3
76.3
(16.0)
(15.2)
142.4
1,890.5
202.3
(69.5)
(174.3)
1,849.0
Current lease liability
268.7
28.2
(221.1)
188.4
259.4
Debt issuance costs
(8.8)
7.3
(1.5)
6.2
4,027.3
Non‑current lease liability
Sub‑total financial debt
4,056.8
Current account liabilities
4.6
TOTAL GROSS FINANCIAL DEBT
(337.7)
(4.8)
(4.8)
(0.7)
4,031.2
9.9
(14.1)
(4.2)
FINANCIAL INSTRUMENTS
9.9
(14.1)
(4.2)
Current accounts assets
(4.7)
9.4
Cash
(366.5)
Other financial assets
(52.3)
Ramsay Générale de Santé treasury shares (marketable securities)
(0.3)
306.8
(338.4)
3.9 6.2
Fair value of hedging instruments
4,061.4
306.8
(4.8)
(1.0)
3.4
(5.7)
(0.1)
64.3
(302.2)
(85.2)
(134.2)
0.3
FINANCIAL ASSETS
(423.8)
2.4
(0.1)
(20.6)
(442.1)
TOTAL NET FINANCIAL DEBT
3,647.5
306.8
(336.0)
(4.9)
(28.5)
(3,584.9)
76.3
(45.4)
Impact Statement of Cash Flows
SCF
Financial debt
Impact Statement of Cash Flows
SCF
Lease debt (IFRS 16)
2
(290.6)
Ramsay Santé / Universal Registration Document 2026
87
2
ANNUAL FINANCIAL INFORMATION Financial information concerning the assets, financial position and results of the issuer (and Statutory Auditors’ report)
9.2.2 Euro Private Placement loan and credit agreement At 30 June 2026, the breakdown of the Group’s credit agreement, denominated exclusively in euros, was as follows: 30 June 2026
Original loan lines
Duration (in years)
Term
Amount used
Amount unused
Early repayment
1,450.0
7
13/08/2031
1,450.0
0.0
0.0
Revolving Credit facility
100.0
5
13/08/2029
0.0
100.0
0.0
Capex facility
100.0
5
13/08/2029
15.0
85.0
0.0
1,465.0
185.0
0.0
(in millions of euros)
Term Loan B5
TOTAL
1,650.0
At 30 June 2026, the credit structure was as follows: ■ ■ ■
The purpose of this credit agreement is to finance the general operating needs of the Group’s companies as well as acquisitions and capital expenditure for growth and restructuring. All of these tranches are issued at variable rates.
a EUR 1,450 million “Term Loan B5” tranche indexed to EUR3M+3.25%, maturing in August 2031; a EUR 100 million revolving credit facility indexed to EUR3M+2.75%, maturing in August 2029;
At 30 June 2026, the Ramsay Santé group had no outstanding drawdowns on the Revolving Credit Facility and had drawn down EUR 15 million on the Capex facility.
a Capex facility in the amount of EUR 100 million indexed to EUR3M+2.75%, maturing in August 2029.
At 30 June 2026, the breakdown of the Euro Private Placement loan was as follows: 30 June 2026
Original loan lines
Duration (in years)
Term
Amount used
Amount unused
Early repayment
Euro Private Placement
40.0
7
14/12/2028
40.0
0.0
0.0
Euro Private Placement
60.0
8
14/12/2029
60.0
0.0
0.0
TOTAL
100.0
100.0
0.0
0.0
(in millions of euros)
In December 2021, the Ramsay Santé group issued a fixed‑rate debt instrument in a private placement bond format for EUR 100 million, maturing in 2028 and 2029. As indicated in note 15 Post‑closing events, the Group refinanced its senior debt in July 2026.
88
Ramsay Santé / Universal Registration Document 2026
ANNUAL FINANCIAL INFORMATION Financial information concerning the assets, financial position and results of the issuer (and Statutory Auditors’ report)
9.3
Derivatives
Accounting principles The Group holds derivative financial instruments to hedge its exposure to the risks it faces in the course of its business, mainly interest rate risk.
2
To hedge its exposure to market “interest rate” risk, the Group uses derivative instruments, classified as cash flow hedges (interest rate swaps paying fixed rates). Changes in the fair value of derivatives are recognised differently depending on whether the derivatives are designated as effective or ineffective. The Group therefore applies cash flow hedge accounting (“CFH”): the effective portion of the change in fair value of derivative instruments is recognised directly in other comprehensive income and then recycled in income when the hedged risk impacts profit or loss. The ineffective portion is recognised directly in financial profit (loss).
At 30 June 2026, as in the previous financial year, the derivatives consisted solely of interest rate instruments: 30 June 2026 (in millions of euros)
Assets
30 June 2025
Liabilities
Assets
Liabilities
Interest rate instruments
6.8
1.2
0.2
13.5
Financial derivatives
6.8
1.2
0.2
13.5
9.4
Financial assets and liabilities and fair value hierarchy
9.4.1 Current and non‑current financial assets 9.4.1.1
CURRENT FINANCIAL ASSETS
Current financial assets consist mainly of financial current accounts with non‑consolidated companies and short‑term financial loans and receivables. 9.4.1.3
9.4.1.2
CASH AND CASH EQUIVALENTS
The line “cash and cash equivalents” includes cash and cash equivalents as well as immediately available monetary investments that present a negligible risk of change in value.
NON‑CURRENT FINANCIAL ASSETS
Other non‑current financial assets break down as follows: (in millions of euros)
Note
Non‑consolidated equity investments Loans, deposits and guarantees paid Fair value of hedging instruments
9.2
30 June 2026
30 June 2025
13.7
13.4
120.2
59.4
6.8
0.2
Other non‑current financial assets
114.5
87.0
Total non‑current financial assets
255.2
160.0
The change in loans, deposits and guarantees paid during the financial year was mainly related to the payment of SEK 600 million (EUR 54.2 million) at 30 June 2026 as part of the new management contract for St. Göran hospital.
Ramsay Santé / Universal Registration Document 2026
89
2
ANNUAL FINANCIAL INFORMATION Financial information concerning the assets, financial position and results of the issuer (and Statutory Auditors’ report)
9.4.2 Breakdown of financial assets and liabilities Accounting principles Financial assets ■
■ ■
Assets at amortised cost: these are financial assets held to collect contractual cash flows that consist exclusively of interest and repayment of capital on specific dates. These assets are initially recognised at fair value, then at amortised cost using the effective interest rate method. This category mainly includes cash, trade receivables, deposits and guarantees as well as loans to non‑consolidated companies. Assets at fair value through other comprehensive income: Derivatives documented in a future cash flow hedging relationship are classified in this category. Assets at fair value through profit or loss: this category includes the equity instruments for which the Group has not chosen the option of recognition at fair value through other comprehensive income, all financial assets that are not included in the previous categories, as well as derivatives that are not eligible for hedge accounting.
Financial liabilities ■
■ ■
90
Liabilities at amortised cost: these are initially recognised at the fair value of the counterparty transferred, then at amortised cost, using the effective interest rate method. Transaction costs directly attributable to the issue of a financial liability are deducted from its initial fair value. They are then amortised over the life of the liability using the effective interest rate. This category mainly includes bonds, bank loans in the form of drawdowns of credit lines and bank overdrafts, trade and other payables. Liabilities at fair value through other comprehensive income: this category corresponds mainly to derivatives documented in a future cash flow hedging relationship. Liabilities at fair value through profit or loss: these include debts on commitments to purchase non‑controlling interests for the discounted estimated purchase price, which is adjusted at each reporting date to reflect changes in the exercise price of the options, as well as derivatives that are not eligible for hedge accounting.
Ramsay Santé / Universal Registration Document 2026
ANNUAL FINANCIAL INFORMATION Financial information concerning the assets, financial position and results of the issuer (and Statutory Auditors’ report)
AMORTISED COST, FAIR VALUE THROUGH EQUITY, FAIR VALUE THROUGH PROFIT OR LOSS (in millions of euros)
Note
At amortised cost
Fair value through OCI
Fair value through profit or loss
30 June 2026
FINANCIAL ASSETS Non‑consolidated equity investments
9.4.1.3
Loans, deposits and guarantees paid Fair value of hedging instruments
13.7 120.2
9.2
Other non‑current financial assets
6.8
6.8
15.2
73.4
25.9
114.5
Subtotal Non‑current financial assets
9.4.1.3
135.4
80.2
39.6
255.2
Trade receivables
5.2.4
470.9
Current financial assets
9.2
8.9
8.9
Cash and cash equivalents
9.2
302.2
302.2
Total Financial assets
917.4
2
13.7 120.2
470.9
80.2
39.6
1,037.2
FINANCIAL LIABILITIES Borrowings
9.2
1,854.6
1,854.6
Debt on commitments to purchase non‑controlling interests
22.8
Other non‑current liabilities Suppliers Current financial debt
5.2.4 9.2
Total Financial liabilities
(in millions of euros)
Note
22.8
6.3
6.3
427.7
427.7
68.2
68.2
2,356.8
22.8
2,379.6
At amortised cost
Fair value through OCI
Fair value through profit or loss
30 June 2025
FINANCIAL ASSETS Non‑consolidated equity investments
9.4.1.3
Loans, deposits and guarantees paid Fair value of hedging instruments
13.4 59.4
9.2
Other non‑current financial assets
13.4 59.4
0.2
0.2
3.2
59.8
24.0
87.0
60.0
37.4
160.0
Subtotal Non‑current financial assets
9.4.1.3
62.6
Trade receivables
5.2.4
527.5
Current financial assets
9.2
17.5
17.5
Cash and cash equivalents
9.2
366.5
366.5
Total Financial assets
974.1
527.5
60.0
37.4
1,071.5
FINANCIAL LIABILITIES Borrowings
9.2
1,841.2
1,841.2
Debt on commitments to purchase non‑controlling interests
22.2
Other non‑current liabilities Suppliers Current financial debt Total Financial liabilities
2.7 5.2.4 9.2
22.2
13.5
16.2
432.3
432.3
61.0 2,337.2
61.0 13.5
22.2
2,372.9
Ramsay Santé / Universal Registration Document 2026
91
2
ANNUAL FINANCIAL INFORMATION Financial information concerning the assets, financial position and results of the issuer (and Statutory Auditors’ report)
9.4.3 Fair value hierarchy Accounting principles Under IFRS 13 Fair Value Measurement, fair value measurements of financial instruments are categorised according to a three‑level hierarchy: ■ ■ ■
Level 1: fair value measured by reference to (unadjusted) quoted prices in active markets for identical assets and liabilities; Level 2: fair value measured using models based directly or indirectly on observable market data for the assets or liabilities in question; Level 3: fair value determined using valuation techniques not based on observable market data.
30 June 2026 (in millions of euros)
Fair value
Hierarchy Level 1
Level 3
Non‑consolidated equity investments
13.7
13.7
Fair value of hedging instruments
6.8
6.8
Other non‑current financial assets
99.3
73.4
25.9
FINANCIAL ASSETS
119.8
80.2
39.6
Debt on commitments to purchase non‑controlling interests
22.8
22.8
FINANCIAL LIABILITIES
22.8
22.8
30 June 2025 (in millions of euros)
92
Level 2
Fair value
Hierarchy Level 1
Level 2
Level 3
Non‑consolidated equity investments
13.4
Fair value of hedging instruments
0.2
0.2
Other non‑current financial assets
83.8
59.8
24.0
FINANCIAL ASSETS
97.4
60.0
37.4
Debt on commitments to purchase non‑controlling interests
22.2
Other non‑current liabilities
13.5
13.5
FINANCIAL LIABILITIES
35.7
13.5
Ramsay Santé / Universal Registration Document 2026
13.4
22.2
22.2
ANNUAL FINANCIAL INFORMATION Financial information concerning the assets, financial position and results of the issuer (and Statutory Auditors’ report)
9.5
Financial risk management
9.5.1 Interest rate risk In order to hedge its exposure to the interest rate risk associated with the floating rate interest flows to be disbursed, the Ramsay Santé group enters into interest rate swaps (floating‑rate receiver and fixed‑rate payer). In accordance with the provisions of the credit agreement, the Group is obliged, within six months of the Euribor moving into positive territory for more than 20 working days, to hedge at least 2/3 (but not more than 100%) of the principal amount outstanding on drawdown facilities (excluding the additional uncommitted Capex facility) for a period of at least three years. At 30 June 2026, 76% of the amount drawn was covered with an average fixed rate of 2.46%. The operations have been classified as cash flow hedges in accordance with the requirements of IFRS 9 Financial Instruments.
Derivative instruments are recorded at fair value in the balance sheet. Cumulated changes in the fair value of hedging instruments are recognised in other comprehensive income in equity for the effective portions and in the income statement for the ineffective portions. At 30 June 2026, the fair value of the hedging derivatives was recognised as a liability for EUR (1.2) million and on the asset side for EUR 6.8 million. The entire cumulative change in the fair value of derivatives was deferred to equity for EUR (5.6) million (i.e. EUR (4.2) million after tax) and will be recycled in profit or loss as and when interest coupons are paid. A 10 bps increase or decrease in interest rates would impact the Group’s equity by EUR 2.6 million and EUR (2.6) million respectively.
Exposure to interest rate risk on financial debt (before and after hedging) breaks down as follows: 30 June 2026 (in millions of euros)
30 June 2025
Outstanding
Share
Outstanding
Share
Fixed rate
475
23%
268
14%
Variable rate
1,591
77%
1,690
86%
Total before hedging
2,065
100%
1,958
100%
Fixed rate
1,590
77%
1,733
88%
Variable rate
476
23%
225
12%
2,065
100%
1,958
100%
Total after hedging
ANALYSIS OF THE SENSITIVITY OF FINANCIAL EXPENSES TO CHANGES IN INTEREST RATES On the basis of the Group’s debt at 30 June 2026, and despite its fixed‑rate position (EUR 1,590 million out of a total of EUR 2,065 million), the Group is nevertheless sensitive to a rise in interest rates (the hedging rate is not 100%). A 100bps rise in short‑term rates would impact financial expenses by nearly EUR 4.8 million per year.
Ramsay Santé / Universal Registration Document 2026
93
2
2
ANNUAL FINANCIAL INFORMATION Financial information concerning the assets, financial position and results of the issuer (and Statutory Auditors’ report)
9.5.2 Liquidity risks At 30 June 2026, the undiscounted contractual flows on outstanding financial liabilities by maturity date are as follows: At 30 June 2026 (in millions of euros)
2027
2028
2029
2030
Total
Senior debt
15.5
1,465.0
1,480.5
Capitalisation of issue costs
(0.3)
(0.3)
(0.3)
(0.6)
(1.5)
1.8
40.0
60.0
101.8
Security Trust
30.5
50.1
20.7
94.4
195.7
Other borrowings
16.8
14.6
17.4
93.6
142.4
Leasehold loans on real estate
209.5
194.0
172.1
1,385.5
1,961.1
Leasehold loans on movable assets
49.9
36.3
36.7
24.4
147.3
Other financial liabilities (including current account liabilities)
3.9
3.9
TOTAL
327.6
334.7
306.6
3,062.3
4,031.2
At 30 June 2025 (in millions of euros)
2026
2027
2028
2029
Total
Senior debt
15.5
1,465.0
1,480.5
Capitalisation of issue costs
(1.3)
(1.5)
(1.5)
(4.5)
(8.8)
Euro Private Placement bond issue
1.8
40.0
60.0
101.8
Security Trust
30.5
30.5
50.1
115.7
226.8
Other borrowings
9.9
10.9
11.7
64.8
97.3
Leasehold loans on real estate
222.0
205.2
186.9
1,411.2
2,025.3
Leasehold loans on movable assets
46.8
33.8
24.0
29.3
133.9
Other financial liabilities (including current account liabilities)
4.6
4.6
329.8
278.9
311.2
3,141.5
4,061.4
Euro Private Placement bond issue
TOTAL
9.5.3 Foreign exchange risks Ramsay Santé group’s activities are carried out mainly by subsidiaries operating in the eurozone, however following the acquisition of the Capio group, the activity carried out in Scandinavia is subject to foreign exchange risk. Intragroup financing made available to Scandinavian subsidiaries and for which repayment is neither planned nor probable is considered to be an integral part of net investments made abroad; the exchange differences generated at the time of their successive remeasurements at each balance sheet date are then recognised directly in other comprehensive income, in accordance with the provisions of IAS 21 Effects of Changes in Foreign Exchange Rates.
94
Ramsay Santé / Universal Registration Document 2026
ANNUAL FINANCIAL INFORMATION Financial information concerning the assets, financial position and results of the issuer (and Statutory Auditors’ report)
Note 10
Workforce, employee‑related expenses and benefits, remuneration
10.1 Workforce 30 June 2026
2
30 June 2025
Average workforce (FTEs)
37,040
34,972
Workforce at end of period (number)(1)
40,597
40,494
(1) The headcount figures shown in the table below differ from those presented in chapter 4, section 4.4.1 ‘Ramsay Santé’s Human Capital’ (S1‑16) of this document. These figures do not include employees in Italy, unlike the headcount figures shown in the table above.
10.2 Employee‑related expenses These are presented in note 5.2.1 Employee benefits.
10.3 Pension and similar commitments Accounting principles Ramsay Santé contributes to employee benefit plans that provide retirement and post‑employment benefits to employees, retired employees and eligible dependants. For Ramsay Santé, the majority of commitments are defined‑contribution pension plans. Defined‑benefit plans may be financed by investments in various instruments, such as insurance contracts or equity securities and bonds. Contributions to defined‑contribution pension plans are recognised as expenses in the income statement.
10.3.1 Actuarial assumptions An actuarial valuation of the liabilities was carried out as at 30 June 2026 using the following assumptions, defined on the basis of recommendations from independent experts: Retirement age with voluntary departure at the initiative of the employee
30 June 2026
30 June 2025
65 years
65 years
Salary trends
2.00% to 4.00%
1.75% to 4.00%
Discount rate at opening
3.00% to 4.00%
3.50% to 4.00%
Discount rate at closing
3.50% to 4.05%
3.00% to 4.00%
Expected return on plan assets
2.00% to 4.00%
2.00% to 4.00%
With regard to the discount rate, the standard specifies that the rate to be used to discount post‑employment benefit obligations (whether funded or unfunded) should be determined by reference to a market rate at the closing date based on Tier 1 corporate bonds.
Ramsay Santé / Universal Registration Document 2026
95
2
ANNUAL FINANCIAL INFORMATION Financial information concerning the assets, financial position and results of the issuer (and Statutory Auditors’ report)
10.3.2 Summary of the financial position The financial position relating to retirement bonus obligations for Group companies breaks down as follows: (in millions of euros)
Present value of financial obligations Fair value of plan assets Net balance sheet commitment (in millions of euros)
30 June 2026
30 June 2025
271.5
266.3
(244.0)
(223.2)
27.5
43.1
30 June 2026
30 June 2025
Pension plans
100.9
102.9
Retirement commitment
100.9
102.9
Pension plan surplus
73.4
59.8
Pension assets
73.4
59.8
Net balance sheet commitment
27.5
43.1
30 June 2026
30 June 2025
266.3
250.7
Cost of services rendered during the year
10.5
13.0
Financial cost
8.6
9.0
Benefits paid
(9.4)
(9.6)
Actuarial difference: (gain)/loss
(5.2)
(1.1)
Exchange differences
0.7
4.3
271.5
266.3
30 June 2026
30 June 2025
223.2
186.8
Expected return on plan assets
6.5
6.8
Employer contributions
13.9
22.1
Benefits paid
(2.9)
(3.4)
Actuarial difference on plan assets gain/(loss)
3.0
6.7
Exchange differences
0.3
4.2
244.0
223.2
30 June 2026
30 June 2025
Financial position at the beginning of the financial year (I) - (II)
43.1
63.9
Financial position at the end of the financial year (III) - (IV)
27.5
43.1
10.3.3 Changes in the financial position The change in the financial position of retirement bonus obligations breaks down as follows: (in millions of euros)
Actuarial debt at the beginning of the financial year (I)
Actuarial debt at the end of the financial year (III)
(in millions of euros)
Fair value of assets at the beginning of the financial year (II)
Fair value of plan assets at the end of the financial year (IV)
(in millions of euros)
96
Ramsay Santé / Universal Registration Document 2026
ANNUAL FINANCIAL INFORMATION Financial information concerning the assets, financial position and results of the issuer (and Statutory Auditors’ report)
From 1 July 2025 to 30 June 2026
From 1 July 2024 to 30 June 2025
Cost of services rendered during the financial year
(10.5)
(13.0)
Financial cost
(8.6)
(9.0)
Expected return on plan assets
6.5
6.8
Benefits paid
(6.5)
(6.2)
Reversal of provisions
6.5
6.2
(12.6)
(15.2)
30 June 2026
30 June 2025
102.9
107.6
Expense for the financial year
10.2
6.8
Employer contributions paid
3.8
Benefits paid
(6.5)
(6.2)
Change in actuarial gains and losses in equity
(5.7)
(9.7)
0.6
100.9
102.9
(in millions of euros)
Expenses recognised in the income statement
2
10.3.4 Reconciliation table The reconciliation of the provision for retirement bonuses at 30 June 2026 breaks down as follows: (in millions of euros)
Note
Provision for retirement at the beginning of the financial year
Exchange differences Provision for retirement at the end of the financial year
B
An asset was recognised over three plans at 30 June 2026. Only one plan has a surplus on pension plans. (in millions of euros)
30 June 2026
30 June 2025
Pension plan surplus at the beginning of the financial year
59.8
43.7
Expense for the financial year
(2.3)
0.6
Employer contributions
13.9
16.8
Change in actuarial gains and losses in equity
2.6
(3.2)
Exchange differences
(0.6)
1.9
73.4
59.8
Pension plan surplus at the end of the period
Note
9.4.1.3
10.3.5 Sensitivity of retirement bonus obligations The table below shows the impact of a change in the discount rate and an increase in wages on retirement bonuses: 30 June 2026 Sensitivity (in millions of euros)
Discounting -0.50%
Discounting +0.50%
Wages +0.50%
Retirement bonus obligations
111.2
100.0
111.3
Ramsay Santé / Universal Registration Document 2026
97
2
ANNUAL FINANCIAL INFORMATION Financial information concerning the assets, financial position and results of the issuer (and Statutory Auditors’ report)
10.4 Remuneration and similar benefits granted to members of the Board of Directors and to the Chief Executive The table below shows the total remuneration and similar benefits granted to the members of the Board of Directors and to the Chief Executive for the financial years ended 30 June 2025 and 30 June 2026. From 1 July 2025 to 30 June 2026
From 1 July 2024 to 30 June 2025
1,650.7
1,476.5
Termination benefits
Share‑based payments
1,650.7
1,476.5
(in thousands of euros)
Short‑term benefits received
TOTAL
Note 11
Income tax
Accounting principles The tax expense for the financial year is comprised of the current tax expense and deferred tax expense. It includes the amount recognised in France for the Value Added Tax (CVAE) as the Group considers it to meet the IAS 12 definition of an income tax. Deferred tax is calculated and recognised using the balance sheet method on all temporary differences between the carrying amount of assets and liabilities in the consolidated balance sheet and their tax value, with the exception of the specific cases set out in IAS 12 Income taxes, for which no deferred tax is to be recognised. Deferred taxes are measured at the expected tax rate for the period in which the asset is realised or the liability is settled. Deferred tax assets on tax loss carryforwards are recognised when it is probable that they can be used in the future, based on the taxable profit outlook resulting from the business plans prepared by the Group’s entities projected over five years. The carrying amount of deferred tax assets is reviewed at each year‑end and may be adjusted based on changes in the likelihood of achieving a sufficient taxable profit. Any material change between future tax results and the assumptions used could result in an increase or decrease in the carrying amount of deferred tax assets, which could have a material effect on the balance sheet and profit (loss). Deferred tax assets and liabilities are offset, particularly in the case of tax consolidations, when there is a legally enforceable right to offset tax assets and liabilities, and the assets and liabilities relate to the same entity or to different entities that intend either to settle current tax assets and liabilities on a net basis or to realise the assets and settle the liabilities simultaneously, in each future period in which significant amounts of deferred tax assets or liabilities are expected to be recovered or settled.
98
Ramsay Santé / Universal Registration Document 2026
ANNUAL FINANCIAL INFORMATION Financial information concerning the assets, financial position and results of the issuer (and Statutory Auditors’ report)
11.1
Tax expense for the financial year
BREAKDOWN OF INCOME TAX From 1 July 2025 to 30 June 2026
From 1 July 2024 to 30 June 2025
Tax expense payable (standard rate)
(23.1)
(9.3)
CVAE
(6.5)
(6.8)
Adjustment for current tax from prior financial years
(0.7)
1.7
Tax credits and other
0.4
0.5
Current taxes
(29.9)
(13.9)
Deferred taxes
10.4
12.3
(19.5)
(1.6)
(in millions of euros)
Income tax
As of 30 June 2026, Ramsay Générale de Santé SA is the head of a tax consolidation group under French law comprising 177 members (including the parent company). The member company shall pay to the parent company, as a contribution to the payment of the Group’s corporation tax as well as any additional contribution to corporation tax, regardless of the effective amount of said taxes, a sum equal to that which would have been charged to its income or long‑term capital gain for the financial year if it had been taxed separately, less any tax deduction rights that the member company would have been entitled to in the absence of consolidation.
2
The international tax reform drawn up by the OECD, known as “Pillar 2”, notably designed to establish a minimum tax rate of 15% in each jurisdiction where the Group operates, came into force in France in 2024. It also includes an immediate temporary exemption from the recognition of deferred taxes resulting from the implementation of this reform, which the Group has applied. After analysing the texts in the current regulations and their consequences, the Group has passed the tests for temporary protection regimes and is not subject to any additional tax in the jurisdictions in which it operates.
11.2 Reconciliation between the theoretical and effective tax rates In accordance with IFRS, the theoretical tax for the financial years ended 30 June 2025 and 30 June 2026 is calculated on the basis of the consolidated profit before tax to which the applicable tax rate in France is applied. For the financial year ended 30 June 2026, this corresponds to a theoretical net income of EUR 3.6 million, which is reconciled with the net expense actually recognised of EUR 19.5 million. From 1 July 2025 to 30 June 2026 In value
Profit before tax Theoretical tax charge
From 1 July 2024 to 30 June 2025
In rate
(13,8)
In value
In rate
(36,5)
3.6
-25.83%
9.4
-25.83%
Impact of tax rates different from the standard rate
1.2
-8.9%
0.3
-0.9%
Tax adjustment for prior years
0.6
-4.1%
1.7
-4.5%
Unrecorded deferred tax assets on tax loss for the year
(5.6)
40.3%
(3.7)
10.2%
2.9
-8.1%
Tax credits
2.6
-19.0%
2.3
-6.2%
CVAE
(4.8)
34.9%
(5.1)
13.9%
Use of uncapitalised losses and capitalisation of deferred tax assets not related to profit or loss in the financial year
Non‑taxable items
0.6
-1.6%
Permanent differences
(2.9)
20.9%
(3.0)
8.3%
Tax without base
(3.0)
21.4%
(5.8)
-61.9%
Restatement of finance expenses
(12.3)
88.9%
1.0
-7.5%
(1.2)
3.3%
(19.5)
141.1%
(1.6)
4.5%
Other Tax and effective tax rate of the Group
Ramsay Santé / Universal Registration Document 2026
99
2
ANNUAL FINANCIAL INFORMATION Financial information concerning the assets, financial position and results of the issuer (and Statutory Auditors’ report)
11.3 Current tax assets and liabilities Changes related to business 30 June 2025 activity
(in millions of euros)
Note
Other changes
30 June 2026
Current tax assets (I)
B
6.3
1.0
7.3
Current tax liabilities (II)
B
5.4
7.8
13.2
0.9
(6.8)
(5.9)
Change in current tax assets and liabilities (III) = (I) - (II) Corporation tax paid during the financial year
SCF
(17.9)
(21.3)
Tax assets are advance tax payments that have not been offset against tax payable. Tax liabilities correspond to income tax yet to be paid.
11.4 Deferred tax assets and liabilities The main types of deferred taxes are as follows: NET DEFERRED TAXES 30 June 2025
Impacts on income
Other changes
30 June 2026
Pension commitments
16.6
(0.7)
(1.3)
14.6
Rental
21.4
9.3
30.7
Valuation differences
(28.1)
3.8
(24.3)
Difference between tax / accounting depreciation periods
(9.8)
(8.9)
(0.1)
(18.8)
Fair value of hedging instruments
3.4
(4.9)
(1.5)
Miscellaneous provisions recognised in particular as part of PPA
17.1
(0.2)
(0.4)
16.5
SAAS costs
4.7
(0.8)
0.1
4.0
Losses carried forward in France
20.5
(2.0)
18.5
Losses carried forward in Scandinavia
10.0
7.4
17.4
Other
29.5
2.5
0.1
32.1
TOTAL
85.3
10.4
(6.5)
89.2
(in millions of euros)
Note
30 June 2026
30 June 2025
Deferred tax assets
B
127.6
114.7
Deferred tax liabilities
B
38.4
29.4
89.2
85.3
(in millions of euros)
TOTAL
11.5 Unrecognised deferred taxes The amount of unrecognised deferred tax assets amounted to EUR 37.7 million at 30 June 2026. These relate to tax loss carryforwards in France (EUR 28.4 million), Denmark (EUR 8.2 million), Sweden (EUR 0.6 million) and Norway (EUR 0.5 million).
100
Ramsay Santé / Universal Registration Document 2026
ANNUAL FINANCIAL INFORMATION Financial information concerning the assets, financial position and results of the issuer (and Statutory Auditors’ report)
11.6 Taxes on income and expenses recognised directly in equity (in millions of euros)
30 June 2026
30 June 2025
on the change in translation differences
0.4
on the change in actuarial differences relating to retirement bonus obligations
(2.0)
(1.8)
on the change in fair value of hedging instruments
(4.9)
3.5
Tax on income and expenses recognised directly in equity
(6.5)
1.7
DEFERRED TAXES:
Note 12
2
Equity and earnings per share
Accounting principles Equity is broken down into two items: equity attributable to owners of the parent and non‑controlling interests. The latter represents the portion of the equity of consolidated companies attributable to their minority shareholders. Transactions with holders of non‑controlling interests that result in a change in ownership interest in a subsidiary, without loss of control, affect equity only. At the level of the economic entity as a whole, control is not modified. The value of the subsidiary’s assets and liabilities remains unchanged.
The Ramsay Santé group is committed to managing its capital (equity and financial debt) from a long‑term perspective, in order to ensure the continuity of its operations, maintain an optimal financial structure in terms of cost of capital, profitability for its shareholders and security for all third parties with whom it has a relationship.
12.1 Share capital At 30 June 2026, share capital amounted to EUR 82.7 million. This amount corresponds to 110,389,690 shares with a nominal value of EUR 0.75 (fully paid‑up). Shares
30 June 2026
30 June 2025
Number of shares at the beginning of the financial year
110,389,690
110,389,690
Number of shares at the end of the financial year
110,389,690
110,389,690
Theoretical voting rights
219,184,657
219,999,110
Registered treasury shares
20,301
20,301
Bearer treasury shares
6,881
5,176
219,157,475
219,973,633
Capital increase
Shares without voting rights
Exercisable voting rights
Ramsay Santé / Universal Registration Document 2026
101
2
ANNUAL FINANCIAL INFORMATION Financial information concerning the assets, financial position and results of the issuer (and Statutory Auditors’ report)
12.2 Income and expenses recognised directly in equity Amounts are presented net of any impact of deferred taxes. (in millions of euros)
30 June 2026
30 June 2025
(35.3)
(44.8)
1.1
9.5
(34.2)
(35.3)
EXCHANGE DIFFERENCES Opening reserves Change Reserves at closing ACTUARIAL GAINS AND LOSSES ON OBLIGATIONS FOR RETIREMENT BONUSES (14.6)
(19.5)
Change in actuarial gains and losses
Opening reserves
6.3
4.9
Reserves at closing
(8.3)
(14.6)
(9.9)
0.0
FAIR VALUE OF HEDGING INSTRUMENTS Opening reserves Change in fair value
14.1
(9.9)
Reserves at closing
4.2
(9.9)
3.5
3.0
OTHER Opening reserves Change in fair value
2.3
0.5
Reserves at closing
5.8
3.5
12.3 Dividends No dividends were paid to the Group’s shareholders during the financial years ended in 2026 and 2025.
12.4 Non‑controlling interests Non‑controlling interests mainly comprise: ■ ■ ■
interests in certain property companies (SCI), in particular SCI de la Clinique Jouvenet in the 16th arrondissement of Paris; the public hospital’s interest in the Italian subsidiary Centro Ortopedico Di Quadrante Spa; practitioners’ interests in medical imaging companies.
12.5 Net earnings per share Accounting principles Net earnings per share
Net earnings per share are calculated by dividing the net profit attributable to owners of the parent by the weighted average number of shares outstanding during the financial year, after deducting the number of treasury shares, i.e. 110,362,508 shares. Diluted net earnings per share
No instrument granting deferred access to the share capital of Ramsay Santé is in place. Consequently, there is no dilutive effect on profit (loss).
102
Ramsay Santé / Universal Registration Document 2026
ANNUAL FINANCIAL INFORMATION Financial information concerning the assets, financial position and results of the issuer (and Statutory Auditors’ report)
30 June 2026
30 June 2025
(48.3)
(54.1)
110,389,690
110,389,690
(1)
27,182
25,477
110,362,508
110,364,213
(0.44)
(0.49)
110,362,508
110,364,213
(0.44)
(0.49)
Net profit attributable to owners of the parent (in millions of euros) Weighted number of shares during the financial year (including treasury shares) Number of treasury shares Weighted number of shares during the financial year Undiluted net profit per share (in euros) Dilutive effect of subscription plan Weighted number of shares during the financial year taking into account the dilutive effect Diluted net earnings per share (in euros)
2
(1) This amount includes the number of treasury shares (20,301 shares) and bearer shares held under the liquidity agreement (6,881 shares).
Note 13
Unrecognised items
13.1 Off‑balance sheet commitments 30 June 2026
30 June 2025
GUARANTEES AND DEPOSITS
Commitments
Commitments
(in millions of euros)
Given
Received
Given
Received
Bank guarantees received and bank guarantees given
222.4
335.3
18.1
47.4
Pledged securities
2,601.9
2,760.9
Other guarantees
9.4
8.9
2,851.8
3,152.4
Real estate mortgages
TOTAL
At 30 June 2026, the Group’s off‑balance sheet commitments amounted to EUR 2,851.8 million, compared with EUR 3,152.4 million at 30 June 2025. They consist of EUR 2,601.9 million in securities pledged under the credit agreement.
13.2 Litigation and contingent liabilities Neither the Group nor any of its subsidiaries is currently involved in any significant litigation or conflict, the consequences of which would not be covered by a provision recorded in the closing balance sheet as at 30 June 2026.
Ramsay Santé / Universal Registration Document 2026
103
2
ANNUAL FINANCIAL INFORMATION Financial information concerning the assets, financial position and results of the issuer (and Statutory Auditors’ report)
Note 14
Statutory Auditors’ fees
(in thousands of euros - excluding tax)
Certification of individual and consolidated financial statements and half‑yearly limited review Certification of sustainability information Services other than certification of financial statements TOTAL
Note 15
ERNST & YOUNG
DELOITTE & ASSOCIÉS
From 1 July 2025 to 30 June 2026
From 1 July 2025 to 30 June 2026
2,449.8
1,455.8
245.0
850.0
25.0
3,299.8
1,725.8
Post‑closing events
Ramsay Santé senior debt refinancing
Hôpital Privé Dijon‑Bourgogne real estate refinancing
On 22 July 2026, Ramsay Générale de Santé finalised the refinancing of its senior debt for a total amount of EUR 1,750 million, including EUR 1,550 million under Term Loan B and EUR 200 million under a revolving credit facility.
On 20 July 2026, the Group exercised the EUR 13 million purchase option provided for in the real estate finance lease agreement for its Dijon‑Bourgogne site, which had expired. At the same time, on 31 July 2026, it mobilised a new tranche of Fiducie‑Sûreté (Fiducie) debt in the amount of EUR 67.5 million over 10 years, thus strengthening its liquidity under attractive conditions and diversifying its sources of financing as well as its maturity profile. This financing, orchestrated by Natixis, was supported by a consortium comprising several Groupe BPCE, La Banque Postale and Bpifrance entities.
To set up this new Term Loan B, the Group benefited from the support of existing investors and new lenders. Its pricing is indexed to EUR3M+3.50%. This transaction provides the Group with a long‑term financing framework thanks to the extension of the maturities of the senior debt from 2031 to 2033 and the refinancing of the “Euro Private Placement” loans of EUR 100 million maturing in 2028 and 2029. It simplifies the Group’s financing structure while preserving the continuity and stability of the Group’s financing, with a change of control clause now compatible with the distribution envisaged by Ramsay Health Care (as a reminder, Ramsay Health Care has announced its plan to distribute its 52.79% stake in Ramsay Santé to its own shareholders).
Note 16
Other information
16.1 Related‑party information Transactions with related parties concern: ■ ■
remuneration and similar benefits granted to members of the Board of Directors and the chief executive; transactions with companies over which Ramsay Santé exercises significant influence or has joint control.
16.1.1 Transactions with other companies related to the Group Ramsay Santé has not entered into any significant transactions with other related companies.
104
Ramsay Santé / Universal Registration Document 2026
ANNUAL FINANCIAL INFORMATION Financial information concerning the assets, financial position and results of the issuer (and Statutory Auditors’ report)
16.1.2 Investments in equity‑accounted companies There are no significant equity‑accounted investments at Group level. 30 June 2026 Companies (in millions of euros)
30 June 2025
Amount
Share of income
Amount
Share of income
All companies
0.2
0.2
TOTAL
0.2
0.2
Note 17
2
Main entities included in the scope of consolidation
LIST OF MAIN CONSOLIDATED ENTITIES 30 June 2026
30 June 2025
% interest
% control
% interest
% control
Clinique du Sport
100.00
100.00
100.00
100.00
Clinique des Platanes
100.00
100.00
100.00
100.00
Clinique des Cèdres
100.00
100.00
100.00
100.00
Clinique de l’Atlantique
100.00
100.00
100.00
100.00
Clinique Jean Le Bon
99.50
99.50
99.50
99.50
Clinique Claude Bernard
100.00
100.00
100.00
100.00
100.00
100.00
Capio La Croix du Sud
100.00
100.00
100.00
100.00
MHP - Médipôle Hôpital Privé
99.97
100.00
99.97
100.00
SNC Capio Médipôle Lyon Villeurbanne
99.97
100.00
99.97
100.00
Polyclinique du Beaujolais
100.00
100.00
100.00
100.00
Clinique de Beaupuy
100.00
100.00
100.00
100.00
Clinique de Domont
100.00
100.00
100.00
100.00
Clinique Aguiléra
100.00
100.00
100.00
100.00
SAS Scanner Aguiléra
51.00
51.00
51.00
51.00
Clinique Belharra
99.22
99.22
99.22
99.22
GCS Centre de Cardiologie du Pays Basque
74.61
75.00
74.61
75.00
Clinique de la Sauvegarde
99.25
100.00
99.25
100.00
Hôpital Privé Claude Galien
100.00
100.00
100.00
100.00
Centre médical Ris Orangis
100.00
100.00
100.00
100.00
Centre médical d’Argenteuil
100.00
100.00
100.00
100.00
Hôpital Privé Clairval
100.00
100.00
100.00
100.00
Imagerie de Clairval
95.20
95.20
95.20
95.20
Hôpital Privé Jacques Cartier
99.76
99.82
99.76
99.82
Imagerie Médicale Jacques Cartier
64.95
64.95
64.95
64.95
L’Angio – Service Intercliniques d’Imagerie Médicale
49.99
50.00
49.99
50.00
Full consolidation
Clinique du Parisis
Ramsay Santé / Universal Registration Document 2026
105
2
ANNUAL FINANCIAL INFORMATION Financial information concerning the assets, financial position and results of the issuer (and Statutory Auditors’ report)
30 June 2026
30 June 2025
% interest
% control
% interest
% control
Clinique de Choisy
98.47
98.48
98.47
98.48
Clinique Philaé
100.00
100.00
100.00
100.00
Hôpital Privé des Peupliers
100.00
100.00
100.00
100.00
Clinique de l’Amandier
99.99
100.00
99.99
100.00
Clinique de la Résidence du Parc
100.00
100.00
100.00
100.00
Clinique de la Défense
100.00
100.00
100.00
100.00
Clinique Maussins‑Nollet
100.00
100.00
100.00
100.00
Clinique du Chalonnais (formerly Val de Seille)
100.00
100.00
100.00
100.00
Hôpital Privé Sainte Marie Chalon
98.92
98.92
98.92
98.92
Hôpital Privé Antony
100.00
100.00
100.00
100.00
CERS Cap Breton
100.00
100.00
100.00
100.00
Ancienne Clinique Jeanne d’Arc SA
99.99
99.99
99.99
99.99
Hôpital Privé Drôme Ardèche
100.00
100.00
100.00
100.00
Hôpital Privé Dijon Bourgogne (formerly SIMA)
99.99
99.99
99.99
99.99
IRM du Parc
50.95
51.03
50.95
51.03
Clinique Eugénie
100.00
100.00
100.00
100.00
Clinique de la Roseraie
100.00
100.00
100.00
100.00
Clinique de l’Ange Gardien
100.00
100.00
100.00
100.00
Clinique du Moulin
100.00
100.00
100.00
100.00
Clinique de l’Auzon
99.00
99.00
99.00
99.00
Clinique d’Yvelines
100.00
100.00
100.00
100.00
Clinique de l’Espérance
100.00
100.00
100.00
100.00
Clinique Mon Repos
100.00
100.00
100.00
100.00
Clinique de Change Notre Dame de Pritz
100.00
100.00
100.00
100.00
Mas du Vendômois
100.00
100.00
100.00
100.00
Clinique Belle Allée
100.00
100.00
100.00
100.00
Clinique Psychiatrique du Parc
100.00
100.00
100.00
100.00
Clinique de l’Escrébieux
95.04
95.04
95.04
95.04
LIST OF MAIN CONSOLIDATED ENTITIES 30 June 2026
30 June 2025
% interest
% control
% interest
% control
Clinique Saint‑Martin (Ollioules)
100.00
100.00
100.00
100.00
Clinique des Monts du Forez
100.00
100.00
100.00
100.00
Clinique Saint Michel
100.00
100.00
100.00
100.00
Clinique des Quatre Saisons
100.00
100.00
100.00
100.00
Clinique Pen An Dalar
100.00
100.00
100.00
100.00
Full consolidation
106
Ramsay Santé / Universal Registration Document 2026
ANNUAL FINANCIAL INFORMATION Financial information concerning the assets, financial position and results of the issuer (and Statutory Auditors’ report)
30 June 2026
30 June 2025
% interest
% control
% interest
% control
Clinique du Château du Tremblay
100.00
100.00
100.00
100.00
Clinique Rech
100.00
100.00
100.00
100.00
Clinique Le Gouz
100.00
100.00
100.00
100.00
Clinique des Trois Cyprès
100.00
100.00
100.00
100.00
Clinique du Pont de Gien
100.00
100.00
100.00
100.00
Clinique Ronsard
100.00
100.00
100.00
100.00
Clinique de Saint‑Victor
100.00
100.00
100.00
100.00
Alpha
100.00
100.00
100.00
100.00
La Recouvrance
100.00
100.00
100.00
100.00
Hôpital de jour L’Angélique
100.00
100.00
100.00
100.00
Centre d’Imagerie Mermoz
49.99
50.00
49.99
50.00
Clinique du Landy
100.00
100.00
100.00
100.00
Hôpital Privé de Bois Bernard
99.54
99.54
99.54
99.54
Hôpital Privé Jean Mermoz
99.98
99.98
99.98
99.98
Imhotep
50.09
50.10
50.09
50.10
Société d’Imagerie Watteau
51.00
51.00
51.00
51.00
Société d’Imagerie Médicale de Bois Bernard
99.99
99.99
99.99
99.99
Hôpital Privé Pays de Savoie
99.10
99.10
99.10
99.10
Clinique Kennedy
97.34
97.34
97.34
97.34
Hôpital Privé de Villeneuve d’Ascq
99.85
99.85
99.85
99.85
Clinique d’Argonay
98.72
98.72
98.72
98.72
Hôpital Privé Armand Brillard
98.81
98.81
98.81
98.81
Clinique Jouvenet
99.92
99.92
99.92
99.92
Hôpital Privé de l’Estuaire
99.84
99.84
99.84
99.84
SRR Petit Colmoulins
99.84
99.84
99.84
99.84
Hôpital Privé Saint‑Martin – Caen
100.00
100.00
100.00
100.00
Clinique Monticelli‑Vélodrome
99.99
99.99
99.99
99.99
SIM des Peupliers
51.00
51.00
51.00
51.00
Clinique Saint Ame
98.10
98.90
98.10
98.90
Hôpital Privé de l’Est Parisien
100.00
100.00
100.00
100.00
Société d’Imagerie Médicale Douai
51.92
51.94
51.92
51.94
Société d’Imagerie Médicale Saint‑Martin Caen
100.00
100.00
100.00
100.00
Clinique Bon Secours
100.00
100.00
100.00
100.00
Centre d’Imagerie Médicale d’Aulnay (CIMA)
55.00
55.00
55.00
55.00
Clinique Blomet
100.00
100.00
100.00
100.00
Clinique Marcel Sembat
100.00
100.00
100.00
100.00
Clinique Geoffroy Saint Hilaire
100.00
100.00
100.00
100.00
Hôpital Privé de la Louvière
99.98
99.98
99.96
99.96
Ramsay Santé / Universal Registration Document 2026
2
107
2
ANNUAL FINANCIAL INFORMATION Financial information concerning the assets, financial position and results of the issuer (and Statutory Auditors’ report)
30 June 2026
30 June 2025
% interest
% control
% interest
% control
IRM Bachaumont
50.95
50.95
50.95
50.95
SAS Scanner Bachaumont Paris Centre
51.00
51.00
51.00
51.00
TEP Jean Perrin
50.09
50.10
50.09
50.10
TEP Henri Becquerel
50.09
50.10
50.09
50.10
Hôpital Privé de Marne Chantereine
99.98
100.00
99.98
100.00
Hôpital Privé de l’Ouest Parisien
99.98
100.00
99.98
100.00
Hôpital Privé de Parly II
99.98
100.00
99.98
100.00
Hôpital Privé de la Seine Saint Denis
99.98
100.00
99.98
100.00
Clinique des Martinets
99.98
100.00
99.98
100.00
Hôpital Privé du Vert Galant
99.98
100.00
99.98
100.00
Hôpital Privé Paul d’Egine
99.98
100.00
99.98
100.00
Société Scanner du Vert Galant
55.09
55.10
55.09
55.10
Centre d’Imagerie Nucléaire de la Plaine de France
94.70
94.71
94.70
94.71
Clinique du Bois d’Amour
99.98
100.00
99.98
100.00
SASU HPMV
99.99
100.00
99.99
100.00
Centre d’Imagerie en Coupe du Blanc Mesnil
54.99
55.00
54.99
55.00
SAS IRM Champigny
50.99
51.00
50.99
51.00
Scanner Champigny
51.04
51.05
51.04
51.05
IRM Bry
50.99
51.00
50.99
51.00
IRM Marne Chantereine
50.99
51.00
50.99
51.00
Centre d’Imagerie Médicale de Drancy
54.99
55.00
54.99
55.00
Scanner Marcel Sembat
50.00
50.00
50.00
50.00
LIST OF MAIN CONSOLIDATED ENTITIES 30 June 2026
30 June 2025
% interest
% control
% interest
% control
Hôpital Privé de l’Est Lyonnais
100.00
100.00
100.00
100.00
Centre Médicale Pierrelate
100.00
100.00
100.00
100.00
Centre médical d’Oyonnax
100.00
100.00
100.00
100.00
Centre médical de Bourg de Péage
100.00
100.00
100.00
100.00
Clinique La Parisière
99.95
99.99
99.95
99.99
IRM‑CCBB Clinique Marcel Sembat
55.00
55.00
55.00
55.00
SAS Imagerie Blomet
50.10
50.10
50.10
50.10
Polyclinique du Parc Drevon
100.00
100.00
100.00
100.00
SAS IRM Martinets
54.99
55.00
54.99
55.00
SAS imagerie en coupe Jouvenet Cortambert
50.96
51.00
50.96
51.00
Centre d’imagerie médicale du Bourget
55.00
55.00
55.00
55.00
Full consolidation
108
Ramsay Santé / Universal Registration Document 2026
ANNUAL FINANCIAL INFORMATION Financial information concerning the assets, financial position and results of the issuer (and Statutory Auditors’ report)
30 June 2026
30 June 2025
% interest
% control
% interest
% control
Centre d’imagerie médicale Lambert
51.00
51.00
51.00
51.00
SAS Imagerie médicale du Landy
50.00
50.00
50.00
50.00
Centre d’imagerie du Plateau Bezons
100.00
100.00
100.00
100.00
Centre de Santé pour tous
100.00
100.00
100.00
100.00
SAS Alliance Imagerie 21
50.99
51.00
50.99
51.00
SAS Imagerie Saint Jean des Vignes
50.45
51.00
50.45
51.00
Centre de Santé pour tous - Lyon
100.00
100.00
100.00
100.00
SAS IRM Beclere
51.00
51.00
51.00
51.00
Haussmann Services de Santé
100.00
100.00
100.00
100.00
Centre de Santé Haussmann
100.00
100.00
100.00
100.00
Centre médical Ramsay Santé Versailles
100.00
100.00
100.00
100.00
Centre médical Ramsay Santé Annemasse
100.00
100.00
100.00
100.00
Clinique Les Rosiers
100.00
100.00
100.00
100.00
Clinique Iris Marcy l’Etoile
100.00
100.00
100.00
100.00
Clinique Saint‑Barnabé
100.00
100.00
100.00
100.00
CERS Saint Raphaël
100.00
100.00
100.00
100.00
Clinique de Châtillon (formerly Fauvettes)
95.45
95.45
95.45
95.45
100.00
100.00
Clinique de Provence‑Bourbonne
100.00
100.00
100.00
100.00
Clinique de Champigny
100.00
100.00
100.00
100.00
Clinique de Montevrain
100.00
100.00
100.00
100.00
Centre médical Ramsay Santé Toulouse
100.00
100.00
100.00
100.00
SAS Imagerie Claude Bernard
100.00
100.00
100.00
100.00
Centre médical Ramsay Santé France
100.00
100.00
100.00
100.00
SCI Ramsay Santé Soins Primaires
100.00
100.00
100.00
100.00
Step
100.00
100.00
100.00
100.00
Rhône Assistance
100.00
100.00
100.00
Ambulances Davin
100.00
100.00
100.00
Centre Médico‑Chirurgical et Obstétrical d’Evry (Mousseau)
100.00
100.00
100.00
100.00
Clinique de Villeneuve Saint Georges
99.79
99.79
99.79
99.79
Hôpital Privé La Montagne Lambert
100.00
100.00
100.00
100.00
Clinique de la Muette
100.00
100.00
100.00
100.00
Clinique du Plateau
97.32
97.32
97.32
97.32
Hôpital Privé de Versailles - Franciscaines SAS
100.00
100.00
100.00
100.00
Clinique Convert
99.99
99.99
99.99
99.99
Clinique de l’Union
100.00
100.00
100.00
100.00
Le Marquisat
100.00
100.00
100.00
100.00
Baya Hôtel et SPA
Ramsay Santé / Universal Registration Document 2026
2
109
2
ANNUAL FINANCIAL INFORMATION Financial information concerning the assets, financial position and results of the issuer (and Statutory Auditors’ report)
30 June 2026
30 June 2025
% interest
% control
% interest
% control
Scanner IRM Villeneuve Saint Georges
50.89
51.00
50.89
51.00
Hôpital Privé Métropole Nord
98.14
98.47
98.14
98.47
Clinique Océane
100.00
100.00
100.00
100.00
Centre d’Imagerie Monticelli Vélodrome
95.12
95.12
95.12
95.12
Clinique du Bourget
100.00
100.00
100.00
100.00
Centre de Radiothérapie Savoie Nord
100.00
100.00
100.00
100.00
Institut de Radiothérapie de Hautes Energies (IRHE)
99.99
100.00
99.99
100.00
Centre de Radiothérapie Beauregard SA
65.00
65.00
65.00
65.00
Iridis Marseille
100.00
100.00
100.00
100.00
SAS SIM des Peupliers
100.00
100.00
100.00
100.00
Centro Ortopedico Di Quadrante SpA
49.00
49.00
49.00
49.00
Hôpital Privé de la Loire
97.88
97.88
97.88
97.88
LIST OF MAIN CONSOLIDATED ENTITIES (HOLDINGS) 30 June 2026
30 June 2025
% interest
% control
% interest
% control
Ramsay Générale de Santé
100.00
100.00
100.00
100.00
Compagnie Générale de Santé
100.00
100.00
100.00
100.00
Ramsay Santé (GIE)
100.00
100.00
100.00
100.00
Ramsay Hospitalisation (GIE)
100.00
100.00
100.00
100.00
Performance Achat au Service de la Santé
100.00
100.00
100.00
100.00
Médipsy SA
100.00
100.00
100.00
100.00
Dynamis
100.00
100.00
100.00
100.00
Alphamed
99.98
99.67
99.98
99.67
Hôpital Privé Métropole
99.69
99.69
99.69
99.69
Capio Santé
100.00
100.00
100.00
100.00
Capio Gestion (GIE)
95.41
96.43
95.41
96.43
Capio Cliniques
100.00
100.00
100.00
100.00
Capio Rhône‑Alpes
99.99
99.99
99.99
99.99
Générale de Santé Italia SpA
100.00
100.00
100.00
100.00
Générale de Santé Toscana Srl
100.00
100.00
100.00
100.00
Full consolidation
110
Ramsay Santé / Universal Registration Document 2026
ANNUAL FINANCIAL INFORMATION Financial information concerning the assets, financial position and results of the issuer (and Statutory Auditors’ report)
LIST OF MAIN CONSOLIDATED ENTITIES 30 June 2026
30 June 2025
% interest
% control
% interest
% control
Capio AB
100.00
100.00
100.00
100.00
Capio Group Services AB
100.00
100.00
100.00
100.00
Capio Lundby Sjukhus AB
100.00
100.00
100.00
100.00
Capio Närsjukvård AB
100.00
100.00
100.00
100.00
Hälsoval Bergaliden AB
100.00
100.00
100.00
100.00
Göingekliniken AB
100.00
100.00
100.00
100.00
Hantverksdoktorn AB
100.00
100.00
100.00
100.00
Capio Vårdcentraler AB
100.00
100.00
100.00
100.00
Capio Specialistkliniker AB
100.00
100.00
100.00
100.00
Capio Medocular AB
100.00
100.00
100.00
100.00
Capio Specialistcenter AB
100.00
100.00
100.00
100.00
Capio Movement AB
100.00
100.00
100.00
100.00
Capio Sverige AB
100.00
100.00
100.00
100.00
Capio Support AB
100.00
100.00
100.00
100.00
Capio fastighet Vesslan 34 i Örebro AB
100.00
100.00
100.00
100.00
Capio Go AB
100.00
100.00
100.00
100.00
Capio Bemanning och Rekrytering AB
100.00
100.00
100.00
100.00
Capio Sjukvård AB
100.00
100.00
100.00
100.00
Capio Primärvård AB
100.00
100.00
100.00
100.00
Capio Vårdcentral Gävle AB
96.80
96.80
95.20
95.20
Capio Ortopediska Huset AB
100.00
100.00
100.00
100.00
Capio Hjärnhälsan AB
100.00
100.00
100.00
100.00
Capio Närvård AB
100.00
100.00
100.00
100.00
Capio Läkargruppen AB
91.00
91.00
91.00
91.00
Capio Artro Clinic AB
100.00
100.00
100.00
100.00
Capio St Görans Sjukhus AB
99.97
99.97
99.97
99.97
Capio St Görans Radiologi AB
99.97
99.97
99.97
99.97
Capio Geriatrik AB
100.00
100.00
100.00
100.00
Capio Geriatrik Nacka AB
100.00
100.00
100.00
100.00
Capio Familjeläkarna Falkenberg AB
100.00
100.00
100.00
100.00
Ultraljudsbarnmorskorna i Stockholm AB
100.00
100.00
100.00
100.00
Globen Ögonklinik AB
100.00
100.00
100.00
100.00
Capio Läkarhus AB
100.00
100.00
100.00
100.00
Capio Legevisitten AB
100.00
100.00
100.00
100.00
Capio Hälso och Sjukvård AB
100.00
100.00
100.00
100.00
Capio Vårdval AB
100.00
100.00
100.00
100.00
2
Full consolidation
Ramsay Santé / Universal Registration Document 2026
111
2
ANNUAL FINANCIAL INFORMATION Financial information concerning the assets, financial position and results of the issuer (and Statutory Auditors’ report)
30 June 2026
30 June 2025
% interest
% control
% interest
% control
Capio Curera AB
100.00
100.00
100.00
100.00
Capio Nova Företagshälsa AB
100.00
100.00
100.00
100.00
Capio Nova AB
100.00
100.00
100.00
100.00
Capio Nova Hälsoval AB
100.00
100.00
100.00
100.00
Capio Vårdcentral Kista AB
100.00
100.00
100.00
100.00
Capio Norrlandskliniken Umeå AB
100.00
100.00
100.00
100.00
Capio Skindoc AB
100.00
100.00
100.00
100.00
Capio Vårdcentral Johannelund AB
100.00
100.00
100.00
100.00
Capio Stockholms Ögonklinik Holding AB
100.00
100.00
100.00
100.00
Capio Stockholms Ögonklinik AB
100.00
100.00
100.00
100.00
Capio Ögonspecialisterna i Stockholm AB
71.00
71.00
71.00
71.00
Läkarmottagningen Riddarfjärden KB
100.00
100.00
100.00
100.00
Capio Sports Medicine AB
80.00
80.00
80.00
80.00
LIST OF MAIN CONSOLIDATED ENTITIES 30 June 2026
30 June 2025
% interest
% control
% interest
% control
GHP Specialty Care AB (publ)
100.00
100.00
100.00
100.00
Capio Idrottscentrum AB
100.00
100.00
100.00
100.00
Capio Arytmi Center Stockholm AB
97.00
97.00
97.00
97.00
Capio Ortho Center Göteborg AB
97.51
97.51
96.26
96.26
GHP Neuro Center Göteborg AB
75.00
75.00
75.00
75.00
GHP Gastro Center Göteborg AB
98.00
98.00
98.00
98.00
GHP Medicinskt Centrum Göteborg AB
51.00
51.00
51.00
51.00
GHP Spine Center Göteborg AB
93.40
93.40
93.40
93.40
GHP International AB
100.00
100.00
100.00
100.00
Capio Gastro Center Skåne AB
100.00
100.00
100.00
100.00
Capio Orthocenter Skåne AB
87.45
87.45
87.45
87.45
Capio Specialisttandläkarna Stockholm KB
97.00
97.00
97.00
97.00
Capio Specialisttandläkarna Tandteknik AB
97.00
97.00
97.00
97.00
Capio Specialisttandläkarna Nacka KB
97.00
97.00
97.00
97.00
Capio Specialisttandläkarna AB
97.00
97.00
97.00
97.00
Capio Specialisttandläkarna Norrköping KB
97.00
97.00
97.00
97.00
Capio Partner AB
100.00
100.00
100.00
100.00
Capio Spine Center Stockholm AB
97.50
97.50
97.50
97.50
Capio Ortho Center Stockholm AB
92.00
92.00
92.00
92.00
Capio Urologcentrum AB
98.00
98.00
98.00
98.00
Full consolidation
112
Ramsay Santé / Universal Registration Document 2026
ANNUAL FINANCIAL INFORMATION Financial information concerning the assets, financial position and results of the issuer (and Statutory Auditors’ report)
30 June 2026
30 June 2025
% interest
% control
% interest
% control
GHP Hud Holding AB
78.09
78.09
56.18
56.18
Capio Hudcentrum Hagastaden AB
78.09
78.09
56.18
56.18
Capio Hudcentrum Hagastaden FM AB
78.09
78.09
56.18
56.18
Capio Hudcentrum vid Sophiahemmet AB
78.09
78.09
56.18
56.18
Capio Hudcentrum vid Sophiahemmet AB
78.09
78.09
56.18
56.18
Capio Kurgkliniken Stockholm AB
96.32
96.32
94.00
94.00
Capio Gastro Center Stockholm AB
98.33
98.33
98.33
98.33
GHP Specialisttandläkarna Stockholm AB
97.00
97.00
97.00
97.00
Capio Urokirurgiskt Centrum Stockholm AB
55.00
55.00
55.00
55.00
Capio Medicinskt Centrum AB
91.00
91.00
91.00
91.00
Capio Spine Center Rehab Göteborg AB
91.25
91.25
88.73
88.73
Capio Hemsjukvård AB
100.00
100.00
100.00
100.00
Capio Mottagning AB
100.00
100.00
100.00
100.00
Capio Alva AB
100.00
100.00
100.00
100.00
Capio Skin AB
100.00
100.00
100.00
100.00
Capio Skin KB
91.00
100.00
91.00
100.00
Capio Norge Holding AS
100.00
100.00
100.00
100.00
Volvat Medisinske Senter AS
100.00
100.00
100.00
100.00
Capio Anoreksi Senter AS
100.00
100.00
100.00
100.00
100.00
100.00
Volvat Medisinske Senter Nord og Midt‑Norge AS
2
LIST OF MAIN CONSOLIDATED ENTITIES 30 June 2026
30 June 2025
% interest
% control
% interest
% control
Volvat Barcode AS
100.00
100.00
100.00
100.00
Helsetelefonen
100.00
100.00
100.00
100.00
Spiren Fertilitetsklinikk AS
70.00
70.00
70.00
70.00
Volvat Spiren Oslo AS
70.00
70.00
70.00
70.00
Capio Fastleger AS
79.79
79.79
59.60
59.60
Capio Fastleger Rana AS
54.20
54.20
54.20
54.20
Capio Deutsche Klinik GmbH
100.00
100.00
100.00
100.00
100.00
100.00
Capio Danmark Holding A/S
100.00
100.00
100.00
100.00
Capio A/S
100.00
100.00
100.00
100.00
Capio Specialistklinikker A/S
100.00
100.00
100.00
100.00
WeCare Holding ApS
68.25
68.25
68.25
68.25
Alles Laegehus A/S
68.25
68.25
68.25
68.25
Full consolidation
Capio UK Ltd
Ramsay Santé / Universal Registration Document 2026
113
2
ANNUAL FINANCIAL INFORMATION Financial information concerning the assets, financial position and results of the issuer (and Statutory Auditors’ report)
30 June 2026
30 June 2025
% interest
% control
% interest
% control
Vikteam A/S
68.25
68.25
68.25
68.25
WeCare2 Holding ApS
51.00
51.00
51.00
51.00
Institut For Mental Sundhet ApS
37.98
37.98
37.98
37.98
GHP Middle East LLC
100.00
100.00
100.00
100.00
Allemanshälsan City AB
100.00
100.00
100.00
100.00
Allemanshälsan Aleroz Lunden AB
100.00
100.00
100.00
100.00
Qurant Företagshälsa AB
97.60
97.60
97.60
97.60
All Sociétés Civiles Immobilières controlled by the Ramsay Santé group are fully consolidated.
114
Ramsay Santé / Universal Registration Document 2026
ANNUAL FINANCIAL INFORMATION Financial information concerning the assets, financial position and results of the issuer (and Statutory Auditors’ report)
2.3.2.2 Statutory auditors’ report on the consolidated financial statements For the year ended 30 June 2026
2
This is a translation into English of the Statutory Auditors’ report on the financial statements of Ramsay Générale de Santé issued in French and it is provided solely for the convenience of English‑speaking users. This Statutory Auditors’ report includes information required by European regulation and by French law, such as information about the appointment of the statutory auditors or verification of the management report and other documents provided to shareholders. This report should be read in conjunction with, and construed in accordance with, French law and professional auditing standards applicable in France.
To the Shareholders of Ramsay Générale de Santé,
OPINION In compliance with the engagement entrusted to us by your Shareholder’s meeting, we have audited the accompanying consolidated financial statements of Ramsay Générale de Santé for the year ended June 30, 2026. In our opinion, the consolidated financial statements give a true and fair view of the assets and liabilities and of the financial position of the Group as at June 30, 2026 and of the results of its operations for the year then ended in accordance with International Financial Reporting Standards as adopted by the European Union. The audit opinion expressed above is consistent with our report to the Audit Committee. BASIS FOR OPINION AUDIT FRAMEWORK
We conducted our audit in accordance with professional standards applicable in France. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion. Our responsibilities under those standards are further described in the “Statutory Auditors’ Responsibilities for the Audit of the Consolidated Financial Statements” section of our report. INDEPENDENCE
We conducted our audit engagement in compliance with the independence requirements of the French Commercial Code (code de commerce) and the French Code of Ethics (code de déontologie) for statutory auditors, for the period from July 1, 2025 to the date of our report, and specifically, we did not provide any prohibited non‑audit services referred to in Article 5(1) of Regulation (EU) No 537/2014. JUSTIFICATION OF ASSESSMENTS – KEY AUDIT MATTERS In accordance with the requirements of Articles L. 821‑53 and R.821‑180 of the French Commercial Code (code de commerce) relating to the justification of our assessments, we inform you of the key audit matters relating to risks of material misstatement that, in our professional judgment, were of most significance in our audit of the consolidated financial statements of the current period, as well as how we addressed those risks. These matters were addressed in the context of our audit of the consolidated financial statements as a whole, approved in the conditions mentioned above, and in forming our opinion thereon, and we do not provide a separate opinion on specific items of the consolidated financial statements.
Ramsay Santé / Universal Registration Document 2026
115
2
ANNUAL FINANCIAL INFORMATION Financial information concerning the assets, financial position and results of the issuer (and Statutory Auditors’ report)
●
GOODWILL VALUATION
(Notes 6.1 and 6.4 to the consolidated financial statements) Key Audit Matter
As of June 30, 2026, the net carrying amount of goodwill was €2,063.4 million, compared with total assets of €6,682.1 million, as disclosed in Note 6.1 to the consolidated financial statements. In accordance with IAS 36, goodwill is tested for impairment annually, as described in Note 6.4 to the consolidated financial statements. For the purposes of the Group’s impairment testing, goodwill is allocated to groups of Cash‑Generating Units (CGUs). An impairment loss is recognized whenever the recoverable amount of the tested group of assets is lower than its carrying amount. The recoverable amount retained is higher of the fair value less costs of disposal and the value in use, which is determined based on discounted future cash flows. As of June 30, 2026, the impairment tests performed by the company did not result in the recognition of any impairment loss. We considered the valuation of goodwill to be a key audit matter given: ■ The significance of goodwill in relation to the Group’s consolidated financial statements ■ The estimates and judgments made by Management in determining the key assumptions for calculating value in use, and ■ The sensitivity of the value in use to the assumptions used, particularly regarding revenue growth, including changes in care service tariffs, discount rates, and perpetual growth rates.
Our audit responses
Our audit procedures included: obtaining an understanding of the process established by management for preparing and approving the estimates and assumptions used in the impairment tests, and ■ assessing whether the methodology applied by the Group complied with the requirements of IAS 36. With respect to the data and assumptions underlying the assessment of the value in use of goodwill, our procedures included: ■ assessing the consistency of the data and assumptions used by management to prepare the cash flow projections with the 2027–2031 Corporate Plan, ■ comparing the cash flow projections used by management with historical performance and with the forecasts included in the prior year’s Corporate Plan, and ■ with the assistance of our valuation specialists, assessing the discount rates and perpetual growth rates used by management by comparing them with our own estimates based on market data as of June 30, 2026. We also verified, on a sample basis, the mathematical accuracy of the impairment tests performed by the Company, including the calculation of the recoverable amounts. Lastly, we assessed the appropriateness of the disclosures in Note 6.4 to the consolidated financial statements, particularly those relating to the assumptions used and the sensitivity analyses. ■
SPECIFIC VERIFICATION We have also performed, in accordance with professional standards applicable in France, the specific verifications required by laws and regulations of the information pertaining to the Group presented in the management report of the Board of Directors. We have no matters to report as to its fair presentation and its consistency with the consolidated financial statements. OTHER LEGAL AND REGULATORY VERIFICATIONS OR INFORMATION FORMAT OF PRESENTATION OF THE CONSOLIDATED FINANCIAL STATEMENTS INTENDED TO BE INCLUDED IN THE ANNUAL FINANCIAL REPORT
We have also verified, in accordance with the professional standard applicable in France relating to the procedures performed by the statutory auditor relating to the annual and consolidated financial statements presented in the European single electronic format, that the presentation of the consolidated financial statements intended to be included in the annual financial report mentioned in Article L. 451‑1‑2, I of the French Monetary and Financial Code (code monétaire et financier), prepared under the responsibility of Chief Executive Officer, complies with the single electronic format defined in the European Delegated Regulation No 2019/815 of 17 December 2018. As it relates to consolidated financial statements, our work includes verifying that the tagging of these consolidated financial statements complies with the format defined in the above delegated regulation. Based on the work we have performed, we conclude that the presentation of the consolidated financial statements intended to be included in the annual financial report complies, in all material respects, with the European single electronic format. We have no responsibility to verify that the consolidated financial statements that will ultimately be included by your company in the annual financial report filed with the AMF are in agreement with those on which we have performed our work. APPOINTMENT OF THE STATUTORY AUDITORS
We were appointed as statutory auditors of Ramsay Générale de Santé Company by the Shareholder’s meeting held on June 1st, 2001 for DELOITTE & ASSOCIES and December 16, 2015 for ERNST & YOUNG Audit. As at June 30, 2026, DELOITTE & ASSOCIES and ERNST & YOUNG Audit were in the 26th year and 11th year of total uninterrupted engagement respectively.
116
Ramsay Santé / Universal Registration Document 2026
ANNUAL FINANCIAL INFORMATION Financial information concerning the assets, financial position and results of the issuer (and Statutory Auditors’ report)
RESPONSIBILITIES OF MANAGEMENT AND THOSE CHARGED WITH GOVERNANCE FOR THE CONSOLIDATED FINANCIAL STATEMENTS Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with International Financial Reporting Standards as adopted by the European Union, and for such internal control as management determines is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error. In preparing the consolidated financial statements, management is responsible for assessing the Company’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless it is expected to liquidate the Company or to cease operations. The Audit Committee is responsible for monitoring the financial reporting process and the effectiveness of internal control and risks management systems and where applicable, its internal audit, regarding the accounting and financial reporting procedures. The consolidated financial statements were approved by the Board of Directors. STATUTORY AUDITORS’ RESPONSIBILITIES FOR THE AUDIT OF THE CONSOLIDATED FINANCIAL STATEMENTS OBJECTIVES AND AUDIT APPROACH
Our role is to issue a report on the consolidated financial statements. Our objective is to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with professional standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements. As specified in Article L.821‑55 of the French Commercial Code (code de commerce), our statutory audit does not include assurance on the viability of the Company or the quality of management of the affairs of the Company. As part of an audit conducted in accordance with professional standards applicable in France, the statutory auditor exercises professional judgment throughout the audit and furthermore: ■
■ ■ ■
■ ■
Identifies and assesses the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, designs and performs audit procedures responsive to those risks, and obtains audit evidence considered to be sufficient and appropriate to provide a basis for his opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Obtains an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the internal control. Evaluates the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management in the consolidated financial statements. Assesses the appropriateness of management’s use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company’s ability to continue as a going concern. This assessment is based on the audit evidence obtained up to the date of his audit report. However, future events or conditions may cause the Company to cease to continue as a going concern. If the statutory auditor concludes that a material uncertainty exists, there is a requirement to draw attention in the audit report to the related disclosures in the consolidated financial statements or, if such disclosures are not provided or inadequate, to modify the opinion expressed therein. Evaluates the overall presentation of the consolidated financial statements and assesses whether these statements represent the underlying transactions and events in a manner that achieves fair presentation. Obtains sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Group to express an opinion on the consolidated financial statements. The statutory auditor is responsible for the direction, supervision and performance of the audit of the consolidated financial statements and for the opinion expressed on these consolidated financial statements.
Ramsay Santé / Universal Registration Document 2026
117
2
2
ANNUAL FINANCIAL INFORMATION Financial information concerning the assets, financial position and results of the issuer (and Statutory Auditors’ report)
REPORT TO THE AUDIT COMMITTEE
We submit a report to the Audit Committee which includes in particular a description of the scope of the audit and the audit program implemented, as well as the results of our audit. We also report, if any, significant deficiencies in internal control regarding the accounting and financial reporting procedures that we have identified. Our report to the Audit Committee includes the risks of material misstatement that, in our professional judgment, were of most significance in the audit of the consolidated financial statements of the current period and which are therefore the key audit matters, that we are required to describe in this report. We also provide the Audit Committee with the declaration provided for in Article 6 of Regulation (EU) N° 537/2014, confirming our independence within the meaning of the rules applicable in France such as they are set in particular by Articles L.821‑27 to L.821‑34 of the French Commercial Code and in the French Code of Ethics (code de déontologie) for statutory auditors. Where appropriate, we discuss with the Audit Committee the risks that may reasonably be thought to bear on our independence, and the related safeguards. Paris‑La Défense, 6 October 2026 The Statutory Auditors The French original signed by
118
DELOITTE & ASSOCIÉS
ERNST & YOUNG Audit
Jean‑Pierre Agazzi
Aymeric de La Morandière
Ramsay Santé / Universal Registration Document 2026
ANNUAL FINANCIAL INFORMATION Financial information concerning the assets, financial position and results of the issuer (and Statutory Auditors’ report)
2.3.3
Company financial statements
The Company’s parent company financial statements are presented in thousands of euros. 30 June 2026
BALANCE SHEET - ASSETS (in thousands of euros)
Net
Net
Concessions, patents and similar rights
1.4
1.4
1.4
TOTAL INTANGIBLE ASSETS
1.4
1.4
1.4
TOTAL PROPERTY, PLANT AND EQUIPMENT
0
0
0
1,570,770.2
1,570,770.2
1,570,770.2
1.1
1.1
1.1
1,229,792.2
1,229,792.2
1,203,363.3
Investments Other long‑term investments Loans Other financial assets
Gross
Depreciation, amortisation and impairment
313.9
124.8
189.1
181.2
TOTAL FINANCIAL ASSETS
2,800,877.4
124.8
2,800,752.6
2,774,315.8
TOTAL FIXED ASSETS (I)
2,800,878.8
124.8
2,800,754.0
2,774,317.2
0
0
TOTAL INVENTORY
0
Advances and deposits paid on orders
59.0
59.0
81.3
Trade receivables and related accounts
2,106.9
2,106.9
1,969.9
Other receivables
117,836.9
117,836.9
43,851.1
TOTAL RECEIVABLES
120,002.8
120,002.8
45,902.3
Marketable securities
218.1
218.1
218.1
Cash and cash equivalents
7,553.3
7,553.3
6,962.7
TOTAL CASH
7,771.4
7,771.4
7,180.8
Prepaid expenses TOTAL CURRENT ASSETS (II) Deferred loan issue costs (III) Exchange differences – assets (IV) GRAND TOTAL (I TO IV)
452.5
452.5
324.3
128,226.7
128,226.7
53,407.4
0
0
7,804.8
28,597.4
28,597.4
27,688.8
2,957,578.1
2,863,218.2
2,957,702.9
124.8
2
30 June 2025
Ramsay Santé / Universal Registration Document 2026
119
2
ANNUAL FINANCIAL INFORMATION Financial information concerning the assets, financial position and results of the issuer (and Statutory Auditors’ report)
BALANCE SHEET - LIABILITIES (in thousands of euros)
30 June 2026
30 June 2025
Share capital
82,792.3
82,792.3
Issue, merger and contribution premiums
600,910.9
600,910.9
6,205.2
6,205.2
7.3
7.3
Other reserves
12,257.6
12,257.6
Total reserves
18,470.1
18,470.1
Legal reserve Regulated reserves
Retained earnings
72,075.8
70,325.1
PROFIT (LOSS) FOR THE FINANCIAL YEAR
(1,899.2)
1,750.7
Regulated provisions
15,547.3
15,547.3
TOTAL EQUITY (I)
787,897.2
789,796.4
0
0
Provisions for liabilities
28,597.4
27,688.8
Provisions for charges
508.7
398.6
29,106.1
28,087.4
TOTAL OTHER EQUITY (II)
TOTAL PROVISIONS FOR LIABILITIES AND CHARGES (III) Bonds
101,792.2
101,783.1
Loans and debts with credit institutions and institutional investors
1,480,131.5
1,480,115.8
TOTAL FINANCIAL DEBT
1,581,923.7
1,581,898.9
Trade payables and related accounts
5,460.7
1,516.2
Tax and social security liabilities
16,018.5
26,559.2
Other liabilities
537,171.9
435,360.0
TOTAL OPERATING LIABILITIES TOTAL LIABILITIES (IV) Exchange differences – liabilities (V) GRAND TOTAL – LIABILITIES (I TO V)
120
Ramsay Santé / Universal Registration Document 2026
558,651.1
463,435.4
2,140,574.8
2,045,334.3
0
0
2,957,578.1
2,863,218.2
ANNUAL FINANCIAL INFORMATION Financial information concerning the assets, financial position and results of the issuer (and Statutory Auditors’ report)
INCOME STATEMENT 30 June 2026 INCOME STATEMENT (in thousands of euros) Services production sold NET REVENUE Write‑back of depreciation and provisions Other income
France
Export 1,972.5
Total
30 June 2025
1,972.5
1,886.4
1,972.5
1,886.4
168.4
14,253.3
50.9
0.1
2,191.8
16,139.8
Other purchases and external expenses
23,224.0
28,742.8
Taxes and duties and similar payments
790.9
196.0
Wages and salaries
1,235.2
1,060.2
Social security contributions
495.1
305.1
Operating allowances
110.1
107.6
305.5
154.3
TOTAL OPERATING INCOME (I)
Other charges TOTAL OPERATING EXPENSES (II) OPERATING PROFIT
26,160.8
30,566.0
(23,969.0)
(14,426.2)
Financial income from investments
72,546.3
70,377.1
Other interest and similar income
4,093.0
10,202.7
Reversals of provisions
27,818.6
39,607.8
816.1
104.2
Positive exchange rate differences Net proceeds from the disposal of investment securities and cash and cash equivalents TOTAL FINANCIAL INCOME (V)
3.0
0.0
105,277.0
120,291.8
Financial depreciation and provisions
36,693.1
36,899.6
Interest and similar charges
111,288.2
123,813.3
Negative exchange rate differences
42.5
177.7
TOTAL FINANCIAL EXPENSES (VI)
148,023.8
160,890.6
FINANCIAL PROFIT (LOSS)
(42,746.8)
(40,598.8)
CURRENT PROFIT BEFORE TAX (I - II + III - IV + V - VI)
(66,715.8)
(55,025.0)
Extraordinary income on management operations
0.0
787.3
Extraordinary income on capital operations
0.0
396.6
TOTAL EXTRAORDINARY INCOME (VII)
0.0
1,183.9
Extraordinary charges on management operations
0.0
10.7
Extraordinary charges on capital operations
0.0
392.3
TOTAL EXTRAORDINARY EXPENSES (VIII)
0.0
403.0
EXTRAORDINARY PROFIT (LOSS) (VII - VIII)
0.0
780.9
2
Employee profit‑sharing (IX) Income tax (X)
(64,816.6)
(55,995)
TOTAL INCOME (I + III + V + VII)
107,468.8
137,615.4
TOTAL EXPENSES (II + IV + VI + VIII + IX + X)
109,368.0
135,864.7
PROFIT OR LOSS (TOTAL INCOME – TOTAL EXPENSES)
(1,899.2)
1,750.7
Ramsay Santé / Universal Registration Document 2026
121
2
ANNUAL FINANCIAL INFORMATION Financial information concerning the assets, financial position and results of the issuer (and Statutory Auditors’ report)
2.3.3.1
Significant events of the financial year
Announcement of the planned distribution by Ramsay Health Care to its shareholders of its stake in Ramsay Générale de Santé On 20 February 2026, Ramsay Santé took note of the project announced by its shareholder, Ramsay Health Care Limited (RHC), to carry out a distribution in kind of its 52.79% stake in Ramsay Générale de Santé to its own shareholders. This Project would be implemented through a “scheme of arrangement” under Australian law that would be subject to the approval of RHC’s Board of Directors and its shareholders, as well as the required judicial and regulatory approvals. Ramsay Santé will diligently analyse all the legal, financial and operational implications that may arise from this operation and will ensure that the stability of its capital structure is preserved in a context of potential expansion of the free float. According to information provided by RHC, the Project could be implemented in the fourth quarter of 2026, subject to the required approvals. In accordance with the applicable regulations, Ramsay Santé has carried out the information and consultation procedure with its employee representative bodies.
2.3.3.2
Accounting rules and methods
The annual financial statements of Ramsay Générale de Santé SA have been prepared in accordance with the new ANC Regulation No. 2022‑06, which amends ANC Regulation No. 2014‑03 on the French General Accounting Plan (Plan comptable général - PCG) with a view to modernising financial statements and the nomenclature of financial statements. It is mandatory for financial years beginning on or after 1 January 2025. This regulation has resulted in: ■ ■ ■ ■
the introduction of a new definition and presentation of extraordinary profit (loss); the abolition of the technique of transferring expenses; the modernisation of the chart of accounts and the updating of the nomenclature of financial statements; the introduction of a new presentation for financial statements.
The financial statements for the financial year ended 30 June 2025 have not been restated retrospectively to reflect the new rules. Under French rules, a change in accounting regulations is classified as a change in accounting policy. For this financial year commencing on 1 July 2025, the main effects on the Company’s financial statements resulting from the application of this regulation are as follows:
■
■
disposals of financial fixed assets are recognised in financial profit (loss), rather than in extraordinary profit (loss). with regard to loan issuance costs, the cost‑allocation method is no longer used when recognising them in the accounts. They are now recognised directly as financial expenses, spread over the term of the loan using a method that reflects the economic spread of the expense.
The accounting conventions have been applied fairly, in compliance with the principle of prudence, and in accordance with the following basic assumptions which aim to provide a true and fair view of the Company’s assets, financial position and results: ■ ■ ■
going concern; consistency of methods from one financial year to another; independence of financial years.
A) INTANGIBLE ASSETS
Intangible assets acquired are recorded in the balance sheet at their acquisition cost less accumulated amortisation and any impairment losses. B) FINANCIAL ASSETS
Equity securities are recorded in the balance sheet at their acquisition cost. Acquisition costs are included in the cost of the securities and are amortised over five years. They are subject to impairment testing, carried out at each closing date in order to verify that their net carrying amounts do not exceed their value in use. Value in use is the present value of the sum of future cash flows before tax and financial items of the entities held by Ramsay Générale de Santé SA. If the value in use is lower than the net carrying amount of the equity investments, an impairment loss is recognised in financial profit (loss). Future cash flows used for impairment testing are calculated on the basis of a 5‑year corporate plan. The terminal value takes into account a perpetual growth rate of 1.75% for France and 2.00% for the Nordics. The discount rate used reflects market players’ current assessments of the time value of money and the risks specific to the asset or group of assets. It is 8.04% for France and 6.98% for the Nordics. Loans denominated in foreign currencies are valued at the exchange rate prevailing on the closing date. The difference resulting from the discounting at the latter rate is, where applicable, recorded in the balance sheet under “Exchange differences”. A provision for unrealised foreign exchange losses is recorded in the income statement.
The exchange rates used to convert currencies into euros are as follows:
122
At 30 June 2026
Closing price
Average price
SEK (Sweden)
11.0749
10.9149
Ramsay Santé / Universal Registration Document 2026
ANNUAL FINANCIAL INFORMATION Financial information concerning the assets, financial position and results of the issuer (and Statutory Auditors’ report)
C) RECEIVABLES AND PAYABLES
E) DEFERRED EXPENSES
Receivables and payables are recognised at their nominal value.
The only remaining deferred expenses are loan issue costs, which are amortised over the term of the relevant loan.
A provision for impairment of receivables is made when the inventory value is lower than the carrying amount.
Since 1 January 2025, in accordance with the new regulation, the amortisation of loan issue costs is presented in financial profit (loss).
Trade receivables mainly include intragroup receivables. D) MARKETABLE SECURITIES
Marketable securities are recorded at their acquisition cost. The Company’s treasury shares recorded under “Marketable securities” as “Available treasury shares” are not classed as being allocated to a specific plan and are impaired if their carrying amount is higher than the market price at the end of the financial year. At 30 June 2026, the Company had 20,301 treasury shares with a carrying amount of EUR 218,111.17. As their market value was higher than their net carrying amount at the end of the financial year, no impairment was recognised.
F) PROVISIONS FOR LIABILITIES AND CHARGES
A provision is recognised for any Company obligation to a third party that can be estimated with sufficient reliability and gives rise to a probable outflow of resources without equivalent consideration. G) PENSION COMMITMENTS
Pension commitments are valued in accordance with ANC Recommendation No. 2013‑02 of 7 November 2013, as modified on 5 November 2021.
The main actuarial assumptions used to value the commitments at 30 June 2026 are as follows: 30 June 2026
30 June 2025
Discount rate
4.05%
3.61%
Rate of wage increase
2.00%
1.75%
Employee expense rate
50.40%
50.40%
Retirement age
65 years
65 years
26 years and under
28.06%
28.06%
27 to 29 years
15.35%
15.35%
30 to 34 years
9.44%
9.44%
35 to 39 years
6.56%
6.56%
40 to 44 years
5.80%
5.80%
45 to 49 years
4.17%
4.17%
50 to 54 years
2.99%
2.99% 2.12%
Staff turnover rate
55 to 59 years
2.12%
60 to 62
1.21%
1.21%
Over 62 years old
0.00%
0.00%
TH‑TF 00‑02
TH‑TF 00‑02
Mortality table
At 30 June 2026, retirement benefits totalled EUR 416,780 and are included under off‑balance sheet commitments.
Calculations are performed for each tax‑consolidated company as though they had been taxed separately.
H) EXTRAORDINARY PROFIT (LOSS)
The additional tax benefit or expense resulting from the difference between the sum of taxes owed by each of the consolidated subsidiaries and the tax calculated on the basis of the overall income is recorded by Ramsay Générale de Santé SA.
Items are recognised on the basis of an analysis of the various transactions carried out during the financial year, thus making it possible to determine their current or extraordinary nature. Income and expenses directly related to a major and exceptional event are recognised in extraordinary profit (loss). I)
CORPORATION TAX
Ramsay Générale de Santé SA has opted for the tax consolidation regime (Article 223 A et seq. of the French General Tax Code). The Company is the parent company of the tax consolidation scope.
For the financial year, the French corporation tax rate under ordinary law was 25%. The social contribution is equal to 3.3% of the reference corporation tax less a deduction of EUR 763,000. The exceptional contribution on large companies is also calculated on the reference corporate income tax.
Ramsay Santé / Universal Registration Document 2026
123
2
2
ANNUAL FINANCIAL INFORMATION Financial information concerning the assets, financial position and results of the issuer (and Statutory Auditors’ report)
2.3.3.3
Notes to certain balance sheet and income statement items
A) STATEMENT OF FIXED ASSETS AT 30 JUNE 2026
(in thousands of euros)
Gross value at the beginning of the financial year
Acquisitions and contributions
Disposals and Gross value at the end reimbursements of the financial year
Other intangible assets
1.4
1.4
TOTAL (I)
1.4
1.4
1,570,770.2
1,570,770.2
1.1
1.1
Investments Other long‑term investments Loans and other financial assets
1,203,674.3
40,841.4
(14,409.6)
1,230,106.1
TOTAL (II)
2,774,445.6
40,841.4
(14,409.6)
2,800,877.4
GRAND TOTAL (I + II)
2,774,447.0
40,841.4
(14,409.6)
2,800,878.8
The breakdown of financial assets is as follows: At 30 June 2026
At 30 June 2025
Compagnie Générale de Santé securities
763,769.4
763,769.4
Capio AB securities
807,000.8
807,000.8
TOTAL SECURITIES
1,570,770.2
1,570,770.2
Compagnie Générale de Santé loans
690,000
690,000
Capio AB loans
503,015.2
463,301.1
36,777.0
50,062.2
1,229,792.2
1,203,363.3
315.0
312.1
2,800,877.4
2,774,445.6
Accrued interest on intra‑group loans TOTAL LOANS Other financial assets TOTAL
Financial assets include intragroup loans. Several intragroup loans between Ramsay Générale de Santé and Capio AB were outstanding at the end of June 2026 and break down as follows: ■ ■ ■ ■
SEK 5,138 million already outstanding at 30 June 2025; an additional SEK 80 million set up on 8 January 2026; an additional SEK 200 million set up on 20 January 2026; an additional SEK 152 million set up on 11 February 2026.
Additional financing of SEK 75 million (on 7 July 2025) and SEK 77 million (on 9 October 2025) was set up. These two loans were repaid in full on 3 February 2026. The equivalent value of these loans on the balance sheet at 30 June 2025 was EUR 513,015,205.
The exchange rate used for the conversion was the exchange rate at the end of the period as presented in section 2.3.3.2 B). Annual interest, payable quarterly, is 5.85%. The loans may be repaid within 3 days of a notice from Ramsay Générale de Santé. The loan between Ramsay Générale de Santé and Compagnie Générale de Santé has a fixed interest rate of 6.15%, payable in arrears. This loan has a renewable term of one year, with a current maturity of 22 August 2026. At 30 June 2026, Ramsay Générale de Santé SA held 6,881 of its own shares under a liquidity agreement managed by CIC MARKET SOLUTIONS, for a net carrying amount of EUR 313.9 thousand at the end of the year. As the market value was EUR 189.1 thousand, an impairment of EUR 124.8 thousand was recognised at 30 June 2026. The movements during the financial year generated a net capital gain of EUR 3.0 thousand.
124
Ramsay Santé / Universal Registration Document 2026
ANNUAL FINANCIAL INFORMATION Financial information concerning the assets, financial position and results of the issuer (and Statutory Auditors’ report)
B) MATURITY OF RECEIVABLES AND PAYABLES AT 30 JUNE 2026
Gross amount
Up to one year
At more than one year
1,229,792.2
36,777.0
1,193,015.2
1,230,106.1
36,777.0
1,193,329.1
2,106.9
2,106.9
Income tax
7,823.6
7,823.6
Value added tax
1.8
1.8
109,976.1
109,976.1
STATEMENT OF RECEIVABLES Loans Other financial assets
313.9
TOTAL RECEIVABLES RELATED TO FIXED ASSETS Trade receivables and related accounts
2
313.9
Personnel and related accounts State and other local authorities Groups and associates Miscellaneous debtors TOTAL RECEIVABLES RELATED TO CURRENT ASSETS Prepaid expenses TOTAL RECEIVABLES
STATEMENT OF DEBTS
Gross amount
94.4
94.4
120,002.8
120,002.8
452.5
452.5
1,350,561.4
157,232.3
At more than one year and less Up to one year than five years
1,193,329.1
More than five years
Bonds
101,792.2
1,792.2
100,000.0
Loans from credit institutions and institutional investors
1,480,131.5
15,131.5
15,000.0
1,450,000.0
5,460.7
5,460.7
115,000.0
1,450,000.0
Other borrowings and financial debts Trade payables and related accounts Personnel and related accounts
741.5
741.5
Social security and other social agencies
478.2
478.2
Income tax
13,547.4
13,547.4
Value added tax
1,084.8
1,084.8
166.6
166.6
536,108.1
536,108.1
1,063.8
1,063.8
2,140,574.8
575,574.8
State and other local authorities
Guaranteed bonds Other tax
Debts on fixed assets and related accounts Groups and associates Other liabilities Debt representing borrowed securities Deferred income TOTAL LIABILITIES
Other receivables
Other debts
The “other receivables” item amounts to EUR 117,836.9 thousand.
The “other debts” item under liabilities amounts to EUR 537,171.9 thousand and corresponds mainly to the cash current account with Centrale Ramsay Santé for EUR 536,108.1 thousand.
It mainly consists of: ■ ■ ■
state tax credits for EUR 7,823.6 thousand; the current account with Compagnie Générale de Santé in the amount of EUR 108,863.8 thousand;
The “tax and social security liabilities” item under liabilities amounts to EUR 16,018.5 thousand. It mainly consists of tax liabilities on tax‑consolidated subsidiaries and liabilities due to the French State in respect of the VAT Group.
the Group VAT current account with members that had a debit position at 30 June 2026 in the amount of EUR 1,112.3 thousand.
Prepaid expenses amounted to EUR 452.5 thousand and relate to operating expenses.
Ramsay Santé / Universal Registration Document 2026
125
2
ANNUAL FINANCIAL INFORMATION Financial information concerning the assets, financial position and results of the issuer (and Statutory Auditors’ report)
C) STATEMENT OF PROVISIONS AND IMPAIRMENT OF ASSETS AT 30 JUNE 2026
NATURE OF PROVISIONS (in thousands of euros)
30 June 2025
Allocations
Reversals
30 June 2026
Excessive depreciation
15,547.3
15,547.3
TOTAL I
15,547.3
15,547.3
Provisions for foreign exchange losses
27,688.8
28,597.4
398.6
110.1
28,087.4
28,707.5
(27,688.8)
29,106.1
Provisions for other financial assets
129.8
124.8
(129.8)
124.8
TOTAL III
129.8
124.8
(129.8)
124.8
43,764.5
28,832.3
(27,818.6)
44,778.2
Other provisions for liabilities and charges TOTAL II
GRAND TOTAL (I + II + III) Of which operating allowances and reversals
110.1
Of which financial allowances and reversals
28,722.2
(27,688.8)
28,597.4 508.7
(27,818.6)
Of which extraordinary allowances and reversals Regulated provisions
The change in excessive depreciation is as follows: (in thousands of euros)
30 June 2025
Allocations
Reversals
30 June 2026
Excessive depreciation
15,547.3
15,547.3
TOTAL
15,547.3
15,547.3
Excessive depreciation relates to the acquisition costs of the Capio AB group. Provisions for liabilities and charges
In consideration of his involvement in the development of the Group, the Board of Directors’ meeting of 20 October 2021, on the recommendation of the Appointments and Remuneration Committee, decided to set up a long‑term incentive plan for the Chief Executive Officer in the form of multi‑year variable remuneration conditional on the achievement of several economic and qualitative performance criteria assessed over five financial years until 2026. (in thousands of euros)
30 June 2025
Allocations
LTI provisions
398.6
110.1
508.7
TOTAL
398.6
110.1
508.7
D) ACCRUED INCOME
It represents a total of EUR 36,777 thousand and relates to interest accrued as at 30 June 2026 on intra‑group loans.
126
Ramsay Santé / Universal Registration Document 2026
Reversals
30 June 2026
E) ACCRUED EXPENSES
They represent a total of EUR 22,000.3 thousand and correspond to: ■
EUR 15,131.5 thousand in interest on loans;
■
EUR 4,612.1 thousand in accrued expenses due to suppliers;
■
EUR 1,195.8 expensed;
thousand
in
bonuses
■
EUR 1,060.9 expenses.
thousand
in
miscellaneous
on
objectives accrued
ANNUAL FINANCIAL INFORMATION Financial information concerning the assets, financial position and results of the issuer (and Statutory Auditors’ report)
F) LOAN ISSUANCE COSTS
Loan issuance costs have been capitalised and are amortised over the repayment period of the loans to which they relate.
As stated in the note to the financial statements relating to events after the closing date, Ramsay Générale de Santé finalised the refinancing of its senior debt on 22 July 2026. Consequently, as at 30 June 2026, the Company has recognised the costs associated with the debts that will be derecognised and have not yet been amortised directly in profit or loss. The impact on net financial income was EUR (6.6) million.
At 30 June 2025, the loan issuance costs related to the latest debt transactions have been capitalised. Depreciation/ amortisation of loan issuance costs is recognised in the financial result.
The flows of capitalised loan issuance costs are shown in the table below: (in thousands of euros)
Capitalised loan issuance costs at 30 June 2025
Capitalisation of the issuance costs of new bank loans
Loan issuance costs recycled through profit or loss
7,804.8
166.0
(6,629.6)
Loan issuance costs
Depreciation/ amortisation of loan Capitalised loan issuance issuance costs costs at 30 June 2026 (1,341.2)
0.0
G) EXCHANGE DIFFERENCES
H) CHANGES IN EQUITY
The foreign exchange loss of EUR 28,597.4 corresponds to the difference between the historical value of loans to Capio AB in foreign currencies and their value at the closing date.
The Company’s capital consists of 110,389,690 shares with a nominal value of EUR 0.75 amounting to EUR 82,792.3 thousand.
Items (in thousands of euros)
30 June 2025
Increase
Decrease
Dividend distribution
Appropriation of profit N‑1
30 June 2026
Share or individual capital
82,792.3
82,792.3
Share premium, merger premium, contribution premium, etc.
600,910.9
600,910.9
6,205.2
6,205.2
Legal reserve Regulated reserves
7.3
7.3
Other reserves
12,257.6
12,257.6
Retained earnings
70,325.1
Profit for the financial year
1,750.7
Regulated provisions
15,547.3
15,547.3
789,796.4
787,897.2
TOTAL EQUITY
I)
(1,899.2)
1,750.7
72,075.8
(1,750.7)
(1,899.2)
EURO PRIVATE PLACEMENT LOAN AND CREDIT AGREEMENT
At 30 June 2026, the breakdown of the Group’s credit agreement, denominated exclusively in euros, was as follows: 30 June 2026
Original loan lines
Duration (in years)
Term
Amount used
Amount unused
Early repayment
1,450,000.0
7
13/08/2031
1,450,000.0
0.0
0.0
Revolving credit facility
100,000.0
5
13/08/2029
0
100,000.0
0.0
Capex facility
100,000.0
5
13/08/2029
15,000.0
85,000.0
0.0
1,465,000.0
185,000.0
0.0
(in thousands of euros)
Term Loan B5
TOTAL
1,650,000.0
At 30 June 2026, the structure of the loan was as follows: ■ ■ ■
EUR 1,450,000 thousand “Term Loan B5” tranche indexed to EUR3M+3.25%, maturing in August 2031; EUR 100,000 thousand revolving credit facility indexed to EUR3M+2.75%, maturing in August 2029; Capex facility in the amount of EUR 100,000 thousand indexed to EUR3M+2.75%, maturing in August 2029.
The purpose of this credit agreement is to finance the general operating needs of the Group’s companies as well as acquisitions and capital expenditure for growth and restructuring. All of these tranches are issued at variable rates. At 30 June 2026, the Ramsay Santé group had no outstanding drawdowns on the Revolving Credit Facility and had drawn down EUR 15,000 thousand on the Capex facility. At 30 June 2026, the Company used interest rate hedging instruments to protect itself against a rise in interest rates. At that date, 76.1% of the amount drawn down was covered.
Ramsay Santé / Universal Registration Document 2026
127
2
2
ANNUAL FINANCIAL INFORMATION Financial information concerning the assets, financial position and results of the issuer (and Statutory Auditors’ report)
At 30 June 2025, the breakdown of the Euro Private Placement loan was as follows: 30 June 2026 (in thousands of euros)
Original loan lines Duration (in years)
Euro Private Placement
Term
Amount used
Amount unused
Early repayment
40,000.0
0.0
0.0
40,000.0
7
14/12/2028
Euro Private Placement
60,000.0
8
14/12/2029
TOTAL
100,000.0
In December 2021, Ramsay Générale de Santé issued a fixed‑rate debt instrument in a private placement bond format for EUR 100,000 thousand maturing in 2028 and 2029.
60,000.0
0.0
0.0
100,000.0
0.0
0.0
As described in the note detailing events after the closing date, the Company successfully refinanced its senior Term Loan B debt contract and its Euro Private Placement loans on 22 July 2026.
J) FINANCIAL PROFIT (LOSS)
The financial profit (loss), amounting to EUR (42,749.8) thousand, includes the impact of the following transactions: Financial expenses
Financial income
Income from loans Group
72,546.3
Financial provisions
36,693.1
Interest on debt
82,495.5
Bank charges
27,818.6
4.4
Net interest on swaps
7,759.6
17.4
Current account interest
21,028.7
4,073.8
Other
1.8
Foreign exchange gain
816.1
Foreign exchange loss
42.5
Net proceeds from the disposal of investment securities and cash and cash equivalents
3.0
TOTAL
148,023.8
income tax amounted to EUR 4.7 million, including EUR 0.8 million for the exceptional contribution on the profits of large companies.
L) BREAKDOWN OF REVENUE
Revenue of EUR 1,972.5 thousand management fees invoiced to Capio AB.
corresponds
to
For the financial year ended 30 June 2026, the tax consolidation income recognised in the financial statements of Ramsay Générale de Santé SA amounted to EUR 69.5 million. It corresponds to the sum of the tax expenses of the beneficiary subsidiaries that are members of the tax consolidation group.
M) CORPORATION TAX ■
Ramsay Générale de Santé SA company tax The Company had a tax loss for the financial year of EUR 57.5 million.
■
Overall result of tax consolidation At 30 June 2026, the Ramsay Générale de Santé tax consolidation group reported a profit. The amount of corporate
105,277.0
■
Breakdown of income and related income tax
Breakdown of tax
Before tax
Tax
After tax
Current profit
(66,715.8)
0.0
(66,715.8)
Income from tax consolidation
58,840.6
58,840.6
Corporation tax
(4,679.6)
(4,679.6)
Tax credits ACCOUNTING PROFIT (LOSS) ■
(66,715.8)
10,655.6
10,655.6
64,816.6
(1,899.2)
Information on deferred or unrealised tax position Ramsay Générale de Santé SA’s tax loss carryforwards amounted to EUR 458 million as of 30 June 2025.
128
Ramsay Santé / Universal Registration Document 2026
ANNUAL FINANCIAL INFORMATION Financial information concerning the assets, financial position and results of the issuer (and Statutory Auditors’ report)
2.3.3.4 Other information A) WORKFORCE AND REMUNERATION
The Company’s headcount comprises only the Group’s Chief Executive Officer, whose remuneration is EUR 1,235.2 thousand. Remuneration allocated to directors amounts to EUR 305.5 thousand.
The Chief Executive Officer has a company car as a benefit in kind, the use of which is valued at EUR 4.1 thousand for the financial year ended 30 June 2026.
B) TABLE OF SUBSIDIARIES AND EQUITY INVESTMENTS
Subsidiaries and equity investments
Reserve and retained earnings before Capital appropriation
Share of capital held (in %)
Carrying amounts of securities held Gross
Net
Dividends Guarantees received and Revenue by the Loans and endorseexcluding Company advances ments given taxes for the Profit for the during the granted not by the last financial last financial financial yet repaid Company year year year
A - Detailed information (in thousands of euros) Subsidiaries (+50% of the share capital held by the Company) Compagnie Générale de Santé
148,621
97,173
100
763,770
763,770
726,777
0
59,293
(389,662)
Capio AB
6,500
405,188
100
807,001
807,001
503,015
0
1,993
0
Capio AB’s balance sheet data has been converted at the closing rate of 30 June 2026. Capio AB’s income statement data has been translated at the average exchange rate on 30 June 2026 (EUR 1 = SEK 11.2884).
C) OFF‑BALANCE SHEET COMMITMENTS
Other commitments given
Guarantee given
On 30 June 2026, the amount of retirement benefits totalled EUR 416,780.
As Principal Founder of the Ramsay Santé Corporate Foundation and in order to comply with the legal commitments arising from the bylaws of the Foundations, Ramsay Générale de Santé requested a bank guarantee from the Caisse d’Epargne et de Prévoyance Île‑de‑France, which was counter‑guaranteed by Ramsay Générale de Santé. Its outstanding amount at 30 June 2026 was EUR 3,192,000 and its maturity date is 30 June 2028.
D) TRANSACTIONS WITH RELATED PARTIES
There are no significant transactions with related parties (other than wholly owned subsidiaries) that have not been entered into under normal market conditions.
2.3.3.5 Events after the closing date The Company’s successful refinancing of its senior debt contract On 22 July 2026, Ramsay Générale de Santé finalised the refinancing of its senior debt for a total amount of EUR 1,750 million, including EUR 1,550 million under Term Loan B and EUR 200 million under a revolving credit facility. To set up this new Term Loan B, the Company benefited from the support of existing investors and new lenders. Its pricing is indexed to EUR3M+3.50%.
This transaction provides the Company with a long‑term financing framework thanks to the extension of the maturities of the senior debt from 2031 to 2033 and the refinancing of the “Euro Private Placement” loans of EUR 100 million maturing in 2028 and 2029. It also simplifies the Company’s financing structure while preserving the continuity and stability of the Company’s financing, with a change of control clause now compatible with the distribution envisaged by Ramsay Health Care (as a reminder, Ramsay Health Care has announced its plan to distribute its 52.79% stake in Ramsay Santé to its own shareholders).
Ramsay Santé / Universal Registration Document 2026
129
2
2
ANNUAL FINANCIAL INFORMATION Financial information concerning the assets, financial position and results of the issuer (and Statutory Auditors’ report)
2.3.3.6 Parent company activity report at 30 June 2026 2.3.3.6.1 Review of the Company’s activities Ramsay Générale de Santé SA is the parent company of the Ramsay Santé group, which conducts all of its activities in the healthcare and hospital services sector. It operates as a holding company through financial investments that enable it to have direct or indirect control of the Group’s companies.
Operating expenses at 30 June 2026 amounted to EUR 26,160.8 thousand compared to EUR 30,566.0 thousand at 30 June 2025. This decrease of EUR 4,405.2 thousand is mainly due to: ■
It has opted for the tax consolidation regime, which includes the parent company as head of the tax consolidation group and its main French subsidiaries. It also implements the Group’s external financing policy in order to maintain a certain level of liquidity to meet its commitments and investment needs.
■
2.3.3.6.2 Significant events of the financial year Announcement of the planned distribution by Ramsay Health Care to its shareholders of its stake in Ramsay Générale de Santé
■
On 20 February 2026, Ramsay Santé took note of the project announced by its shareholder, Ramsay Health Care Limited (RHC), to carry out a distribution in kind of its 52.79% stake in Ramsay Générale de Santé to its own shareholders. This Project would be implemented through a “scheme of arrangement” under Australian law that would be subject to the approval of RHC’s Board of Directors and its shareholders, as well as the required judicial and regulatory approvals. Ramsay Santé will diligently analyse all the legal, financial and operational implications that may arise from this operation and will ensure that the stability of its capital structure is preserved in a context of potential expansion of the free float. According to information provided by RHC, the Project could be implemented in the fourth quarter of 2026, subject to the required approvals. In accordance with the applicable regulations, Ramsay Santé has carried out the information and consultation procedure with its employee representative bodies.
■
2.3.3.6.3 Results at 30 June 2026 Revenue amounted to EUR 1,972.5 thousand. It corresponds in full to the invoicing of management fees to Capio AB. Operating profit at 30 June 2026 amounted to a loss of EUR 23,969.0 thousand compared to a loss of EUR 14,426.2 thousand at 30 June 2025, i.e. down EUR 9,542.8 thousand. Total operating income was down over the financial year. It amounted to EUR 2,191.8 thousand compared to EUR 16,139.8 thousand at 30 June 2025. This decrease is primarily attributable to the recognition of deferred loan issuance costs, arising from the two‑stage refinancing of the senior debt facility during the previous financial year. The expense transfer technique has since been removed from the new General Chart of Accounts currently in force, and transactions must now be recorded directly in the appropriate accounts.
130
Ramsay Santé / Universal Registration Document 2026
■
a decrease in other purchases and external expenses of EUR 5,569.7 thousand, mainly due to the combined effect of (i) a gain arising from the recognition, in the previous financial year, of loan issuance costs associated with the two‑stage refinancing of the credit facility, and (ii) non‑recurring expenses relating to consultancy fees incurred following Ramsay Health Care’s announcement of its plan to distribute its stake in Ramsay Générale de Santé to its shareholders; an increase in taxes, duties and similar payments of EUR 594.9 thousand, mainly due to a pro rata VAT adjustment during the fiscal year; a slight increase of EUR 365.0 thousand in salaries and social security contributions; stable operating allowances; an increase in other expenses of EUR 151.2 thousand.
The financial result at 30 June 2026 amounted to a loss of EUR 42,746.8 thousand compared to a loss of EUR 40,598.8 thousand at 30 June 2025, i.e. a deterioration of EUR 2,148.0 thousand. Financial income decreased by EUR 15,014.8 thousand and the change is mainly due to: ■ ■ ■
an increase of EUR 2,169.2 thousand in financial income from intragroup loans compared to 30 June 2025; a decrease of EUR 6,102.1 thousand in interest income; a decrease of EUR 11,847.7 thousand in reversals of provisions related to unrealised losses for the previous financial year.
Financial expenses decreased by EUR 12,866.8 thousand year‑on‑year, with this change being attributable in particular to a reduction in interest and similar charges. Current profit before tax showed a loss of EUR 66,715.8 thousand at the end of June 2026, compared with a loss of EUR 55,025.0 thousand at the end of June 2025, i.e. a deterioration of EUR 11,690.8 thousand. At 30 June 2026, income tax consisted of a surplus of EUR 58.8 million in respect of the tax consolidation and tax income related to various tax credits in the amount of EUR 10.7 million. The amount of corporate income tax amounted to EUR 4.7 million, including EUR 0.8 million for the exceptional contribution on the profits of large companies. The Company’s net profit at 30 June 2026 was a loss of EUR 1.9 million compared to a profit of EUR 1.7 million at 30 June 2025. The outlook for the future is presented in section 2.5 of the Group’s Universal Registration Document.
ANNUAL FINANCIAL INFORMATION Financial information concerning the assets, financial position and results of the issuer (and Statutory Auditors’ report)
2.3.3.6.4 Table of results for the last five financial years Nature of indications (in thousands of euros)
30 June 2022
30 June 2023
30 June 2024
30 June 2025
30 June 2026
I – CAPITAL AT THE END OF THE FINANCIAL YEAR a) Share capital (in euros)
82,792
82,792
82,792
82,792
82,792
b) Number of ordinary shares
110,390
110,390
110,390
110,390
110,390
d‑1) by conversion of bonds
d‑2) by exercise of subscription rights
1,972
c) Number of existing shares with priority dividends (without voting rights)
2
d) Maximum number of shares to be created:
II – RESULTS FOR THE FINANCIAL YEAR a) Revenue excluding tax
861
979
875
1,886
b) Profit before tax and calculated expenses
(37,973)
(42,909)
(55,980)
(56,845)
c) Income tax
(35,283)
(49,354)
(61,419)
(55,995)
(64,817)
d) Employee profit‑sharing due for the financial year Depreciation, amortisation and provisions
18,182
45,604
(11,544)
2,601
(8,985)
Profit after tax and calculated expenses
(20,873)
(39,159)
16,983
1,751
(1,899)
Distributed profit for the financial year III – EARNINGS PER SHARE (IN EUROS) a) Profit after tax but before calculated expenses
(0.02)
0.06
0.05
0.01
(0.10)
b) Profit after tax and calculated expenses
(0.19)
(0.35)
0.15
0.02
(0.02)
c) Net ordinary dividend per share IV – PERSONNEL a) Average headcount
1
1
1
1
1
b) Payroll amount for the financial year
1,379
1,186
1,160
1,060
1235
c) Amount paid in social benefits for the financial year (social security, retirement benefits, etc.) (in euros)
575
372
332
305
495
Ramsay Santé / Universal Registration Document 2026
131
2
ANNUAL FINANCIAL INFORMATION Financial information concerning the assets, financial position and results of the issuer (and Statutory Auditors’ report)
2.3.3.6.5 Information on supplier and customer payment terms Article D.441‑I: 1° of the French Commercial Code: Invoices received but not paid at the end of the financial year whose term has expired
In thousands of euros
0 days (indicative)
1 to 30 days
31 to 60 days
61 to 90 days
Article D.441‑I: 2° of the French Commercial Code: Invoices issued but not paid at the end of the financial year whose term has expired
Total 91 days and (1 day and 0 days more more) (indicative)
1 to 30 days
31 to 60 days
61 to 90 91 days days and more
Total (1 day and more)
(A) LATE PAYMENT BAND Number of invoices concerned
19
8
2
4
39
53
1
1
0
0
1
2
Total amount of invoices concerned (specify excluding or including VAT)
5,057.9
18.4
171.8
96.9
115.7
402.8
51
1,972
0
0
84
2,056
Percentage of the total amount of purchases excluding or including VAT for the financial year
19%
0%
1%
0%
0%
2%
2.5%
100%
0%
0%
0%
100%
Percentage of revenue for the financial year (specify excluding or including VAT)
(B) INVOICES EXCLUDED FROM (A) RELATING TO DISPUTED OR UNRECORDED DEBTS AND RECEIVABLES Number of invoices excluded Total amount of invoices excluded (specify excluding or including VAT) (C) REFERENCE PAYMENT TERMS USED (CONTRACTUAL OR LEGAL TERM – ARTICLE L.441‑6 OR ARTICLE L.443‑1 OF THE FRENCH COMMERCIAL CODE) Payment terms used to calculate late payments
Legal deadline of 30 days excluding contractual changes (remains less than 45 days)
2.3.3.6.6 Equity held Ramsay Générale de Santé holds 100% of the shares in Compagnie Générale de Santé and 100% of the shares in Capio AB, its only two subsidiaries. The activities of Compagnie Générale de Santé and Capio AB is identical to that of their parent company.
2.3.3.6.7 Financing Thanks to two successive transactions carried out during the previous financial year, Ramsay Générale de Santé succeeded in optimising the cost of its senior debt while extending its maturity. At 30 June 2026, the Company’s financing consisted of three credit lines: ■ ■
■
132
a “Term Loan B5” tranche for a total amount of EUR 1,450 million with a bullet maturity in August 2031; a Capex loan tranche for a total amount of EUR 100 million, maturing in August 2029, to finance acquisitions and capital expenditure for Group companies. EUR 15 million had been drawn down at 30 June 2026; a revolving credit tranche for a total amount of EUR 100 million to finance the Group’s general needs and working capital requirements, with a bullet maturity in August 2029.
Ramsay Santé / Universal Registration Document 2026
Legal deadline of 30 days
In December 2021, the Company also issued a fixed‑rate debt instrument in a private placement bond format for EUR 100 million maturing in 2028 and 2029. As described in events after the closing date, the Company successfully refinanced its senior Term Loan B debt contract and its Euro Private Placement loans on 22 July 2026. The Company has a cash current account with Centrale Ramsay Santé, which had a total credit of EUR 536,108.1 thousand at 30 June 2026. Ramsay Générale de Santé also acts as a lender to its subsidiaries Capio AB and Compagnie Générale de Santé. During the financial year, the Company issued three additional loans to Capio AB, respectively for SEK 80 million on 8 January 2026 and SEK 200 million on 20 January 2026. An intragroup loan of SEK 138 million was already outstanding at 30 June 2025. During the financial year, additional funding of SEK 75 million (arranged on 7 July 2025) and SEK 77 million (arranged on 9 October 2025) was secured; both loans were repaid in full on 3 February 2026. The equivalent value in euros of the loan to Capio AB on the balance sheet at 30 June 2026 was EUR 503,015,205. The Company renewed its loan to Compagnie Générale de Santé during the financial year in the amount of EUR 690,000 thousand. At closing, accrued interest amounted to EUR 36,777 thousand.
ANNUAL FINANCIAL INFORMATION Financial information concerning the assets, financial position and results of the issuer (and Statutory Auditors’ report)
2.3.3.6.8 Equity transactions
2.3.3.6.10 Events after the closing date
At 30 June 2026, Ramsay Générale de Santé SA held 6,881 of its own shares under a liquidity agreement managed by CIC MARKET SOLUTIONS, for a net carrying amount of EUR 313.9 thousand at the end of the year. As the market value was EUR 189.1 thousand, an impairment of EUR 124.8 thousand was recognised at 30 June 2026.
THE COMPANY’S SUCCESSFUL REFINANCING OF ITS SENIOR DEBT CONTRACT
The movements during the financial year generated a net capital loss of EUR 3.0 thousand.
2.3.3.6.9 Remuneration The Company’s headcount comprises only the Group’s Chief Executive Officer, whose remuneration is EUR 1,235.2 thousand. Remuneration allocated to directors amounts to EUR 305.5 thousand. The Chief Executive Officer has a company car as a benefit in kind, the use of which is valued at EUR 4.1 thousand for the financial year ended 30 June 2026.
On 22 July 2026, Ramsay Générale de Santé finalised the refinancing of its senior debt for a total amount of EUR 1,750 million, including EUR 1,550 million under Term Loan B and EUR 200 million under a revolving credit facility. To set up this new Term Loan B, the Company benefited from the support of existing investors and new lenders. Its pricing is indexed to EUR3M+3.50%. This transaction provides the Company with a long‑term financing framework thanks to the extension of the maturities of the senior debt from 2031 to 2033 and the refinancing of the “Euro Private Placement” loans of EUR 100 million maturing in 2028 and 2029. It also simplifies the Company’s financing structure while preserving the continuity and stability of the Company’s financing, with a change of control clause now compatible with the distribution envisaged by Ramsay Health Care (as a reminder, Ramsay Health Care has announced its plan to distribute its 52.79% stake in Ramsay Santé to its own shareholders).
Ramsay Santé / Universal Registration Document 2026
133
2
2
ANNUAL FINANCIAL INFORMATION Financial information concerning the assets, financial position and results of the issuer (and Statutory Auditors’ report)
2.3.3.7 Statutory auditors’ report on the financial statements For the year ended 30 June 2026 This is a translation into English of the Statutory Auditors’ report on the financial statements of Ramsay Générale de Santé issued in French and it is provided solely for the convenience of English‑speaking users. This Statutory Auditors’ report includes information required by European regulation and by French law, such as information about the appointment of the statutory auditors or verification of the management report and other documents provided to shareholders. This report should be read in conjunction with, and construed in accordance with, French law and professional auditing standards applicable in France.
To the Shareholders of Ramsay Générale de Santé,
OPINION In compliance with the engagement entrusted to us by your Shareholder’s meeting, we have audited the accompanying financial statements of Ramsay Générale de Santé for the year ended June 30, 2026. In our opinion, the financial statements give a true and fair view of the assets and liabilities and of the financial position of the Company as at June 30, 2026 and of the results of its operations for the year then ended in accordance with French accounting principles. The audit opinion expressed above is consistent with our report to the Audit Committee. BASIS FOR OPINION AUDIT FRAMEWORK
We conducted our audit in accordance with professional standards applicable in France. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion. Our responsibilities under those standards are further described in the "Statutory Auditors’ Responsibilities for the Audit of the Financial Statements" section of our report. INDEPENDENCE
We conducted our audit engagement in compliance with independence requirements of the French Commercial Code (code de commerce) and the French Code of Ethics (code de déontologie) for statutory auditors, for the period from July 1st, 2025 to the date of our report, and specifically we did not provide any prohibited non‑audit services referred to in Article 5(1) of Regulation (EU) No 537/2014. EMPHASIS OF MATTER Without qualifying our opinion, we draw attention to the change in accounting policies resulting from the first‑time application of ANC Regulation No. 2022‑06, the effects of which are set out in particular in Note 2.3.3.2 to the financial statements. JUSTIFICATION OF ASSESSMENTS – KEY AUDIT MATTERS In accordance with the requirements of Articles L.821‑53 and R. 821‑180 of the French Commercial Code relating to the justification of our assessments, we inform you of the key audit matters relating to risks of material misstatement that, in our professional judgment, were of most significance in our audit of the financial statements of the current period, as well as how we addressed those risks. These matters were addressed in the context of our audit of the financial statements as a whole, approved in the conditions mentioned above, and in forming our opinion thereon, and we do not provide a separate opinion on specific items of the financial statements.
134
Ramsay Santé / Universal Registration Document 2026
ANNUAL FINANCIAL INFORMATION Financial information concerning the assets, financial position and results of the issuer (and Statutory Auditors’ report)
●
VALUATION OF INVESTMENTS IN SUBSIDIARIES
(Notes 2.3.3.2 B) and 2.3.3.3 A) to the financial statements) Key Audit Matter
Our audit responses
As of June 30, 2026, Ramsay Générale de Santé holds equity investments in companies that themselves hold the shares of the Group’s operating companies, with a net carrying amount of €1,570.8 million. As stated in Note 2.3.3.2 B) to the annual financial statements, the impairment tests for these equity investments are based on the determination of a value in use, which corresponds to the discounted value of the sum of the future pre‑tax cash flows and financial items of the entities held by your company. We considered the assessment of these equity investments to be a key audit matter given: ■ their significance in the annual financial statements, ■ the estimates and judgments made by Management in determining the key assumptions underlying value in use for impairment testing, and in particular, the sensitivity of the resulting valuations to revenue growth including changes in care service tariffs, discount rates and perpetual growth rates.
Our procedures consisted primarily of obtaining an understanding of the process established by management for preparing and approving the estimates and assumptions used in the impairment tests. Our procedures relating to the data and assumptions underlying the assessment of the value in use of the equity investments consisted primarily of: ■ assessing the consistency of the data and assumptions used by management to prepare the cash flow projections with the 2027–2031 Corporate Plan; ■ comparing the cash flow projections used by management with historical performance and with the forecasts included in the prior year’s Corporate Plan; and ■ assessing, with the assistance of our valuation specialists, the discount and growth rates used by management, by comparing them with our own estimates based on market data as of June 30, 2026. We also verified, on a sample basis, the mathematical accuracy of the impairment tests performed by the Company in connection with the calculation of the recoverable amounts.
2
SPECIFIC VERIFICATION We have also performed, in accordance with professional standards applicable in France, the specific verifications required by laws and regulations. INFORMATION GIVEN IN THE MANAGEMENT REPORT AND IN THE OTHER DOCUMENTS WITH RESPECT TO THE FINANCIAL POSITION AND THE FINANCIAL STATEMENTS PROVIDED TO SHAREHOLDERS
We have no matters to report as to the fair presentation and the consistency with the financial statements of the information given in the management report of Board of Directors and in the other documents with respect to the financial position and the financial statements provided to Shareholders. We attest the fair presentation and the consistency with the financial statements of the information relating to payment deadlines mentioned in Article D.441‑6 of the French Commercial Code (code de commerce). REPORT ON CORPORATE GOVERNANCE
We attest that the Chairman’s report on corporate governance sets out the information required by Article L. 225‑37‑4, L.22‑10‑10 and L.22‑10‑9 of the French Commercial Code. Concerning the information given in accordance with the requirements of Article L. 22‑10‑9 of the French Commercial Code (code de commerce) relating to remunerations and benefits received by or awarded to the directors and any other commitments made in their favour, we have verified its consistency with the financial statements, or with the underlying information used to prepare these financial statements and, where applicable, with the information obtained by your Company from controlled enterprises included in the scope of consolidation. Based on these procedures, we attest the accuracy and fair presentation of this information. With respect to the information relating to items that your company considered likely to have an impact in the event of a takeover bid or exchange offer, provided pursuant to Article L. 22‑10‑11 of the French Commercial Code (code de commerce), we have agreed this information to the source documents communicated to us. Based on these procedures, we have no observations to make on this information. OTHER INFORMATION
In accordance with French law, we have verified that the required information concerning the purchase of investments and controlling interests and the identity of the shareholders and holders of the voting rights has been properly disclosed in the management report.
Ramsay Santé / Universal Registration Document 2026
135
2
ANNUAL FINANCIAL INFORMATION Financial information concerning the assets, financial position and results of the issuer (and Statutory Auditors’ report)
OTHER LEGAL AND REGULATORY VERIFICATIONS OR INFORMATION FORMAT OF PRESENTATION OF THE FINANCIAL STATEMENTS INTENDED TO BE INCLUDED IN THE ANNUAL FINANCIAL REPORT
We have also verified, in accordance with the professional standard applicable in France relating to the procedures performed by the statutory auditor relating to the annual and consolidated financial statements presented in the European single electronic format, that the presentation of the financial statements intended to be included in the annual financial report mentioned in Article L. 451‑1‑2, I of the French Monetary and Financial Code (code monétaire et financier), prepared under the responsibility of Chief Executive Officer, complies with the single electronic format defined in the European Delegated Regulation No 2019/815 of 17 December 2018. Based on the work we have performed, we conclude that the presentation of the financial statements intended to be included in the annual financial report complies, in all material respects, with the European single electronic format. We have no responsibility to verify that the financial statements that will ultimately be included by your company in the annual financial report filed with the AMF are in agreement with those on which we have performed our work. REPORT ON INCOME TAX FOR THE YEAR ENDED JUNE 30, 2025
As your Company is subject to the requirements of Article L. 233‑28‑2 of the French Commercial Code (code de commerce), we certify that the report on income tax for the year ended June 30, 2025, has been published and made available to the public free of charge in accordance with the provisions of that Article. It is not our responsibility to express an opinion on the content and electronic format of this report. APPOINTMENT OF THE STATUTORY AUDITORS
We were appointed as statutory auditors of Ramsay Générale de Santé Company by the Shareholder’s meeting held on June 1st, 2001 for DELOITTE & ASSOCIES and December 16, 2015 for ERNST & YOUNG Audit. As at June 30, 2026, DELOITTE & ASSOCIES and ERNST & YOUNG Audit were in the 26th year and 11th year of total uninterrupted engagement respectively. RESPONSIBILITIES OF MANAGEMENT AND THOSE CHARGED WITH GOVERNANCE FOR THE FINANCIAL STATEMENTS Management is responsible for the preparation and fair presentation of the financial statements in accordance with French accounting principles, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. In preparing the financial statements, management is responsible for assessing the Company’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless it is expected to liquidate the Company or to cease operations. The Audit Committee is responsible for monitoring the financial reporting process and the effectiveness of internal control and risks management systems and where applicable, its internal audit, regarding the accounting and financial reporting procedures. The financial statements were approved by the Board of Directors. STATUTORY AUDITORS’ RESPONSIBILITIES FOR THE AUDIT OF THE FINANCIAL STATEMENTS OBJECTIVES AND AUDIT APPROACH
Our role is to issue a report on the financial statements. Our objective is to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with professional standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements. As specified in Article L.821‑55 of the French Commercial Code, our statutory audit does not include assurance on the viability of the Company or the quality of management of the affairs of the Company.
136
Ramsay Santé / Universal Registration Document 2026
ANNUAL FINANCIAL INFORMATION Financial information concerning the assets, financial position and results of the issuer (and Statutory Auditors’ report)
As part of an audit conducted in accordance with professional standards applicable in France, the statutory auditor exercises professional judgment throughout the audit and furthermore: ■
■ ■ ■
■
Identifies and assesses the risks of material misstatement of the financial statements, whether due to fraud or error, designs and performs audit procedures responsive to those risks, and obtains audit evidence considered to be sufficient and appropriate to provide a basis for his opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Obtains an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the internal control. Evaluates the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management in the financial statements. Assesses the appropriateness of management’s use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company’s ability to continue as a going concern. This assessment is based on the audit evidence obtained up to the date of his audit report. However, future events or conditions may cause the Company to cease to continue as a going concern. If the statutory auditor concludes that a material uncertainty exists, there is a requirement to draw attention in the audit report to the related disclosures in the financial statements or, if such disclosures are not provided or inadequate, to modify the opinion expressed therein. Evaluates the overall presentation of the financial statements and assesses whether these statements represent the underlying transactions and events in a manner that achieves fair presentation.
REPORT TO THE AUDIT COMMITTEE
We submit a report to the Audit Committee which includes in particular a description of the scope of the audit and the audit program implemented, as well as the results of our audit. We also report, if any, significant deficiencies in internal control regarding the accounting and financial reporting procedures that we have identified. Our report to the Audit Committee includes the risks of material misstatement that, in our professional judgment, were of most significance in the audit of the financial statements of the current period and which are therefore the key audit matters that we are required to describe in this report. We also provide the Audit Committee with the declaration provided for in Article 6 of Regulation (EU) N° 537/2014, confirming our independence within the meaning of the rules applicable in France such as they are set in particular by Articles L.821‑27 to L.821‑34 of the French Commercial Code and in the French Code of Ethics (code de déontologie) for statutory auditors. Where appropriate, we discuss with the Audit Committee the risks that may reasonably be thought to bear on our independence, and the related safeguards. Paris‑La Défense, 6 October 2026 The Statutory Auditors The French original signed by DELOITTE & ASSOCIÉS
ERNST & YOUNG Audit
Jean‑Pierre Agazzi
Aymeric de La Morandière
Ramsay Santé / Universal Registration Document 2026
137
2
2
ANNUAL FINANCIAL INFORMATION Financial information concerning the assets, financial position and results of the issuer (and Statutory Auditors’ report)
2.3.4
Age of financial information
The Company’s most up‑to‑date financial information is that presented in this Universal Registration Document.
2.3.5
Dividend distribution policy
2.3.5.1
Dividends paid over the last three financial years
The Company has not paid any dividends during the last three financial years (information provided pursuant to Article 243bis of the French General Tax Code).
2.3.5.2 Dividend distribution policy The Company’s dividend policy is defined by its corporate bodies based on the distribution capacity, cash position and financial needs of the Company and its subsidiaries. The Company does not intend to distribute any dividends for the financial year ended 30 June 2026.
2.3.5.3 Limitation period Pursuant to the provisions of the General Code of Public Property, dividends not claimed within five years of their payment date are deemed expired and acquired by the State (Article L.1126‑1, CGPPP).
2.3.6
Disputes
2.3.6.1
Dispute management
With regard to disputes and litigation, the Group’s provisioning policy is described in note 8 to the consolidated financial statements in this chapter.
2.3.6.2 Significant disputes See note 8 of the notes to the consolidated financial statements in this chapter. In addition, on 7 October 2026, the Lyon Court of Appeal handed down its decision in the dispute relating to the Hôpital Privé Jean Mermoz. This decision confirms the judgment of the first instance and, in particular, the absence of liability of
2.3.7
Significant changes in the financial or commercial position
See section 2.3 of this chapter.
138
the Group’s companies as well as the conviction of the opposing parties. The financial and accounting consequences of this decision are currently being analysed.
Ramsay Santé / Universal Registration Document 2026
ANNUAL FINANCIAL INFORMATION Cash and capital
2.4 Cash and capital
2
2.4.1
Financing
2.4.1.1
Terms of the credit agreement in force as of the date of this document
At 30 June 2026, the Group’s credit agreement consisted of the following lines: ■ ■ ■
EUR 1,450 million “Term Loan B5” tranche indexed to EUR3M+3.25% maturing in August 2031; EUR 100 million “Revolving Credit Facility” indexed to EUR3M+2.75% maturing in August 2029; Capex facility in the amount of EUR 100 million indexed to EUR3M+2.75% maturing in August 2029 of which EUR 15 million has been drawn down.
At 30 June 2026, the credit agreement includes, amongst other things, certain covenants, failure to comply with which may result in the amounts made available becoming due and payable immediately. In particular, it includes clauses governing: ■ ■ ■ ■ ■
asset disposals; additional borrowing, particularly in relation to property; external growth transactions; distributions paid to shareholders; as well as certain financing non‑recourse factoring.
operations
such
as
The credit agreement also includes a financial covenant requiring compliance with a maximum leverage ratio when more than 40% of the Revolving Credit Facility is drawn down. As at 30 June 2026, as this line had not been drawn, this covenant did not apply.
2.4.1.2
Finally, the credit agreement contains representations and warranties, as well as provisions relating to any instances of default. An annual bonus/malus system has been implemented on four CSR indicators considered the most relevant for the Group, with one “green” indicator on the energy consumption of the clinical buildings in France in CO2 equivalent, and three “health” indicators (employee satisfaction in France and the development of a new internal psychosocial risk prevention plan, a progress indicator on the satisfaction of patients in healthcare facilities in France, Sweden and Denmark, and lastly, an indicator on the business plan for the opening of local care centres in France and the development of teleconsultation in Sweden). In the context of the credit agreement, pledges of financial securities accounts were granted simultaneously or successively, as the case may be, by the Company and certain of its subsidiaries. A complete table of these pledges as at 30 June 2026 is provided in chapter 6 of this document, section 6.4.1.5. After the end of the financial year, the credit agreement described above was refinanced on 22 July 2026; see section 2.4.3 ‘Main new financing put in place’ of this document.
Euro Private Placement
As part of the Group’s voluntary policy of commitment to sustainable development and diversification of its sources of financing, a private bond was issued for EUR 100 million in December 2021 in two tranches, one for EUR 40 million with a 7‑year maturity (maturing in 2028) and the other for EUR 60 million with an 8‑year maturity (maturing in 2029).
2.4.2
The level of the leverage ratio also plays a role in determining certain conditions applicable to the Group, particularly with regard to margins, additional debt and distributions to shareholders.
As at the date of publication of this document, the two Euro Private Placement loans were repaid in full on 22 July 2026 as part of the refinancing carried out on that same date (see section 2.4.3 ‘Main new financing put in place’).
Cash and capital
Detailed information on consolidated cash flow and financing flows as well as the net borrowing cost is provided in specific tables and information in the notes to the consolidated financial statements (see section 2.3.2 of this chapter 2).
Ramsay Santé / Universal Registration Document 2026
139
2
ANNUAL FINANCIAL INFORMATION Cash and capital
2.4.3
Debt position at 30 June 2026
Net financial debt (including lease debt but excluding operating lease debt) at 30 June 2026 was EUR 1,638.7 million, compared to EUR 1,675.4 million at 30 June 2025. For information purposes, as at 30 June 2026, the leverage ratio stands at 4.7 The application of IFRS 16 Leases contributed EUR 1,946.2 million to the net financial debt at 30 June 2026. Total net financial debt, which includes this lease liability under IFRS 16 Leases, thus amounted to EUR 3,584.9 million at 30 June 2026. Non‑current borrowings and financial debt amounted to EUR 1,854.6 million, current financial debt amounted to EUR 68.2 million, and net cash stood at EUR 302.2 million. The non‑current lease liability amounted to EUR 1,849.0 million and the current lease liability amounted to EUR 259.4 million. At 30 June 2026, the Group had a credit agreement for a total amount of EUR 1,465 million drawn down and EUR 185 million of undrawn credit. It is broken down into three distinct tranches: ■ ■
■
a EUR 1,450 million “Term Loan B5” tranche indexed to EUR3M+3.25% maturing in August 2031; EUR 100 million for the Revolving Credit Facility maturing in August 2029 (indexed at EUR3M+2.75% in the event of a drawdown); a EUR 100 million ‘Capex facility’ maturing in August 2029 (indexed at EUR3M+2.75% in the event of a drawdown), of which EUR 15 million has been drawn down.
The credit facility is intended to finance the Group’s general requirements, as well as its authorised external growth initiatives and capital expenditure. All of its tranches are issued at variable rates. At 30 June 2026, 76% of the amount drawn was covered with an average fixed rate of 2.46%. Main new financing put in place: On 22 July 2026, Ramsay Santé completed the refinancing of its senior debt for a total amount of EUR 1,750 million, of which EUR 1,550 million had been drawn down as at the date of publication of this document, comprising: ■
■
a ‘Term Loan B’ tranche of EUR 1,550 million, maturing in 2033, indexed to EUR3M+3.50%, placed at an issue price of 99.0%; a multi‑currency Revolving Credit Facility of EUR 200 million, maturing in 2033, indexed to EUR3M+3.00%, which was entirely undrawn as at the date of publication of this document.
This transaction has enabled the Group to extend the maturities of its senior debt from 2031 to 2033 and to simplify
140
Ramsay Santé / Universal Registration Document 2026
its financing structure, in particular by refinancing the Euro Private Placement loans totalling EUR 100 million, maturing in 2028 and 2029. As part of this transaction, the EUR 15 million drawn down from the existing ‘Capex facility’ has been repaid in full. The new credit agreement also provides for the establishment of a security package in favour of the lenders. This includes security over the relevant entities’ bank accounts and significant intra‑group receivables, in accordance with the thresholds set out in the financing documentation. It is a ‘sustainability‑linked’ loan, the margin on which may be adjusted annually depending on the achievement of four environmental and social key performance indicators (KPIs) set out in the loan documentation. It is intended to finance or refinance the Group’s existing debt, as well as the costs associated with such refinancing and, more generally, the Group’s general requirements and working capital needs, including its capital expenditure, authorised acquisitions, investments and reorganisation measures. This refinancing was arranged with the participation of three arranging banks: BNP Paribas, Crédit Agricole Corporate & Investment Bank (acting as global coordinator) and Natixis, all three acting as arranging banks. The entire existing portfolio of interest rate swaps relating to financing prior to 22 July 2026, representing a notional amount of EUR 1,115 million, was retained as part of the refinancing, with an average fixed rate of 2.46%. Real estate refinancing of the Dijon‑Bourgogne Private Hospital: On 20 July 2026, the Group exercised the EUR 13 million purchase option provided for in the real estate finance lease agreement for its Dijon‑Bourgogne site, which had expired. At the same time, on 31 July 2026, it raised a further tranche of debt from Fiducie‑Sûreté (‘Fiducie’) amounting to EUR 67.5 million over 10 years, thereby strengthening its liquidity on favourable terms and diversifying its sources of funding as well as its maturity profile. This financing, arranged by Natixis, was backed by a consortium comprising several entities from the BPCE Group, La Banque Postale and Bpifrance. The financing arranged in the form of a security trust has retained its structure as ‘sustainability‑linked’ financing. In accordance with the contractual interest rate hedging obligations attached to this financing, as at the date of publication of this document, 60% of the amount of the new tranche of financing had been hedged against interest rate fluctuations.
ANNUAL FINANCIAL INFORMATION Information on profit trends, forecasts and estimates
2.5 Information on profit trends, forecasts and estimates
2 2.5.1
Recent developments and outlook
As a mission‑led company committed to creating a lasting impact, the Ramsay Santé group has developed a diverse and integrated care offer, underpinned by medical excellence, as well as a proven model of digital innovation and knowledge‑sharing across its various countries. Over the past three years, the Ramsay Santé group has demonstrated the resilience of its growth and profitability, thanks to the success of its performance plans and a strengthened and flexible financial structure: ■
■
■
■
Robust revenue growth in France, driven by sustained growth in volumes against a backdrop of constraints on price increases; Strong organic growth in the Nordic countries, driven by favourable price and volume trends in primary care, revenue growth at St Göran and sustained demand at the Group’s specialist facilities; Resilient profitability despite significant headwinds, with performance plans having enabled the Company to absorb both the end of temporary support measures and the underfunding caused by inflation; A strengthened financial structure following the successful refinancing, with debt maturities extended to 2033 and a simplified funding structure;
2.5.2
(1)
■
Significant financial flexibility thanks to the Group’s property portfolio, valued at EUR 1.5 billion; A clear and consistent path towards debt reduction.
Opening up to new investors alongside Crédit Agricole Assurances, a long‑term shareholder in the Group, marks a new milestone for the Ramsay Santé group. Ramsay Health Care (RHC), which currently holds a 52.79% stake in Ramsay Santé, has announced its intention to distribute its entire holding to its own shareholders. This distribution in kind is expected to take place in December 2026 (1) and could lead to a significant broadening of the shareholder base. Ramsay Santé has also applied for listing as an exempt foreign entity on the Australian Securities Exchange (ASX), via CHESS Depositary Interests (CDIs). With a long‑standing independent strategy, funding structure and governance framework, the Group is entering this new phase in a strong financial position, further bolstered by its recent refinancing. Crédit Agricole Assurances, which holds a 39.82% stake in Ramsay Santé through its subsidiary Predica, has also reaffirmed its commitment as a long‑term shareholder, as well as its confidence in the Group’s strategy, its management team and its growth potential.
Group profit forecasts
By building on its integrated care offer, strengthening its MSO network and investing in complementary activities, Ramsay Santé is aiming for solid organic growth over the coming years. At the same time, the Group will take a number of measures to improve its profitability and generate robust cash flow, through rigorous capital allocation and the optimisation of its financing structure and costs. Its short- and medium‑term financial outlook is as follows: ■
■
Financial year 2027: revenue growth (2) between 2.0% and 3.0% and stable EBITDA margin (compared to financial year 2026);
■
■
■
Financial year 2029: revenue growth (2) of around 3.0% per annum (3) and a gradual improvement in the EBITDA margin; Gross capital expenditure representing approximately 4.0% of revenue on average over the period from the 2027 financial year to the 2029 financial year; Ongoing debt reduction, with a target net debt (4)/EBITDA (pre‑IFRS) ratio of less than 4.0x.
The targets communicated for the 2027 financial year were established on the basis of the Group’s scope as it existed on 30 June 2026 and in accordance with the accounting principles applied to prepare the Group’s consolidated financial statements.
The distribution is subject to compliance with the usual conditions, including approval by RHC’s Board of Directors, RHC’s shareholders, and the Australian courts and regulatory authorities.
(2) Excluding currency effect. (3) CAGR for financial years 2026 to 2029. (4) Based on the latest known tax framework; in France, the CVAE is set to remain in place for the financial years 2027 to 2029, whilst the temporary surcharge on corporation tax is assumed not to be renewed after 2026. Ramsay Santé / Universal Registration Document 2026
141
2
ANNUAL FINANCIAL INFORMATION Information on profit trends, forecasts and estimates
2.5.3
Group objectives
Ramsay Santé is embarking on a new chapter in the Group’s development with ‘Connecting Care 2030’, its new four‑year strategic roadmap, which was presented at the Capital Markets Day on 17 September 2026. Building on its integrated European healthcare platform, this plan aims to improve patient outcomes and access to care, whilst supporting profitable and sustainable growth. It forms part of the Ramsay Santé group’s ambition to provide high‑quality care for everyone, at every stage of their healthcare pathway. ‘Connecting Care 2030’ places medical excellence and the patient at the heart of the Group’s next phase of development. The plan sets out a clear path towards robust organic growth and sustainable margin improvement, based on five strategic pillars: ■
Strengthening an integrated and accessible care offer. The Ramsay Santé group will draw on its unique integrated offering, covering the entire patient journey, with multiple points of entry and a network of facilities firmly established in the main urban areas. This organisational structure offers the Group significant growth potential in its existing markets. It will strengthen its care offers in areas where it already has recognised expertise, drawing on its MSO network and the development of primary care in Sweden, as well as continuing to roll out its imaging capabilities.
■
Amplifying the digital transformation of the care offer. The Ramsay Santé group will continue to digitise patient care pathways and expand the use of data and artificial intelligence across its entire platform, with a view to improving both the patient journey and the care offer. This will involve the use of telemedicine and remote monitoring tools, primary care pathways incorporating artificial intelligence and revenue cycle management tools, as well as the wider roll‑out of digital tools and artificial
142
Ramsay Santé / Universal Registration Document 2026
intelligence to streamline administrative processes, support clinical decision‑making and improve operational efficiency. ■
Actively managing the business portfolio and contracts. The Ramsay Santé group will continue to actively manage its portfolio of assets and contracts, rather than simply seeking to expand it, in order to focus its resources on those activities offering the best prospects for growth and profitability. Continuing to optimise and streamline the portfolio will help to improve margins through better utilisation of capacity, better alignment of activities with changes in patient demand, and a more agile and efficient network.
■
Continuing cost optimisation initiatives. The Ramsay Santé group will continue to roll out targeted performance plans in France and the Nordic countries. Improvements in profit margins will depend not only on cost reductions, but also on better utilisation of existing capacity, increased operating theatre use rates, greater efficiency amongst medical teams, optimisation of procurement and administrative costs, better workforce planning and more efficient work processes.
■
Accelerating profitable growth through new growth drivers. In addition to growing its existing operations, the Ramsay Santé group will develop additional sources of revenue by capitalising on the strengths of its healthcare platform. In particular, the Group plans to expand its home care and outpatient mental health services, as well as its private health insurance and occupational health services in Sweden, thereby creating new sources of profitable growth alongside its core businesses.
ANNUAL FINANCIAL INFORMATION Property and equipment
2.6 Property and equipment 2.6.1
Management of property assets
2.6.1.1
Ramsay Santé’s real estate strategy
2
Ramsay Santé operates a large and strategic real estate portfolio for the conduct of its business. Its real estate assets are modern, well‑maintained and keep pace with sector developments in terms of technical platforms, security and medical needs in general, enabling it to welcome and treat a large number of patients in the best possible conditions.
its regional positionings. Consequently, Ramsay Santé has leased, in several stages, a portion of its real estate assets, both existing and new facilities (resulting from mergers or new creations) with the following objectives:
The Group regularly fine‑tunes its real estate policy in the context of its long‑term strategy based on refocusing on its core business as a hospital care provider and strengthening
■
■
optimised management of leased facilities through the standardisation of leases; arrangement of partnerships with a limited number of qualified investors to assist the Group in streamlining its property management and the financing of restructuring and/or modernisation projects.
At 30 June 2026, the portfolio of assets leased in France from the Group’s three main real estate companies breaks down as follows: Partner
Number of assets
In July 2023, Primonial REIM finalised the first phase of its acquisition of Icade’s 64% stake in Icade Santé, for an amount of EUR 1.4 billion. Primonial REIM became Praemia REIM on 1 July 2024 following the transfer of the Primonial brand as part of the sale of the Primonial Ingénierie & Développement business to the Crystal group on 28 June 2024. The Group will continue its programme to develop and modernise its real estate portfolio, with a focus on extending facilities in the MCO segment (particularly in the context of mergers), the restructuring of mental health facilities to offer patient care that meets current standards, and the creation of small day hospitals.
2.6.1.2
■
■
BNPP Reim
Total
53
4
57
Such projects are fully aligned with Ramsay Santé’s strategy which is based on structuring its network of facilities around territorial divisions with the ultimate aim of having three types of facilities: ■
■ ■
leading private hospitals offering a comprehensive range of care and diagnostic services, centres of excellence and serving the public interest; smaller, specialised facilities; day hospitals and primary care centres.
Real estate management policy
Ramsay Santé follows a policy of continuous streamlining, modernisation and improvement to ensure its facilities best meet the healthcare needs of local populations. In this context, its main projects concern: ■
Praemia Reim
the creation of new sites (creation of community day hospitals, relocation of ageing facilities, etc.); major restructuring such as extensions to increase capacity, whether linked to new health authorisations or not; small restructurings or modernisations often carried out during the year.
In recent years, the Group has completed major non‑recurring investment programmes to replace, consolidate and restructure its assets. These programmes are designed to ensure the growth and profitability of the asset portfolio. In parallel with these operations, the Group oversees the technical management of the various components of its real estate assets (safety/fire, air conditioning, fluids and electricity) and coordinates the implementation of maintenance plans by ensuring cost optimisation and the associated budgetary monitoring.
Ramsay Santé / Universal Registration Document 2026
143
2
ANNUAL FINANCIAL INFORMATION Property and equipment
The Group has initiated an energy audit of its real estate portfolio in conjunction with the real estate companies holding the building leases. To date, 103 audits have been carried out to identify priority actions to be carried out in the facilities in question to achieve the objectives set under Decree No. 2019‑771 of 23 July 2019 on obligations to take action to
reduce final energy consumption in tertiary buildings (known as the “Tertiary Decree”). A medium‑term investment programme is being drawn up, although work to improve the energy performance of buildings has already been carried out or is underway (part of this work is being carried out or paid for by the lessors, where applicable).
2.6.2
General description of the real estate assets occupied by the healthcare facilities
2.6.2.1
Geographical locations of Ramsay Santé facilities in France and the Nordic countries
The Ramsay Santé group’s facilities are spread over a large part of the country, covering some of the largest geographical regions (Île‑de‑France, Auvergne‑Rhône‑Alpes, Bourgogne‑Franche‑Comté, Provence‑Alpes‑Côte d’Azur, Hauts‑de‑France, Normandy). These regions have a high population density and some of them are experiencing population growth above the national average.
Ramsay Santé has facilities in Sweden, Norway and Denmark, mainly located in the most populated areas, which are also growing faster than the national average.
2.6.2.2 General description of the real estate assets occupied by the healthcare facilities in France and the Nordic countries In France, the Group’s real estate assets accounted for a total surface area of 1,412,600 m2 at 30 June 2026.
The average size of mental health facilities is around 4,300 m2.
The individual surface areas of facilities range between 1,000 m2 and 53,000 m2, with an average of 11,000 m2 – their size depends on the hospitalisation needs of the region.
The average size of healthcare centres is around 1,000 m2.
The average size of MSO facilities is nearly 16,000 m2 with considerable differences between specialist clinics or clinics in central Paris and multi‑speciality private hospitals equipped with key technical platforms, chiefly outside Paris.
In the Nordic countries, the real estate portfolio represented a total surface area of 402,401 m2 at 30 June 2026. The surface areas of facilities range between 150 m2 and 57,000 m2, with their size corresponding to the hospitalisation needs of the region.
The average size of the medical care and rehabilitation facilities is 6,500 m2, exceeding 10,000 m2 only occasionally.
2.6.2.3 Predominance of rental properties in France and the Nordic countries At the end of June 2026, the real estate portfolio in France consisted mainly of rented sites: Owned
342,124 m2
i.e. 24.22%
Rental
2
1,031,491 m
i.e. 73.02%
Leased
38,985 m2
i.e. 2.76%
TOTAL
1,412,600 M2
100%
The assets held by Primonial Reim, Praemia Healthcare (formerly Icade Santé) and BNPP Reim account for 57.59% of the surface area operated and 79.66% of the surface area rented.
144
Ramsay Santé / Universal Registration Document 2026
ANNUAL FINANCIAL INFORMATION Property and equipment
At the end of June 2026, the real estate portfolio in the Nordic countries also consisted mainly of rented sites: Owned
4,647 m2
i.e. 1.15%
Rental
2
397,754 m
i.e. 98.85%
Leased
2
0m
i.e. 0%
TOTAL
2
100%
402,401 M
2
2.6.2.4 Group property assets by type of holding At the end of June 2026, the Ramsay Santé group had a real estate portfolio with a net carrying amount of EUR 2,347 million, of which 18% corresponded to real estate sites owned outright, 2% to sites held under real estate leases, and
the remainder consisting of the net carrying amount of the construction work carried out at sites where the Group is a simple tenant and the rights of use are attached to operating leases.
CONSOLIDATED NET CARRYING VALUE OF THE RAMSAY SANTÉ GROUP NCA (in thousands of euros)
Percentage
423,228
18%
Rights of use attached to property leases
52,767
2%
Buildings on sites where the Group is a simple tenant
188,839
8%
Subtotal Net property assets owned or with a purchase option attached
664,834
28%
Rights of use attached to operating leases
1,682,879
72%
TOTAL PROPERTY ASSETS
2,347,713
100%
Nature of the right
Full ownership
2.6.3
The Group’s main movable equipment assets
The facilities have movable equipment, including radiotherapy and imaging equipment which falls under the category of major equipment. This equipment is either owned by the Group, leased or financed. In accordance with applicable
accounting standards, all of this heavy‑duty hospital equipment is fully recognised in the Group’s consolidated financial statements.
Ramsay Santé / Universal Registration Document 2026
145
2
ANNUAL FINANCIAL INFORMATION Property and equipment
2.6.4
Material investments made during the financial year ended 30 June 2026
During the 2025‑2026 financial year, the Group continued to restructure its portfolio of facilities, driven by a sustained investment programme to reorganise the care offer.
Clinique Saint Martin in Ollioules, which specialises in mental health, is also undergoing restructuring and extension work to increase its capacity and improve the care conditions.
The transfer of the chemotherapy activities from Clinique Drevon to the Valmy site made it possible to bring together all oncology care facilities at a single site and to increase patient capacity within a more efficient platform.
The Group continued to pursue its major programme of implementing new cross‑sectional imaging authorisations, with 11 pieces of equipment (six MRIs and five scanners) during the financial year, compared to 10 the previous year.
The commissioning of the third radiotherapy bunker at the IRHE centre in Bobigny in April 2026 confirmed the site’s role as a key player in oncology care in Seine‑Saint‑Denis. The installation of a third accelerator at the Peupliers radiotherapy centre is underway, supporting the specialisation of the technical platform and the evolution of oncology needs. The extension and renovation work at Clinique de la Recouvrance (mental health), completed at the end of 2025, has provided increased hospitalisation capacity and care spaces tailored to the needs of the region.
It is also continuing to equip its facilities with state‑of‑the‑art equipment, both for new installations and upgrades.
The Group also transferred the medical care and rehabilitation (MCR) activities of Clinique du Val de Lys to CSCO Lille in the summer of 2025, with a view to regional reorganisation and the streamlining of the technical platforms. Work is continuing on the restructuring of Hôpital Privé Drôme Ardèche to accommodate the medical and surgical activities of Clinique Générale de Valence, with the transfer of the MCR activities to Clinique La Parisière in Bourg‑de‑Péage.
146
Ramsay Santé / Universal Registration Document 2026
Another strategic area of development for the Group came to fruition with the opening of a new mental health day hospital in Alençon at the end of 2025. In summary, over the last 12 months, Ramsay Santé has spent EUR 193 million on its industrial investments, which can be broken down as follows: ■
■
EUR 144 million on maintenance, replacement of medical and technical equipment, as well as regulatory and safety compliance including EUR 23 million for projects to modernise information systems; EUR 49 million on capacity expansion and innovation projects.
ANNUAL FINANCIAL INFORMATION
2
Ramsay Santé / Universal Registration Document 2026
147
148
Ramsay Santé / Universal Registration Document 2026
3.1
RISK FACTORS
151
3.1.1 3.1.2
Sector risks Risks related to the Group’s own growth and strategy Financing and market risks Operational risks Risks for healthcare professionals Other risks identified in view of their particularities in the field of health
151
160
3.2
RISK MANAGEMENT
163
3.2.1 3.2.2 3.2.3
163 163
3.2.5 3.2.6 3.2.7
Internal control objectives and guidelines Risk mapping Internal control stakeholders and organisational framework within the Group General operation of internal control and procedures in place Management and monitoring of internal control Ramsay Santé Crisis Unit Quality initiatives within the Group’s facilities
165 168 168 169
3.3
COVERAGE OF RISKS
170
3.3.1 3.3.2 3.3.3 3.3.4 3.3.5
Civil liability insurance Property damage insurance Construction insurance Coverage of other risks Claims management
170 171 171 172 172
3.1.3 3.1.4 3.1.5 3.1.6
3.2.4
154 155 156 158
164
3
RISK FACTORS AND RISK MANAGEMENT
Ramsay Santé / Universal Registration Document 2026
149
3
RISK FACTORS AND RISK MANAGEMENT
The Ramsay Santé group is exposed to various risks which, even if they are addressed in a structured manner, may have an adverse effect on the Group, its reputation, its business, its financial position or its results. Investors are therefore encouraged to carefully review all the information in this chapter, which outlines the risk factors related to the Group’s business, before deciding whether to acquire or subscribe for Company shares. Based on risk mapping, the most material risks in terms of potential criticality (decreasing) and the treatment measures implemented are presented.
The Group’s risk identification process, overseen by the Risk Department, involves all of the Group’s key managers, including the members of the Executive Committee. The Company’s Board of Directors oversees this process with the support of (i) the Risk Committee, which comprises various officers (e.g. risk, crisis, human resources andIT systems) and examines the quarterly reports, including indicators used to monitor changes in the main risk categories and (ii) the Audit Committee, which specifically examines financial risks. The work of these two Committees is organised in accordance with the provisions of the internal regulations (1).
TABLE OF THE MAIN RISKS Risk category
Risk factors Risks related to the pricing of healthcare services
SECTOR RISKS
Risk related to the sensitive nature of obtaining and maintaining operating authorisations Risks related to obtaining and renewing contracts in Sweden
RISKS RELATED TO THE GROUP'S OWN GROWTH AND STRATEGY
Risks related to real estate or IT system projects Integration risks Risks related to the Group's debt and financing covenants
FUNDING AND MARKET RISKS
Interest rate risks Foreign exchange risks Risks related to high inflation in Western European countries
OPERATIONAL RISKS Risks related to healthcare activities Risks related to the recruitment of caregivers Risks related to the recruitment of practitioners RISKS FOR HEALTHCARE PROFESSIONALS
Risks related to labour relations Risks related to the recruitment of facility managers
OTHER RISKS IDENTIFIED IN VIEW OF THEIR PARTICULARITIES IN THE FIELD OF HEALTH
(1)
150
In this regard, see chapter 6 of this document.
Ramsay Santé / Universal Registration Document 2026
Cyber risk Risks related to regulatory changes
Change
RISK FACTORS AND RISK MANAGEMENT Risk factors
3.1
Risk factors
The Group operates in the field of public health, an area whose entry point mainly involves obtaining, maintaining and renewing authorisations or agreements subject to stringent regulations. These risks are classified as sector‑specific and arise from the significant predominance of these activities at Group level. These risks are dealt with first.
It is difficult to present the probability of occurrence and the impact on the Group with objective relevance due to the large number of facilities, their geographical distribution across Western Europe, their varying sizes and the various activities carried out within them, which makes any overall assessment difficult to interpret.
The risks are then categorised in a logical order for ease of reading, starting with the most significant risk in each category.
The Group believes that its strong geographical dispersion, backed by an economic and legal architecture chosen by the Group and reflected in the large number of subsidiaries, divided between operational and service or support entities, moderates these risks to a large extent.
3.1.1
Sector risks
Consequently, most of the Company's activities and those of its subsidiaries fall within the scope of regulations comprising a legal component (health law) and an economic component (pricing elements). This regulatory environment and the diversity of the Group’s locations generate risks that, despite
3.1.1.1
the Group's efforts to control them, may negatively impact its image, reputation, expenses or results. Strict compliance with the aforementioned frameworks is part of managing these risks.
Risks related to the pricing of healthcare services
The health policies in France, particularly the annual pricing policy, form part of the broader objective of controlling health expenditure and reducing public deficits. For several years, the financing of care by the country’s budget and hospital stay rates decreed in this context have been eroded. Medical protocols and instructions are under pressure to streamline the number of medical procedures, particularly affecting the volume of care offered by the Group’s facilities. Social Security may reduce or even eliminate reimbursement levels for certain treatments or drugs, meaning patients would pay a larger portion of the costs of medical care. Lastly, changes in healthcare pricing policies may lead to a reduction in public funding for patient admission and care, or the payment of public subsidies. This could have an adverse effect on the Group’s activity. Many reforms have been implemented during a transition phase, including those relating to mental health, medical care, and rehabilitation. The effects of these reforms are still being assessed, and others are being prepared by the supervisory authorities, such as reform of activity payment rates. Although the Group is committed to implementing measures to compensate for insufficient price reductions or increases in view of rising costs, it cannot guarantee that it will be able to bridge the gap between price changes decided by public authorities and increases in purchasing costs. At the same time, the steady growth of outpatient surgery is having an adverse effect on the revenue generated by hotel services, which are not covered by Social Security. In October 2025, the National Union of Health Insurance Funds decided to reduce full technical flat‑rate payments for undepreciated scanners and MRIs gradually, with this reduction being phased in until January 2027, when it will reach 12.6%. In January
2026, the government announced stability in tariffs for healthcare facilities in medicine, surgery and obstetrics. The delisting of a certain number of medical devices was also announced in January 2026. Given the political instability and the very high level of public debt in France (117.5% of GDP), the outlook for future changes in tariffs is currently rather unfavourable. The Court of Auditors recommends capping the annual national health insurance expenditure target (Objectif national des dépenses de l'assurance maladie – ONDAM) at between 2% and 2.5% per year (compared to 3.1% in 2026). In 2025, public hospitals' overall deficit remained high, representing 2.1% of revenue, or EUR 2.3 billion. The deficit of the 32 university hospitals amounted to around EUR 800 million. Lastly, a study by Roland Berger in April 2026 found that around half of private hospitals and facilities (46%) were in deficit. In the Nordic countries, negotiations must also be conducted with public authorities or private insurers to revise contractual rates. The outcome of these negotiations may be insufficient to cover the increase in costs. When contracts are renewed, they are subject to significant competition, with the price offered by competing operators being one of the criteria used by public authorities for decision‑making. The Group continuously analyses the performance of its facilities and business units, implementing global productivity actions and ad hoc remediation plans, such as service closures and activity transfers. The Group is also heavily involved in negotiations with hospital federations, other major players in the for‑profit private sector and various representative bodies.
Ramsay Santé / Universal Registration Document 2026
151
3
3
RISK FACTORS AND RISK MANAGEMENT Risk factors
3.1.1.2
Risks related to obtaining and maintaining operating authorisations
The operation of a clinic, hospital or medical centre requires authorisation from the ARS. This is necessary when creating any healthcare facility, converting or grouping care activities, installing major equipment (including its acquisition or change), changing the location of an existing facility, or renewing authorisations.
Clinique du Landy, both of which are part of the Ramsay Santé group. Such decisions by supervisory authorities force facilities to define a litigation strategy to defend their activities.
These authorisations are generally issued on the provision that the conditions of establishment and technical operating conditions are met, as well as the applicable procedures for assessing and controlling the quality of the services provided, as stipulated by the laws in force. A request to obtain or renew an authorisation may be refused. If such a refusal is contested, the facility may not be successful in presenting its case. Changes to the applicable rules, regulations or filing formalities may require investment or generate additional restrictions.
In Sweden, regions can review the authorisations granted to private healthcare groups to provide certain healthcare services to patients on a commercial basis (accounting for over 40 per cent of revenue). They may decide to withdraw some of these authorisations or replace them with contracts. This would result in a decrease in the Group's activity and results. This is currently happening in certain regions of Sweden, mainly Stockholm and Gothenburg. The Stockholm regional executive has therefore decided to review the “care choice” accreditations granted to private providers in certain specialities, such as psychiatry, ophthalmology, dermatology and geriatrics. This may ultimately result in a decrease in activity and results.
The supervisory authorities, and in particular the ARS, continuously control compliance with the technical operating and implementation conditions. The ARS may implement a procedure to suspend authorisations at any time in the event of non‑compliance, and may even withdraw the authorisation in question.
To prevent this risk, the Group has implemented a set of measures to ensure rigorous monitoring of control and quality procedures, overseen by the Quality Department in France in particular. Regular audits are carried out to ensure compliance with regulatory provisions and the proper application of the Group’s quality procedures.
Non‑renewal, suspension or limitation of activities, or withdrawal of operating authorisations, would lead to a drop in footfall, which could have an adverse effect. For example, the Île‑de‑France Regional Health Agency (ARS) reviewed authorisations for cancer treatment activities, particularly surgery and drug treatment, in line with the 2022 reform which strengthened requirements in terms of activity thresholds and implemented a grading system for care. Following the review, 117 establishments were authorised, eight fewer than before the reform. Six facilities did not obtain renewal, including Hôpital Privé Geoffroy Saint‑Hilaire and
In Sweden, each business unit monitors the key performance indicators defined in the contract and implements corrective measures if the actual performance falls below the target.
3.1.1.3
In certain cases, the Group’s network of facilities enables it to relocate activities if authorisations are lost.
Risks related to obtaining and renewing contracts in Sweden
The majority of revenue in Sweden comes from short‑term agreements signed with regional authorities following calls for tenders (accounting for more than 50% of revenue). Despite the care taken by Swedish management in responding to calls for tenders, and despite the Group’s excellent reputation for quality of care, it is still possible that a contract will not be renewed, or that a tender will not be won, if competitors present a more attractive offer to the public authorities. The contract for Saint Göran Hospital in Stockholm was renewed
152
More generally, the Group strives to maintain trusting relationships with public authorities, acting in the public interest while defending its own interests in all countries in which it operates. This involves making the necessary administrative appeals where appropriate.
Ramsay Santé / Universal Registration Document 2026
in October 2025, commencing in January 2026 and lasting eight years (with the possibility of extension for a further four years). Each business unit in Sweden constantly monitors the contract portfolio and anticipates contract renewals. The renewal of the contract portfolio is the subject of an ad hoc indicator in the quarterly report prepared by the Risk Department.
RISK FACTORS AND RISK MANAGEMENT Risk factors
3.1.1.4
Risks related to complex regulations applicable to healthcare activities
Extensive regulations govern the day‑to‑day creation, extension and operation of medical and care facilities. The installation and technical operating conditions frequently change. The applicable standards relating to health and safety, hospital facilities, personnel, medical equipment and devices, the preservation and communication of medical records, environmental protection, and the disposal of waste from care activities constitute a very large and complex regulatory framework. The Group cannot guarantee that all of its facilities comply fully with these regulations and standards. Changes in the nature, interpretation or application of these regulations could call certain practices into question, leading to changes in facilities, materials, equipment, personnel management or services offered. This could result in substantial expenses being incurred, investment programmes being modified or operating expenses rising.
3.1.1.5
To protect itself against the potential consequences of regulatory changes, the Group monitors regulations with the support of its central services and the help of specialised external consultants. This enables the Group to ensure that its activities comply with current legislation and anticipate significant changes in applicable regulations.
Risk of calling into question the invoicing of services
In France, the Social Security system, which covers most healthcare costs, can dispute invoices issued by healthcare facilities or occasionally claim reimbursement of benefits for various reasons. Such action by Social Security, which is keen to recover sums it considers to have been paid in error, can lead to temporary difficulties and expose the Group's facilities to defence and recourse expenses, or make it difficult for them to reimburse the requested amounts. Facilities may make regulatory interpretations on pricing that could be challenged by public authorities, who may require unfavourable adjustments. Disputes with the authorities regarding the calculation of sums payable, as well as audits relating to compliance with applicable laws, regulations and internal policies, may increase the cost and complexity of the Group’s invoicing processes. It should be noted that the so‑called 'T2A' controls resumed in France in autumn 2024, after a long period during which they were not carried out. The last controls took place in 2019, before the Covid‑19 crisis. As part of the campaign launched in 2025, the Group underwent six inspections in the first half of 2026. These
3.1.1.6
Specific constraints during major health crises in France, such as pandemics, epidemics, climatic episodes, crises or major floods, are also liable to affect operations and financial parameters. It should be noted that the economic impact of a potential pandemic could be greater due to the high debt of many countries and the difficulty of implementing a coordinated global policy in the current fragmented world. However, the management of patients in Western Europe who have recently been exposed to viruses without antiviral treatment (such as hantavirus, Andes virus and Ebola virus) is currently effective.
inspections covered inpatient and outpatient beds for the period from 1 March to 31 December 2024. In Sweden and Denmark, the public authorities (the regions) may also challenge the invoicing of certain services whose contractual conditions are subject to interpretation. Invoicing audits are currently underway at a number of primary care centres in Denmark ( Alles Laegehus). The Group has set up a local and central medical information organisation to reduce risk by implementing various measures, such as relevant coding of procedures, relaying best practices by the School of Medical Information Technicians (Technicien/Technicienne de l'Information Médicale – TIM) and monitoring standardised protocols. Medical experts are also available if necessary. In Sweden and Denmark, the Group actively and transparently collaborates with supervisory authorities in the event of a different interpretation of invoicing rules. It corrects the relevant practices if necessary and reinforces its internal control rules where appropriate.
Risks related to the dynamic, competitive environment
Competition from other hospitals and clinics, both public and private, as well as competition between private healthcare groups in general, could lead to the Group’s local facilities becoming unstable, or to oversupply resulting in a drop in volumes, or even negative trade‑offs by health authorities. Competition could also limit facilities' ability to attract patients or expand their businesses. In a context of significant disparities in size and coverage, Ramsay Santé is facing increased competition from the public hospital sector in France. This sector has benefited from several measures to raise caregivers' salaries, as well as a much higher increase in hospital rates in March 2024 than the
for‑profit private sector has experienced. The same is true in Sweden and Denmark, where the public sector is seeking to take over activities currently entrusted to the private sector, despite long waiting times for patients. To address the competitiveness of the public sector, the Group prioritises the attractiveness of its facilities. This involves efforts to ensure a sustained high level of investment, among other things. Thanks to its practitioners and qualified caregivers, it offers its patients high‑quality care within its facilities. The Group considers the continuous improvement of the quality and safety of care to be a strategic area for its development.
Ramsay Santé / Universal Registration Document 2026
153
3
3
RISK FACTORS AND RISK MANAGEMENT Risk factors
The Group also conducts dynamic sector monitoring to maintain an up‑to‑date view of market opportunities.
3.1.2
Risks related to the Group’s own growth and strategy
In order to present a coherent care offer, the Group has developed through individual or comprehensive initiatives to position or reposition its activities, as well as through external growth. Limited room for manoeuvre, technological developments and entry into new market segments – even though, in the context of public health, the term carries an economic connotation that would be reductive given the full
3.1.2.1
Restructuring existing real estate assets to implement new activities or improve the efficiency of existing ones can be complex and costly, particularly given the current high inflation in construction costs resulting from the health crisis. Similarly, finding real estate opportunities (for example, for the creation of mental health day hospitals in city centres) can be challenging, whether for lease or acquisition, and may delay the implementation of health authorisations that would strengthen the Group’s care offer. This could also lead to significant costs that would undermine the expected results. The Group also has to contend with new digital competitors that are becoming increasingly active in the healthcare sector. It must ensure that it provides patients and partners with digital solutions that facilitate the care pathway while guaranteeing safety. This involves implementing digital projects and modernising IT systems, for which interoperability is essential. These projects are often complex and require specialised, scarce resources; constant attention to data protection and information system security; and costly investments. These projects carry inherent implementation risks in terms of costs and duration, and failure is always possible, which could have a significant impact on the rollout of the Group’s strategy.
Ramsay Santé has a Real Estate Department in France comprising competent and experienced project managers. The department uses a proven project management methodology, and a project management team (including an architect and a technical design office) is assigned to each major project to minimise design and execution risks. Real estate project management is subject to a specific control procedure (section 3.2.4.4). In Sweden, most large‑scale real estate projects are managed by lessors. Similarly, each IT Systems Department implements a project portfolio management methodology based on the Group’s strategic and operational priorities, enabling better resource allocation. Major projects are managed in a highly structured way, with dedicated resources for the contracting authority to ensure that solutions meet the needs identified by business lines, and for project management. These projects are governed by a Steering Committee, which typically includes members of the Group’s Executive Committee to ensure strategic alignment. In France, the IT Systems Project Portfolio Review Committee regularly meets to identify priority projects at Group level and make decisions regarding priorities.
Integration risks
Synergies and other benefits are expected with each acquisition. However, if these synergies and benefits do not materialise as planned, or if the Group fails to integrate operational processes and IT systems, retain practitioners or key personnel, or respond to unforeseen events, circumstances, litigation or legal obligations due to legal or regulatory constraints, or a negative reaction from patients or
154
range of issues at stake – give rise to risks in terms of strategic ambition and implementation. Despite rigorous reviews of operations such as acquisitions or restructurings, prospects for internal or external growth could be limited due to changes favouring models that differ from those developed by Ramsay Santé or due to high costs. New constraints could also hinder development.
Risks related to real estate or IT systems projects
In some cases, the implementation of the Group’s strategy is based on real estate or IT system projects.
3.1.2.2
Lastly, the Group constantly analyses the performance of its facilities and business units, adapting to the competition by taking the necessary actions to obtain new authorisations, develop new activities, and improve the effectiveness of its care offering. Conversely, it may also close services or discontinue certain activities.
Ramsay Santé / Universal Registration Document 2026
suppliers following a major acquisition, the Company may not fully achieve its objectives. Therefore, Ramsay Santé cannot guarantee that synergies will exist or be achieved within the provided timeframe, as the potential achievement and extent of expected synergies depend on factors and assumptions, some of which are beyond its control.
RISK FACTORS AND RISK MANAGEMENT Risk factors
The Group’s ability to achieve the expected cost synergies could be affected by one or more of the risks relating to its activity, as described in this document. Additionally, the costs incurred in achieving the synergies could exceed expectations, or additional unforeseen costs could arise, reducing shareholder value. Failure to achieve the expected synergies or control cost increases in this context could have a material adverse effect on Ramsay Santé’s activities, operating profit, financial position and outlook.
3.1.2.3
The Group establishes ad hoc organisations tailored to the challenges posed by acquisitions. The Group’s management monitors integration operations and results in relation to the acquisition business plan. Additionally, Ramsay Santé pays particular attention to disseminating the Group’s common values to all stakeholders, including practitioners, facility managers, employees, patients, administrations and suppliers.
3
Risks related to external growth transactions
The Group’s strategy hinges on its ability to identify suitable acquisition targets, conduct relevant audits, develop profitability assumptions, negotiate favourable terms and conditions for transactions, and integrate acquired facilities into the Group. As well as the risk of failing to identify attractive targets or of carrying out planned transactions on favourable terms and conditions (particularly financial terms), the Group may face competition for targets that meet its criteria. Furthermore, an external growth transaction may require an opinion or authorisation from the competition authorities due to the market share that the transaction would represent. If the procedure is unsuccessful, for example if the authorities refuse to give a favourable opinion on the transaction, this could negatively affect the Group’s activity, financial position
and operating profits. Acquired facilities may not always align with the Group’s quality requirements, organisational standards or expected profitability ratios. Similarly, integration actions and associated costs or expected savings may require more time or protocols to be reviewed. The Group continuously monitors sector and regulatory plans, seeks appropriate advice, and maintains an ongoing dialogue with stakeholders. Each strategic plan undergoes a structured development process that takes into account major changes in the business sector and geographic markets. Transactions involving external growth are subject to strict review and control procedures, with validation at the highest level of the Company (see section 3.2.4.3).
3.1.3
Financing and market risks
3.1.3.1
Risks related to the Group’s debt and financing covenants
A detailed description of the Group’s debt and financing is provided in section 2.4 of this document. The Group’s financing agreements contain certain stipulations that could limit its financial and operational flexibility. In particular, they may: ■
■ ■
Regulate the completion of certain transactions, including acquisitions, investments, asset disposals, restructuring operations and capital transactions; Regulate the use of new financing, as well as the granting of collateral or guarantees; Provide for the allocation of certain cash flows to debt repayment, thereby reducing the resources available for other uses.
In addition, the Group’s financing agreements contain standard clauses that restrict its operational freedom. These clauses primarily relate to collateral and the completion of acquisitions or investments, as well as limiting the Group’s ability to take on additional financial debt, grant loans and dispose of assets. The agreements also contain clauses for
mandatory early repayment or repayment at the lender’s initiative (notably in the event of a change of control or asset disposals), as well as accelerated early repayment clauses for certain events. The Group regularly monitors compliance with financial commitments and repayment deadlines to anticipate financing needs and maintain an appropriate level of liquidity. The Group also diversifies its sources of financing and extends and renegotiates its financing terms depending on market opportunities. Following the close of the financial year on 30 June 2026, the Group undertook several financing operations, primarily focused on refinancing and extending the maturity of its debt (see section 2.4.3 ‘Main new financing put in place’ of this document). On 22 July 2026, Ramsay Générale de Santé entered into a new senior credit agreement totalling EUR 1.75 billion. This included a term tranche of EUR 1.55 billion (Facility B) and a revolving credit facility of EUR 200 million.
Ramsay Santé / Universal Registration Document 2026
155
3
RISK FACTORS AND RISK MANAGEMENT Risk factors
This new financing enabled the refinancing of the Group’s existing debt: Facility B (EUR 1.45 billion), a Capex/Acquisition line (EUR 100 million), a revolving credit facility (EUR 100 million) and two Euro PP bonds (EUR 100 million). This operation strengthens the Group’s financial flexibility, extending the maturities of its senior debt from 2031 to 2033, while also simplifying its financing structure. It also proactively preserves the continuity and stability of the Group’s financing with a change‑of‑control clause that is now compatible with the distribution envisaged by RHC.
3.1.3.2
Interest rate risks
Due to its variable‑rate debt, the Group is exposed to the risk of changes in interest rates. To mitigate this risk, the Group uses standard interest rate hedging instruments, primarily interest rate swaps, caps and floors. This approach qualifies its hedging instruments as cash flow hedges in accordance with IFRS 9. As of 30 June 2026, the notional amount of the hedging instruments represented approximately 76% of the outstanding amount of EUR 1,465 million of the relevant debt, including the €15 million drawn down from the Capex facility.
3.1.3.3
Based on the hedging instruments in place on 30 June 2026, an increase of 100 basis points in interest rates would lead to an increase in financial expenses of around EUR 3.5 million
Ramsay Health Care
Demerger Booklet Distribution of Securities in Ramsay Santé by Ramsay Health Care
VOTE IN FAVOUR Each Ramsay Director recommends that Ramsay Shareholders vote in favour of the resolutions to approve the Demerger of Ramsay Santé. The Independent Expert has concluded that, in the absence of a superior proposal, the Demerger is in the best interests of Ramsay Shareholders.
This is an important document and requires your immediate attention. You should read this document in its entirety prior to deciding whether or not to vote in favour of the resolutions to approve the Demerger. If you are in any doubt as to what you should do, you should seek independent legal, financial, taxation or other professional advice before voting on the Demerger.
Financial Adviser
Legal Adviser
Important information General This Demerger Booklet is important. Ramsay Shareholders should carefully read this Demerger Booklet in its entirety before making a decision as to how to vote on the Demerger Resolutions to be considered at the General Meeting and the Scheme Meeting.
Investment decisions The information contained in this Demerger Booklet does not constitute financial product advice and has been prepared without taking into account the individual investment objectives, financial situation or needs of any particular Ramsay Shareholder or any other person. The information in this Demerger Booklet should not be relied upon as the sole basis for any investment decision. Ramsay Shareholders should seek independent legal, financial, taxation and other professional advice before making any investment decision.
Purpose of this Demerger Booklet This Demerger Booklet sets out the effects of the Demerger, certain information required by law and all other information known to the Ramsay Directors which is material to the decision of Ramsay Shareholders to vote in favour of, or against, the Demerger Resolutions to effect the Capital Reduction and the Scheme (other than information previously disclosed to Ramsay Shareholders) and includes: • a statement of all the information known to Ramsay that is material to Ramsay Shareholders in deciding how to vote on the Capital Reduction Resolution, as required by section 256C(4) of the Corporations Act; and
tax, goods and services tax and stamp duty implications of the Demerger for Ramsay Shareholders who, amongst other things, are residents of Australia for Australian income tax purposes.
Status of this Demerger Booklet
A copy of this Demerger Booklet has been lodged with ASIC in accordance with section 256C(5) of the Corporations Act and registered by ASIC under section 412(6) of the Corporations Act. ASIC has been requested to provide a statement in accordance with section 411(17)(b) of the Corporations Act, that ASIC has no objection to the Scheme. If ASIC provides that statement, it will be produced to the Court at the time of the Second Court Hearing.
This Demerger Booklet is not a prospectus lodged under chapter 6D of the Corporations Act. Section 708(17) of the Corporations Act provides that chapter 6D of the Corporations Act does not have effect in relation to any offer of securities if it is made under a compromise or arrangement under part 5.1 of the Corporations Act, approved at a meeting held as a result of an order made by the court under section 411(1) or (1A) of the Corporations Act.
Neither ASIC nor any of its officers takes any responsibility for the contents of this Demerger Booklet.
Foreign jurisdictions and shareholders and Selling Shareholders
Role of ASX Neither ASX nor any of its officers takes any responsibility for the contents of this Demerger Booklet. The fact that Ramsay Santé Securities may be listed on the ASX does not make any statement regarding, and should not be taken in any way as an indication of, the merits of an investment in Ramsay Santé.
Important notice associated with Court order under section 411(1) of the Corporations Act
• the explanatory statement, as required by section 412 of the Corporations Act, in relation to the Scheme. The Demerger is conditional on (amongst other things) both of the Demerger Resolutions being passed. Information regarding the Demerger Resolutions is set out in the Notices of Meeting in Section 12.
• has formed any view as to the merits of the Scheme or as to how Ramsay Shareholders should vote (on this matter Ramsay Shareholders must reach their own decision); or
This Demerger Booklet (other than the Independent Expert’s Report and the Investigating Accountant’s Report) has been prepared by Ramsay as at the date of this Demerger Booklet and Ramsay is responsible for the content of this Demerger Booklet. Deloitte Corporate Finance Pty Limited has prepared the Independent Expert’s Report and takes responsibility for that report. A copy of that report is set out in Section 7. Ernst & Young has prepared the Investigating Accountant’s Report and takes responsibility for that report. A copy of that report is set out in Section 6. PricewaterhouseCoopers has reviewed and agrees with Section 5 relating to the description given of the Australian income
ii
The Notices of Meeting are set out in Section 12.
Role of ASIC
The fact that under section 411(1) of the Corporations Act the Court has ordered that the Scheme Meeting be convened and has approved the explanatory statement contained in this Demerger Booklet required to accompany the Notice of Scheme Meeting does not mean that the Court:
Preparation of and responsibility for this Demerger Booklet
Notices of Meeting
• has prepared, or is responsible for the contents of the explanatory statement contained in this Demerger Booklet.
Notice of Second Court Hearing At the Second Court Hearing, the Court will consider whether to approve the Scheme following the vote at the Scheme Meeting. Any Ramsay Shareholder may appear at the Second Court Hearing, expected to be held at the Supreme Court of New South Wales in Sydney on 27 November 2026 at 9.15am. Any Ramsay Shareholder who wishes to oppose approval of the Scheme at the Second Court Hearing may do so by filing with the Court and serving on Ramsay a notice of appearance in the prescribed form together with any affidavit that the Ramsay Shareholder proposes to rely on.
Ramsay Health Care Limited Demerger Booklet
Ramsay Shareholders who are Ineligible Overseas Shareholders will not receive Ramsay Santé Securities under the Demerger. Ramsay Santé Securities that would otherwise be transferred or issued under the Demerger to Ineligible Overseas Shareholders and to Small Shareholders who did not opt-out of the Sale Facility and the Ramsay Employee Equity Trustee (such Small Shareholders and the Ramsay Employee Equity Trustee also referred to in this document as Selling Shareholders), will be transferred or issued to the Sale Agent to be sold under the Sale Facility, with the net proceeds of such sale to be paid to Ineligible Overseas Shareholders and Selling Shareholders. Refer to Section 4.9
75
177
Important information The information in this report is general information only and is not intended to be relied upon as advice to investors or potential investors. It does not take into account your objectives, financial situation or needs. Investors should consult with their own legal, tax, business and/or financial advisers in connection with any investment decision. Past performance information should not be relied upon as (and is not) an indication of future performance.
About this report
Forward looking statements This report contains forward-looking statements in relation to Ramsay Health Care Limited (Ramsay) and its subsidiaries (together the Group), including with respect to the Group’s business and operations, financial position, and strategies. This report also includes forward-looking statements regarding climate change and other sustainability issues for Ramsay, including the Group’s resilience under climate scenarios.
We have used this framework to outline the key value drivers of the business performance, the Company’s strategy and the key trends driving it and the risks and opportunities around achieving the strategy. Ramsay is committed to progressing the United Nations Sustainable Development Goals (SDGs) and we have mapped our priority goals to our material sustainability issues (page 16). Further information on our sustainability performance is contained in our FY26 Sustainability Data Book available with our FY26 online annual reporting suite.
While these forward-looking statements reflect Ramsay’s expectations at the date of this Report, they are not guarantees or predictions of future performance or statements of fact. These statements involve known and unknown risks and uncertainties. Many factors could cause outcomes to differ, possibly materially, from those expressed in the forward-looking statements. These factors include: • general financial and economic conditions in various countries, including Australia, England, Wales, France, Sweden, Denmark, Norway;
This report has been designed to be read in its entirety and in conjunction with the Financial Statements in Section 5. This is the fourth year that the Annual Report has been prepared with reference to the Value Reporting Foundation’s Integrated Reporting Framework.
View our annual reporting suite ramsayhealth.com/en/investors/results-and-reports/
• operating results; • changes in private health insurer indexation and/or pricing;
Key dates As at 24th September 2026
• industry competition, fluctuations in actual demand and/ or loss of market share for Ramsay’s healthcare services; • legislative, fiscal and regulatory developments, including: – changes in government and/or government policy, including funding decisions and actions by the UK Government in relation to the NHS; and – other actions of regulatory bodies and governmental authorities such as changes in taxation and interest rates set by central banks; • technological changes, including pace of adoption of new technologies; • the extent, nature and location of physical and transitional impacts of climate-related risks; and • geopolitical developments, including political risks and the impact of armed conflict and political instability (such as the ongoing conflicts in Ukraine and in the Middle East) on economic activity and supply chain disruption to clinical and non-clinical products supplied to the Ramsay Group. Ramsay makes no representation, warranty, assurance or guarantee as to the accuracy, completeness or likelihood of fulfilment of any forward-looking statement, any outcomes expressed or implied in any forward-looking statement or any assumptions on which a forwardlooking statement is based. To the maximum extent permitted by law, Ramsay and its officers do not accept any responsibility for the accuracy or completeness of any forward-looking statements, whether as a result of new information, future events or results or otherwise. In addition, there are limitations with respect to scenario analysis, including any climate-related scenario analysis, and it is difficult to predict which, if any, of the scenarios might eventuate. Scenarios do not constitute definitive or probable outcomes and they rely on assumptions that may or may not prove to be correct or eventuate, and scenarios may be impacted by additional factors to the assumptions disclosed. No undue reliance Except as required by applicable laws or regulations, the Ramsay Group does not undertake to publicly update, review or revise any forward-looking statements or to advise of any change in assumptions on which any such statement is based. Readers are cautioned not to place undue reliance on forward-looking statements. Non-IFRS financial information In this report, references to AASB are to the Australian Accounting Standards Board and IFRS to the International Financial Reporting Standards. There are references to IFRS and non-IFRS (non-statutory) financial information in this report. Non-IFRS financial measures are financial measures other than those defined or specified under any relevant accounting standard and may not be directly comparable with other companies’ information, although Ramsay considers these measures provide useful information in relation to the Group’s performance. Non-IFRS information is unaudited, however the numbers have been derived from the underlying financial information used in the preparation of the audited financial statements.
Annual General Meeting 2026 The 2026 Annual General Meeting will be held on Tuesday 24 November at 10:00am in the Grand Ballroom in the Fullerton Hotel Sydney. Full details will be available in Ramsay’s Notice of Meeting.
Ramsay Santé demerger The shareholder meetings to approve the in-specie distribution of Ramsay Santé shares will be held on Tuesday 24 November 2026, immediately after the 2026 AGM. Full details will be available in the demerger booklet. Note: Both the AGM and the meeting to approve the in-specie distribution will be on the same day, Tuesday 24 November.
Indicative Key Dates for 2027 Results Release Dates
Dividend Payment Dates – Ordinary Shares
Dividend Payment Dates – CARES
Interim Results: Thursday 25 February
Interim Dividend: Thursday 25 March (record date 4 March)
Tuesday 20 April (record date 1 April)
Preliminary Final Results: Thursday 26 August
Final Dividend: Wednesday 29 September (record date 8 September)
Monday 20 October (record date 29 September)
Annual General Meeting 2027 The 2027 Annual General Meeting of Ramsay Health Care Limited is scheduled to be held on 23 November 2027. Full details will be provided closer to the date.
Ramsay Health Care Annual Report 2026
3
1 Year in Review 2026 Highlights Group Financial Highlights
Operational Highlights
$18.6bn
+3.3%
Revenue from contracts with customers +4.2% (cc)
Increase in hospital admissions in Australia (excl. Peel Health Campus and Border Cancer Hospital)
$364.1m
~+90bps
Underlying NPAT excluding non recurring items +22.9% (cc)
In utilisation of Australian treatment capacity while we added 22 new theatres/ procedure rooms
$329.2m
$150m
NPAT attributable to owners of the parent +1,284% (cc)
Invested in development projects in Australia focused on procedural capacity in major hospitals in growth corridors
91cps
70+ NPS
+13.8% Fully franked full year dividend
High NPS in Australia, France, Sweden and Ramsay UK
4
Ramsay Health Care Annual Report 2026
Year in Review
Ramsay Cares Highlights
Our Business
51% Sustained 50/50 gender balance across our senior leadership.
Financial Performance
31%
6.5m
Financial Results
Generated more than 6.5m kWh from 6.6MW of onsite renewable energy projects.
Additional information
80% Achieved FY26 sustainability assessment target, by assessing 80% of suppliers (by share of global spend) through independent services.
Ramsay Health Ramsay HealthCare CareAnnual AnnualReport Report2026 2026
Governance
Exceeded FY26 target to reduce greenhouse gas emissions by 25% from 2020 baseline. On track for 42% reduction by FY30.
5
1.1 Message from the Chair
Members of the Board and Group Executive Leadership Team at the recently upgraded Joondalup Private Hospital Campus
Dear Shareholder, FY26 was a period of positive change for Ramsay, as we continue to transform our business in Australia and simplify our portfolio to improve capital returns. In July 2025 we implemented a new operating model streamlining the Group and Australian executive structures, to support our focus on the transformation of the Australian business, bringing significant experience to the leadership team from both the healthcare sector and other industries. The new Group Executive has moved quickly to build out our capability in key areas including commercial and national operational excellence. It is pleasing to see the positive momentum across the business and while there remains a lot to do and the macro environment remains difficult, we are seeing the benefits of our initiatives starting to flow through to earnings.
The Board is pleased to determine a fully franked final dividend of 48.5 cents per share (cps) an increase of 21.3% on the pcp taking the full year dividend to fully franked 91.0 cps. This represents a full year payout ratio from underlying net profit after tax of 60.3%.
FY26 Financial Performance
De-merger of Ramsay Santé
Ramsay reported a Net Profit after Tax and non-controlling interests of $329.2m, a significant improvement on the prior corresponding period (pcp). This primarily reflects EBIT growth in Australia and both UK businesses.
During the year we have worked closely with our advisors to progress the evaluation of strategic options for our 52.8% shareholding in Ramsay Santé. This work culminated in an announcement in February that we intended to move forward with a proposal to separate Ramsay Santé from Ramsay through an in-specie distribution of Ramsay’s shareholding in Ramsay Santé to our shareholders. The separation is subject to Ramsay shareholders voting in favour of the proposal at a scheme meeting to be held on 24 November 2026.
The Australian business reported an 11.2% increase in underlying EBIT driven by activity growth, higher levels of acuity and theatre utilisation, improved Private Health Insurance indexation and cost management. The UK Acute hospital business reported a 10.3% (cc) increase in Underlying EBIT, with the impact of lower NHS volumes, as a result of UK Government budgetary constraints, offset by a focus on higher acuity and private work, and the contribution from operational initiatives. Elysium's performance turnaround plan is underway and beginning to gain traction, including central cost reduction, agency reduction, site optimisation and fee uplifts. Elysium was also impacted by reduced NHS demand for overnight care settings.
6
Ramsay Health Care Annual Report 2026
Ramsay Santé reported a reduced underlying loss after minority interests despite a €20m reduction in French government subsidies and the continued inadequacy of French hospital tariff indexation (+0.5% for 2025 and ~0% for 2026) relative to cost inflation. Performance improvement initiatives, focused on cost efficiencies, have partially mitigated these negative impacts. The Nordics business reported another good result reflecting activity growth and the benefits of the new St Göran eight-year contract.
The proposal to separate recognises the fundamentally different geographic focus, strategies and capital profiles of Ramsay and Ramsay Santé. The Board believes that a separation will support shareholder value over time through: • Simplification of Ramsay portfolio, enabling management to focus on transformation and growth potential of its core Australian hospitals business • Simplification of Ramsay’s reported financial profile through deconsolidation of Ramsay Santé from Ramsay’s financial statements
• Limited separation complexity, given Ramsay Santé already operates independently of Ramsay including separate financing and balance sheet arrangements • Opportunity for Ramsay shareholders to retain ownership interest in Ramsay Santé
Board Update
In FY27 we will see further changes to the Board, with founding Director Michael Siddle retiring following the conclusion of the 2026 Annual General Meeting, combined with Dr Claudia Süssmuth Dyckerhoff’s retirement effective on 31 August 2026 and the appointment of Dr Tracey Batten from 1 January 2027.
• The transformation of our market leading Australian hospital business; • Strengthening our capital discipline and improving capital returns across the portfolio; and • Evolving our culture of people caring for people to innovate and drive performance. Over the next two months we will continue working towards the proposed separation of Ramsay Santé and, subject to shareholder and regulatory approval, aim to deliver a positive outcome for Ramsay shareholders.
Thank You I would like to say thank you to all our people for their commitment to supporting and caring for our patients and the communities in which we serve. It is our teams both on the frontline and supporting our business, who ensure that our culture and values prevail in everything we do. We also appreciate the close working relationship we have with our doctors who care for our patients. Lastly and importantly, thanks also to my fellow directors and importantly our shareholders for your ongoing support. Sincerely,
David Thodey
Additional information
In January 2027, we are pleased to be welcoming Dr Tracey Batten to the Board, as a Non-Executive Director. Dr Batten brings over 30 years' experience in the healthcare sector gained in non-executive and executive roles, and medical practitioner and clinical roles. Further information about Tracey’s experience is available in the ASX Announcement dated 24 September 2026.
In FY27, together with the senior management team, the Board remain committed to delivering on our three priorities:
Financial Results
In August 2026, we farewelled Claudia Süssmuth Dyckerhoff. Claudia who joined the Ramsay Board in October 2018 and has served as a member of the Risk Management Committee. Claudia’s health industry insights and expertise have strengthened Ramsay’s governance and oversight processes, particularly in relation to risk management.
In FY27, we expect the Funding Group1 to deliver another year of underlying EBIT growth and margin improvement, supported by EBIT growth across Australia and both UK businesses. Our focus remains on strengthening cash flow, maintaining capital discipline across all businesses to improve returns, and successfully integrating National Capital Private Hospital in Canberra following completion of the acquisition at the end of August 2026.
On behalf of the Board, I want to thank Michael and Claudia for their dedication, commitment and service to Ramsay and wish them well for the future.
1
Governance
Michael’s journey started with Ramsay in 1968 and, since then, he has made immense contributions to Ramsay. Michael has been a Director since 1975, having served as Chairman from 2014 to 2023, and previously as Deputy Chaiman for 17 years. Michael’s expertise and deep insight into the private hospital industry have played a significant role in bringing Paul Ramsay’s vision to life and shaping Ramsay into the Company that it is today. I encourage shareholders to attend our 2026 AGM, where we will have the opportunity to express our gratitude and best wishes to Michael.
Priorities and Outlook
Financial Performance
We continually review and evaluate the Board’s composition to maintain a balanced mix of skills, experience and perspectives, so that the Board is well placed to guide Ramsay in a dynamic environment. FY26 was a year of change, as announced last year, we welcomed Craig Drummond to the Board and as a member of the Audit Committee in July 2025 and farewelled James McMurdo from the Board in November 2025.
The Board maintains an active program of visiting our sites and speaking directly to our people and clinicians. These direct interactions provide valuable insights into how Ramsay’s values are reflected in daily practice and influence the delivery of patient care. In FY26, this included four days in Perth, where the Board was joined by the Group Executive team and spent time at Joondalup Health Campus, including visiting the public Emergency Department and the recently upgraded private hospital, and spending time with some of our doctor partners and team at the largest hospital in Ramsay’s portfolio, Hollywood Private.
Our Business
Preparation for the de-merger is on track, shareholders will receive further information, including instructions on how to lodge your vote, in October 2026.
Ramsay remains dedicated to upholding strong corporate governance and reinforcing our culture, values and principles. During FY26, Ramsay updated the charters of its Board and our four standing Board Committees and several policies, including our Code of Conduct, to align with contemporary market and company practices. Further information is available in the FY26 Corporate Governance Statement.
Year in Review
• Improved focus for Ramsay Santé, an already established, independently managed and publicly listed business, to continue to pursue its European focused strategy and transformation
Corporate Governance
Funding Group - Australia and the UK only
Ramsay Health Care Annual Report 2026
7
1.2 Message from the CEO
Ramsay Chair David Thodey and Managing Director and CEO Natalie Davis with Anniee O’Doherty, Deputy Director Clinical Services, Joondalup Health Campus and Hollie Stein a graduate nurse in Obstetrics and Gynaecology
Dear Shareholder, I am pleased to report that FY26 has been a good year for Ramsay, with progress against our strategic priorities, with transformation accelerating in our Australian business, and performance and returns on capital improving across the Group. First and foremost, I would like to acknowledge our incredible people and clinicians for their dedication to providing outstanding care for our patients, which is reflected in our high patient NPS scores and clinical excellence in every region. FY26 Group Financial Performance Our financial results reflect the momentum building across the business and the impact of our strategic initiatives, with all three regions reporting improved underlying financial performance. Group revenue from customers grew by 4.2% (cc) to $18.6 billion, including strong 8% growth in Australia, benefiting from improved utilisation of our facilities, increasing case acuity in priority therapeutic areas and improved revenue indexation. A focus on operating efficiency and transformation in each region resulted in Group underlying EBIT increasing by 11.8% (cc) and underlying net profit after tax and non-controlling interests increasing by 22.9% (cc). The Funding Group, which comprises our UK and Australia businesses, reported a 12% (cc) increase in underlying EBIT, and 17.9% (cc) increase in underlying net profit after tax and non-controlling interests. Group reported net profit after tax and non-controlling interests was $329 million, a significant improvement on the prior year. We have strengthened capital discipline, focusing growth and development capex on expanding procedural capacity in Australia, reflected in Group ROIC improving by 30bps to 4.6% and Funding Group ROIC improving by 60bps to 6.3%.
8
Ramsay Health Care Annual Report 2026
Our focus on performance improvement initiatives and cash conversion has seen Australia and both UK businesses deliver positive net cashflow for the period, with Funding Group leverage improving to less than 2.0x. The Board has determined a final fully franked dividend of 48.5 cents per share, an increase of 21.3%, taking the full year dividend to 91 cents per share, up 13.8% on the prior period and representing a payout ratio of 60.3% of underlying earnings. Delivering on our Priorities Last year, I outlined three key priorities for the business:
- The multi-year transformation of our market-leading Australian hospital business;
- Strengthening capital discipline and improving returns across the portfolio; and
- Evolving our culture to innovate and accelerate delivery. I am pleased to report that we have made good progress against each of these priorities, with our strengthened Group Executive team adding capability in key commercial and operational areas and enabling us to accelerate the pace of our transformation. In our Australian business, we are transforming the business behind our 'Big 5' hospital operations improvement initiatives; • Our strategic focus on Growth powered by enhanced data insights has delivered activity growth in high-acuity and priority therapeutic areas and improved theatre utilisation. • A focus on Procurement initiatives has driven margin expansion through better hospital product purchasing decisions and the standardisation of non-clinical services including dining. • The Revenue Cycle Management initiative has driven improved cash collections and we have developed a
transformation roadmap to guide the standardisation and automation of our administrative and cash collection processes.
continued partnerships with universities to support future medical workforce pathways and student development.
• We have implemented a range of programs to strengthen our Workforce, resulting in record graduate recruitment and targeted hiring across the business to reduce agency use. The rollout of our smart rostering technology solution is underway and should enable greater employee flexibility and improve roster effectiveness when complete; and
Clinical excellence and innovation remain key drivers of Ramsay’s strategy across all regions to improve patient outcomes, enhance the patient and clinician experience and strengthen long-term healthcare sustainability. Key quality metrics in Australia during the year were above sector averages, including 44% fewer unplanned re-admissions within 28 days.
• We continue to invest in our technology platforms to enable our hospital operations, including upgrading our Patient Administration System. We are also carefully exploring AI use cases to improve our administrative processes.
Importantly, we are also well progressed with our proposed separation of Ramsay Santé, which is on track for completion in late 2026, subject to a shareholder vote in November and regulatory approvals. We believe the demerger will support longterm value creation for Ramsay shareholders.
Investing in Our People, Clinical Excellence and Innovation Across all our regions, Ramsay’s people continue to deliver high-quality care. In FY26, Ramsay focused on strengthening leadership capability, improving employee experience, supporting well-being and creating more connected workplaces.
We delivered more than 1.2 million student placement hours in our Australian hospitals and recruited more than 770 nursing and midwifery graduates, half of whom had completed a Ramsay hospital placement.
In the UK, apprenticeships continue to support workforce development across clinical and operational roles, with more than 170 apprentices undertaking programs ranging from nursing to healthcare support and digital capability. Ramsay UK also
I am proud of the progress we have made this year to continue the transformation of our Group. Looking ahead to FY27, our positive momentum is expected to continue, we expect EBIT growth in Australia and the UK. On 1 September 2026, we announced the completion of the acquisition of National Capital Private Hospital in Canberra and welcomed the team and clinicians to Ramsay. National Capital has a long-standing reputation for clinical excellence, and we will build on this foundation to continue to innovate and grow the hospital’s services. We will continue to build on Ramsay’s clinical excellence in Australia for the benefit of our patients, by investing in clinical innovation and connecting hospital and healthcare services in our priority therapeutic areas – cardiology, orthopaedics and cancer care, to be Australia’s most trusted leading healthcare provider. The Group Executive will host an investor day on 30 November 2026, we look forward to sharing our progress and plans as we continue to evolve Ramsay for the future and grow long term shareholder value. Finally, I would like to thank our people and clinicians once again for their unwavering commitment to providing excellent care to our patients, and to you our shareholders for your ongoing support. Sincerely
Additional information
The Ramsay Australia Leadership Academy had 333 leaders participate across 17 cohorts in FY26. In addition to our Leadership Academy, we have developed a 6-month intensive clinical leadership development experience, the Nurse Leaders of Tomorrow program, focusing on operational, financial and strategic aspects of leading in healthcare. We had 25 nurses graduate in FY26.
Outlook
Financial Results
We also expanded the Professional Pathways Program, designed to strengthen nursing workforce pipelines and support nurses transitioning into acute clinical practice. More than 150 nurses were recruited across 17 sites during the first phase of the program, with strong participant feedback and further recruitment planned across.
Importantly, our disclosures outline key climate-related risks and opportunities over the short, medium and long-term and also our key decarbonisation levers as part of our transition planning. We are making good progress against our 2030 Scope 1 and 2 greenhouse gas (GHG) emission targets and 2028 supplier engagement targets.
Governance
In Australia, we have been focusing on listening to employees and responding to feedback with visible action. This included local engagement initiatives, leadership development, new digital communication channels and practical improvements to support employees in their day-to-day work.
This year we updated our climate disclosures to align with the requirements under the new Australian Sustainability Reporting Standards.
Financial Performance
Pleasingly, we progressed our transformational initiatives while building on our culture of ‘people caring for people’ and maintaining high patient NPS scores and clinical excellence across the Group. Our focus is always on maintaining our high clinical and safety standards and we have continued to invest in these throughout the year.
Sustainability
Our Business
Our focus on strengthening capital discipline and improving capital returns across the portfolio has resulted in the Funding Group return on capital employed improving by 150bps to 14.8%. Our UK businesses and Ramsay Santé delivered growth in underlying EBIT through operational improvements, mitigating funding headwinds.
In Australia the Ramsay Research and Development Network continued to grow with a presence at 22 sites and a 28% increase in activity in FY26, bringing leading clinical innovation to patients across our network.
Year in Review
The strong performance of our Australia business was supported by improved indexation from our private health insurer payors. During the year, we signed a new partnership agreement with one of our major insurers, which will enable us to focus on collaborating to strengthen our private health proposition.
Ramsay continues to invest in clinical leadership, advanced technologies, research capability and innovative models of care. These investments are supporting greater access to healthcare, expanded clinical capabilities, improved operational efficiency and reinforcing Ramsay’s position as a leader in delivering high-quality, patient-centred care in its key markets.
Natalie Davis Managing Director and Group CEO
Ramsay Health Care Annual Report 2026
9
2 Our Business 2.1 Ramsay Health Care
Ramsay Cares
Ramsay provides quality healthcare services in Australia, in the UK comprising two businesses Ramsay UK hospitals and Elysium mental health services and in Europe through its 52.79% ownership of Ramsay Santé, which operates in France and the Nordics region. Ramsay has always focused on maintaining the highest standards of quality and safety, being an employer of choice and operating the business based on our purpose of 'people caring for people'.
Ramsay Health Care is committed to being a leader in sustainable healthcare.
3
Pr e re c a iti su v e n t at pp e a lt h u n o r ti i v e h o m m n g lo c al c
S u p r ti n g local copmom u n it i e s
for our co m m
si o n in sp rc Re sou
uni
Includes Ramsay Surgical Centre Cleveland opened in August 2026 and National Capital acquired in August 2026 Includes the management of Joondalup and Noosa public health campuses Refer ASX announcement 20 February 2026 - Update on Strategic Review of Ramsay Santé – proposal to separate Ramsay Santé from Ramsay
10
Ramsay Health Care Annual Report 2026
b g le
v al a n c re in se g ar ch
The Ramsay Way
People caring for people
es
d
Red ope ucin rat g ion
ty
Waste and recyc ling
2
ts ien at y t ri
Ener wategy and r us e
t lane ur p ro fo
1
Our le p peo
e pl
an
Ramsay has announced a proposal to distribute its Ramsay Santé shares to Ramsay shareholders. The proposed distribution is expected to be implemented through a scheme of arrangement and is subject to Ramsay Board, shareholder and regulatory approvals.3
Stronger Communities > We believe in supporting preventative healthcare and giving back to the communities we serve. We achieve this through research and training, volunteer programs, education campaigns and activities that address local healthcare needs.
A d ic n cli
Ramsay Santé is a leading private health care provider in Europe, operating 491 healthcare facilities across five countries. In France, Ramsay Santé has a market leading position in acute care and mental health facilities. In Denmark, Norway and Sweden, Ramsay Santé operates facilities including primary care units, specialist clinics and hospitals. Ramsay Santé employs more than 40,000 employees and its facilities treat more than 13 million patients each year. Ramsay Health Care owns 52.79% of Ramsay Santé listed on the European financial markets’ platform Euronext.
Thriving Planet > We are committed to minimising our environmental footprint by reducing the impact of our operations and supply chain. This includes improving energy efficiency, reducing waste and sustainable procurement practices.
rom our act f mp ply chain e i sup th and s
Ramsay Santé
Healthier People > We prioritise the needs of our employees, patients and doctors. This includes advancing employee health and well-being, patient safety and professional development.
ate im Cl ction a
In January 2022, Ramsay acquired Elysium Healthcare, a leading independent provider of specialist mental health and care services across England and Wales. Following the recent restructure, Elysium operates 88 sites with approximately 2,196 beds. Elysium employs ~8,900 people.
Our Ramsay Cares strategy rests on three key pillars:
Our peop l are o e and ur pr p io
Ramsay UK has a network of 34 acute hospitals and day procedure centres providing a comprehensive range of clinical specialities to private and self-insured patients as well as to patients referred by the NHS. Ramsay UK cares for more than 215,000 patients per year and employs +7,500 people.
Three pillars for positive change
for ou rp eo
UK
Sustainability is a core value in The Ramsay Way. We recognise its importance to our employees, patients, doctors and our longterm success. Through Ramsay Cares, we strive to make a lasting positive impact on the world.
pat Our ien ts
Ramsay Australia operates private acute hospitals delivering complex care including in its priority therapeutic areas, cardiology, oncology, orthopaedics and mental health. Ramsay Australia has 711 hospitals, clinics and day surgery units2 and is Australia’s largest private hospital operator. Ramsay’s operations include mental health facilities as well as the operation of two public hospitals. Ramsay also provides hospital in the home and telehealth services and operates 31 allied health clinics. In addition, Ramsay has established the Ramsay Pharmacy retail franchise network which supports 63 community pharmacies and 37 in-hospital dispensaries. Ramsay Australia admits +1.2m patients annually and employs +35,000 people.
Aligning with our values
doctors Ourclinicians and
Australia
Our Ramsay Cares sustainability strategy ensures we operate as a responsible business, focused on the interconnected well-being of our people, the environment and the communities we serve.
Group Executive Leadership Team Our strengthed executive leadership team is now in place with the experience to lead our transformation and to bring focus and capabilities to the Australian business.
Year in Review
Natalie Davis Group CEO & Managing Director
Andrew Coombs Chief Commercial Officer Australia
Nick Costa Managing Director Ramsay UK Hospitals
Joe O’Connor Managing Director Elysium Healthcare
Pascal Roché Managing Director Ramsay Santé
Colleen Harris Group Executive People
Anthony Neilson Group Executive Finance
Dr Brindan Suresh Group Executive Health & Strategy
Dr John Doulis Group Executive Technology & Digital
Henrietta Rowe Group Executive Legal & Company Secretariat
Our Business
Stuart Winters Chief Operating Officer Australia
Financial Performance Governance Financial Results Additional information
Ramsay Health Care Annual Report 2026
11
2.2 About Ramsay Australia Our market- leading Australian hospital business Ramsay Australia has strategically located hospitals providing trusted quality health care in high acuity therapeutic areas, delivered by dedicated clinicians to more than one million people each year.
26% market share of Private Health Insurance hospital benefits1
71
3 Ramsay Psychology clinics
100 Ramsay Pharmacies and dispensaries
hospitals2 with 10 Emergency Departments3, including:
44 owned property assets3
10 Surgical Centres3
12
Ramsay Health Care Annual Report 2026
31 Ramsay Health Plus clinics
+1.2m
79,000
Emergency Department attendances4
home health services4
210,000
5.6m
73.6
Health Plus attendances4
pharmacy scripts
hospital admissions
4
Year in Review
240,736 4
Patient Net Promoter Score4
Our Business
35,000+ employees Financial Performance
~9,000 doctor partners
Governance
22 clinical trial sites (largest private network)
Financial Results
High admissions market share in key therapeutic areas5:
1 2
3
4 5
Additional information
30% cardiology 25% cancer 30% orthopaedics APRA Quarterly Private Hospital Statistics rolling 12 months to 30th June 2026 Includes Joondalup and Noosa operated under public contracts. Includes Ramsay Surgical Centre Cleveland opened in August 2026 and National Capital acquired in August 2027 Does not include Ramsay Surgical Centre Glenferrie, Ramsay Clinic Thirroul, Coolenberg Day Surgery, Attadale Rehabilitation Hospital that were closed in FY26. For 12 mths to 30 June 2026. Market share of admissions across NSW, VIC, WA and QLD. Source: Hardes & Associates 2025. Orthopaedics excludes rehab.
Ramsay Health Care Annual Report 2026
13
2.3 Ramsay Australia 2030 Strategy Our vision is to be Australia’s most trusted leading healthcare provider and to deliver long-term value for shareholders through the five pillars of our strategy. Our strategy will innovate Ramsay to: • Lead in local catchments, particularly growing our services, patient care and relationships with specialists and GPs in communities around our strategically located hospitals • Differentiate ourselves in priority therapeutic areas including cardiology, orthopaedics and cancer care • Create ‘One Ramsay’ advantages powered by digital and AI to capture the synergies enabled by our market leading scale • Connect patient and doctor journeys, in particular from hospital care to community based care • Work with our communities and partners to shape Australia’s leading healthcare system for the future
We will measure progress with clear financial and non-financial metrics. Early indicators include our patient, doctor and people NPS metrics, growth in admissions, cost efficiencies through ‘one Ramsay’ advantages and revenue indexation that better matches cumulative cost growth.
14
Ramsay Health Care Annual Report 2026
Lifting growth and strengthening our core:
Differentiate by investing in priority Therapeutic Areas
Year in Review
Lead in local catchments
Our Business
Connect patient and doctor journeys
pe partners to sha
lth
ou rc om mu niti es an d
Financial Performance
th wi rk Wo
Create ‘one Ramsay’ advantages powered by digital and AI
sy ste m
e
P
eo l ple op caring for pe
a he r e ett b a
Clinical Employee Outcomes Engagement
Doctor NPS
Revenue Growth
Admissions growth
EBIT Growth
Return on Invested Capital (ROIC)
Financial Results
Measures
Governance
Patient NPS
Additional information
Ramsay Health Care Annual Report 2026
15
2.4 Operating Environment and Key Risks Material Issues
Sustainable Development Goals
Our material issues are the areas that matter most to our stakeholders and impact our business drivers, competitive position and our ability to create long-term value for all stakeholders. As well as engaging stakeholders to gauge their keys areas of focus and emerging issues, Ramsay’s materiality assessment is informed by the Sustainability Accounting Standards Board Materiality Map and reviewed annually by our Group Sustainability Committee.
We are committed to driving action toward the Sustainable Development Goals (SDGs), as adopted in 2015 by the United Nations and member countries. The key development goals Ramsay is focused on are mapped to our material risks below.
Clinical Quality and Excellence
People and culture
Data and digital
• Quality, safety and patient experience • Clinical outcomes • Doctor and clinician wellbeing • Research and development
• Cultural and engagement • Global workforce challenges • Safety, mental and physical wellbeing • Diversity and inclusion • Labour relations
• Digital transformation • Cyber security • Protecting data and privacy • Transform/adapt systems and processes to support workforce and patient outcomes • AI enabled opportunities and risks
Robust and resilient business model
Integrated quality assets and infrastructure
Good governance
Being able to deliver growth, clinical excellence and shareholder returns and effectively respond to disruption and changing models of care.
• Growth and development pipelines and renewal • Strategic investments • Physical and digital infrastructure
Climate action and environment
Caring for communities
Responsible sourcing
Delivering for the local and global community through R&D (including clinical trials), teaching hospitals and community partnerships.
Responsible sourcing to improve social and environmental outcomes and supply chain transparency and traceability.
• Net zero emissions and climate risk • Energy, water and resource use (including single-use) • Waste and biodiversity
16
Ramsay Health Care Annual Report 2026
Governance, transparency, risk management, business ethics, diversity, independence and tax transparency.
External Trends External trends play a critical role in our ability to create long term value for all stakeholders. It is imperative that Ramsay adapts to structural shifts in healthcare at pace.
Workforce challenges
Clinical innovation
Shorter length of stay and community care
Pressure in public health systems Patient as consumer, with increasing expectations
Year in Review
Changing clinician work preferences
Digital and AI to reduce admin burden
Ramsay is committed to meeting high standards of risk management. Effective risk management is a collaborative effort and is engrained in our Ramsay culture. Ramsay faces a number of business risks that could affect our operations, strategies and financial prospects. Climate related risks are outlined in the Sustainability Report (see page 27).
Financial Performance
Ramsay owns 52.79% of Ramsay Santé which is listed on the European financial markets platform Euronext. Through its 5 positions on the Ramsay Santé Board, Ramsay seeks to enhance Ramsay Santé’s governance processes, including in relation to risk management. Ramsay Santé is supported by its own funding arrangements underpinned by secured loan facilities, with no recourse to the Ramsay Funding Group. For further information please refer to Ramsay Santé’s Universal Registration Document. In February 2026, Ramsay announced its proposal to distribute all of its shareholding in Ramsay Santé to Ramsay shareholders (the Demerger). The Demerger requires, amongst other things, Ramsay shareholder approval by the required majorities at a scheme meeting and a general meeting, and Court approval. There is a potential risk that the required Ramsay shareholder approvals and Court approval are not obtained and the Demerger does not proceed. In such an event, Ramsay shareholders will retain their existing Ramsay shares which would continue to include an indirect interest in Ramsay Santé.
Our Business
Risk Management
The key risks are described below, together with relevant mitigation strategies. 1
Material issues:
• Inability to develop and implement strategy • Increased costs to the business, for example associated with employee turnover and/or shortages, wage remediation, as well as increased resourcing needs to respond to complex regulatory and legislative requirements • Reputational damage and/or financial penalties due to serious injury to a person as a consequence of failure to maintain a safe workplace • Operational disruption due to strikes or other forms of industrial action • Inability to compete for resources, particularly in markets with workforce shortages
Ramsay strives to continue to be an employer of choice to attract and retain employees, by: • Ensuring an attractive employee value proposition (i.e remuneration, flexible working, career progression, succession planning, training and development) and tracking staff engagement • Maintaining an effective workplace health and safety framework which includes policies, training, incident management, monitoring and reporting of safety performance • Investment in projects, technology and infrastructure • Focusing on The Ramsay Way values and our purpose of people caring for people • Ramsay conducts ongoing and ordinary wage assurance processes and will undertake remediation where necessary • Ramsay is focusing on simplifying its enterprise agreements when renegotiating in order to reduce complexity, improve pay accuracy and provide greater certainty for its employees.
This report does not identify every risk that could affect Ramsay’s business and the actions taken to mitigate these risks cannot provide absolute assurance that a risk will not materialise. Risks presented in this section are in no particular order.
Ramsay Health Care Annual Report 2026
17
Additional information
1
HOW RAMSAY IS RESPONDING
Financial Results
Workforce developments (company, industry or legislative driven) may also lead to increased and complex obligations, disputes and industrial action and/or disruptions to our operations, which can result in increased cost, litigation and reputational damage.
POTENTIAL IMPACT
Governance
RISK People / workforce People are Ramsay’s most important asset and are key to the organisation’s ongoing success. It is important that Ramsay continues to attract and retain world class talent and provides a safe working environment.
RISK Clinical Quality & Safety The safety of our patients and the delivery of high quality clinical care is fundamental to Ramsay’s success. Material issues:
POTENTIAL IMPACT
HOW RAMSAY IS RESPONDING
• Reputational damage as a consequence of poor clinical outcomes • Financial loss resulting from potential significant medical malpractice incidents or claims • Potential impact on ability to recruit and retain clinicians and employees • Inability to operate a facility if it is not accredited
Ramsay has in place a comprehensive Clinical Governance Framework, which includes:
Government Policy and Regulation Ramsay operates in the • healthcare industry which is subject to extensive laws, regulations, policies and ethical standards (which may vary by jurisdiction). Government • policy may materially impact the role of Ramsay in provision of healthcare and/or the affordability of private health insurance. • Material issues:
Policies may effectively reduce the role of the private sector in a country’s health system, including the involvement of the private sector in the provision of healthcare to public patients Economic factors or regulations may impact the affordability of private health insurance (particularly in Australia) and result in a reduction in the level of private health insurance coverage Government intervention in response to public health needs (e.g. pandemic response and restrictions on the nature and scale of elective surgery) • Increased wage costs associated with changes to government/regulatory policy
Funders - Health Insurance funds and government sources Ramsay relies on funding • Unsatisfactory terms with major insurers provided by private health or changes to government funding insurers and governments in arrangements (e.g. due to pressure the provision of its services. on government budgets and debt Changes in government or levels impacting government funding of health insurance funding health care) (including costs of health • Revenue indexation negotiated with insurance) could have a material payors and/or government tariff settings impact on Ramsay’s operations. not adequately reflecting cumulative cost increases across the sector and acuity/ Material issues: complexity of patient needs • Declines in private health insurance membership or shifts to lower levels of coverage due to affordability issues given economic pressures and/or premium increases Relationships with doctors The recommendation of a • Loss of doctors and associated patient’s doctor is often the patient referrals most significant factor in a • Inability to provide leading patient’s choice of hospital clinical services in many of Ramsay’s regions. • Additional costs associated with doctors' Most doctors operating or decisions e.g. theatre times, use of working at Ramsay hospitals supplies and timing of patient discharge are not employees (except in • Impacts to revenue as a result of Scandinavia) and have a choice changing doctor working practices of where to practice. Material issues:
18
Ramsay Health Care Annual Report 2026
• Clinical effectiveness to ensure a high standard of quality and continuous improvement • Clinical risk management ensuring our services are safe and minimise risk of error, and tracking our quality through measures such as clinical incidents and patient experience • Credentialing, licensing, accreditation and training frameworks • Consumer participation involving patients and carers in quality improvement and business planning through feedback Ramsay closely monitors and seeks to provide input into current and proposed government policy and regulation in each country in which it operates through: • Maintaining and developing relationships with government in all regions in which it operates. This takes place at all levels of government and at various levels within the business (e.g. at a national and local level) • Membership and/or leadership in various industry representative bodies including in relation to policy reform impacting the sustainability of the private health sector.
Ramsay plays an important role in supporting the health systems in the regions in which it operates. Ramsay works to partner with both private health insurers and government funders and seeks to have proactive dialogue with stakeholders including around reimbursement models. Our commitment to clinical quality as well as provision of cost effective, outcome focused care demonstrates to third party funders the value in contracting with Ramsay.
• Ramsay continually invests in its facilities and workforce (e.g. theatres, equipment and nurses). • Ensuring strong relationships with doctors through an attractive doctor value proposition (i.e regular support and engagement, including providing education forums and opportunities for innovative research) and regular surveys listening to doctor feedback. • Customer feedback (e.g. Net Promoter Score, complaints etc.) is closely monitored as this also impacts on doctor recommendations to patients.
POTENTIAL IMPACT
HOW RAMSAY IS RESPONDING
• Delays, cost overruns or failure to realise anticipated benefits from major technology and digital programs. • Operational disruption arising from technology system outages, implementation failures or inadequate system performance. • Reduced patient, clinician or employee experience due to ineffective digital solutions or low adoption of new technologies. • Inability to respond effectively to changing consumer expectations, emerging technologies or industry innovation. • Failure to adequately govern the use of emerging technologies, including artificial intelligence. • Poor decision making, operational inefficiencies, reputational damage or regulatory breach due to inappropriate or ineffective use of AI (e.g. inaccurate output or inappropriate use of data)
Ramsay continues to invest in technology, digital capabilities and infrastructure to support patient care, operational efficiency and long-term growth. This includes:
• Suboptimal patient experience or patient harm due to delays or disruption to service delivery • Potential consequences for individuals (including patients and employees) of a privacy breach • Increased costs as a result of recovery strategies and/or financial penalties • Reputational and brand damage as a consequence of a cyber breach
• Cybersecurity risk is addressed through a Global Cybersecurity Framework which includes the adoption of the United States National Institute of Standards and Technology (NIST) cyber security framework and controls associated with prevention, detection and recovery. In addition, the Framework is externally validated, routinely tested and subject to ongoing review and continuous improvement. • Ramsay also seeks to foster strong relationships with authorities, regulators and external advisors. • Monitoring developments in cyberattacks including in relation to the use of AI.
• Cost increases caused by geopolitical tensions and / or inflation • International sanctions may impact the availability of supply • Modern slavery risk in Ramsay's supply chain • Severe weather in key regions may temporarily disrupt supply chains • Short term industry wide supply disruptions and/or product recalls
Ramsay closely monitors its supply chain risks and seeks to mitigate its risk through a number of actions including:
• Increased costs associated with wage negotiations • Increased costs as a result of high levels of inflation • Increased interest costs as a result of high levels of interest rates • Cost of living pressures may result in consumers delaying or not seeking care at private hospitals due to out of pocket fees, PHI excess fees in policies or downtiering of PHI coverage
Ramsay enters into Enterprise Agreements and other arrangements with unions and employee groups over several years to provide certainty of future wage increases.
Material issues:
Material changes in the levels of inflation and/or interest rates could have a material impact on Ramsay's financial performance.
Good supplier relationship management Alternate supply arrangements Monitoring of international sanctions Global procurement strategy that leverages diverse supply chains • Responsible sourcing procurement strategy
Ramsay has regional procurement functions who contract with preferred suppliers, leveraging volume and market competition to achieve preferred pricing to limit the impact of inflation. Ramsay negotiations with health funds and government engagement seek to gain increases in
Ramsay Health Care Annual Report 2026
19
Additional information
Macroeconomic / financial risk Ramsay's cost base is subject to various different levels of wage, supply cost and energy price inflation as well as changes to interest rates on its debt.
• • • •
Financial Results
Material issues:
Governance
Supply Chain Ramsay’s global operations rely on international supply chains. Geopolitical tensions and global or regional economic conditions may impact cost, availability and sustainability of supply which may impact the ability of Ramsay in its provision of healthcare.
Financial Performance
Cyber security Ramsay handles and stores personal information, including health information, digitally and in paper form for its customers and employees. A cybersecurity incident may result in damage or interruption to Ramsay’s information or operational systems, or those provided by third party vendors.
Our Business
Material issues:
• Maintaining governance and oversight of major technology and transformation programs, including regular monitoring of delivery, risks, costs and benefits realisation, and prioritisation of technology investments • Investing in modernisation of core technology platforms and digital solutions to improve customer, clinician and employee experiences • Monitoring emerging technologies and innovation opportunities, including artificial intelligence, to enhance service delivery while maintaining appropriate governance and risk controls • Establishing governance frameworks, policies and oversight mechanisms for the responsible development, procurement or use of artificial intelligence. • Building workforce capability and awareness to support the responsible adoption and use of AI technologies. • Monitoring emerging AI regulations, industry developments and best practices to ensure continued alignment with legal, ethical and stakeholder expectations.
Year in Review
RISK Technology & Digital Ramsay's strategy includes the effective delivery of technology and digital initiatives to support clinical excellence, operational efficiency, workforce productivity and improved patient and clinician experiences. Failure to successfully enable the business through technology change, realise expected benefits, maintain the reliability of critical technology systems, or appropriately govern the adoption and use of artificial intelligence (AI) may impact Ramsay's operations and strategic objectives. AI technologies present opportunities to enhance productivity, decision-making and service delivery, but may also introduce risks relating to accuracy, bias, privacy, ethics, regulatory compliance and accountability.
RISK Material issues:
POTENTIAL IMPACT • Government budget and public debt pressures impacting publicly funded services
HOW RAMSAY IS RESPONDING prices and tariffs to offset the impact of wage and cost inflation. Ramsay’s Treasury functions take out interest rate hedges to reduce volatility in earnings resulting from changes in interest rates. Ramsay engages with governments on policy reform to support affordable and accessible healthcare.
Competition, innovation, developments and acquisitions Ramsay’s growth strategy may • Limited growth or inability to be impacted by industry maintain earnings disruption, innovation, the • Limited improvement in service delivery actions of our competitors, or when compared to competitors the ability to identify future • Difficulty in attracting and acquisitions or generate returns retaining employees on developments. • Inability to fully respond to industry changes Material issues: • Redundancy of services and assets • Cost increases and/or delay to developments as a consequence of third party insolvency in the construction industry Legal and regulatory Ramsay operates in a highly regulated industry. Facilities are required to be licensed under various legislation in the jurisdictions within which they operate. Ramsay may also be involved in disputes or litigation, for example, with patients, suppliers, funders, regulatory bodies, or employees.
• Reputational damage due to lack of compliance or disputes • Costs associated with litigation (e.g. legal costs and damages) or lack of compliance (e.g. penalties)
Innovation is a key component of Ramsay’s strategy. This involves transformational projects associated with operational efficiencies, digital strategies, market growth opportunities and new business models. Ramsay continues to invest in its facilities (new and existing), its workforce and in new technologies to ensure that it is meeting consumer needs now and in the future. Prior to undertaking any acquisition or development, Ramsay undertakes comprehensive due diligence to identify key risks and ensure appropriate valuation, uses external advisors and all acquisitions and developments are considered by the appropriate executive committee or the Board. Ramsay has a framework to manage and monitor its legal and regulatory obligations. This includes compliance with local laws, employee training and effective management of licensing and accreditation.
Material issues:
Capital structure (Funding Group1) Ramsay’s capital structure for • the Funding Group is designed • to support its strategy and to • be resilient to changes in equity • and debt markets. Material issues:
Constrained capacity to execute strategy Increased costs of funding Reduced availability of funding A lower credit rating likely leading to an increase in funding costs and/or less funding sources
Ramsay’s capital management plan is designed to ensure a strong balance sheet to support its strategy over the medium to long term. This includes a plan for maintaining diverse sources of capital, ongoing monitoring and compliance, with limits and other thresholds as set out in the Treasury Policy. A robust capital structure is maintained to provide capacity within Ramsay's lender base at efficient pricing. The balance sheet can be flexed in the short term to accommodate strategic investments such as acquisitions and capital expenditure. The Treasury policy provides a framework for the management and regular reporting to the Board of financial risks including liquidity and refinancing risk, interest rate risk, foreign exchange risk and counterparty credit risk.
Sustainability and climate change Ramsay is committed to • sustainability and being resilient to a changing climate • through our Ramsay Cares Sustainability Strategy. Material issues:
Loss of reputation leading to inability to attract employees and capital investment Increased operating costs from being energy inefficient and exposure to more extreme weather events • Missed opportunities in responding to a transition to a low carbon economy
1 Refer to the Operating and Financial Review in section 3 for details of the Funding Group
20
Ramsay Health Care Annual Report 2026
The Ramsay Cares Sustainability Strategy outlines a shared vision for sustainability across the global businesses. Ramsay Cares sets measurable targets and is supported by an investment plan. Key focus areas include the mental health and the wellbeing of its people, setting the foundations to reduce its energy and emissions intensity and an emphasis on responsible sourcing within its medical supply chains. Information in relation to climate related risks and Ramsay's approach to management of those risks is included in the Sustainability Report on page 27 of this report.
2.5 Our People Supporting our people, strengthening capability and building a connected culture
In Australia, a strong emphasis was placed on listening to employees and responding to feedback with visible action. This included local engagement initiatives, leadership development, new communication channels and practical improvements to support employees in their day-to-day work.
Developing leadership and supporting growth
In Australia, we delivered more than 1.2 million student placement hours in our hospitals and recruited more than 770 nursing and midwifery graduates, half of whom had completed a Ramsay hospital placement.
A new National Employee Orientation program was launched during the year, helping employees reconnect with Ramsay’s history, values and purpose while creating a more consistent onboarding experience across the business. The rollout of SmartRecruiters and a new internal careers portal also supported a more streamlined and connected approach to recruitment and internal mobility, making it easier for employees to explore opportunities across Ramsay. In the UK, apprenticeships continued to support workforce development across clinical and operational roles, with more than 170 apprentices undertaking programs ranging from nursing and Operating Department Practice to healthcare support and digital capability. Ramsay UK also continued partnerships with universities to support future medical workforce pathways and student development. In response to outdated rostering systems, the UK launched the Workforce Evolution Programme to modernise our systems to simplify how we plan, manage and support our workforce.
Financial Performance
Elysium Healthcare’s Managing within Elysium leadership program launched in FY26 to strengthen management capability and support consistent leadership practices across the organisation.
Governance
Graduate nurses and midwives at Greenslopes Private Hospital, Brisbane.
Listening, connection and employee experience Creating a more connected and responsive employee experience remained a strong focus throughout the year. More than two-thirds of Ramsay Australia employees participated in the FY26 Employee Survey, with results improving across all measured areas compared with the previous survey. Employees reported stronger sentiment around work-life balance, leadership and Ramsay as a place to work, with 76 per cent saying they feel respected at work, 72 per cent saying their role makes good use of their skills and 72 per cent reporting they can maintain a healthy work-life balance.
Ramsay’s Global Graduate Program continued to support the development of future leaders, with four graduates across Australia and the UK completing their final rotations and a new
Ramsay Health Care Annual Report 2026
21
Additional information
The Ramsay Australia Leadership Academy continued to expand, supporting leaders at all levels across the business. Since launching in early 2024, more than 1,000 leaders have participated in programs aligned to Ramsay’s CARE (Coach, Achieve, Relate and Evolve) Leadership Pillars to acquire the skills to grow and lead with confidence. We have received 550 registrations for upcoming intakes to the Australian Leadership Academy which shows strong demand. We are also starting to see leaders who participated in programs already coming back to register again for the next level program – demonstrating that they saw value in the experience and have appetite to continue their leadership development journey.
The 14th cohort of Ramsay Santé France’s certified “Proximity Management” programme launched in March 2026, empowering frontline leaders to develop talent, drive innovation and support high-quality patient care. Financial Results
During FY26, Ramsay also expanded the Professional Pathways Program, designed to strengthen nursing workforce pipelines and support nurses transitioning into acute clinical practice. More than 150 nurses were recruited across 17 sites during the first phase of the program, with strong participant feedback and further recruitment planned across FY27.
Our Business
Ramsay also continued investing in career pathways and workforce development initiatives to support future capability and respond to workforce pressures across healthcare.
Additional initiatives focused on supporting hospital executive teams and strengthening leadership capability in operational settings. This included tailored onboarding programs for new chief executive officers, executive coaching for senior leaders and leadership workshops designed to strengthen team effectiveness and support collaboration across hospitals and services.
Year in Review
Across Australia, the UK and Europe, Ramsay’s people continue to deliver high-quality care while supporting patients, families and communities through increasingly complex healthcare environments. In FY26, Ramsay focused on strengthening leadership capability, improving employee experience, supporting wellbeing and creating more connected and responsive workplaces.
cohort of eight graduates commencing the two-year program during FY26.
Following the survey, local leaders across Australia worked with teams to develop and implement action plans shaped directly by employee feedback. National priorities were introduced to support a more consistent focus on communication, leadership visibility, career development and employee experience across the business. In May 2026, a new enterprise employee communication platform was launched in Australia. Ramsay Pulse is designed to strengthen connection across geographically dispersed teams and improve access to information, recognition and leadership communication. Enterprise bargaining activity progressed constructively during the year, supported by a greater emphasis on early engagement, listening and proactive workforce relations at site level. We completed six enterprise bargaining agreements in FY26.
Ramsay Way Innovation and Excellence Award winner Maryanne Georges (centre) with the Strathfield Private Hospital team. The annual Ramsay Way Awards recognise employees and teams driving innovation, leadership and clinical quality across the business.
Wellbeing and safety
Across the Group, Ramsay continued to strengthen inclusion and belonging initiatives and support a workforce that reflects the communities it serves.
Supporting employee well-being and creating psychologically safe workplaces remained central to Ramsay’s people strategy. Ramsay continued to expand initiatives focused on psychosocial safety, mental health and occupational violence prevention. Mental Health First Aid training continued, with more than 1,000 employees now certified as mental health first aiders, helping colleagues access early support and reducing stigma around mental health in the workplace. In Australia, a new Employee Assistance Program provider, Converge, was introduced during the year, expanding access to well-being support services for employees and their families. Ramsay also strengthened its focus on employee voice and workplace culture through ongoing promotion of Speak Up channels and practical initiatives designed to support respectful, safe and inclusive workplaces. Ramsay continued to perform strongly in rehabilitation and return to work outcomes, with our return to work rate remaining above 95 per cent and continuing to outperform both Comcare and industry averages. During the year, Ramsay UK achieved the Armed Forces Gold Covenant recognising the strength of our support for the Armed Forces community.
FY26 Female representation
56%
50%
51%
59%
65%
79%
Board members
Senior leadership
Managers
Non-executive directors
Facility CEOs
All employees
Ramsay UK achieved Level 2 Disability Confident status during the year and received the 2025 Onvero Inclusive Culture Award, recognising its commitment to inclusive leadership, employee resource groups and creating workplaces where employees feel valued and supported.
Looking ahead Ramsay’s people remain central to the delivery of safe, highquality care and the long-term sustainability of the business. In FY27, Ramsay will continue focusing on leadership capability, employee wellbeing, workforce development and creating more connected and responsive workplaces. Priorities will include strengthening communication and engagement, supporting future workforce pipelines and continuing to simplify systems and processes to improve employee experience.
“By listening more closely to At Elysium Healthcare, well-being initiatives included expanded employee support services, financial well-being resources and targeted leadership development programs focused on supporting employee engagement and retention.
Recognition and inclusion Ramsay continued to recognise employees who demonstrate The Ramsay Way through leadership, innovation, compassion and commitment to patient care. The 2025 National Ramsay Way Awards celebrated outstanding individuals and teams across the business, with nominations increasing on the previous year and highlighting the depth of talent and commitment across Ramsay’s hospitals and services.
22
Ramsay Health Care Annual Report 2026
our employees and investing in leadership, wellbeing and capability, we are creating workplaces where our people feel supported to grow, contribute and deliver excellent care." Colleen Harris Group Executive People
2.6 Clinical excellence and innovation Clinical excellence and innovation remain key drivers of Ramsay’s strategy to improve patient outcomes, enhance the patient and clinician experience and strengthen long-term healthcare sustainability.
Advancing clinical excellence through technology
patients in more communities will benefit from world-class surgical technology designed to support more personalised care, improved accuracy and faster recovery times. Stuart Winters Chief Operating Officer, Ramsay Australia
Ramsay Santé - Capio’s digi-physical care model combines digital and face-to-face services to provide seamless access to care, delivering approximately 860,000 digital consultations annually and making digital care available across all 102 health centres.
Enhancing patient experience Every patient interaction is an opportunity to create a positive healthcare experience. Ramsay tracks this through Net Promoter Score (NPS), which measures how likely patients are to recommend our services. During FY26, all regions maintained excellent NPS scores above 70, highlighting the confidence patients place in our people, our care and the experiences we deliver. Net Promoter Scores 100
+89.0 +89.4 +74
+72.3 +73.6
+74
50
Additional information
Ramsay UK - Robotic surgery capabilities were expanded across key hospitals, including the introduction of the CORI® robotic surgical system at Fitzwilliam Hospital for hip and knee replacement procedures, improving surgical precision and supporting faster recovery.
Nicola Ware Director Ramsay Research & Development Network
Financial Results
A web-based version of Ramsay’s oncology information system (CHARM), streamlining oncologist’s remote access to our chemotherapy prescribing tools, was piloted at John Flynn Private Hospital.
important milestone for our network and demonstrates our ability to deliver high-quality clinical trials at scale while maintaining a strong focus on participant experience and operational excellence.
Governance
The rollout of the K2 Foetal Monitoring and Maternity Information System across all 15 maternity hospitals represents a significant investment in maternity care, equipping clinical teams with real-time information to enhance patient safety, support clinical excellence and improve outcomes for mothers and babies.
“Achieving GCSA Certification is an
Financial Performance
“This investment means more
Ramsay entered a new era for research with the launch of the Ramsay Research and Development Network (RRDN) – a unified, connected home for clinical trials and innovation by bringing together our people, processes and trial units under one coordinated framework. With more than 22 research sites nationally, RRDN is one of Australia’s largest private clinical trial networks, connecting patients with research opportunities closer to home while supporting the delivery of global studies. The RRDN was awarded certification to the GCSA Global Quality Standard for Clinical Research sites.
Our Business
Ramsay Australia continued to invest in technology, purchasing 10 new Stryker MAKO and six Da Vinci robots, one of Australia’s largest investments in surgical technology. The robots are now in action in our major hospitals with a young woman with bowel cancer becoming the first patient to undergo a robotic bowel resection at Ramsay's Sunshine Coast University Private, benefiting from the minimally invasive procedure by returning home the following day.
New era for research and clinical trials
Year in Review
During FY26, Ramsay continued to invest in clinical leadership, advanced technologies, research capability and innovative models of care across its international network. These investments supported greater access to healthcare, expanded clinical capabilities, improved operational efficiency and reinforced Ramsay’s position as a leader in delivering high-quality, patient-centred care across in its key markets.
0 Ramsay Australia
2025
Ramsay UK (acute)
Ramsay Santé (France)
2026
Ramsay Health Care Annual Report 2026
23
At Elysium Healthcare’s The Spinney Hospital, a mental health facility for men over 18 years, the Oasis Café (above) was co-designed by service users and staff to create a welcoming therapeutic space that supports recovery, wellbeing and meaningful engagement. Early results showed increased participation, confidence and motivation among service users, highlighting the value of recovery-focused activities and empowering people to help shape the environments that support their wellbeing.
Improving patient outcomes through clinical leadership and collaboration Ramsay Australia continued to deliver strong clinical quality and safety outcomes. Performance against Australian Council on Healthcare Standards (ACHS) clinical indicators for July to December 2025 was significantly better than the national benchmark, including 69% fewer pressure injuries (excluding Stage 1 and 2 pressure injuries), 67% fewer medication errors resulting in harm and 44% fewer unplanned readmissions within 28 days. These results reflect our ongoing focus on evidence-based care, patient safety, continuous improvement and collaboration across our hospitals and services. The Ramsay Psychiatry Symposia virtual series brings together psychiatrists, psychiatry registrars and mental health professionals from Ramsay Mental Health (Australia), Elysium Healthcare (UK) and Capio (Sweden) to share knowledge, clinical insights and emerging evidence. With 1,105 registrations in FY26—up 54% on the previous year—the program supports the delivery of contemporary, evidence-based mental health care, helping clinicians improve outcomes and experiences for patients across our international network. Ramsay UK continued to demonstrate strong clinical leadership through its partnership with the National Health Service (NHS), working collaboratively to deliver high-quality patient care and share expertise across the healthcare system. This commitment to clinical excellence was recognised at the 2026 HealthInvestor Awards, where Ramsay UK was named Private Hospital Group of the Year, reflecting the dedication, innovation and leadership of teams across the network.
““The judges commended Ramsay’s strong KPIs, excellent NPS scores and compelling case studies, alongside clear innovation in sustainability. They also noted impressive growth and Ramsay’s major contribution to supporting NHS elective care.” Nick Costa Managing Director UK Hospitals
24
Ramsay Health Care Annual Report 2026
Capio’s St Göran’s Hospital (above) in Stockholm shared first place in Sweden’s prestigious SWEDEHEART 2025 national quality index for cardiac care, demonstrating strong clinical leadership and a commitment to continuous quality improvement. The recognition reflects excellence in evidence-based cardiac care and outstanding patient outcomes.
Expanding capacity and improving access to quality care During FY26, Joondalup Health Campus in Western Australia completed a major $307.9 million expansion, jointly funded by the State and Australian Governments, that significantly increased healthcare capacity for Perth’s growing northern communities. The redevelopment delivered new medical, surgical, mental health and cardiac facilities, including 60 additional public beds. Combined with Ramsay’s $166 million private hospital expansion, completed in February 2026, the campus is now one of the largest integrated health campuses in Australia, improving access to high-quality care for patients across the region. During FY26, Ramsay Australia expanded its Emergency Department Nurse Liaison program, where experienced nurses working alongside public hospital emergency departments help eligible patients access treatment sooner at Ramsay hospitals. This collaborative model improves patient flow across the health system and on the Sunshine Coast alone, facilitated more than 540 patient transfers in its first 12 weeks. Elysium Healthcare partnered with Derbyshire County Council to establish Dove House (below), a six-bed specialist complex care service that opened in January 2026. The service supports people with complex learning disability and autism needs to transition from long-stay hospital settings, develop greater independence and access care that is better matched to their needs.
2.7 Caring for our planet and community Ramsay is driving practical, measurable change in how we deliver care, manage resources and support communities. From reducing waste and emissions in our hospitals to partnering on local health initiatives, our teams continue to demonstrate that sustainability is part of how we work every day.
More sustainable solutions
Caring for Community Our Ramsay Cares strategy focuses on contributing to healthier, more resilient communities across research and education, community partnerships and responsible sourcing.
Turning surplus into support Ramsay UK has partnered with Uniting Uniforms (below), which provides access to free or subsidised school uniforms to children. The partnership creates volunteering opportunities and diverts spare uniforms from waste. Ramsay UK hospitals have also donated surplus medical equipment, consumables and furniture to support those in need. Year in Review
Ramsay continues to work on more sustainable choices and invest in energy efficiency measures. See our first Sustainability Report (Section 2.8) under the Australian Sustainability Reporting Standards for more information on our climate response.
Switching for the better
“It has been truly refreshing to
Ramsay Australia's Waverley Private Hospital teamed up with Project Net Zero, a 100% Indigenous owned business providing de-fit and make-good services to help recover loose furniture and fixed assets. As a result, 96% of the surplus furniture was repurposed with two community organisations.
Financial Performance
witness the rapid transition in York to decommissioning all nitrous oxide use and then to hear this action is spreading across the Ramsay network.
Our Business
Across the Group, anaesthetists and theatre teams are reducing emissions by switching to lower-impact anaesthetic options. Anaesthetic gas emissions have fallen by 39% since FY25, driven by lower desflurane use and reduced nitrous oxide use through point-of-care delivery and leak reduction. In the past 12 months, Ramsay Santé cut nitrous emissions by 60% and Ramsay Australia by 27%. While Ramsay UK decommissioned most piped nitrous networks, reducing nitrous oxide emissions by 57%.
Dr Brian Williams Anaesthetist consultant, Ramsay UK Clifton Park Hospital in York
A partnership between artist Lucy Pittaway and Elysium is creating Tiny Forests across Elysium services, providing greener spaces that support mental health, wellbeing and sustainability for the people we support, their families, carers and staff. Inspired by Lucy’s pledge to plant a tree for every Sycamore Gap print sold, the initiative is now helping create tailored green spaces co-designed with each service.
Waverley Private Hospital was able to repurpose 573kg of surplus furniture
Inclusive coffee cart opens at Dudley Private Hospital
Governance
Tiny Forests
Financial Results
Inclusive employment coffee cart launches at Dudley Private Hospital
Find out more at ramsayhealth.com/ramsaycares
Ramsay Health Care Annual Report 2026
25
Additional information
A design competition invited Elysium service users to celebrate nature, community and sustainability. The winning design now features across Tiny Forests materials, creating a lasting mark on the initiative
NDIS provider Wangarang has launched a new supported employment coffee cart at Dudley Private Hospital, Orange creating fresh opportunities for people with disability while serving quality coffee to staff, patients and visitors. Dudley Private Hospital CEO, Jo Brown, said “Our hospital is a place of care, but it is also part of the community we serve, and initiatives like this create meaningful opportunities for people with disability to build skills and confidence in a real workplace environment. ”
Triathlon Pink partnership extended to 2029
Ramsay Santé Foundation Ramsay Santé Corporate Foundation continued to highlight the importance of preventive health care through its annual public forums and long standing Prevent2Care program.
Ramsay Health Care has reaffirmed its long standing commitment to supporting women's health and wellbeing, announcing a three-year extension of its partnership with Triathlon Pink. This event is one of Australia's largest female-focused participation event series, and the partnership has helped raise more than $2.6 million for the National Breast Cancer Foundation for breast cancer research.
“Triathlon Pink is much more than a sporting event. It creates an environment where women feel supported to challenge themselves, prioritise their wellbeing and achieve goals they may never have thought possible. Andrew Coombs Chief Commercial Officer - Australia, Ramsay Health Care
Making children's hospital journeys easier St Andrew’s Ipswich Private Hospital’s partnership with Daisy’s Days is supporting children and families throughout their hospital journey. To help make that journey a little easier, Daisy's Days created a unique story-colouring book featuring Daisy and her outback friends. The partnership has helped establish the Daisy’s Days Travel Assistance Program, which assists families in remote Australian regions with travel costs so their children can access medical treatment.
Ramsay Santé Brigitte Cachon at the National Prevention Week Symposium
The first National Health Prevention Week featured a symposium and 775 events across France, with 20 Ramsay Santé facilities organising local initiatives to make prevention a top health priority for citizens. Prevent2Care, the first health prevention incubator created by the Ramsay Santé Foundation, delivered its seventh cohort and launched the eighth. Since its inception in 2018, there have been 190 startups and non-profit organisations, and six million people reached through this initiative.
Ramsay Santé Mission Company Since 2022, Ramsay Santé has advanced its purpose-driven roadmap, focused on access to care and stronger patient– clinician dialogue. This includes the European rollout of Choosing Wisely, which promotes the right care for each patient, and Lakaa, a platform for managing and sharing performance and CSR actions, now deployed in 72% of facilities in France. Ramsay Santé has also finalised its mission dashboard, enabling regular monitoring of commitments and progress.
Responsible sourcing Key achievement Achieved FY26 sustainability assessment target, by assessing 80% of suppliers (by share of global spend) through independent services.
Ramsay operates a complex global supply chain of more than 20,000 suppliers across 65+ countries. We partner with suppliers to ensure our purchasing decisions positively impact people, the planet and the communities we serve. Our expectations are set out in Ramsay’s Global Responsible Sourcing Policy, which covers business ethics, human rights and labour standards, community engagement and environmental responsibility. We achieved the key FY26 target of assessing 80% of supplier spend through sustainability assessments and remain on track to reach 85% by FY27. During FY26, Ramsay joined Supply Nation and Social Traders, strengthening our commitment to social procurement and supplier diversity. In FY26, we spent $1.95M with Indigenous-owned businesses and $0.11M with certified social enterprises.
Daisy’s Days Founder Katie Waardenburg at St Andrew's Private Hospital
26
Ramsay Health Care Annual Report 2026
Read our Modern Slavery Statement at ramsayhealth.com/sustainability-governance
2.8 Sustainability Report Table of Contents Section
Reference 27
Governance
28
Risk Management
31
Strategy
32
Metrics and targets
43
Directors declaration
47
Independent Auditor's Report
48
Year in Review
About the Sustainability Report
2.8.1 About the Sustainability Report About this ASRS Report
Statement of compliance
Connected information This report should be read in conjunction with consolidated financial statements of the Group for the year ended 30 June 2026 (5 Financial Results). All monetary amounts in this report are expressed in Australian dollars, which is the presentation currency of the Group’s consolidated financial statements, and are rounded to the nearest hundred thousand dollar, unless otherwise stated.
Transitional relief The Group has elected to apply the following transitional relief under AASB S2 for its first annual reporting period (for the year ended 30 June 2026): • not required to disclose comparative information, as permitted under AASB S2 paragraph C3. • not required to disclose Scope 3 greenhouse gas (GHG) emissions, as permitted under AASB S2 paragraph C4(b). Key judgements and measurement uncertainties The preparation of this Sustainability Report requires the Group to exercise judgement in identifying material climate-related information and to make estimates and assumptions in measuring emissions, anticipated financial effects and climate resilience.
Table 1 Description Materiality assessment GHG emissions measurement
Climate-related scenario analysis
Ramsay Health Care Annual Report 2026
27
Additional information
Climate resilience assessment
Financial Results
Quantification of anticipated financial effects Identification of climate-related risks and opportunities
Areas of key judgement and measurement uncertainty Materiality is assessed from the perspective of primary users of general purpose financial reports, considering both quantitative and qualitative factors relevant to climate-related risks and opportunities. Quantification of emissions requires application of estimates where data is not available or not practically available at the time of reporting. Judgement has been exercised when selecting estimates using recent available data and/or proxies. Uncertainties arise from variables used to quantify the potential impact of climate-related risks and climaterelated opportunities (CRROs) on the Group’s operations over the short, medium and long term. There is a wide range of potential outcomes for the anticipated effects of the Group’s CRROs over the short to long term. In identifying and assessing CRROs, Ramsay used all reasonable and supportable information available without undue cost or effort for a comprehensive understanding of the CRROs. Ramsay also exercised judgement in identifying and assessing CRROs that could reasonably be expected to affect its prospects. The assessment considered potential impacts across Ramsay’s global strategy, business model, operations, infrastructure, supply chain, workforce, service demand, revenue and financial planning. Ramsay has exercised judgement in selecting climate-related scenarios to test the resilience of its strategy and business model. The scenarios were selected to consider a range of plausible future outcomes, including an orderly transition scenario and a hot house world scenario. These scenarios are intended to explore potential impacts and business responses under different climate conditions rather than predict the future. Different scenario choices, climate pathways, policy responses or assumptions could result in different outcomes. Ramsay applied judgement in assessing the resilience of its strategy and business model, including the effectiveness of existing controls, the significance of areas of uncertainty and Ramsay’s capacity to adapt over time. The assessment is based on current information and existing controls, and may change as climate science, regulation, market expectations, data availability and Ramsay’s own capabilities evolve.
Governance
Table 1 summarises the most significant sources of judgement and uncertainty in preparing the report and which have been prioritised based on their potential to influence the Group’s financial outcomes and strategic decisions.
Financial Performance
This Sustainability Report has been prepared in accordance with Australian Sustainability Reporting Standard AASB S2 Climate-related Disclosures (AASB S2) and the Corporations Act 2001 (Cth).
Our Business
This Sustainability Report has been prepared for Ramsay Health Care Limited and its subsidiaries (together, Ramsay or the Group), for the year ended 30 June 2026. Unless otherwise stated, this report reflects the same reporting boundary as the Group’s consolidated financial statements.
2.8.2 Governance Table 2 illustrates Ramsay’s climate-related governance structure, highlighting the relationship between the Board, management roles and supporting functions. This table focuses on governance in relation to climate-related matters only.
Board oversight Under the Board Charter, the Board has ultimate oversight of the Group's strategic direction on sustainability, including considering, reviewing and monitoring climate-related risks and opportunities, trade-offs, as part of its decision-making processes and oversight of major transactions. The Board oversees Ramsay’s five-year business strategy and approves the annual budget, which includes the provision of capital expenditure to address ESG and sustainability requirements, including climate-related risks and opportunities.
The Board is responsible for approving this Sustainability Report and setting the Group’s material sustainability and governance policies, practices, plans and targets (for example, climate-related targets), including in relation to: • exposure to climate change risks and opportunities; • the climate resilience of the Group’s strategy and business model; and • implications for the Group’s financial position, financial performance and cash flows. The Board is also responsible for monitoring systems of risk management, including pertaining to climate-related risks. The Board approves relevant climate-related targets, monitors performance against them, and approves recommendations from the People & Remuneration Committee about the inclusion of climate-related metrics in executive remuneration.
Table 2 Ramsay Board The Board is responsible for the oversight of key corporate governance policies and risk management. It sets the risk appetite for climate-related risks and opportunities, approves key policies and sustainability initiatives and disclosures. Audit Committee Risk People & Nomination & Management Committee Remuneration Committee Governance Committee Management Roles Group CEO & Managing Director (MD) Responsible for the day-to-day management of Ramsay, including climate-related matters. Group Executive Committee (ExCo) Group Executive Finance Responsible for overseeing the rollout of Ramsay Cares Responsible for incorporating climate-related matters into strategy (which includes climate-related elements) globally financial practices, financial reporting (including climate-related and in each region, integration with strategy and corporate financial disclosures) and disclosure activities for alignment to plan; considers material sustainability risks and opportunities financial reporting. including social, environmental and climate risk. Management functions Group Capital Committee Australian Risk Committee Group Sustainability Committee (GSC) Responsible for overseeing Supports ExCo in its Cross-functional climate working group that supports the ExCo and the effective allocation management of risk and Board on social and environmental risks and opportunities that of capital to support provides oversight of the may impact on long-term value creation and reputation. Ramsay achieving its material risks to the Ramsay Supports ExCo by focussing on delivery of the Ramsay Cares strategic objectives. Australia business. sustainability strategy, including in relation to the implementation Chaired by the Group In relation to climate-related of sustainability initiatives, emissions reduction programs, energy Executive Finance. matters, responsible for transition initiatives and broader climate-related priorities across all overseeing and managing regions including identifying and monitoring CRROs. sustainability (including Comprises of the Group Sustainability Officer (Chair), Regional environmental and social Sustainability Leads and representatives from Group Finance, Risk, sustainability) related risks. Legal, People and Procurement. Chaired by the Group Chief Risk Officer. All Australian Group Executives are members. Support functions Group Sustainability Finance Strategy & Operations Risk Officer & Regional (including Sustainability) Sustainability Leads Responsible for overseeing Responsible for overseeing Responsible for integrating Responsible for overseeing Ramsay’s sustainability financial reporting and climate-related considerations Ramsay’s risk management function including business planning and into business strategy and and internal audit frameworks development of the Ramsay budgeting for Ramsay, growth initiatives. supporting transparent and Cares sustainability strategy, including as it pertains to reliable disclosure by assuring policies, and climate-related climate-related matters. the integrity of controls, targets. Conducts scenario processes, and reporting analysis. Together with the across the organisation. other supporting functions, leads the preparation of the Group’s external reporting and climate-related internal progress reports for review by the ExCo and Board committees.
28
Ramsay Health Care Annual Report 2026
The Board is updated at least annually on sustainability (including CRROs). In FY26, the Board continued to oversee sustainability and climate matters, which included: • continuing to embed climate risk and opportunity considerations into global strategy, key business decisionmaking processes and executive remuneration frameworks and outcomes • monitoring Ramsay’s performance on sustainability including climate-related targets;
• considering and approving the Group’s FY25 Impact Report (and the associated climate-related and broader strategy). • considering and approving the Global Sustainability Policy, which outlines Ramsay’s commitment to be a sustainable and responsible business.
Board Committees The Board's oversight of climate-related matters is supported by its four standing Committees, each with a distinct role and
All Directors have access to Committee papers and have a standing invitation to attend Committee meetings of which they are not a member, subject to any conflicts. At each Board meeting, the Chair of each Committee gives an update on the significant discussion, decisions and recommendations which took place at the relevant Committee meeting held immediately prior to the Board meeting. In addition to Committee cross-membership, this structured information flow enables the Board to be well informed about climate-related risks and opportunities in order to monitor and assess implications for Ramsay’s strategy and its climaterelated targets.
Ramsay Health Care ABN 57 001 288 768
ASX: RHC Full Year 26 Results 12 months to 30th June 2026
Ramsay Health Care Limited ABN 57 001 288 768 Level 7, Tower B 7 Westbourne Street St Leonards NSW 2065 Australia Telephone: +61 2 9433 3444 Facsimile: +61 2 9433 3460 www.Ramsayhealth.com
TABLE OF CONTENTS DISCLAIMER
3
1 APPENDIX 4E – KEY MATTERS
4
Results for Announcement to the Market
4
2 OPERATING AND FINANCIAL REVIEW
5
2.1 Who We Are
5
2.2 Group Performance
6
2.2.1 Overview of Group Results
6
2.2.2 Underlying Group Result
7
2.2.3 Revenue Breakdown by type
8
2.2.4 Financing Costs and Tax
9
2.2.5 Group Balance sheet
9
2.2.6 Group Cashflow
10
2.3 Funding Group Performance
10
2.3.1 Overview Funding Group Earnings Performance 2.3.2 Funding Group Balance Sheet and Cashflow
10 11
2.4 Group Outlook
12
2.5 Divisional Performance
13
2.5.1 Australia (including global head office costs)
13
2.5.1.1 Result Summary
13
2.5.1.2 Review of Results
13
2.5.1.3 Capital Expenditure
14
2.5.1.4 Focus Areas and Outlook
14
2.5.2 United Kingdom
15
2.5.2.1 Result Summary
15
2.5.2.2 Review of Result
16
2.5.2.3 Capital Expenditure
17
2.5.2.4 Focus Areas and Outlook 2.5.3 Europe
17 18
2.5.3.1 Result Summary
18
2.5.3.2 Review of Results
19
2.5.3.4 Demerger of Ramsay Santé
20
2.5.3.5 Focus Areas and Outlook
20
3 FINANCIAL RESULTS
21
Consolidated Income Statement
22
Consolidated Statement of Comprehensive Income
23
Consolidated Statement of Financial Position
24
Consolidated Statement of Changes in Equity
25
Consolidated Statement of Cash Flows
26
Notes to the Financial Statements
27
2
Ramsay Health Care Limited Appendix 4E and Full Year Results 2026
Disclaimer
Forward-looking statements This report contains forward-looking statements in relation to Ramsay Health Care Limited (Ramsay) and its subsidiaries (together the Group), including with respect to the Group’s business and operations, financial position, and strategies. This report also includes forward-looking statements regarding climate change and other sustainability issues for Ramsay, including the Group’s resilience under climate scenarios. While these forward-looking statements reflect Ramsay’s expectations at the date of this Report, they are not guarantees or predictions of future performance or statements of fact. These statements involve known and unknown risks and uncertainties. Many factors could cause outcomes to differ, possibly materially, from those expressed in the forward-looking statements. These factors include: • general financial and economic conditions in various countries, including Australia, England, Wales, France, Sweden, Denmark, Norway; • operating results; • changes in private health insurer indexation and/or pricing; • industry competition, fluctuations in actual demand and/ or loss of market share for Ramsay’s healthcare services; • legislative, fiscal and regulatory developments, including: – changes in government and/or government policy, including funding decisions and actions by the UK Government in relation to the NHS; and – other actions of regulatory bodies and governmental authorities such as changes in taxation and interest rates set by central banks. • technological changes, including pace of adoption of new technologies; • the extent, nature and location of physical and transitional impacts of climate-related risks; and • geopolitical developments, including political risks and the impact of armed conflict and political instability (such as the ongoing conflicts in Ukraine and in the Middle East) on economic activity and supply chain disruption to clinical and non-clinical products supplied to the Ramsay Group. Ramsay makes no representation, warranty, assurance or guarantee as to the accuracy, completeness or likelihood of fulfilment of any forward-looking statement, any outcomes expressed or implied in any forward-looking statement or any assumptions on which a forward-looking statement is based. To the maximum extent permitted by law, responsibility for the accuracy or completeness of any forward-looking statements, whether as a result of new information, future events or results or otherwise, is disclaimed. In addition, there are limitations with respect to scenario analysis, including any climate-related scenario analysis, and it is difficult to predict which, if any, of the scenarios might eventuate. Scenarios do not constitute definitive or probable outcomes and they rely on assumptions that may or may not prove to be correct or eventuate, and scenarios may be impacted by additional factors to the assumptions disclosed. No undue reliance Except as required by applicable laws or regulations, the Ramsay Group does not undertake to publicly update, review or revise any forward-looking statements or to advise of any change in assumptions on which any such statement is based. Readers are cautioned not to place undue reliance on forward-looking statements. Non-IFRS financial information In this report, references to AASB are to the Australian Accounting Standards Board and IFRS to the International Financial Reporting Standards. There are references to IFRS and non-IFRS (non-statutory) financial information in this report. Non-IFRS financial measures are financial measures other than those defined or specified under any relevant accounting standard and may not be directly comparable with other companies’ information, although Ramsay considers these measures provide useful information in relation to the Group’s performance. Non-IFRS information is unaudited, however the numbers have been derived from the underlying financial information used in the preparation of the audited financial statements.
Ramsay Health Care Limited Appendix 4E and Full Year Results 2026
3
Financial Results
The information in this report is general information only and is not intended to be relied upon as advice to investors or potential investors. It does not take into account your objectives, financial situation or needs. Investors should consult with their own legal, tax, business and/or financial advisers in connection with any investment decision. Past performance information should not be relied upon as (and is not) an indication of future performance.
1 Appendix 4E – Key Matters Results for Announcement to the Market Twelve Mths Ended 30th June A$'m Revenue from contracts with customers Total revenue and other income (less interest income)2 Earnings before finance costs, tax, depreciation, amortisation and rent (EBITDAR) Earnings before finance costs, tax, depreciation, amortisation and impairment (EBITDA) Earnings before finance costs and tax (EBIT) Financing costs associated with leases (AASB16) Net other financing costs Income tax expense Net profit/(loss) after tax Attributable to non-controlling interests Net profit/(loss) after tax after non controlling interests Interim Convertible Adjustable Rate Equity Securities (CARES) dividend per share ($) Final Convertible Adjustable Rate Equity Securities (CARES) dividend per share ($) Franking - CARES (%) Interim ordinary dividend per share (¢) Final ordinary dividend per share (¢) Franking ordinary dividend (%) Basic Earnings per share (after CARES dividend) (¢)3 Fully diluted earnings per share (after CARES dividend) (¢) Fully diluted underlying earnings per share (after CARES dividend) (¢) Net tangible assets/(liabilities) per ordinary share ($)4 Weighted average number of ordinary shares (m) Fully diluted weighted average number of shares (m)
2026 2025 18,577.8 17,673.8 18,690.3 17,779.3 2,469.1 2,323.5 2,308.6 1,105.4 (290.1) (301.7) (192.2) 321.4 7.8 329.2 2.96 3.36 100 42.5 48.5 100 136.2 135.8 151.0 (2.9) 230.2 230.8
Chg 5.1% 5.1% 6.3%
Chg cc1 4.2% 4.2% 5.6%
2,159.4 6.9% 6.4% 706.2 56.5% 56.9% (286.6) (1.2%) (0.5%) (317.8) 5.1% 6.4% (55.5) (246.3%) (251.9%) 46.3 594.2% 606.4% (22.3) 135.0% 124.7% 24.0 1,271.7% 1,283.9% 3.32 (10.8%) 3.07 9.3% 100 40.0 6.3% 40.0 21.3% 100 3.0 3.0 125.3 20.5% 27.0% (4.3) 32.6% 27.7% 229.4 0.3% 230.0 0.3%
1 Constant currency 2 Does not include intersegment income 3 EPS attributable to equity holders of the parent 4 Includes right of use assets
Explanation of results Ramsay reported a 1,271.7% increase in Net Profit after Tax and non-controlling interests compared to the prior corresponding period (pcp) to $329.2m. The improvement primarily reflects a 17.9% (cc) increase in underlying earnings from the Funding Group1 and the impact of a $291m post tax impairment booked in the prior year related to the UK region. The percentage movement in financial results compared to the prior period is impacted by the foreign currency translation of the Australian dollar (AUD) versus the Euro (EUR) and the British Pound (GBP) compared to the pcp. Results are provided in both reported currency and constant currency (cc). For further explanation of results please refer to the accompanying Review of Results of Operations and ASX announcement.
Dividends A fully franked final dividend of 48.5 cents per share (cps) has been determined taking the full year dividend to fully franked 91.0 cps. This represents a full year payout ratio from underlying net profit after tax of 60.3%. The Dividend Reinvestment Plan (DRP) will not operate for this dividend.
Other information required by Listing Rule 4.2A Additional Appendix 4E disclosure requirements can be found in the 30 June 2026 Full Year Financial Report and the accompanying Operating and Financial Review, Results Presentation and ASX announcement. The audit of this report by EY is in progress.
1
4
Funding Group - Ramsay Health Care Limited and its subsidiaries excluding Ramsay Santé.
Ramsay Health Care Limited Appendix 4E and Full Year Results 2026
2 Operating and Financial Review 2.1 Who We Are Financial Results
Ramsay Health Care (Ramsay) provides quality healthcare services in its core market in Australia, in the UK comprising two businesses Ramsay UK hospitals and Elysium mental health services and in Europe through its 52.79% ownership of Ramsay Santé, which operates in France and the Nordics region. Ramsay was founded in 1964 by Paul Ramsay AO (1936-2014) and has always focused on maintaining the highest standards of quality and safety, being an employer of choice and operating the business based on our purpose of 'people caring for people'. Ramsay listed on the Australian Stock Exchange in 1997 and has a market capitalisation of A$10.2bn1 and an enterprise value (EV) of A$15.4bn1 (EV of A$21.1bn inclusive of lease liabilities). Ramsay’s interests are split across three regions:
Australia Ramsay Australia's core focus is operating private acute hospitals delivering complex care including in its priority therapeutic areas, cardiology, oncology, orthopaedics and psychology. Ramsay Australia has 70 hospitals, clinics and day surgery units2 and is Australia’s largest private hospital operator. Ramsay’s operations include mental health facilities as well as the operation of two public hospitals. Ramsay also provides hospital in the home and telehealth services and operates 31 allied health clinics. In addition, Ramsay has established the Ramsay Pharmacy retail franchise network which supports 62 community pharmacies and 41 in-hospital dispensaries. Ramsay Australia admits more than 1.2m patients annually and employs +36,000 people. Our vision is to be Australia's most trusted leading healthcare provider.
UK Ramsay UK has a network of 34 acute hospitals and day procedure centres providing a comprehensive range of clinical specialities to private and self-insured patients as well as to patients referred by the NHS. Ramsay UK cares for more than 215,000 patients per year and employs more than 7,500 people. In January 2022, Ramsay acquired Elysium Healthcare, a leading independent provider of specialist mental health and care services across England and Wales. Following the recent restructure Elysium operates 88 sites with approximately 2,196 beds. The business employs ~8,900 people.
Ramsay Santé Ramsay Santé is a leading private health care provider in Europe, operating 487 healthcare facilities across five countries in Europe. In France, Ramsay Santé has a market leading position in acute care and mental health facilities. In Denmark, Norway and Sweden, Ramsay Santé operates facilities including primary care units, specialist clinics and hospitals. Ramsay Santé also operates a 93-bed hospital in Italy. Ramsay Santé employs more than 40,000 employees and its facilities treat more than 13 million patients each year. Ramsay Health Care owns 52.79% of Ramsay Santé which is listed on the European financial markets’ platform Euronext. On 20 February 2026, Ramsay announced a proposal to distribute Ramsay Santé shares held by Ramsay to Ramsay shareholders. If approved, Ramsay shareholders will receive shares in Ramsay Santé proportional to their Ramsay shareholding by way of an in-specie distribution. The proposed distribution is expected to be implemented through a scheme of arrangement and is subject to Ramsay Board, shareholder and regulatory approvals.3
1 2 3
Closing price as of 25 August 2026 Includes the management of Joondalup and Noosa public health campuses Refer ASX announcement 20 February 2026 - Update on Strategic Review of Ramsay Santé – proposal to separate Ramsay Santé from Ramsay
Ramsay Health Care Limited Appendix 4E and Full Year Results 2026
5
2.2 Group Performance 2.2.1 Overview of Group Results Twelve Mths Ended 30th June A$'m Australia UK Europe Total segment revenue & other income (less interest income)2 Australia UK Europe EBITDAR Rent on short term or low value leases Australia UK Europe EBITDA Depreciation Amortisation & impairment3 Australia UK Europe EBIT Financing costs (AASB16 Leases) Net other financing costs (net of interest income) Profit/(Loss) before Tax Income tax expense Net Profit/(Loss) after tax Attributable to non-controlling interests Net Profit/(Loss) after tax after non-controlling interests Items excluded from Underlying EBIT Underlying EBIT Items excluded from underlying NPAT after non-controlling interests Underlying Profit after tax after non-controlling interests Final dividend per share (¢) Total dividend per share (¢) Basic Earnings per share (after CARES dividend) (¢) Fully diluted earnings per share (after CARES dividend) (¢) Fully diluted underlying earnings per share (after CARES dividend) (¢) Weighted average number of ordinary shares (m) Fully diluted weighted average number of shares (m) 1 Constant currency 2 Includes intersegment revenue 3 FY25 result includes impairment of $305.2m against the UK cash generating unit
6
Ramsay Health Care Limited Appendix 4E and Full Year Results 2026
2026 2025 Chg Chg cc1 6,818.1 6,322.7 7.8% 7.8% 2,605.0 2,661.7 (2.1%) (1.2%) 9,275.5 8,802.8 5.4% 3.2% 18,698.6 17,787.2 5.1% 4.2% 905.5 829.1 9.2% 9.2% 351.2 321.8 9.1% 10.6% 1,212.4 1,172.6 3.4% 1.7% 2,469.1 2,323.5 6.3% 5.6% (160.5) (164.1) 2.2% 4.8% 892.7 816.6 9.3% 9.3% 347.4 317.2 9.5% 11.1% 1,068.5 1,025.6 4.2% 2.7% 2,308.6 2,159.4 6.9% 6.4% (1,146.4) (1,086.8) (5.5%) (4.1%) (56.8) (366.4) 84.5% 84.0% 629.9 560.2 12.4% 12.4% 176.9 (144.3) 222.6% 227.3% 298.6 290.3 2.9% 2.9% 1,105.4 706.2 56.5% 56.9% (290.1) (286.6) (1.2%) (0.5%) (301.7) (317.8) 5.1% 6.4% 513.6 101.8 404.5% 413.3% (192.2) (55.5) (246.3%) (251.9%) 321.4 46.3 594.2% 606.4% 7.8 (22.3) 135.0% 124.7% 329.2 24.0 1,271.7% 1,283.9% (56.8) (336.4) 83.1% 78.2% 1,162.2 1,042.6 11.5% 11.8% (34.9) (281.3) 87.6% 83.4% 364.1 305.3 19.3% 22.9% 48.5 40.0 21.3% 91.0 80.0 13.8% 136.2 3.0 135.8 3.0 151.0 125.3 20.5% 27.0% 230.2 229.4 0.3% 230.8 230.0 0.3%
2.2.2 Underlying Group Result 2026
2025
Chg
Chg cc1
6,804.1 2,594.9 9,260.6
6,319.8 2,661.7 8,799.9
7.7% (2.5%) 5.2%
7.7% (1.5%) 3.0%
18,659.6 915.4 356.0 1,232.5 2,503.9 (160.5) 902.6 352.2 1,088.6 2,343.4 (1,146.4) (34.8) 639.8 160.5 31.1 191.6 330.8 1,162.2 (591.8) 570.4 (205.0) 365.4 (1.3) 364.1
17,781.4 828.1 328.7 1,176.2 2,333.0 (164.1) 815.6 324.1 1,029.2 2,168.9 (1,086.8) (39.5) 575.5 147.3 22.0 169.3 297.8 1,042.6 (592.6) 450.0 (147.0) 303.0 2.3 305.3
4.9% 10.5% 8.3% 4.8% 7.3% 2.2% 10.7% 8.7% 5.8% 8.0% (5.5%) 11.9% 11.2% 9.0% 41.4% 13.2% 11.1% 11.5% 0.1% 26.8% (39.5%) 20.6% (156.5%) 19.3%
4.0% 10.5% 9.6% 3.1% 6.8% 4.6% 10.7% 10.0% 4.2% 7.7% (4.1%) 12.7% 11.2% 10.3% 43.5% 14.6% 11.4% 11.8% 1.2% 32.3% (45.1%) 24.1% (221.9%) 22.9%
151.0
125.3
20.5%
27.0%
Financial Results
Twelve mths ended 30 June A$'m CONTINUING OPERATIONS Australia UK Europe Underlying segment revenue & other income (less interest income)2 Australia UK Europe Group Underlying EBITDAR Rent on short term or low value leases Australia UK Europe Group Underlying EBITDA Depreciation Amortisation & impairment Australia _Ramsay UK _Elysium Total UK region Europe Group Underlying EBIT Underlying interest Underlying PBT Underlying tax Underlying NPAT Underlying non-controlling interests Underlying NPAT ex non-controlling interests Fully diluted underlying earnings per share (after CARES dividend) (¢) 1 constant currency 2 Includes intersegment revenue
Items excluded from underlying profit are reported as not representing the underlying performance of Ramsay, whether positively or negatively. Underlying profit excludes the impact of significant: impairment (or reversal of impairment) of assets (site and goodwill); acquisition, divestment and restructuring costs; gains or losses on assets disposal or fair value revaluation; and one-off events and items of a significant nature such as natural disasters, legal disputes, tax claims and insurance claims.
Items excluded from the FY26 underlying results A$'m Net profit on disposal of non-current assets and businesses Provision for employee costs related to prior periods Impairment of carrying value of assets Restructuring costs Acquisition, disposal and development costs/benefits Total EBIT Impact Income tax impact Non-controlling interests net of tax Net (loss)/profit after tax and non-controlling interests impact
Australia 14.0 (20.5) (3.4) (9.9) 2.2 (7.7)
UK 10.1 (9.9) (14.9) (14.7) 3.7 (11.0)
Europe 14.9 7.7 (12.1) (19.7) (23.0) (32.2) 6.9 9.1 (16.2)
RHC Group 39.0 (12.8) (22.0) (34.6) (26.4) (56.8) 12.8 9.1 (34.9)
Items excluded from FY26 Underlying Results include: • $39.0m net profit on the disposal of non-current assets and businesses including a $14m profit on the disposal of Ramsay Australia's ~10% shareholding in online healthcare specialist booking service HotDoc; $10.1m in profits associated with the restructuring of Elysium's portfolio of sites; and the gain on the restructure of two sites in Ramsay Santé's portfolio ($19.1m) partially offset by a loss on the sale of its medical transport business ($6.5m); • Following a Fair Work Commission (FWC) decision (ANMF v Ramsay Health Care Australia [2024] FWC 3518), relating to the interpretation of how to calculate annual leave and annual leave loading payments under the NSW Nurses and Midwives’ Enterprise Agreement 2021-2023, Ramsay has recognised a $20.5m provision. The combination of factors that led to this interpretation issue
Ramsay Health Care Limited Appendix 4E and Full Year Results 2026
7
were isolated to this Agreement and does not affect the current Ramsay Health Care New South Wales Nurses and Midwives Enterprise Agreement 2023-2026.; • The reversal of an employee provision created in FY24 that is no longer needed in Ramsay Santé ($7.7m); • Site impairments in the UK, largely related to an Elysium site closure and Ramsay Santé's of $22m; • $34.6m of costs associated with the restructure of the Ramsay Santé and Elysium portfolios, including site closures; and • Acquisition, disposal and development costs in Australia ($3.4m) and Ramsay Santé ($26.4m) including costs related to the demerger of Ramsay Santé1 ($16m) and the costs associated with the proposed acquisition of National Capital Private Hospital in the Australian Capital Territory.
Items excluded from the FY25 underlying results A$'m Net profit on disposal / acquisition of development assets, non-current assets and businesses Impairment of the carrying value of assets Transaction costs/ Acquisition, disposal, revaluation and development costs/benefits Total EBIT Impact Net swap mark to market movements Total (loss)/profit before tax impact Tax liability provision release Income tax impact Non-controlling interests net of tax Net (loss)/profit after tax and non-controlling interests impact
Australia
UK
Europe
RHC Group
2.9 (16.3)
(306.7)1
2.9 (3.9)
5.8 (326.9)
(1.9) (15.3) (15.3) 4.3
(6.9) (313.6) (313.6) 16.1
(6.5)2 (7.5) (11.8) (19.3) 64.5 6.6 (24.6)
(15.3) (336.4) (11.8) (348.2) 64.5 27.0 (24.6)
(11.0)
(297.5)
27.2
(281.3)
1 Includes $1.5m impairments associated with Ramsay UK 2 Includes the remeasurement of options to buy back minority interests in a primary care business in Denmark $7.6m
Items excluded from FY25 Underlying Results included: • A non-cash impairment of $305m (£151m) (post tax impact $291m (£144m) taken against the value of the UK region CGU (cash generating unit) in 1HFY25 reflecting the ongoing underperformance of the Elysium Healthcare (Elysium) business compared to the original business plan at the time of the acquisition in January 2022.2 The underperformance of the business was driven primarily by minimum wage increases, the rise in the National Insurance levy and lower than expected occupancy levels at some existing and new sites. The impairment was split into a $57m (£28m) site impairment and a $248m (£123m) goodwill impairment within the UK region CGU; • The release of a non-cash, uncertain tax liability provision taken up by Ramsay at the time of the acquisition of an interest in Ramsay Santé in 2015. The tax provision of $64.5m ($34m after non-controlling interests) was released in 1HFY25 as the time period required to hold the provision has lapsed; • A negative non-cash mark to market on a swap in Ramsay Santé's debt funding of $11.8m booked in 1HFY25. The swap was closed out in 1HFY25; and • Net impairments taken in the Australian business in 2HFY25 of $16.3m including an impairment against the leased and fixed asset value of Ramsay Psychology clinics, reflecting the shift to new models of care in the provision of mental health services.
2.2.3 Revenue Breakdown by type Twelve Mths Ended 30th June A$'m Revenue from contracts with customers Interest income Other income - income from government grants Other income - income from the sale of development assets Other income - net profit on acquisition/disposal of non-current assets and businesses Other income - miscellaneous Total revenue and other income before inter-segment revenue including interest income
2026 18,577.8 16.6 2.2
2025 17,673.8 17.4 29.2 10.1
Chg 5.1% (4.6%) (100.0%) (78.2%)
Chg cc1 4.2% (2.9%) (100.0%) (77.5%)
39.0 71.3
5.8 60.4
572.4% 18.0%
592.6% 19.8%
18,706.9
17,796.7
5.1%
4.2%
1 Constant currency
Growth in revenue across the Group was driven by an increase in activity in Australia and Ramsay Santé, higher levels of acuity in all regions, mix and payor indexation. Income from Government grants ceased as the French Government withdrew its revenue guarantee support from 1st January 2025 and there were no further significant grants or subsidies provided in FY26. In the prior period the revenue guarantee booked was €20m.
1 2
8
Refer ASX announcement 20th February 2026 Refer ASX announcement 11th February 2025
Ramsay Health Care Limited Appendix 4E and Full Year Results 2026
Net profit on the disposal of non-current assets and businesses including a $14m profit on the disposal of Ramsay Australia's ~10% shareholding in online healthcare specialist booking service HotDoc. Refer Divisional Performance for further details
2.2.4 Financing Costs and Tax Total net financing costs for the Consolidated Group (excl. AASB16 lease costs) declined 6.4% (cc) primarily reflecting the $11.8m mark to market in the prior period. Excluding the mark to market in the prior period, net financing costs (excl. AASB16 lease costs) decreased 2.7% (cc) on the pcp to $301.7m.
2.2.5 Group Balance sheet A$'m Working capital Property plant & equipment Intangible assets Current & deferred tax assets Other assets/(liabilities)1 Capital employed (before right of use assets) Right of use assets Capital employed Capitalised Lease Liability (AASB16) Net Debt (excl. lease liability debt & excl. derivatives)2 Total shareholders funds Invested Capital Return on capital employed (ROCE) (%)3 Return on invested capital (Accounting ROIC) (%)4 Return on invested capital (Cash ROIC) (%)5
30-6-2026 728.3 5,701.4 5,975.5 217.1 (1,189.7) 11,432.6 4,429.8 15,862.4 5,704.7 4,563.9 5,593.8 15,862.4 11.0 4.6 11.9
31-12-2025 787.9 5,954.0 6,317.2 226.5 (1,127.5) 12,158.1 4,958.8 17,116.9 6,247.8 5,145.9 5,723.2 17,116.9 9.9 4.3 11.1
30-6-2025 596.5 5,820.0 6,431.1 205.8 (1,342.2) 11,711.2 5,333.0 17,044.2 6,583.0 4,752.5 5,708.7 17,044.2 9.9 4.3 11.5
1 Employee entitlement liability/obligations have been reclassified from creditors to provisions in prior years 2 Net debt has been restated to exclude derivatives to align with the Funding Group leverage calculation 3 ROCE 12 month rolling Underlying EBIT/average of opening & closing capital employed excluding goodwill 4 Accounting ROIC = 12 mth rolling Underlying EBIT*(1-tax)/average of opening & closing invested capital 5 Cash ROIC = 12 month rolling NOPAT / average of opening & closing invested capital (excluding lease liabilities)
Key changes in the balance sheet since 30th June 2025 relate to: • The impact of currency translation ~$300m; • Working capital movements in Ramsay Santé associated with the timing of support payments from the French Government; • Elysium portfolio restructure resulted in $300m reduction to right of use assets and corresponding movement in capitalised lease liability; • The increase in underlying property, plant and equipment as new developments in Australia are completed; and • Ramsay previously presented its current employee entitlement liabilities, primarily comprising annual leave and long service leave, within Current Trade and Other Creditors in the Statement of Financial Position. Management has reassessed the presentation of these balances and determined that classification as Current Provisions more appropriately reflects their nature. Accordingly, prior year comparatives as at 30 June 2025 have been updated by reclassifying $1,262m from Working Capital to Current Provisions. There was no impact to Total Current Liabilities.
1
CVAE - The contribution on the added value of companies (CVAE) is a local tax payable by French companies with a turnover above €0.5m and is used to fund local administration".
Ramsay Health Care Limited Appendix 4E and Full Year Results 2026
9
Financial Results
The reported effective tax rate for the period was 37.4% compared to 54.5% in the pcp (FY25 effective rate included the release of an uncertain tax position liability taken up by Ramsay at the time of the acquisition of an interest in Ramsay Santé in 2015 and the non-deductible goodwill impairment in the UK CGU). The underlying effective tax rate for the period was 35.9% compared to 32.7% in the pcp. The higher rate relative to corporate tax rates in the jurisdictions Ramsay operates, reflects the impact of CVAE1 taxes and Ramsay Santé's loss before tax result in the FY26 period.
2.2.6 Group Cashflow Twelve Mths Ended 30th June A$'m EBITDA from continuing operations Changes in working capital Finance costs Income tax paid Movement in other items Operating cash flow Capital expenditure Free cash flow Net divestments/(acquisitions) Interest & dividends received and deposits paid Cash flow after investing activities Dividends paid Other financing cash flows Net (decrease)/increase in cash
2026 2,308.6 (131.8) (594.9) (193.3) 42.1 1,430.7 (734.2) 696.5 115.1 (44.5) 767.1 (238.0) (551.0) (21.9)
2025 2,159.4 89.5 (592.0) (210.1) 34.0 1,480.8 (776.6) 704.2 (5.2) 16.5 715.5 (190.7) (440.5) 84.3
Chg 6.9% (247.3%) (0.5%) 8.0% 23.8% (3.4%) 5.5% (1.1%) 2,313.5% (369.7%) 7.2% (24.8%) (25.1%) (126.0%)
• Operating cashflow reflects a 46% improvement in operating cashflow in the Funding Group offset by a negative working capital variance in Ramsay Santé primarily reflecting the timing of support payments from the French Government; • Australia, the UK Acute business and Elysium were net cashflow positive for the 12 month period; • The decline in capex reflects reduced investment in developments in Australia combined with lower capex in the UK region and flat spend in Ramsay Santé in local currency compared to the pcp; • Investing cashflow includes the €26m refundable net deposit paid by Ramsay Santé as part of the new St Göran (Sweden) eight year contract along with a sale and leaseback in Santé and investment sale in Australia; • Dividends paid increased 24.8% reflecting the suspension of the dividend reinvestment plan (DRP) for the FY25 final dividend
2.3 Funding Group Performance The Funding Group is comprised of Ramsay Health Care and all its subsidiaries, excluding Ramsay Santé. The Funding Group's investment in Ramsay Santé is recorded as an investment on the balance sheet at $837.4m at the end of the period ($964.6m in pcp difference reflects exchange rate translation impact). Ramsay's banking covenants and Fitch credit rating are based on the Funding Group's earnings profile and net debt.
2.3.1 Overview Funding Group Earnings Performance Twelve Mths Ended 30th June A$'m Australia UK Total segment revenue and other income Employee benefits & contractor costs EBITDAR EBITDA Australia UK EBIT Financing costs (AASB16 Leases) Net other financing cost (net of interest income) Net profit after tax after non-controlling interests Items excluded from underlying EBIT Underlying EBIT Items excluded from underlying net profit after tax and non controlling interests Underlying Net Profit after tax and non controlling interests EBITDA margin (%) Underlying EBIT margin (%) Return on capital employed (ROCE) (%)2 Return on invested capital (ROIC) (%)3
2026 6,818.1 2,605.0 9,423.1 (5,174.4) 1,256.7 1,240.1 629.9 176.9 806.8 (149.9) (109.6) 379.7 (24.6) 831.4
2025 6,322.7 2,661.7 8,984.4 (4,940.5) 1,150.9 1,133.8 560.2 (144.3) 415.9 (152.1) (104.2) 36.7 (328.9) 744.8
(18.7) 398.4 13.2% 8.8% 14.8% 6.3%
(308.5) 345.2 12.6% 8.3% 13.3% 5.7%
1 constant currency 2 ROCE 12 month rolling Underlying EBIT/average of opening & closing capital employed excluding goodwill 3 Accounting ROIC = 12 mth rolling Underlying EBIT*(1-tax)/average of opening & closing invested capital
10
Ramsay Health Care Limited Appendix 4E and Full Year Results 2026
Change 7.8% (2.1%) 4.9% (4.7%) 9.2% 9.4% 12.4% 222.6% 94.0% 1.4% (5.2%) 934.6% 92.5% 11.6%
Change cc1 7.8% (1.2%) 5.2% (5.2%) 9.2% 9.4% 12.4% 224.4% 93.2% 0.9% (4.9%) 921.4% 87.6% 12.0%
93.9% 15.4% 60bps 50bps 150bps 60bps
90.0% 17.9% 124bps 60bps
Australia reported 11.2% growth in Underlying EBIT driven by higher activity growth, higher levels of acuity and theatre utilisation, improved PHI1 indexation and cost management. The full year result was partially offset by a decline in the contribution from the Joondalup Health Campus (-$26m), reflecting the new funding mechanism which was partially mitigated by operational actions. Reported EBIT increased 12.4% and includes profits on the sale of a ~10% investment in Hotdoc off set by a provision raised related to a Fair Work decision, for additional employee related expenses in prior years (refer Section 2.2.2 for further detail) and fees associated with the acquisition of National Capital Private Hospital. (Refer Section 2.3.1 Australian Performance for further information).
Depreciation and amortisation declined 39.6% primarily reflecting the $305m impairment taken in the UK CGU in the pcp. Depreciation increased 7.3% over the period primarily reflecting the completion of new developments in the Australian region. Total net financing costs for the Funding Group (excl. AASB16 lease costs) increased 5.2% primarily reflecting higher base rates and a lower level of hedging over the period. Funding Group interest cover remained strong at 8.94x. During FY26, $2.5bn of Funding Group debt facilities were refinanced resulting in tenor extension and 30bps margin improvement for the syndicated loan facility. The weighted average cost of debt for the Funding Group (excluding CARES2) for FY27 is expected to be approximately 5.5%. Approximately 60% of the Funding Group‘s floating rate debt in FY27 is hedged at an average base rate (excluding lending margin) of 3.6%. The effective underlying tax rate for the period was 29.4% compared to 28% in the pcp.
2.3.2 Funding Group Balance Sheet and Cashflow Funding Group Balance Sheet $'m Working capital Property plant & equipment Intangible assets Current & deferred tax assets Other assets/(liabilities) Capital employed (before right of use assets) Right of use assets Capital employed Capitalised Lease Liability(AASB16) Net Debt (excl. lease liability debt & excl. derivatives) Total shareholders funds Invested Capital Funding group interest cover (x) Funding Group Leverage ratio (x)1 Return on capital employed (ROCE) (%)
30-06-26 496.4 3,881.6 2,717.7 219.2 372.4 7,687.3 1,281.0 8,968.3 2,218.6 1,912.8 4,836.9 8,968.3 8.94 1.83 14.8
31-12-25 543.2 3,927.2 2,795.1 217.4 515.4 7,998.3 1,630.6 9,628.9 2,615.2 2,109.3 4,904.4 9,628.9 8.59 2.22 13.1
30-06-25 508.5 3,838.0 2,863.9 198.7 528.3 7,937.4 1,694.9 9,632.3 2,710.0 2,028.9 4,893.4 9,632.3 8.93 2.18 13.3
1 Leverage ratio for the purposes of banking covenants calculated -Funding Group adjusted net debt (excl lease liabilities and derivatives )/Funding Group adjusted Underlying EBITDA
Key changes in the Funding Group balance sheet since 30th June 2025 relate to: • The impact of currency translation ~$300m; • Working capital movement reflects focus on cash collection in both Australia and UK with a particular focus on aged debtors; • Elysium portfolio restructure resulted in $300m reduction to right of use assets and corresponding movement in capitalised lease liability; • The increase in property plant and equipment and new developments in Australia following the completion of developments; and • The Group previously presented its current employee entitlement liabilities, primarily comprising annual leave and long service leave, within Current Trade and Other Creditors in the Statement of Financial Position. Management has reassessed the presentation of these balances and determined that classification as Current Provisions more appropriately reflects their nature. Accordingly, prior year comparatives as at 30 June 2025 have been updated by reclassifying $436.9m from Current Trade and Other Creditors to Current Provisions. There was no impact to Total Current Liabilities. Funding Group leverage at 30 June 2026 was 1.83x in line with the Funding Group's target of less than 2.5x. 1 2
Private Health Insurance CARES - Convertible Adjustable Rate Equity Securities
Ramsay Health Care Limited Appendix 4E and Full Year Results 2026
11
Financial Results
The UK region reported 14.6% (cc) growth in underlying EBIT reflecting a 10.3% (cc) increase in Underlying EBIT from Ramsay Acute and 43.5% (cc) increase in underlying EBIT from Elysium. The UK acute hospital business was impacted by NHS budgetary constraints resulting in lower NHS volumes compared to the pcp partially offset by higher private pay volumes. Lower NHS volume was mitigated by a focus on higher acuity and private work, as well as operational initiatives. Elysium's performance turnaround plan is underway and beginning to gain traction, including central cost reduction, agency reduction, site optimisation and fee negotiation. Elysium was impacted by reduced NHS activity in overnight care settings. Reported EBIT for the UK region increased 224.4% (cc) reflecting improved performances from both businesses and the large impairment to the UK CGU in the prior period. (Refer Section 2.3.2 UK Region Performance for further information).
Funding Group Cashflow Twelve Mths Ended 30th June A$'m EBITDA from operations Changes in working capital Finance costs Income tax paid Movement in other items Operating cash flow Capital expenditure Free cash flow Net divestments/(acquisitions) Interest & dividends received Cash flow after investing activities Dividends paid Other financing cash flows Net increase/(decrease) in cash
2026 1,240.1 12.1 (273.4) (159.0) 49.3 869.1 (486.7) 382.4 34.2 9.0 425.6 (209.6) (108.4) 107.6
2025 1,133.8 (84.9) (265.4) (180.9) (6.9) 595.7 (537.0) 58.7 (10.9) 7.3 55.1 (165.5) 150.8 40.4
Chg 9.4% 114.3% (3.0%) 12.1% 814.5% 45.9% 9.4% 551.4% 413.8% 23.3% 672.4% (26.6%) (171.9%) 166.3%
• Operating cashflow increased 45.9% including an improvement in working capital reflecting a focus on revenue cycle management and strengthening manual claiming processes to improve working capital across the regions (cash conversion cycle2 in Australia reduced by 4 days); • Australia, the UK Acute business and Elysium were all net cashflow positive for the 12 month period; • Tax paid reduced from the prior period reflecting tax payments related to the profit on sale of Ramsay Sime Darby in the pcp; • Movement in other items includes a one off $20.5m provision raised in Australia related to a prior period following a FWC decision. (see Section 2.2.2 for further details); • The reduction in capital expenditure reflects reduced spend in the UK region and flat spend in Australia reflecting a focus on the utilisation of existing capacity; • Proceeds from the sale of businesses primarily reflects the disposal of Ramsay's ~10% holding in HotDoc, combined with asset sale proceeds in Elysium and Australia; and • Dividends paid increased 26.6% reflecting the suspension of the dividend reinvestment plan (DRP) for the FY25 final dividend (DRP operated in the pcp).
2.4 Group Outlook Assuming the proposed separation of Ramsay Santé is approved by shareholders, Ramsay Santé will be reported as a discontinued business in the 1H and FY27 results reflecting: • The result from 5.5 months of ownership will be treated as a discontinued business in 1H • Costs associated with the demerger of Ramsay Santé (including $16m incurred to 30 June 2026), to be detailed in demerger booklet. Ramsay Funding Group is expected to report EBIT growth and EBIT margin improvement in FY27, with growth in EBIT in Australia and both UK businesses. • Australia targeting incremental YoY EBIT growth (Including and excluding Nat Cap) and margin expansion3 driven by activity growth, improved capacity utilisation, revenue indexation in line with cost indexation, and operational improvement initiatives, as well as $10-15m increase in investment in IT, technology and transformation; • National Capital expected to be EPS accretive in first 12 mths of ownership, transition opex costs of $9-11m in FY27;4 • UK Hospitals expect growth in EBIT in FY27 driven by higher acuity, private work focus and ongoing operational efficiencies; • Elysium targeting growth in EBIT as they continue delivery of turnaround plan, with weak market demand expected to continue; • Funding Group net financing expense (inclusive of AASB 16 lease costs) forecast to be $280-300m; • Funding Group effective tax rate on underlying earnings is expected to be ~30%; • Funding Group total capex guidance $480-520m. • Dividend payout ratio expected to be 60-70% of underlying Group net profit after tax and non-controlling interests.
For further detail refer to Divisional Outlook Statements
3 4
Including and excluding Nat Cap Transition costs expected to be skewed to 1H results. Transition costs will be excluded from Underlying Earnings
12
Ramsay Health Care Limited Appendix 4E and Full Year Results 2026
2.5 Divisional Performance 2.5.1 Australia (including global head office costs) 2.5.1.1 Result Summary 2026 5,254.1 626.3 913.2 2.2 14.0 8.3 6,818.1 (3,545.4) 905.5 (12.8) 892.7 (253.2) (9.6) 629.9 (52.6) 577.3 (9.9) 639.8 9.40% 52.0% 17.4%
2025 4,864.3 592.3 855.3 2.9 7.9 6,322.7 (3,266.2) 829.1 (12.5) 816.6 (231.2) (25.2) 560.2 (51.6) 508.6 (15.3) 575.5 9.10% 51.7% 16.5%
Chg 8.0% 5.7% 6.8% 382.8% 5.1% 7.8% (8.5%) 9.2% (2.4%) 9.3% (9.5%) 61.9% 12.4% (1.9%) 13.5% 35.3% 11.2% 30bps 30bps 90bps
1,242.3 68.8% 2,802.3 1,234.3 2,792.4
1,213.1 68.7% 2,734.0 1,194.7 2,707.3
2.4% 10bps 2.5% 3.3% 3.1%
1 Revenue from customers = revenue from hospital admissions and out-patients; less pharmacy revenue and other revenue including prothesis 2 Other includes prothesis revenue, rental income and other 3 Refer Section 2.2.2 for further details on items not included in Underlying EBIT 4 12 month rolling Underlying EBIT/average of opening & closing capital employed excluding goodwill 5 Inpatient and day admissions (days) 6 Like for like excludes Peel and Border Cancer Hospitals that have transitioned back to public operation
2.5.1.2 Review of Results The 11.2% growth in underlying EBIT in Australia reflects good activity growth, higher capacity utilisation and higher levels of acuity combined with improved PHI indexation; partially offset by the forecast decline in the performance of Joondalup Health Campus (Joondalup) reflecting indexation under the new funding mechanism agreed with the WA Government in March 2024 not keeping up with cost inflation. The impact at Joondalup was partially mitigated by operational initiatives resulting in a net negative $26m impact. Revenue from customers increased 8.0% driven by a 2.4% increase in total hospital admissions (3.3% increase in admissions on a like for like basis1) higher case acuity and improved payor indexation. Revenue flowing from the private hospital portfolio2 increased 8.4%. Revenue from public funded admissions (including public in private) increased 6.5% (9.5% like for like1) reflecting good growth in activity at Joondalup and an increase in public activity in private primarily in 1H. Activity growth (on a like for like basis1) reflects: • Surgical admissions increased 4.1% representing 53.8% of total admissions (53.4% in pcp); • Non-surgical admissions increased 2.5% driven by a 3.2% increase in medical admissions, a 3.8% increase in rehab and flat maternity admissions, partially offset by a decline in mental health admissions -3.9% (overnight mental health admissions increased 0.9%); • Day admissions increased 3.8% growing more strongly than overnight admissions +2.3% and includes the contribution from new short stay surgical centres at Charlestown and Caloundra opened during the year; • Privately funded admissions increased 2.8% and publicly funded admissions (including public in private) increased 9.5% reflecting strong growth in activity at Joondalup and good growth in public activity in our private hospitals (from a low base) in 1H; and 1 2
Like for like - excludes Peel and Border Cancer Hospital that transitioned back to public operation in 1HFY25 and 2HFY26 respectively Excludes Joondalup Public Hospital, Noosa Hospital and Peel Hospital
Ramsay Health Care Limited Appendix 4E and Full Year Results 2026
13
Financial Results
Twelve Mths Ended 30th June A$'m Revenue from customers1 Pharmacy Other2 Income from the sale of development assets Net profit on disposal of non-current assets and acquisition of businesses Intersegment revenue Total segment revenue and other income (less interest income) Employee benefits & contractor costs EBITDAR Rent EBITDA Depreciation Amortisation and impairment EBIT Financing costs associated with leases (AASB16 leases) EBIT after financing costs associated with leases Items excluded from underlying EBIT3 Underlying EBIT Underlying EBIT margin (%) Employee benefits as a % of revenue ROCE (%)4 Volume Metrics Admissions ('000) % day admissions IPDA's ('000)5 Admissions (like for like) ('000)6 IPDA's (like for like )6 ('000)
• IPDA's (Inpatient and day admission days) increased 3.1%. Overnight IPDA's +3.0% vs +2.3% in overnight admissions reflecting higher acuity mix in surgical, medical and rehab. Revenue from pharmacies increased 5.7% reflecting growth in activity in both hospital dispensaries and community pharmacies. Other revenue includes prothesis revenue, rental income from medical suites and other miscellaneous revenue. Growth primarily reflects the growth in activity through the hospitals. Employee benefits and contractor costs includes a $20.5m provision for employee costs related to prior periods, raised following a FWC decision. (see Section 2.2.2 for further details). Removing the impact of this, employee costs increased 7.9% on pcp but as a percentage of revenue were flat at 51.7%. Excluding the impact of the new pricing mechanism at Joondalup labour costs declined as a % of revenue. The 9.5% increase in depreciation reflects the opening of new developments in FY25 and FY26 including 3 new theatres at Warringal and new surgical centre openings at Caloundra and Charlestown. Over the FY26 year 22 theatres and other treatment rooms were opened. Amortisation declined over the pcp reflecting a $16.3m net impairment taken in FY25 (primarily an impairment against the leased and fixed asset value of Ramsay Psychology Clinics following the closure of the majority of the clinics). Underlying EBIT increased 11.2% and reflects: • Increased activity levels, higher acuity, an overall improvement in capacity utilisation and improved PHI indexation; • The negative impact of lower funding associated with the management of Joondalup Public. The estimated -$37m gross impact of the new funding mechanism was partially mitigated through additional volume, cost and productivity initiatives (-$26m impact); and • Opex associated with transformation and digital activities was marginally lower reflecting the restructure of these programs to optimise spend. Reported EBIT increased 12.4% on the pcp and includes: • $3.8m of costs associated with the proposed acquisition of National Capital Private Hospital in the Australian Capital Territory; • $14.1m profit on the disposal of Ramsay's ~10% shareholding in online healthcare specialist booking service HotDoc; • A $20.5m provision raised following a FWC decision (refer Section 2.2.2 for further details).
2.5.1.3 Capital Expenditure Total capital expenditure in Australia in FY26 was $365.4m compared to $361.8m in the pcp. The spend was split: • Development projects - $150.4m ($197.2m in pcp); • Other growth projects - $40.6m ($19m in pcp); • IT, Digital and data projects - $17.5m ($21.4m in pcp); and • Routine and maintenance projects - $156.9m ($124.2m in pcp). Development capex spend in FY26 was focused on large projects including the completion of the ~$173m redevelopment of Joondalup Private (Perth) and the final phase of the Warringal Private Hospital (Melbourne) as well as the expansion of treatment capacity at some of our larger hospitals. Development capex was supplemented by incentive payments paid by landlords ($30.8m) on leased sites being developed. The incentive payments will be capitalised into the value of the lease and amortised over time. The increase in routine and maintenance spend reflects investment in ensuring that clinical quality, safety and amenity standards are maintained in Ramsay's leading hospital network. The increase in other growth projects includes investment in robotics in our key hospitals.
2.5.1.4 Focus Areas and Outlook Focus Areas
Outlook
• Continue growth, utilisation focus and operational efficiency improvements with ‘Big 5’ Hospital Operations Initiatives – growth, procurement, revenue cycle management, workforce, technology & AI enablement
Australia targeting incremental YoY EBIT growth (Including and excluding Nat Cap) and margin expansion driven by activity growth, improved capacity utilisation, revenue indexation in line with cost indexation, and operational improvement initiatives, and including a $10-15m increase in opex investment in IT, technology and transformation.
• Continue focus on patient, doctor and employee experience, and clinical excellence
3
• Build service differentiation in our priority therapeutic areas, including continued expansion of Ramsay Research and Development Network (clinical trials)
• National Capital acquisition expected by 1 September 2026 expected to be EPS accretive in first 12 mths of ownership, including transition opex costs of $9-11m in FY273
• Integrate National Capital Private Hospital into Ramsay network
• FY27 full year forecast capex range $380-410m including capex associated with National Capital $6-10m
Transition costs skewed to the 1HFY27. Transition costs will be excluded from Underlying NPAT in the FY27 result
14
Ramsay Health Care Limited Appendix 4E and Full Year Results 2026
2.5.2 United Kingdom 2.5.2.1 Result Summary 2026
2025
Chg
Chg cc1
1,566.7 0.7 1,567.4 (793.8) 274.1 (3.2) 270.9 (107.7) (4.2) 159.0 (80.5) 78.5 (1.5) 160.5 10.2% 50.6% 14.6% 79.1
1,568.1 0.6 1,568.7 (798.0) 258.6 (3.8) 254.8 (104.8) (4.2) 145.8 (84.1) 61.7 (1.5) 147.3 9.4% 50.9% 13.1% 108.4
(0.1%) 16.7% (0.1%) 0.5% 6.0% 15.8% 6.3% (2.8%) 9.1% 4.3% 27.2% 9.0% 80bps (30bps) 150bps (27.0%)
0.9% 34.5% 0.9% 0.3% 7.4% 16.0% 7.8% (3.8%) 5.4% 11.0% 3.4% 30.6% 10.3% 90bps 102bps (26.3%)
1,026.6 11.0 1,037.6 (835.2) 77.1 (0.6) 76.5 (50.2) (8.4) 17.9 (16.8) 1.1 (13.2) 31.1 3.0% 80.5% 3.4% 42.2
1,083.8 9.2 1,093.0 (876.3) 63.2 (0.8) 62.4 (47.3) (56.8) (41.7) (16.4) (58.1) (63.7) 22.0 2.0% 80.2% 2.2% 66.8
(5.3%) 19.6% (5.1%) 4.7% 22.0% 25.0% 22.6% (6.1%) 85.2% 142.9% (2.4%) 101.9% (79.3%) 41.4% 100bps 30bps 120bps 36.8%
(4.5%) 31.3% (4.2%) 3.7% 23.9% 28.3% 24.6% (7.2%) 83.7% 142.5% (3.4%) 101.4% (77.8%) 43.5% 118bps 36.2%
2,605.0 (1,629.0) 351.2 347.4 176.9 (14.7) 191.6 121.3
2,661.7 (1,674.3) 321.8 317.2 (144.3) (313.6) 169.3 175.2
(2.1%) 2.7% 9.1% 9.5% 222.6% 95.3% 13.2% 30.8%
(1.2%) 1.8% 10.6% 11.1% 227.3% 95.1% 14.6% (30.1%)
1 Constant currency 2 FY25 Includes Elysium site impairment but excludes $248m of goodwill impairment against the UK cash generating unit 3 Refer Section 2.2.2 for further details on items excluded from underlying EBIT 4 FY25 includes an impairment taken against the UK region of $305.2m 5 Refer Section 2.2.2 for further details on items items not included in Underlying EBIT
Ramsay Health Care Limited Appendix 4E and Full Year Results 2026
15
Financial Results
Twelve Mths Ended 30th June A$'m Ramsay UK - Acute hospital business Revenue from contracts with customers Other income Total revenue and other income Employee benefits & contractor costs EBITDAR Rent EBITDA Depreciation Amortisation and impairment EBIT Financing costs associated with leases (AASB16 Leases) EBIT less financing costs associated with leases Items excluded from underlying EBIT3 Underlying EBIT Underlying EBIT margin (%) Employee benefits as a % of revenue ROCE (%) Capital Expenditure $'m Elysium - Mental Health Care Revenue from contracts with customers Other income Total revenue and other income Employee benefits & contractor costs EBITDAR Rent EBITDA Depreciation Amortisation and impairment2 EBIT Financing costs associated leases (AASB16 Leases) EBIT less financing costs associated with leases Items excluded from underlying EBIT3 Underlying EBIT Underlying EBIT margin (%) Employee benefits as a % of revenue ROCE (%) Capital Expenditure $'m UK Segment Total segment revenue and other income Employee benefits & contractor costs Total EBITDAR Total EBITDA Total EBIT4 Items excluded from underlying EBIT5 Underlying EBIT Total Capital Expenditure ($'m)
Overview of UK region result in local currency Twelve Mths Ended 30th June £'m Total Revenue and other income EBITDAR EBITDA EBIT1 Items excluded from underlying EBIT Underlying EBIT
2026 1,315.8 177.8 175.9 89.6 (7.7) 97.3
2025 1,330.7 161.2 158.9 (70.4) (155.2) 84.8
Chg (1.1%) 10.3% 10.7% 227.3% 95.0% 14.7%
1 FY25 includes the impairment taken against the UK region of £151m
2.5.2.2 Review of Result The UK region reported a 14.6% (cc) increase in Underlying EBIT reflecting a focus by the UK acute hospital business on higher acuity admissions and private pay activity, combined with operational initiatives to offset lower NHS activity for the 12 month period; combined with an improved result from Elysium as its turnaround plan begins to gain traction, including central cost reduction, agency reduction, site optimisation and fee negotiation. In FY26, Reported EBIT includes net costs of $14.7m primarily related to the restructure of the Elysium business. Reported EBIT for the UK region in FY25 included the negative impact of a $305m pre-tax impairment taken against the value of the UK region CGU reflecting the underperformance of the Elysium business. Ramsay UK and Elysium were both free cashflow positive after capex in FY26.
Ramsay UK The UK acute hospital business reported a 0.9% (cc) increase in revenue reflecting a 5.4% decline in total admissions offset by a higher level of case acuity, payor mix and higher tariffs. NHS volumes declined 8.2% reflecting NHS funding constraints, partially offset by a 2.9% increase in private pay volumes reflecting a 4% increase in insured volumes and 0.7% increase in self pay volumes. Private pay admissions (insured and self pay) represented 27.4% of total admissions (25.2% in pcp). The NHS tariff for the year commencing 1 April 2025 was increased from the original announcement of net 2.15% to 2.83% to reflect pay increases for some healthcare workers. The increase in the tariff was backdated to the start of the tariff year. The backdated indexation for the period 1 April 2025 to 30 June 2025, included in this result, was £0.9m ($1.8m) compared to £3.5m ($7.1m) in the pcp. Wage increases above tariff indexation (staff inflation ~3.5%) and a higher National insurance payment (estimated impact £4m) from 6 April 2025 offset the increase in indexation. Indexation for the NHS year commencing 1 April 2026 has been recently revised to 1.24% reflecting pay awards, and will be backdated to the start of the NHS year. The amount relating to 1 April 2026 to 30 June 2026 will be recognised in the FY27 accounts. The business has continued to increase average case acuity levels through a purposeful focus on case and payor mix, driving a 6.7% lift in average revenue per admission. This combined with strategic actions taken to reduce agency levels and other business transformation measures, underpinned by previous investment in digital capability, resulted in underlying EBIT increasing 10.3% (cc) and EBIT margins increasing 90bps to 10.3% (cc). Digital and data opex was $13.3m (£6.5m) compared to $21.4m (£10.5m) in the prior period with investment focused on customer, team and doctor experience as well as operating transformation.
Elysium As part of the review of the performance of its portfolio, Elysium reduced available beds at underperforming sites by 9.8% over the twelve month period. Average paid beds declined 6.8% and average occupancy increased 50bps to 86.1%, reflecting the closure of 239 beds, and the changing patterns of referrals and approach to treating patients by the NHS. Revenue was 4.2% (cc) lower reflecting the decline in average paid beds, partially offset by increased fee rates as patients and resident mix evolved over the year through a mix of national tariff awards, spot fee negotiations and patient/resident churn which resulted in a blended 4.4% increase in the average daily fee. Underlying EBIT increased 43.5% (cc) and included the impact of the 6.7% increase in the National Living wage from 1 April 2025 and the 4.1% increase on 1 April 2026 as well as other salary rises (wage increase of 5.5% overall) and the increase in the National Insurance contributions (£5.6m increase on pcp). The impact of turnaround initiatives gained traction in 2H including a focus on central costs and agency labour. Phase 3 central cost reduction programs are in progress (34 FTE reduction in addition to 127 FTEs in earlier phases). Employee benefits and contractor costs included $16.2m of redundancy costs ($6.4m in pcp). Removing redundancy costs, employee costs as a percentage of revenue declined 70bps reflecting a focus on labour efficiency, in particular agency costs which declined as a percentage of revenue. Reported EBIT includes a net cost of $13.2m reflecting a gain of $10.1m (£5.2m) associated with the restructure of its portfolio of sites including the sale and lease back of several sites and the sale of one site; the impairment of three sites $8.4m (£4.4m) and costs associated with the restructure of the portfolio $14.7m (£7.8m) including redundancy costs. The business closed 7 sites over the 12 month period and has 5 sites up for the sale at the current time with the aim of releasing capital. New CEO, Joe O'Connor, was appointed during the period and commenced in January 2026. Joe has taken the program of work under way following the strategic and performance diagnostic completed with external advisors earlier in 2025 and developed this further with turnaround focus and initiatives continuing to build in FY27.
16
Ramsay Health Care Limited Appendix 4E and Full Year Results 2026
2.5.2.3 Capital Expenditure Capital expenditure in the UK reflected $42.2m (£21.3m) for Elysium and $79.1m (£40.0m) for Ramsay UK made up of: • Development projects- $11.6m ($37.5m in pcp); • Other growth projects- $15.8m ($22.5m in pcp); • Routine and maintenance $81.5m ($99.7m in pcp); and • IT hardware software and digital and data - $12.4m ($15.5m in pcp) Capital expenditure in Elysium declined from £33.4m to £21.3m and was focused on maintenance, site refurbishments and ward conversions. Capital expenditure in the Ramsay UK business declined from £54.3m to £40.0m and included ongoing re-investment in the portfolio with a particular focus on facility improvements and refurbishments. Financial Results
2.5.2.4 Focus Areas and Outlook
Ramsay UK Outlook • Expect growth in EBIT in FY27 driven by higher acuity, growth in private volumes and ongoing operational efficiencies; and • Indexation for the NHS year commencing 1 April 2026 has been recently revised to 1.24% reflecting pay awards, and will be backdated to the start of the NHS year. The amount relating to 1 April 2026 to 30 June 2026 will be recognised in the FY27 accounts. Focus Areas • Continued focus on private growth (self pay and PMI) • Continue to work closely with local and national NHS stakeholders to attract NHS work and target acuity • Ongoing delivery of efficiency transformation programmes across Finance and Operations; including rostering initiatives and creation of finance shared service hubs; • Ongoing focus on cash flow generation.
Elysium Outlook • Expect growth in EBIT in FY27 as Elysium continues delivery of its turnaround plan • Expecting and planning for weak market demand conditions to continue in FY27 Focus Areas • Delivering performance improvement plan including ongoing reductions in the cost base, and maintaining available beds to reflect local demand levels: – Further improvements to labour mix including reducing agency costs and optimising mix through targeted permanent frontline recruitment. Elysium annual wage review from 1 July 2026 increased minimum rates paid from £12.85 to £13.11 per hour, compared to an increase of 4.1% in the National minimum wage; – Continue to negotiate with all payors for appropriate fee uplifts reflecting service complexity, targeting blended increase above NHS tariff increase; and – Increasing the conversion rate of new patient opportunities, including a focus on complex recovery services, referred to as enhanced packages of care. • Site divestment program, for permanently closed sites. • Focus on timely cash collection and continue to improve cashflow.
Ramsay Health Care Limited Appendix 4E and Full Year Results 2026
17
2.5.3 Europe 2.5.3.1 Result Summary Twelve Mths Ended 30th June A$'m France Revenue from contracts with customers Income from government grants Other income - net profit on disposal of non-current assets and businesses Total segment revenue and other income Employee benefits & contractor costs EBITDAR Rent EBITDA Depreciation Amortisation & impairment EBIT Financing costs associated with leases (AASB16 Leases) EBIT less financing costs associated with leases Items excluded from underlying EBIT Underlying EBIT contribution Nordics Revenue from contracts with customers Other income - net profit on disposal of non-current assets and businesses Total segment revenue and other income Employee benefits & contractor costs EBITDAR Rent EBITDA Depreciation Amortisation & impairment EBIT Financing costs associated with leases (AASB16 Leases) EBIT less financing costs associated with leases Items excluded from underlying EBIT Underlying EBIT contribution Europe - Total Revenue from contracts with customers Total segment revenue and other income Employee benefits & contractor costs Total EBITDAR Total EBITDA Total EBIT Reported net loss after tax and non-controlling interests Items excluded from underlying EBIT Underlying EBIT contribution Net financing costs excluding items not in underlying NPAT Underlying Loss before tax Tax benefit/(expense) excluding items from underlying NPAT Underlying non-controlling interests excluding items from underlying NPAT Underlying loss after tax & non-controlling interests2 Underlying EBIT margin (%) Employee benefits as a % of revenue ROCE (%)3
2026
2025
Chg
Chg cc1
6,309.8
6,065.0 29.2
4.0% (100.0%)
2.1% (100.0%)
24.2 6,334.0 (3,552.6) 870.1 (126.5) 743.6 (541.5) (17.5) 184.6 (116.7) 67.9 (22.1) 206.7
3.8 6,098.0 (3,435.4) 888.2 (128.2) 760.0 (521.8) (19.6) 218.6 (118.0) 100.6 (5.4) 224.0
536.8% 3.9% (3.4%) (2.0%) 1.3% (2.2%) (3.8%) 10.7% (15.6%) 1.1% (32.5%) (309.3%) (7.7%)
547.9% 2.0% (1.5%) (3.5%) 3.5% (3.5%) (1.7%) 9.4% (15.2%) 2.8% (29.8%) (309.1%) (7.4%)
2,941.5
2,704.5
8.8%
6.7%
2,941.5 (1,976.0) 342.3 (17.4) 324.9 (193.8) (17.1) 114.0 (23.5) 90.5 (10.1) 124.1
0.3 2,704.8 (1,840.8) 284.4 (18.8) 265.6 (181.7) (12.2) 71.7 (16.5) 55.2 (2.1) 73.8
(100.0%) 8.8% (7.3%) 20.4% 7.4% 22.3% (6.7%) (40.2%) 59.0% (42.4%) 63.9% (381.0%) 68.2%
(100.0%) 6.7% (5.3%) 18.2% 9.8% 20.2% (4.7%) (37.9%) 56.5% (39.7%) 61.6% (380.0%) 65.6%
9,251.3 9,275.5 (5,528.6) 1,212.4 1,068.5 298.6 (50.5) (32.2) 330.8 (332.3) (1.5) (38.4)
8,769.5 8,802.8 (5,276.2) 1,172.6 1,025.6 290.3 (12.7) (7.5) 297.8 (336.3) (38.5) (10.4)
5.5% 5.4% (4.8%) 3.4% 4.2% 2.9% (297.6%) (329.3%) 11.1% 1.2% 96.1% (269.2%)
3.3% 3.2% (2.5%) 1.7% 2.7% 2.9% (282.9%) (335.8%) 11.4% 3.4% 108.0% (327.0%)
5.6 (34.3) 3.6% 59.6% 6.7%
9.0 (39.9) 3.4% 59.9% 6.1%
37.8% 14.0% 20bps (30bps) 60bps
52.9% 20.1% 40bps
1 constant currency 2 Refer Section 2.2.2 for further details on items excluded from underlying EBIT and NPAT 3 ROCE = 12 month rolling Underlying EBIT /average of opening & closing capital employed (pre goodwill)
18
Ramsay Health Care Limited Appendix 4E and Full Year Results 2026
Overview of European region result in local currency 2026 5,181.0 5,400.2 708.0 624.6 176.5 (193.4) (16.9) (19.7) 7.7 (28.9) (19.0) 195.5
2025 4,998.5 5,233.8 696.2 608.5 171.0 (207.4) (36.4) 37.3 (8.8) (7.9) (4.4) 175.4
Chg 3.7% 3.2% 1.7% 2.6% 3.2% 6.8% 53.6% (152.8%) 187.5% (265.8%) (329.4%) 11.4%
2.5.3.2 Review of Results Ramsay Santé reported a reduced underlying loss after minority interests despite a €20m reduction in French government subsidies and the continued inadequacy of French hospital tariff indexation (+0.5% for 2025 and ~0% for 2026) relative to cost inflation. Performance initiatives, focused on cost efficiencies, partially mitigating the funding impact. The Nordics business reported another good result reflecting growth in activity and the benefits of the new St Göran eight year contract and assisted by stronger Nordic currencies against the euro (~3% uplift to revenue in euros on pcp). Underlying EBIT increased 11.4% (cc) reflecting a 65.6% (cc) increase in EBIT from the Nordics (~3% related to the strength in the SEK against the euro) region driven by a good result from Sweden, partially offset by a lower result from France reflecting growth in activity and the benefits of its transformation and cost control programs, offset by the withdrawal of the revenue guarantee support program and procurement and labour inflation higher than indexation. Reported EBIT includes $32.2m of net expenses associated with restructuring of underperforming sites, transaction costs associated with the proposed demerger with Ramsay, site impairments, partially offset by the sale and lease-back of four real estate assets in France and acquisition disposal and development costs/benefits. Net interest costs (excl AASB16 lease costs) declined 11.7% in local currency primarily reflecting the negative non-cash mark to market of a hedging instrument in the prior year (€7.2m). Cash net interest costs (excluding the mark to market and accelerated amortisation of borrowing costs in both FY25 and FY26 following the refinancing of debt facilities) declined 4.5% reflecting lower base rates. The movement in the reported loss after minority interests primarily reflects the inclusion in Ramsay's FY25 accounts of a non-recurring €39m (pre-minority interests) tax liability provision release.
France
Revenue from patients increased 2.1% (cc) driven by a 2.5% growth in MSO1 admissions with good growth in day admissions (4%). The
French Governments revenue guarantee support program was discontinued from 1 January 2025, the prior period included revenue
guarantee payments of $32.9m (€20m). The French Government withheld the prudential coefficient1 payment in the 2025 year as it did
for the 2024 year.
The French base indexation for the tariff year commencing 1 March 2025 was 0.5%. The tariff for the CY2026 is 0%, indexation in
January and February 2026 benefited, compared to the pcp, from the inclusion of the CICE coefficient (tax credit for competitiveness and
employment) of 2.17% that was not applied to January and February 2025 and is now embedded in the tariff base.
Underlying EBIT declined 7.4% (cc) reflecting the discontinuation of the revenue guarantee combined with the impact of inflation above
tariff indexation. The business has a range of transformation plans in place which assisted in mitigating these issues.
Reported EBIT includes $22.1m (€13.3m) of net costs related to:
• A $14.8m (€9m) gain associated with the restructure of the business including an accounting gain on the sale and lease back of 4 real
estate assets in France, the gain on sale of one property and the sale of the loss making medical transport business;
• Impairment of one clinic in the French portfolio, $6.8m (€4.2m);
• $13.9m ( €8.5m) of restructuring costs associated with the rationalisation and reorganisation of activities in particular maternity services;
• A $7.7m (€4.7m) reversal of a one-off provision for annual leave raised in FY24 no longer required; and
• Acquisition and disposal costs of $23.9m (€14.5m) including $16m (€9.8m) of costs incurred in Australia and Europe associated with
the demerger with Ramsay.
Nordics Revenue from patients increased 6.7%cc compared to the pcp, primarily reflecting an increase in revenue in Sweden driven by the growth in its Proximity Care business, activity under the new eight year contract with St Göran, Orthopaedics and Elderly Care, an improved result from Denmark combined with the benefit of a stronger currency (~€51m). 1
The French Government uses the prudential coefficient as a mechanism to withhold a portion of hospital tariffs to mitigate the risk of exceeding the national health insurance expenditure target. The coefficient is equivalent to 0.7% of the tariffs for MSO (medical surgical and obstetrics) services provided by health service providers. The amount is withheld from billings throughout the year and its release is typically confirmed in December each year for the calendar year then ended.
Ramsay Health Care Limited Appendix 4E and Full Year Results 2026
19
Financial Results
Twelve Mths Ended 30th June €'m Patient revenue Total Revenue and other income EBITDAR EBITDA EBIT Net interest Loss before tax Tax Non-controlling interests Net loss after tax and non-controlling interests Items excluded from underlying EBIT Underlying EBIT
Underlying EBIT increased 56.5% (cc) reflecting a strong result from Sweden, driven by activity growth, the new St Göran eight year contract and cost control and productivity measures. The reported result includes $10.1m of net costs including: • The $5.2m (€3.2m) impairment of a right of use site in Sweden due to the exit of the lease following rationalisation of activities; and • Net restructuring and acquisition and development costs/benefits of $4.9m (€8.1m) inclusive of the reversal of a provision for litigation costs related to a prior period.
2.5.3.3 Capital Expenditure Total capital expenditure in FY26 was $247.5m (€143.9m) flat YoY in local currency split between: • Development projects - $43.4m ($60.9m in pcp); • IT , Digital and data - $39.9m ($20.5m in pcp); • Other growth projects - $17.4m ($14.4m in pcp); and • Routine and maintenance capital expenditure - $146.8m ($143.8m in pcp). Growth projects during the period included the installation of 11 new imaging equipment sites improving digital patient access and driving revenue and margin improvement.
2.5.3.4 Demerger of Ramsay Santé Separation plans associated with the demerger of Ramsay Santé are on track: • Expect to release Scheme booklet in October with the Scheme meeting to be held on 24th November. If the proposal approved implementation expected by mid-December • Assuming the proposed separation of Ramsay Santé is approved by shareholders, Ramsay Santé will be reported as a discontinued business in the 1H and FY27 results reflecting: – The result from 5.5 months of ownership will be treated as a discontinued business in 1H – Costs associated with the demerger of Ramsay Santé (including the $16m incurred to 30 June 2026), to be detailed in demerger booklet. The benefits of the proposal for Ramsay shareholders include: • Simplification of Ramsay portfolio, enabling management to focus on transformation and growth potential of its core Australian hospitals business • Simplification of Ramsay’s reported financial profile through de-consolidation of Ramsay Santé from Ramsay’s financial statements • Improved focus for Ramsay Santé, an already established, independently managed and publicly listed business, to continue to pursue its European focused strategy and transformation • Limited separation complexity, given Ramsay Santé already operates independently of Ramsay including separate financing and balance sheet arrangements • Opportunity for Ramsay shareholders to retain ownership interest in Ramsay Santé On July 22nd, 2026, Ramsay Santé announced the closing of its €1.75 billion refinancing, enhancing the group’s financial flexibility, extending senior debt maturities from 2031 to 2033 and simplifying its capital structure. It also pre-emptively preserves the continuity and stability of its financing arrangements, with a change of control provision structured to accommodate the contemplated distribution of Ramsay’s shareholding in Ramsay Santé. The refinancing will provide Ramsay Santé and all its stakeholders with a long-term financing framework and strengthen the Group’s capacity to pursue its long-term ambitions.
2.5.3.5 Focus Areas and Outlook Ramsay Santé will continue to focus on: • The implementation of efficiency plans both in France and the Nordics coupled with restructuring actions flowing from the review of its portfolio of assets; • Growth in Sweden driven by the full year impact of the new St Göran contract; • Advocating for fair remuneration of its services in France; • Development of more profitable value pools such as imaging in and day medical activity in France and contract renewal and bids in the Nordics; and • Focus on cashflow generation, capex allocation will target restructuring projects and investment enabling development of higher margin areas such as imaging.
20
Ramsay Health Care Limited Appendix 4E and Full Year Results 2026
3 Financial Results Contents 22
CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
23
CONSOLIDATED STATEMENT OF FINANCIAL POSITION
24
CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
25
CONSOLIDATED STATEMENT OF CASH FLOWS
26
NOTES TO THE FINANCIAL STATEMENTS
27
OVERVIEW
27
Basis of preparation
27
III ASSETS AND LIABILITIES – OPERATING AND INVESTING
45
a b
New and amended accounting standards and interpretations, effective 1 July 2025
27
8
Working capital
45
9
Business combinations
48
Accounting standards and interpretations issued or amended but not yet effective
27
10
Property, plant and equipment
50
11
Right of use assets
52
d
Basis of consolidation
27
12
Intangible assets
53
e
Significant accounting judgements, estimates and assumptions
28
13
Impairment of non-financial assets
56
f
Current versus non-current classification
28
14
Taxes
58
g
Foreign currency translation
28
15
Other assets/liabilities (net)
62
16
Net tangible assets/(liabilities)
69
c
I RESULTS FOR THE YEAR
29
1
Segment information
29
2
Revenue and other income
31
3
Expenses
4 5
IV RISK MANAGEMENT
70
17
70
Financial risk management
V OTHER INFORMATION
74
33
18
Share based payment plans
74
Dividends
34
19
Capital commitments and contingent liabilities
76
Earnings per share
35
II CAPITAL – FINANCING
36
20 Subsequent events
76
6
Equity
37
21
76
7
Net debt
39
Related party transactions
22 Auditors’ remuneration
77
23 Information relating to subsidiaries
78
24 Closed group
81
25 Parent entity information
83
26 Material partly–owned subsidiaries
83
27
83
Status of audit
Ramsay Health Care Limited Appendix 4E and Full Year Results 2026
21
Financial Results
CONSOLIDATED INCOME STATEMENT
Consolidated Income Statement FOR THE YEAR ENDED 30 JUNE 2026
Revenue from contracts with customers Interest income Other income Total revenue and other income Employee benefit and contractor costs Occupancy costs Service costs Medical consumables and supplies Depreciation, amortisation and impairment Total expenses, excluding finance costs Profit before tax and finance costs Finance costs Profit before income tax Income tax Net profit after tax for the year Attributable to non-controlling interests Attributable to owners of the parent Net profit after tax for the year
Earnings per share (EPS) attributable to equity holders of the parent Basic earnings per share (after CARES dividend) Diluted earnings per share (after CARES dividend)
Note 2.a 2.b 3
3
3 14
5 5
The above Consolidated Income Statement should be read in conjunction with the accompanying notes.
22
Ramsay Health Care Limited Appendix 4E and Full Year Results 2026
2026 $m 18,577.8 16.6 112.5 18,706.9 (10,703.0) (757.5) (792.5) (4,128.7) (1,203.2) (17,584.9) 1,122.0 (608.4) 513.6 (192.2) 321.4 (7.8) 329.2 321.4
2025 $m 17,673.8 17.4 105.5 17,796.7 (10,216.7) (728.5) (727.5) (3,947.2) (1,453.2) (17,073.1) 723.6 (621.8) 101.8 (55.5) 46.3 22.3 24.0 46.3
Cents per Share
Cents per Share
136.2 135.8
3.0 3.0
Consolidated Statement of Comprehensive Income FOR THE YEAR ENDED 30 JUNE 2026 2026 $m 321.4
2025 $m 46.3
15.c
13.8
12.9
Items that may be subsequently reclassified to net profit Cash flow hedges Taken to equity Transferred to Income Statement Foreign currency translation
57.2 10.5 (299.6)
(57.2) (16.0) 378.9
Income tax benefit/(expense) relating to these items Other comprehensive (loss)/income, net of tax Total comprehensive income Attributable to non-controlling interests Attributable to owners of the parent Total comprehensive income
13.8 (204.3) 117.1 (15.0) 132.1 117.1
(0.5) 318.1 364.4 84.3 280.1 364.4
Net profit after tax for the year Items that will not be reclassified to net profit Actuarial gain on defined employee benefit obligation
The above Consolidated Statement of Comprehensive Income should be read in conjunction with the accompanying notes.
Ramsay Health Care Limited Appendix 4E and Full Year Results 2026
23
Financial Results
Note
Consolidated Statement of Financial Position AS AT 30 JUNE 2026 2026 $m
2025 $m
729.9 2,269.5 403.2 0.5 12.0 226.6 22.6 3,664.3 40.6 3,704.9
784.4 2,506.7 404.4 1.2 12.6 282.2 48.8 4,040.3 4,040.3
101.7 5,701.4 4,429.8 5,975.5 518.3 10.9 29.6 121.3 231.4 17,119.9 20,824.8
110.8 5,820.0 5,333.0 6,431.1 499.6 10.4 0.4 107.1 122.8 18,435.2 22,475.5
8.c 7.b 7.c 15.d 15.a 14
1,944.4 84.2 544.1 2.3 1,409.0 81.7 4,065.7
2,314.6 78.5 607.8 7.8 1,380.1 76.8 4,465.6
7.b 7.c 15.a 15.c 15.d
5,209.6 5,160.6 352.5 166.8 0.3 44.0 231.5 11,165.3 15,231.0 5,593.8
5,458.4 5,975.2 366.9 184.5 34.9 51.7 229.6 12,301.2 16,766.8 5,708.7
2,285.9 (41.0) 252.2 1.6 2,457.3 4,956.0 637.8 5,593.8
2,285.9 (55.7) 252.2 212.5 2,328.7 5,023.6 685.1 5,708.7
Note ASSETS Current assets Cash and cash equivalents Trade and other receivables Inventories Derivative financial instruments Income tax receivables Prepayments Other current assets Assets held for sale Total current assets Non-current assets Other financial assets Property, plant and equipment Right of use assets Intangible assets Deferred tax assets Prepayments Derivative financial instruments Defined employee benefit assets Other receivables Total non-current assets TOTAL ASSETS LIABILITIES Current liabilities Trade and other creditors Loans and borrowings Lease liabilities Derivative financial instruments Provisions Income tax payables Total current liabilities Non-current liabilities Loans and borrowings Lease liabilities Provisions Defined employee benefit liabilities Derivative financial instruments Other creditors Deferred tax liabilities Total non-current liabilities TOTAL LIABILITIES NET ASSETS EQUITY Issued capital Treasury shares Convertible Adjustable Rate Equity Securities (CARES) Other reserves Retained earnings Parent interests Non-controlling interests TOTAL EQUITY
7.a 8.a 8.b 15.d 14
15
10 11 12 14 15.d 15.c 8.a
14
6.a 6.b 6.c
The above Consolidated Statement of Financial Position should be read in conjunction with the accompanying notes.
24
Ramsay Health Care Limited Appendix 4E and Full Year Results 2026
Consolidated Statement of Changes in Equity FOR THE YEAR ENDED 30 JUNE 2026
Issued Capital (Note 6.a)
As at 1 July 2024 Net profit after tax for the year Other comprehensive income Total comprehensive income Dividends paid Shares issued – Dividend Reinvestment Plan Treasury shares vesting to employees Share based payment expense for employees As at 30 June 2025
Noncontrolling Interests
Total
$m 2,285.9
$m (55.7) 14.7
$m 252.2
$m 212.5 (202.2) (202.2) (14.7)
$m 2,328.7 329.2 5.1 334.3 (205.7)
$m 685.1 (7.8) (7.2) (15.0) (32.3)
$m 5,708.7 321.4 (204.3) 117.1 (238.0)
6.0
6.0
2,285.9
(41.0)
252.2
1.6
2,457.3
637.8
5,593.8
2,246.8
(63.0)
252.2
(38.6) 250.9 250.9
2,500.2 24.0 5.2 29.2 (200.7)
629.9 22.3 62.0 84.3 (29.1)
5,527.5 46.3 318.1 364.4 (229.8)
39.1
39.1
7.3
(7.3)
7.5
7.5
2,285.9
(55.7)
252.2
212.5
2,328.7
685.1
5,708.7
The above Consolidated Statement of Changes in Equity should be read in conjunction with the accompanying notes.
Ramsay Health Care Limited Appendix 4E and Full Year Results 2026
25
Financial Results
As at 1 July 2025 Net profit after tax for the year Other comprehensive income/(loss) Total comprehensive income/(loss) Dividends paid Treasury shares vesting to employees Share based payment expense for employees As at 30 June 2026
Attributable to Equity Holders of the Parent Treasury Shares CARES Other Retained (Note 6.b) (Note 6.c) Reserves Earnings
Consolidated Statement of Cash Flows FOR THE YEAR ENDED 30 JUNE 2026
Note Cash flows from operating activities Receipts from customers Payments to suppliers and employees Income tax paid Lease finance costs Other finance costs Net cash flows from operating activities Cash flows from investing activities Purchase of property, plant and equipment and intangible assets Proceeds from sale of businesses and other non-current assets Interest and dividends received Interest-bearing deposits paid Business combinations, net of cash received Net cash flows used in investing activities Cash flows from financing activities Dividends paid to equity holders of the parent Dividends paid to non-controlling interests Repayment of lease principal Payment of refinancing costs Proceeds from borrowings Repayment of borrowings Net cash flows used in financing activities Net (decrease)/increase in cash and cash equivalents Net foreign exchange differences on cash held Cash and cash equivalents at the beginning of year Cash and cash equivalents at the end of year
14 3 7.a
9
4
7.a
2026 $m
2025 $m
18,718.1 (16,499.2) (193.3) (290.1) (304.8) 1,430.7
17,942.5 (15,659.6) (210.1) (286.6) (305.4) 1,480.8
(734.2) 118.2 11.4 (55.9) (3.1) (663.6)
(776.6) 20.4 16.5 (25.6) (765.3)
(205.7) (32.3) (592.1) (7.6) 12,212.0 (12,163.3) (789.0) (21.9) (32.6) 784.4 729.9
(161.6) (29.1) (508.8) (24.9) 10,029.0 (9,935.8) (631.2) 84.3 37.8 662.3 784.4
The above Consolidated Statement of Cash Flows should be read in conjunction with the accompanying notes.
26
Ramsay Health Care Limited Appendix 4E and Full Year Results 2026
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2026
Overview This section sets out the basis on which the Ramsay Group’s financial report is prepared as a whole. Where a material accounting policy is specific to a note, the policy is described within that note.
a Basis of preparation This general purpose financial report: • has been prepared in accordance with Australian Accounting Standards, other authoritative pronouncements of the Australian Accounting Standard Board (AASB) and the Corporations Act 2001; • has been prepared on the basis of historical cost, except for derivative financial instruments measured at fair value; • complies with International Financial Reporting Standards as issued by the International Accounting Standards Board; • is presented in Australian Dollars; • presents reclassified comparative information where necessary to conform to changes in presentation in the current year; • presents all values as rounded to the nearest hundred thousand dollars, unless otherwise stated under the option available under ASIC Corporations (Rounding in Financial / Directors’ Reports) Instrument 2026/183.
b New and amended accounting standards and interpretations, effective 1 July 2025 The Group has adopted all new and amended Australian Accounting Standards and Interpretations issued by the AASB that are relevant to the Group and effective for reporting periods beginning on or after 1 July 2025, all of which did not have a material impact on the financial statements.
c Accounting standards and interpretations issued or amended but not yet effective New and amended standards and interpretations issued by the AASB that will apply for the first time in the next annual financial statements are not expected to impact the Group as they are either not relevant to the Group’s activities or require accounting which is consistent with the Group’s current accounting policies. The Group does not early adopt any Australian Accounting Standards and Interpretations issued or amended but are not yet effective.
d Basis of consolidation The consolidated financial statements comprise the financial statements of Ramsay Health Care Limited (the Company, or the Parent Entity) and its subsidiaries (together, the Group, or the consolidated entity) as at and for the period ended 30 June each year. Control is achieved when the Group is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect those returns through its power over the investee. When the Group has less than a majority of the voting or similar rights of an investee, the Group considers all relevant facts and circumstances in assessing whether it has power over an investee, including: • The contractual arrangement with the other vote holders of the investee • Rights arising from other contractual arrangements • The Group’s voting rights and potential voting rights. The Group re-assesses whether or not it controls an investee if facts and circumstances indicate that there are changes to one or more of the three elements of control. Consolidation of a subsidiary begins when the Group obtains control over the subsidiary and ceases when the Group loses control of the subsidiary. Assets, liabilities, income and expenses of a subsidiary acquired or disposed of during the year are included in the Consolidated Financial Statements from the date the Group gains control until the date the Group ceases to control the subsidiary. Profit or loss and each component of Other Comprehensive Income (OCI) are attributed to the equity holders of the parent of the Group and to the non-controlling interests, even if this results in the non-controlling interests having a deficit balance. When necessary, adjustments are made to the financial statements of subsidiaries to bring their accounting policies in line with the Group’s accounting policies. All intra-group assets and liabilities, equity, income, expenses and cash flows relating to transactions between members of the Group are eliminated in full on consolidation. A change in the ownership interest of a subsidiary, without a loss of control, is accounted for as an equity transaction. If the Group loses control over a subsidiary, it derecognises the related assets (including goodwill), liabilities, non-controlling interests and other components of equity while any resultant gain or loss is recognised in profit or loss. Any investment retained is recognised at fair value.
AASB 18 Presentation and Disclosure in Financial Statements will apply for the annual reporting period beginning 1 July 2027. This standard introduces new requirements for the presentation and disclosure of financial information. The Group is currently in the process of assessing the impact of the standard.
Ramsay Health Care Limited Appendix 4E and Full Year Results 2026
27
Financial Results
Ramsay Health Care Limited is a for profit company limited by shares incorporated in Australia whose shares are publicly traded on the Australian Securities Exchange.
g Foreign currency translation
e Significant accounting judgements, estimates and assumptions In applying the Group’s accounting policies, management has made a number of judgements, estimates and assumptions concerning the future. The key judgements, estimates and assumptions that are material to the financial statements relate to the following areas:
Note 7.c Note 9 Note 10 Note 12 Note 13 Note 14 Note 15.a Note 15.c Note 18
Lease liabilities Business combinations Property, plant and equipment Intangible assets Impairment of non-financial assets Taxes Provisions Defined employee benefit obligation Share based payment plans
Page 43 Page 48 Page 50 Page 53 Page 56 Page 58 Page 62 Page 65 Page 74
f Current versus non-current classification The Group presents assets and liabilities in the Consolidated Statement of Financial Position based on current/non-current classification. An asset is current when it is: • Expected to be realised or intended to be sold or consumed in the normal operating cycle • Expected to be realised within twelve months after the reporting period • Held primarily for trading, or • Cash and cash equivalent unless restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. All other assets are classified as non-current. A liability is current when: • It is expected to be settled in the normal operating cycle • It is due to be settled within twelve months after the reporting period • Held primarily for trading, or • There is no right at the end of the reporting period to defer settlement of the liability for at least twelve months after the reporting period. The Group classifies all other liabilities as non-current. Deferred tax assets and liabilities are classified as non-current assets and liabilities.
28
Ramsay Health Care Limited Appendix 4E and Full Year Results 2026
Both the functional and presentation currency of Ramsay Health Care Limited and its Australian subsidiaries is Australian dollars (A$). Each entity in the Group determines its own functional currency and items included in the financial statements of each entity are measured using that functional currency. Transactions in foreign currencies are initially recorded in the functional currency by applying the exchange rates ruling at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are retranslated at the rate of exchange ruling at the reporting date. Non-monetary items that are measured in terms of historical cost in a foreign currency are translated using the exchange rate as at the date of the initial transaction. Non-monetary items measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was determined. The functional currencies of material overseas subsidiaries are: British pounds for the UK entities and Euro for the French entities. As at the reporting date the assets and liabilities of the overseas subsidiaries are translated into the presentation currency of Ramsay Health Care Limited at the rate of exchange ruling at the reporting date and the Income Statements are translated at the weighted average exchange rates for the year. The exchange differences arising on the translation are taken directly to a separate component of equity. On disposal of a foreign entity, the deferred cumulative amount recognised in equity relating to that particular foreign operation is recognised in the Income Statement.
I Results for the Year This section provides additional information on the Group results for the year, including further detail on results by segment, revenue, expenses, earnings per share and dividends.
1 Segment information Financial Results
The segment information note discloses the financial performance and total assets and liabilities of each of the Group's reportable segments.
Identification of reportable segments The Group has identified its operating segments based on components of the Group that engage in business activities for which internal reports (discrete financial information) are regularly reviewed and used by the Managing Director (the chief operating decision maker) in assessing performance and in determining the allocation of resources. These operating segments are primarily based on the country in which services are provided, as this is the Group’s major risk and has the most effect on the rate of return, due to differing currencies and differing health care systems in the respective countries. From these operating segments, and application of aggregation and quantitative thresholds, the Group has determined its reportable segments, being Australia, UK, France and the Nordics.
Types of services The reportable operating segments derive their revenue primarily from providing health care services to both public and private patients in the community.
Accounting policies and inter-segment transactions Transfer prices between operating segments are on an arm’s length basis in a manner similar to transactions with third parties. Segment revenue, segment expense and segment results include transfers between the segments. These transfers are eliminated on consolidation. The accounting policies used by the Group in reporting segments are the same as those contained throughout the accounts and in prior periods.
Segment assets and liabilities
Australia $m
UK $m
France $m
Nordics $m
Adjustments & Eliminations $m1
Total $m
As at 30 June 2026 Segment assets Segment liabilities
10,403.8 (4,155.6)
5,021.4 (2,511.5)
8,750.9 (7,138.5)
3,866.7 (2,084.1)
(7,218.0) 658.7
20,824.8 (15,231.0)
As at 30 June 2025 Segment assets Segment liabilities
10,210.7 (4,099.5)
5,665.7 (3,682.6)
9,720.9 (7,994.5)
4,143.2 (2,239.2)
(7,265.0) 1,249.0
22,475.5 (16,766.8)
2026 $m 18,698.6 (8.3) 16.6 18,706.9
2025 $m 17,787.2 (7.9) 17.4 17,796.7
1 Adjustments and eliminations consist of investments in subsidiaries and intercompany balances, which are eliminated on consolidation.
Segment revenue reconciliation to Income Statement
Total segment revenue and other income Intersegment revenue elimination Interest income Total revenue and other income The Group has adjusted prior year comparatives to ensure consistency with current year presentation.
Ramsay Health Care Limited Appendix 4E and Full Year Results 2026
29
1 Segment information (Continued) Segment financial performance Australia $m
UK $m
France $m
Nordics $m
Total $m
Year ended 30 June 2026 Revenue from contracts with customers Other income Total revenue and other income before intersegment revenue Intersegment revenue Total segment revenue and other income
6,733.2 76.6 6,809.8 8.3 6,818.1
2,593.3 11.7 2,605.0 2,605.0
6,309.8 24.2 6,334.0 6,334.0
2,941.5 2,941.5 2,941.5
18,577.8 112.5 18,690.3 8.3 18,698.6
Employee benefit and contractor costs
(3,545.4)
(1,629.0)
(3,552.6)
(1,976.0)
(10,703.0)
905.5
351.2
870.1
342.3
2,469.1
(12.8)
(3.8)
(126.5)
(17.4)
(160.5)
892.7
347.4
743.6
324.9
2,308.6
(262.8) 629.9
(170.5) 176.9
(559.0) 184.6
(210.9) 114.0
(1,203.2) 1,105.4 (591.8) (192.2) 321.4 7.8
Earnings before interest, tax, depreciation, amortisation and rent (EBITDAR)1 Rent2 Earnings before interest, tax, depreciation and amortisation (EBITDA)3 Depreciation, amortisation and impairment Earnings before interest and tax (EBIT)4 Net finance costs Income tax expense Profit after tax from continuing operations Attributable to non-controlling interests Net profit from continuing operations attributable to owners of the parent
329.2
Year ended 30 June 2025 Revenue from contracts with customers Other income Total revenue and other income before intersegment revenue Intersegment revenue Total segment revenue and other income
6,252.4 62.4 6,314.8 7.9 6,322.7
2,651.9 9.8 2,661.7 2,661.7
6,065.0 33.0 6,098.0 6,098.0
2,704.5 0.3 2,704.8 2,704.8
17,673.8 105.5 17,779.3 7.9 17,787.2
Employee benefit and contractor costs
(3,266.2)
(1,674.3)
(3,435.4)
(1,840.8)
(10,216.7)
829.1
321.8
888.2
284.4
2,323.5
(12.5)
(4.6)
(128.2)
(18.8)
(164.1)
816.6
317.2
760.0
265.6
2,159.4
(256.4) 560.2
(461.5) (144.3)
(541.4) 218.6
(193.9) 71.7
(1,453.2) 706.2 (604.4) (55.5) 46.3 (22.3)
Earnings before interest, tax, depreciation, amortisation and rent (EBITDAR)1 Rent2 Earnings before interest, tax, depreciation and amortisation (EBITDA)3 Depreciation, amortisation and impairment Earnings before interest and tax (EBIT)4 Net finance costs Income tax expense Profit after tax from continuing operations Attributable to non-controlling interests Net profit from continuing operations attributable to owners of the parent
24.0
1 "EBITDAR" is a non-statutory profit measure and represents profit before interest, tax, depreciation, amortisation, impairment and rent. 2 Rent includes rental costs of short term or low value assets together with any related rent costs, including rent related taxes that could not be capitalised as part of lease liabilities. 3 "EBITDA" is a non-statutory profit measure and represents profit before interest, tax, depreciation, amortisation and impairment. 4 "EBIT" is a non-statutory profit measure and represents profit before interest and tax.
The Group has adjusted prior year comparatives to ensure consistency with current year presentation.
30
Ramsay Health Care Limited Appendix 4E and Full Year Results 2026
2 Revenue and other income The Group primarily derives revenue from providing health care and related services to both public and private patients in the community.
2.a Revenue from contracts with customers
Revenue from patients Rental revenue Revenue from ancillary services Revenue from contracts with customers
2025 $m 17,085.1 117.5 471.2 17,673.8
Accounting Policies Revenue is recognised and measured at the amount of the consideration received or receivable to the extent that the performance obligations under contracts have been satisfied and the revenue can be reliably measured. The following specific recognition criteria must also be met before revenue is recognised:
Revenue from patients Revenue from patients is recognised on the date on which the services are provided to the patient.
Rental revenue Rental income is accounted for on a straight-line basis over the lease term. Contingent rental income is recognised as income in the periods in which it is earned. Lease incentives granted are recognised in the Income Statement as an integral part of the total rental income.
Revenue from ancillary services Income from ancillary services is recognised on the date the services are provided to the customer. The Group has applied the practical expedient in AASB 15 Revenue from Contracts with Customers and has not disclosed information about remaining performance obligations, as contracts with customers are generally short‑term in duration. Where services have been provided to patients but not yet billed at the reporting date, the related revenue is accrued for and presented within trade and other receivables (Refer Note 8.a).
Ramsay Health Care Limited Appendix 4E and Full Year Results 2026
31
Financial Results
2026 $m 17,987.9 117.8 472.1 18,577.8
2 Revenue and other income (Continued) 2.b Other income 2026 $m Other income – income from government grants Other income – miscellaneous Total
112.5 112.5
2025 $m 29.2 76.3 105.5
Accounting Policies Other Income - Income from Government Grants Government grants are recognised when there is reasonable assurance that the grant will be received and all the attached conditions will be complied with. Grants are accounted for on a gross basis in revenue and expenses, by the Group. Where retention of a government grant is dependent on the Group satisfying certain criteria, it is initially recognised as deferred income. When the criteria for retention have been satisfied, the deferred income balance is recognised as other income.
Other Income - Miscellaneous Miscellaneous income includes: • Income from sale of development assets is recognised when the control of the development asset is transferred to the purchaser. • Net profit on disposal of non-current assets, including Property, plant and equipment, Intangible assets and Investments. Refer to Note 10 and Note 12 for details on the accounting policies. • Sundry income.
32
Ramsay Health Care Limited Appendix 4E and Full Year Results 2026
3 Expenses A breakdown of specific expenses helps users understand the financial performance of the Group.
Note
2026 $m
2025 $m
10 10 11 11
196.0 451.2 458.9 40.2 1,146.3
176.1 370.7 442.8 97.2 1,086.8
(ii) Amortisation Amortisation – Service concession assets Amortisation – Other Total
12 12
11.6 23.3 34.9
11.7 27.8 39.5
(iii) Impairment Impairment – Land and buildings Impairment – Plant and equipment Impairment – Assets under construction Impairment – Right of use assets – Leased property Impairment – Goodwill Impairment – Service concession assets Total
10, 13 10, 13 10, 13 11, 13 12, 13 12, 13
8.5 3.1 5.2 5.2 22.0
21.5 4.5 7.7 43.8 248.4 1.0 326.9
1,203.2
1,453.2
15.2 7.7 0.9
18.9 8.3 0.9
8,677.7 322.4 1,251.7 445.2 6.0 10,703.0
8,336.0 304.3 1,184.1 381.6 10.7 10,216.7
328.3 290.1 618.4 (10.0) 608.4
343.0 286.6 629.6 (7.8) 621.8
Total depreciation, amortisation and impairment (iv) Property rental costs (included in occupancy costs) Expenses relating to short term leases Expenses relating to leases of low value assets Variable lease payments
7.c 7.c 7.c
(v) Employee benefit and contractor costs Wages and salaries Superannuation and pension costs Social charges and contributions on wages and salaries Other employment Share-based payments Total (vi) Finance costs Interest expenses Finance charges – Lease liability Finance costs capitalised Total
7.c
Accounting Policies Finance Costs Finance costs include interest, amortisation of discounts or premiums related to borrowings and other costs incurred in connection with the arrangement of borrowings. Financing costs are expensed as incurred unless they relate to a qualifying asset. A qualifying asset is an asset which generally takes more than 12 months to get ready for its intended use or sale. In these circumstances, the financing costs are capitalised to the cost of the asset. Where funds are borrowed by the Group for the acquisition or construction of a qualifying asset, the amount of financing costs capitalised are those incurred in relation to that borrowing.
Ramsay Health Care Limited Appendix 4E and Full Year Results 2026
33
Financial Results
(i) Depreciation Depreciation – Buildings Depreciation – Plant and equipment Depreciation – Right of use assets – Leased property Depreciation – Right of use assets – Leased plant and equipment Total
4 Dividends Dividends are a portion of Ramsay Group’s profit that are paid out to its shareholders, in return for their investment.
Parent Entity 2026 2025 $m $m (i) Dividends determined and paid during the year on ordinary shares: Current year interim dividend paid Franked dividends – ordinary (42.5 cents per share) (2025: 40.0 cents per share)
97.9
91.9
Previous year final dividend paid Franked dividends – ordinary (40.0 cents per share) (2025: 40.0 cents per share)1 Total dividends paid on ordinary shares
92.1 190.0
91.6 183.5
(ii) Dividends proposed and not recognised as a liability on ordinary shares: Current year final dividend proposed Franked dividends – ordinary (48.5 cents per share) (2025: 40.0 cents per share)
111.7
92.1
(iii) Dividends determined and paid during the year on CARES: Current year interim and previous year final dividend paid Franked dividends – CARES
15.7
17.2
(iv) Dividends proposed and not recognised as a liability on CARES: Current year final dividend proposed Franked dividends – CARES
8.7
8.0
1,071.8
1,006.2
14.4 1,086.2
14.7 1,020.9
(51.6) 1,034.6
(42.9) 978.0
(v) Franking credit balance The amount of franking credits available for the subsequent financial year are: franking account balance as at the end of the financial year at 30% (2025: 30%) franking credits that will arise from the payment of income tax payable as at the end of the financial year2 The amount of franking credits available for future reporting periods: impact on the franking account of dividends proposed or determined before the financial report was authorised for issue but not recognised as a distribution to equity holders during the period
1 The Dividend Reinvestment Plan (DRP) has been suspended indefinitely and did not operate for the final FY25 dividend and subsequently. During the year ended 30 June 2025, $39.1m of dividend payments were reinvested into ordinary shares of the Group. 2 As Ramsay Health Care Ltd and its 100% owned Australian subsidiaries have formed a tax consolidated group, effective 1 July 2003, this represents the current tax payable for the Australian group.
The tax rate at which paid dividends have been franked is 30% (2025: 30%). $120.4 million (2025: $100.1 million) of the proposed dividends will be franked at the rate of 30% (2025: 30%).
34
Ramsay Health Care Limited Appendix 4E and Full Year Results 2026
5 Earnings per share Earnings per share is the portion of post-tax profit allocated to each Ramsay ordinary share.
Weighted average number of ordinary shares used in calculating basic earnings per share Effect of dilution – share rights not yet vested Weighted average number of ordinary shares adjusted for the effect of dilution
2025 $m 24.0 (17.2) 6.8
2026 Number of Shares (m) 230.2 0.6 230.8
2025 Number of Shares (m) 229.4 0.6 230.0
The share rights granted to Executives but not yet vested, have the potential to dilute basic earnings per share. There have been no other transactions involving ordinary shares or potential ordinary shares between the reporting date and the date of completion of these financial statements. 2026 Cents per Share Earnings per share (EPS) attributable to equity holders of the parent Basic earnings per share (after CARES dividend) Diluted earnings per share (after CARES dividend)
2025 Cents per Share
136.2 135.8
3.0 3.0
Calculation of earnings per share Basic earnings per share Basic earnings per share amounts are calculated by dividing net profit for the year attributable to ordinary equity holders of the parent (after deducting the CARES dividend) by the weighted average number of ordinary shares outstanding during the year.
Diluted earnings per share Diluted earnings per share amounts are calculated by dividing the net profit attributable to ordinary equity holders of the parent (after deducting the CARES dividend) by the weighted average number of ordinary shares outstanding during the year plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares.
Ramsay Health Care Limited Appendix 4E and Full Year Results 2026
35
Financial Results
Net profit for the year attributable to owners of the parent Less: dividend paid on Convertible Adjustable Rate Equity Securities (CARES) Profit used in calculating basic and diluted (after CARES dividend) earnings per share
2026 $m 329.2 (15.7) 313.5
II Capital – Financing This section discusses how the Ramsay Group manages funds and maintains capital structure, including bank borrowings, related finance costs and access to capital markets.
How the Group manages its capital – Financing The Group manages its capital structure with the objective of ensuring it will continue as a going concern as well as maintaining optimal returns to shareholders and benefits for its stakeholders. The Group also aims to maintain a capital structure that is consistent with its targeted credit ratings, ensuring sufficient headroom is available within such ratings to support its growth strategies at an optimised cost of capital. Prudent liquidity reserves in the form of committed undrawn bank debt facilities and cash are maintained in order to accommodate its expenditures and any potential market disruption. The Group may raise or retire debt, adjust its dividend policy (including use and terms of the dividend reinvestment plan), return capital to shareholders, issue new shares or financial instruments containing characteristics of equity, or sell assets to reduce debt in order to achieve the optimal capital structure. The Group’s capital is comprised of equity plus net debt. Net debt is calculated as interest bearing liabilities, lease liabilities, less cash assets. Refer to Note 4 for details of dividends paid during, or determined for the year ended 30 June 2026. The Group monitors its capital structure primarily by reference to its debt financial covenants and credit rating gearing metrics. Debt levels under the Group’s financial covenants are assessed relative to the cash operating profits (EBITDA) of the Group that are used to service debt. This ratio is calculated as Net Debt/EBITDA and is 4.5x for the year ended 30 June 2026 (2025: 5.3x), however lending facilities within the Group contain calculations and thresholds specific to each facility and borrowing groups having access to such facilities. The Group has committed senior debt funding with various maturities up to March 2040. As such, certain subsidiaries must comply with various financial and other undertakings in particular, the following customary financial undertakings: • Total Net Leverage Ratio (Adjusted Net Debt1/Adjusted EBITDA2) • Interest Cover Ratio (Adjusted EBITDA2/ Net Interest) • Minimum Shareholders Funds • Guarantors Adjusted EBITDA2 Coverage Ratio • Guarantors Assets Coverage Ratio
Details of Capital – Financing are as follows: Equity Net Debt
1
2
Note 6 7
2026 $m 5,593.8 10,268.6 15,862.4
2025 $m 5,708.7 11,335.5 17,044.2
Adjusted Net Debt represents net debt excluding lease liabilities, adjusted for foreign currency loans and cash translated at average rates (rather than year-end spot rates) Adjusted EBITDA represents Earnings before Interest, Tax, Depreciation, Amortisation and Impairment adjusted to deduct all rental expenses under any lease arrangements, and exclude non-recurring gains or losses.
36
Ramsay Health Care Limited Appendix 4E and Full Year Results 2026
6 Equity 2026 $m 2,285.9 (41.0) 252.2 1.6 2,457.3 637.8 5,593.8
Note 6.a 6.b 6.c
Issued capital Treasury shares Convertible Adjustable Rate Equity Securities (CARES) Other reserves Retained earnings Non-controlling interests
2025 $m 2,285.9 (55.7) 252.2 212.5 2,328.7 685.1 5,708.7 Financial Results
6.a Issued capital Issued capital represents the amount of consideration received for the ordinary shares issued by Ramsay Health Care Limited (the Company).
Issued and paid up capital
As at 1 July Shares issued – Dividend Reinvestment Plan As at 30 June
2026 Number (m) 230.8 230.8
2026 $m 2,285.9 2,285.9
2025 Number (m) 229.8 1.0 230.8
2025 $m 2,246.8 39.1 2,285.9
Terms and conditions of issued capital Ordinary Shares Ordinary shares have the right to receive dividends as declared and, in the event of winding up the Company, to participate in the proceeds from the sale of all surplus assets in proportion to the number of and amounts paid up on shares held. Ordinary shares entitle their holder to one vote, either in person or by proxy, at a meeting of the Company. The Dividend Reinvestment Plan (DRP) has been suspended indefinitely and did not operate for the final FY25 dividend and subsequently.
Accounting Policies Ordinary shares Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of new shares or options are shown in equity as a deduction, net of tax, from the proceeds.
6.b Treasury shares Treasury shares are the shares repurchased on the open market, for the share rights issued to employees under the Employee Share Plan.
2026 $m 41.0
0.6 million ordinary shares (2025: 0.9 million ordinary shares)
2025 $m 55.7
Nature & Purpose Treasury shares are shares in the Company held by the Employee Share Plan and are deducted from equity.
Ramsay Health Care Limited Appendix 4E and Full Year Results 2026
37
6 Equity (Continued) 6.c Convertible Adjustable Rate Equity Securities (CARES) Convertible Adjustable Rate Equity Securities (CARES) are non-cumulative, redeemable and convertible preference shares in Ramsay Health Care Limited.
Issued and paid up capital
2.6 million CARES shares fully paid (2025: 2.6 million CARES shares fully paid)
2026 $m 252.2
2025 $m 252.2
Terms and conditions of CARES Issuer Security Face Value Dividends
Ramsay Health Care Limited Convertible Adjustable Rate Equity Securities (CARES) which are a non-cumulative, redeemable and convertible preference share in Ramsay. $100 Per CARES. The holder of each CARES is entitled to a preferred, non-cumulative, floating rate dividend equal to: Dividend Entitlement = (Dividend Rate x Face Value x N) / 365 where: N is the number of days in the Dividend Period The payment of Dividends is at the Directors’ discretion and is subject to there being funds legally available for the payment of Dividends and the restrictions which apply in certain circumstances under the financing arrangements.
Dividend Rate
If declared, the first Dividend will be payable on each CARES in arrears on 20 October 2005 and thereafter on each 20 April and 20 October until CARES are converted or exchanged. The Dividend Rate for each Dividend Period is calculated as: Dividend Rate = (Market Rate + Margin) x (1-T) where: The Market Rate is the 180 day Bank Bill Swap Rate applying on the first day of the Dividend Period expressed as a percentage per annum. The Margin for the period to 20 October 2010 was 2.85% per annum. It was determined by the Bookbuild held on 26 April 2005. T is the prevailing Australian corporate tax rate applicable on the Allotment Date.
Step-up Franking
Conversion or exchange by Ramsay
As Ramsay did not convert or exchange by 20 October 2010, the Margin was increased by a one-time step up of 2.00% (200 basis points) per annum. One-time 2.00% (200 basis points) step-up in the Margin at 20 October 2010 Ramsay expects the Dividends paid on CARES to be fully franked. If a Dividend is not fully franked, the Dividend will be grossed up to compensate for the unfranked component. If, on a Dividend Payment Date, the Australian corporate tax rate differs from the Australian corporate tax rate on the Allotment Date, the Dividend will be adjusted downwards or upwards accordingly. CARES have no maturity. Ramsay may convert or exchange some or all CARES at its election for shares or $100 in cash for each CARES on 20 October 2010 and each Dividend Payment Date thereafter. Ramsay also has the right to: • convert or exchange CARES after the occurrence of a Regulatory Event; and • convert CARES on the occurrence of a Change in Control Event.
Conversion Ratio
Ranking Participation Voting Rights
38
Ramsay cannot elect to convert or exchange only some CARES if such conversion or exchange would result in there being less than $50 million in aggregate Face Value of CARES on issue. The rate at which CARES will convert into Shares will be calculated by reference to the market price of Shares during 20 business days immediately preceding, but not including, the conversion date, less a conversion discount of 2.5%. An adjustment is made to the market price calculation in the case of a Change in Control Event. The Conversion Ratio for each CARES will not be greater than 400 shares. CARES rank equally amongst themselves in all respects and are subordinated to all creditors but rank in priority to Shares. Unless CARES are converted into Shares, CARES confer no rights to subscribe for new shares in any fundraisings by Ramsay or to participate in any bonus or rights issues by Ramsay. CARES do not carry a right to vote at general meeting of Ramsay except in limited circumstances.
Ramsay Health Care Limited Appendix 4E and Full Year Results 2026
7 Net debt Cash and cash equivalents Loans and borrowings – current Lease liabilities – current Loans and borrowings – non-current Lease liabilities – non-current
Note 7.a 7.b 7.c 7.b 7.c
2026 $m 729.9 (84.2) (544.1) (5,209.6) (5,160.6) (10,268.6)
2025 $m 784.4 (78.5) (607.8) (5,458.4) (5,975.2) (11,335.5) Financial Results
7.a Cash and cash equivalents Cash and cash equivalents comprise of cash at bank, cash on hand and short-term deposits with a maturity of less than three months. This note presents the amount of cash on hand at year end, together with further reconciliation in relation to the Statement of Cash Flows.
Cash at bank and on hand
2026 $m 729.9
2025 $m 784.4
Cash at bank earns interest at floating rates based on daily bank deposit rates. Short-term deposits are made for varying periods of between one day and three months, depending on the immediate cash requirements of the Group, and earn interest at the respective short-term deposit rates.
Accounting Policies Cash and cash equivalents Cash and short-term deposits in the Statement of Financial Position comprise cash at bank and on hand and short-term deposits with an original maturity of three months or less. For the purposes of the Statement of Cash Flows, cash and cash equivalents consist of cash and cash equivalents as defined above, net of outstanding bank overdrafts and restricted cash (nil as at 30 June 2026 and 30 June 2025).
Ramsay Health Care Limited Appendix 4E and Full Year Results 2026
39
7 Net debt (Continued) Reconciliation of net profit after tax to net cash flows from operations
Net profit after tax for the year Adjustments for: Depreciation, amortisation and impairment Interest income Share-based payments Net profit on disposal of non-current assets Other Changes in assets & liabilities: Deferred tax Receivables Other assets Creditors, accruals and other liabilities Provisions Inventories Current tax Net cash flows from operating activities
2026 $m 321.4
2025 $m 46.3
1,203.2 (16.6) 6.0 (38.9) (7.7)
1,453.2 (17.4) 10.7 (7.6) (3.4)
(17.3) 65.0 (54.7) (69.4) 48.1 (20.8) 12.4 1,430.7
(125.4) 157.9 (88.4) 91.5 (9.3) (4.2) (23.1) 1,480.8
Reconciliation of liabilities arising from financing activities
Loans and borrowings – current Loans and borrowings – non-current Lease Liabilities Total
Loans and borrowings – current Loans and borrowings – non-current Lease Liabilities Total
40
As at 1 July 2025 $m 78.5 5,458.4 6,583.0 12,119.9
As at 1 July 2024 $m 134.1 4,949.9 5,854.1 10,938.1
Cash Flows $m 12.4 36.3 (592.1) (543.4)
Cash Flows $m (61.8) 155.0 (508.8) (415.6)
Ramsay Health Care Limited Appendix 4E and Full Year Results 2026
Foreign Exchange Movement $m (6.7) (266.1) (455.2) (728.0)
Foreign Exchange Movement $m 5.7 358.1 573.7 937.5
New Leases $m 443.4 443.4
New Leases $m 270.4 270.4
Disposal/ Termination or Reassessment of Leases $m (274.4) (274.4) Disposal/ Termination or Reassessment of Leases $m 398.7 398.7
(19.0) (19.0)
As at 30 June 2026 $m 84.2 5,209.6 5,704.7 10,998.5
Other $m 0.5 (4.6) (5.1) (9.2)
As at 30 June 2025 $m 78.5 5,458.4 6,583.0 12,119.9
Other $m
7 Net debt (Continued) 7.b Loans and borrowings This note outlines the Group's loans and borrowings, which are predominantly from banks and other financial institutions, with varying maturities.
Current Secured bank loans: € Other Loans1 Total current loans and borrowings
2026 $m
2025 $m
Up to Jun 2027
84.2 84.2
78.5 78.5
Non-current Unsecured bank and other financial institution loans: A$ 1,500,000,000 Syndicated Facility Loan2 A$ 500,000,000 Syndicated Facility Term Loan3 A$ Bi-lateral Facilities A$ 100,000,000 Bi-lateral Term Loan4
Up to Oct 2030 Nov 2029 Up to Nov 2028 Nov 2028
1,196.2 497.3 349.6 100.0 2,143.1
1,300.0 496.6 259.3 100.0 2,155.9
Secured bank loans: € 1,650,000,000 Syndicated Term Loan5 € Other Loans1
Up to Aug 2031 Up to Mar 2040
2,420.3 480.9 2,901.2
2,614.4 508.7 3,123.1
Up to Dec 2029
165.3 5,209.6 5,293.8
179.4 5,458.4 5,536.9
Secured/Unsecured corporate notes: € 100,000,000 Euro Private Placement Notes6 Total non-current loans and borrowings Total loans and borrowings
1 Includes amortising mortgage loans that are secured by a first charge over certain Ramsay Santé and controlled entities’ land, buildings and the shares of real estate subsidiaries. 2 Syndicated revolving bank debt facility with tranches maturing in October 2028, October 2029 and October 2030. 3 Syndicated Term Loan Facility issued in November 2023 4 Bi-lateral term loan facility repayable in full on maturity. 5 Syndicated term loan facilities repayable in full on maturity. The lenders only have recourse to Ramsay Santé and certain Ramsay Santé controlled entities. 6 Euro Private Placement Notes, maturing in December 2028 and December 2029.
The Group reported undrawn headroom under the facilities of $1,135.9 million as at 30 June 2026 (2025: $1,126.8 million).
Ramsay and its controlled entities excluding Ramsay Santé Group (Funding Group) During the period 1 July 2025 to 30 June 2026, A$2,455 million of facilities were refinanced, including: • A$1,500 million syndicated facility with each tranche extended by 2 years delivering new maturities of October 2028, October 2029 and October 2030; and • A$955 million of bilateral facilities extended by up to 2 years. A bilateral facility was increased by A$25 million during the period, bringing the total committed facility limit to A$2,980 million. The covenant package, group guarantees and other common terms and conditions in respect of the debt facilities are governed under a Common Terms Deed Poll (CTDP). As at 30 June 2026, the Funding Group has non-current loans and borrowings of a total carrying amount of A$2,143.1 million, with financial covenants that require compliance with specific conditions to maintain the right to defer settlement for at least twelve months after the reporting period. These liabilities are classified as non-current in accordance with AASB 101 Presentation of Financial Statements, as amended by AASB 2022-6.
Ramsay Health Care Limited Appendix 4E and Full Year Results 2026
41
Financial Results
Maturity
7 Net debt (Continued) Pursuant to the CTDP, the Funding Group is required to comply with the following financial covenants at the end of each annual and semi-annual reporting period: • Total Net Leverage Ratio (Adjusted Net Debt1/Adjusted EBITDA2) • Interest Cover Ratio (Adjusted EBITDA2/Net Interest) • Guarantors Adjusted EBITDA2 Coverage Ratio • Guarantors Assets Coverage Ratio The Funding Group was in compliance with the above financial covenants as at 30 June 2026 and expected to remain compliant with these covenants for the next reporting period. Funding Group's facilities remain 83% sustainability linked loans.
Ramsay Santé and its controlled entities (Ramsay Santé Group) Whilst there was no significant change to loans and borrowings during the period, Ramsay Santé refinanced a former financial lease with a new €65 million mortgage loan. There are no compliance requirements for Ramsay Santé with any specified financial covenants, to maintain the right to defer settlement of its non-current liabilities for at least twelve months after the reporting period. Ramsay Santé Group's facilities remain 87% sustainability linked loans. On 22 July 2026, Ramsay Santé announced the close of a €1,750m senior debt refinancing comprising €1,550m Term Loan B and €200m revolving credit facility delivering extended maturities to 2033. In July 2026, Ramsay Santé refinanced the real estate finance lease that had reached maturity at its Dijon-Bourgogne facility through the payment of the €13m option available, and simultaneously added a new tranche of security trust (“Fiducie”) debt amounting to €67.5m for a 10-year tenure, hence increasing liquidity by €54m.
Fair values The fair values of the Group’s interest bearing loans and borrowings are determined by using the discounted cash flow method with discount rates that reflect market interest rates, specific country risk factors, individual creditworthiness of the counterparties and the other risk characteristics associated with the underlying debts. Unless disclosed below, the carrying amount of the Group’s current and non-current borrowings approximate their fair value. The fair values have been calculated by discounting the expected future cash flows at prevailing market interest rates depending on the type of borrowings. For the financial year, the variable market-based interest rates vary from 3.51% to 4.48% (2025: 3.68% to 4.51%) for Australia and 2.00% to 2.194% (2025: 2.22% to 3.69%) for France respectively. The fair value of the interest bearing loans and borrowings was estimated using the level 2 method valuation technique in which the lowest level of input that is significant to the fair value measurement is directly or indirectly observable. Set out in the table below is a comparison by carrying amounts and fair value of the Group’s Interest bearing loans and borrowings. 2025
2026 Carrying Amount
Bank loans Corporate notes
$m 5,128.5 165.3 5,293.8
Fair Value $m 5,538.2 170.0 5,708.2
Carrying Amount $m 5,357.5 179.4 5,536.9
Fair Value $m 5,898.5 188.9 6,087.4
Interest rate, foreign exchange & liquidity risk Details regarding interest rate, foreign exchange and liquidity risk is disclosed in Note 17.
Assets pledged as security The carrying amounts of assets pledged as security for loans and borrowings are set out in the following table: 2026 $m Fixed and floating charge Fixed assets Investment holdings in subsidiaries Total non-current assets pledged as security
1
2
29.9 4,669.8 4,699.7
2025 $m 84.9 5,547.8 5,632.7
Adjusted Net Debt represents net debt excluding lease liabilities and derivatives, adjusted for foreign currency loans and cash translated at average rates (rather than year-end spot rates) Adjusted EBITDA represents Earnings before Interest, Tax, Depreciation, Amortisation and Impairment adjusted to deduct all rental expenses under any lease arrangements, and exclude non-recurring gains or losses
42
Ramsay Health Care Limited Appendix 4E and Full Year Results 2026
7 Net debt (Continued) Accounting Policies Loans and borrowings Interest bearing loans and borrowings are initially recorded at the amount of proceeds received (fair value) less directly attributable transaction costs. After initial recognition, interest bearing loans and borrowings are subsequently measured at amortised cost using the EIR method. Losses are recognised in profit or loss when the liabilities are derecognised. Financial Results
7.c Lease liabilities The Group has lease contracts for the use of hospitals, office space and various items of equipment and vehicles which it uses in its operations. Leases of hospitals and office space can have lease terms between 5 and 120 years, while vehicles and equipment generally have lease terms between 5 and 10 years.
Generally, the Group is restricted from assigning and subleasing the leased assets. A number of the lease contracts include extensions, termination options and variable lease payments, which are discussed below. The Group also has certain leases of equipment with lease terms of 12 months or less and leases of office equipment with a low value. The Group applies the ‘short term lease’ and ‘lease of low value assets’ recognition exemptions for these leases.
As at 1 July Additions Disposals or terminations Payments Accretion of interest Reassessment of lease terms Reclassification Exchange differences As at 30 June
2026 $m 6,583.0 443.4 (22.3) (882.2) 290.1 (281.2) 29.1 (455.2) 5,704.7
2025 $m 5,854.1 270.4 (0.5) (795.4) 286.6 399.2 (5.1) 573.7 6,583.0
Current lease liabilities Non-current lease liabilities Total lease liabilities
2026 $m 544.1 5,160.6 5,704.7
2025 $m 607.8 5,975.2 6,583.0
2026 $m (592.1) (290.1)
2025 $m (508.8) (286.6)
(23.8)
(28.1)
(906.0)
(823.5)
Cash outflows
Repayment of lease principal Lease finance costs Other lease payments - low value assets, short term and variable lease payments (included in payments to suppliers and employees) Total cash outflows for leases
Ramsay Health Care Limited Appendix 4E and Full Year Results 2026
43
7 Net debt (Continued) Accounting Policies All leases are accounted for by recognising a right of use asset and a lease liability except for: • Leases of low value assets, being those generally with a cost of $50,000 or less; and • Leases with a term of 12 months or less.
Lease liabilities Lease liabilities are measured at the present value of the contractual payments due to the lessor over the lease term, with the discount rate determined by reference to the rate inherent in the lease unless (as is typically the case) this is not readily determinable, in which case the Group’s incremental borrowing rate on commencement of the lease is used. Variable lease payments are only included in the measurement of the lease liability if they depend on an index or rate. In such cases, the initial measurement of the lease liability assumes the variable element will remain unchanged throughout the lease term. Other variable lease payments are expensed in the period to which they relate. On initial recognition, the carrying value of the lease liability also includes: • amounts expected to be payable under any residual value guarantee; • the exercise price of any purchase option granted in favour of the group if it is reasonably certain to exercise that option; • any penalties payable for terminating the lease, if the term of the lease has been estimated on the basis of the termination option being exercised.
Lease assets Right of use assets are initially measured at the amount of the lease liability, reduced for any lease incentives received, and increased for: • lease payments made at or before commencement of the lease; • initial direct costs incurred; and • the amount of any provision recognised where the group is contractually required to dismantle, remove or restore the leased asset. Subsequent to initial measurement, lease liabilities increase as a result of interest charged at a constant rate on the balance outstanding and are reduced for lease payments made. Right of use assets are amortised on a straight line basis over the shorter of the useful life of the asset or the term of the lease. Lease liabilities are remeasured when there is a change in future lease payments arising from a change in an index or rate or when there is a change in the assessment of the term of the lease. The Group applies the short term lease recognition exemption to its short term lease of equipment, being those leases that have a lease term of 12 months or less from the commencement date and do not contain a purchase option. The Group also applies the low-value assets recognition exemption to leases of equipment that are considered to be of low value. Lease payments on short term leases and leases of low value assets are recognised as an expense on a straight line basis over the lease term.
Key Accounting Judgements, Estimates and Assumptions Lease term The Group determines the lease term as the non-cancellable term of the lease, together with any periods covered by an option to extend the lease if it is reasonably certain to be exercised, or any periods covered by an option to terminate the lease, if it is reasonably certain not to be exercised. The Group has the option, under some of its leases to lease the assets for additional terms. The Group applies judgement in evaluating whether it is reasonably certain to exercise the options to renew. That is, it considers all relevant factors that create an economic incentive for it to exercise the renewal. After commencement date, the Group reassess the lease term if there is a significant event or change in circumstances that is within its control and affects its ability to exercise (or not exercise) the option to renew.
Discount rates The lease payments are discounted using the interest rate implicit in the lease or the lessee’s incremental borrowing rate (IBR). The IBR is the rate of interest that the lessee would have to pay to borrow over a similar term, and with a similar security, the funds necessary to obtain an asset of a similar value to the right of use asset in a similar economic environment. The IBR therefore requires estimation when no observable rates are available (such as for subsidiaries that do not enter into financing transactions) or when they need to be adjusted to reflect the terms and conditions of the lease.
44
Ramsay Health Care Limited Appendix 4E and Full Year Results 2026
III Assets and Liabilities – Operating and Investing This section outlines how the Ramsay Group manages its assets and liabilities to generate profit.
How the Group manages its overall financial position
Details of Assets and Liabilities – Operating and Investing are as follows:
Working capital Property, plant and equipment Right of use assets Intangible assets Current and deferred tax assets (net) Other liabilities (net)
Note 8 10 11 12 14 15
2026 $m 728.3 5,701.4 4,429.8 5,975.5 217.1 (1,189.7) 15,862.4
2025 $m 596.5 5,820.0 5,333.0 6,431.1 205.8 (1,342.2) 17,044.2
2026 $m 2,269.5 403.2 (1,944.4) 728.3
2025 $m 2,506.7 404.4 (2,314.6) 596.5
8 Working capital Trade and other receivables (current) Inventories Trade and other creditors (current)
8.a 8.b 8.c
Consistent with prior periods, the Group actively manages the collection of debtor receipts and creditor payments. Any surplus or deficit in working capital is managed through efficient use of the debt facilities and cash balances.
8.a Trade and other receivables Trade and other receivables primarily consist of amounts outstanding from Governments, Health Funds and SelfInsured patients for delivering health care and related services, together with accrued revenue for services provided but not yet billed at the reporting date. Refer to Note 2 for the Group’s revenue recognition policy.
Current Trade and other receivables Allowances for impairment loss Non-current Rental property bonds and guarantees receivable Other Total
2026 $m
2025 $m
2,443.1 (173.6) 2,269.5
2,701.5 (194.8) 2,506.7
36.5 194.9 231.4 2,500.9
36.1 86.7 122.8 2,629.5
Ramsay Health Care Limited Appendix 4E and Full Year Results 2026
45
Financial Results
The Group manages its overall financial position by segregating its Statement of Financial Position into two categories; Assets and Liabilities – Operating and Investing and Capital – Financing. Assets and Liabilities – Operating and Investing is managed at both the site and group level while Capital – Financing (refer to section II) is managed centrally.
8 Working capital (Continued) Allowances for impairment loss An allowance for expected credit loss (ECL) is recognised based on the difference between the contractual cash flows and the expected cash flows. The Group has applied a simplified approach in calculating ECLs by establishing a provision matrix for forward-looking factors specific to the debtors and the economic environment. Movements in the allowances for impairment loss were as follows: 2026 $m (194.8) (109.6) 12.8 118.0 (173.6)
As at 1 July Charge for the year Exchange differences Amounts written off As at 30 June
2025 $m (155.4) (128.0) (15.6) 104.2 (194.8)
Ageing analysis At 30 June, the ageing analysis of trade and other receivables is as follows:
2026 2025
Total $m 2,674.5 2,824.3
Neither past due nor impaired $m 1,925.9 1,996.5
0-30 Days PDNI1 $m 117.1 191.4
31-60 Days PDNI1 $m 57.6 103.1
61-90 Days PDNI1 $m 42.0 50.9
91+ Days PDNI1 $m 358.3 287.6
Considered impaired $m 173.6 194.8
1 PDNI – Past due not impaired
Receivables past due but not considered impaired are: $575.0 million (2025: $633.0 million). Payment terms on these amounts have not been re-negotiated as based on the credit history of receivables past due not considered impaired, management believes that these amounts will be fully recovered. This is due to the fact that the Group mainly deals with Government Authorities and creditworthy Health Funds.
Fair value Due to the short term nature of the current receivables, the carrying value approximates fair value. The carrying values of the discounted non-current receivables approximates their fair values.
Credit risk The maximum exposure to credit risk for current receivables is their carrying value. Collateral is not held as security. The Group’s credit risk is low in relation to trade debtors because the majority of transactions are with the Government and Health Funds. The maximum exposure to credit risk for non-current receivables at the reporting date is the carrying value of these receivables. The majority of the non-current receivables are assessed as low risk.
Foreign exchange & interest rate risk Details regarding foreign exchange and interest rate risk exposure are disclosed in Note 17.
46
Ramsay Health Care Limited Appendix 4E and Full Year Results 2026
8 Working capital (Continued) 8.b Inventories Inventories include medical supplies to be consumed in providing future patient services, and development assets, including medical suites to be sold, that are currently under construction.
2025 $m 386.2 18.2 404.4
Inventory expense Medical supplies and development assets recognised as an expense for the year ended 30 June 2026 totalled $4,128.7 million (2025: $3,947.2 million) for the Group. This expense has been included in the expense category 'medical consumables and supplies' in the Income Statement.
Accounting Policies Inventories are recorded using the FIFO method and are valued at the lower of cost and net realisable value. Net realisable value is the estimated selling price in the ordinary course of business, less estimated costs of completion and the estimated costs necessary to make the sale.
8.c Trade and other creditors Trade and other creditors consists of amounts owing to suppliers for goods and/or services delivered, accrued salaries and wages payable to employees for services rendered but unpaid at the reporting date and customer amounts paid in advance of provision of services.
2026 $m 1,432.2 512.2 1,944.4
Trade creditors Accrued expenses Total
2025 $m 1,728.1 586.5 2,314.6
The Group previously presented its current employee entitlement liabilities, primarily comprising annual leave and long service leave, within Current Trade and Other Creditors in the Statement of Financial Position. The Group has reassessed the presentation of these balances and determined that classification as Current Provisions more appropriately reflects their nature. Accordingly, prior year comparatives as at 30 June 2025 have been updated by reclassifying $1,262.0 million from Current Trade and Other Creditors to Current Provisions. There was no impact to Total Current Liabilities.
Fair value Trade and other creditors amounts are non-interest bearing and are normally settled on 30-60 day terms. Due to the short term nature of these payables, their carrying value is assumed to approximate their fair value.
Interest rate, foreign exchange & liquidity risk Details regarding interest rate, foreign exchange and liquidity risk exposure are set out in Note 17.
Ramsay Health Care Limited Appendix 4E and Full Year Results 2026
47
Financial Results
Amount of medical supplies to be consumed in providing future patient services – at cost Development assets to be sold that are currently under construction – at cost Total
2026 $m 384.3 18.9 403.2
9 Business combinations Ramsay’s growth has been driven, in part, by acquisitions of businesses within the healthcare sector.
Information on current year acquisitions The Group acquired certain businesses in Europe during the year ended 30 June 2026. The summarised amounts for these business combinations for the year ended 30 June 2026 are shown below and have been determined on a provisional basis only. These businesses are all within the healthcare sector. $m Assets Liabilities Fair value of identifiable net assets Goodwill arising Fair value of consideration transferred
0.3 (4.1) (3.8) 6.9 3.1
The cash outflow as a result of the business combinations is as follows: Cash paid in the year to 30 June 2026 Net cash acquired with the subsidiaries Net consolidated cash outflow
(3.1) (3.1)
Cash paid in the year to 30 June 2026 Deferred consideration Total consideration
(3.1) 0.1 (3.0)
Direct costs relating to the business combinations – included within service costs
(1.0)
Information on prior year acquisitions The Group acquired certain healthcare businesses during the year ended 30 June 2025. The purchase price accounting that was determined on a provisional basis at 30 June 2025, has now been finalised with no material changes. Refer to Note 10 in the Group’s annual financial statements for the year ended 30 June 2025 for detail of prior year acquisitions.
48
Ramsay Health Care Limited Appendix 4E and Full Year Results 2026
9 Business combinations (Continued) Accounting Policies
Financial Results
Business combinations are accounted for using the acquisition method. The consideration transferred in a business combination is measured at fair value and is calculated as the sum of the business combination date fair values of the assets transferred by the acquirer, the liabilities incurred by the acquirer to former owners of the acquiree and the equity issued by the acquirer, and the amount of any non-controlling interest in the acquiree. For each business combination, the acquirer measures the non-controlling interest in the acquiree either at fair value or at the proportionate share of the acquiree's identifiable net assets. Business combination related costs are expensed as incurred. In accounting for a business combination, the Group assesses the financial assets and liabilities assumed for appropriate classification and designation in accordance with the contractual terms, economic conditions, the Group’s operating or accounting policies and other pertinent conditions as at the business combination date. This includes the separation of embedded derivatives in host contracts by the acquiree. Any contingent consideration to be transferred by the acquirer will be recognised at fair value at the business combination date. Contingent consideration classified as an asset or liability that is a financial instrument and within the scope of AASB 9 Financial Instruments, is measured at fair value with changes in fair value recognised in profit or loss. If the contingent consideration is not within the scope of AASB 9, it is measured in accordance with the appropriate standard. Contingent consideration that is classified as equity is not remeasured and subsequent settlement is accounted for within equity.
Key Accounting Judgements, Estimates and Assumptions The Group recognises the identifiable assets and liabilities of businesses at their business combination date fair values, except for lease liabilities and right of use assets, which are measured at the present value of the remaining lease payments as if the acquired lease were a new lease at the acquisition date and where the right of use asset is further adjusted for favourable and unfavourable terms. Where a significant amount of freehold land and buildings are recognised in the business combination, the fair value is determined by an external valuer using an approach relevant to the market in that country.
Ramsay Health Care Limited Appendix 4E and Full Year Results 2026
49
10 Property, plant and equipment Property, plant and equipment represents the investment by the Group in tangible assets such as land, buildings, hospital fit-outs and medical equipment.
Land & Buildings $m 30 June 2026 Cost Accumulated depreciation and impairment Movement: As at 1 July 2025 Additions Transferred from assets under construction Business combinations Reclassification Depreciation Impairment (Note 13) Disposals Exchange differences As at 30 June 2026 30 June 2025 Cost Accumulated depreciation and impairment Movement: As at 1 July 2024 Additions Transferred from assets under construction Business combinations Reclassification Depreciation Impairment (Note 13) Disposals Exchange differences As at 30 June 2025 30 June 2024 Cost Accumulated depreciation and impairment
50
Ramsay Health Care Limited Appendix 4E and Full Year Results 2026
Plant & Equipment $m
Assets Under Construction $m
Total $m
5,472.7 (1,592.8) 3,879.9
4,213.4 (2,825.2) 1,388.2
433.3 433.3
10,119.4 (4,418.0) 5,701.4
3,918.5 72.1 229.2 51.6 (196.0) (8.5) (35.8) (151.2) 3,879.9
1,393.8 373.8 99.0 0.5 (451.2) (3.1) (19.7) (4.9) 1,388.2
507.7 285.2 (328.2) (0.3) (5.2) (14.1) (11.8) 433.3
5,820.0 731.1 0.5 51.3 (647.2) (16.8) (69.6) (167.9) 5,701.4
5,430.3 (1,511.8) 3,918.5
4,143.0 (2,749.2) 1,393.8
507.7 507.7
10,081.0 (4,261.0) 5,820.0
3,659.8 105.8 195.0 4.4 (21.0) (176.1) (21.5) (11.9) 184.0 3,918.5
1,226.9 337.9 124.1 0.1 (370.7) (4.5) (1.4) 81.4 1,393.8
496.9 336.0 (319.1) (14.3) (7.7) (1.5) 17.4 507.7
5,383.6 779.7 4.5 (35.3) (546.8) (33.7) (14.8) 282.8 5,820.0
4,929.2 (1,269.4) 3,659.8
3,672.9 (2,446.0) 1,226.9
496.9 496.9
9,099.0 (3,715.4) 5,383.6
10 Property, plant and equipment (Continued) Accounting Policies Assets Under Construction is stated at cost, net of accumulated impairment losses, if any. Land and Buildings and Plant and Equipment are stated at cost less accumulated depreciation and any accumulated impairment losses. Such cost includes the cost of replacing parts that are eligible for capitalisation when the cost of replacing the parts is incurred. Depreciation is calculated, consistent with the prior year, on a straight-line basis over the estimated useful life of the assets as follows: Financial Results
• Buildings and integral plant – 40 to 60 years • Plant and equipment, other than plant integral to buildings – various periods not exceeding 10 years The assets’ residual values, useful lives and depreciation methods are reviewed, and adjusted if appropriate, at each financial year end.
Impairment The carrying values of property, plant and equipment are reviewed for impairment at each reporting date, with the recoverable amount being estimated when events or changes in circumstances indicate that the carrying value may be impaired. The recoverable amount of property, plant and equipment is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. For an asset that does not generate largely independent cash inflows, recoverable amount is determined for the cash-generating unit to which the asset belongs, unless the asset's value in use can be estimated to be close to its fair value. An impairment exists when the carrying value of an asset or cash-generating unit exceeds its estimated recoverable amount. The asset or cash-generating unit is then written down to its recoverable amount. Impairment losses are recognised in the Income Statement in the expense category 'depreciation, amortisation and impairment'. An assessment is also made at each reporting date as to whether there is any indication that previously recognised impairment losses may no longer exist or may have decreased. If such indication exists, the recoverable amount is estimated. A previously recognised impairment loss is reversed only if there has been a change in the estimates used to determine the asset’s recoverable amount since the last impairment loss was recognised. If that is the case the carrying amount of the asset is increased to its recoverable amount. That increased amount cannot exceed the carrying amount that would have been determined, net of depreciation, had no impairment loss been recognised for the asset in prior years. Such reversal is recognised in profit or loss. After such a reversal the depreciation charge is adjusted in future periods to allocate the asset’s revised carrying amount, less any residual value, on a systematic basis over its remaining useful life.
Derecognition & disposal An item of property, plant and equipment is derecognised upon disposal or when no further future economic benefits are expected from its use or disposal. Any gain or loss arising on derecognition of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the asset) is included in the Income Statement in the year the asset is derecognised.
Key Accounting Judgements, Estimates and Assumptions Useful lives of assets are estimated based on historical experience. The useful life of assets are assessed annually and adjusted where deemed necessary.
Ramsay Health Care Limited Appendix 4E and Full Year Results 2026
51
11 Right of use assets A right of use asset represents the Group’s, as a lessee, right to use an asset over the life of a lease. See note 7.c for the Group’s lease arrangements and related lease liabilities recognised.
Leased Property $m 30 June 2026 Cost Accumulated depreciation and impairment Movement: As at 1 July 2025 Additions Reclassification Depreciation Impairment (Note 13) Reassessment of lease terms Disposals or terminations Exchange differences As at 30 June 2026 30 June 2025 Cost Accumulated depreciation and impairment Movement: As at 1 July 2024 Additions Reclassification Depreciation Impairment (Note 13) Reassessment of lease terms Disposals or terminations Exchange differences As at 30 June 2025 30 June 2024 Cost Accumulated depreciation and impairment
52
Ramsay Health Care Limited Appendix 4E and Full Year Results 2026
Leased Plant & Equipment $m
Total $m
7,306.8 (3,170.0) 4,136.8
595.7 (302.7) 293.0
7,902.5 (3,472.7) 4,429.8
5,021.1 300.3 (93.3) (458.9) (5.2) (281.0) (14.0) (332.2) 4,136.8
311.9 111.3 (40.2) (0.2) (89.8) 293.0
5,333.0 411.6 (93.3) (499.1) (5.2) (281.2) (14.0) (422.0) 4,429.8
8,280.1 (3,259.0) 5,021.1
625.4 (313.5) 311.9
8,905.5 (3,572.5) 5,333.0
4,489.0 169.1 0.7 (442.8) (43.8) 398.2 (0.1) 450.8 5,021.1
286.4 100.9 (9.8) (97.2) 1.0 (0.6) 31.2 311.9
4,775.4 270.0 (9.1) (540.0) (43.8) 399.2 (0.7) 482.0 5,333.0
7,076.3 (2,587.3) 4,489.0
540.9 (254.5) 286.4
7,617.2 (2,841.8) 4,775.4
12 Intangible assets The Group’s investment in intangible assets includes goodwill, service concession assets, brand names and software.
Goodwill $m
Movement: As at 1 July 2025 Additions Business combinations Reclassification Amortisation Disposals Exchange differences As at 30 June 2026 30 June 2025 Cost Accumulated amortisation and impairment Movement: As at 1 July 2024 Additions Business combinations Reclassification Amortisation Disposals Impairment (Note 13) Exchange differences As at 30 June 2025 30 June 2024 Cost Accumulated amortisation and impairment
Other1 $m
Total $m
5,812.9 (235.7) 5,577.2
219.5 (168.9) 50.6
587.9 (240.2) 347.7
6,620.3 (644.8) 5,975.5
6,006.2 6.9 (435.9) 5,577.2
62.1 6.1 (11.6) (6.0) 50.6
362.8 30.7 3.4 (23.3) (1.9) (24.0) 347.7
6,431.1 36.8 6.9 3.4 (34.9) (1.9) (465.9) 5,975.5
6,264.2 (258.0) 6,006.2
266.8 (204.7) 62.1
606.2 (243.4) 362.8
7,137.2 (706.1) 6,431.1
5,744.9 20.9 (5.2) (248.4) 494.0 6,006.2
59.7 1.2 2.2 (11.7) (1.0) 11.7 62.1
335.3 25.0 (8.3) (27.8) (0.2) 38.8 362.8
6,139.9 25.0 22.1 (6.1) (39.5) (5.4) (249.4) 544.5 6,431.1
5,744.9 5,744.9
243.0 (183.3) 59.7
546.9 (211.6) 335.3
6,534.8 (394.9) 6,139.9
1 Mainly brands and on-premise software costs, including both purchased and internally generated software.
Ramsay Health Care Limited Appendix 4E and Full Year Results 2026
53
Financial Results
30 June 2026 Cost Accumulated amortisation and impairment
Service Concession Assets $m
12 Intangible assets (Continued) Accounting Policies Goodwill Goodwill acquired in a business combination is initially measured at cost being the excess of the cost of the business combination over the Group’s interest in the net fair value of the acquiree’s identifiable assets, liabilities and contingent liabilities. The key factor contributing to the goodwill relates to the synergies existing within the acquired businesses and also expected to be achieved as a result of combining these facilities with the rest of the Group. Following initial recognition, goodwill is measured at cost less any accumulated impairment losses. Goodwill is determined to have an indefinite life. Goodwill is reviewed for impairment, annually or more frequently if events or changes in circumstances indicate that the carrying value may be impaired. For the purpose of impairment testing, goodwill acquired in a business combination is, from the acquisition date, allocated to each of the Group’s cash-generating units, or groups of cash-generating units, that are expected to benefit from the synergies of the combination, irrespective of whether other assets or liabilities of the Group are assigned to those units or groups of units. Each unit or group of units to which the goodwill is so allocated such that: • It represents the lowest level within the Group at which the goodwill is monitored for internal management purposes; and • Is not larger than an operating segment determined in accordance with AASB 8 Operating Segments. Impairment is determined by assessing the recoverable amount of the cash-generating unit (group of cash-generating units), to which the goodwill relates. When the recoverable amount of the cash-generating unit (group of cash-generating units) is less than the carrying amount, an impairment loss is recognised. When goodwill forms part of a cash-generating unit (group of cash-generating units) and an operation within that unit is disposed of, the goodwill associated with the operation disposed of is included in the carrying amount of the operation when determining the gain or loss on disposal of the operation. Goodwill disposed of in this manner is measured based on the relative values of the operation disposed of and the portion of the cash-generating unit retained. Impairment losses recognised for goodwill are not subsequently reversed.
Service concession assets Service concession assets represent the Group’s right to operate hospitals under Service Concession Arrangements. Service concession assets constructed by the Group are recorded at the fair value of consideration received or receivable for the construction services delivered. Service concession assets acquired by the Group are recorded at the fair value of the assets at the date of acquisition. All service concession assets are classified as intangible assets. To the extent that the Group has an unconditional right to receive cash or other financial assets under the Service Concession Arrangements a financial asset (in Note 8.a Other non-current receivables) has been recognised. The financial asset is measured at fair value on initial recognition and thereafter at amortised cost using the effective interest rate method. The financial asset will be reflected on initial recognition and thereafter as a ‘loan or receivable’.
Other Intangible assets Intangible assets acquired separately are measured on initial recognition at cost. The cost of an intangible asset acquired in a business combination is its fair value as at the date of acquisition. Following initial recognition, intangible assets are carried at cost less any accumulated amortisation and any accumulated impairment losses. Internally generated intangible assets, excluding capitalised software development costs, are not capitalised and expenditure is charged against profits in the year in which the expenditure is incurred. The useful lives of intangible assets are assessed to be either finite or indefinite. Intangible assets with finite lives are amortised over the useful life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. Amortisation is calculated, consistent with the prior year, on a straight-line basis over the estimated useful life of the assets as follows: • Service Concession Asset – over the term of the arrangement • Software - 2 to 10 years The amortisation period and the amortisation method for an intangible asset with a finite useful life is reviewed at least at each financial year end. Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset are accounted for by changing the amortisation period or method, as appropriate, which is a change in accounting estimate. The amortisation expense on intangible assets with finite lives is recognised in the Income Statement. Intangible assets with indefinite useful lives are tested for impairment annually either individually or at the cash-generating unit level consistent with the methodology outlined for goodwill impairment testing. Such intangibles are not amortised. The useful life of an intangible asset with an indefinite life is reviewed each reporting period to determine whether indefinite life assessment continues to be supportable. If not, the change in the useful life assessment from indefinite to finite is accounted for as a change in an accounting estimate and is thus accounted for on a prospective basis.
54
Ramsay Health Care Limited Appendix 4E and Full Year Results 2026
12 Intangible assets (Continued) Accounting Policies
Useful lives Amortisation method used
Brands Indefinite Not applicable
Acquired
Acquired
Software costs Finite Amortised over the period of expected future benefit from the related project on a straight line basis Internally generated/Acquired
When an indication of impairment exists. The amortisation method is reviewed at each financial year end.
Annually or more frequently if events or changes in circumstances indicate that the carrying value may be impaired.
When an indication of impairment exists. The amortisation method is reviewed at each financial year end.
Financial Results
Internally generated or acquired Impairment testing
Service Concession Assets Finite Amortised over the period of the arrangement
Gains or losses arising from derecognition of an intangible asset are measured as the difference between the net disposal proceeds and the carrying amount of the asset and are recognised in the Income Statement when the asset is derecognised.
Key Accounting Judgements, Estimates and Assumptions Useful lives of assets are estimated based on historical experience and the expected period of future consumption of embodied economic benefits. Useful lives are reviewed annually and adjustments made where deemed necessary.
Ramsay Health Care Limited Appendix 4E and Full Year Results 2026
55
13 Impairment of non-financial assets An impairment loss is recognised in the income statement when the carrying value of an asset or a cash‑generating unit (CGU) exceeds its estimated recoverable amount. The Group reviews the carrying value of assets and CGUs at least annually, and/or when there is an indication that the asset or CGU may be impaired or a previously recognised impairment may be reversed (assets other than goodwill).
An asset is assessed at the end of each reporting period whether there is any indication that it may be impaired. Irrespective of whether there is any indication of impairment, goodwill is tested for impairment on an annual basis, as a minimum. If any indicator of impairment is identified, the recoverable amount of an asset is assessed against its carrying value to identify any impairment. The recoverable amount is the higher of fair value less costs to sell and value in use (VIU). Carrying value is calculated at the original cost of an asset, less the accumulated amount of any depreciation or amortisation, together with any previously booked impairments.
Goodwill and other non-financial assets Goodwill arises when the Group acquires a business. It is the portion of the purchase price that is higher than the sum of the fair value of net assets acquired, which represents the synergies expected to arise from the acquisition. Goodwill acquired through business combinations is allocated to the cash generating units expected to benefit from the synergies of the business combination. Goodwill has been allocated to the cash generating units or group of cash generating units shown in the table below.
30 June 2026 30 June 2025
Australia $m 1,016.2 1,016.2
Pharmacy $m 165.9 165.9
UK $m 1,484.8 1,625.6
France $m 1,322.7 1,432.4
Nordics $m 1,587.6 1,766.1
Total $m 5,577.2 6,006.2
30 June 2025 impairment As disclosed in the 31 December 2024 financial statements, the trading performance of the Elysium business (part of the UK cashgenerating units) was adversely impacted. Accordingly impairment testing was performed on the UK CGU goodwill and the Elysium sites where impairment indicators were present. This resulted in the recognition of impairment losses in the UK CGU in the Income Statement for the half year ended 31 December 2024: • $248.4 million impairment of UK CGU goodwill • $56.8 million impairment of property, plant and equipment and right of use assets in 13 Elysium sites In addition $21.7 million of impairment was recognised in other regions in the financial year ended 30 June 2025, leading to total impairment of non-current assets (other than goodwill) of $78.5 million (Note 3).
30 June 2026 impairment $22.0 million of impairment was recognised in the current year in relation to property, plant and equipment and right of use assets (Note 3).
56
Ramsay Health Care Limited Appendix 4E and Full Year Results 2026
13 Impairment of non-financial assets (Continued) Key Accounting Judgements, Estimates and Assumptions
Terminal growth rate (Year 5+) 30 June 2026 30 June 2025 Pre-tax discount rate 30 June 2026 30 June 2025
Australia %
Pharmacy %
UK %
France %
3.0 3.0
2.0 2.0
2.25 2.25
1.75 1.75
2.00 2.75
12.1 11.8
13.2 14.0
10.2 10.2
6.2 6.0
6.7 7.0
Financial Results
The recoverable amount of all CGUs have been determined based on a value in use calculation using cash flow projections as at 30 June 2026 based on financial estimates approved by senior management and the Board of Directors covering the following financial year. In determining the 2027 (year 1) cash flow projections, management has factored in the performance of the Group in the current year. A growth factor is then applied to the following 4 years through to the end of the value in use models. Key assumptions used in the value in use calculations are outlined in the table below. Significant assumptions used in the impairment testing are inherently subjective and in times of economic uncertainty, the degree of subjectivity is higher than it might otherwise be. Nordics %
Key inputs in the value in use calculations are: • Earnings before interest, tax, depreciation, amortisation and rent ('EBITDAR') estimates – reflect risk-adjusted cash flow estimates underpinned by assumptions on hospital occupancy rates, revenue rates, and wage and other cost increases. • Terminal Growth rate estimates – based on management’s estimates of long term growth rates for each of the CGUs. • Discount rates – reflect management’s estimate of the time value and the risks specific to each of the CGUs that are not already reflected in the cash flows. In determining appropriate discount rates for each unit, regard has been given to the weighted average cost of capital of the entity as a whole and adjusted for country and business risk specific to the CGU. Management has performed sensitivity testing by CGU based on assessing the effect of changes in key assumptions. As at 31 December 2024, the UK CGU had nil headroom due to the impairment recognised. The UK CGU’s headroom remains relatively low and as such, a reasonable possible change in a assumption which is not offset by a positive change in another assumption may lead to an impairment. Breakeven sensitivity testing was performed on the UK CGU by; decreasing the terminal growth rate from 2.25% to 1.7% which results in the carrying value equalling the recoverable amount; increasing the pre-tax discount rate from 10.2% to 10.9% results in the carrying value equalling the recoverable amount; and reducing the first year earnings before interest, tax, depreciation, amortisation and rent growth rate assumption by 4.0%, with consequential impact to later years, results in the carrying value equalling the recoverable amount. For Australia, Pharmacy, France and the Nordics, management do not consider that a reasonably possible change in a key assumption would result in the carrying value of goodwill exceeding the recoverable amount.
Ramsay Health Care Limited Appendix 4E and Full Year Results 2026
57
14 Taxes This note provides an analysis of the income tax expense and deferred tax balances, including a reconciliation of the tax expense recognised, reconciled to the Group's net profit before tax at the Group's applicable tax rate. A deferred tax asset or liability is created when there are temporary differences between the accounting profit and taxable profit, representing a future income tax receivable or payable.
(i) Income tax expense 2026 $m The major components of income tax expense are: Current income tax Current income tax charge Adjustment relating to prior year tax returns Deferred income tax Relating to origination and reversal of temporary differences Adjustments in respect of deferred income tax of previous years Income tax expense reported in the Consolidated Income Statement
2025 $m
207.7 (6.4)
185.4 (3.6)
(28.8) 19.7 192.2
(117.0) (9.3) 55.5
Release of tax provision Income tax in the Consolidated Income Statement for the year ended 30 June 2025 includes the release of a $64.5 million tax provision ($34.0 million after non-controlling interests) taken up by the Group at the time of the acquisition of an interest in Ramsay Santé in 2015, as the time period to hold the provision lapsed.
(ii) Numerical reconciliation between aggregate tax expense recognised in the Consolidated Income Statement and tax expense calculated per the statutory income tax rate 2026 $m
2025 $m
A reconciliation between tax expense and the product of the accounting profit before income tax multiplied by the Group’s applicable income tax rate is as follows: Accounting profit before tax
513.6
101.8
At the Parent Entity’s statutory income tax rate of 30% (2025: 30%) Expenditure not allowable for income tax purposes Amounts not assessable for income tax purposes Other French income tax expense Foreign tax rate adjustment due to differences in rates between Australia and Other Countries Release of Ramsay Santè acquisition tax provision Non-deductible goodwill impairment Adjustments in respect of prior year Other Income tax expense reported in the Consolidated Income Statement
154.1 11.5 (4.0) 7.7 (0.9) 13.3 10.5 192.2
30.5 21.4 (3.5) 8.2 18.2 (64.5) 62.1 (12.9) (4.0) 55.5
58
Ramsay Health Care Limited Appendix 4E and Full Year Results 2026
14 Taxes (Continued) (iii) Recognised tax assets and liabilities 2026 Deferred income tax $m 270.0 9.1 13.8 (6.1) 286.8
2025 Current income tax $m (89.5) (181.8) 210.1 (2.8) (0.2) (64.2)
2025 Deferred income tax $m 142.3 126.3 (4.1) 4.6 0.9 270.0
Statement of Financial Position 2026 2025 $m $m Amounts recognised in the Statement of Financial Position for Deferred Income Tax at 30 June: Deferred tax liabilities Inventory Deferred revenue Depreciable assets Derivatives Right of use assets and other assets Gross deferred tax liabilities Set-off of deferred tax assets Net deferred tax liabilities
(23.4) (24.9) (320.6) (16.9) (191.1) (576.9) 345.4 (231.5)
(22.0) (21.9) (322.2) (347.8) (713.9) 484.3 (229.6)
Deferred tax assets Employee provisions Other provisions and lease liabilities Unearned income Losses Derivatives Other carried forward deductions Gross deferred tax assets Set-off of deferred tax liabilities Net deferred tax assets
236.1 433.4 6.9 120.9 66.4 863.7 (345.4) 518.3
245.8 555.7 10.1 115.7 11.3 45.3 983.9 (484.3) 499.6
Ramsay Health Care Limited Appendix 4E and Full Year Results 2026
59
Financial Results
As at 1 July (Charged)/credited to income Credited/(charged) to equity Payments Exchange differences Acquisitions and disposals of subsidiary As at 30 June
2026 Current income tax $m (64.2) (201.3) 193.3 2.5 (69.7)
14 Taxes (Continued) (iv) Tax consolidation Ramsay Health Care Limited and its 100% owned Australian resident subsidiaries formed a tax consolidated group effective 1 July 2003. Ramsay Health Care Limited is the head entity of the tax consolidated group. Members of the group have entered into a tax funding and sharing arrangement in order to allocate income tax expense to the wholly owned subsidiaries using a group allocation method on a modified standalone basis. In addition, the agreement provides for the allocation of income tax liabilities between the entities should the head entity default on its tax payment obligations. No amounts have been recognised in the financial statements in respect of this agreement on the basis that the possibility of default is remote.
Tax effect accounting by members of the tax consolidated group Members of the tax consolidated group have entered into a tax funding agreement. The tax funding agreement provides for the allocation of current and deferred taxes using a group allocation method, on a modified standalone basis in accordance with the principles of AASB 112 Income Taxes. Allocations under the tax funding agreement are made every six months. The allocation of taxes under the tax funding agreement is recognised as an increase/decrease in the subsidiaries' inter-company accounts with the tax consolidated group head company. There is no difference between the current and deferred tax amounts allocated under the tax funding agreement and the amount subsequently charged to the subsidiary. Therefore, there is no contribution/distribution of the subsidiaries' equity accounts. As a result of tax consolidation, intercompany assets of Ramsay Health Care Limited have increased by $54.1 million (2025: increased by $56.2 million). This is included in the summarised information relating to Ramsay Health Care Limited. Refer to Note 25.
(v) Tax losses At 30 June 2026, there were nil (2025: nil) losses carried forward in the Ramsay Health Care Ltd tax consolidated group and therefore no resulting deferred tax asset has been recognised. $120.9 million (2025: $115.7 million) has been recognised as deferred tax assets in relation to tax losses in other tax jurisdictions. The Group has unrecognised deferred tax assets of $74.3 million (2025: $62.3 million) relating to unused tax losses and other carried forward deductions where it is not probable that they can be utilised in the foreseeable future.
(vi) International Tax Reform – Pillar Two Model Rules The Organisation for Economic Co-operation and Development (OECD) Pillar Two legislation has been enacted or substantively enacted in certain jurisdictions the Group operates and became effective for the Group from 1 July 2024. The Group is in scope of the enacted or substantively enacted legislation, including in the Group’s parent jurisdiction (being Australia) as at the reporting date. Based on the full year result, the Group has satisfied the safe harbour tests or its effective tax rate exceeded 16 per cent in the jurisdictions in which it operates and therefore, the application of the rules does not have any current tax impact on the Group for the year ended 30 June 2026. The Group continues to monitor the developments around the implementation and enactment of Pillar Two income taxes and the detailed impact assessment of Pillar Two income taxes is ongoing. The Group applies the mandatory exception to recognising and disclosing information about deferred tax assets and liabilities related to Pillar Two income taxes, as provided in the Amendments to AASB 112 Income Taxes.
Accounting Policies Income tax Current tax assets and liabilities for the current and prior periods are measured at the amount expected to be recovered from or paid to the taxation authorities. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted by the reporting date. Deferred income tax is provided on all temporary differences at the reporting date between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes.
60
Ramsay Health Care Limited Appendix 4E and Full Year Results 2026
14 Taxes (Continued) Accounting Policies Deferred income tax liabilities are recognised for all taxable temporary differences except: • when the deferred income tax liability arises from the initial recognition of; – goodwill;
Financial Results
– an asset or liability in a transaction that: i. is not a business combination; ii. at the time of the transaction, affects neither the accounting profit nor taxable profit or loss; and iii. at the time of the transaction, does not give rise to equal taxable and deductible temporary difference; or • when the taxable temporary difference is associated with investments in subsidiaries, associates or interests in joint ventures, and the timing of the reversal of the temporary difference can be controlled and it is probable that the temporary difference will not reverse in the foreseeable future. Deferred income tax assets are recognised for all deductible temporary differences, carry-forward of unused tax assets and unused tax losses, to the extent that it is probable that taxable profit will be available against which the deductible temporary differences and the carry-forward of unused tax credits and unused tax losses can be utilised, except: • when the deferred income tax asset relating to the deductible temporary difference arises from the initial recognition of an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss; or • when the deductible temporary difference is associated with investments in subsidiaries, associates or interests in joint ventures, in which case a deferred tax asset is only recognised to the extent that it is probable that the temporary difference will reverse in the foreseeable future and taxable profit will be available against which the temporary difference can be utilised. Deferred tax assets are recognised for unused tax losses to the extent that it is probable that taxable profit will be available against which the losses can be utilised. Judgement is required to determine the amount of deferred tax assets that can be recognised, based upon the likely timing and the level of future taxable profits, together with future tax planning strategies. The carrying amount of deferred income tax assets is reviewed at each reporting date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred income tax asset to be utilised. Unrecognised deferred income tax assets are reassessed at each reporting date and are recognised to the extent that it has become probable that future taxable profit will allow the deferred tax asset to be recovered. Deferred income tax assets and liabilities are measured at the tax rates that are expected to apply to the year when the asset is realised or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted at the reporting date. Income taxes relating to items recognised directly in equity are recognised in equity and not in the Income Statement. Deferred tax assets and deferred tax liabilities are offset only if a legally enforceable right exists to set off current tax assets against current tax liabilities and the deferred tax assets and liabilities relate to the same taxable entity and the same taxation authority.
Other taxes Revenues, expenses and assets are recognised net of the amount of GST except: • where the GST incurred on a purchase of goods and services is not recoverable from the taxation authority, in which case the GST is recognised as part of the cost of acquisition of the asset or as part of the expense item as applicable; and • receivables and payables are stated with the amount of GST included. The net amount of GST recoverable from, or payable to, the taxation authority is included as part of receivables or payables in the Statement of Financial Position. Cash flows are included in the Statement of Cash Flows on a gross basis and the GST component of cash flows arising from investing and financing activities which is recoverable from, or payable to, the taxation authority are classified as operating cash flows.
Key Accounting Judgements, Estimates and Assumptions In determining the Group’s deferred tax assets and liabilities, management is required to make an estimate about the availability of future taxable profits and cash flows. Changes in circumstances will alter expectations, which may impact the amount of tax losses and temporary differences recognised.
Ramsay Health Care Limited Appendix 4E and Full Year Results 2026
61
15 Other assets/liabilities (net) Note Prepayments – current and non-current Other assets – current Assets held for sale Defined employee benefit assets Other financial assets – non-current Other receivables – non-current Provisions – current and non-current Defined employee benefit obligation Other creditors – non-current Net derivative assets/(liabilities) – current and non-current
15.c 8.a 15.a 15.c 15.d
2026 $m 237.5 22.6 40.6 121.3 101.7 231.4 (1,761.5) (166.8) (44.0) 27.5 (1,189.7)
2025 $m 292.6 48.8 107.1 110.8 122.8 (1,747.0) (184.5) (51.7) (41.1) (1,342.2)
Accounting Policies The Group classifies non-current assets as assets held for sale if their carrying amounts will be recovered principally through a sale transaction rather than through continuing use. Assets held for sale are measured at the lower of their carrying amount and fair value less costs to sell. Assets held for sale as at 30 June 2026 include Property, Plant and Equipment.
15.a Provisions A provision is a liability with uncertain timing and amount, but the expected settlement amount can be reliably estimated by the Group. The main provisions held are in relation to insurance, restructuring, legal obligations, unfavourable contracts and employee benefits.
Current Restructuring provision Insurance provision Unfavourable contracts Legal and compliance provision Self-insured workers compensation Employee and Director entitlements Other provisions Non-current Restructuring provision Insurance provision Unfavourable contracts Legal and compliance provision Self-insured workers compensation Employee and Director entitlements Other provisions Total Total excluding Employee and Director entitlements Refer Note 8c for details on reclassification of Current Employee and Director comparatives.
62
Ramsay Health Care Limited Appendix 4E and Full Year Results 2026
2026 $m
2025 $m
14.0 13.1 3.3 45.9 9.9 1,310.2 12.6 1,409.0
18.7 13.0 3.6 37.7 8.0 1,262.0 37.1 1,380.1
40.3 74.5 30.8 140.2 15.0 46.4 5.3 352.5 1,761.5 404.9
21.1 68.3 37.0 177.7 12.9 44.7 5.2 366.9 1,747.0 440.3
15 Other assets/liabilities (net) (Continued) Movements in provisions (excluding Employee and Director entitlements)
Total $m 440.3 103.4 (66.7) (47.2) (24.9) 404.9
Current Non-current As at 30 June 2026
14.0 40.3 54.3
13.1 74.5 87.6
3.3 30.8 34.1
45.9 140.2 186.1
9.9 15.0 24.9
12.6 5.3 17.9
98.8 306.1 404.9
Current Non-current As at 30 June 2025
18.7 21.1 39.8
13.0 68.3 81.3
3.6 37.0 40.6
37.7 177.7 215.4
8.0 12.9 20.9
37.1 5.2 42.3
118.1 322.2 440.3
Nature and timing of provisions Restructuring provision The restructuring provision primarily relates to the restructuring of the Group subsequent to acquisitions. Provisions are recognised in the year a constructive obligation arises.
Insurance provision Insurance policies are entered into to cover the various insurable risks. These policies have varying levels of deductibles and retentions. The medical malpractice provision covers deductibles and retentions arising under the Group's medical malpractice insurance policies, and covers both reported and estimated 'incurred but not reported' claims. The provision also covers estimated potential uninsured claims.
Unfavourable contracts This provision consists of VAT and other taxes payable on impaired right of use assets for certain leases.
Legal and compliance provision The legal and compliance provision primarily relates to amounts provided for litigation that is currently in the court process or a matter under review by a relevant authority.
Self-insured workers compensation The Australian Group is self-insured for workers compensation claims. Provisions are recognised based on claims reported and an estimate of claims incurred but not reported. These provisions are determined on a discounted basis, using an actuarial valuation performed at each reporting date. The Australian Group has entered into bank guarantees in relation to its self-insured workers compensation obligations, refer to Note 19.
Employee and Director entitlements Short-term employee and director entitlements Employee and director entitlements expected to be settled within 12 months after the end of the period are recognised as short-term employee and director entitlements. These provisions are measured at the amounts expected to be paid when settled.
Long-term employee and director entitlements Employee and director entitlements not expected to be settled within 12 months after the end of the period are recognised as long-term employee and director entitlements. These provisions are measured at the present value of expected future payments to be made. In determining the provision, consideration is given to expected future wage and salary levels, experience of employee departures and periods of service. Expected future payments are discounted using market yields at the reporting date on high-quality corporate bonds with terms to maturity and currencies that match, as closely as possible, the estimated future cash outflows.
Ramsay Health Care Limited Appendix 4E and Full Year Results 2026
63
Financial Results
As at 1 July 2025 Business combinations Arising during the year Utilised during the year Unused amounts reversed Exchange differences As at 30 June 2026
Selfinsured Unfavourable Legal and workers Other Restructuring Insurance contracts compliance compensation provisions $m $m $m $m $m $m 39.8 81.3 40.6 215.4 20.9 42.3 50.6 19.2 2.7 19.1 11.8 (25.2) (12.4) (3.5) (3.1) (15.1) (7.4) (7.1) (13.4) (26.7) (3.8) (0.5) (3.0) (15.5) (2.1) 54.3 87.6 34.1 186.1 24.9 17.9
15 Other assets/liabilities (net) (Continued) Accounting Policies Provisions are recognised when the Group has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. Where the Group expects some or all of a provision to be reimbursed, for example under an insurance contract, the reimbursement is recognised as a separate asset but only when the reimbursement is virtually certain. The expense relating to any provision is presented in the Income Statement net of any reimbursement. If the effect of the time value of money is material, provisions are determined by discounting the expected future cash flows at a pre-tax rate that reflects current market assessments of the time value of money and, where appropriate, the risks specific to the liability. Where discounting is used, the increase in the provision due to the passage of time is recognised as a finance cost.
Key Accounting Judgements, Estimates and Assumptions The insurance provision is actuarially assessed at each reporting period using a probability of sufficiency between 80% - 95% based on differing exposures to risk. The greatest uncertainty in estimating the provision is the costs that will ultimately be incurred which is estimated using historical claims, market information and other actuarial assessments. Included in the insurance provision is an amount for claiming handling expenses at between 5%-10% of the estimated Ramsay claim cost.
64
Ramsay Health Care Limited Appendix 4E and Full Year Results 2026
15 Other assets/liabilities (net) (Continued) 15.b Superannuation commitments The Group contributes to industry and individual superannuation funds established for the provision of benefits to employees of entities within the economic entity on retirement, death or disability. Benefits provided under these plans are based on contributions for each employee and for retirement are equivalent to accumulated contributions and earnings. All death and disability benefits are insured with various life insurance companies. The entity contributes to the funds at various agreed contribution levels, which are not less than the statutory minimum.
15.c Defined employee benefit obligation Financial Results
A defined benefit plan is an employer-based program that pays retirement benefits based on a predetermined formula such as the employee’s length of employment, age and salary history. The Group has a defined employee benefit obligation in France as required to be paid under local legislation. There is also a defined benefit obligation in the Nordics. In contrast to a defined contribution plan, the employer, not the employee, is responsible for all of the planning and investment risk of a defined benefit plan. The Group has a defined contribution obligation in other jurisdictions. Refer Note 15.b.
The following tables summarise the funded status and amounts recognised in the consolidated Statement of Financial Position for the plans: 2026 $m Net (liability) included in the Statement of Financial Position Present value of defined benefit obligation Fair value of plans assets Net (liability) – non-current
(448.9) 403.4 (45.5) 2026 $m
As presented on the Statement of Financial Position Net defined benefit obligation asset Net defined benefit obligation liability
As at 1 July Service cost (recognised in Note 3 superannuation and pension costs) Interest income/(expense) Total amount recognised in profit or loss Actuarial gain/(loss) Total amount recognised in other comprehensive income Contributions by employer Benefits paid Exchange differences As at 30 June
2025 $m (477.7) 400.3 (77.4) 2025 $m
121.3 (166.8) (45.5)
107.1 (184.5) (77.4)
2025 Fair value of plan assets $m 301.3
Total $m (103.1)
Present value of obligation $m (477.7)
2026 Fair value of plan assets $m 400.3
Total $m (77.4)
Present value of obligation $m (404.4)
(17.9) (14.6)
11.1
(17.9) (3.5)
(21.8) (15.1)
11.4
(21.8) (3.7)
(32.5) 8.6
11.1 5.2
(21.4) 13.8
(36.9) 1.7
11.4 11.2
(25.5) 12.9
8.6 15.2 37.6 (448.8)
5.2 23.8 (5.1) (32.0) 403.3
13.8 23.8 10.1 5.6 (45.5)
1.7 16.0 (54.1) (477.7)
11.2 37.0 (5.7) 45.1 400.3
12.9 37.0 10.3 (9.0) (77.4)
2026 $m (13.8) 12.9
2025 $m (12.9) 26.7
Actuarial losses/(gains) recognised in the Statement of Comprehensive Income Cumulative actuarial losses recognised in the Statement of Comprehensive Income
Ramsay Health Care Limited Appendix 4E and Full Year Results 2026
65
15 Other assets/liabilities (net) (Continued) The principal actuarial assumptions used in determining obligations for the liabilities are shown below (expressed as weighted averages):
Discount rate Future salary increases Future pension increases
2026 % 3.5 to 4.0 2.0 to 4.0 2.0 to 4.0
2025 % 3.3 to 4.0 1.8 to 4.0 1.8 to 4.0
Accounting Policies The Group has defined employee benefit obligations in the Nordics and in France, arising from local legislative requirements. The cost of providing benefits under these obligations are determined using the projected unit credit method using actuarial valuations. Actuarial gains and losses for the defined obligation are recognised in full in the period in which they occur in Other Comprehensive Income. Such actuarial gains and losses are also immediately recognised in retained earnings and are not reclassified to profit or loss in subsequent periods. Unvested past service costs are recognised as an expense on a straight line basis over the average period until the benefits become vested. Past service costs are recognised immediately if the benefits have already vested, immediately following the introduction of, or changes to, the obligation. The defined benefit liability comprises the present value of the defined benefit obligation (using a discount rate based on corporate bonds) less unrecognised past service costs.
Key Accounting Judgements, Estimates and Assumptions The actuarial valuation involves making assumptions about discount rates, future salary increases and mortality rates. All assumptions are reviewed at each reporting date. In determining the appropriate discount rates, the interest rates of corporate bonds in France and the Nordics is considered. The mortality rate is based on publicly available mortality rates for France and the Nordics. Future salary increases are based on expected future inflation rates in France and the Nordics.
15.d Derivative financial instruments A derivative is a financial instrument typically used to manage an underlying risk, using futures, swaps and options. The value change of a derivative is related to changes in a variable, such as interest rate or foreign exchange rate. The Group uses derivatives to manage exposure to foreign exchange and interest rate risk.
2026 $m Current assets Interest rate and foreign exchange derivative contracts – cash flow hedges Non-current assets Interest rate and foreign exchange derivative contracts – cash flow hedges Current liabilities Interest rate and foreign exchange derivative contracts – cash flow hedges Interest rate and foreign exchange derivative contracts – economic hedges Non-current liabilities Interest rate and foreign exchange derivative contracts – cash flow hedges Net derivative assets/(liabilities)
66
Ramsay Health Care Limited Appendix 4E and Full Year Results 2026
2025 $m 0.5
1.2
29.6 30.1
0.4 1.6
(2.3)
(7.7) (0.1)
(0.3) (2.6) 27.5
(34.9) (42.7) (41.1)
15 Other assets/liabilities (net) (Continued) Instruments used by the Group Derivative financial instruments are used by the Group in the normal course of business in order to hedge exposure to fluctuations in interest and foreign exchange rates.
Interest rate swaps and forward foreign exchange contracts – cash flow hedges Interest bearing loans in Australian Dollar of the Group currently bear an average variable base interest rate excluding margin of 4.42% (2025: 3.86%). Interest bearing loans in Euro of the Group currently bear a variable base interest rate excluding margin of 2.19% (2025: 2.24%). In order to reduce the variability of the future cash flows in relation to the interest bearing loans, the Group has entered into Australian Dollar and Euro interest rate swap contracts under which it has a right to receive interest at variable rates and to pay interest at fixed rates. Swaps in place cover approximately 69% (2025: 84%) of variable base interest rate loans drawn as at 30 June 2026. Financial Results
To reduce the foreign exchange risk of expected purchases, the Group enters into foreign exchange forward contracts which are designated in a cash flow hedge relationship.
Interest rate risk Information regarding interest rate risk exposure is set out in Note 17.
Credit risk Credit risk arises from the potential failure of counterparties to meet their obligations at maturity of contracts. This arises on derivative financial instruments with unrealised gains. Management constantly monitor the fair value of favourable contracts outstanding with any individual counterparty. Management only deal with prime financial institutions with appropriate credit ratings in order to manage this credit risk.
Fair value of derivative financial instruments The fair value of the derivative financial instruments was estimated using the level 2 method valuation technique and is summarised in the table above. The most frequently applied valuation techniques include forward pricing and swap models, using present value calculations. The models incorporate various inputs including the credit quality of counterparties, foreign exchange spot and forward rates and interest rate curves. The changes in counterparty credit risk had no material effect on the hedge effectiveness assessment for derivatives designated in hedge relationships. The Group uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximising the use of relevant observable inputs and minimising the use of unobservable inputs. Information about the valuation techniques and inputs used in determining the fair value of various assets and liabilities are disclosed in the relevant notes. All assets and liabilities for which fair value is measured or disclosed in the financial statements are categorised within the fair value hierarchy, described as follows, based on the lowest level input that is significant to the fair value measurement as a whole:
Level 1 Level 2 Level 3
Quoted (unadjusted) market prices in active markets for identical assets or liabilities Valuation techniques for which the lowest level input that is significant to the fair value measurement is directly or indirectly observable Valuation techniques for which the lowest level input that is significant to the fair value measurement is unobservable
Ramsay Health Care Limited Appendix 4E and Full Year Results 2026
67
15 Other assets/liabilities (net) (Continued) For assets and liabilities that are recognised in the financial statements on a recurring basis, the Group determines whether transfers have occurred between Levels in the hierarchy by re-assessing categorisation (based on the lowest level input that is significant to the fair value measurement as a whole) at the end of each reporting period. There were no transfers between Level 1 and Level 2 or between Level 2 and Level 3 during the year. The notional principal amounts and period of expiry of the interest rate derivatives contracts are as follows: 2026 $m 885.4 2,502.2 250.0 1,113.4 248.0 4,999.0
0-1 years 1-2 years 2-3 years 3-5 years Over 5 years
2025 $m 1,620.9 952.0 1,320.0 1,398.4 269.1 5,560.4
The interest rate derivatives require settlement of net interest receivable or payable each 90 days. They are settled on a net basis. The swaps are measured at fair value and all gains and losses attributed to the hedged risk are taken directly to equity and re-classified to the Income Statement when the interest expense is recognised.
Accounting Policies The Group uses derivative financial instruments such as interest rate swaps to hedge its risks associated with interest rates. Such derivative financial instruments are initially recognised at fair value on the date on which a derivative contract is entered into and are subsequently remeasured to fair value. Derivatives are carried as assets when the fair value is positive and as a liability when the fair value is negative. Any gains or losses arising from changes in the fair value of derivatives are taken directly to profit or loss, except for the effective portion of cash flow hedges, which is recognised in Other Comprehensive Income, and later classified to profit and loss when the hedge item affects profit or loss. For the purposes of hedge accounting, hedges are classified as: • fair value hedges when they hedge the exposure to changes in the fair value of a recognised asset or liability; • cash flow hedges when they hedge exposure to variability in cash flows that is attributable either to a particular risk associated with a recognised asset or liability or to a highly probable forecast transaction or the foreign currency risk in an unrecognised firm commitment; or • hedges of a net investment in a foreign operation. At the inception of a hedge relationship, the Group formally designates and documents the hedge relationship to which the Group wishes to apply hedge accounting and the risk management objective and strategy for undertaking the hedge. The documentation includes identification of the hedging instrument, the hedged item, the nature of the risk being hedged and how the Group will assess whether the hedging relationship meets the hedge effectiveness requirements (including the analysis of sources of hedge ineffectiveness and how the hedge ratio is determined). A hedging relationship qualifies for hedge accounting if it meets all of the following effectiveness requirements: • There is an economic relationship between the hedged item and the hedging instrument; • The effect of credit risk does not ‘dominate the value changes’ that result from that economic relationship; and • The hedge ratio of the hedging relationship is the same as that resulting from the quantity of the hedged item that the Group actually hedges and the quantity of the hedging instrument that the Group actually uses to hedge that quantity of hedged item.
68
Ramsay Health Care Limited Appendix 4E and Full Year Results 2026
15 Other assets/liabilities (net) (Continued) Accounting Policies Hedges that meet the strict criteria for hedge accounting are accounted for as follows:
Cash flow hedges
Financial Results
The effective portion of the gain or loss on the hedging instrument is recognised directly in Other Comprehensive Income in the cash flow hedge reserve, while any ineffective portion is recognised immediately in the Income Statement as other operating expenses. The Group uses predominantly interest rate swap contracts as hedges of its exposure to fluctuations in interest rates. There is an economic relationship between the hedged item and the hedging instrument as the term of the interest rate swap matches the terms of the variable rate loan (that is, notional amount, maturity, base rate, payment and reset dates). Amounts recognised as Other Comprehensive Income are transferred to profit or loss when the hedged transaction affects profit or loss, such as when the hedged financial income or financial expense is recognised. When the hedged item is the cost of a non-financial asset or non-financial liability, the amounts recognised as Other Comprehensive Income are transferred to the initial carrying amount of the non-financial asset or liability. If the forecast transaction or firm commitment is no longer expected to occur, the cumulative gain or loss previously recognised in Other Comprehensive Income is transferred to the Income Statement. If the hedging instrument expires or is sold, terminated or exercised without replacement or rollover, or if its designation as a hedge is revoked, any cumulative gain or loss previously recognised in Other Comprehensive Income remains in Other Comprehensive Income until the forecast transaction or firm commitment affects profit or loss.
Subsequent measurement For financial instruments not traded in an active market, the fair value is determined using appropriate valuation techniques. Such techniques may include: • Using recent arm’s length market transaction; • Reference to the current fair value of another instrument that is substantially the same; or • A discounted cash flow analysis or other valuation models.
Fair value of derivative financial instruments The Group measures financial instruments, such as, derivatives, at fair value at each reporting date. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either: • In the principal market for the asset or liability; or • In the absence of a principal market, in the most advantageous market for the asset or liability. The principal or the most advantageous market must be accessible by the Group. The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest.
16 Net tangible assets/(liabilities) Net Tangible Assets/(Liabilities) (NTA) are the total assets minus intangible assets and total liabilities, divided by the number of ordinary shares of the Company currently on issue at the reporting date. Net tangible assets/(liabilities) include right of use assets as the underlying leases are for physical assets.
Net tangible (liabilities) per ordinary share
2026 $ per Share (2.90)
2025 $ per Share (4.30)
Ramsay Health Care Limited Appendix 4E and Full Year Results 2026
69
IV Risk Management This section discusses the Group’s exposure to various risks and shows how these could affect the Group’s financial position and performance.
17 Financial risk management This note provides a summary of the Group’s exposure to key financial risks, including interest rate, foreign currency, credit and liquidity risks, along with the Group’s policies and strategies to mitigate these risks. There have been no material changes to the Group's risk management policies since 1 July 2025.
Primary responsibility for identification and control of financial risks rests with the Audit Committee under the authority of the Board. The Board reviews and agrees policies for managing each of the risks identified below, including the setting of limits for trading in derivatives, hedging cover of foreign currency and interest rate risk, credit allowances, and future cash flow forecast projections. The Group's principal financial instruments comprise receivables, payables, bank loans and overdrafts, cash and short-term deposits, derivatives, and other financial assets. The Group manages its exposure to key financial risks, including market risk (interest rate and foreign currency risk), credit risk and liquidity risk in accordance with the Group's financial risk management policy. The objective of the policy is to support the delivery of the Group's financial targets whilst protecting future financial security. The Group enters into derivative transactions, principally interest rate swap contracts, foreign exchange forward and swap contracts. The purpose is to manage the interest rate and currency risks arising from the Group's operations and its sources of finance. The main risks arising from the Group's financial instruments are interest rate risk, foreign currency risk, credit risk and liquidity risk. The Group uses different methods to measure and manage different types of risks to which it is exposed. These include monitoring levels of exposure to interest rate and foreign exchange risk and assessments of market forecasts for interest rate and foreign exchange. Ageing analyses and monitoring of specific credit allowances are undertaken to manage credit risk and liquidity risk is monitored through the development of future rolling cash flow forecasts. The Group has entered into Syndicated Facility Agreements with its Banks. The Syndicated Facility Agreements are with prime financial institutions. By entering into Syndicated Facility Agreements with a number of financial institutions in addition to Bilateral Facility Agreements, the Group has reduced its counterparty risk.
Interest rate risk Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate due to changes in market interest rates. The Group's exposure to market interest rates relates primarily to the Group's long-term debt obligations with floating interest rates. The level of debt is disclosed in Note 7.b. At reporting date, the Group had the following mix of financial assets and liabilities exposed to variable interest rates: 2026 $m Financial Assets Cash and cash equivalents Financial Liabilities Bank Loans Net exposure
2025 $m
729.9
784.4
(1,454.9) (725.0)
(779.7) 4.7
Interest rate derivatives contracts are outlined in Note 15.d, with a net positive fair value of $27.5 million (2025: net negative $40.8 million) which are exposed to fair value movements if interest rates change.
70
Ramsay Health Care Limited Appendix 4E and Full Year Results 2026
17 Financial risk management (Continued)
Interest rate sensitivity
The following sensitivity analysis has been determined based on the exposure to interest rates for both derivative and non-derivative instruments at the end of the reporting period and the stipulated change taking place at the beginning of the financial year and held constant throughout the reporting period. At the end of the reporting period, as specified in the following table, if the interest rates had been higher or lower than the year end rates and all other variables were held constant, the consolidated entity’s post tax profit and Other Comprehensive Income would have been affected as follows: Judgements of reasonably possible movements:
Other Comprehensive Income Higher/(Lower) 2026 2025 $m $m
(4.7) 4.7
(3.6) 3.6
17.8 (18.3)
27.7 (28.8)
1.3 (1.3)
0.3 (0.3)
(1.7) 1.7
3.5 (3.5)
31.9 (33.3)
33.8 (35.6)
Foreign currency risk Foreign currency risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. The Group’s exposure to the risk of changes in foreign exchange rates relates primarily to the Group’s operating activities (when revenue or expense is denominated in a different currency from the functional currency). The Group manages its foreign exchange rate exposure within approved policy parameters by utilising foreign currency swaps and forwards. When a derivative is entered into for the purpose of being a hedging instrument, the Group negotiates the terms of those derivatives to match the terms of the hedged exposure. For hedges of forecast transactions, the derivatives cover the period of exposure from the point the cash flows of the transactions are forecasted up to the point of settlement of the resulting receivable or payable that is denominated in foreign currency.
Foreign currency sensitivity The following table demonstrates the sensitivity to a reasonably possible changes in Euro exchange rates, with all other variables held constant. The impact on the Group’s equity is in relation to the loan and cash balances of the Group's subsidiary. The Group’s exposure to foreign currency changes for all other currencies is not material. Post Tax Profit Higher/(Lower) 2026 2025 $m $m Euro (EUR) +10% (2025: +10%) -10% (2025: -10%)
Other Comprehensive Income Higher/(Lower) 2026 2025 $m $m
168.8 (206.3)
173.5 (211.6)
Ramsay Health Care Limited Appendix 4E and Full Year Results 2026
71
Financial Results
AUD +100 basis points (2025: +100 basis points) -100 basis points (2025: -100 basis points) GBP +100 basis points (2025: +100 basis points) -100 basis points (2025: -100 basis points) EUR +100 basis points (2025: +100 basis points) -100 basis points (2025: -100 basis points)
Post Tax Profit Higher/(Lower) 2026 2025 $m $m
17 Financial risk management (Continued) Credit risk Credit risk arises from the financial assets of the Group, which comprise cash and cash equivalents, trade and other receivables, derivative instruments and other financial instruments. The Group's exposure to credit risk arises from potential default of the counter party, with a maximum exposure equal to the carrying amount of these instruments. Exposure at reporting date is addressed in each applicable note.
Trade receivables The Group trades only with recognised, creditworthy third parties, and as such collateral is generally not requested. The majority of transactions are with the Governments and Health Funds. The Group’s credit policy requires all debtors to pay in accordance with agreed terms. The payment terms for the major debtors range from 15 days to 30 days. Collectability of trade receivables is reviewed on an ongoing basis at an operating unit level. Individual debts that are known to be uncollectable are written off when identified. An impairment provision is recognised based on expected credit loss where the Group measures the impairment using a lifetime expected loss allowance for all trade receivables. Financial difficulties of the debtor, default payments or debts more than 60 days overdue are considered indicators of potential default. The amount of the impairment loss is the receivable carrying amount compared to the present value of estimated future cash flows, discounted at the original effective interest rate. The Group’s credit risk is spread across a number of Health Funds and Governments. Whilst the Group does have significant credit risk exposure to a single debtor or group of related debtors, the credit quality of these debtors is considered high, as they are either Health Funds, governed by the prudential requirements of APRA, or Governments. The credit quality of financial assets that are neither past due nor impaired is considered to be high, due to the absence of defaults, and the fact that the Group deals with creditworthy Health Funds and the Governments. Management has also put in place procedures to constantly monitor the exposures in order to manage its credit risk.
Financial instruments and cash deposits Credit risks related to balances with banks and financial institutions are managed by Ramsay Group Treasury in accordance with Board approved policies. Such policies only allow financial derivative instruments to be entered into with high credit quality financial institutions. In addition, the Board has approved the use of these financial institutions, and specific internal guidelines have been established with regard to limits, dealing and settlement procedures. Limits are set to minimise the concentration of risks and therefore mitigate financial loss through potential counterparty failure. The investment of surplus funds is made only with approved counterparties and within credit risk in relation to derivatives undertaken in accordance with the consolidated entity’s hedging and risk management activities. The Group does not hold any credit derivatives to off-set its credit risk exposure. The Group’s maximum exposure for financial derivative instruments is noted in the liquidity table below.
72
Ramsay Health Care Limited Appendix 4E and Full Year Results 2026
17 Financial risk management (Continued) Liquidity risk Liquidity risk arises from the financial liabilities of the Group and the Group’s subsequent ability to meet their obligations to repay their financial liabilities as and when they fall due. The Group's objective is to maintain a balance between continuity of funding and flexibility through the use of bank overdrafts, bank loans, bonds and leases. To monitor existing financial assets and liabilities as well as to enable an effective controlling of future risks, Ramsay has established management reporting covering its worldwide business units that reflects expectations of management’s expected settlement of financial assets and liabilities.
The table below summarises the maturity profile of the Group’s financial liabilities based on contractual undiscounted payments. Less than 3 months $m As at 30 June 2026 Trade and other liabilities Loans and borrowings Lease liabilities Financial derivatives
As at 30 June 2025 Trade and other liabilities Loans and borrowings Lease liabilities Financial derivatives
3 to 12 months $m
1 to 5 years $m
5 years $m
Total $m
(1,901.8) (410.7) (174.3) (1.2) (2,488.0)
(282.3) (522.9) (1.8) (807.0)
(3,186.2) (2,297.5) (0.4) (5,484.1)
(2,521.9) (6,590.6) (9,112.5)
(1,901.8) (6,401.1) (9,585.3) (3.4) (17,891.6)
(2,267.6) (324.2) (178.9) 0.7 (2,770.0)
(258.1) (536.8) (9.2) (804.1)
(3,235.8) (2,368.4) (36.1) (5,640.3)
(2,931.8) (5,738.9) 0.5 (8,670.2)
(2,267.6) (6,749.9) (8,823.0) (44.1) (17,884.6)
The disclosed financial derivative instruments in the above table are the net undiscounted cash flows. However, those amounts may be settled gross or net.
Ramsay Health Care Limited Appendix 4E and Full Year Results 2026
73
Financial Results
The Group continually reviews its liquidity position including cash flow forecasts to determine the forecast liquidity position and maintain appropriate liquidity levels.
V Other Information This section includes other information that must be disclosed to comply with the accounting standards and other pronouncements, but that is not immediately related to individual line items in the financial statements.
18 Share based payment plans A share based payment is a transaction in which the Group receives goods or services in exchange for rights to its own shares. Ramsay operates a performance rights scheme, where share rights may be issued to eligible employees.
An executive performance rights scheme was established in January 2004 where Ramsay Health Care Limited may, at the discretion of the Board, grant rights over the ordinary shares of Ramsay Health Care Limited to executives of the consolidated entity. The rights are issued for nil consideration and are granted in accordance with the plan’s guidelines established by the Directors of Ramsay Health Care Limited. The rights cannot be transferred and will not be quoted on the ASX. Non-executive directors are not eligible for this plan. Information with respect to the number of rights granted under the Executive Performance Rights Plan is as follows: 2025
2026 Number of Rights 616,120 405,850 (274,905) 747,065
Balance at beginning of year granted vested forfeited Balance at end of year Exercisable at end of year
Weighted Average Fair Value $ 25.62 $ 37.36
Number of Rights 607,191 292,058 (283,129) 616,120
Weighted Average Fair Value $ 21.87 $ 45.79
The following table summarises information about rights held by participants in the Executive Performance Rights Plan as at 30 June 2026:
Grant Date 15-Dec-23 13-Dec-24 28-Feb-25 15-Dec-25
Vesting Date1 31-Aug-26 31-Aug-27 31-Aug-27 31-Aug-28
Number of Rights subject to market condition (i.e. TSR) 86,830 102,768 940 183,020 373,558
Weighted Average Fair Value2 $20.60 $8.92 $8.92 $17.97
Number of Rights subject to nonmarket condition (i.e. EPS) 86,814 102,755 936 183,002 373,507
Weighted Average Fair Value3 $48.49 $34.82 $34.82 $33.27
1 The vesting date shown is the most likely vesting date subject to full satisfaction of the respective performance conditions. 2 Fair value at grant date of Rights with TSR vesting condition has been valued using Monte Carlo simulation (using the Black-Scholes framework). 3 Fair value at grant date of Rights with EPS non-market condition is equal to the share price on valuation date less the discounted value of dividends forsaken over the vesting period.
74
Ramsay Health Care Limited Appendix 4E and Full Year Results 2026
18 Share based payment plans (Continued) Accounting Policies The Group provides benefits to employees (including Executive Directors) of the Group in the form of share-based payment transactions, whereby employees render services in exchange for shares or rights over shares (equity-settled transactions). There is currently one plan in place to provide these benefits, being the Executive Performance Rights Plan (Equity-settled transactions), which provides benefits to senior executives and Directors. Financial Results
The cost of these equity settled transactions with employees is measured by reference to the fair value at the date at which they were granted. The fair value is determined by an external valuer. In valuing equity-settled transactions, no account is taken of any performance conditions, other than conditions linked to the price of the shares of Ramsay Health Care Limited (market conditions).
Equity-settled transactions The cost of equity-settled transactions is recognised, together with a corresponding increase in equity (Share Based Payment Reserve), over the period in which the performance conditions are fulfilled, ending on the date on which the relevant employees become fully entitled to the award (vesting date). The cumulative expense recognised for equity-settled transactions at each reporting date until vesting date reflects: • The extent to which the vesting period has expired and • The number of awards that, in the opinion of the Directors of the Group, will ultimately vest. This opinion is formed based on the best available information at reporting date. No adjustment is made for the likelihood of market performance conditions being met as the effect of these conditions is included in the determination of fair value at grant date.
Treasury Shares Shares in the Group held by the Executive Performance Rights Plan are classified and disclosed as Treasury shares and deducted from equity.
Key Accounting Judgements, Estimates and Assumptions Performance rights are issued for nil consideration and are granted in accordance with the plan’s guidelines established by the Directors of Ramsay Health Care Limited. The fair value of share rights with a Total Shareholder Return (TSR) vesting condition (market based condition) are estimated using Monte Carlo simulation (using the Black-Scholes framework) to model Ramsay’s future security price and TSR performance against a comparator group. The Earnings per Share (EPS) vesting condition is a non-market vesting condition. The value of the Rights with EPS condition is equal to the share price on valuation date less the discounted value of dividends forsaken over the vesting period. The following weighted average assumptions were used for grants made on 15 December 2023, 15 December 2024 and 15 December 2025:
Dividend yield Expected volatility Risk-free interest rate Effective life of incentive right
Granted 15-Dec-25 2.26% 25.68% 3.23% 3 years
Granted 15-Dec-24 2.17% 26.90% 3.89% 3 years
Granted 15-Dec-23 1.49% 25.94% 3.86% 3 years
The expected volatility is based on the historic volatility (based on the remaining life of the options), adjusted for any expected changes to future volatility due to publicly available information. The dividend yield reflects the assumption that the current dividend payout will continue with no anticipated increases. The expected life of the rights is based on historical data and is not necessarily indicative of exercise patterns that may occur. The expected volatility reflects the assumption that the historical volatility is indicative of future trends, which may also not necessarily be the actual outcome.
Ramsay Health Care Limited Appendix 4E and Full Year Results 2026
75
19 Capital commitments and contingent liabilities Capital commitments are the Group's contractual obligation to make future payments in relation to purchases of assets. Contingent liabilities are possible future cash payments arising from past events. They are not recognised in the financial statements because the obligation will be confirmed only by uncertain future events, or because payment is not considered probable or the amount cannot be reliably measured.
19.a Capital commitments Significant capital expenditure contracted for at the end of the reporting period but not recognised as liabilities is as follows:
Property, plant and equipment
2026 $m 61.1
2025 $m 160.9
19.b Contingent liabilities The Group has a number of bank guarantees to third parties for various operational and legal purposes, none of which are individually material to the Group. No provision has been made in the financial statements in respect of these bank guarantees, as the probability of having to make a payment under these guarantees is considered remote. The only material guarantee is for workers compensation self-insurance liabilities as required by State WorkCover authorities for $44.2 million as at 30 June 2026 (2025: $44.2 million). No provision has been made in the financial statements in respect of these contingencies. However, a provision for self-insured risks relating to workers compensation claims has been provided for, along with provisions for legal and compliance matters (Refer Note 15.a).
20 Subsequent events This note outlines events which have occurred between the reporting date, being 30 June 2026, and the date these financial results are released.
Ramsay Santé closed its refinancing of its €1,750 million senior debt facilities on 22 July 2026, and the refinance of a real estate finance lease in July 2026. Refer Note 7.b for details. There have been no other significant events after the reporting date that may significantly affect the Group’s operations in future years, the results of these operations in future years or the Group’s state of affairs in future years.
21 Related party transactions This note discloses the Group’s transactions with its related parties, including their relatives or related businesses.
Transactions with Related Party Entities As at 30 June 2026 there were no outstanding transactions (2025: $nil) to be billed to or billed from related party entities.
76
Ramsay Health Care Limited Appendix 4E and Full Year Results 2026
22 Auditors’ remuneration This note summarises the total remuneration received or receivable by the Group’s external auditors for their audit, assurance and other services.
2025 $
3,347,600
3,282,014
259,000
172,600
64,986 110,000 3,781,586
67,000 75,000 3,596,614
6,471,968
6,454,135
10,669
8,258
Total
207,617 2,754,703 9,444,957 13,226,543
227,509 6,689,902 10,286,516
The total fees paid to Ernst & Young member firms by service type are: Audit services Other assurance services Non-audit services Total
9,819,568 269,669 3,137,306 13,226,543
9,736,149 180,858 369,509 10,286,516
Amounts received or due and receivable by non-Ernst & Young audit firms for: Audit or review of the financial report Other assurance services Total
2,502,485 421,156 2,923,641
2,407,381 500,520 2,907,901
Amounts received or due and receivable by Ernst & Young (Australia) for: An audit or review of the financial report of the entity and any other entity in the consolidated group Fees for other assurance and agreed-upon-procedures services under other legislation or contractual arrangements where there is discretion as to whether the service is provided by the auditor or another firm Other services in relation to the entity and any other entity in the consolidated group Tax compliance Advisory services Amounts received or due and receivable by overseas member firms of Ernst & Young (Australia) for: An audit or review of the financial report of the entity and any other entity in the consolidated group Fees for other assurance and agreed-upon-procedures services under other legislation or contractual arrangements where there is discretion as to whether the service is provided by the auditor or another firm Other services in relation to the entity and any other entity in the consolidated group Tax compliance Advisory services
Ramsay Health Care Limited Appendix 4E and Full Year Results 2026
77
Financial Results
2026 $
23 Information relating to subsidiaries This note provides a list of all the significant entities controlled by the Group as at the reporting date, including those included in the Closed Group.
Name RHC Nominees Pty Limited1 RHC Developments Pty Limited1 Ramsay Health Care Investments Pty Limited1 Ramsay Hospital Holdings Pty. Ltd.1 Ramsay Hospital Holdings (Queensland) Pty Limited1 Ramsay Finance Pty Limited1 Ramsay Aged Care Holdings Pty Limited1 Ramsay Aged Care Properties Pty Limited1 RHC Ancillary Services Pty Limited1 Linear Medical Pty Limited1 Newco Enterprises Pty Ltd1 Sydney & Central Coast Linen Services Pty Ltd1 Benchmark Healthcare Holdings Pty Limited1 Benchmark Healthcare Pty Ltd1 AHH Holdings Health Care Pty Limited1 AH Holdings Health Care Pty Limited1 Ramsay Centauri Pty Limited1 Alpha Healthcare Pty Limited1 Ramsay Health Care Australia Pty Limited1 Donvale Private Hospital Pty. Ltd.1 The Benchmark Hospital Group Pty. Ltd.1 Dandenong Valley Private Hospital Pty. Ltd.1 Benchmark – Surrey Pty Ltd1 Benchmark – Peninsula Pty. Ltd.1 Benchmark – Donvale Pty Ltd1 Benchmark – Windermere Pty. Ltd.1 Benchmark – Beleura Pty. Ltd.1 Beleura Properties Pty. Ltd.1 Affinity Health Holdings Australia Pty Limited1 Affinity Health Finance Australia Pty Limited1 Affinity Health Pty Limited1 Affinity Health Foundation Pty Ltd1 Affinity Health Holdings Indonesia Pty Ltd1 Hospitals of Australia Pty Limited1 Glenferrie Private Hospital Pty Ltd1 Relkban Pty. Limited1 Relkmet Pty. Limited1 Votraint No. 664 Pty Limited1 Votraint No. 665 Pty Limited1 Australian Medical Enterprises Pty Limited1 AME Hospitals Pty Ltd1 Victoria House Holdings Pty Ltd1 C&P Hospitals Holdings Pty Limited1 HCoA Hospital Holdings (Australia) Pty Limited1 AME Properties Pty Ltd1 AME Superannuation Pty Ltd1 1 Entities included in the deed of cross guarantee as required for the instrument
78
Ramsay Health Care Limited Appendix 4E and Full Year Results 2026
Country of Incorporation Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia
% Equity Interest 2026 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100%
2025 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100%
23 Information relating to subsidiaries (Continued) Name
Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia
% Equity Interest 2026 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100%
2025 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100%
Financial Results
Attadale Hospital Property Pty Ltd1 Glengarry Hospital Property Pty Ltd1 Hadassah Pty. Ltd.1 Rannes Pty. Limited1 Hallcraft Pty Limited1 Jamison Private Hospital Property Pty Ltd1 Affinity Health (FP) Pty Limited1 Armidale Hospital Pty Limited1 Caboolture Hospital Pty Limited1 Joondalup Hospital Pty Limited1 Joondalup Health Campus Finance Pty Limited1 Logan Hospital Pty Limited1 Noosa Privatised Hospital Pty Limited1 AMNL Pty Limited1 Mayne Properties Pty Ltd1 Port Macquarie Hospital Pty Limited1 HCoA Operations (Australia) Pty Limited1 Hospital Corporation Australia Pty Ltd1 Dabuvu Pty Ltd1 HOAIF Pty Limited1 HCA Management Pty. Limited1 Malahini Pty. Ltd.1 Tilemo Pty Ltd1 Hospital Affiliates of Australia Pty Ltd1 C.R.P.H Pty. Limited1 Hospital Developments Pty Ltd1 P.M.P.H. Pty. Limited1 Pruinosa Pty Ltd1 Australian Hospital Care Pty Limited1 Australian Hospital Care (Allamanda) Pty. Ltd.1 Australian Hospital Care (Latrobe) Pty. Ltd.1 Australian Hospital Care 1988 Pty. Ltd.1 AHC Foundation Pty. Ltd.1 AHC Tilbox Pty Limited1 Australian Hospital Care (Masada) Pty. Ltd.1 Australian Hospital Care Investments Pty. Ltd.1 Australian Hospital Care (MPH) Pty. Ltd.1 Australian Hospital Care (MSH) Pty. Ltd.1 Australian Hospital Care (Pindara) Pty. Ltd.1 Australian Hospital Care (The Avenue) Pty. Ltd.1 Australian Hospital Care Retirement Plan Pty Ltd1 eHealth Technologies Pty Limited1 Health Technologies Pty. Ltd.1 Rehabilitation Holdings Pty Ltd1 Bowral Management Company Pty Ltd1
Country of Incorporation
1 Entities included in the deed of cross guarantee as required for the instrument
Ramsay Health Care Limited Appendix 4E and Full Year Results 2026
79
23 Information relating to subsidiaries (Continued) Name Simpak Services Pty Limited1 APL Hospital Holdings Pty. Ltd.1 Alpha Pacific Hospitals Pty Ltd1 Health Care Corporation Pty Ltd1 Alpha Westmead Private Hospital Pty Limited1 Illawarra Private Hospital Holdings Pty Ltd1 Northern Private Hospital Pty. Limited1 Westmead Medical Supplies Pty Limited1 Herglen Pty Ltd1 Mt Wilga Pty Limited1 Sibdeal Pty. Limited1 Workright Pty Limited1 Adelaide Clinic Holdings Pty. Ltd.1 E Hospital Pty. Limited1 New Farm Hospitals Pty. Ltd.1 North Shore Private Hospital Pty Limited1 Phiroan Pty Ltd1 Ramsay Health Care (Asia Pacific) Pty Limited1 Ramsay Health Care (South Australia) Pty Limited1 Ramsay Health Care (Victoria) Pty. Ltd.1 Ramsay Health Care Services (QLD) Pty Limited1 Ramsay Health Care Services (VIC) Pty Limited1 Ramsay Health Care Services (WA) Pty Limited1 Ramsay Pharmacy Retail Services Pty Ltd1 Ramsay Professional Services Pty Limited1 Ramsay Diagnostics (No 1) Pty Limited1 Ramsay Diagnostics (No 2) Pty Limited1 Ramsay Health Care (UK) Limited Ramsay Health Care Holdings UK Limited Ramsay Health Care UK Operations Limited2 Ramsay Générale de Santé SA2 Capio AB2 Ramsay Elysium Holdings Limited2 1 Entities included in the deed of cross guarantee as required for the instrument 2 This entity owns a number of subsidiaries, none of which are individually material to the Group
80
Ramsay Health Care Limited Appendix 4E and Full Year Results 2026
Country of Incorporation Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia UK UK UK France Sweden UK
% Equity Interest 2026 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 52.8% 52.8% 100%
2025 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 52.8% 52.8% 100%
24 Closed group This note presents the consolidated financial performance and position of the Australian wholly owned subsidiaries, which together with the Parent Entity, Ramsay Health Care Limited, are referred to as the Closed Group.
Entities subject to instrument Pursuant to Instrument 2016/785, relief has been granted to the entities in the table of subsidiaries in Note 23, (identified by footnote 1) from the Corporations Act 2001 requirements for preparation, audit and lodgement of their financial reports.
The consolidated Income Statement and Statement of Financial Position of the entities that are members of the Closed Group are as follows:
Consolidated Income Statement Profit before tax Income tax expense Net profit for the year Retained earnings at the beginning of the year Dividends paid Retained earnings at the end of the year
Closed Group 2026 2025 $m $m 467.6 369.4 (150.3) (150.0) 317.3 219.4 2,624.5 2,605.8 (205.7) (200.7) 2,736.1 2,624.5
Ramsay Health Care Limited Appendix 4E and Full Year Results 2026
81
Financial Results
As a condition of the Instrument, these entities entered into a Deed of Cross Guarantee on 22 June 2006 or have subsequently been added as parties to the Deed of Gross Guarantee by way of Assumption Deeds dated 24 April 2008, 27 May 2010, 24 June 2011, 20 October 2015, 17 December 2015 and 14 May 2019. The effect of the deed is that Ramsay Health Care Limited has guaranteed to pay any deficiency in the event of winding up of a wholly owned Australian entity or if they do not meet their obligations under the terms of overdrafts, loans, leases or other liabilities subject to the guarantee. The controlled entities have also given a similar guarantee in the event that Ramsay Health Care Limited is wound up or if it does not meet its obligation under the terms of overdrafts, loans, leases or other liabilities subject to the guarantee.
24 Closed group (Continued) Consolidated Statement of Financial Position ASSETS Current assets Cash and cash equivalents Trade and other receivables Inventories Derivative financial instruments Prepayments Other current assets Assets held for sale Total current assets Non-current assets Other financial assets Property, plant and equipment Right of use assets Intangible assets Deferred tax assets Prepayments Derivative financial instruments Other receivables Total non-current assets TOTAL ASSETS LIABILITIES Current liabilities Trade and other creditors Lease liabilities Derivative financial instruments Provisions Income tax payables Total current liabilities Non-current liabilities Loans and borrowings Lease liabilities Provisions Derivative financial instruments Total non-current liabilities TOTAL LIABILITIES NET ASSETS EQUITY Issued capital Treasury shares Convertible Adjustable Rate Equity Securities (CARES) Other reserves Retained earnings TOTAL EQUITY Refer Note 8c for details on reclassification of Current Employee and Director comparatives.
82
Ramsay Health Care Limited Appendix 4E and Full Year Results 2026
Closed Group 2026 2025 $m $m
19.2 1,465.6 142.1 0.5 56.0 5.8 1,689.2 38.7 1,727.9
52.0 2,053.2 133.2 1.2 56.2 9.3 2,305.1 2,305.1
3,503.9 3,058.6 514.3 1,049.2 209.4 10.9 18.3 26.7 8,391.3 10,119.2
2,936.5 2,942.1 485.7 1,050.4 182.4 10.4 21.3 7,628.8 9,933.9
606.6 38.7 0.3 523.4 7.6 1,176.6
597.5 48.8 0.4 455.2 12.7 1,114.6
2,143.1 682.9 146.3 0.3 2,972.6 4,149.2 5,970.0
2,155.9 637.8 134.1 18.1 2,945.9 4,060.5 5,873.4
2,285.9 (41.0) 252.2 736.8 2,736.1 5,970.0
2,285.9 (55.7) 252.2 766.5 2,624.5 5,873.4
25 Parent entity information This note presents the stand-alone summarised financial information of the parent entity Ramsay Health Care Limited.
2026 $m
Current liabilities Total liabilities Issued capital Other equity Total shareholders’ equity Net profit for the year after tax
3,271.1 3,411.1
2,725.1 2,863.8
2.7 2.7
6.6 6.6
2,285.9 1,122.5 3,408.4
2,285.9 571.3 2,857.2
751.4
216.8
As a condition of the Instrument (set out in Note 24), Ramsay Health Care Limited has guaranteed to pay any deficiency in the event of winding up of a controlled entity or if they do not meet their obligations under the terms of overdrafts, loans, leases or other liabilities subject to guarantee.
26 Material partly–owned subsidiaries This note provides information of the significant subsidiaries that the Group owns less than 100% shareholding in.
Ramsay Santé (formerly Ramsay Générale de Santé) has a material non-controlling interest (NCI): This entity represents the French and Nordic segments for management and segment reporting. Financial information in relation to the NCI is provided below:
Proportion of equity interest and voting rights held by non-controlling interests Refer to Note 23 which discloses the equity interest held by the Ramsay Group. The remaining equity interest is held by the noncontrolling interest. Voting rights for Ramsay Santé at 30 June 2026 are 53.0% (2025: 53.0%). The remaining interest is held by the non-controlling interest.
Accumulated balances of non-controlling interests Refer to the Consolidated Statement of Changes in Equity.
Profit allocated to non-controlling interests Refer to the Consolidated Income Statement.
Summarised Statement of Profit or Loss and Statement of Financial Position for 2026 and 2025 Refer to Note 1. The French and Nordic segments consist only of this subsidiary that has a material non-controlling interest.
Summarised cash flow information 2026 $m 581.9 (225.7) (463.2) (107.0)
Operating Investing Financing Net increase in cash and cash equivalents
2025 $m 846.1 (229.7) (607.9) 8.5
27 Status of audit This report is based on accounts which are in the process of being audited.
Ramsay Health Care Limited Appendix 4E and Full Year Results 2026
83
Financial Results
Information relating to Ramsay Health Care Limited Current assets Total assets
2025 $m
People caring for people
Natalie Davis
Managing Director and Group CEO
FY26
Results Presentation For the twelve months ended 30 June 2026
Anthony Neilson
Group CFO
Important Information The information in this presentation is general background information about Ramsay Health Care Limited and its subsidiaries (together, the Ramsay Group), with respect to the Ramsay Group’s business and operations, financial position and strategies and is current as at 27 August 2026. This presentation is in summary form and is not necessarily complete. It should be read together with the Ramsay Health Care Limited’s FY26 Preliminary Final Report and FY26 Results Announcement, lodged with the ASX on 27 August 2026. No advice This presentation is not intended to be relied upon as advice to investors or potential investors and does not take into account the investment objectives, financial situation or needs of any particular investor. The information contained in this document has not been audited in accordance with the Australian Auditing Standards. Forward looking statements This presentation contains forward looking statements. While these forward-looking statements reflect Ramsay’s expectations at the date of this presentation, they are not guarantees or predictions of future performance or statements of fact. These statements involve known and unknown risks and uncertainties. Many factors could cause outcomes to differ, possibly materially, from those expressed in the forward-looking statements. These factors include:
•
general financial and economic conditions in various countries, including Australia, England, Wales, France, Sweden, Denmark, Norway;
•
operating results;
•
changes in private health insurer indexation and/or pricing;
•
industry competition, fluctuations in actual demand and/or loss of market share for Ramsay’s healthcare services;
•
legislative, fiscal and regulatory developments, including: –
changes in government and/or government policy, including funding decisions and actions by the UK Government in relation to the NHS; and
–
other actions of regulatory bodies and governmental authorities such as changes in taxation and interest rates set by central banks;
FY26 Results Presentation
•
technological changes, including pace of adoption of new technologies;
•
the extent, nature and location of physical and transitional impacts of climate-related risks; and
•
geopolitical developments, including political risks and the impact of armed conflict and political instability (such as the ongoing conflicts in Ukraine and in the Middle East) on economic activity and supply chain disruption to clinical and non-clinical products supplied to the Ramsay Group.
No representation, warranty or liability Ramsay makes no representation, warranty, assurance or guarantee as to the accuracy, completeness or likelihood of fulfilment of any forward-looking statement, any outcomes expressed or implied in any forward-looking statement or any assumptions on which a forward-looking statement is based. To the maximum extent permitted by law, responsibility for the accuracy or completeness of any forward-looking statements, whether as a result of new information, future events or results or otherwise, is disclaimed. No undue reliance Except as required by applicable laws or regulations, the Ramsay Group does not undertake to publicly update, review or revise any forward-looking statements or to advise of any change in assumptions on which any such statement is based. Readers are cautioned not to place undue reliance on forward-looking statements. Other information This presentation should be read in conjunction with other publicly available material. Further information including historical results and a description of the activities of the Ramsay Group is available on our website: ramsayhealth.com/au/investors.
2
Table of contents
4
5
8
26
36
37
Progress to date
Group Financials
Group Overview
Group Outlook
Regional Performance
Appendix
3
Delivering on CEO Priorities Transformation momentum in market-leading Australian hospital business
Evolving our culture ‘people caring for people’ to innovate and drive performance
All regions delivered EBIT improvement
Strong patient NPS scores across the Group
UK Hospitals mitigated 8% decline in NHS activity, through acuity, private work and cost management
Clinical excellence across the Group, including key Australian quality metrics above sector averages
Underlying EBIT growth 11.2% and margin expansion 30bps
Elysium turnaround gained traction through site and ward closures to match demand and reduction in central and agency costs
New funding mechanism at Joondalup Public Campus partially mitigated, net ($26m) impact
Group capex below revised range at $729m (cc), growth & development spend focused on Australia and procedural capacity
Ramsay and Development Network in Australia growing national clinical trials capability, with increase to 22 sites and 28% growth in activity in FY263
Optimisation of portfolio, 4 sites closed and excess land holdings being sold²
Funding Group ROCE +150bps to 14.8%
Activity growth 3.3%¹, growth in admitting VMOs 3.3% and improved theatre utilisation +90bps Improved revenue indexation relative to cost inflation
Completion of National Capital Private Hospital acquisition – expected by 1 September 2026 1. 2. 3.
Stronger capital discipline and improving capital returns across the portfolio
Ramsay Santé proposed in-specie distribution on track for completion in 2026, subject to Ramsay shareholder vote in November
Group Executive team building capability in key areas including Commercial and National Operational Excellence Support office (global and Aus) combined and located adjacent to Ramsay Private North Shore hospital.
Like for like - excludes Peel and Border Cancer Hospital that transitioned back to public operation in 1HFY25 and 2HFY26 respectively Ramsay Surgical Centre Glenferrie, Ramsay Clinic Thirroul, Coolenberg Day Surgery, Attadale Rehabilitation Hospital, and land holdings in Nowra, Nambour, Ipswich and Townsville Defined as number of total trials as at 30 Jun 2026 vs 30 Jun 2025. Total trials includes active trials as well as trials with follow up
FY26 Results Presentation
4
FY26 Group Financial Performance
+11.8% EBIT and +22.9% NPAT underlying growth, Funding Group Leverage <2.0x
Revenue1
Underlying EBIT ²
Underlying NPAT ² ³
Reported NPAT ³
$18.6bn
$1,162m
$364m
$329m
+4.2% (cc) vs FY25
+11.8% (cc) vs FY25
+22.9%(cc) vs FY25
+1,283.9%(cc) vs FY25
Underlying EPS²
DPS
Funding Group Leverage
ROIC⁵
151.0cps
91cps
1.83x
4.6%
+27% (cc) vs FY25
+13.8%, payout ratio 60.3%⁴
Target leverage <2.5x
+30bps
Revenue from contracts with customers. Details on items excluded from underlying EBIT and underlying NPAT refer to the Appendix slides 39 & 40 and Section 2.2.2 of the Operating and Financial Review. Net profit after tax and non-controlling interests attributable to owners of the parent Full year payout ratio based on Underlying NPAT after non controlling interests Accounting ROIC = 12 month rolling Underlying EBIT * (1- tax) / average of opening & closing invested capital
FY26 Results Presentation
5
Underlying¹ Performance
Underlying EBIT and NPAT performance driven by improved performance across all regions
Group underlying NPAT result (+22.9% cc) and Funding Group (+17.9% cc) driven by:
Twelve months ended 30 June A$’m
2026
2025
Change
Change cc²
Australia
639.8
575.5
11.2%
11.2%
Ramsay UK (acute hospital business)
160.5
147.3
9.0%
10.3%
Elysium
31.1
22.0
41.4%
43.5%
Funding Group Underlying EBIT
831.4
744.8
11.6%
12.0%
Ramsay Santé Underlying EBIT
330.8
297.8
11.1%
11.4%
1,162.2
1,042.6
11.5%
11.8%
Funding Group Underlying NPAT after non controlling interests
398.4
345.2
15.4%
17.9%
Ramsay Santé Underlying loss after tax and non-controlling interests
(34.3)
(39.9)
14.0%
20.1%
Group Underlying NPAT after non-controlling interests
364.1
305.3
19.3%
22.9%
Group Underlying EBIT
Underlying earnings – For detail on items excluded from underlying earnings refer Appendix slide 39 & 40 and Operating and Financial Review Constant currency
FY26 Results Presentation
•
11.2% Underlying EBIT growth in Australia driven by good activity growth, higher levels of acuity and theatre utilisation, improved PHI indexation and cost management;
•
Australia 2H momentum, Underlying EBIT (+15.9%) and EBIT margins (+70bps), boosted by the impact of Cyclone Alfred and other items in the pcp;
•
Result impacted by a decline in contribution from Joondalup Health Campus ($26m), reflecting new funding mechanism partially mitigated by operational actions;
•
Australian underlying EBIT margin increased +30bps.
•
10.3% cc Underlying EBIT growth in UK Acute, despite soft NHS volumes, driven by a focus on higher acuity and private pay activity combined with operational initiatives.
•
43.5% cc Underlying EBIT growth in Elysium driven by performance turnaround plan including site and ward closures, central and agency cost reduction, and fee uplifts.
•
Ramsay Santé 11.4% cc growth in Underlying EBIT driven by a good result from Sweden. Partial mitigation of reduced funding in France through operational initiatives.
•
Total underlying interest costs were 1.2% cc lower reflecting lower borrowing costs and higher lease interest
•
Effective underlying tax rate 35.9% vs 32.7% driven by Ramsay Santé.
6
People caring for people
Regional Performance
Australia
Transformation building momentum, with improved patient experience and clinical excellence Customers, People and Clinical Excellence at our heart Patient NPS improved +1.3 to 73.6 Doctor and Team NPS improved, and several EBAs finalised Clinical Excellence metrics ahead of Australian Council on Healthcare Standards key sector benchmarks, eg. 44% fewer unplanned readmissions within 28 days Digital systems implemented to support clinical operations including remote foetal monitoring at all maternity sites
‘Big 5’ Initiatives Gaining Traction Growth: Activity growth 3.3%³, growth in admitting VMOs 3.3%² and improved theatre utilisation ~+90bps¹ Procurement: Benefits ahead of target, commenced rollout of ‘At Your Request’ dining. Revenue Cycle Management: Strong cash collections, transformation roadmap defined to automate processes. Labour: Record graduate intakes and new national hiring initiatives to reduce agency usage. Technology solution for Smart Rostering underway. Technology: Commenced rollout of key systems to support hospital operations; pilot AI use cases deployed.
Progress against 2030 Strategy, whilst maintaining capital discipline Catchment strategies deployed, including entry into ACT catchment through proposed acquisition of National Capital Private Hospital (expected by 1 September 2026) New multi-year partnership agreed with major insurer. 4 payor agreements in place with annual indexation linked to sector metrics Growth in Ramsay and Development Network (Clinical Trials) increase to 22 sites and 28% growth in activity⁴ Uplift in capital discipline and focus on utilisation of existing capacity with capex flat on pcp, underperforming sites closed or reconfigured, and surplus land holdings identified for sale
Utilisation and capacity includes theatres, cath labs and procedure rooms actively in use during the period. Excludes Border Cancer Hospital and Pindara Day Procedure Centre. Utilisation is measured on standard capacity of 570 minutes per room per day, 5 days a week, excluding public holidays and weekends. Defined as YTD average of monthly counts of revenue-generating VMOs with >1 admission in the past quarter.
Defined as number of total trials as at 30 Jun 2026 vs 30 Jun 2025. Total trials includes active trials as well as trials with follow up
Like for like - excludes Peel and Border Cancer Hospital that transitioned back to public operation in 1HFY25 and 2HFY26 respectively
FY26 Results Presentation
8
Australia
EBIT and margin growth driven by activity and acuity, improved indexation and cost management Twelve months ended 30 June A$’m
2026
2025
Change
Revenue from customers¹
5,254.1
4,864.3
8.0%
Total segment revenue and other income
6,818.1
6,322.7
7.8%
EBITDA
892.7
816.6
9.3%
EBIT
629.9
560.2
12.4%
Items² excluded from underlying EBIT
(9.9)
(15.3)
35.3%
Underlying EBIT contribution
639.8
575.5
11.2%
Underlying EBIT margin (%)
9.40%
9.10%
30bps
ROCE (%)³
17.4%
16.5%
90bps
Capital Expenditure
365.4
361.8
1.0%
1,234.3
1,194.7
3.3%
68.7
68.4
30bps
2,792.4
2,707.3
3.1%
Volume metrics Admissions ('000) (like for like)⁴ Day admissions as % of total admissions (like for like)⁴ IPDAs ('000)⁵ (like for like)⁴
Revenue from customers = revenue from hospital admissions and out-patients; less pharmacy revenue and other revenue which includes prothesis revenue Further details on items excluded from underlying results refer to the Appendix and Section 2.2.2 of the Review of results of operations ROCE calculated as 12 month rolling Underlying EBIT / average of opening and closing capital employed pre goodwill.
Like for like - excludes Peel and Border Cancer Hospital that transitioned back to public operation in 1HFY25 and 2HFY26 respectively
Inpatient and day admissions (days).
FY26 Results Presentation
Revenue growth¹ (+ 8%) driven by: • Admissions⁴ increased 3.3% • Overnight IPDAs⁴ ⁵ +3.0% vs overnight admissions
- 2.3% reflecting higher level of acuity in surgical, medical and rehab admissions • Improved revenue indexation from PHI agreements completed in FY25/26 Underlying EBIT growth (+ 11.2%) includes: • Higher activity levels and acuity, increased theatre utilisation and PHI indexation offsetting current cost inflation • The impact of the new funding mechanism at Joondalup public, partially offset by on-site mitigation actions including timely discharge focus, agency reduction and increased winter activity, net impact (-$26m) Underlying EBIT margin increased +30bps. • Underlying labour costs as % of revenue flat, (lower excluding Joondalup) • Supplies as % revenue lower, driven by procurement savings Reported EBIT² (+12.4%) includes items not in the Underlying result (net -$9.9m) including: profit on asset and investment sales, transaction costs and provision for prior period employee costs. (refer Slides 39 & 40 for further details)
9
Improving industry fundamentals, with hospital coverage growing, and payout ratio beginning to improve Private health insurance coverage growing
Payout ratio1 beginning to improve
Insured Persons with Hospital Cover, millions (LHS)
Hospital Benefits / Hospital Premiums %
% of Population covered (RHS)
14.0
55%
12.8
94%
50%
10.0 45.8%
8.0
90%
Australians with hospital cover growing on average 2.5% p.a. in last 3 years to 12.8 million people, now at 45.8% of population
•
Payout ratios from PHI to private hospitals lifting to 86% for the 12 months to Mar 2026, but still not at pre-COVID levels of 88%
•
Private hospitals (excluding day hospital and surgical centres) remain predominant setting for private healthcare, with 85% of PHI benefits2 in the 12 months to March 2026, compared to 4% for day surgeries. Private hospitals (excl. day hospitals) are evolving services and undertaking 64% of all day admissions2.
•
Within hospital cover, Silver Tier is now the most popular choice with 38% of coverage3, down-tiering from Gold, negatively impacting mental health and maternity services.
Pre-covid: 88%
88% 45%
86%
86%
6.0 4.0
40%
84% 82%
2.0
•
92%
12.0
0.0
Key Market Trends
Source: APRA
Mar 18
Mar 20
Mar 22
Mar 24
Mar 26
35%
80%
Source: APRA
FY18
FY20
FY22
FY24
LTM
Payout ratio defined as hospital treatment claims incurred by health insurers divided by hospital treatment premium revenue. It excludes General treatment (ancillary) claims and revenue. Source: APRA. Total benefits and admissions defined to include day hospitals, public hospitals, hospital substitution and overnight private hospitals. Source: Private health insurance reform data quarterly trends report December 2025, Department of Health, Disability and Ageing
FY26 Results Presentation
10
Ramsay Australian activity trends¹
Strong growth in core Surgical and Day activity and higher inpatient acuity Admission growth by Service⁵
Admission growth by Admission Type
Admission growth by Funding Type 9.5%
4.1%
3.2%
3.8%
2.8%
3.8%
2.7%
2.3%
Maternity
0.1% Surgical
Medical
Private
Rehab
3
Public DVA
Day Only
Overnight
2
Mental Health
-3.9% 0% • •
% of total admissions
100%
Surgical % of total admissions +40bps – with Growth focus by hospitals Mental Health decline driven by day admissions; overnight admissions represent 73% of MH patient revenue and are +0.9%
FY26 Results Presentation
0%
% of total admissions
100%
•
Public admissions growth reflects growth in activity at Joondalup and an increase in public in private
0% • •
% of total admissions
100%
Overnight IPDAs⁴ +3% reflecting higher acuity mix in surgical, medical and rehab Day admissions boosted by opening of new surgical centres at Charlestown and Caloundra in FY26
Admissions growth vs pcp excluding Peel Health Campus and Border Cancer Hospitals that have transitioned back to public operation Mental Health refers to admissions at both stand-alone mental health clinics and within mental health wards in acute hospitals. It does not include outpatient (e.g. Psychology) Department of Veterans’ Affairs IPDA – inpatient and day admission (days) Following further interrogation of Joondalup activity data post the new contract 7,467 surgical admissions have been reclassified as medical day admissions in FY26 and 1,098 in FY25
11
Data insights and sales force uplift supporting growth in VMOs, complex therapeutic activity and theatre utilisation Growth focus: Data insights and sales force uplift supporting activity growth, acuity and theatre utilisation
Utilisation increased ~+90bps in FY26 while we added 22 new theatres/ procedural rooms
Continued focus on increasing theatre utilisation and expanding ‘at capacity’ sites Utilisation variance across Ramsay hospitals1,2,3
•
Improved catchment-based data insights and theatre utilisation insights
Utilisation and capacity trends1,2
•
Quarterly growth planning across key catchments and by therapeutic areas
463
•
•
455
3.3% growth in admitting VMOs4, supported by improved Business Development capability and GP Liaison resourcing allocation aligned to key catchments and enabled by new CRM solution Increased robotics usage supported by improved utilisation tracking across hospitals
90 Optimise mix / acuity. Expand capacity to 80 facilitate further growth
485
Utilisation is highest in our largest hospitals. Our 'top 5' sites have on average ~13 theatres.
70 60
Optimise use of 50 existing capacity
50%
40 69%
69%
70%
Our 'lowest 20' utilisation sites have on average ~4 theatres.
30 20 10 0
FY24 1. 2. 3. 4.
77%
FY25
FY26
80-85+%
Lowest 20 Ramsay sites
Top 20 Ramsay sites
Top 5 Ramsay sites
Utilisation and capacity includes theatres, cath labs and procedure rooms that were in use during the period. Excludes Border Cancer Hospital and Pindara Day Procedure Centre. Utilisation is measured on standard capacity of 570 minutes per room per day, when in use, for 5 days a week, excluding public holidays and weekends. Analysis of variation is based on a simple average of FY25 utilisation for sites ranked in terms of performance on utilisation, and excludes Coolenberg, Glenferrie and Charlestown. Defined as average of monthly counts of revenue-generating VMOs with >1 admission.
FY26 Results Presentation
12
Australia capex
Development investment focused on procedural capacity in major hospitals in growth corridors • Total capex $365m flat on pcp, below original full year forecast $410-440m due to lower than forecast development capex reflecting focus on utilisation of existing facilities and timing of reimbursements from landlords ($30.8m)
Development capex (A$m)
• FY26 development capex $150m reflecting large developments at Joondalup Private and Warringal. 22 theatres¹ and procedure rooms opened in FY26
208
• The increase in routine & maintenance reflects investment in the existing facility portfolio to ensure strategically located sites are fit for purpose in the future and continue to meet high clinical, safety and amenity standards
197 154
107
• The increase in ‘other growth’ capex includes investment in robotics • FY27 full year forecast capex range $380-410m including capex associated with National Capital $6-10m
150 120
45
48
101
109
• Final phase of Warringal Private Hospital (Melbourne) expansion including emergency department (opened 12 Aug), 1 new cath lab, 1 replacement
FY23
FY24
• Hollywood Private Hospital (Perth) procedural capacity expansion including 2 theatres and 2 cath labs by December 2026
FY26 Capital Expenditure by category compared to pcp (A$m)
• Treatment capacity expansion at St George Private Hospital (Sydney) includes 2 cath labs in progress due for completion in Q4FY27
362 365
FY27 development capex focused on procedural capacity in major hospitals including: • Recently completed and opened Cleveland surgical centre in Qld (3 theatres)
77 FY25
102
2H
1H
FY26
380-410m
• Westmead Private Hospital 1 new theatre, and carpark expansion H2 FY27 • Campbelltown (Sydney) Surgical Centre development commencing. • Expect 11 theatres or cath labs expected to open in FY27. This is in addition to 3 theatres (2 Strathfield, 1 Port Macquarie) that opened at the end of FY26 that we are now focused on ramping up 1.
124
157
197
150 19
+6 Charlestown, +2 Beleura, +1 Avenue, +3 Joondalup (Public), +6 Joondalup (Private), +1 Peninsula, +2 Strathfield and +1 Port Macquarie
FY26 Results Presentation
Routine & Compliance
Development
41
22 17
Other Growth Digital & IT FY25 FY26
Total
FY27 Forecast
13
FY27: Focus on continuing performance momentum ‘Big 5’ Hospital Initiatives Growth
Procurement
Revenue Cycle Management
Workforce
Doctor recruitment, theatre and robot utilisation continued focus
Rollout of ‘Switch and Save’ data tool to enable better hospital product purchasing decisions
Transformation mobilisation and quick wins, focussing on:
Workforce planning and recruitment linked to Growth
•
Admission process digitalisation
•
Clinical documentation and coding standardisation
Agency reduction and skill mix operational focus
Catchment growth plans Ramp up of new developments Uplift of sales force of GPLOs1 and BDMs2 National Capital Private Hospital integration
'At Your Request’ dining scale up, food menu standardisation and food category procurement initiatives Rapid tendering of non-clinical categories
•
Claims generation efficiencies
•
Commencing rollout of upgraded Patient Administration System (PAS) software
Negotiation of EBAs3 Design of future rostering model
Data, Technology and AI to Enable our Hospital Teams Growth data insights
Clinical spend data insights
Procedural profitability
Contract Management System
CRM4 software
Prostheses tracking
FY26 Results Presentation
1General Practice Liaison Officers
2Business Development Managers
Patient Administration System Upgrade AI use cases
3Enterprise Bargaining Agreement 4Customer Relationship Management
Time and Attendance and Smart Rostering system and team app
Australia
Continued focus on delivery of multi-year transformation Focus areas
Outlook
Continue growth, utilisation focus and operational efficiency improvements with ‘Big 5’ Hospital Operations Initiatives – growth, procurement, revenue cycle management, workforce, technology & AI enablement
• Australia targeting incremental yoy EBIT growth (Including and excluding National Capital) and margin expansion¹ driven by activity growth, improved capacity utilisation, revenue indexation in line with cost indexation, operational improvement initiatives, and including a $10-15m increase in investment in IT technology and transformation.
Continue focus on patient, doctor and employee experience, and clinical excellence
• National Capital expected to be EPS accretive in first 12 mths of ownership, transition opex costs of $9-11m in FY27² • FY27 full year forecast capex range $380-410m including capex associated with National Capital $6-10m
Build service differentiation in our priority therapeutic areas, and grow Ramsay Research and Development Network (clinical trials) Integrate National Capital Private Hospital into Ramsay network
Note: Artist’s impression
FY26 Results Presentation
Including and excluding National Capital Transition costs expected to be skewed to 1HFY27. Transition costs will be excluded from Underlying earnings
15
UK Region Focus on performance improvement in our UK businesses mitigating NHS weak demand UK Hospitals
Elysium
Focus on high acuity, private and operational excellence mitigating NHS headwinds
Turnaround beginning to gain traction in a challenging market
NHS volumes declined in FY26 by 8%, with activity headwinds from Q2.
Ongoing weak market demand from local authorities, with more care in community settings and faster discharge.
Maintained market leading patient NPS score of 89 and strong uptick in doctor and employee advocacy scores and engagement
Turnaround plan beginning to realise results, with underlying EBIT improving to pcp:
Focus on case complexity and private activity growth to mitigate weak NHS volumes due to budgetary constraints
Addressing overcapacity – 7 site closures and additional temporary ward closures decreasing capacity by 239 beds vs prior year. Bed closures over the year resulted in month of June occupancy increasing vs prior year to 87.2%
Cost reduction – reduction in agency labour use and central cost reduction. Phase 3 central cost reduction in progress (34 FTE reduction in addition to 127 FTEs in earlier phases)
Obtained 4.4% average fee uplift, reflecting complexity of patient services
Operational excellence focus at sites to reflect lower activity levels and efficiency focus at corporate level Improving cashflow through focus on cash collections and disciplined capital spend
Improvement in care quality with % of services rated Good or Outstanding increasing from 79% to 82% New CEO Joe O’Connor commenced January 2026 and new Chief Medical Officer appointed and commenced in July 2026.
FY26 Results Presentation
16
UK Hospitals
+10.3% EBIT growth driven by focus on private volumes, higher acuity and operational excellence Twelve months ended 30 June A$’m
2026
2025
Change
Change cc³
1,567.4
1,568.7
(0.1%)
0.9%
EBITDA
270.9
254.8
6.3%
7.8%
EBIT
159.0
145.8
9.1%
11.0%
Items¹ not included in Underlying EBIT
(1.5)
(1.5)
Underlying EBIT contribution
160.5
147.3
9.0%
10.3%
Underlying EBIT margin (%)
10.2%
9.4%
80bps
79.1
108.4
(27.0%)
(26.3%)
14.6%
13.1%
150bps
102bps
Revenue and other income
Capital Expenditure ROCE (%)²
Revenue growth (+0.9%cc) driven by: • Improved average revenue per case (+6.7%), reflecting higher acuity and growth in private work • NHS tariff indexation for FY25/26⁴ of 2.83%.⁵ The announced FY26/27 tariff of 0.03% was recently revised to 1.24%, backdated amount will be included in FY27 • Overall admissions decline of 5.4%, driven by 8.2% reduction in NHS volumes partially offset by a 2.9% increase in private volumes driven by 4% increase in PMI⁶ Underlying EBIT (+10.3%cc) driven by:
Volume metrics Admissions ('000)
218.9
231.4
(5.4%)
• Underlying EBIT margins +80bps to 10.2%
Day admissions as a % of total admissions
80.7%
80.8%
(10bps)
NHS admissions as a % of total admissions
72.6%
74.8%
(220bps)
• Labour costs as a percentage of revenue declined 30bps despite labour inflation higher than tariff
For further detail on items excluded from underlying earnings refer the Appendix and Section 2.2.2 of the Review of results of operations ROCE calculated as 12 month rolling Underlying EBIT / average of opening and closing capital employed pre goodwill. Constant currency Tariff year commences 1st April Backdated amount of 25/26 tariff included in the FY26 results £0.9m compared to £3.5m in FY25 PMI- private medical insurance
• Increased acuity, higher PMI admissions and focus on consistently good operational excellence across all sites • Result impacted by higher National Insurance costs (£4m) • ROCE +102bps (cc) reflecting improved earnings and a focus on capital management
FY26 Results Presentation
17
UK Hospitals
Focus on higher acuity, growth in private work and operational efficiencies Focus areas
Outlook
• Continued focus on private growth (self pay and PMI)
• Expect growth in EBIT in FY27 driven by higher acuity, growth in private volumes and ongoing operational efficiencies
• Continue to work closely with local and national NHS stakeholders to attract NHS work and target acuity • Ongoing delivery of efficiency transformation programmes across Finance and Operations; including rostering initiatives and creation of finance shared service hubs
• The FY26/27 NHS tariff¹ has been recently revised to 1.24% reflecting pay awards and will be backdated to the 1 April 2026 (start of the NHS year). The amount relating to 1 April 2026 to 30 June 2026 will be recognised in FY27 accounts.
• Ongoing focus on cash flow generation
- NHS tariff year commencing 1st April
FY26 Results Presentation
18
Elysium
Revenue (- 4.2% cc) driven by:
Turnaround underway to right size capacity to demand and mitigate cost pressures Twelve months ended 30 June A$’m
• Activity levels in acute and rehab. remain soft reflecting change in NHS approach • 6.8% reduction in paid beds and flat average occupancy rate partially mitigated by average daily fee +4.4%
2026
2025
Change
Change cc³
1,037.6
1,093.0
(5.1%)
(4.2%)
EBITDA
76.5
62.4
22.6%
24.6%
EBIT
17.9
(41.7)
142.9%
142.5%
Items¹ excluded from underlying EBIT
(13.2)
(63.7)
79.3%
77.8%
Underlying EBIT contribution
31.1
22.0
41.4%
43.5%
Underlying EBIT margin
3.0%
2.0%
100bps
ROCE²
3.4%
2.2%
120bps
118bps
Capital Expenditure
42.2
66.8
(36.8%)
(36.2%)
Average Paid Beds
1,981
2,126
(6.8%)
Average Occupancy
86.1%
86.0%
10bps
Revenue and other income
Volume metrics
For further detail on items excluded from underlying earnings refer the Appendix and the Review of results of operation. 1HFY25 includes Elysium site impairment but excludes the $248m goodwill impairment to the UK cash generating unit ROCE calculated as 12 month rolling Underlying EBIT / average of opening and closing capital employed pre goodwill. Constant currency.
FY26 Results Presentation
• Available beds were adjusted to weaker demand throughout the year. 239 beds were closed and 7 sites were shut with patients and residents transferred to other sites where possible. Occupancy for the month of June was 87.2%. Underlying EBIT (+ 43.5% cc) reflecting: • Average fee uplift only partially offsetting wage pressures including national minimum wage increase of 5.5% and national insurance impact of £5.6m on pcp • Impact of turnaround initiatives gained traction in 2H including focus on central costs and agency labour. Phase 3 central cost reduction in progress (34 FTE reduction in addition to 127 FTEs in earlier phases) • Focus on working capital and reduction in capex drive free cashflow. • Reported EBIT + 142.5% cc includes net costs of $13.2m encompassing net costs of $4.8m on the restructure of its portfolio and site impairments of $8.4m. Further details on items not included in Underlying EBIT is on Slides 39 & 40
19
Elysium
Focused on ongoing delivery of turnaround plan Focus areas
Outlook
Delivering performance improvement plan including ongoing reductions in the cost base, and maintaining available beds to reflect local demand levels
•
Expect growth in EBIT in FY27 as Elysium continues delivery of its turnaround plan
•
Expecting and planning for weak market demand conditions to continue in FY27
• Further improvements to labour mix including reducing agency costs and optimising mix through targeted permanent frontline recruitment. Elysium annual wage review from July 1 2026 increased minimum rates paid from £12.85 to £13.11 per hour, compared to an increase of 4.1% in the National minimum wage; • Continue to negotiate with all payors for appropriate fee uplifts reflecting service complexity, targeting blended increase above NHS tariff increase; and • Increasing the conversion rate of new patient opportunities, including a focus on complex recovery services, referred to as enhanced packages of care • Site divestment program, for permanently closed sites • Focus on timely cash collection and continue improving cashflow
FY26 Results Presentation
Europe
On track with separation plans, continuing to focus on performance improvement Demerger via in-specie distribution progressing to shareholder vote in November
Proposal to separate Ramsay Santé from Ramsay Group via an in-specie distribution of its full 52.8% stake to its shareholders well progressed Ramsay Santé has announced that they have completed a refinancing of their debt, with a change of control provision consistent with the proposed separation, applied to the ASX for listing of CDIs, and are convening a Capital Markets Day on 17 September 2026. RHC Demerger meeting and shareholder vote progressing towards 24 November 2026 Simplifies portfolio, allowing RHC Management to focus on the transformation and growth potential of its core Australian hospitals business.
FY26 Results Presentation
France
Nordics
Focus on operational initiatives to mitigate funding headwinds
Realise business potential in Sweden
Focus on cost control, operational efficiency programs, cash generation and disciplined capital management.
Strong performance driven by Sweden in key services lines including primary care and St Göran
Continued reduction in central costs, agency costs and procurement savings
Transition to St Göran new contract commenced 5 January 2026 for 8+4 additional years on improved terms
Focus on coding accuracy and profitable growth in day medicine and imaging Re-organisation of some sites including targeted closures of some maternity sites
Further productivity gains in all Nordic countries
Continued advocacy for improved tariffs that more fairly reflect increases in costs High patient NPS maintained (74)
21
Europe Reduced underlying loss despite funding headwinds Twelve months ended 30 June A$’m
2026
2025
Change Change cc⁶
Total revenue and other income
9,275.5
8,802.8
5.4%
3.2%
EBITDA
1,068.5
1,025.6
4.2%
2.7%
EBIT
298.6
290.3
2.9%
2.9%
Net loss after tax and non-controlling interests
(50.5)
(12.7)
297.6%
282.9%
Items excluded from underlying EBIT¹
(32.2)
(7.5)
329.3%
335.8%
France - underlying EBIT contribution
206.7
224.0
(7.7%)
(7.4%)
Nordics - underlying EBIT contribution
124.1
73.8
68.2%
65.6%
Underlying EBIT
330.8
297.8
11.1%
11.4%
Items excluded from the Loss after tax and non-controlling interests¹
(16.2)
27.2
(159.6%)
Underlying loss after tax and non-controlling interests
(34.3)
(39.9)
14.0%
Underlying EBIT margin (%)
3.6%
3.4%
20bps
ROCE (%)⁵
6.7%
6.1%
60bps
40bps
Capital expenditure
247.5
239.6
3.3%
1728.0
1693.7
2.0%
70.6
69.7
90bps
20.1%
Volume metrics Admissions ('000)² Day admissions as % of total admissions 1. 2. 3. 4. 5. 6.
Revenue growth (+3.2% cc) reflects: • • • •
2026 French tariffs of 0%³ No revenue guarantee (€20m in pcp) Prudential coefficient⁴ not repaid in December 2025 Overall MSO² activity growth +2.0%
Underlying EBIT (+11.4% cc) year on year: • Growth in the Nordics driven by Sweden, St Göran and Proximity Care • St Göran new contract commenced 5 January 2026 for 8+4 additional years on improved terms • Performance in France impacted by tariff below cost inflation and the withdrawal of the revenue guarantee • Focus on operational improvement programs partially mitigating lower funding in France • Cash borrowing costs declined 4.5% reflecting lower base rates • Reported EBIT includes $32.2m of net costs including: associated with the restructure of its portfolio ($19.7m); site impairments ($12.1m); and costs associated with the demerger process ($16m) (Refer Slide 39 & 40 for further details)
Further detail on items excluded from underlying results refer to the Appendix and the Review of results of operations MSO (medical, surgical and obstetrics) day + inpatient excludes FCR and day sessions France + Nordics region. Further information on tariffs available at Section 2.3.3 of the OFR. Tariff year commencing 1 January 2026 French Government uses the prudential coefficient as a mechanism to withhold a portion of hospital tariffs to mitigate the risk of exceeding target national health insurance expenditure. ROCE calculated as 12 month rolling Underlying EBIT / average of opening and closing capital employed pre goodwill. Constant currency.
FY26 Results Presentation
22
Europe
Focus on profitable growth and performance improvement initiatives in all regions Focus areas
Outlook
Assuming the proposed separation of Ramsay Santé is approved by shareholders, Ramsay Santé will be reported as a discontinued business in the 1H and FY27 results reflecting: • The result from 5.5 months of ownership, will be treated as a discontinued • Growth in Sweden driven by the full-year effect of the new St Göran business in 1H contract Ramsay Santé will host a Capital Markets Day on 17th• Costs associated with the demerger of Ramsay Santé (including $16m incurred to 30 June 2026), to be detailed in demerger booklet. September 2026 in Paris, at which the Ramsay Santé’s • Development of more profitable value pools such as imaging and day medical activityroadmap, in France, as well as contract renewal and bidsand in next strategic operational priorities medium• Tariff indexation in France for the 26/27 year of 0% from 1 January 2026 the Nordics • The implementation of efficiency plans both in France and the Nordics coupled with restructuring actions flowing from the review of its portfolio of assets
term financial ambitions will be presented. This event will give the opportunity showcase Ramsay Santé’s • Advocating for fair remuneration to of its services in France renewed ambition to pursue profitable growth while • continuing Focus on cashflow generation, capex allocation will target to deliver excellent patient care, supported by a restructuring projects and investment enabling development of higher and broader shareholding. margin areas such new as imaging
Ramsay Santé Capital Markets Day Ramsay Santé will host a Capital Markets Day on 17th September 2026 in Paris. The event will be webcast. FY26 Results Presentation
23
Proposal to separate Ramsay Santé from Ramsay
Process for separation of Ramsay Santé on track, with shareholder vote on 24 November
Strategic Rationale
Summary of proposal After completion of a comprehensive strategic review of Ramsay’s share ownership in Ramsay Santé, the Board proposes to (subject to all approvals¹): • Distribute Ramsay Santé shares held by Ramsay-to-Ramsay shareholders (i.e. an in-specie distribution) • Assist Ramsay Santé to put in place arrangements so that Ramsay shareholders may hold their interest in Ramsay Santé through CHESS Depositary Interests (CDIs) which would be tradeable on the ASX
The proposal to separate recognises the fundamentally different geographic focus, strategies and capital profiles of Ramsay and Ramsay Santé. Benefits of the proposal include: •
Simplification of Ramsay portfolio, enabling management to focus on transformation and growth potential of its core Australian hospitals business
•
Simplification of Ramsay’s reported financial profile through deconsolidation of Ramsay Santé from Ramsay’s financial statements
•
Improved focus for Ramsay Santé, an already established, independently managed and publicly listed business, to continue to pursue its European focused strategy and transformation
•
Limited separation complexity, given Ramsay Santé already operates independently of Ramsay including separate financing and balance sheet arrangements
•
Opportunity for Ramsay shareholders to retain ownership interest in Ramsay Santé
Subject to obtaining applicable approvals, and Ramsay shareholders voting in favour via a scheme of arrangement, Ramsay would expect to complete the in-specie distribution at the end of calendar 2026. The meeting held for the shareholder vote will be held on 24 November 2026.
Key dates¹ Ramsay Santé Capital Markets Day planned for 17 September 2026 Demerger booklet will be published in October 2026 AGM and shareholders meeting to vote on the demerger: 24 November 2026 Expected completion of transaction: December 2026 1.
Subject to shareholder and regulatory approvals
FY26 Results Presentation
24
‘Ramsay Cares’ - People, Planet and Community Progress Net Zero Emissions Target update Ramsay remains on track with both our 2030 Scope 1 and 2 greenhouse gas (GHG) emission targets and 2028 supplier engagement targets. Ramsay is committed to working with its partners to understand and address GHG emissions across its large and complex supply chain, however its progress in this area is limited to how quickly its suppliers are able to reduce and manage their own Scope 1 and 2 GHG emissions. As a result, Ramsay has revised its long-term net-zero GHG targets taking into account the current and anticipated commercial and operating environment: • The Group will now target net zero (Scope 1 and 2) GHG emissions (equity share) by 2050 (instead of 2040). • Ramsay UK and Elysium Healthcare will target net zero Scope 3 GHG emissions by 2050. The Group’s net zero Scope 3 GHG target will be considered following engagement with suppliers, as per our near-term target.
• Achieved FY26 supplier sustainability assessment target, by assessing over 80% of suppliers (by share of global spend) through independent services • Strengthened our commitment to supplier diversity and joined Supply Nation and Social Traders.
• High Patient NPS scores across the UK, Australia, France and Sweden (70+) • Strong clinical excellence including Ramsay Research and Development Network expansion in Australia • Inclusive culture with 50% female representation across Board and senior leadership1 • 1,000+ employees certified in Mental Health First Aid, with target of 3% of permanent staff across Australia and UK
- Board (non-executive directors) and senior leadership includes Group Executive and their direct reports
FY26 Results Presentation
• Achieved 31% greenhouse gas (GHG) emissions reduction (equity share, Scope 1 & 2, compared to 2020 baseline) • 6.5m kWh renewable electricity generated from 6.6MW solar installations across 40 hospitals and clinics • 59% reduction in anaesthetic gas GHG emissions since 2022 • Funding Group Climate Transition Plan defined and underway
25
People caring for people
Group Financials
Anthony Neilson Group Chief Financial Officer
FY26 Group financial performance
Underlying result reflects momentum in Australia and focus on operational improvement programs Twelve months ended 30 June A$’m
Underlying Net Profit¹ (+22.9% cc) reflects:
2026
2025
Change
Change cc²
Underlying segment revenue & other income (less interest income)
18,659.6
17,781.4
4.9%
4.0%
Underlying EBITDA
2,343.4
2,168.9
8.0%
7.7%
Underlying EBIT
1,162.2
1,042.6
11.5%
11.8%
Underlying Net profit after tax and non-controlling interests¹
364.1
305.3
19.3%
22.9%
Underlying EBITDA margin
12.6%
12.2%
40bps
Underlying EBIT margin
6.2%
5.9%
30bps
Reported EBITDA
2,308.6
2,159.4
6.9%
6.4%
Reported EBIT
1,105.4
706.2
56.5%
56.9%
Reported Net Profit/(Loss) after tax and non-controlling interests
329.2
24.0
Underlying EPS (cps)
151.0
125.3
20.5%
27.0%
Further details of items excluded from underlying results refer Appendix and Review of results of operations. Constant currency.
• Transformation momentum in Australia underpinned by activity growth, higher acuity, improved utilisation and revenue indexation, and cost management •
All regions delivered on programs focused on operational efficiencies to mitigate cost pressures
• 4%(cc) increase in depreciation reflects the completion of new developments in the last twelve months in Australia including Joondalup Private • Effective tax rate 35.9% vs 32.7% reflecting higher effective rate in Ramsay Santé Reported Net Profit (+ 1,284% cc) includes; • $34.9m of items not in the underlying result including asset sales, site impairments and restructure costs (refer Slides 39 & 40 for further detail. • Effective reported tax rate 37.4% vs 54.5% in pcp due to provision release in Ramsay Santé and goodwill impairment in UK CGU in pcp
Fully franked final dividend of 48.5cps, 60.3% full year payout ratio
FY26 Results Presentation
27
Cash flow statement
Australia and UK businesses free cashflow positive
Twelve months ended 30 June A$’m
2026
2025
Change
EBITDA from continuing operations
2,308.6
2,159.4
6.9%
Changes in working capital
(131.8)
89.5
(247.3%)
Finance costs
(594.9)
(592.0)
(0.5%)
Income tax paid¹
(193.3)
(210.1)
8.0%
Movement in other items
42.1
34.0
23.8%
Operating cash flow
1,430.7
1,480.8
(3.4%)
Capital expenditure
(734.2)
(776.6)
5.5%
Free cash flow
696.5
704.2
(1.1%)
Net divestments/(acquisitions)
115.1
(5.2)
2,313.5%
Interest & dividends received and deposits paid
(44.5)
16.5
(369.7%)
Cash flow after investing activities
767.1
715.5
7.2%
Dividends paid
(238.0)
(190.7)
(24.8%)
Other financing cash flow
(551.0)
(440.5)
(25.1%)
Net (decrease)/increase in cash
(21.9)
84.3
(126.0%)
Tax paid in FY25 includes tax paid on the profit on the sale of Ramsay Sime Darby JV
FY26 Results Presentation
• Operating cashflow reflects a 46% improvement in operating cashflow in the Funding Group offset by a negative working capital variance in Ramsay Santé primarily reflecting the timing of payments from the French Government; • Australia, the UK Acute business and Elysium (the Funding Group) were net cashflow positive for the 12-month period; • The decline in capex reflects lower capex in the UK region and flat spend in Ramsay Santé in local currency compared to the pcp; • Investing cashflows include the €26m refundable deposit paid by Ramsay Santé as part of the new eight- year St Goran contract along with a sale and leaseback in Santé and investment sale in Australia; • Dividends paid increased 24.8% reflecting the suspension of the dividend reinvestment plan (DRP) for the FY25 final dividend (DRP operated in the pcp).
28
Consolidated Balance Sheet
ROCE improving, reflecting earnings growth and capital discipline A$'m
30/06/26
31/12/25
30/06/25
728.3
787.9
596.5
Property plant & equipment
5,701.4
5,954.0
5,820.0
Intangible assets
5,975.5
6,317.2
6,431.1
217.1
226.5
205.8
Other assets/(liabilities)³
(1,189.7)
(1,127.5)
(1,342.2)
Capital employed (before right of use assets)
11,432.6
12,158.1
11,711.2
Right of use assets
4,429.8
4,958.8
5,333.0
Capital employed
15,862.4
17,116.9
17,044.2
Capitalised leases (AASB16)
5,704.7
6,247.8
6,583.0
Net debt (excl. lease liability debt & excl. derivatives)
4,563.9
5,145.9
4,752.5
Total shareholders funds
5,593.8
5,723.2
5,708.7
Invested capital
15,862.4
17,116.9
17,044.2
Return on capital employed (ROCE) (%)¹
11.0
9.9
9.9
Return on invested capital (ROIC) (%)²
4.6
4.3
4.3
Working capital³
Current & deferred tax assets
Return metrics
• The net impact of currency translation is ~$300m; • Working capital movements in Ramsay Santé associated with Government receivables; • Underlying increase (after depreciation) in property plant and equipment as new developments in Australia are completed; • Elysium portfolio restructure resulted in $300m reduction to right of use assets and corresponding movement in capitalised lease liability • The Ramsay Consolidated Group weighted average cost of debt (excluding CARES) at 30 June was 5.2% • ~69% of Consolidated Group's floating rate debt is hedged at an average base rate of 3.0% (excluding lending margin)
ROCE calculated as 12 month rolling Underlying EBIT / average of opening & closing capital employed pre goodwill. Accounting ROIC = 12 month rolling Underlying EBIT * (1- tax) / average of opening and closing invested capital Current employee entitlement liabilities, primarily comprising annual leave and long service leave was previously booked, within Current Trade and Other Creditors in the Statement of Financial Position. Management has reassessed the presentation of these balances and determined that classification as Current Provisions more appropriately reflects their nature. Accordingly, prior year comparatives as at 30 June 2025 and 31 December 2024 have been restated by reclassifying $1,262.0m and $1,084.5m respectively from Working Capital to Current Provisions. There was no impact to Total Current Liabilities.
FY26 Results Presentation
29
Funding Group¹ performance
Transformation momentum in Australia and benefits of operational improvements in the UK 12 months ended 30 June A$’m
Underlying Net Profit +17.9% cc reflects:
2026
2025
Change
Change cc⁴
Total segment revenue and other income
9,423.1
8,984.4
4.9%
5.2%
EBITDAR
1,256.7
1,150.9
9.2%
9.2%
EBITDA
1,240.1
1,133.8
9.4%
9.4%
EBIT
806.8
415.9
94.0%
93.2%
Financing costs (AASB16 leases)
(149.9)
(152.1)
1.4%
0.9%
Net other financing costs (net interest income)
(109.6)
(104.2)
(5.2%)
(4.9%)
Net Profit after tax and non-controlling interests
379.7
36.7
934.6%
921.4%
Items excluded from underlying EBIT
(24.6)
(328.9)
92.5%
87.6%
Underlying EBIT
831.5
744.8
11.6%
12.0%
(18.7)
(308.5)
93.9%
90.0%
398.4
345.2
15.4%
17.9%
EBITDA margin (%)
13.2%
12.6%
60bps
Underlying EBIT margin (%)
8.8%
8.3%
50bps
ROCE (%)²
14.8%
13.3%
150bps
124bps
ROIC (%)³
6.3%
5.7%
60bps
60bps
Items excluded from underlying net profit after tax and noncontrolling interests Underlying Net profit after tax after non-controlling interests
FY26 Results Presentation
• 11.2% growth in Underlying EBIT in Australia driven by activity, improved utilisation, higher acuity improved indexation and a focus on costs • +10.3% cc in Underlying EBIT from UK Acute, higher acuity, private work and operational initiatives mitigated lower NHS volumes • +43.5% cc in Underlying EBIT from Elysium reflecting initial benefits of turnaround plan mitigating reduced activity • 7.3% increase in depreciation reflects the completion of new developments in Australia • Financing costs (ex AASB16 Leases) increased 4.9% cc reflecting higher base rates over the period • Effective underlying tax rate 29.1% (28% pcp) ROIC +60bps to 6.3% and ROCE +124bps cc to 14.8% • Improved profitability in each region and focus on capital discipline supporting lift in capital returns
Comprised of Ramsay Health Care Limited and all its subsidiaries, excluding Ramsay Santé (the Funding Group’s investment in Ramsay Santé is recorded as an investment on the balance sheet). ROCE = 12 month rolling Underlying EBIT / average of opening and closing capital employed pre goodwill. Accounting ROIC = 12 mth rolling Underlying EBIT *(1-tax)/average of opening & closing invested capital Constant currency.
30
Funding Group¹ - Cashflow, Debt and Leverage Focus on cashflow drives lower leverage
• Australia and the two UK businesses were net cashflow positive for the year
Twelve months ended 30 June A$’m
2026
2025
Change
EBITDA from continuing operations
1,240.1
1,133.8
9.4%
12.1
(84.9)
114.3%
Finance costs
(273.4)
(265.4)
(3.0%)
Income tax paid
(159.0)
(180.9)
12.1%
Movement in other items
49.3
(6.9)
814.5%
Operating cash flow
869.1
595.7
45.9%
Capital expenditure
(486.7)
(537.0)
9.4%
Free cash flow
382.4
58.7
551.4%
Net divestments/(acquisitions)
34.2
(10.9)
413.8%
Interest & dividends received
9.0
7.3
23.3%
Cash flow after investing activities
425.6
55.1
672.4%
Dividends paid
(209.6)
(165.5)
(26.6%)
• $1,066m of liquidity at 30 June 2026 leverage post National Capital acquisition expected to be in the range of <2.50x5
Other financing cash flow
(108.4)
150.8
(171.9%)
• Fitch BBB- investment grade rating affirmed
Net increase in cash
107.6
40.4
166.3%
Funding Group Leverage (x)2
1.83
2.18
Funding Group Net Debt $’bn3
1.9
2.0
Changes in working capital
Funding Group – excludes Ramsay Santé (funded by standalone debt facilities). Banking covenants and Fitch rating based on the Funding Group earnings profile and net debt. Leverage ratio for the purposes of banking covenants calculated as Bank Net debt / Funding Group Underlying EBITDA adjusted to deduct all rental expenses under any lease arrangement. Bank Net debt (excl lease liability debt and derivatives). Does not include an allocation for overhead costs. Refer to Appendix for full list of hospitals Investment grade credit rating must apply to leverage between 3.50x - 4.00x otherwise leverage not to exceed 3.50x Convertible Adjustable-Rate Equity Securities (CARES) are non-cumulative, redeemable and convertible preference shares.
FY26 Results Presentation
• Growth in EBITDA underpinned by strong cash flows generated by the Australian hospital portfolio including 44 owned hospitals generating $808.6m in EBITDAR⁴ for the period • Disciplined capital management with improved working capital position and lower capex spend • Sale of investment in Hotdoc • Bank leverage ratio at 30 June 2026 was 1.83x (target Funding Group leverage <2.50x) below covenant threshold of 4.00x5 • Interest cover remains strong at 8.94x
• The weighted average cost of debt for the Funding Group (excluding CARES6) for FY27 expected to be ~5.5% . ~60% of floating rate debt in FY27 is hedged at an average base rate (excl. lending margin) of 3.6% • During FY26, $2,455m of debt facilities were refinanced resulting in tenor extension and 30bps margin improvement for the syndicated loan facility
31
Ramsay Santé - Debt and leverage
Leverage maintained at 4.70x, reflecting focus on financial discipline Ramsay Santé – bank net debt1 and leverage ratio2
4.70x
5.30x
4.70x
1.7
1.8
1.6
Jun-25
Dec-25
Jun-26
Net Debt (IAS17) €'bn
Leverage Ratio (IAS17) (x)
• Ramsay Santé remains supported by its own funding arrangements underpinned by secured loan facilities, with no recourse to the Ramsay Funding Group • €487m of liquidity at 30 June 2026 comprising €185m undrawn bank facilities and €302m cash. Committed facilities total €2,045m including undrawn senior facilities • Credit rating Moody’s B1 (negative) / S&P B+(stable) • July 2026, Ramsay Santé refinanced €1,750m of senior debt comprising €1,550m Term Loan B and €200m revolving credit facility that was well supported by both new and existing lenders. The new facilities priced at E+350bps and delivered tenor extension of 2 years to 2033. • Weighted average cost of debt at 30 June 2026 approximately 5.2% (post refinancing 5.4%) • Well-protected interest rate profile (70% of Senior Debt hedged at fixed rates) • 87% of Ramsay Santé debt facilities are Sustainability Linked Loans
- Leverage Net Debt (excl lease liability debt) for calculating bank leverage.
- Leverage Ratio as per Ramsay Santé banking covenants based on IAS17 calculation.
- Convertible Adjustable Rate Equity Securities (CARES) are non-cumulative, redeemable and convertible preference share
FY26 Results Presentation
32
Focus on capital management and cash flow drives lower Funding Group leverage Improve capital allocation & returns Capital expenditure in the UK lower than pcp and Europe flat to pcp – both regions’ capex focused on existing facilities Australian Capex flat on pcp, below forecast range. Focused development spend on procedural capacity in priority catchments Optimisation of portfolio - Elysium 7 sites and 239 beds closed over FY26. 5 facilities held for sale. Australia, 4 sites closed, sites to be sold and additional land holdings¹ being sold Improved utilisation of theatres in Australia, ~+90bps inclusive of 22 new theatres opening in FY26 Funding Group ROCE +124bps (cc) to 14.8% Ramsay Santé separation on track for shareholder vote
Maintain leverage within target range and rating
Improve cash flow Australia and both UK businesses net cashflow positive Focus on revenue cycle management and strengthening manual claiming processes to improve working capital across the regions (cash conversion cycle² in Australia reduced by 4 days) Group capex down 6.1% (cc) reflecting focus on cashflow and utilisation of existing facilities in UK and Europe Disciplined cost management across the Funding Group, underlying EBITDAR margin +60bps, underlying employee benefits as % of revenue declined 20bps
Funding Group Refinancing completed in 1HFY26 at improved pricing and longer tenor, with 30bps margin improvement on Funding Group syndicated loan facility Leverage end of period 1.83x lower than prior period. Proforma leverage post acquisition of National Capital Private Hospital within target range of <2.5x Group Final Dividend 48.5cps fully franked, an increase of 21.3%, full year dividend to 91cps. Full year payout ratio of 60.3%, consistent with our target range of 60-70% of underlying net profit after tax and noncontrolling interests
Ramsay Surgical Centre Glenferrie, Ramsay Clinic Thirroul, Coolemberg Day Surgery, Attadale Rehabilitation Hospital (site sold in July 2026), and land holdings in Nowra, Nambour, St Andrews and Townsville Excludes pharmacy
FY26 Results Presentation
33
Capital expenditure
Group capex down 6.1% (cc)¹ reflecting disciplined approach to new investment Australia $’m
362
Chart Title
UK Region £’m
365
777
149
21 20 124
FY25
41
19 8 11
61 6 8
50
41
FY25
FY26
Development
296
25
36
88
158
FY26
144
143
197 17
Group A$’m
Ramsay Santé €’m
23
12 9
10
57 56
734
729
205
203
70 74
69 73
6
Digital & Data & IT hardware
86
86
368
385
384
FY25
FY26
FY25
FY26
FY26 (cc)¹
Other growth
Routine & Compliance
• Group capital expenditure down 6.1% (cc) on pcp driven by lower development spend across the Group with the focus on improving utilisation
• UK below pcp and Santé flat in local currency reflecting capital discipline in the current funding environment
• Funding Group capex down 9% on pcp to $487.9m (cc)
• Development capex in the UK region relates to re-purposing and refurbishing existing facilities, with growth capex in Elysium ceased in February 2025
• Development capex in Australia focused on expanding procedural capacity in priority catchments. Spend lower than forecast and pcp following increased focus on theatre utilisation • Joondalup private hospital development total spend ~$14m below budget FY26 Results Presentation
• Group routine & maintenance spend reflects an increase in Australian investment in the existing facility portfolio to ensure strategically located sites are fit for purpose in the future and continue to meet high clinical, safety and amenity standards offset by some savings in UK.
- Constant currency
34
People caring for people
CEO Outlook
Natalie Davis Managing Director and Group CEO
Priorities and outlook
Continued focus on delivering priorities Focus areas
Outlook
Deliver transformation of market leading Australian hospital business • 'Big 5' Hospital Operations Initiatives – Growth, Procurement, Workforce, Revenue Cycle Management, Technology & AI enablement • Nat Cap Integration (expected ownership from 1 September 2026)
Assuming the proposed separation of Ramsay Santé is approved by shareholders, Ramsay Santé will be reported as a discontinued business in the 1H and FY27 results: • The result from 5.5 months of ownership, will be treated as a discontinued business in 1H • Costs associated with the demerger of Ramsay Santé (including $16m incurred to 30 June 2026), to be detailed in demerger booklet.
Evolve our culture of 'People caring for people' to innovate and drive performance
Ramsay Funding Group is expected to report EBIT growth and EBIT margin improvement in FY27, with growth in EBIT in Australia and both UK businesses. • Australia targeting incremental yoy EBIT growth (Including and excluding Nat Cap) and margin expansion¹ driven by activity growth, improved capacity utilisation, revenue indexation in line with cost indexation, and operational improvement initiatives, as well as $10-15m increase in opex investment in IT, technology and transformation. • National Capital expected to be EPS accretive in first 12 mths of ownership, transition opex costs of $9-11m in FY27² • UK Hospitals expect growth in EBIT in FY27 driven by higher acuity, private work focus and ongoing operational efficiencies • Elysium targeting growth in EBIT as they continue delivery of turnaround plan, with weak market demand expected to continue
Investor day
• Funding Group net financing expense (inclusive of AASB 16 lease costs) forecast to be $280-300m • Funding Group effective tax rate on underlying earnings is expected to be ~30% • Funding Group total capex guidance $480-520m
Investor Day with Group Executive to be held 30 November 2026
• Dividend payout ratio expected to be 60-70% of underlying Group net profit after tax and non-controlling interests
Strengthen capital discipline and improve capital returns across the portfolio • Ramsay Santé separation to be put to shareholder vote at AGM on 24th November 2026
FY26 Results Presentation
-
Including and excluding Nat Cap
-
Transition costs expected to be skewed to 1H results. Transition costs will be excluded from Underlying earnings
36
People caring for people
Appendix
Funding structure Consolidated Group
Funding Group¹
Paul Ramsay Foundation
Public Shareholders
16.4%⁷
83.6%⁷
Ramsay Health Care Limited (ASX listed; BBB-Stable)
Ramsay Santé
Consolidated Group³ Revenue: $18.7bn EBIT: $1,105m
Funding Group³ Revenue: $9.4bn EBIT: $807m Net Debt⁴: $1.9bn Leverage⁴ (1.83x): Market Cap.: $10.2bn⁶
FY26 Results Presentation
UK subsidiaries²
• Comprised of Ramsay Health Care Limited and all its subsidiaries. • Ramsay reports its financial results on a Consolidated Group basis, with financial results for Ramsay Santé being reported on a fully consolidated basis. • There are no debt facilities provided to the Consolidated Group.
Ramsay Santé³ Revenue: €5.4bn EBIT: €177m Net Debt⁴: €1.6bn Leverage⁴ (4.7x): Market Cap.: €1.2bn⁵ 52.79%
Australian subsidiaries
Consolidated Group
Ramsay Santé and subsidiaries (Euronext listed; B1/ Negative, B+/ Stable)
- Financial covenants and the Fitch rating only apply to the Funding Group.
- Either wholly owned or controlled by Ramsay Health Care Limited,
- 12 months to 30 June 2026
- As at 30 June 2026 Adjusted Net Debt excluding lease liabilities and derivatives
- Based on 110.4m shares
- Based on 230.8 m shares
- As at 31 July 2026
Funding Group • Comprised of Ramsay Health Care Limited and all its subsidiaries², excluding Ramsay Santé (the Funding Group’s investment in Ramsay Santé is recorded as an investment on the balance sheet). • The Funding Group effectively represents Ramsay’s Australian and UK operations¹.
Ramsay Santé • Ramsay Santé is separately self-funded by covenant light, secured debt facilities with no recourse to the Funding Group.
38
Reconciliation of FY26 Result from Underlying¹ to Statutory Consolidated Group EBIT Reconciliation Group Underlying EBIT ($A’m)
Consolidated Group NPAT Reconciliation 1,162.2
Group Underlying Profit after tax and non-controlling interests ($A’m)
364.1
Net profit on disposal of non-current assets and businesses
39.0
Net profit on disposal of non-current assets and businesses
23.2
Restructuring costs
(34.6)
Restructuring costs
(18.8)
Impairment of carrying value of assets
(22.0)
Impairment of carrying value of assets
(12.8)
Acquisition, disposal and development costs/benefits
(26.4)
Acquisition, disposal and development costs/benefits
(14.6)
Provision for employee costs related to prior periods
(12.8)
Provision for employee costs related to prior periods
(11.9)
Group Reported Net Profit after tax and non-controlling interests ($A’m)
329.2
Group Reported EBIT ($A’m)
1,105.4
Funding Group EBIT Reconciliation
Funding Group NPAT Reconciliation
Funding Group Underlying EBIT ($A’m)
831.4
Funding Group Underlying Profit after tax and non-controlling interests ($A’m)
398.4
Net profit on disposal of non-current assets and businesses
24.1
Net profit on disposal of non-current assets and businesses
17.4
Restructuring costs
(14.9)
Restructuring costs
(11.1)
Impairment of carrying value of assets
(9.9)
Impairment of carrying value of assets
(7.4)
Acquisition, disposal and development costs/benefits
(3.4)
Acquisition, disposal and development costs/benefits
(2.7)
Provision for employee costs related to prior periods
(20.5)
Provision for employee costs related to prior periods
(14.9)
Funding Group Reported EBIT ($A’m)
806.8
Funding Group Reported Net Profit after tax and non-controlling interests ($A’m)
379.7
Items excluded from underlying profit are reported as not representing the underlying performance of Ramsay, whether positively or negatively. Items excluded from underlying profit may include; impairment (or reversal of impairment) of assets (site and goodwill); acquisition and divestment costs; restructuring costs; gains or losses on assets disposal or fair value revaluations; and one-off non-recurring or extraordinary events e.g. natural disasters, legal disputes, tax claims, insurance claims.
FY26 Results Presentation
39
Items Excluded from Underlying EBIT and NPAT FY26 Reported NPAT includes items of ($34.9m) excluded from the underlying result: •
•
Net profit on the disposal of non-current assets and businesses including a $14m profit on the disposal of Ramsay Australia's ~10% shareholding in online healthcare specialist booking service HotDoc; $10.1m in profits associated with the restructuring of Elysium's portfolio of sites; and the net accounting gain on the restructure of sites in Ramsay Santé's portfolio (+$21.4m) combined with a loss on the sale of its medical transport business (-$6.5m) Following a Fair Work Commission (FWC) decision (ANMF v Ramsay Health Care Australia [2024] FWC 3518), relating to the interpretation of how to calculate annual leave and annual leave loading payments under the NSW Nurses and Midwives’ Enterprise Agreement 2021-2023, Ramsay has recognised a $20.5m provision. The combination of factors that led to this interpretation issue was isolated to this Agreement and does not affect the current Ramsay Health Care New South Wales Nurses and Midwives Enterprise Agreement 2023-2026;
•
The reversal of provisions created in prior periods no longer required in Ramsay Santé (+$7.7m)
•
Site impairments in the UK related to Elysium (-$8.4m), Ramsay UK ($1.5m) and Ramsay Santé (-$12.1m);
•
Costs associated with the restructure of the Elysium (-$14.9m) and Ramsay Santé (-$19.7m) portfolios;
•
Acquisition & disposal costs in Australia and Ramsay Santé reflecting the costs of the demerger (-$23m in Europe includes -$16m associated with the demerger to 30 June 2026) and the reversal of a litigation provision; and the costs associated with the proposed acquisition of National Capital Private Hospital ($3.4m)
FY25 Reported NPAT included items ($281.3m) excluded from the underlying result:
FY26 (A’$m)
Australia
UK
Europe
Total Group
Net profit on disposal of non-current assets and businesses
14.0
10.1
14.9
39.0
Provision for employee costs related to prior periods
(20.5)
7.7
(12.8)
Impairment of carrying value of assets
(9.9)
(12.1)
(22.0)
Restructuring costs
(14.9)
(19.7)
(34.6)
Acquisition, disposal and development costs/benefits
(3.4)
(23.0)¹
(26.4)
Total EBIT Impact
(9.9)
(14.7)
(32.2)
(56.8)
Income tax impact
2.2
3.7
6.9
12.8
9.1
9.1
(7.7)
(11.0)
(16.2)
(34.9)
Non-controlling interests net of tax Net (loss)/profit after tax and non-controlling interests impact 1.
Includes $16m of costs associated with the demerger of Ramsay Santé incurred to-date in both Australia ($6.3m) and France ($9.7m, €5.7m) and the reversal of a litigation provision (+14.7m)
FY25 (A’$m)
Australia
UK
Europe
Total Group
2.9
2.9
5.8
(Impairment)/Reversal of impairment of carrying value of assets
(16.3)
(306.7)¹
(3.9)
(326.9)
Acquisition, disposal and development costs/benefits
(1.9)
(6.9)
(6.5)
(15.3)
Total EBIT Impact
(15.3)
(313.6)
(7.5)
(336.4)
Net swap mark to market movements
(11.8)
(11.8)
Total (loss)/profit before tax impact
(15.3)
(313.6)
(19.3)
(348.2)
64.5
64.5
4.3
16.1
6.6
27.0
(24.6)
(24.6)
(11.0)
(297.5)
27.2
(281.3)
Net profit on disposal / acquisition of development assets, non-current assets & businesses
•
$291m post tax impairment of UK region (£144m) against the UK CGU related to the underperformance of Elysium
•
$34m (after NCI) release of a non-cash tax provision taken up at the time of Ramsay Santé acquisition
Income tax impact
$11.8m pre-tax non-cash negative mark to market movement on interest rate swap in Ramsay Santé
Net (loss)/profit after tax and non-controlling interests impact
$16.3m pre-tax impairments & asset write-downs in Australia
• •
FY26 Results Presentation
Tax liability provision release Non-controlling interests net of tax
Impairment includes a $1.5m site impairment in Ramsay UK.
40
Australian hospital portfolio
44 owned facilities generating EBITDAR of $808.6m pre overhead cost allocation1
New South Wales
Facility Type
North Shore Private Hospital St George Private Hospital Westmead Private Hospital Lake Macquarie Private Hospital Wollongong Private Hospital Kareena Private Hospital Strathfield Private Hospital Warners Bay Private Hospital Ramsay Clinic Northside Port Macquarie Private Hospital Baringa Private Hospital Mt Wilga Private Hospital Albury Wodonga Private Hospital Southern Highlands Private Hospital Nowra Private Hospital Dudley Private Hospital Hunters Hill Private Hospital Tamara Private Hospital Ramsay Clinic Wentworthville Figtree Private Hospital Berkeley Vale Private Hospital Castlecrag Private Hospital Ramsay Surgical Centre Miranda Ramsay Clinic Macarthur Ramsay Surgical Centre Orange Ramsay Clinic Cremorne Armidale Private Hospital Ballina Day Surgery Western Sydney Priv. Oncology and Infusion Centre Ramsay Surgical Centre Coffs Harbour Ramsay Surgical Centre Charlestown Total New South Wales
Private Hospital Private Hospital Private Hospital Private Hospital Private Hospital Private Hospital Private Hospital Private Hospital Mental Health Clinic Private Hospital Private Hospital Rehabilitation Hospital Private Hospital Private Hospital Private Hospital Private Hospital Private Hospital Private Hospital Mental Health Clinic Private Hospital Mental Health + Rehab Private Hospital Surgical Centre / Day Surgery Mental Health Clinic Surgical Centre / Day Surgery Mental Health Private Hospital Surgical Centre / Day Surgery Day Infusion Centre Surgical Centre / Day Surgery Surgical Centre
Western Australia
Facility Type
Joondalup Health Campus Hollywood Private Hospital Glengarry Private Hospital Total Western Australia
Public + Private Hospital Private Hospital Private Hospital
Owned / Leased
Licenced Beds
Theatres, Proc. Rooms, Cath Labs
Leased Owned Owned Owned Leased Owned Owned Owned Owned Owned Owned Owned Owned Leased Owned Owned Leased Owned Owned Leased Leased Owned Leased Owned Leased Owned Leased Owned by JV Leased Owned Leased 31
351 276 216 187 171 170 97 122 137 72 78 119 80 73 62 62 40 45 68 58 49 37 47 31 30 12 2,690
27 20 17 12 17 8 11 5 7 5 8 5 4 4 4 5 3 4 4 2 2 1 6 181
Owned / Leased
Licenced Beds
Leased Owned Owned 3
796 950 77 1,823
Theatres, Proc. Rooms, Cath Labs 25 30 2 57
Emergency Department Potential Potential Yes Potential
Facility Type
Greenslopes Private Hospital John Flynn Private Hospital Pindara Private Hospital St Andrew's - Ipswich Private Hospital Sunshine Coast University Private Hospital North West Private Hospital Cairns Private Hospital Noosa Hospital Hillcrest - Rockhampton Private Hospital Nambour Selangor Private Hospital Ramsay Clinic New Farm Caboolture Private Hospital The Southport Private Hospital Ramsay Surgical Centre Cairns Short Street Day Surgery
Private Hospital Private Hospital Private Hospital Private Hospital Private Hospital Private Hospital Private Hospital Public Hospital Private Hospital Private Hospital Mental Health Clinic Private Hospital Mental Health + Rehab Surgical Centre / Day Surgery Surgical Centre / Day Surgery Mental Health + Rehab / Day Surgery Mental Health + Rehab Surgical Centre / Day Surgery Surgical Centre / Day Surgery
Ramsay Clinic Caloundra Ramsay Clinic Cairns Pindara Day Procedure Centre Ramsay Surgical Centre Cleveland Total Queensland
1 + 3 potential
Emergency Department Yes Yes 2
EBITDAR result is for the 12 months ended 30 June 2026 and includes Ramsay Surgical Centre Glenferrie, Ramsay Clinic Thirroul, Coolenberg Day Surgery and Attadale Rehabilitation Hospital now closed, Note: Cleveland Surgical Centre opened August 2026 this is on a leased site
FY26 Results Presentation
Queensland
Owned / Leased
Licenced Beds
Theatres, Proc. Rooms, Cath Labs
Owned Owned Owned Owned Leased Owned Owned Leased Owned Owned Owned Leased Leased Leased Leased
700 358 323 222 164 150 142 92 66 76 114 43 90
36 18 19 11 12 14 10 4 4 3 3 5 3
Owned
47
3
Owned Leased Leased 18
30 2,617
3 3 151
Emergency Department Yes Yes Yes Yes Potential
Yes
5 + 1 potential
Victoria
Facility Type
Owned / Leased
Licenced Beds
Theatres, Proc. Rooms, Cath Labs
Emergency Department
Peninsula Private Hospital
Private Hospital
Leased
350
13
Yes
Warringal Private Hospital
Private Hospital
Owned
252
19
Yes
The Avenue Private Hospital Beleura Private Hospital Frances Perry House Waverley Private Hospital Mitcham Private Hospital Ramsay Clinic Albert Road Donvale Rehabilitation Hospital Masada Private Hospital Shepparton Private Hospital Linacre Private Hospital Northern Private Hospital Wangaratta Private Hospital Victorian Day Procedure Centre Total Victoria
Private Hospital Private Hospital Private Hospital Private Hospital Private Hospital Mental Health Clinic Rehabilitation Hospital Private Hospital Private Hospital Private Hospital Private Hospital Private Hospital Surgical Centre / Day Surgery
Owned Leased Leased Owned Owned Owned Owned Owned Owned Owned Leased Owned Leased 15
152 217 93 98 123 123 85 94 88 64 106 39 1,884
13 6 5 8 5 4 4 5 5 3 2 92
1 + 1 potential
South Australia
Facility Type
Owned / Leased
Licenced Beds
Theatres, Proc. Rooms, Cath Labs
Ramsay Clinic Adelaide Ramsay Day Clinic Kahlyn Total South Australia
Mental Health Clinic Mental Health Clinic
Owned Leased 2
91 40 131
Emergency Department
41
Funding Group- Balance Sheet A$'m
30/06/26
31/12/25
30/06/25
496.4
543.2
508.5
Property plant & equipment
3,881.6
3,927.2
3,838.0
Intangible assets
2,717.7
2,795.1
2,863.9
Current & deferred tax assets
219.2
217.4
198.7
Other assets/(liabilities)
372.4
515.4
528.3
Capital employed (before right of use assets)
7,687.3
7,998.3
7,937.4
Right of use assets
1,281.0
1,630.6
1,694.9
Capital employed
8,968.3
9,628.9
9,632.3
Capitalised leases (AASB16)
2,218.6
2,615.2
2,710.0
Net debt (excl. lease liability debt & excl. derivatives)
1,912.8
2,109.3
2,028.9
Total shareholders funds
4,836.9
4,904.4
4,893.4
Invested capital
8,968.3
9,628.9
9,632.3
Funding group interest cover (x)
8.94
8.59
8.93
Funding Group Leverage ratio (x)
1.83
2.22
2.18
Return on capital employed (ROCE) (%)¹
14.8
13.1
13.3
Working capital
Key metrics
• The net impact of currency translation ~$300m. • Working capital movement reflects focus on cash collection in both Australia and UK with a particular focus on aged debtors. • Elysium portfolio restructure resulted in $300m reduction to right of use assets and corresponding movement in capitalised lease liability. • Property plant and equipment includes new developments in Australia following the completion of developments partially offset by asset sales and portfolio restructure in Australia and Elysium. • ROCE improved 150bps on pcp¹. • Funding Group leverage ratio decreasing to 1.83x.
ROCE calculated as 12 month rolling Underlying EBIT / average of opening & closing capital employed pre goodwill. In constant currency ROCE 14.6%
FY26 Results Presentation
42
Ramsay Santé - Balance Sheet A$'m
30/06/26
31/12/25
30/06/25
232.0
244.7
88.0
Property plant & equipment
1,819.9
2,026.8
1,982.0
Intangible assets
3,257.8
3,522.0
3,567.2
(2.2)
9.1
7.1
Other assets/(liabilities)
(724.7)
(738.3)
(905.7)
Capital employed (before right of use assets)
4,582.8
5,064.3
4,738.6
Right of use assets
3,148.8
3,328.2
3,638.1
Capital employed
7,731.6
8,392.5
8,376.7
Capitalised leases (AASB16)
(3,486.1)
(3,632.5)
(3,873.0)
Net debt (excl. lease liability debt & excl. derivatives)
(2,651.1)
(3,036.5)
(2,723.7)
Total shareholders funds
(1,594.4)
(1,723.5)
(1,780.0)
Invested capital
(7,731.6)
(8,392.5)
(8,376.7)
Working capital
Current & deferred tax assets
• Movements in working capital primarily relate to the timing of periodic true up of payments with the French Government. • In local currency net debt was 5% below pcp. • During the period, Ramsay Santé refinanced a finance lease with a new €65m mortgage loan. • As part of the restructure of the portfolio Ramsay Santé did a sale and lease back of some properties in the portfolio raising €44.6m. • ROCE improved 60bps on pcp (40bps cc)¹.
Key metrics Return on capital employed (ROCE) (%)¹
6.7
6.2
6.1
Leverage ratio (x)
4.7
5.3
4.7
• Movements in individual balance sheet items have been impacted by currency movements over the year.
ROCE calculated as 12 month rolling Underlying EBIT / average of opening & closing capital employed pre goodwill. In constant currency ROCE 6.5%
FY26 Results Presentation
43
People caring for people
27 August 2026 Ramsay Health Care FY26 Results - Presentation Speech Good morning everyone, and welcome to Ramsay Health Care's full year results presentation for the twelve months ended 30 June 2026. I am Natalie Davis, the Managing Director and Group CEO, and I am joined today by our Group CFO, Anthony Neilson. Today we will share our financial results and the significant progress we have made over the past year in transforming the business. I am pleased that we are maintaining high patient NPS scores and clinical excellence in every region, building transformation momentum in the Australian business, and improving performance and capital returns across the Group. I would like to thank our incredible people and our clinicians who dedicate themselves to our patients and are the foundation of our success. Slide 4– Delivering on CEO Priorities Turning to Slide 4 we have made good progress delivering against our three key priorities:
- First, the multi-year transformation of our market-leading Australian hospital business;
- Second, strengthening capital discipline and improving returns across the portfolio; and third
- Evolving our culture to innovate and accelerate delivery. Our strengthened Group Executive team and the capability they are building in key commercial and operational areas has enabled us to accelerate the pace of our transformation. In Australia, our high acuity growth focus, improved theatre utilisation, revenue indexation and cost management has delivered underlying EBIT growth of 11.2% and +30bps uplift in EBIT margin. Importantly, we are also well progressed with our proposed separation of Ramsay Santé, which is on track for completion in late 2026, subject to a shareholder vote in November. Slide 5 – FY26 Group Financial Performance Turning to Slide 5, looking at the headline numbers in constant currency movements for the full year: • • • •
1
Revenue was $18.6 billion 1, reflecting 4.2% growth driven by 8% growth in revenue from customers in Australia; Underlying EBIT increased 11.8% and underlying NPAT increased 22.9% reflecting focus on improving performance through transformation programs in each region. Reported NPAT was $329m; We have strengthened capital discipline, focusing growth and development capex on Australia and procedural capacity, reflected in Group ROIC increasing by 30bps and Funding Group ROIC +60bps to 6.3%; Our focus on performance improvement and cash conversion has seen Australia and both UK businesses net cashflow positive for the period, and improved our Funding Group leverage to less than 2.0x;
Revenue from contracts with customers
•
The Board has determined a final fully franked dividend of 48.5 cents per share, which is up 21.3% taking the full year dividend to 91 cents per share up 13.8% on the prior period and represents a payout ratio of 60.3% of underlying earnings.
These results highlight the momentum building across our business and the positive impact of our strategic initiatives. Slide 6 – Underlying Performance Slide 6 provides more detail on our underlying result and the split between the Funding Group contribution and Ramsay Santé. All regions improved performance. Australia reporting 11.2% growth in Underlying EBIT on 8% growth in revenue¹. Both UK businesses reported growth in earnings through operational initiatives mitigating the impact of lower funding by the NHS. Ramsay Santé’s improved EBIT was driven by its Swedish business and performance improvement initiatives, more than offsetting the difficult funding environment in France. Slide 7 - Regional Performance Moving to focus on each region Slide 8 – Australia - Transformation building momentum Starting with Australia on Slide 8 our transformation continues to build momentum driven by our 'Big 5' hospital operations improvement initiatives. Our strategic focus on growing in high-acuity and priority therapeutic areas, improving theatre utilisation, and focus on procurement initiatives has driven admissions and revenue growth, and margin expansion. Pleasingly, we achieved this alongside improved patient, doctor, and team NPS scores. With the new executive team in place we have started to accelerate the execution of our 2030 strategy. We are looking forward to National Capital Private Hospital joining our Ramsay network next week and serving the local community. During the year we signed a new partnership agreement with one of our major insurers, which will enable us to focus on collaborating to strengthen the private health proposition. We have grown our Ramsay Research and Development network to 22 sites, and continue to grow clinical trials activity with a 28% increase. Slide 9 – Australia: EBIT and margin growth Turning to the Australian result in more detail on Slide 9 the business delivered 11.2% growth in underlying EBIT driven by: • • •
Higher activity and acuity levels and improved utilisation of treatment capacity; Improved private health insurance (PHI) indexation; and Effective cost management.
We reported a 30bps improvement in underlying EBIT margin, to 9.4%. The EBIT impact of the new funding mechanism at Joondalup Public Campus was partially mitigated to approximately -$26 million by actions including a focus on timely discharge of patients, agency reduction and increased winter activity, as our clinicians continued to provide excellent care to the local community. Underlying labour costs were flat as a percentage of revenue and lower excluding the impact of Joondalup funding, reflecting a focus on reduced agency use over the period.
We were also able to lower supply costs as a percentage of revenue through procurement savings by approximately 50bps. Our portfolio optimisation efforts have continued, with four sites closed and excess land holdings put up for sale. Slide 10 – Improving industry fundamentals Before moving to the key drivers of our results, Slide 10 details some of the underlying trends in the Australian private healthcare market. The market is showing improving fundamentals with hospital coverage continuing to grow, as Australians prioritise their healthcare, growing by 2.5% pa in the last 3 years and payout ratios gradually improving, however, with some way to go. Acute private hospitals remain the predominant setting for private healthcare and are evolving their services to include day procedures. Down-tiering from gold policies to silver hospital coverage continues, impacting private mental health and maternity in particular. Slide 11 – Australian activity trends Delving deeper into Ramsay Australia’s activity trends on Slide 11, excluding the impact of Peel and Border Cancer Hospital which have both returned to public operation, you can see we observed strong growth in our core surgical and day activity, coupled with higher inpatient acuity: • • •
Surgical admissions, which account for more than half of our total admissions grew 4.1% increasing 40bps as a percentage of our total admissions reflecting our focus on growth in key therapeutic areas; Medical admissions were up 3.2% and rehabilitation admissions increased by 3.8%; and Mental health admissions declined by 3.9%, mainly due to declining day admissions, with overnight mental health admissions (which contribute the majority of our revenue in mental health) increasing by 0.9%.
Looking at funding types, private admissions grew 2.8%, public admissions increased by 9.5% reflecting strong activity at Joondalup and a 7.7% increase in public-in-private activity. Day only admissions increased by 3.8%, boosted by new surgical centres at Charlestown and Caloundra, while overnight IPDAs increased by 3%, reflecting a higher overnight acuity mix. Slide 12 – Data insights and sales force uplift Moving to Slide 12 and our strategic use of data insights and the uplift in our sales force are supporting growth in the number of visiting medical officers (VMOs), our share of complex therapeutic activity, and improved theatre utilisation. We achieved: • 3.3% growth in admitting VMOs enabled by improved catchment based data insights; • Our theatre utilisation improved to 70% in FY26 from 69% in FY25, as we opened an additional 22 new theatres during the 12-month period, indicating our success in increasing utilisation of theatres at our key sites; and • We increased robotics usage supported by improved robotics utilisation tracking. Slide 13 – Australian Capex - Development investment focused on procedural capacity Turning to capex on Slide 13, total capex was $365m which was flat on the prior period and below the original forecast of $410-440m reflecting: lower than forecast development spend, as we focus on improving utilisation of existing facilities; and the timing of reimbursements from landlords of $30.8m primarily associated with the developments at key leased sites Peninsula and Beleura. Our development investment in Australia remains focused on increasing procedural capacity in major hospitals within growth corridors.
In total we opened 22 theatre and procedure rooms during the period. The increase in routine & maintenance capex reflects an investment in existing facilities to ensure strategically located sites are fit for purpose in the future and continue to meet high clinical, safety and amenity standards. In FY27 we are planning to open 11 new theatres/cath labs at sites including our largest hospital Hollywood in Perth and St George in Sydney. We are in the final phase of our Warringal Private expansion, including our recently opened Emergency Department. Slide 14 - FY27 Continuing performance momentum with the Big 5 Turning to FY27 on Slide 14 we will continue with our key programs to drive the transformation of the business with our initiatives underpinned and enabled by our investment in data, technology and AI. We have defined our technology roadmap, with priorities including: • Upgrade of our Patient Administration System, which will be part of our broader Revenue Cycle Management transformation to speed up cash collection, improve accuracy to reduce rework, and streamline administrative manual processes. • Smart Rostering System and team app, to enable flexible working, reduce administrative burden for our hospital teams and improve effectiveness of our rosters. Slide 15 Australia Focus areas and Outlook Moving to Slide 15 and the outlook. As we continue to focus on delivery of our multi-year transformation, Australia is targeting incremental yoy EBIT growth, both including and excluding the Nat Cap acquisition, and margin expansion driven by activity growth, improved capacity utilisation, revenue indexation in line with cost indexation, operational improvement initiatives, and including a $10-15m increase in investment in IT, technology and transformation. National Capital is expected to be Underlying EPS accretive in first 12 months of ownership, transition operating costs are expected to be in the range of $9-11m in FY27. Total capex for Australia is expected to be $380-410m, inclusive of Nat Cap. Slide 16 – UK Region: Focus on performance improvement Moving to the UK region on Slide 16, where both our UK Hospitals and Elysium businesses have focused on performance improvement plans to mitigate weakness in NHS funding. Pleasingly, both businesses delivered an increase in Underlying EBIT and were net cashflow positive. UK Hospitals focused on acuity, private activity growth and cost management to mitigate NHS funding headwinds from Q2. The Elysium turnaround is beginning to gain traction under the leadership of new CEO Joe O’Connor, in weak market conditions, through a focus on right-sizing our services to local demand and cost reduction. Slide 17 – UK Hospitals Performance Moving to each business in turn beginning on Slide 17, our UK Hospitals delivered underlying EBIT growth of 10.3% in constant currency, successfully mitigating an 8% decline in NHS activity and tariff indexation below cost growth. The result was achieved through a focus on higher complexity NHS work and private activity growth of 2.9%, which drove a 6.7% increase in average revenue per admission. The business focused on a disciplined cost management resulting in labour costs as a percentage of revenue declining by 30bps and the EBIT margin improving 80bps.
Slide 18 – UK Hospitals: Focus areas and Outlook Turning to the outlook on Slide 18 and we expect Ramsay UK to deliver EBIT growth in FY27 with the focus on: • Driving higher acuity and growth in private medical insurance (PMI) and self-pay activity; • Ongoing delivery of efficiency transformation programmes across Finance and Operations; including rostering initiatives and creation of finance shared service hubs; and • Continuing to work closely with local and national NHS stakeholders to attract NHS work and target acuity. NHS tariff guidance for the year beginning 1 April 2026 has been recently lifted to 1.24%, the backdated amount related to 1 April 2026 to 30 June 2026 will be included in the FY27 result. Slide 19 – Elysium: Turnaround underway Turning to Elysium’s result on Slide 19, the turnaround plan gained traction in the second half of FY26, delivering a 43% growth in underlying EBIT for the year. This was achieved through: • Site and ward closures to match local demand. • Reduced central and agency costs including a reduction in FTE’s; • Average fee uplift of 4.4% reflecting complexity of patient services: and • There was also a strong focus on working capital and a reduction in debtors which combined with reduced capex drove positive cashflow. Elysium’s reported result includes a net $13.2m of costs associated with its restructure including site impairments of net $9.9m Slide 20 – Elysium: Outlook and Focus Areas Our focus for Elysium on Slide 20 is to continue delivering on the turnaround plan, which includes: • Increasing conversion rate of new patient opportunities, including a focus on complex recovery services • Further improvements to labour mix including reducing agency costs further • Negotiating with payors for appropriate fee uplifts reflecting service complexity We are targeting EBIT growth in FY27 as the business turnaround continues to progress. Slide 21 – Europe: On track with separation plans Turning to Europe, on Slide 21 we are on track with our separation plans for Ramsay Santé to support long term value creation for Ramsay shareholders, as we move towards a Ramsay shareholder vote in late November. The business has continued to focus on performance improvement in both France and the Nordics. Slide 22 – Europe: Reduced underlying loss despite funding headwinds Moving to Slide 22 and despite funding headwinds in France, Ramsay Santé reported a reduced underlying loss in Europe. The Nordics region delivered a strong result, driven by Sweden's performance including the impact of the new St Göran 8-year contract and improved performance in its other services including Proximity Care. France has multiple work streams on foot focused on operational efficiency which partially mitigated the funding shortfall.
Slide 23 – Europe: Focus on profitable growth and performance improvement initiatives in all regions Turning to Slide 23 Ramsay Santé’s focus in FY27 will include: • Cost control, efficiency, and cash generation; • Growing profitable activity, including growth in Sweden and the full year impact of the new St Göran contract; and • Sustained advocacy for fair tariff outcomes in France; Slide 24 – Process for separation of Ramsay Sante Turning to Slide 24 the proposed separation of Ramsay Santé is well on track with the Demerger meeting for the shareholder vote progressing towards 24 November 2026. The benefits of the demerger proposal include: • • • • •
Simplifying Ramsay’s portfolio, enabling us to focus on transformation and growth potential of our core Australian hospitals business; It also simplifies our reported financial profile through deconsolidation of Ramsay Santé from Ramsay’s financial statements; Demerger should improve Ramsay Santé’s focus, an already established, independently managed and publicly listed business, to continue to pursue its European focused strategy and transformation; There is limited separation complexity, given Ramsay Santé already operates independently of Ramsay including separate financing and balance sheet arrangements; and It gives our shareholders the opportunity to retain ownership interest in Ramsay Santé
Assuming shareholders vote in favour of the separation and regulatory approval, Ramsay Santé will be treated as a discontinued business line item in our FY27 half and full year results. Costs associated with the demerger will be detailed in the Scheme booklet. Slide 25 – 'Ramsay cares' sustainability strategy update Moving to sustainability on Slide 25 and Ramsay remains on track with both our 2030 Scope 1 and 2 greenhouse gas (GHG) emission targets and 2028 supplier engagement targets. We are committed to working with our partners to understand and address GHG emissions across our supply chain, however, our progress in this area is limited to how quickly our suppliers are able to reduce and manage their own Scope 1 and 2 GHG emissions. As a result we have revised our longterm net-zero GHG targets taking into account the current and anticipated commercial and operating environment: • •
We will now target net zero (Scope 1 and 2) GHG emissions (equity share) by 2050 (instead of 2040). Ramsay UK and Elysium Healthcare will target net zero Scope 3 GHG emissions by 2050.
Our net zero Scope 3 GHG Group target will be considered following engagement with our suppliers in line with our near-term target. Slide 26 – Group Financials I will now hand over to Anthony to provide a more detailed look at our financial performance. Thank you, Natalie and good morning, everyone.
Slide 27 – FY26 Group Financial Performance Moving to our Group financial performance on Slide 27, important to note that all regions reported EBIT growth in local currency, reflecting positive transformation momentum in Australia and a focus on operational improvement programs across all regions. This drove a 30bps improvement in EBIT margins to 6.2%, with cost discipline resulting in a 20bps improvement in employee costs as a percentage of revenue and a 10bps improvement in medical supplies and consumables as a % of revenue. Underlying EPS grew 27% in constant currency. The underlying effective tax rate was approximately 35%, consistent with our guidance. Reported tax was slightly higher at approximately 37%, these rates are high relative to corporate tax rates in the jurisdictions Ramsay operates reflecting the impact of French CVAE2, a corporate value add tax and Ramsay Santé's loss before tax result in the FY26 period. The final dividend of 48.5 cents per share brings the full year dividend to 91 cents per share, up 13.8% from FY25, with a payout ratio of 60.3% of underlying earnings. Slide 28 – Cash flow Statement Turning to Slide 28 we continued to maintain a strong focus on cash generation. Operating cashflow reflects a 46% improvement in the Funding Group, coming from Australia and both UK businesses, offset by a negative working capital variance in Ramsay Santé primarily reflecting the timing of payments from the French Government versus the prior period. The decline in capex spend reflects capital discipline in development expenditures in Australia and the UK operations. This resulted in free cash flow of $697m which was relatively flat (-1%) compared to prior year. Net cash inflow from divestments mainly relates to sale and leaseback of 4 sites in France and sale of Hotdoc investment in Australia. Dividends paid increased, reflecting the suspension of the Dividend Reinvestment Plan for the final dividend in FY25. Slide 29 – Consolidated Balance Sheet Moving to Slide 29 our Consolidated Balance Sheet remains stable with key changes relating to: • • • •
The net impact of currency translation on the balance sheet was approximately ~$300 million reduction in net assets; Underlying increase in property, plant, and equipment includes the completion of developments in Australia partially offset by the restructure of portfolios in all regions; Working capital movements mainly relate to movements in Ramsay Santé associated with the timing of Government receivables; and The Elysium portfolio restructure resulted in $300m reduction to right of use assets.
ROCE increased 110bps to 11% for the Group. Slide 30 – Underlying Funding Group Performance Turning to Slide 30 and the Funding Group (which excludes Ramsay Santé) delivered underlying NPAT growth of 17.9% to $398.4m with a 5.2% increase in revenue in constant currency. 2 CVAE – The contribution on the added value of companies is a local tax payable by French companies with a turnover above €0.5m and is used to fund local administrations
This result was driven by underlying EBIT growth across all businesses, with an improved performance in Australia of +11.2% in underlying EBIT, a +10.3% underlying EBIT contribution from our UK Acute business and a +43.5% increase in underlying EBIT for Elysium. The result included a: • • •
7.3% increase in depreciation reflecting the completion of major projects in Australia over the period; Higher financing costs reflecting an increase in base rates over the period and reduced hedging compared to the pcp; and Underlying tax rate of approximately 29%.
ROCE for the Funding Group increased 124bps to 14.8%. Slide 31 – Funding Group – Cashflow, Debt and Leverage Moving to Slide 31 the Funding Group’s leverage has decreased to 1.83x and remains well below our target range of 2.5x, Interest cover is also strong at 8.94x. All business in the Funding Group were net cashflow positive for the year, showing a strong focus on improving cashflow, working capital management, capital allocation and returns across the Funding group. We maintained liquidity of $1.066 billion, some of which will be utilised for the $251m (ex GST) acquisition of National Capital next week. Leverage is expected to continue to be below our target range post the acquisition. The weighted average cost of debt in FY27 is currently expected to be approximately 5.5% and approximately 60% of our Funding Group debt is hedged for FY27. In FY27 total net interest costs (inclusive of AASB 16 lease costs) for the Funding Group are forecast to be $280-300m Slide 32 – Ramsay Santé - Debt and leverage On Slide 32, Ramsay Santé remains well supported by its own funding arrangements. In July 2026 they announced the completion of a refinancing of €1.75 billion of senior debt, extending the tenor by two years to 2033 and including a change of control provision consistent with our proposed separation. Its bank leverage ratio was 4.7x at 30 June 2026 and liquidity stood at €487 million, comprising €185 million in undrawn bank facilities and €302 million in cash. Slide 33 – Focus on capital management and cash flow Turning to Slide 33 and as I have shown above in the results, our focus on improving capital management and cashflows delivered improved returns and lowered leverage for the Funding Group over the period. Disciplined cost management across the Funding Group, resulted in underlying EBITDAR margin +60bps and underlying employee benefits as % of revenue declining 20bps. Activities over the period included: • • •
A focus on revenue cycle management and improving working capital across all businesses with cash conversion in Australia improving by 4 days over the period with further work to do; Focus on utilisation of facilities and portfolio optimisation resulted in a decrease in capital expenditure and improved capital allocation across the business; Cash generation from portfolio optimisation will continue in Australia and Elysium.
These activities and focus on improved results drove an improvement in the Funding Group ROCE by 124bps in constant currency to 14.8%. Slide 34 – Capital expenditure Turning to Slide 34 and group capital expenditure was A$734.2 million, a decrease of 6.1% in constant currency reflecting: • • •
Disciplined development spend in Australia, focused on expanding procedural capacity; Lower capital expenditure in the UK and flat in Europe, reflecting our capital discipline in the current funding environment, mainly due to lower development and growth expenditures; and Routine and compliance spend was increased in Australia to ensure our hospitals are future fit, our high clinical quality and safety standards and the amenity of our hospitals is maintained.
Our forecast range for Funding Group capex in FY27 is $480-520m, consistent with FY26 spend of $495m ($488m cc). Overall, we made good progress from a financial perspective in FY26, with the Company in a strong financial position to continue to deliver in FY27. With that I will now hand you back to Natalie for the Outlook and closing remarks. Natalie Davis: Thank you, Anthony. Slide 35 – CEO Outlook Slide 36 – Priorities and outlook Turning to Slide 36 in closing, I want to reiterate our commitment to continuing delivery of our strategic priorities. In FY27, we expect to continue the positive momentum with EBIT growth expected in Australia and the UK businesses. We are looking forward to completing the National Capital acquisition, caring for the local community and welcoming the team to Ramsay next week. We are preparing for the proposed separation of Ramsay Santé in December, subject to Ramsay shareholder vote on the 24th November. The Group Executive will host an investor day on the 30 November, to share our progress and plans as we continue to evolve Ramsay for the future. I am proud of the progress we have made as a team and our unwavering commitment to providing excellent care to our patients. Thank you for joining us and we will now open the floor for questions. Authorised for release by Henrietta Rowe, Group Executive Legal & Company Secretariat.
Appendix 4D Half-Year Financial Report 26 February 2026: Ramsay Health Care (Ramsay) (ASX: RHC) today releases its Appendix 4D for the six months ended 31 December 2025. A presentation of the results hosted by Group CEO and Managing Director, Natalie Davis and Group Executive Finance, Anthony Neilson, will commence at 10.00am this morning followed by a question and answer session. A webcast of the event will be hosted on the Ramsay Health Care website: https://www.ramsayhealth.com/en/investors/presentations/ To pre-register for the HY26 Half Year Results briefing please click on the link below: Ramsay Health Care HY26 Results Webcast A recording and transcript of the webcast will be available on the website later in the day. Authorised for release by the Ramsay Health Care Board of Directors.
People caring for people
1H FY26 Results Presentation
For the six months ended 31 December 2025
Natalie Davis Managing Director and Group CEO
Anthony Neilson Group CFO
Important Information The information in this presentation is general background information about Ramsay Health Care Limited and its subsidiaries (together, the Ramsay Group), with respect to the Ramsay Group’s business and operations, financial position and strategies and is current as at 26 February 2026.
No advice This presentation is in summary form and is not necessarily complete. It should be read together with the Ramsay Health Care Limited’s Appendix 4D and Review of Results of Operations lodged on 26 February 2026. It is not intended to be relied upon as advice to investors or potential investors and does not take into account the investment objectives, financial situation or needs of any particular investor. The information contained in this document has not been audited in accordance with the Australian Auditing Standards.
No representation, warranty or liability Ramsay makes no representation, warranty, assurance or guarantee as to the accuracy, completeness or likelihood of fulfilment of any forward-looking statement, any outcomes expressed or implied in any forward-looking statement or any assumptions on which a forward-looking statement is based. To the maximum extent permitted by law, responsibility for the accuracy or completeness of any forward-looking statements, whether as a result of new information, future events or results or otherwise, is disclaimed.
Forward looking statements This presentation contains forward looking statements. While these forward-looking statements reflect Ramsay’s expectations at the date of this presentation, they are not guarantees or predictions of future performance or statements of fact. These statements involve known and unknown risks and uncertainties. Many factors could cause outcomes to differ, possibly materially, from those expressed in the forward-looking statements. These factors include general economic conditions; changes in government and policy; actions of regulatory bodies and other governmental authorities such as changes in taxation or regulation; technological changes; the extent, nature and location of physical impacts of climate change; and geopolitical developments.
No undue reliance Except as required by applicable laws or regulations, the Ramsay Group does not undertake to publicly update, review or revise any forward-looking statements or to advise of any change in assumptions on which any such statement is based. Readers are cautioned not to place undue reliance on forward-looking statements.
2
1HFY26 Results Presentation
Other information This presentation should be read in conjunction with other publicly available material. Further information including historical results and a description of the activities of the Ramsay Group is available on our website: ramsayhealth.com/au/investors.
CEO Priorities Progress to date
Focus on transformation of market-leading Australian hospital business
Strengthen capital discipline and improve capital returns across the portfolio
Patient, team and doctor NPS improvement
Capex expected to be below previous guidance range 2H spend lower than 1H, focus on higher utilisation of existing assets in Australia.
Patient and People NPS scores, and clinical excellence remain high across the Group
Ramsay Private at Joondalup Health Campus opened on 18th Feb, development cost under budget by ~$14m.
Ramsay Research and Development Network launched in Australia, growing national clinical trials capability across 21 of our sites
Strong admissions and IPDA growth, with focus on high acuity services Growth in theatre utilisation, with continued investment in procedural capacity in major hospitals Joondalup Public Campus partial mitigation on track, including reduction in agency spend. Optimisation of portfolio, including recently announced closures of Ramsay Surgical Centre Glenferrie and Ramsay Clinic Thirroul (services transferred to other hospitals and clinics) Expected completion of National Capital Private Hospital acquisition Q1F27
3
1HFY26 Results Presentation
Ramsay Sante: Announcement of intention to complete an in-specie distribution by the end of 2026, subject to a shareholder vote Elysium: Turnaround progressing with new CEO Joe O’Connor commenced 12 January 2026, central and agency costs reduced, and available beds decreased to align to lower market demand. Site optimisation in progress
Evolve our culture of ‘people caring for people’ to innovate and drive performance
Group Executive team reset complete, strengthening capability and supporting faster delivery Ramsay Australia 2030 strategy translated into a focused agenda with quarterly delivery rhythm in place, guiding investment decisions and priorities
People caring for people
Group Performance Overview Natalie Davis
Managing Director and Group CEO
1HFY26 Group financial performance Underlying Group NPAT ³ growth of 8.1%² and EPS growth of 8.6%² reflected in higher H1 dividend
Revenue1
Underlying EBIT ²
Underlying NPAT ² ³
Reported NPAT ³
$9.3bn
$536.7m
$171.7m
$160.7m
+9.7% vs 1HFY25
+7.3% vs 1HFY25
+8.1% vs 1HFY25
+253.2% vs 1HFY25
Underlying EPS²
DPS
Funding Group Leverage
ROIC⁵
71cps
42.5cps
2.22x
4.3%
+8.6% vs 1HFY25
+6.3%, payout ratio 60%⁴
Target leverage <2.5x
1HFY25: 4.3%
5
1HFY26 Results Presentation
Revenue from contracts with customers. Details on items excluded from underlying EBIT and underlying NPAT refer to the Appendix and Section 2.2.2 of the Review of results of operations. 1HFY25 Underlying result excluded items of $263.8m primarily reflecting the post tax impairment of the UK region related to the underperformance of Elysium Net profit after tax and non-controlling interests attributable to owners of the parent Payout ratio based on Underlying NPAT after non controlling interests Accounting ROIC = 12 month rolling Underlying EBIT * (1- tax) / average of opening & closing invested capital
Group underlying¹ performance
Group underlying EBIT and NPAT performance driven by improving performance in Australian business Six months ended 31 December A$’m
2025
2024
Change
Change cc²
Australia
330.9
309.0
7.1%
7.1%
Ramsay UK
77.0
74.0
4.1%
(0.7%)
Elysium
12.1
14.9
(18.8%)
(22.2%)
Funding Group Underlying EBIT
420.0
397.9
5.6%
4.5%
Ramsay Santé Underlying EBIT
116.7
102.2
14.2%
4.4%
Group Underlying EBIT
536.7
500.1
7.3%
4.5%
Funding Group Underlying NPAT after non controlling interests
200.9
191.4
5.0%
4.8%
Ramsay Santé Underlying loss after tax and noncontrolling interests
(29.2)
(32.5)
10.2%
16.6%
Group Underlying NPAT after non-controlling interests
171.7
158.9
8.1%
9.1%
6
Underlying earnings – For detail on items excluded from underlying earnings refer Appendix and Review of Results of Operations Constant currency
1HFY26 Results Presentation
Group underlying NPAT result (+9.1%cc) driven by: • 7.1% growth in Australian EBIT reflecting good activity growth, higher levels of acuity, combined with improved PHI indexation and cost management • Australian result partially offset by decline in Joondalup Health Campus contribution, given new funding mechanism impact partially mitigated by operational actions • Australian EBIT margin ex-Joondalup +40bps • Improved EBIT and a reduced net loss from Ramsay Santé, with growth in Sweden and performance improvement actions partially offsetting the impact of lower funding in France • Elysium down on pcp with initiatives gaining traction
Regional Performance
People caring for people
Ramsay Australia 2030 Strategy
We are innovating to be Australia’s most trusted leading healthcare provider and to grow long-term shareholder value through the five pillars of our strategy
Measures 8
1HFY26 Results Presentation
Patient NPS Admissions Growth
Clinical Outcomes Revenue Growth
Employee Engagement EBIT Growth
Doctor NPS
Return on Capital Employed (ROCE)
Australia
Momentum building in core hospital business underpinned by growth in doctors, admissions, acuity and theatre utilisation Customers, People and Clinical Excellence at our heart
Growth in admissions and utilisation
Continued focus on cost efficiencies and capital discipline
Patient NPS improved to 72.9
Admissions and IPDA growth led by strong growth in surgical activity and 4% increase vs pcp in admitting VMOs3, as hospital teams completed second growth sprint enabled by catchment data insights
‘Big 5’ Hospital Operations Initiatives continued focus:
Focus on utilisation of theatre capacity, with theatre utilisation +1.3% in last 12 months1 with 16 new theatres opened1 in 2025 including at Joondalup, Charlestown, Warringal, Caloundra and Beleura
• Food on Demand and 'standardised' menu proof of concept pilots in progress
Doctor and Team NPS improved Clinical trials capability strengthened, with launch of national Ramsay Research and Development Network linking 21 sites across our hospitals, with 23% growth in clinical trials activity4. Rollout of digital foetal monitoring and maternity information system to continue to support clinicians and strengthen clinical safety commenced Victorian & Queensland nurses EBA negotiations have commenced
9
1HFY26 Results Presentation
Growth in Market share of benefits paid +0.4% for the last 12 months vs pcp2 Entry into attractive catchment through proposed acquisition of National Capital Private Hospital (expected 1Q FY27)
• Transition to single national waste provider
• Continued focus on labour productivity, skill mix and reduction of agency spend Digital & data opex spend on track to be at or below FY25 spend Uplift in capital discipline and focus on utilisation of existing capacity within catchments. FY26 Australian development capex now expected to be below lower end of previous guidance
- Utilisation and capacity includes theatres, cath labs and procedure rooms actively in use during the period. Excludes Border Cancer Hospital and Pindara Day Procedure Centre. Utilisation is measured on standard capacity of 570 minutes per room per day, 5 days a week, excluding public holidays and weekends.
- Measured as the total private health insurance revenue (excluding prostheses) relating to episodes discharged in the period divided by total hospital benefits paid per APRA Quarterly Private Hospital Statistics
- Defined as YTD average of monthly counts of revenue-generating VMOs with >1 admission in the past quarter.
- Defined as number of total trials as at 31 Dec 2025 vs 30 Jun 2025. Total trials includes active trials as well as trials with follow up
Australia
Growth driven by private admissions, increased acuity, improved indexation and cost management Six months ended 31 December A$’m
2025
2024
Change
Revenue from customers¹
2,641.0
2,440.6
8.2%
Total segment revenue and other income
3,417.3
3,168.0
7.9%
EBITDA
455.6
427.3
6.6%
EBIT
328.2
307.4
6.8%
Items² excluded from underlying EBIT
(2.7)
(1.6)
(68.8%)
Underlying EBIT contribution
330.9
309.0
7.1%
Underlying EBIT margin (%)
9.7%
9.8%
(10bps)
ROCE (%)³
16.5
16.8
(30bps)
Capital Expenditure
202.5
162.2
24.8%
Volume metrics Admissions ('000) (ex-Peel)⁴
631.9
612.9
3.1%
Day admissions as % of total admissions
69.0
68.6
+40bps
1,421.7
1,379.1
3.1%
IPDAs ('000)⁵ (ex- Peel)⁴
10
Revenue from customers = revenue from hospital admissions and out-patients; less prosthesis revenue and pharmacy revenue Further details on items excluded from underlying results refer to the Appendix and Section 2.2.2 of the Review of results of operations ROCE calculated as 12 month rolling Underlying EBIT / average of opening and closing capital employed pre goodwill. The management of Peel Health Campus was handed back to the WA Government in August 2024. Admissions inclusive of Peel increased 2.4% Inpatient and day admissions (days).
1HFY26 Results Presentation
Revenue growth¹ (+ 8.2%) driven by: • Admissions (ex-Peel Health Campus⁴) increased 3.1% • IPDAs⁵ +3.1% reflecting higher level of acuity in surgical, medical and rehab admissions • Improved revenue indexation from PHI agreements completed in FY25 Underlying EBIT growth (+7.1%) includes: • Higher activity levels and acuity, increased theatre utilisation and PHI indexation offsetting current wage inflation • The impact of the new funding mechanism at Joondalup, partially offset by on-site mitigation actions including timely discharge focus, agency reduction and increased winter activity • EBIT margin ex-Joondalup improved 40bps • Reported EBIT includes $2.7m of transaction costs associated with the proposed acquisition of National Capital Private Hospital in the ACT expected to complete Q1F27
Australian activity trends¹ Strong growth in core Surgical and Day activity and higher inpatient acuity Admission growth by Service
Admission growth by Admission Type
Admission growth by Funding Type
11% 5.7%
2.7% 0.1% Surgical
Medical
2.4%
3.6%
1.5%
2.0%
Maternity Private
Rehab -1.5%
Day
Public 3 DVA
Overnight
Psych 2 -4.5%
0%
% of total admissions
• Strong growth in Surgical • Medical IPDAs +3.8% reflecting higher-acuity
11
1HFY26 Results Presentation
100%
0%
% of total admissions
• Solid growth in core Private • Public driven by NSW and Joondalup
100%
0%
% of total admissions
100%
• Strong growth in Day • Overnight IPDAs +3.1% reflecting higher acuity
- Admissions growth vs pcp excluding Peel Health Campus contract which returned to WA Government in August 2024
- Psych refers to admissions for mental health at both stand-alone mental health clinics and within mental health wards in general hospitals. It does not include outpatient (e.g. Psychology)
- Department of Veterans’ Affairs
Australia
Development investment focused on procedural capacity in major hospitals in growth corridors • Total capex $202m increased 24.7% compared to pcp reflecting significant developments in progress including Joondalup Private and Warringal • FY26 development capex range of $170-190m below previous range of $200250m due to disciplined focus on utilisation of existing facilities • Full year capex range $385-400m down from $410-440m
Development capex compared to pcp by half (A$m) 208
FY26 range $170-190m
197 154
• Development investment focused on expanding procedural capacity in major hospitals in priority catchments. 23 theatres and procedure rooms¹ expected to open in FY26
107
• Investment in existing facility portfolio to ensure strategically located sites are fit for purpose in the future
101
109
FY23
FY24
Projects in FY26 include: • Completion of the ~$173m expansion of Joondalup Private (Perth) includes 6 theatres and 2 procedure rooms opened February 2026 • Final phase of Warringal Private Hospital (Melbourne) expansion including emergency department and new day surgery (due to open 2QFY27) • Strathfield Private Hospital (Sydney) expansion includes 2 theatres due to be completed by June 2026 • Hollywood Private Hospital (Perth) procedural capacity expansion including 2 cath labs forecast completion June 2026 and 2 theatres by December 2026 • Expansion of Beleura Private Hospital (Melbourne) including 2 theatres opened in November 2025 • Theatre expansion at St George Private Hospital (Sydney) includes 2 theatres in progress 12
1HFY26 Results Presentation
11 in H1 (+6 Charlestown, +2 Beleura, +3 Joondalup) and 12 in H2 (+1 Avenue, +5 Joondalup, +1 Peninsula, +2 Strathfield, +2 Hollywood, +1 Port Macquarie)
120
45
68
102
77 FY25
2H
FY26
1HFY26 Capital Expenditure by category compared to pcp (A$m)
202
162 67 73
77
102
7 Routine & Compliance
Development
15
Other Growth 1HFY25
11 12 Digital & IT
1HFY26
Total
1H
Australia
Continued focus on delivery of multi-year transformation
Focus areas
Outlook
• Continue activity growth momentum through implementation of data-led growth plans and strategies in our priority therapeutic areas and catchments.
• EBIT growth momentum in Australia to continue driven by growth in activity in priority therapeutic areas, revenue indexation, cost focus and partial mitigation of the impact of the new funding mechanism at Joondalup²
• Continue to optimise portfolio and services within and across catchments • Focus on operational excellence to increase theatre utilisation, improve labour efficiency through reduction of agency and optimised skill mix, and create further procurement savings through 'one-Ramsay' approach • Continue operational mitigation plan at Joondalup public² campus including reduction in agency spend
• Prioritise Digital & Data investments to support Growth, Revenue Cycle Management, including upgrade of patient administration system, Workforce including smart rostering, and Procurement.
• Full year capex expected to be $385-400m, with a development capex range $170m-190m, down from previous guidance of $200-250m, due to strengthened capital discipline and ongoing focus on higher utilisation of existing assets. • Proposed acquisition of National Capital Private Hospital is expected to transition into the Ramsay portfolio 1Q FY27 and be EPS accretive in first 12 months
• Complete negotiations of Victorian and Queensland nurses EBAs¹ • Continue to focus on recovering from payors the gap created by cumulative revenue indexation below cost indexation, with one major contract renewal in 2H FY26
13
1HFY26 Results Presentation
Enterprise bargaining agreement Joondalup public agreement was renewed in March 2024 initially extended to June 2043, with the funding mechanism changed and linked to the WA State Price. Ramsay remains committed to our long-standing public private partnership at Joondalup campus and to serving the health care needs of the growing community in North Perth.
UK Region
Focus on performance improvement given NHS budgetary pressures UK Hospitals
Focus on high acuity, private and operational excellence, with market headwinds on NHS activity Continued high patient NPS (+89)¹ and clinical excellence. Yorkshire clinic rated 'Outstanding' by CQC². Strong base of NHS-funded work and local partnerships, although headwinds on activity felt in Q2 due to NHS budgetary constraints. Focus on high acuity NHS work, reflected in growth in average revenue per case. Focus on growing private (PMI³ and self-pay) volumes, including launch of local campaigns emphasising fast treatment for private patients, and strong growth in PMI Continued focus on operational excellence and efficiency, with further cost measures underway in H2
Elysium
Turnaround beginning to gain traction in a challenging market Ongoing weak market demand from local authorities, with lower referrals into Acute services and lower demand for inpatient Rehab services with more care in community settings and faster discharge. Turnaround plan underway, with progress on: • Site optimisation – available beds reduced by 163 in the half, driving improved December occupancy rate 86.9% • Cost reduction – Phase 2 central cost reduction recently completed delivering 49 FTE saving (first phase reduced 78 FTE), and continued agency reduction focus • Fee negotiation – Achieved blended rate above NHS tariff, reflecting complexity of services New CEO Joe O’Connor commenced 12 January 2026
14
1HFY26 Results Presentation
1 July – 31 December 2025 Care Quality Commission UK Private Medical Insurance
UK Hospitals
NHS funding impacted activity at end of period, mitigated by higher acuity and a focus on operational excellence Six months ended 31 December A$’m
2025
2024
Change
Change cc³
Revenue and other income
810.4
747.0
8.5%
3.5%
EBITDA
133.5
126.0
5.9%
1.1%
EBIT
75.1
73.4
2.3%
(2.4%)
Items¹ not included in Underlying EBIT
(1.9)
(0.6)
(216.7%)
(202.7%)
Underlying EBIT contribution
77.0
74.0
4.1%
(0.7%)
Underlying EBIT margin (%)
9.5
9.9
(40bps)
(41bps)
Capital Expenditure
49.1
41.0
19.8%
14.3%
ROCE (%)²
13.0
12.6
40bps
(28bps)
Volume metrics Admissions ('000)
111.4
113.1
(1.5%)
Day admissions as a % of total admissions
81.0
80.8
+20bps
NHS admissions as a % of total admissions
74.0
74.6
(60bps)
15
For further detail on items excluded from underlying earnings refer the Appendix and Section 2.2.2 of the Review of results of operations ROCE calculated as 12 month rolling Underlying EBIT / average of opening and closing capital employed pre goodwill. Constant currency Tariff year commences 1st April Tariff for the 25/26 year was initially set at 2.15% and was later lifted to 2.83%. 1HFY26 EBIT includes backpay for the period 1 April - 30 June 2025 of £0.9m compared with back pay in 1HFY25 of £3.5m
1HFY26 Results Presentation
Revenue growth (+3.5%cc) driven by: • Improved average revenue per case (+5.2%), reflecting higher acuity case-mix • NHS tariff indexation for FY25/26⁴ of 2.83% • Overall admissions decline of 1.5%, driven by a 2.3% reduction in NHS volumes partially offset by a 0.8% increase in private volumes driven by PMI 4.6% increase
Underlying EBIT (-0.7%cc) driven by: • Excluding back dated indexation of £0.9m in 1HFY26 and £3.5m in pcp, underlying EBIT margins increased 30bps to 9.3%⁵ • Increased acuity, higher PMI admissions and focus on consistently good operational excellence across all sites • Result impacted by higher National Insurance costs (£2.8m) and labour inflation of ~3.5%
UK Hospitals
Focus on private growth and operational excellence to mitigate NHS funding uncertainty Focus areas
Outlook
• Drive growth of PMI and self-pay activity to mitigate reduced NHS volumes, and ongoing focus on acuity
• NHS activity outlook for 3QFY26 expected to remain negative compared to pcp due to NHS budget constraints and activity management for remainder of UK fiscal year to 31 March
• Implement cost reduction plans including reduction of flex labour to match activity levels and review of central spend including creation of finance shared service centre hubs • Build on and create technology-enabled efficiency measures including labour rostering
• Continue negotiations and discussions with local and national key NHS stakeholders
Year commencing 1 April 2026.
16
1HFY26 Results Presentation
• Mitigating plans in place to reduce impact of NHS activity management. • As the #1 NHS private hospital services provider, Ramsay UK remains well positioned to support the UK Government’s objectives to reduce elective surgery, outpatient and diagnostics wait lists when anticipated additional funding is made available in the new NHS fiscal year (from 1 April) with a strong pipeline of patients through its outpatient clinics.
• NHS tariff guidance for FY26/27 0.03%1, consisting of a cost uplift factor of 2.03% including a 2.0% pay uplift assumption, and efficiency factor of 2.0%.
Elysium
Turnaround underway to mitigate cost pressures and weak demand Six months ended 31 December A$’m
Revenue decline (-2.1cc%) driven by:
2025
2024
Change
Change cc³
Revenue and other income
541.2
528.4
2.4%
(2.1%)
EBITDA
38.2
36.8
3.8%
(0.7%)
EBIT
12.1
(42.1)
128.7%
127.5%
(57.0)
Underlying EBIT contribution
12.1
14.9
(18.8%)
(22.2%)
Underlying EBIT margin (%)
2.2%
2.8%
(60bps)
(60bps)
ROCE (%)²
1.8%
4.8%
(300bps)
(305bps)
Capital Expenditure
27.0
34.4
(21.5%)
(25.1%)
• Wage pressures including national minimum wage, increase of 5.5% and national insurance impact of £4m in the half
Average Paid Beds
2,022
2,133
(5.2%)
• Depreciation increased due to the new sites that came online over the last 12 months
Average Occupancy (%)
85.6
87.1
(150bps)
Items¹ excluded from underlying EBIT
Volume metrics
17
For further detail on items excluded from underlying earnings refer the Appendix and the Review of results of operation. 1HFY25 includes Elysium site impairment but excludes the $248m goodwill impairment to the UK cash generating unit ROCE calculated as 12 month rolling Underlying EBIT / average of opening and closing capital employed pre goodwill. Constant currency.
1HFY26 Results Presentation
• Lower occupancy with 2,022 paid beds down 5.2% and occupancy rate down 150bps to 85.6%, partially mitigated by average daily fee +4.5% pcp • Over the six-month period, available beds were adjusted to weaker demand.163 beds were closed resulting in occupancy rate for month of December of 86.9% above last year by 0.2%
Underlying EBIT margin reduction (-60bps), though EBITDA margin +5bps due to:
• Turnaround impact gained traction towards the end of the period • ROCE reflects higher capital employed associated with new sites that came on in FY25 (approved projects prior to the pause on growth capex in February 2025) and lower earnings.
Elysium
Turnaround beginning to achieve positive impacts in challenging market
Focus areas
Outlook
• New CEO Joe O’Connor commenced 12 January 2026
• Ongoing focus on performance improvement, expect the turnaround to continue to gain traction
• Continued focus on delivering performance improvement plan including adjustment of cost base, available beds, services and sites to current levels of market demand. Portfolio review commenced with 5 sites expected to be closed in 2H
• Uncertain demand for services due to changing market and NHS and local ICB1 budget constraints.
• Focus on increasing conversion rates, with a particular focus on complex, enhanced packages of care
• The NHS tariff for FY26/27 0.03%2 . Targeting blended rate across payors for 26/27 above this level.
• Ongoing focus on reducing agency costs and labour mix to mitigate a further increase in minimum wage
• UK national minimum wage to increase a further 4.1% from 1 April 2026
• Continue to negotiate with all payors to lift indexation for 26/27 year, targeting blended increase above NHS tariff increase
• Development capex other than committed capex ceased in February 2025
18
1HFY26 Results Presentation
Integrated Care Boards (ICBs) are NHS organisations responsible for planning health services for their local population in the UK. Year commencing 1st April 2026
Europe
Progressing towards separation while continuing to focus on performance improvement
Demerger via in-specie distribution Proposal to separate Ramsay Santé from Ramsay Group via an in-specie distribution of its full 52.8% stake to its shareholders If implemented, Ramsay shareholders would receive shares in Ramsay Santé proportional to their Ramsay shareholding by way of an in-specie distribution Enables Ramsay Group to simplify its portfolio, allowing Management to focus on the transformation and growth potential of its core Australian hospitals business whilst Santé continues to pursue its European focused strategy and transformation
19
1HFY26 Results Presentation
France
Focus on cost control and efficiency to mitigate funding headwinds
Nordics
Realise business potential in Sweden and turnaround Denmark and Norway
Performance improvement initiatives achieving results above targets including overhead cost reduction, revenue cycle management and procurement
Good growth and strong performance in Nordics driven by Sweden, in key service lines including primary care, elderly & mobility and St Göran hospital
Ongoing focus on cash generation and collection.
Transition to new St Göran contract in Stockholm Sweden from 5th January 2026 for 8+4 additional years with improved terms
Continued advocacy for improved tariffs that more fairly reflect increases in costs
Turnaround focus in Denmark and overhead cost reduction underway in Norway
Europe
Reduced underlying loss despite funding headwinds Six months ended 31 December A$’m
2025
2024
Change
Change cc⁶
Total revenue and other income
4,614.8
4,141.1
11.4%
2.5%
Revenue growth (+2.5%cc) reflects:
EBITDA
491.1
461.5
6.4%
(2.2%)
• French tariffs of 0.5%³
EBIT
105.0
101.3
3.7%
(5.3%)
• No prudential coefficient⁴ repaid in December 2025
Loss before tax
(60.7)
(70.5)
13.9%
20.7%
Net loss after tax and non-controlling interests
(36.6)
(3.5)
• Activity growth of 2.9%, with strong growth in day admissions
Items excluded from underlying EBIT¹
(11.7)
(0.9)
France - underlying EBIT contribution
59.5
75.7
(21.4%)
(26.9%)
Nordics - underlying EBIT contribution
57.2
26.5
115.8%
98.2%
Underlying EBIT
116.7
102.2
14.2%
4.4%
Items excluded from the Loss after tax and non-controlling interests¹
(7.4)
29.0
Underlying loss after tax and non-controlling interests
(29.2)
(32.5)
10.2%
16.6%
Underlying EBIT margin (%)
2.5%
2.5%
ROCE (%)⁵
6.2%
5.2%
100bps
79bps
Capital expenditure
139.5
138.7
0.6%
(7.5%)
Leverage (x)
5.3x
5.4x
Admissions ('000)²
808.1
785.6
2.9%
Day admissions as % of total admissions
69.6%
69.0%
+60bps
Further detail on items excluded from underlying results refer to the Appendix and the Review of results of operations MSO (medical, surgical and obstetrics) day + inpatient excludes FCR and day sessions. Further information on tariffs available at Section 2.3.3 of the OFR
20
1HFY26 Results Presentation
Underlying EBIT margin flat year on year: • Overall underlying EBIT negative in France, with growth driven by Sweden • Reduction in French subsidies of €20m half on half, partially mitigated by performance initiatives • D&A flat in local currency Underlying net interest costs (excl AASB16 lease costs) declined 4% in local currency • Reflecting lower base rates and borrowing cost amortisation in the pcp not re-occurring
Volume metrics
• Strong growth in Sweden in Primary care, St Göran hospital through appropriate management of length of stay, and Elderly services
The French Government uses the prudential coefficient as a mechanism to withhold a portion of hospital tariffs to mitigate the risk of exceeding the national health insurance expenditure target. ROCE calculated as 12 month rolling Underlying EBIT / average of opening and closing capital employed pre goodwill. Constant currency.
Reported EBIT includes $11.7m of costs relating to: • Costs associated with restructuring services at underperforming sites, transaction costs and net profit on the disposal/liquidation of assets
Europe
Focus on cost control, efficiency and cash generation, and realising business potential in Sweden Focus areas
Outlook
• Focus on cost control, operational efficiency, cash generation and disciplined capital management
• Activity growth in Europe expected to continue in the 2H, driven by day admissions, partially offset by the impact of 3 day French doctors strike in January;
• Sustained advocacy for fair tariff outcomes in France
• Tariff indexation in France for the 26/27 year of 0% from 1 January 2026;
• French business focused on implementing performance improvement plans including central cost reduction, revenue cycle management, optimisation of services and cash collections.
• St Göran new contract commenced 5 January 2026 for 8+4 additional years on improved terms
• Nordics business focused on growing activity, cross-referrals and continuing performance momentum in Sweden, successful transition of St Göran hospital to new agreement terms, and implementing cost-saving efforts and performance improvement plans in Norway and Denmark
21
1HFY26 Results Presentation
Europe
Proposal to separate Ramsay Santé from Ramsay
Summary of proposal
Strategic Rationale
After completion of a comprehensive strategic review of Ramsay’s share ownership in Ramsay Santé, the Board proposes to (subject to all approvals¹):
•
Simplification of Ramsay portfolio, enabling Management to focus on transformation and growth potential of its core Australian hospitals business
•
Distribute Ramsay Santé shares held by Ramsay to Ramsay shareholders (i.e. an in-specie distribution)
•
•
Assist Ramsay Santé to put in place arrangements so that Ramsay shareholders may hold their interest in Ramsay Santé through CHESS Depositary Interests (CDIs) which would be tradeable on the ASX
Improved focus for Ramsay Santé, an already established, independently managed and publicly listed business, to continue to pursue its European focused strategy and transformation
•
Subject to obtaining applicable approvals, and Ramsay shareholders voting in favour via a scheme of arrangement, Ramsay would expect to complete the inspecie distribution in the fourth quarter of calendar 2026
Limited separation complexity, given Ramsay Santé already operates independently of Ramsay including separate financing and balance sheet arrangements
•
Opportunity for Ramsay shareholders to retain ownership interest in Ramsay Santé
•
Simplification of Ramsay’s reported financial profile through deconsolidation of Ramsay Santé from Ramsay’s financial statements
- Shareholder and regulatory approvals
22
1HFY26 Results Presentation
People caring for people
Group Financials Anthony Neilson
Group Chief Financial Officer
FY25 Group financial performance Underlying NPAT Growth +8.1%
Underlying Net profit¹ +8.1% reflects: 2025
2024
Change
Change cc²
Underlying segment revenue & other income (less interest income)
9,381.1
8,581.1
9.3%
4.3%
• Activity growth across Australia and Europe combined with higher acuity across Australia and the UK, and revenue indexation in Australia
Underlying EBITDA
1,132.8
1,054.6
7.4%
2.8%
• Focus on operational efficiencies across all regions to mitigate cost pressures
Underlying EBIT
536.7
500.1
7.3%
4.5%
• A 7.9% (1.6% cc) increase in depreciation reflecting development assets in Australia coming online
Underlying Net profit after tax and non-controlling interests ¹
171.7
158.9
8.1%
9.1%
Items excluded from underlying EBITDA¹
(14.4)
(3.0)
Items excluded from underlying EBIT¹
(16.3)
(308.5)
• Effective underlying Group tax rate 36% (stat tax rate 37.7%), 35.5% in pcp reflects the 1H impact of CVAE taxes in France and Ramsay Santé's loss before tax result given its lower company tax rate of 25%.
Items excluded from underlying NPAT after non-controlling interests¹
(11.0)
(263.8)
Underlying EBITDA margin (%)
12.1
12.3
(20bps)
(20bps)
Underlying EBIT margin (%)
5.7
5.8
(10bps)
(10bps)
1,118.4
1,051.6
6.4%
2.0%
Reported EBIT
520.4
191.6
171.6%
164.8%
Reported Net Profit/(Loss) after tax and non-controlling interests
160.7
(104.9)
253.2%
255.4%
Underlying EPS (cps)
71.0
65.4
8.6%
9.6%
Six months ended 31 December A$’m
Reported EBITDA
- Further details of items excluded from underlying results refer Appendix and Review of results of operations.
- Constant currency.
24
1HFY26 Results Presentation
• Full year effective underlying Group tax rate expected to be approx. 35% reflecting the higher effective tax rate in Ramsay Santé Reported Net Profit +253% includes $11m of items not included in the underlying result including: • Primarily transaction costs in Australia and Ramsay Santé ($10.8m) 1HFY25 included: • $291m post tax impairment taken against UK CGU reflecting Elysium’s weak performance • $11.8m pre tax mark to market on a swap in Ramsay Santé’s interest expense • $34m (after NCI) release of a tax provision taken up at the time of Ramsay Santé acquisition • Fully franked final dividend of 42.5 cps 60% payout on Underlying NPAT
Cash flow statement Operating cash flow improvement driven by Australia, focus on cash generation across all regions Six months ended 31 December A$’m
2025
2024
Change
EBITDA from continuing operations
1,118.4
1,051.6
6.4%
Changes in working capital
(191.4)
(211.9)
9.7%
Finance costs
(298.9)
(291.5)
(2.5%)
Income tax paid
(104.4)
(113.7)
8.2%
Movement in other items
(173.4)
(134.9)
(28.5%)
Operating cash flow
350.3
299.6
16.9%
Capital expenditure
(418.1)
(375.8)
(11.3%)
Free cash flow
(67.8)
(76.2)
11.0%
Net divestments/(acquisitions)
2.5
(6.0)
141.7%
Interest & dividends received
6.5
12.1
(46.3%)
Cash flow after investing activities
(58.8)
(70.1)
16.1%
Dividends paid
(113.3)
(94.3)
(20.1%)
Other financing cash flow
(140.3)
(169.1)
17.0%
Net decrease in cash
(312.4)
(333.5)
6.3%
- Tax paid in 1HFY25 includes tax paid on the profit on the sale of Ramsay Sime Darby
25
1HFY26 Results Presentation
• Operating cashflow +16.9% driven primarily by improved performance in Australia and lower tax paid than the prior period¹ • The increase in capex reflects higher investment in developments in Australia with capex in the UK region and Ramsay Santé both lower in local currency compared to the pcp. • Dividends paid increased 20% reflecting the suspension of the dividend reinvestment plan (DRP) for the FY25 final dividend (DRP operated in the pcp). • No material change to loans and borrowings however Ramsay Santé refinanced a former finance lease with a new €65m mortgage loan
Consolidated Balance Sheet
Increase in capital employed driven by Australian developments A$'m
31/12/25
30/06/25
31/12/24
787.9
596.5
897.9
Property plant & equipment
5,954.0
5,820.0
5,561.6
Intangible assets
6,317.2
6,431.1
6,112.1
226.5
205.8
176.1
Other assets/(liabilities)³
(1,127.5)
(1,342.2)
(1,221.0)
Capital employed (before right of use assets)
12,158.1
11,711.2
11,526.7
Right of use assets
4,958.8
5,333.0
4,825.7
Capital employed
17,116.9
17,044.2
16,352.4
Capitalised leases (AASB16)
6,247.8
6,583.0
6,010.9
Net debt (excl. lease liability debt & excl. derivatives)
5,145.9
4,752.5
4,903.5
Total shareholders funds
5,723.2
5,708.7
5,438.0
Invested capital
17,116.9
17,044.2
16,352.4
Working capital³
Current & deferred tax assets
Return metrics Return on capital employed (ROCE) (%)¹
9.9
9.9
9.7
Return on invested capital (ROIC) (%)²
4.3
4.3
4.3
- ROCE calculated as 12 month rolling Underlying EBIT / average of opening & closing capital employed pre goodwill.
- Accounting ROIC = 12 month rolling Underlying EBIT * (1- tax) / average of opening and closing invested capital
- Current employee entitlement liabilities, primarily comprising annual leave and long service leave was previously booked, within Current Trade and Other Creditors in the Statement of Financial Position. Management has reassessed the presentation of these balances and determined that classification as Current Provisions more appropriately reflects their nature. Accordingly, prior year comparatives as at 30 June 2025 and 31 December 2024 have been restated by reclassifying $1,262.0m and $1,084.5m respectively from Working Capital to Current Provisions. There was no impact to Total Current Liabilities. 26
1HFY26 Results Presentation
• The impact of currency translation on the balance sheet approximately ~$83.5m • The increase in property plant & equipment ex-FX primarily relates to the completion of developments in the Australian business • Consolidated Net Debt (ex-leases) is Funding Group $2.1bn and Ramsay Santé $3bn • The Ramsay Consolidated Group weighted average cost of debt (excluding CARES) at 31 December 2025 was 5.2% • ~67% of Consolidated Group‘s floating rate debt in 2HFY26 hedged at an average base rate of 3% (excluding lending margin)
Funding Group¹ performance
Underlying performance delivered by Australia 6 months ended 31 December A$’m
2025
2024
Change
Change cc⁵
4,763.6
4,438.0
7.3%
6.0%
EBITDAR
634.9
598.1
6.2%
5.2%
EBITDA
627.3
590.1
6.3%
5.3%
EBIT
415.4
90.3
360.0%
355.5%
Financing costs (AASB16 leases)
(76.4)
(74.9)
(2.0%)
1.1%
Net other financing costs (net interest income)
(54.1)
(50.6)
(6.9%)
(7.1%)
Net Profit after tax and non-controlling interests
197.3
(101.4)
294.6%
294.2%
Items excluded from underlying EBIT
(4.6)
(307.6)
Underlying EBIT
420.0
397.9
5.6%
4.5%
Items excluded from underlying net profit after tax and noncontrolling interests
(3.6)
(292.8)
Underlying Net profit after tax after non-controlling interests
200.9
191.4
5.0%
4.8%
EBITDA margin (%)
13.2%
13.3%
(10bps)
(10bps)
Underlying EBIT margin (%)
8.8%
9.0%
(20bps)
(20bps)
ROCE (%)²
13.1%
13.9%
(80bps)
ROIC (%)³
5.7%
6.0%
(30bps)
Leverage (x)
2.22x
2.07x
2,120.7
1,991.3
(6.4%)
Revenue and other income
Funding Group adjusted net debt (excl. lease liability debt and excl. derivatives) ⁴ 27
1HFY26 Results Presentation
Underlying Net profit +5% reflects: • Driven by a 7.1% increase in underlying EBIT in Australia partially offset by a flat EBIT contribution from the UK region • Margins impacted by performance of Elysium, reporting growth in revenue offset by lower EBIT reflecting higher labour costs and lower occupancy • Total interest costs (incl. AASB16 leases) increased 1.3%cc reflecting higher average base rates over the period and slightly higher drawn debt • Effective underlying tax rate 29.4% (28.7% pcp)
- Comprised of Ramsay Health Care Limited and all its subsidiaries, excluding Ramsay Santé (the Funding Group’s investment in Ramsay Santé is recorded as an investment on the balance sheet).
- ROCE = 12 month rolling Underlying EBIT / average of opening and closing capital employed pre goodwill.
- Accounting ROIC = 12 mth rolling Underlying EBIT *(1-tax)/average of opening & closing invested capital
- Calculation used for covenant purposes
- Constant currency.
Funding Group¹ - Debt and leverage
Leverage in target band, remains well supported by core Australian hospital cashflows Funding Group¹ – bank net debt2 and leverage ratio³ 6.0
4.00
5.0 4.0
2.07x
2.22x
2.18x
3.0
2.00
2.0
• Refinancing of $2.05bn debt facilities tenor extended and 30bps improvement in margin on syndicated loan facility • Interest cover remains strong at 8.59x
1.0 0.0
• Funding Group’s unsecured debt facilities are underpinned by the strong cash flows generated by the Funding Group and the ownership of the majority of the Australian hospital portfolio. The Australian property portfolio comprises 47 owned hospital sites which generated $764.5m in EBITDAR⁴ for the 12mths ended 31 December 2025
2.0
2.0
2.1
Dec-24
Jun-25
Dec-25
Bank Net Debt $'bn²
Leverage Ratio (x)³
0.00
• $838m of liquidity at 31 December 2025 comprising $730m undrawn bank facilities and $108m cash. $251m proposed acquisition of National Capital Private Hospital to be funded from existing facilities, leverage expected to be in the range of <2.50x • Bank leverage ratio at 31 December 2025 was 2.22x (target Funding Group leverage <2.50x) below covenant level of 4.00x⁵ • Fitch BBB- investment grade rating affirmed during the period • The weighted average cost of debt at 31 December 2025 was approximately 5.0% (excluding CARES6)
Notes: 1. Funding Group – excludes Ramsay Santé (funded by standalone debt facilities). Banking covenants and Fitch rating based on the Funding Group earnings profile and net debt. 2. Bank Net debt (excl lease liability debt and derivatives). 3. Leverage ratio for the purposes of banking covenants calculated as Bank Net debt / Funding Group Underlying EBITDA adjusted to deduct all rental expenses under any lease arrangement . 4. Does not include an allocation for overhead costs. Refer to Appendix for full list of hospitals 5. Investment grade credit rating must apply to leverage between 3.50x - 4.00x otherwise leverage not to exceed 3.50x 6. Convertible Adjustable Rate Equity Securities (CARES) are non-cumulative, redeemable and convertible preference shares.
28
1HFY26 Results Presentation
• For 2H FY26, approximately 65% of the Funding Group debt is hedged at an average base rate (excluding lending margin) of 3.6%
Ramsay Santé - Debt and leverage Ramsay Santé bank leverage and debt metrics (IAS17) (€’bn)
5.40x 4.70x
5.30x
• Ramsay Santé remains supported by its own funding arrangements underpinned by secured loan facilities, with no recourse to the Ramsay Funding Group • €391m of liquidity at 31 December 2025 comprising €185m undrawn bank facilities and €206m cash. Committed facilities total €2,065m including undrawn senior facilities • Weighted average cost of debt at 31 December 2025 approximately 5.3%
1.8
1.7
1.8
Dec-24
Jun-25
Dec-25
Ramsay Santé Net Debt (IAS17) €'bn¹ Ramsay Santé Leverage Ratio (IAS17) (x)²
- Leverage Net Debt (excl lease liability debt) for calculating bank leverage.
- Leverage Ratio as per Ramsay Santé banking covenants based on IAS17 calculation. 29
1HFY26 Results Presentation
• Credit rating Moody’s B1 (negative) / S&P BB- (stable)
Focus on capital management and cash flow Improve capital allocation & returns International portfolio • Growth capital in Elysium paused in February 2025, with turnaround underway including bed and site optimisation. • Strategic review of shareholding in Ramsay Sante completed. Capex focused on maintenance and lower year on year. • Group Capital Committee, sponsored by CFO Australia • Focus development capex on procedural capacity in priority catchments (beds by exception) • Operational focus on lifting theatre utilisation of existing assets, as well as strengthening robot utilisation across hospitals • Catchment driven optimisation of services and assets (versus individual hospital business cases), including ongoing site portfolio review • Growth capex focused on investment to drive differentiation in clinical services 30
1HFY26 Results Presentation
Improve cash flow • Revenue cycle management focus to enable faster cash collection across all regions • Investment in systems, tools and resources to drive improved working capital management • Cost out and efficiency programs underway in all regions • Performance improvement and operating cash flow targets included in group scorecards
Maintain leverage & rating Funding Group • Refinancing completed at improved pricing and longer tenor - 30bps margin improvement on Funding Group syndicated loan facility • Improve capital allocation to fund strategic growth opportunities in Australia, while maintaining leverage and credit rating • Proforma leverage post-acquisition of National Capital Private Hospital within target range of <2.50x Group • Interim Dividend 42.5cps, an increase of 6.3%, and payout ratio of 60%, consistent with our target range of 60-70% of underlying net profit after tax and noncontrolling interests fully franked
Capital expenditure
Capex modified for current environment, UK and Santé spend lower in local currency Australia $’m
UK Region £’m
Group A$’m
Ramsay Santé €’m
Chart Title 376
202 162
85 102
77 11 7
12 15
67
73
1HFY25
1HFY26
Development
17
39
37
8 4 3
5 3 5
24
24
1HFY25
1HFY26
Digital & Data & IT hardware
78 20
10 9
4 10
49
44
1HFY25
1HFY26
Other growth
122
418
148
403
144
32 29
36 33
32
193
201
193
1HFY25
1HFY26
1HFY26cc¹
34
Routine & Compliance
• Total Group capital expenditure A$418m, increase driven by strategic development projects in Australia (FX impact $15m)
• UK (-5.1%) and European (-8.2%) spend below pcp in local currency due to capital discipline in the current environment
• Development capex in Australia focused on expanding procedural capacity in priority catchments. Spend lower than forecast following increased focus on theatre utilisation
• Development capex in the UK region relates to re-purposing and refurbishing existing facilities, with growth capex in Elysium ceased in February 2025
• Joondalup private hospital development total spend ~$14m below budget
• Full year capex below guidance forecast now in the range $755-795m. Capex lower in 2H than 1H spend
31
1HFY26 Results Presentation
- Constant currency
People caring for people
CEO wrap-up Natalie Davis
Managing Director and Group CEO
Priorities and outlook CEO priorities
FY26 results are expected to reflect:
Focus on transformation of market leading Australian hospital business • Continue activity growth momentum, focused on priority Therapeutic Areas • Focus on operational excellence through ‘Big 5’ Hospital Operations Initiatives, including 'one-Ramsay' procurement and Revenue Cycle Management transformation
• EBIT growth momentum in Australia to continue driven by growth in activity¹ in priority therapeutic areas, revenue indexation, cost focus and partial mitigation of the impact of the new funding mechanism at Joondalup;
Strengthen capital discipline and improve capital returns across the portfolio • Heighted focus on capital discipline across portfolio. Growth capex focused on procedural capacity in major hospitals in Australia • Progress demerger of Ramsay Santé from Ramsay Group, with expected execution by final quarter of calendar year 2026 subject to shareholder vote Evolve our culture of 'People caring for people' to innovate and drive performance • New Group Executive Team focused on strengthening capabilities and delivering at pace
• UK Hospitals - NHS activity outlook for 3QFY26 expected to remain negative compared to pcp due to NHS budget constraints and activity management for remainder of UK fiscal year to 31 March. Mitigating plans in place to reduce impact; • Ramsay UK remains well positioned when anticipated additional funding is made available in the new NHS fiscal year (from 1 April), with a strong pipeline of patients through its outpatient clinics; • Elysium ongoing focus on performance improvement plan expect the turnaround to continue to gain traction; • Activity growth in Europe expected to continue in the 2H, driven by day admissions, partially offset by the impact of French 3-day doctors strike in January; • Net financing expense (inclusive of AASB 16 lease costs) is forecast to be $590m-$610m; • Full year effective underlying Group tax rate expected to be approx. 35% reflecting the higher tax rate in Ramsay Santé; • Group capex guidance lowered to $755m-$795m, 2H lower than 1H;
33
1HFY26 Results Presentation
Activity growth in Australia ex-Peel hospital campus
• The dividend payout ratio for the year is expected to be 60-70% of underlying net profit after tax and non-controlling interests.
People caring for people
Appendix
Funding structure Consolidated Group
Funding Group¹
Paul Ramsay Foundation
Public Shareholders
17%⁷
83%⁷
Ramsay Health Care Limited (ASX listed; BBB-Stable)
Ramsay Santé
Consolidated Group³ Revenue: $18.6bn EBIT: $1,079.2m
Funding Group³ Revenue: $9.3bn EBIT: $766.9m Net Debt⁴: $2,120.7m Leverage⁴ 2.22 (x): Market Cap.: $8.7bn⁶
35
1HFY26 Results Presentation
UK subsidiaries²
• Comprised of Ramsay Health Care Limited and all its subsidiaries. • Ramsay reports its financial results on a Consolidated Group basis, with financial results for Ramsay Santé being reported on a fully consolidated basis. • There are no debt facilities provided to the Consolidated Group.
Ramsay Santé³ Revenue: €5.3bn EBIT: €178.3m Net Debt⁴: €1,845m Leverage⁴ 5.3 (x): Market Cap.: €1.2bn⁵ 52.79%
Australian subsidiaries
Consolidated Group
Ramsay Santé and subsidiaries (Euronext listed; B1-PD/ Negative, BB-/ Stable)
Financial covenants and the Fitch rating only apply to the Funding Group. Either wholly owned or controlled by Ramsay Health Care Limited, Rolling 12 months to 31 December 2025 underlying EBIT As at 31 December 2025 Adjusted Net Debt excluding lease liabilities and derivatives Based on 110.4m shares Based on 230.8 m shares As at 31 January 2026
Funding Group • Comprised of Ramsay Health Care Limited and all its subsidiaries², excluding Ramsay Santé (the Funding Group’s investment in Ramsay Santé is recorded as an investment on the balance sheet). • The Funding Group effectively represents Ramsay’s Australian and UK operations¹.
Ramsay Santé • Ramsay Santé is separately self-funded by covenant light, secured debt facilities with no recourse to the Funding Group.
Breakdown by Region Australia
UK
Europe
Total Group
Net profit on disposal of non-current assets and businesses
2.6
2.6
Impairment of carrying value of assets
(1.9)
(1.9)
Restructuring costs
(6.2)
(6.2)
Acquisition, disposal and development costs/benefits
(2.7)
(8.1)
(10.8)
Total EBIT Impact
(2.7)
(1.9)
(11.7)
(16.3)
Total (loss)/profit before tax impact
(2.7)
(1.9)
(11.7)
(16.3)
Income tax impact
0.5
0.5
1.0
2.0
3.3
3.3
(2.2)
(1.4)
(7.4)
(11.0)
Australia
UK
Europe
Total Group
3.4
3.4
(Impairment)/Reversal of impairment of carrying value of assets
0.3
(305.8)¹
(305.5)
• $291m post tax impairment of UK region (£144m) related to underperformance of Elysium
Acquisition, disposal and development costs/benefits
(1.9)
(0.2)
(4.3)
(6.4)
Total EBIT Impact
(1.6)
(306.0)
(0.9)
(308.5)
• $34m (after NCI) release of a non-cash tax provision taken up at the time of Ramsay Santé acquisition
Net swap mark to market movements
(11.8)
(11.8)
Total (loss)/profit before tax impact
(1.6)
(306.0)
(12.7)
(320.3)
64.5
64.5
0.5
14.3
3.4
18.2
(26.2)
(26.2)
(1.1)
(291.7)
29.0
(263.8)
1H FY26 Reported NPAT includes items of ($11m) excluded from the underlying result: • Acquisition, disposal and development costs/benefits in Australia and Ramsay Santé; • In Europe the costs associated with restructuring and closing sites; • An impairment loss in relation to property plant and equipment additions to a UK site previously impaired;
1H FY26 (A’$m)
Non-controlling interests net of tax Net (loss)/profit after tax and non-controlling interests impact
• A net gain on disposal/liquidation of assets in Ramsay Santé. 1H FY25 Reported NPAT included items ($263.8m) excluded from the underlying result:
• $11.8m pre-tax non-cash negative mark to market movement on interest rate swap in Ramsay Santé
1H FY25 (A’$m) Net profit on disposal / acquisition of development assets, non-current assets & businesses
Tax liability provision release Income tax impact Non-controlling interests net of tax Net (loss)/profit after tax and non-controlling interests impact
36
1HFY26 Results Presentation
- Impairment includes a $0.6m site impairment in Ramsay UK
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
ETFs Holding Ramsay Health Care Limited
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.
| ETF | Weight in ETF | Shares | Market value | As of |
|---|---|---|---|---|
| DFIC | 0.06% | 249,074 | $ 9.4M | Nov 12, 2026 |
| DFIV | 0.05% | 290,928 | $ 10.98M | Nov 12, 2026 |
| DXIV | 0.05% | 3,054 | $ 115.261K | Nov 12, 2026 |
| DFSI | 0.05% | 14,392 | $ 543.168K | Nov 12, 2026 |
| DFAX | 0.04% | 118,238 | $ 4.462M | Nov 12, 2026 |
| DFAI | 0.03% | 147,622 | $ 5.571M | Nov 12, 2026 |
| AVSD | 0.02% | 1,984 | $ 73.109K | Nov 16, 2026 |
| NTSI | 0.02% | 2,723 | $ 82.968K | Jun 30, 2026 |
| AVDE | 0.01% | 63,523 | $ 2.341M | Nov 16, 2026 |
| DIHP | 0.00% | 3,484 | $ 131.49K | Nov 12, 2026 |